[{"article": "\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\nAbout 1,700 participants were over age 40, had no other known eye diseases and had full eye examination results from the survey.\nOverall, both medical and non-medical approaches are key to treating the disease in the future, Aref added.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\n\u201cIn the past few years, there has been a tremendous increase in interest, and subsequently research, into the ways lifestyle changes can influence diseases,\u201d Hecht told Reuters Health by email.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Tea is widely available and relatively affordable compared to other prepared drinks.", "answer": 2}, {"article": "\"Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies,\" Dr. Stephen Silberstein, director of the headache center at Jefferson University in Philadelphia, said in a statement.\nThe company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\n\"The FDA release of gammaCore is an important advance in the treatment of the pain associated with cluster headache,\u201d Silberstein said in the statement provided by the company.\nIt does not have the side effects or dose limitations of commonly prescribed treatments or the need for invasive implantation procedures, which can be inconvenient, costly and high-risk.\"\nA study in the journal Headache last September showed the treatment appeared to help just over a quarter of cluster headache patients who tried it, versus about 15 percent of those given a sham treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "One of the first questions a cluster headache sufferer will have about the device is: how much does it cost? The article doesn\u2019t offer any information about the cost of the device, or comparison to the\u00a0costs of other treatment. A company release for British audiences described the device in terms of its savings compared to medications (\u201c25% reduction in costs associated with acute treatments such as zolmitriptan, sumatriptan and inhaled oxygen\u201d) but a search on the actual cost of the device and the cost of replacing the pre-loaded doses came up empty-handed.", "answer": 0}, {"article": "Research reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) award CE12-11-4667.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\nSurgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nThe Vanderbilt University Medical Center study led by Daniel Barocas, M.D., MPH, associate professor of Urologic Surgery, compared the side effects and outcomes of contemporary treatments for localized prostate cancer with active surveillance in order to guide men with prostate cancer in choosing the best treatment for them.\nThe authors also reported that:\n\n- Surgery was associated with fewer urinary irritative symptoms, like weak urine stream or urinary frequency, compared to active surveillance.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Typically, we are asking that a release tell us the \u201ccost\u201d of a therapy or drug, but in this case, we wish the release had given some estimate of the cost savings from active surveillance for patients vs. surgery or radiation or both. This is an important point for both individual patients and the broader society since the population of men with prostate cancer is growing and most are likely to be on Medicare.", "answer": 0}, {"article": "Results were similar after two years.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nThe condition is common in people with diabetic retinopathy, which affects up to 45 percent of people with diabetes.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t mentioned and in that oversight is perhaps the biggest flaw of the story \u2013 that it did not explain \u2013 as the New York Times story did \u2013 that there are questions about Lucentis vs. a cheaper alternative. From the NYT: ", "answer": 0}, {"article": "Doctor are taking the first steps to move this treatment beyond the world of the elite athlete.\nThey are packed full of growth factors, of healing factors, and when given into a specific area, you get a hyper-healing response,\" Gearhart says.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\n\"I knew something was wrong, and I knew that I was going to have to take some time to heal,\" Bornstein says.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs, nor any projection of possible future clinical costs.\u00a0 If such a preliminary experimental approach is ready for primetime TV, then it should be ready for even a preliminary discussion of what this approach will cost. ", "answer": 0}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nAdditionally, participants were not assigned to eat walnuts or other foods, and were just asked about their dietary choices.\n\"These results add to the large body of evidence that outline the many benefits of a healthy diet for women.\nBetween 1992 and 2008, the women were asked questions about their physical function, including their ability to perform basic activities of daily living.\nThis new paper prospectively examined the association between the dietary habits of the participants and subsequent impairment in physical function.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Walnuts are reasonably affordable, and most people have some idea of how much they cost.", "answer": 2}, {"article": "\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAccording to Arbelo, 91 percent of patients choose to have ablation to relieve symptoms, while 66 percent do so to improve their quality of life.\nBut the procedure can have complications, which should be considered carefully by doctors and patients, said Arbelo, a senior specialist in the Cardiovascular Institute at the Hospital Clinic of Barcelona in Spain.\nIn addition, 45 percent of patients who had a successful procedure were still taking antiarrhythmia drugs 12 months later.\n\"Further trials are needed to evaluate the benefits and risks of catheter ablation and its potential role as first-line therapy,\" he suggested.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the procedure is often covered by insurance. But it didn\u2019t discuss the costs without insurance (or to the health care system). Estimates put it at roughly $10,000 for the procedure, and quite a bit more once hospital costs are factored in.", "answer": 0}, {"article": "\u201cDoes everybody need to practice at least 20 minutes a day three times a week?\n\u201cAt a certain point in time you learn what your back needs.\u201d\n\nAs an alternative to yoga, stretching may be a viable option.\nThis is a much larger study, and the findings are robust.\u201d\n\nAbout four out of five people experience low back pain at some point in their lives, prompting Americans to spend $50 billion a year on medications, physical therapy and related costs.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention the costs or cost-effectiveness of any of the interventions. These are important issues. Individuals who opt for yoga classes, for instance, may have to bear the costs themselves.\n\n\n\n\n\n\n", "answer": 0}, {"article": "The folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nNews flash: Eggs are really good for you.\nThis place conducts some serious research on diet and weight.\nAfter a two-week gap, the groups were switched.\nThey could have just asked people if they liked eating eggs for breakfast.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of eggs and cereal are not in question.", "answer": 2}, {"article": "But there are still a lot of unanswered questions about immune therapy.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n\"We as a lung cancer community are incredibly excited about the activity of immunotherapy in various aspects of the disease,\" said Pasi Janne, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston.\nIn some patients, just removing the brake is enough to allow the person's immune system to fight and contain the cancer.\nThe new trial looked at a type of lung cancer called squamous cell non-small cell lung cancer, which accounts for about 20%-30% of lung cancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs at all. Other media reports have quoted the company as saying it will charge\u00a0an average of $12,500 a month for Opdivo.", "answer": 0}, {"article": "A medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nSymptoms range from mild stomach or skin reactions to a constriction of the airways.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nBecause even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Discussing costs isn\u2019t particulary relevant with this approach and at this early stage of research. ", "answer": 2}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no mention of costs for any of the\u00a0treatments mentioned, which is especially troubling given that most cosmetic procedures are not covered by insurance. \u00a0", "answer": 0}, {"article": "Kappelmann, N et al.\nDr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nThe research was mainly funded by the Wellcome Trust, with further support from the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre.\n\"We will need clinical trials to test how effective they are in patients who do not have the chronic conditions for which the drugs have been developed, such as rheumatoid arthritis or Crohn's disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of any of these drugs. A Consumer Report article puts many of these drugs in the range of on average $2,000 a month when treating rheumatoid arthritis. It is unclear if the same doses would treat depression. \u00a0This was also an issue in CNN\u2019s story.", "answer": 0}, {"article": "'Reduced infancy and childhood epilepsy following hypothermia-treated neonatal encephalopathy' by Xun Liu, Sally Jary, Frances Cowan and Marianne Thoresen in Epilepsia\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nIt is known that newborn babies who suffer perinatal asphyxia may develop permanent brain injury resulting in cerebral palsy or other conditions, like epilepsy.\nFor up to eight years, the researchers followed 165 infants who were born in the south west and who received cooling therapy at St Michael's Hospital, Bristol, part of University Hospitals Bristol NHS Foundation Trust.\nAlso, the severity of cerebral palsy is milder and seven out of ten are able to walk.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address cost. Given that the cost can run into thousands of dollars, that\u2019s a significant issue.", "answer": 0}, {"article": "Surinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nHe said this was \u201ca difficult but not impossible task\u201d and one that would be made easier by the better understanding of the biological processes gained in this early research.\nIt attacks and breaks down a naturally-occurring protein in the body which normally prevents cancer cells from spreading.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is such an early stage finding it would be premature to throw out cost figures, and there are no comparable treatments that come to mind to serve as cost comparators.", "answer": 2}, {"article": "URBANA, Ill. - Nearly every American who has become a parent in the last decade has heard the slogan, \"breast milk is best,\" and has likely been encouraged to offer breast milk to newborns.\nThe preference for novel objects, an indication of natural curiosity, is a sign of healthy brain development and points towards positive development of learning and memory.\n\"There are so many ways we can alter the composition of the microbiota and they can have very strong benefits.\nOne way to tell is by looking at metabolic end-products - volatile fatty acids (VFAs) - excreted by bacteria during digestion of prebiotic fibers.\nIn early 2016, Dilger and his colleagues worked with piglets to show that a combination of innovative formula components, including prebiotics, may play a role in brain development and behavior.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the associated costs of both formula and prebiotic-enhanced formula which could be considerable considering the amount and length of time an infant would consume it.", "answer": 0}, {"article": "Trulance, taken orally once daily, works locally in the upper GI tract to stimulate secretion of intestinal fluid and support regular bowel function.\n\u201cWith the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.\u201d\n\nAccording to the National Institutes of Health, an estimated 42 million people are affected by constipation.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\u201cNo one medication works for all patients suffering from chronic gastrointestinal disorders,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since the FDA evaluates drugs without consideration of cost we\u2019re rating this Not Applicable. But we look forward to the day when FDA news releases include some mention of cost in its message. The value of a new drug is a function not just of how well it works, but its cost-effectiveness.\nPricing information for Trulance is likely to come soon in the wake of the FDA\u2019s approval. For reference, other drugs aimed at the inflammatory bowel/gastrointestinal disorder market have carried high price tags. One such drug costs about $380 for a month\u2019s supply of 30 capsules.", "answer": 2}, {"article": "Prologo consults for Galil Medical, which funded the study.\n\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nThey lasted an average of 110 seconds before ejaculation, or nearly two minutes, over the three months they were followed, compared with 36 seconds before treatment.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The company estimates that this procedure costs about $3500 \u2014 a cost which obviously would rise if the procedure has to be repeated in order to maintain efficacy as suggested in the story. But we wish the story had more explicitly addressed this:\u00a0 costs that could reach $14,000 a year if effects wear off within 3 months.\u00a0 It also would have been interesting to see some comparison of\u00a0this cost with that of drug therapy and/or psychological counseling.", "answer": 0}, {"article": "All patients were also given physiotherapy, and had their motor skills tested at the start of the trial and on day 90.\nThe cost of caring for its victims, who often have motor function difficulties like paralysis or weakness on one side, puts a heavy burden on already stretched healthcare systems.\nHemiplegia \u2014 paralysis to one side of the body \u2014 and hemiparesis \u2014 weakness on one side of the body \u2014 are the most common disabilities after stroke and scientists believe SSRIs might help improve movement by increasing the level of the brain chemical serotonin in the central nervous system.\nSignificantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\nIn the largest study yet of the effect of this type of antidepressant on stroke recovery, French researchers found that stroke patients given Prozac improved their scores in motor skills tests more than those given a placebo, or dummy pill.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It mentions that the drug is available generically and is generally inexpensive. It also discusses the economic impact of stroke, teeing up the potential downstream cost savings, in terms of disability care avoided, if the benefit of\u00a0fluoxetine in this setting proves to durable.", "answer": 1}, {"article": "(Forget to weigh in or track your meals?\nA recent pilot study with Utah-based Intermountain Healthcare that included about 200 people, all of whom were at high risk of Type 2 diabetes, found that 75 percent of the participants completed the Omada program and lost at least 5 percent of their body weight.\n\"The data really does confirm that when you give people tools and help, instead of just preaching to them, it really does help.\"\nAdditionally, traditional players in the weight loss space, such as Weight Watchers, now offer some similar incentives, such as personal coaching.\nSince last May, he has lost about 50 pounds (52, to be exact, but it fluctuates a bit) and his blood sugar has returned to the normal range.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost in an article about a technology-based treatment program for improving diet and exercise. Readers learn that one person received a body weight scale when he signed onto the program, which raises a big question \u2014 how much does this program cost? What happens cost-wise if you don\u2019t succeed? The program includes personal coaching as well. We always want health stories to mention costs, and for this story on a new, relatively untested weight loss plan, cost seems especially important.\nThe company\u2019s website doesn\u2019t make this information easy to learn either, but does mention that the cost might be covered by health insurance.", "answer": 0}, {"article": "Scientists at a growing number of research centers are pinning their hopes that these images will help them unlock some of the secrets of everything from what causes childhood disorders like Attention Deficit Hyperactivity Disorder to how neurons in the brain process vision and memory.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\nBrain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. It would have been worth mentioning in the story that the out-of-pocket cost of a brain MRI ranges from $1,000 to several thousand dollars depending on the type of test and where it is done. However, most insurance policies do cover some or all of the cost of imaging tests if they\u2019re considered medically necessary.", "answer": 0}, {"article": "Health officials in Norway recommend that pregnant women (and women who are trying to get pregnant) take 400 micrograms of folic acid per day.\nAfter the researchers controlled for factors like these, they calculated that taking the supplements was associated with a 39% lower risk of having a child with autistic disorder.\nAs a result, a cup of enriched white long-grain rice now contains 797 micrograms of folic acid, for example, and a cup of Cheerios has 493 mcg, according to this report from the Harvard Women\u2019s Health Watch.\nThe study also looked at folic acid use later in pregnancy but found no correlation between that and the chances of a child developing an autism spectrum disorder.\nOn the other hand, pregnant women here are also far more likely to consume a healthy amount of the B vitamin because the Food and Drug Administration has required manufacturers of enriched breads, cereals and other grains to fortify them with folic acid since 1998.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs, but since folic acid supplement pills cost only a few cents each, the omission is not important.", "answer": 2}, {"article": "For more information about Wolters Kluwer's solutions and organization, visit http://www.\nJanuary 2, 2018 - In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n\"It seems that migraine surgery patients can recover function and ability to cope with pain very well after surgery, in stark contrast to what has been shown in other pain conditions,\" Dr. Austen and coauthors write.\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\n\"Pain questionnaires used in the evaluation of better-understood and more common pain syndromes have not been applied to migraine surgery,\" Dr. Austen and coauthors write.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not include the cost of this migraine surgery \u2014 nor did it really say what a migraine surgery entails, except for briefly comparing it to a cosmetic forehead-lift. According to the website linked in the news release, a cosmetic forehead-lift (also called a \u201cbrow lift) costs an average of $3,403. However, a look at anecdotal articles online reveals that the cost can often be much more if not covered by insurance \u2014 up to $30,000 in some cases.", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The column includes a cost estimate for the products mentioned.\u00a0 This column is consistently good about including cost information.", "answer": 1}, {"article": "People who were taking medication for OCD continued to do so for the trial.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nThe procedure is noninvasive and doesn't require anesthesia, and the pulses are delivered via an electromagnetic device or coil that is placed or worn on the head.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe FDA first approved TMS devices for major depression in 2008, and in 2013 they were approved to treat pain associated with some types of migraine headaches.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not say how much this treatment cost nor whether insurance covers the costs. Some estimates of TMS put the cost of four to six week courses of five-day-a-week, 20-minute treatments at between $5,000 to $15,000 and up.", "answer": 0}, {"article": "\u201cThe goal is to develop a blood test, such as this one, that can accurately identify cancers in their earliest stages.\u201d\n\nKlein added: \u201cIt is several steps away and more research is needed, but it could be given to healthy adults of a certain age, such as those over 40, to see if they have early signs of cancer.\u201d\nThe test had particularly good results for ovarian and pancreatic cancers, though the number of cancers detected was small.\nThe test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\n\u201cNow, as the NHS marks its 70th anniversary, we stand on the cusp of a new era of personalised medicine that will dramatically transform care for cancer and for inherited and rare diseases,\u201d said Stevens.\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned.\nAs we\u2019ve reported in the past, one company has marketed their similar test with a $1,000 price point.", "answer": 0}, {"article": "Psychological factors or lifestyle factors may play a role, he said.\n\"The question was to see if more weight loss could be achieved if we provided decent quality lifestyle intervention, mostly dietary counseling, along with this medication,\" said study lead author Dr. Kishore Gadde, director of the Obesity Clinical Trials Program at Duke University Medical Center in Durham, N.C.\n\n\"And the answer was yes,\" Gadde said.\n\"But for about a third [of patients], biological issues are at play, such as not easily experiencing satiety signals from the gut to the brain, which senses what your energy intake has been,\" he said.\nMONDAY, Oct. 15, 2012 (HealthDay News) -- A prescription medication originally developed to treat epilepsy may help obese adults shed weight when combined with routine nutritional counseling, researchers say.\nAlthough nearly 55 percent of those on the higher-dose medication shed 5 percent or more of their pre-study weight, that figure was 34 percent among the lower-dose group and 31 percent among the non-medication participants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Zonisimide\u2019s cost is known. It is already being used as an antiseizure medication. The story could have discussed its cost in that setting. Instead, this is one of the 70% of stories we review that include only claims (\u201cshows promise\u201d in this case) but nothing about what the promise costs.", "answer": 0}, {"article": "Plum said that Epigenomics did not see its test as being necessarily in competition with the Exact Sciences test, because the blood-based test would be good alternative for people put off by stool testing.\nThere\u2019s a lot of hope for getting a stool-based test.\u201d\n\nPromising results for the blood-based tests were reported this week at a meeting in Barcelona, Spain.\n\u201cWith stool tests, you need a 90 percent specificity,\u201d said Dr. Bert Vogelstein, a cancer expert at Johns Hopkins University who is also an adviser to the company.\n\u201cIf widely used, and regularly, this test really does have the opportunity to eliminate colon cancer,\u201d said Dr. David A. Ahlquist, a colon cancer expert at the Mayo Clinic and an adviser to Exact Sciences.\nThe company reported Thursday at a meeting of the American Association for Cancer Research that in a trial of 1,100 patients, the test had detected 64 percent of adenomas, or polyps, larger than one centimeter in diameter, and 85 percent of cancers, as judged by the colonoscopies also given to the patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says, \u201cBoth tests would be less expensive than colonoscopy, and potentially more effective.\u201d\u00a0 No specific cost estimate is given.\u00a0 The Philadelphia Inquirer said \u201cThough the cost has not been set, it could be as low as $300 per test.\u201d Reuters reported that the company said earlier that it would aim for $300-400 per test.\nThe story also states that \u201cCompliance with colonoscopy is low, since people don\u2019t want to have one, and the overall cost per detection is high\u201d \u2013 implying that the new test might be more cost-effective.\u00a0 But it\u2019s unclear at this point if that would be true. For example,\u00a0previous stool DNA tests have performed much worse (higher costs, lower efficacy) than colonoscopy in modeling studies.", "answer": 0}, {"article": "\"If your goal is a 30-year knee, you need to avoid high-impact sports,\" says John Wright, an orthopedic surgeon at Brigham and Women's Hospital in Boston.\n\"I know that the technology is capable of this level of athletic function.\nAnd staying as fit and strong as possible is also critical to joint preservation.\nEven the most fit patients face a long period of rehabilitation after surgery and may not be able to resume high-impact activities.\nJoint-replacement patients these days are younger and more active than ever before.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story specified the costs of both primary and revision knee replacement operations.\n\n \n", "answer": 1}, {"article": "\u2022 Online Press registration process: The online registration deadline has expired, we still accept advance registrations though, but the process is slightly different.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\nIndeed, most physical activity guidelines are the same for the middle-aged adults as for the elderly, even though it is estimated that over 60% of the elderly are unable to achieve this same level of exercise.\n\u2022 Credential: either your ID press card or letter of assignment with proof of 3 published articles\n\u2022 Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives\n\u2022 The decision of the ESC Press Office is final regarding all press registration requests.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is always a concern. But in this case, the release mentions \u201cbrisk walking, cycling, swimming or gymnastics\u201d as physical activities, not some fancy exercise devices. So we\u2019ll rate it Not Applicable, although we\u2019d note that some of these activities might not be accessible without a gym membership or other equipment.", "answer": 2}, {"article": "Pancreatic cancer is currently very difficult to detect while it is still resectable.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned.\nAlthough the blood test is experimental, researchers would likely be able to provide a rough estimate of what such a 29-biomarker assay might cost.", "answer": 0}, {"article": "Seven randomized trials with zinc acetate and zinc gluconate lozenges found that the duration of colds was shortened on average by 33%.\nZinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nThe 12% difference between the average effects of the two kinds of lozenges was explained purely by random variation.\nPreviously zinc lozenges containing citric acid were shown to be ineffective in treating colds because citric acid binds zinc ions very tightly and no free zinc is released.\nZinc gluconate is another salt that has been frequently used in zinc lozenges.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made in the release about how much zinc lozenges cost. Zinc supplements can be purchased at pharmacies\u00a0and most supermarkets\u00a0for less than $10.", "answer": 0}, {"article": "For more information, visit http://www.\nEditor's Note: The study authors' and editorial commentary authors' affiliations, acknowledgments, and disclosures of financial support and potential conflicts of interests are available in the study and the commentary, which are embargoed until 12:01 a.m. EST on Thursday, Feb. 4.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nFor an embargoed copy of the study and the commentary, please contact Emily Zaideman (312-558-1770, ezaideman@pcipr.com).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release focuses primarily on using the antiviral drug oseltamivir to treat pregnant flu patients who have been hospitalized. A course of oseltamivir often costs more than $100. For patients with limited resources, or without good insurance coverage, cost could be a factor. And because the drug is on the market, the release could have addressed this with a sentence or two. The release also discusses the importance of vaccination, without addressing cost.", "answer": 0}, {"article": "The study was presented Monday at the annual meeting of the American Society of Hematology in Atlanta.\nOn the other hand, people whose physical activity level had declined after their diagnosis had higher death rates from lymphoma and other causes than those who had not changed their level of physical activity.\n\"Our findings show that physical activity can have a positive impact on survival in lymphoma patients,\" she said in a Mayo news release.\n\"As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients,\" said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic.\nResearch presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is really not applicable here. The story (and the relevant research) focuses on general levels of physical activity, not specific forms of physical activity.", "answer": 2}, {"article": "Among those who are screened, colonoscopy is by far the most popular method in the U.S.\nAnd the drawbacks of colonoscopy \u2014 including the time commitment, not-so-fun preparation, expense and small chance of harm \u2014 are probably keeping some people from participating in colorectal cancer screening.\nOf the two, Richard Wender, a physician and chief cancer control officer of the American Cancer Society, said the FIT is preferable, both because it\u2019s more accurate and because it requires only one poop sample and no changes in diet.\nBecause although colonoscopy certainly has its advantages, direct evidence that it\u2019s the best way to prevent deaths from colorectal cancer is not one of them.\nThe United States Preventive Services Task Force says the net benefit for screening adults age 50-75 is \u201csubstantial,\u201d adding that colorectal cancer is the second-leading cause of cancer death in the country.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give this story a Satisfactory rating in this category since it does mention the $1,000 cost of a colonoscopy and that one of the two at-home screening tests costs about $25.\u00a0 But readers would benefit more by knowing the average costs of the two alternatives, rather than just the cost of one.", "answer": 1}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs for HSCT was not mentioned.", "answer": 0}, {"article": "They think I am crazy, even a [Defeat Autism Now doctor] we once saw,\" said a message posted by a parent on the AutismWeb.com bulletin board in March\n\nParents \"research anything they can get their hands on and there are so many things saying 'Try this or try that' that aren't necessarily safe.\nThe 106-year-old Children's Institute (formerly called the Rehabilitation Institute) plans to fund the room through the $30 million capital campaign it launched in 2005, after buying out its Shady Avenue site from the University of Pittsburgh Medical Center.\n\"We know that the data for this is just emerging, but we feel it's a very safe intervention, and it's empowering for families and very reasonable,\" he said.\nHis findings are complicated, but basically blood tests show 70 percent of his autistic patients have zinc deficiencies (pointing to problems with processing heavy metals), and the vast majority also have immune system problems of varying kinds.\nBut we wonder -- we speculate -- that it's possible if we have children living in a unique environment that has not [previously] been created scientifically that we can make a difference.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article does report costs estimated\u00a0to design the clean room, $500,000, and that a minimum of $1 million dollars annually will be needed to support operating expenses.\u00a0 Cost of the experimental approach were not reported and may not be available at this time because the project is still in the planning stage; however, it is estimated the operational costs will support the experimental approach for only\u00a0four to six experimental subjects per year.\u00a0 ", "answer": 1}, {"article": "WHAT'S NEXT: Researchers said they want to see whether moderate drinking also benefits women with hypertension.\nThe researchers found that people who drank moderate amounts of beer, wine, or liquor had fewer heart attacks, though their risk of death was not significantly different from that of the other subjects in the study.\nCAUTIONS: The study included only male healthcare providers, so it might not be generalizable to a broader population.\nBefore the test, one group was exposed to a negative stereotype: They were told that women do not perform well at spatial reasoning.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of having one or two drinks a day, but most people know what the tab can be.\u00a0 So we consider this criterion not applicable for this story. ", "answer": 2}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are bergamot supplements on the market, but the price was not discussed. The cost of statins is also excluded.", "answer": 0}, {"article": "In its marketing campaign, Cyberonics notes that VNS treatment does not cause the weight gain associated with antidepressants and the confusion and memory loss common after electroconvulsive therapy (ECT), psychiatry's term for shock treatments.\nThe generator emits regular pulses of electricity that are supposed to stimulate serotonin and other brain chemicals believed to regulate mood, according to Cyberonics.\nLast July, a top FDA official, citing the lack of alternatives for severely depressed patients, overruled unanimous opposition by 20 members of his staff and approved the device as a depression treatment for adults who had failed four other treatments.\n\"And we have as much evidence that this works for pancreatic cancer as it does for depression.\nThe electrodes in her neck must remain forever; doctors tell VNS patients that removing them is too risky because tissue grows around them As a result, VNS recipients cannot undergo a full body MRI or therapeutic ultrasound.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains the cost of the device and of the implantation procedure. It also explains that some insurers are reluctant to reimburse for this technology. ", "answer": 1}, {"article": "The Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nHowever, over time, the tumor cells develop additional mutations, enabling them to grow again, even in the presence of the drugs Iressa or Tarceva.\nThe scientists say non-small cell lung cancers that had become invulnerable to the chemotherapy drugs Iressa and Tarceva were stymied in a study by a compound designed and formulated in the Dana-Farber laboratory.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are discussed. But we can understand that since the story is based on an early phase of research \u2013 so early that the question might be about its newsworthiness. ", "answer": 2}, {"article": "Another existing set of guidelines doesn\u2019t call for screening in any children.\nYet among the kids without heart disease in their family, the percentage of children who might benefit from treatment was closer to two percent than to one, meaning that family history didn\u2019t seem to make a difference.\nBut a third of those children didn\u2019t have relatives with heart disease or high cholesterol, and so wouldn\u2019t have been screened under the current guidelines, issued by the government\u2019s National Cholesterol Education Program.\nFor example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story says universal screening would be expensive, but it does not provide any dollar amounts. Cost is clearly relevant to the story. The researchers blame the lack of health care insurance for the high proportion of parents and grandparents of these children who have never had a cholesterol test. The story does not address the issue of how families would pay for ongoing treatment if doctors prescribed it.", "answer": 0}, {"article": "Jaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nNewswise \u2014 DURHAM, N.C. -- Patients suffering from noninfectious uveitis, a group of diseases that causes eye inflammation, can get effective treatment from a corticosteroid alternative that has previously been approved for treatment of arthritis and Crohn\u2019s disease, according to a study led by a Duke Health researcher.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\nThe studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n\nThe study consisted of 217 adults who had active, non-infectious intermediate or posterior uveitis, or panuveitis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No dollar signs here, which \u2014 as we discovered \u2014 is quite an oversight, given the steep costs of adalimumab.\nPrednisone costs about $0.33 per mg, and chronic uveitis patients take anywhere from 10 mg to 60 mg per day. Looking at the minimum number (which patients are usually tapered to 6 months into their treatment), that\u2019s a cost of more than $1,190 a year.\nIn comparison, the name-brand of adalimumab, Humira, costs about $54.49 per mg. In the study, patients received adalimumab on a bi-weekly basis, receiving some 1,640 mg of the drug over 80 weeks if they didn\u2019t drop out. That adds up to a total of $89,400 \u2014 an average of $58,000 per year or $1,120 per week.", "answer": 0}, {"article": "Those drugs could not be used, however, until they received emergency use authorizations from the F.D.A.\nThe government is paying an average of only $450 a course for those other drugs \u2014 only one-fifth of what it is paying for peramivir.\nFor each patient, doctors must call an 800 number or fill out a form on a Web site run by the Centers for Disease Control and Prevention.\nThe question for both investors and federal authorities is how much more of the drug BioCryst can sell.\nWhile some clinical trials showed the drug had an effect in resolving flu symptoms, others did not show statistically significant differences between peramivir and either a placebo or Tamiflu.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story says the federal government is paying about $2,250 per patient for a standard 5-day treatment course. It also notes that the approved alternative treatments are less expensive.", "answer": 1}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n\u201cIron is essential for the development of the central nervous system,\u201d said Parul Christian, an expert in international health at the Johns Hopkins University Bloomberg School of Public Health, whose study appears in the Journal of the American Medical Association.\nCHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. This is a problem because even if the individual doses of iron and folic acid are relatively cheap, their application on a large population, including staff time, monitoring and the attendant paperwork, would no doubt become costly quickly. We\u2019re talking about a study of 676 kids, but there are billions of children worldwide who could benefit from this type of intervention. Some nod to costs should have been made here.", "answer": 0}, {"article": "The research is so early that the drug hasn't been named.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nThe current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nCure rates are lower for people with HCV genotype 1, which includes about 70% of Americans chronically infected with hepatitis C virus; and they are lower still for people who do not respond well to initial treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "SInce the test drug is in the very early stages of development, this criterion is technically not applicable.\u00a0However, the present treatment regimen of an interferon and ribavirin costs thousands of dollars monthly for 6-12 months and it is likely that any newer antivirals will be additive and not replacements.\u00a0A comment on the potential for significant additional costs would have been desirable.\u00a0", "answer": 2}, {"article": "In response to such concerns, researchers revised their consent forms \u2014 the documents that explain a study's risks and benefits to patients \u2014 which had failed to mention the risk of death in chelation therapy.\nThe study was temporarily halted in 2008 because of concerns over ethics and patient safety.\n\"This study has the potential to be extremely dangerous,\" Nissen says.\nFurther analysis showed the benefits were limited to those with diabetes, rather than for patients overall.\nChelation \"should not be administered to any patients for the indication of heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that chelation therapy costs about $5000 out of pocket.", "answer": 1}, {"article": "In an earlier pilot study supported by Life Extension, Drs.\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\nThe team of researchers, led by Dr. Rafael de la Torre, program director of IMIM Hospital del Mar Medical Research Institute and study co-principal investigator, and Dr. Mara Dierssen, group leader at Center for Genomic Regulation, Barcelona, Spain, and study co-principal investigator, proposed that EGCG might have conferred these benefits by inhibiting an enzyme called DYRK1A, which has been implicated in Down syndrome and neurodegenerative conditions including Alzheimer disease.\nThe level of DYRK1A-positive cells is elevated in certain regions of Alzheimer disease patients' brains, and is roughly 20-fold higher in the frontal cortex, compared to normal brains.\nIn acknowledging the novelty of their findings and calling for more research, the Spanish research team noted that \"\u2026this study is the first well-powered trial that shows improvement in adaptive behavior (functional academics) and brain-related changes in young adults with Down's syndrome.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention the cost of the green tree extract used in the study. By going to the manufacturer\u2019s website we found that a bottle of Life Extension Decaffeinated Mega Green Tea Extract with 100 capsules \u2014 about a month\u2019s supply \u2013 is priced at $22.50.", "answer": 0}, {"article": "Researchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\n\"But if my body could be trained to recognize wandering cancers, that might be a cure.\"\nThe cancer, glioblastoma, typically kills within that time.\nSuch research already is under way \u2014 a potential antidote for people whose genetics seemingly fate them for cancer.\n\"The field is promising, but there's always danger in making claims before the real data's in.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs, which are likely to be very high.", "answer": 0}, {"article": "After taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nResearchers then analyzed health status information collected after the women turned 70.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\nA new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of alcohol is not in question.", "answer": 2}, {"article": "Related: Obesity Crisis: Two Billion People Now Overweight and U.S. is One of the Fattest Nations on Earth\n\nAnother benefit from intermittent dieting?\n\"I was really impressed that they still saw almost a two kilogram weight loss during that last period at the end of the four months,\" she tells Newsweek.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nFor those who just can\u2019t give up grains (or regular eating), a new study indicates that being less restrictive is actually better for your waistline.\nPaleo has a devout following who swear by its protein-heavy meals, while intermittent fasters believe that forgoing food for hours on end (which varies, but can include skipping meals for an entire day), provides the best results.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information was included about the nature of the two diets involved in the study or their costs. Readers might want to know if pre-packaged meals were involved, or liquid meals, for example.\nAs we found after reading the study, the food intake of the dieters was highly controlled, and this would presumably cost money to mimic in real life:\n\u201cMeals were prepared by a commercial kitchen under the direction of a dietician and delivered to the participants homes each week.\u201d", "answer": 0}, {"article": "\"They attached, but they were not getting enough food.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\nThe results are published in the current issue of Fertility & Sterility, the international journal of the American Society for Reproductive Medicine.\n\"In this subset of women experiencing multiple early miscarriages, we assume that their embryos were literally starving to death,\" Kliman added.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs.\nCost for generic progesterone range from about $20 to $30 for 30 \u2013 100mg capsules, according to GoodRx\u2019s drug prices tracker.", "answer": 0}, {"article": "The NYU Langone researchers believe that obesity may contribute to the risk for development of psoriasis and psoriatic arthritis through fat tissue-driven systemic inflammation.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\nResults were even more pronounced in those with severe disease activity, with scores falling from 7.7 before surgery to 5.7 after for patients with severe psoriasis, and from 8.2 to 4.8 after surgery for patients with severe psoriatic arthritis.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\n\"These findings can be used to identify people who may benefit most from this type of intervention.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release contained no cost information related to bariatric surgery and its potential complications. Bariatric surgery has become commonplace but it is costly and carries risk. The release should have also mentioned the theoretical costs related to better symptom control for psoriasis sufferers who have undergone bariatric surgery. These could include a possible reduction in costs of anti-inflammatory drugs or other therapies.", "answer": 0}, {"article": "This study was presented at a medical conference.\n\"A key question now is to work out which patients will benefit from the drug -- clearly, some patients do and some don't,\" Johann de Bono, MD, PhD, of the U.K.'s Royal Marsden NHS Foundation Trust, says in a news release.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nOct. 12, 2010 -- Even when medical or surgical castration fails, a potent drug extends survival by four months in patients with metastatic prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs.\u00a0 The competing Wall Street Journal story, by comparison, reported:\u00a0\"Cost could be a factor. The three-treatment Provenge regimen has been controversial partly because of the $93,000 cost. Dendreon has said treatment costs are comparable with chemotherapy if total costs of care are taken into account.\"", "answer": 0}, {"article": "Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.\n\"In clinical trials, TrueTear\u2122 demonstrated increased tear production upon stimulation of the nasal cavity,\" said John Sheppard, M.D., M.M.\nFor the full Directions for Use, please call 1-800-678-1605.\n\"Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years.\nThe direct clinical benefit of temporarily increasing tear production as a therapy for patients with dry eye disease was not assessed as part of these clinical trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though this tear stimulator has been approved for sale, no price is mentioned in the release. After an internet search on costs we came up empty-handed. A specialized device like this is expected to cost a few to several hundred dollars. Will it be covered by insurance plans? The release doesn\u2019t say.", "answer": 0}, {"article": "Professor Bartlett said researchers are constantly looking at new treatment strategies for alcohol abuse and addiction, which is characterised by extended periods of heavy alcohol use, binges and abstinence, and anxiety and depression which contribute to relapse.\n\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\nThe study by Professor Bartlett, Dr Belmer, Dr Patkar and Dr Vanessa Lanoue (Queensland Brain Institute) can be accessed here.\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention within the release as to the cost of this drug, although it is readily available in both China and Japan. Readers have no indication whether the drug is cheap or expensive, an important factor when evaluating its usefulness among those battling binge drinking and alcoholism.", "answer": 0}, {"article": "U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual \"America's Best Hospitals\" survey.\nThe former indication is potentially useful for using IsoPSA for screening by primary care physicians, while the second is helpful for urologists in identifying patients who would benefit from curative intent therapy and other applications.\nBy identifying molecular changes in the prostate specific antigen (PSA) protein, the findings, published online last month by European Urology, suggest that once validated, use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer.\n\"Due to its inherent simplicity, requiring only a blood draw and presenting information to the physician in familiar context using a single number - just like PSA itself - we are quite hopeful in IsoPSA's future utility after further validation studies,\" said Mark Stovsky, M.D., co-author and staff member, Cleveland Clinic Glickman Urological & Kidney Institute.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in this news release \u2014 neither the cost of the test or the potential savings if it decreases false positive results which lead to further testing or treatment.\nA regular PSA test is typically covered by insurance, especially for men over the age of 50. According to Healthcare Bluebook, a PSA test should cost around $48 for patients without insurance, but prices may vary depending on location. This price also does not include the office visit.\nWe feel the news release should give consumers a ballpark estimate of costs, even if it is a new test. Therefore, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\n\u201cCooking the carbohydrate starch alters the chemical bonds in the food,\u201d Arciero explains.\nProducts made from these foods, including bean flour, potato starch, tapioca starch and brown rice flour, also count.\n\u201cThe ensuing structure of those bonds during the cooling process is what makes them resistant to then being digested in the small intestine,\u201d Arciero says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story is dealing with low-cost, widely available foods, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "Boutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\nConsuming enriched pasta, dark bread and cold cereal were especially associated with lower risk, while they observed no similar relation to eating animal sources of protein.\nThey observed that women consuming approximately 6.5 percent of their daily calories as vegetable protein had a significant 16 percent lower risk of early menopause compared to women whose intake was approximately 4 percent of calories.\nEarly menopause, the cessation of ovarian function before age 45, affects about 10 percent of women and is associated with higher risk of cardiovascular disease, osteoporosis and early cognitive decline, the authors note.\nFew studies have evaluated how protein intake is associated with menopause timing, they add, and to their knowledge this is the first to look specifically at early menopause.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Replacing animal products with plant foods wouldn\u2019t significantly raise a person\u2019s food budget and might actually save money.", "answer": 2}, {"article": "That's a potentially life-saving development.\n\u201cAnd the patch may be a way of doing this that is safer.\u201d\n\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said.\nWith this you just slap a little patch on their backs.\u201d\n\nAlthough some volunteers experienced redness and itchiness at the site of the patch, there were no serious side effects.\n\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no effort to describe the likely cost of this \u201cpeanut patch\u201d intervention. Even if a precise number can\u2019t be provided, are we talking tens, hundreds, or thousands of dollars for treatment? Some estimate should be possible at this stage of development.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Women who take bone drugs for several years have a slightly increased chance of suffering an unusual type of thigh fracture, according to a large Canadian study.\n\u201cThe bad news is that overstating the levels of risk of side effects with these drugs \u2014 which the media have been doing for some time now \u2014 has led people to stop the drugs when they should be taking them,\u201d said Dr. Ethel S. Siris, who heads the Toni Stabile Osteoporosis Center at Columbia University in New York.\nApart from atypical fractures, the most serious side effect of the bone drugs is bone death, or osteonecrosis, of the jaw.\nBut that\u2019s a very rare problem, experts say, which only affects about one in 100,000 people on bisphosphonates.\nAnd one preliminary study, published along with the Canadian findings in JAMA, hints that the common heart medication nitroglycerin might also boost bone health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of a year\u2019s treatment should have been included. The story only says the drug are \u201ccheap.\u201d\u00a0 Cheap to one woman may be a financial burden to another.", "answer": 0}, {"article": "\"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human,\" said Dr. Joseph Murray, a professor of medicine in the division of gastroenterology and the department of immunology at the Mayo Clinic, in Rochester, Minn. \"Let's see how it goes with a whole slice of bread.\"\nThey say these are less likely to trigger the autoimmune response that can create a wide range of painful and irritating symptoms.\nThe next step is to show that the enzyme is not toxic and functions as designed in animals.\nSome are very sensitive, and in some it just upsets their stomach a little,\" Siegel said.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this not applicable since the concept is obviously still in the very early stages of development.", "answer": 2}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of nitrous oxide for use during labor in one facility ($250) is included. It\u2019s also mentioned that most insurance plans won\u2019t cover it.\nA bonus that may have been appreciated by readers would have been comparing its price to the two most common approaches for managing labor pain (in the US): epidurals and IV narcotics.", "answer": 1}, {"article": "Hendricks says psychedelics can possibly help patients shift their priorities, or lead to drastic changes in perspective or even spiritual experiences that will help them improve their mental states.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\nThe results showed that those who had taken these substances in their lifetime had a 19% less likelihood of exhibiting psychological distress in the past month, and their reports of suicidal thoughts in the past year were likely to be 14% lower.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nAdditionally, the effects of psychedelics on the developing brain are still largely unknown, meaning they could pose a threat to people with a predisposition to schizophrenia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were cited, perhaps because the drugs are not legally available in the United States. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The agency, he added, remains concerned about \u201cthe proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims.\u201d\n\nIn April, an advisory committee unanimously recommended approval of the drug for the two types of epilepsy.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nThe FDA previously cleared medications containing synthetic versions of THC for nausea for patients getting chemotherapy and for other uses, but it had not approved any drug derived from the plant itself.\nMany parents already are giving children unregulated CBD formulations that are available in medical marijuana dispensaries in the many states where such operations are legal.\nGottlieb noted that the action was \u201cnot an approval of marijuana or all of its components\u201d but rather of one specific CBD medication for a particular use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Some reports suggest the cost of Epidolex will be high and insurance coverage is unclear. The article should have addressed these issues.", "answer": 0}, {"article": "ISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\n\u201cWe worried a lot that chemotherapy could be immunosuppressive,\u201d Wolchok said, noting that that might explain why the average survival benefit was two months instead of four.\n\u201cThis is really unprecedented time to have two new approaches to treat advanced melanoma,\u201d said Dr. Lynn Schuchter of the University of Pennsylvania in Philadelphia, a melanoma expert who moderated a panel discussion of the drugs.\nAbout 18 percent of patients developed a low-grade skin cancer.\n\u201cEven if it diminishes over time, who cares?\u201d\n\n\u201cNearly half of patients treated with the Roche drug had tumor shrinkage, compared with 5.5 percent with chemotherapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2013 only of potential sales volume.\nIsn\u2019t the significant cost of both drugs worth at least one line a story like this?", "answer": 0}, {"article": "Cancer is the No.\n\u201dThe survival difference between late stage and early stage disease in these cancers would account for more than a million lives each year worldwide,\u201d Velculescu said.\nThe first goal would be to try it in people at high risk of cancer but no symptoms yet \u2013 such as smokers, or people with cancer-causing gene mutations like BRCA mutations, Velculescu said.\n\"You don\u2019t want to go screening people for hallmark (cancer) mutations unless you absolutely know that when you find it, that there is a tumor there and that it is a tumor that needs to be treated,\" said Wyndham, who was not involved in the study.\nIt was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story gets a satisfactory in this category by including, \u201cThe genetic sequencing is also expensive right now \u2013 on the order of several thousand dollars for the 30,000 repeats the team did. But costs are coming down steadily, he said.\u201d", "answer": 1}, {"article": "His team\u2019s new approach aims to change that with a simple and inexpensive at-home test option.\nSeveral other home-based tests are already on the market, but Boston researchers say their version can analyze additional aspects of the sample, checking how well the sperm move (known as motility) as well as their concentration.\nAs things stand now, men have to provide samples \u201cin these specific rooms in hospitals under so much stress and embarrassment,\u201d the study\u2019s principal investigator, Hadi Shafiee, PhD, told CBS News.\nIn addition, the developers say it could also potentially be used by men who have had a vasectomy to monitor their progress at home following surgery.\nThat\u2019s the question researchers at Brigham and Women\u2019s Hospital and Massachusetts General Hospital tried to answer when they went about developing a smartphone-based test that men could use to test their semen in the comfort of their homes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Only part of the prototype\u2019s projected cost is discussed: $5 for a microchip device. While this sounds good, the cost of the \u201ctiny weight scale\u201d isn\u2019t mentioned, nor is the \u201coptical attachment\u201d that could be 3D-printed. However, a consumer 3D printer can cost $1,000 or more, not including supplies.\nReaders also are\u00a0told male fertility screening is costly, but we\u2019re never told what the cost is.", "answer": 0}, {"article": "TUESDAY, Dec. 27, 2011 (HealthDay News) -- A new test measuring levels of troponin I in the blood may help determine whether someone is really having a heart attack earlier than is currently possible.\nThe new study looked at a highly sensitive type of troponin I test that may be more accurate in less time.\nThis means that if a test result is negative, the person is not having a heart attack.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\nThe findings appear in the Dec. 28 issue of the Journal of the American Medical Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost \u2013 not of the new troponin I test nor of any existing test.", "answer": 0}, {"article": "Or are these symptoms merely the consequence of the violence of the shock, of which will ultimately only leave a bump behind?\n\"We wondered if it was possible to isolate certain proteins whose presence in the blood increases in the event of mild traumatic brain injury,\u00bb explains Jean-Charles Sanchez, professor at the Department of Internal Medicine of Specialties and the Biomarkers Centre of the Faculty of Medicine of the UNIGE.\nToday, the only reliable diagnosis is the CT Scan, which is only available in some hospitals and, in addition to being expensive, exposes patients to radiations.\nResearchers from the University of Geneva (UNIGE), in collaboration with the Hospitals of Barcelona, Madrid and Seville, have developed a small device - Point-of-Care Test (POCT) - that analyses the level of proteins in the blood and allows, using a single drop of blood, to diagnose the possibility of a mild traumatic brain injury.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of this device isn\u2019t discussed, despite plans to put it on the market. The release noted that the standard way of diagnosing brain injuries are through CT scans. These tests run more than $1,000 a pop, at least in the U.S. The release might have noted how much this test would cost in comparison. Further, if the outcomes of the test are not improved US insurance companies are unlikely to pay for it.", "answer": 0}, {"article": "\"Adolescence is the key time for bone growth.\nAdolescence is the key period for bone development, and poor development at this stage is linked to reduced peak bone mass (the amount of bone mass at the end of the skeletal maturation, around age 30), increased fracture risk and osteoporosis later in life.\n\"Although we didn't study other sports, it's reasonable to suppose that weight-bearing, high-impact, high-intensity exercise like tennis, badminton, basketball and handball will have similar effects to football.\"\nThough swimming and cycling have proven health benefits, the scientists said their study \"raises a question\" about whether they are good for bone development due to the non-weight bearing training - and they say young swimmers and cyclists could benefit from more weight-bearing exercise in training regimes.\nDr Gracia-Marco said: \"The sports we studied are the three most popular in the UK, and it's important to know what effects they have in relation to bone health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no discussion of costs. While a soccer ball isn\u2019t terribly expensive, the boys involved in this study weren\u2019t casually kicking the football around the back yard or the neighborhood soccer pitch; they were \u201caspiring professionals who played as much as nine hours a week,\u201d according to the study\u2019s lead author. That level of training almost guarantees that the boys were participating in traveling soccer teams, and while the costs might be lower in the United Kingdom, where the study was conducted, in the United States, playing on a traveling soccer team is far from cheap. A September 2015 USA Money article described a California family who spent $17,500 annually for their four boys to play competitive soccer, including club fees of $675 per month, $1,500 per year for a private coach, more than $1,000 for cleats and other gear, $100 participation fees per child per tournament, along with the costs of tournament travel. Those costs, of course, might well be higher than average, but the bottom line is that the news release provides no information about the likely cost of having a child playing competitive soccer/football.", "answer": 0}, {"article": "The marketing materials suggested it already had.\n\u201cThe images sort of sell themselves.\u201d\n\nMuch of the criticism focused on the data the task force had used to make its decision, which consisted largely of the results from prospective, randomized clinical trials conducted in the United States.\nDaniel Kopans, a world leader in breast imaging (he wrote the textbook of that name) and a radiologist at MGH, now says that the panel didn\u2019t \u201cunderstand mammography screening.\u201d Furthermore, he adds, the new guidelines had \u201cno biological or scientific reason\u201d behind them.\nEarly data from Rafferty\u2019s trial showed that the same group of women who did benefit from 2-D digital benefited even more dramatically from 3-D. (It\u2019s worth noting that this is not a small group of people.\n\u201cIt\u2019s a step, but it\u2019s a step by a person who has a stride of 7 feet.\u201d \u201cIt\u201d is a 3-D mammography machine, the Selenia Dimensions system, one of which sits in the breast imaging clinic at Massachusetts General Hospital that Rafferty, a radiologist, runs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The piece does state that \u201cthe technology does come with costs, financial and medical\u201d but the financial costs only refer to those incurred by the facility purchasing the equipment.\u00a0 There is no mention of financial costs to the patient who may have a higher co-pay due to the higher cost of 3-D imaging or may have two co-pays because the combo 2-D and 3-D mammograms \u201cconfer the most dramatic jump in benefits.\u201d\u00a0 There is also no mention of whether or not this\u00a0procedure will be covered\u00a0by most health insurance,\u00a0including Medicare.\u00a0 If 3-D imaging is not covered by insurance, the patient will have to cover the\u00a0cost.", "answer": 0}, {"article": "For more information, go to www.bayer.us.\n\"Data show that the use of effective, long-acting birth control methods including intrauterine devices \u2013 or IUDs \u2013 have helped to reduce unintended pregnancies in the United States but we still have a long way to go,\" 2 said Anita L. Nelson, M.D., Professor and Chair, Obstetrics and Gynecology at Western University of Health Sciences, Pomona, Calif. \"Kyleena is highly effective at preventing pregnancy and may be an appropriate choice for women who want a low-dose, non-daily birth control method.\"\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\nThe use of long-acting reversible contraception (LARCs) has increased nearly five-fold in the last decade.3\n\nBecause Kyleena slowly releases levonorgestrel into a woman's uterus, only small amounts of the hormone enter the blood.\n\"With the approval of Kyleena, women have an important new birth control option that provides pregnancy prevention for up to five years,\" said Dario Mirski, M.D., Senior Vice President and Head of Medical Affairs for the Americas, Bayer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed at all. Given that this release was issued by the manufacturer of Kyleena, the oversight is especially odd. If anyone would be able to speak to potential cost, it would be them. The product appears to be similar to another birth control product also marketed by Bayer, called Mirena. It is not easy to find a clear price for Mirena, but a 2014 story on the site ClearHealthCosts says that Mirena costs in the neighborhood of $700 or $800 \u2014 not including any medical fees related to having the device put into place. It is also not clear whether Kyleena may be covered by insurance plans.", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of these two new medications is not addressed. \u00a0Given their possible availability by 2017, the dearth of cost information is a real disservice. Many currently available treatments are very inexpensive, so\u00a0it is important to know\u00a0the costs of the newer medications in order to assess if they are a viable alternative for\u00a0people and\u00a0for health systems.", "answer": 0}, {"article": "Additionally, change in IRLSSGS score was significantly greater for the RLS device (17.22) compared to historic reports for ropinirole versus the placebo (12 versus 8.9 respectively).\nThese results show promise in otherwise healthy individuals for a nonpharmaceutical option that appears to have rather minor, temporary adverse effects for some users,\" said Rob Danoff, DO, an osteopathic family physician and program at Aria Health Care in Philadelphia.\nThe effects included pain (1), pins and needles sensation (2), irritability (3), spasm (1) and warm feet (1).\nClinical Global Impression responses indicated significantly greater improvement with the RLS device (90 percent) compared with ropinirole (63 percent), the current standard dopamine therapy for RLS.\nAccording to the National Institute of Health, RLS may affect as many as 10 percent of the U.S. population, with more than nine million experiencing moderate to severe symptoms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention that this foot wrap sells for $350 per pair. This may be less expensive than the cost of medicines used to treat RLS, something that could have been pointed out as a favorable thing.", "answer": 0}, {"article": "JACC is ranked No.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\n\"This pioneering study represents a very important step in exploring the intersection of child development, cardiovascular health promotion and primordial prevention.\nThere was no difference in score based on parental age, but a higher impact in score was seen for children whose parents were of European origin.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not talk at all about costs, and this three-year intervention including education for 3-5 year-old children sounds as if it could have had substantial cost.", "answer": 0}, {"article": "Please visit http://www.\n\"We put the 2012 UCSF clinical study into the real world and showed it works,\" said lead author Peter Rechmann, DMD, PhD, professor of preventive and restorative dental sciences in the UCSF School of Dentistry.\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nOf the 192 low-risk participants (93 intervention, 99 control), most participants remained low risk, indicating that the assessment correctly identifies who is at risk for caries.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the news release says the research is aimed at lowering costs and reducing the burden for low income patients, we are not given any numbers that describes the value of the intervention.\nThe release only gets as detailed on cost as the excerpts below:\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices. Results appear online Jan. 22, 2018, in Advances in Dental Research.\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe release also doesn\u2019t address the cost of prescription fluoride toothpaste which may actually result in higher costs overall. The number needed to treat was 4, meaning\u00a0that you would have to treat 4 people for one additional person to get benefit. \u00a0This results in the cost of therapy being multiplied by 4 to get the effect found in the study.", "answer": 0}, {"article": "Excellent/Good/Fair/Poor.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nUsing these findings, the researchers then developed an easy-to-calculate risk score for an individual's risk of dying in the next 5 years, based on the most predictive self-reported information, including 13 questions for men and 11 for women.\nThe performance of the score was validated in 35810 participants enrolled at two Scottish centres which were not used to develop the score, and was found to have around 80% accuracy in men and women (table 2).\n\"The Ubble website allows anybody in the UK between forty and seventy years old to calculate their 'Ubble age' and their risk of dying within the next five years compared to the general population, using a simple set of a dozen or so questions,\" says study co-author Professor Erik Ingelsson from Uppsala University, Sweden.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Access to an interactive site for purposes of computing a score predicting one\u2019s risk of dying will be free. However, this should have been stated in the release. We can\u2019t rate the release Satisfactory if there\u2019s no mention of cost at all, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Forteo is covered by Medicare, Miller said.\n\"The bar is high for any preventive treatment -- in the efforts to prevent a fracture that may or may not ever occur, prescribers do not want to prescribe a therapy that causes a new problem.\nTUESDAY, Aug. 16, 2016 (HealthDay News) -- An experimental drug appears to reduce the risk of bone fractures in postmenopausal women with osteoporosis better than a placebo and the currently available drug, a new study finds.\nFor the study, Miller and colleagues randomly assigned nearly 2,500 postmenopausal women with osteoporosis to receive daily injections of abaloparatide, Forteo or a placebo for 18 months.\n\"It shows more bone building and fewer fractures than Forteo, but whether it will replace that drug is still up in the air.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it is not known how much abaloparatide will cost at this stage, the article does discuss\u00a0the cost\u00a0of its would-be competitor, Forteo, which costs about $2,500 a month for those without insurance.", "answer": 1}, {"article": "And on a Tuesday evening earlier this summer, the company partnered with a women\u2019s group to host a conversation about \u201cproactive steps you can take today to reach your future family building goals.\u201d Appetizers, wine, and beer were served \u2014 and, in a gesture to the crowd full of women with pregnancy on their minds, non-alcoholic beverages were on the menu, too.\nBut the report doesn\u2019t explain the prevalence.\nSmith has mostly positive feelings about her Fertilome test.\nWe\u2019re not claiming we\u2019re there,\u201d Beim said.\nThe doctor ordering the test, or a genetic counselor, is supposed to provide that information.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost\u2014since the test is not covered by insurance\u2014gets a prominent spot in this story. Well done.", "answer": 1}, {"article": "I was glad it was done a week before and not the same day as the lumpectomy surgery.\nBecause this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\nNewswise \u2014 Women who need breast surgery to remove an abnormality that cannot be felt, also known as a non-palpable breast lesion, now may benefit from the convenience and comfort provided by an advanced new tissue locating technology offered at Rush University Medical Center.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of new technology is an important consideration in its evaluation by patients and by institutions. The news release neglects to mention that some insurance companies view the Savi Scout device to be experimental despite its FDA approval. In that case, some patients may have to pay out-of-pocket.\nIt\u2019s likely that the real savings comes from reducing the amount of time a woman is in the operating room, leading to decreased down time, but there\u2019s no data on that here either.", "answer": 0}, {"article": "Bauld's research hasn't identified a dependence on nicotine with e-cigarettes in the same way as the addiction resulting from regular cigarettes.\nSince their introduction in 2006, e-cigarettes have become commonplace among smokers trying to kick their habit, with a third of smokers trying to quit in the United Kingdom turning to e-cigarettes to aid them, according to one study .\nThe number of people using a combination of tobacco and e-cigarettes is on the rise, according to Etter, resulting in smokers switching and consuming less tobacco each day.\nBut others in the field of tobacco control disagree, stating that whilst people -- including youth -- may have tried e-cigarettes, the evidence is lacking for their regular use.\n\"E-cigarettes are not the best nicotine delivery devices,\" she says referring to the fact nicotine is not seen to enter the bloodstream as readily when using e-cigarettes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We are disappointed that the story did not give any direct costs for tobacco cigarettes, e-cigarettes, or smoking cessation aids such as nicotine gums and patches.\nThe story does bring cost into the discussion when it quotes a researcher noting that increasing tobacco prices has an effect on consumption. \u201cFor every 10% increase in tax you have 4% reduction in tobacco consumption.\u201d\nBut it would have been easy to attach some real numbers to the claim: A pack per day smoker of tobacco spends roughly $2,500 per year, according to a reference we found at NerdWallet\nConsumption of a similar number of e-cigarettes from a rechargeable device would cost about $600, the same story said.", "answer": 0}, {"article": "TUESDAY, Oct. 16, 2018 (HealthDay News) -- Stimulating a specific set of nerves that are nestled along the spine may deliver relief to those who suffer from chronic back pain and cut the need for opioid painkillers, new research suggests.\nFor uninsured patients, the cost of having spine stimulation devices can range from $15,000 to $50,000 or more, according to a 2008 report funded by the Washington State Department of Labor and Industries.\nSpine stimulation is usually approved only after patients have not responded to other treatment, according to Blue Cross Blue Shield.\nThe therapy, which targets the root ganglion nerves, is more effective than other spine stimulation procedures because it places tiny leads precisely at the area where pain originates, unlike other devices that provide more generalized stimulation, the researchers said.\nIn addition, dorsal root ganglion stimulation requires significantly lower levels of electric current to quell pain, McCarthy said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did great on this criterion. It said the cost of spine stimulation devices \u201ccan range from $15,000 to $50,000 or more, according to a 2008 report funded by the Washington State Department of Labor and Industries.\u201d It also mentioned the procedure \u201cisn\u2019t covered by all insurance companies, so out-of-pocket costs to patients can be very high.\u201d One quibble we did have is that it isn\u2019t clear whether the device to stimulate the dorsal root ganglion is different in cost than the other types of spinal cord stimulation.", "answer": 1}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the costs of either neratinib or veliparib/carboplatin. Both treatments\u00a0are experimental and so do not have a market price, but it should be possible to give a rough estimate of the price range of new cancer drugs when they gain regulatory approval. Although the trials detailed in the news release are too early stage to talk about impending approvals, given that the release raises the possibility of \u2018promise for patients\u2019 (in the headline), we think it\u2019s not too early to consider how much patients would have to pay.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the implant designed especially for women is \u201cmore expensive\u201d (presumably in comparison to most other options) even though its cost-effectiveness remains unknown. Still, we wish the story included an actual cost estimate of the device and its implantation.\u00a0 Readers aren\u2019t given any idea of whether this is a ballpark of $200, $2,000 or $20,000.  ", "answer": 0}, {"article": "Kale and oranges are high in vitamin C, another antioxidant.\n\u201cWe recommend whole fruit and not fruit juice,\u201d says Farvid, \u201cbecause maybe one of the most important ways that fruit decreases risk of breast cancer is through fiber, and even natural fruit juice often has no fiber in it.\u201d\n\nIn another study also published in the , a separate group of researchers found that among 22,000 Danish women, those who added two alcoholic drinks a day on average increased their risk of developing breast cancer by 30% over five years.\nBut the majority of those studies have focused on adults, and it\u2019s becoming clear that many of cancer\u2019s drivers start early in life, with genes and even with childhood exposures to potential carcinogens.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was not discussed, and because this is about fruit, we\u2019ll rate this N/A. However, it is worth pointing out that fresh fruit isn\u2019t something that all consumers can take for granted, since it can be expensive and hard to find in areas known as \u201cfood deserts.\u201d", "answer": 2}, {"article": "George said he believes the approach works by \u201cresetting\u201d electrical activity and restoring normal mood regulation.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nSomething similar is likely happening, he added, with electroconvulsive therapy (ECT), or what is sometimes referred to as \u201celectroshock treatment.\u201d Sixty to 70 percent of depressed people who undergo ECT, in which electrodes placed on the front of the brain induce a convulsion while the patient is anesthetized, will recover.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nAfter three weeks, 14 percent of patients in the real TMS group had recovered from their depression, compared to 5 percent of the sham TMS group; people who had the real treatment were four times as likely to get better as those who got the fake treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss the cost of the TMS machine or the cost of a typical course of treatment. This is a significant\u00a0oversight considering that many health insurance plans offer limited coverage for mental health expenses.\u00a0Does a patient who pays\u00a0out of pocket have any hope of\u00a0affording\u00a0TMS treatment? The article\u00a0doesn\u2019t say.\u00a0", "answer": 0}, {"article": "A week later, under no medication, participants returned to repeat the experiment.\n*\n\nThe fear response was 60% lower in participants who had doxycycline in the first session compared to those who had the placebo, suggesting that the fear memory was significantly suppressed by the drug.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\n\"We have demonstrated a proof-of-principle for an entirely new treatment strategy for PTSD,\" explains Professor Bach.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs. It could have addressed cost through information about the relatively inexpensive antibiotic used in the study or by mentioning the social and economic costs of those afflicted with PTSD.\nEven though the research is called a \u201cproof of concept,\u201d we think if it\u2019s not too soon to issue a news release it shouldn\u2019t be too early to include cost implications.", "answer": 0}, {"article": "Andersson will be available to the media in an embargoed web briefing on Tuesday, March 7, 2017, at 2 p.m.\n\"We think that if you have an active sex life it's probably an indicator of a healthy lifestyle, especially in the oldest quartile--those 70 to 80 years old,\" Andersson said.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\nThe ACC's Annual Scientific Session, which in 2017 will be March 17-19 in Washington, brings together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study was observational and the number of ED drug doses men took was not reported or calculated. Since the study was conducted in Sweden, it\u2019s possible there was no cost for individual patients but the drugs were covered by the national health system.\nSince this release was issued by the American College of Cardiology to an American audience we think some comment on the cost of ED drugs or the cost of treating heart conditions would be appropriate for readers.", "answer": 0}, {"article": "Red and purple fruits owe their colors to...\nThe juice is a beautiful wine-red color and tastes delicious.\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nBut is it especially healthful?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of pomegranates or pomegranate containing products or how these costs compare with other fruits and vegetables considered to be similarly rich in anti-oxidants and particularly polyphenolic compounds.", "answer": 0}, {"article": "The most common adverse reactions were vaginal discharge and abnormal Pap smear.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\"Pain during sexual intercourse is one of the most frequent symptoms of VVA reported by postmenopausal women,\" said Audrey Gassman, M.D., deputy director of the Division of Bone, Reproductive, and Urologic Products (DBRUP) in the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research (CDER).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without consideration of cost, so it\u2019s understandable that they wouldn\u2019t comment on it \u2014 and that\u2019s why we\u2019re rating this Not Applicable. We look forward to the day when any news release about a new drug \u2014 even one from the FDA \u2014 includes some mention of cost in its message. After all, the value of a new drug is a function not just of how well it works, but its cost-effectiveness. With the newly approved Intrarosa are we looking at $10 or $100 for each round of treatment?\nIts active ingredient, DHEA, is sometimes used as a dietary supplement. On Goodrx.com, a bottle of 300 25-mg tablets of Natrol goes for $13.29.", "answer": 2}, {"article": "\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\nFor this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\nDutch researchers presenting the findings at the Genitourinary Cancers Symposium in Orlando, Fla., said that few men with a PSA below 3.0 ng/ml were likely to develop prostate cancer and die of the disease.\nThis compares with 15.7 percent of those with scores from 2 percent to 2.9 percent developing a malignancy and 0.36 percent dying of the disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion about how costs might be affected by any of the three aspects of prostate cancer testing and treatment described in this story. And all three had significant cost implications.", "answer": 0}, {"article": "Israel is director of the respiratory therapy department at Brigham and Women's Hospital in Boston.\n\"By blocking the signal that helps keep mast cells alive, we were hoping to reduce the number of these cells,\" Israel said.\nGleevec (imatinib) reduced the \"twitchiness\" of airways, making them less likely to reflexively constrict when exposed to an allergen or asthma trigger, said senior researcher Dr. Elliot Israel.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\n\"There was a small but significant improvement in the airway narrowing in these patients, which we didn't expect because we didn't think the mast cells were necessarily promoting that airway narrowing all the time,\" Israel said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were glad the story addressed costs, but actual figures would have been more helpful. It says imatinib \u201cmight provide a relatively inexpensive new treatment for asthma patients. Two generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\u201d\nWhile it may cost less than other options, this treatment isn\u2019t what we consider inexpensive, even off-patent. Generic imatinib costs $96.53 to $276.53 per tablet, according to Drugs.com.", "answer": 1}, {"article": "Risk-based screening is a poor approach.\n\"Mammography screening is not perfect but has been shown to markedly reduce the number of women each year who die from breast cancer,\" said Elizabeth Morris, MD, FACR, president of the Society of Breast Imaging.\nI encourage women to speak with their providers about mammography benefits and limitations and create a schedule to get their annual mammograms,\" said Debra Monticciolo, MD, FACR, chair of the American College of Radiology Breast Imaging Commission.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The average cost of an annual mammogram is relatively easy to find, but this news release didn\u2019t address it. The average out-of-pocket expense, per mammogram visit, is about $33. This is about 1/7th the cost of the full tab (approximately $266), according to a 2011 study in Journal of Women\u2019s Health. ", "answer": 0}, {"article": "MONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\n\"The study highlights that if one chooses to use ticagrelor in subjects with acute coronary syndromes, it would be logical to use aspirin 81 milligrams per day (and not 325 mg daily),\" said Dr. Jeffrey S. Berger, assistant professor of medicine and director of cardiovascular thrombosis at NYU Langone Medical Center in New York City.\nIn this latest analysis of PLATO findings, researchers found that patients who took Brilinta with low-dose aspirin were 16 percent less likely than those who took Plavix with low-dose aspirin to have a heart attack or stroke, or to die within a year.\nHeart patients who took Brilinta (ticagrelor) with low-dose aspirin (less than 300 milligrams) had fewer cardiovascular complications than those taking Plavix (clopidogrel) plus low-dose aspirin, researchers found.\nHowever, patients who took Brilinta with higher doses of aspirin (more than 300 milligrams) had worse outcomes than those who took Plavix plus high-dose aspirin, the investigators reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs. Ticagrelor isn\u2019t available in the US. But its cost \u2013 where available elsewhere \u2013 could have been cited. Cost will certainly be an issue if it\u2019s approved because its competitor, clopidogrel, will soon be available in the US as a generic drug.", "answer": 0}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nAnd infection in rats does not follow the same disease course as in humans.\nThere is no treatment or vaccine for parainfluenza.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\nFludase is already in phase 2 clinical trials for use against influenza.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this drug is not on the market, a discussion of cost is not warranted.\u00a0\u00a0 ", "answer": 2}, {"article": "To learn more, visit stjude.org or follow St. Jude at @stjuderesearch\nThe team, led by Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology, published their findings in a recent issue of the journal Cell.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nBoosting the activity of a protective gene and giving patients 'good' gut bacteria could help prevent or slow progression of colorectal cancer, St. Jude Children's Research Hospital scientists have found\n\nMemphis, Tenn., JUNE 19 -- Scientists at St. Jude Children's Research Hospital have discovered how an immune system protein, called AIM2 (Absent in Melanoma 2), plays a role in determining the aggressiveness of colon cancer.\n'We have only scratched the surface of the role of AIM2 in controlling stem cell proliferation and the maintenance of a healthy gut microbiota,' Kanneganti said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. This is not surprising, given that this is an early study, in an animal model, which identifies the role of a particular protein in preventing and, possibly, slowing the progression of colorectal cancer. However, the release explicitly discusses specific therapeutic possibilities, such as interferon therapy to increase AIM2 activity and transferring healthy bacteria into colorectal cancer patients. If you\u2019re going to discuss possible treatment options (even in general terms), it\u2019s worth mentioning what they may cost (even in general terms).", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story is clear on this point, stating: \u201cAll the bisphosphonates are now available in generic form, for as little as $5 a month.\u201d The only point of confusion is that the story also refers to \u201cnewer osteoporosis drugs retailing for hundreds of dollars or more a month.\u201d However, it doesn\u2019t tell us anything else about these drugs, other than their names. (We\u2019ll get back to that in the \u201cCompare Alternatives\u201d section.)", "answer": 1}, {"article": "Related: CDC study finds opioid dependency begins within a few days of initial use\nAs a result, those molecules never reach the brain, preventing the euphoria that may have otherwise resulted.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nIn response, this protective system manufactures antibodies to the drug, including the components that cause the high.\nA vaccine that blocks the high from heroin has just moved one step closer to reality.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the level of development, cost is not a consideration at this juncture.", "answer": 2}, {"article": "River Vision Development Corporation licensed the drug from Roche.\nThe study \u201cincluded some of the worst cases imaginable and we\u2019re now wondering whether the drug might find expanded utility in much-less-severe disease,\u201d Smith told Reuters Health in a telephone interview.\nThe researchers also cautioned that the study only included volunteers with active disease of recent onset so \u201cthe potential of teprotumumab in benefiting patients with milder, less active, or stable disease was not assessed.\u201d\n\nSOURCE: bit.ly/2qSTjSn New England Journal of Medicine, online May 3, 2017.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\nThe marked reduction in bulging is similar to that reported after decompression surgery, Smith and his colleagues write in the New England Journal of medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the potential price of teprotumumab, an important piece of context for the story. Will patients be able to afford this new therapy if it becomes available? Even if exact numbers numbers can\u2019t be pinned down, we know that there are other treatments used to treat the eye bulging that often comes with Grave\u2019s disease and those cost figures should be available. Some suggestion as to whether the new drug might be cheaper or more expensive than are current approaches would be helpful for readers.", "answer": 0}, {"article": "Harvard T.H.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\n\"Previous studies of fiber intake and breast cancer have almost all been non-significant, and none of them examined diet during adolescence or early adulthood, a period when breast cancer risk factors appear to be particularly important,\" said Maryam Farvid, visiting scientist at Harvard Chan School and lead author of the study.\n\"Dietary Fiber Intake in Young Adults and Breast Cancer Risk,\" Maryam S. Farvid, A. Heather Eliassen, Eunyoung Cho, Xiaomei Liao, Wendy Y. Chen, and Walter C. Willett, online February 1, 2016, Pediatrics, 137(3):e20151226 doi: 10.1542/peds.2015-1226\n\nVisit the Harvard Chan School website for the latest news, press releases, and multimedia offerings.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It seems so simple. Add more fiber to your diet to improve health. But one thing many health groups forget to consider when making recommendations for changing one\u2019s diet is the inconsistency in the cost and availability of healthful foods. We\u2019ll rate the release Not Applicable here because most people have a general idea what high-fiber foods will cost. But we wish the release had provided at least a ballpark figure on what the weekly, monthly or annual cost would be to adding more fruit and vegetables to one\u2019s diet. In addition, it needs to be acknowledged more often that there is a large segment of the U.S. population that does not have ready access to grocery stores that sell fresh fruits and vegetables.", "answer": 2}, {"article": "Schubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nThe precise cause of fibromyalgia is unknown \u2014 there are no physical signs, such as inflammation and tissue damage in the painful area \u2014 but some researchers believe the disorder involves problems in how the brain processes pain signals.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\nThat is important because it is possible for patients to benefit from simply receiving attention from a healthcare provider, or being part of small-group sessions with other people suffering from the same condition, for example.\nBut, he explained, pain and emotions are \u201cconnected in the brain,\u201d and emotional factors may act to trigger \u201clearned nerve pathways\u201d that give rise to pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Chronic pain\u00a0takes a huge financial toll in terms of\u00a0direct medical costs and lost productivity,\u00a0but the\u00a0story didn\u2019t \u00a0cover this angle. It would have been interesting to hear how costs of this psychotherapy compare with those of drug therapy. Also, no\u00a0word on whether the costs would be covered by insurance or borne out of pocket by patients. \u00a0\u00a0", "answer": 0}, {"article": "WASHINGTON (Reuters) - Screening smokers and former smokers for lung tumors using three-dimensional X-rays reduced their risk of dying from lung cancer by 20 percent, researchers said on Thursday.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\n\u201cNo one should come away from this announcement believing that it is safe to continue to smoke,\u201d National Cancer Institute director Dr. Harold Varmus told a news conference.\nIn 2006, Dr. Claudia Henschke of New York Presbyterian Hospital-Weill Cornell Medical Center caused a stir when she published a study saying that 80 percent of lung-cancer deaths could be prevented through widespread use of spiral CT.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of diagnostic testing and the return on that investment in both clinical and financial terms should be routinely included in any story. Like many others, this story fails in this regard. Simply describing the cost of the diagnostic test does not provide the reader with an appreciation of the true cost of the testing. The number of people you need to scan to find one with an early stage lung cancer is 304. There are 33 million Americans who smoke daily. At $300 to $1,000 per scan, scanning everyone would cost $9.9 to $33 Billion annually. Any discussion on cost should also include comments on the false positive rate. In this case, 25% to 60% of subjects had a lesion that needed further workup. The financial costs of these false results should have been noted", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nIn their study, funded by the Italian Ministry of Health, the investigators recruited three men and 11 women, ages 22 to 65, with obesity as shown by a body mass index (BMI) of 30 to 45 kg/m2.\n\"These changes suggest a beneficial effect of dTMS on both weight loss and change in microbiota composition,\" Luzi said.\nThey randomly assigned the study subjects to two groups for five weeks to receive 15 sessions--three times per week--of either dTMS (to the insula and prefrontal cortex deep in the brain) or a sham stimulation as a control.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost of dTMS is not mentioned in this release. After doing a bit of independent information gathering, it seems that even though dTMS may be more cost-effective than other more invasive neurostimulation techniques, each session can cost a patient roughly $400-$500, according to PyschologyToday. Individuals in this study underwent 15 sessions each, which amounts to $6000 to $7500 for five weeks of therapy. We don\u2019t know the long-term effects of dTMS on weight loss, nor do we know if, or \u2013 more likely \u2013 how often these sessions would need to be repeated, but it\u2019s easy to see the price for an individual mounting quickly.\nThe release doesn\u2019t mention insurance coverage but costs for this type of therapy are likely to be out-of-pocket.", "answer": 0}, {"article": "The investigators found that Enclomiphene citrate restored blood testosterone levels to normal after 16 weeks while maintaining sperm concentrations, whereas Androgel restored blood testosterone levels but caused marked reductions in sperm concentrations by suppressing the function of the testes.\nOver five months, patients had 10 clinic visits with one overnight stay.\nThe Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification.\n\"One of the basic tenets in medicine is to do no harm.\nRestoring testosterone production in men may be as effective as replacing it, without compromising their fertility.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t give the cost of either of the drugs that are compared in the study.", "answer": 0}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nIt is known that monounsaturated fats can help lower levels of bad cholesterol, reducing the risk of heart attack and stroke.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\nIn the United States avocados are not a mainstream food yet, and they can be expensive, especially at certain times of the year.\nAlso, most people do not really know how to incorporate them in their diet except for making guacamole.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention a direct price for avocados, but it does mention that avocados tend to be expensive in many parts of the country at certain times of the year.", "answer": 1}, {"article": "But natural family planning is not for everyone.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nSo if you could reliably know when you've ovulated as a woman, and then you give that egg two or three days to die, any time after that in the cycle you will not get pregnant because there's no egg to fertilise,\" Dr Susan Walker, a senior lecturer in sexual health at Anglia Ruskin University, told BuzzFeed News.\nAt first she starts to use the app to prevent pregnancy, and when she's ready [to get pregnant] she switches to plan, and usually she gets pregnant quite quickly, because the app already knows her body and cycle.\"\nAnd if you're considering ditching the Pill because remembering to take it each day is too much effort, you probably won't like having to remember to take your temperature every morning.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The\u00a0story states that the app requires a monthly or yearly subscription, which implies it\u2019s not free. But there is no mention of what the subscription costs, which was easily found by visiting the Natural Cycle website (linked in the article). It\u2019s $5.80 per month or $69.90 per year. (For comparison\u2019s sake, the cost for one\u00a0month\u00a0of the pill can cost up to $50 although it\u2019s often covered by many health insurance companies.)", "answer": 0}, {"article": "This study will be presented at a medical conference.\nThe participants were followed for 20-22 years and filled out questionnaires about the foods they ate.\nThe cause of the disease is unknown, and the risk of developing it increases with age.\nNor is it clear why the results differed for men and women.\nThis was an observational study and therefore can\u2019t establish cause and effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The costs of the flavonoid-containing foods mentioned in the story is not in question.", "answer": 2}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes the an additional $20 per mammogram with CAD when billed to Medicare. With the newer technology, costs to public health would increase via additional screening and unnecessary biopsies, and treatment would increase for cancers that may never become problematic (i.e. some forms of DCIS or ductal carcinoma in situ). ", "answer": 1}, {"article": "To automatically receive news releases from UT Southwestern via email, subscribe at http://www.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\n\"The high cure rate is striking when compared to the reported five-year cure rates from other approaches like surgery or conventional radiation, which range between 80 to 90 percent, while the side effects of this treatment are comparable to other types of treatment,\" said Dr. Raquibul Hannan, Assistant Professor of Radiation Oncology and lead author for the study.\nDALLAS - April 18, 2016 - A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.\n\"Our hope is that the high potency of this form of treatment will significantly improve treatment of these patients,\" says Dr. Hannan, the principal investigator of the high-risk prostate SBRT trial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs. We find this disappointing, but also ironic. In a very quick search, we discovered that one of the major topics regarding SBRT is its low-cost relative to the existing therapies. In the Journal of Oncology Practice, authors in 2012 directly compared it cost-wise to another method and concluded: \u201cSBRT for low- to intermediate-risk prostate cancer has great potential cost savings for our health care system payers and may improve access to radiation, increase patient convenience, and boost quality of life for patients.\u201d", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nDr. Lewy dismissed the idea that harm might lurk in a melatonin-laced brownie.\n\u201cA hangover effect has been reported\u201d with large doses, said Anna Rouse Dulaney, a toxicologist with the Carolinas Poison Center.\nBut they are not to be underestimated.\n\u201cFor me, it\u2019s not to chill.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes some pricing estimates for these products.", "answer": 1}, {"article": "More information can be found at http://www.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\n\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Papa.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We were glad to see a very brief mention in the release that if the biomarker research is confirmed in larger studies, it might someday replace what the release calls \u201cexpensive\u201d CT scans used in emergency rooms to try to diagnose concussion. But there is a tacit assumption that the biomarker would replace the use of CT scans. Experience would suggest, however, that new tests tend not to replace existing methods but are simply added to them. We also want to point out that if this new biomarker test became a commonplace screening tool, it could result in over-screening. Tools for screening have to be evaluated very carefully to have the greatest benefit for the right patients.", "answer": 0}, {"article": "While the procedure may look straightforward, it's extremely delicate, said Linda Cormier, a sales representative for Cambridge Endo, whose headquarters is in Framingham, Mass.\nThe hook, grasper and scissors are on the ends of shafts less than one-fifth of an inch wide.\nThe recovery has been pain-free, and the cancer hasn't returned, he said.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nAbout 12,980 die of the cancer each year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of the cost of cryotherapy or how it compares to other available treatments.", "answer": 0}, {"article": "\u201cThe ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,\u201d said Ursula Utz, Ph.D., program director at the NINDS.\nIt is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder.\nThe Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advancements in translational science that bring about tangible improvements in human health.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\nCurrent therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While one could argue that we should give the release a pass given the early stage of the research,\u00a0the drugs discussed are commercially available and it would have been easy to provide cost information.", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of probiotic containing products; there was no discussion of whether there is any sort of price differential between traditional products and those to which probiotics or additional probiotics have been added.", "answer": 0}, {"article": "Statins cut the risk of dying from heart disease by 28% among men, according to the longest study of its kind.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nSenior author Professor Kausik Ray, from Imperial\u2019s School of Public Health, said: \u201cFor the first time, we show that statins reduce the risk of death in this specific group of people who appear largely healthy except for very high LDL levels.\nThey found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nThe 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed. However, statins cost between roughly $313 (generic) to $1,428 (name-brand) per patient per year in the US, according to a 2012 study in Pharmacoptherapy. The costs are much less in the UK: $164 (generic) and $509 (name-brand) per patient per year.", "answer": 0}, {"article": "The DAWN trial included trial locations in the United States, Spain, France, Australia and Canada.\nThe international multi-center clinical study, known as the DAWN trial, randomly assigned 206 stroke victims who arrived at the hospital within six to 24 hours to either endovascular clot removal therapy, known as thrombectomy, or to standard medical therapy.\n\"Our research and clinical teams are immensely proud of these breakthrough findings, which are so profound they will likely result in a paradigm shift that will not be seen again for many years in the field of stroke therapeutics,\" says Michael Frankel, MD, professor of neurology, Emory University School of Medicine, chief of neurology and director of the Marcus Stroke and Neuroscience Center for the Grady Health System.\n\"These findings could impact countless stroke patients all over the world who often arrive at the hospital after the current six-hour treatment window has closed,\" says co-principal investigator Raul Nogueira, MD, professor of neurology, neurosurgery and radiology at Emory University School of Medicine and director of neuroendovascular service at the Marcus Stroke & Neuroscience Center at Grady Memorial Hospital.\n\"Looking at the physiological state of the brain and evaluating the extent of tissue damage and other clinical factors seems to be a better way to decide if thrombectomy will benefit patients as opposed to adhering to a rigid time window,\" says Nogueira.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although preventing disability in stroke patients will clearly save health care dollars, it\u2019s also possible that the additional costs of imaging to identify patients eligible for clot removal after six hours will add to health care costs. But this issue is not addressed. The release also contains no information about the potential number (and overall percentage) of stroke patients who might benefit from late clot removal, further obscuring the potential savings in dollars as well as disability.", "answer": 0}, {"article": "There has never been a safe and effective treatment.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that the company says the price has not been set. It also notes that \u201cIt is a biologic, the most expensive type of drug, and is injected every two weeks.\u201d The story could have offered readers a more detailed picture by noting that a widely prescribed (and heavily advertised) biologic treatment for Crohn\u2019s Disease, Humira, costs about $2,000 per dose or about $50,000 per year. Of course, the amount paid by patients varies widely depending on insurance coverage.", "answer": 1}, {"article": "Another took part in an exercise program.\n\"People need to begin to push themselves in the face of their fatigue, because if you don't, you become deconditioned and you get caught in a cycle which ... makes fatigue worse,\" says Barsky.\nNearly three decades have passed since the debate began about a series of symptoms that have come to be known as chronic fatigue syndrome.\nAnd, like most professionals who treat patients, Bateman eagerly awaits the day when science can finally pinpoint its cause.\nWhen symptoms abate and they feel better, they may go all out, exercising, doing errands and socializing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a significant hole in the story. Any sort of behavioral therapy usually requires multiple visits that can add up to thousands of dollars per month. If you add an exercise program that could require a gym membership or even a personal trainer, this could prove to be far too expensive for the typical chronic fatigue patient.", "answer": 0}, {"article": "The Food and Drug Administration has approved DBS therapy for movement disorders such as Parkinson's disease, tremor and dystonia \u2014 usually in people who haven't responded well to medications.\nFew are willing to undergo brain surgery for the purpose of research.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nIt did not affect anticipation associated with normal behaviors such as meeting a new mouse.\nAnother study published Monday in PNAS suggests that DBS could help boost memory and other research is exploring its use for substance abuse and other reward-seeking behaviors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the article might have been strengthened by including the costs of alternative therapies, it clearly notes the high cost of the implantable device.", "answer": 1}, {"article": "The body naturally synthesizes vitamin D when the skin is exposed to sunlight.\n\u201cHowever,\u201d the researcher said, \u201cthere is a lack of clinical studies of the effect of vitamin D supplementation for preventing respiratory infections.\u201d\n\nFor the current study, Laaksi\u2019s team randomly assigned 164 male military recruits to take either 400 international units (IU) of vitamin D or inactive placebo pills every day for six months \u2014 from October to March, covering the months when people\u2019s vitamin D stores typically decline and when respiratory infections typically peak.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\nAt the end of the study, the researchers found no clear difference between the two groups in the average number of days missed from duty due to a respiratory infection \u2014 which included bronchitis, sinus infections, pneumonia, ear infections and sore throat.\nOn the other hand, a recent study of 162 adults found that those who took 2,000 IU of vitamin D everyday for 12 weeks were no less likely to develop respiratory infections than those given placebo pills.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n\n \nThis story does not mention cost. Sure, vitamin pills cost only pennies a day, but treating everyone would cost billions of dollars a year.\n Assuming just a nickel a day for 400 IU of vitamin D (the dose used in this study), the cost of treating everyone in the U.S. would exceed $5 billion a year. That bill has to be compared to the expected benefits of supplements given to healthy people, which in this trial were not statistically significant, so those billions might just be flushed down the drain.", "answer": 0}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Good job here. The story notes that the monthly cost of Deplin can run as high as $98 and may not be covered by insurance.", "answer": 1}, {"article": "Dr. Eric A. Klein, chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic, said that he would like to see the findings of the new study independently confirmed, but that other studies also have suggested that the risk of cancer is low in men whose P.S.A.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\nBut once cancer is detected, many men, frightened by the diagnosis, opt for aggressive surgical and radiation treatments that do far more damage than their cancers would have, leaving many impotent and incontinent.\nThe results also will reassure men who decide to continue with regular screenings that the benefits most likely outweigh the risks.\nDuring that time, there were 43 cases of advanced prostate cancer and 35 deaths in the group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, though this doesn\u2019t seem relevant to this particular discussion.\u00a0", "answer": 0}, {"article": "Both have made early detection and treatment more precise.\nColorectal cancer is the second leading cause of death among the combined group of men and women who have cancer, according to the National Institutes of Health.\nThe CDC says colonoscopy may also be recommended for people experiencing stomach pain, aches or cramps that don't go away, unexplained weight loss and blood in the stool.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nThe CDC says colonoscopy could reduce the number of colorectal cancer cases by as much as 60 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost should always be a consideration in a discussion of a new technology. Screening tests are no exception There are approximately 100 million adults in the US over the age of 50 years according to the 2010 census report. That is a lot of screening, and the financial implications can loom very large. Although the cost of the test, in this case virtual colonoscopy, is important, it is only one piece of the equation. The removal of suspicious lesions cannot be done in the virtual world, so suspicious lesions identified virtually would require a physical colonoscopy, adding to the overall cost. According to the\u00a0\u00a0Colon Cancer Alliance, a CT colonoscopy costs between $400 \u2013 800. This cost is not covered by Medicare and most commercial insurance companies.", "answer": 0}, {"article": "CDC To Doctors: Anti-HIV Pill No Magic Bullet Against Virus\n\nIn November, researchers revealed a encouraging finding: taking a pill can greatly reduce the risk of getting HIV.\nBut the landmark study, involving 2,500 men who have sex with men, showed that taking Truvada faithfully can reduce the risk of infection by as much as 92 percent.\nTo make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nWhen researchers tested the blood of patients for traces of Truvada, they found many who claimed to have taken the pill regularly weren't telling the truth.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Strong point.\u00a0 The story said, \u201cThere\u2019s one other thing, the CDC says. Make sure patients understand that warding off HIV isn\u2019t cheap. Each pill currently costs around $36, which adds up to more than $13,000 a year. Some insurers might pay, but some might balk\u201d", "answer": 1}, {"article": "Will it help avoid back surgeries, for example, that may or may not have great outcomes?\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\n\"The study can give primary care providers the confidence to tell patients with chronic low back pain to try massage, if the patients can afford to do so,\" Munk said.\nINDIANAPOLIS -- In the first study of its kind, researchers found real-world massage therapy to be an effective treatment for chronic low back pain.\nThe study, \"Real-World Massage Therapy Produces Meaningful Effectiveness Signal for Primary Care Patients with Chronic Low Back Pain: Results of a Repeated Measures Cohort Study,\" was published online March 14 in the journal Pain Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We give the release credit for stating that massages are generally not covered by insurance and that patients typically pay out-of-pocket. And the release provided some important context about cost with this statement from the lead author: \u201cGenerally, people wonder if it is worth it. Will it pay to provide massage to people for an extended period of time? Will it help avoid back surgeries, for example, that may or may not have great outcomes? These are the types of analyses that we hope will result from this study.\u201d\nWhile massage is now offered in nearly all cities and towns, not all readers know how much they will need to shell out for the 10 sessions used in this study.\nA one hour massage averages $60 an hour nationally, so 10 sessions would cost about $600. That\u2019s something people considering this type of therapy would like to know.", "answer": 1}, {"article": "(Reuters Health) - - Exhausted shift workers may be safer driving home at night when they\u2019re exposed to bright light before they hit the road, a small study suggests.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nShift workers with chronic sleep deprivation also face an increased risk of accidents.\nNone of the people who slept at home crashed, and neither did any of the sleep-deprived people who got bright light therapy before getting behind the wheel, the study found.\nTo test the effect of light therapy on driving, researchers did a series of three experiments with 19 adults.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost information is not provided, but\u00a0the cost of a bright light is presumably reasonable.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention cost. In knee replacement there is more to cost than the price of the implant and the hospital and surgeon\u2019s fees. After surgery, patients must plan for time away from work, intensive rehabilitation, and perhaps the cost of an inpatient rehab facility or visiting nurse.", "answer": 0}, {"article": "For more information, see www.scripps.edu.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nThe researchers, led by Dale Boger, co-chair of TSRI\u2019s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.\nCombined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed at all, likely because so much work remains to be done before the modified vancomycin is clinically relevant. However, if it\u2019s not too early to talk about the clinical relevance of the findings (which the release does), then it is not too early to talk about potential cost \u2014 at least in broad terms.\nGiven that producing the modified vancomycin currently involves a 30-step process (which researchers are hoping to streamline), the cost may be considerable. The release goes so far as to say that \u201cthe new vancomycin\u2019s lifesaving powers make its production valuable.\u201d If they\u2019re willing to say that, it would have been worthwhile to discuss, in a sentence or two, whether this new version of vancomycin may be more expensive than existing antibiotics. At any rate, cost should not have been overlooked completely.", "answer": 0}, {"article": "Their improvement was significantly more than the average seen in patients taking just medication, he said.\n\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\nThe study\u2019s results will be submitted for publication in the coming weeks and a follow-up study on 30 patients is planned.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The approach is not yet approved in the US, so it\u2019s understandable that costs here were not included.\u00a0 The story did note that \u201cIn Israel, the treatment costs $6.000.\u201d\nBut we aren\u2019t certain what exactly is the definition of \u201ctreatment.\u201d\u00a0 Is that in total or for each session?\u00a0 According to the company\u2019s website, patients receive daily treatments, five days a week for 6 weeks to start.\u00a0 At $6,000 per session (in Israel) that is $180,000.\u00a0 The published proof of concept study (http://www.springerlink.com/content/27622j8188653442/ ) suggested the need for twice a week treatments for an additional 3 months.\u00a0 That is another $144,000 if the cost is as described.\u00a0 So, is the cost $6,000 or $324,000?", "answer": 0}, {"article": "The study was presented Monday at the annual meeting of the American College of Cardiology in Orlando, Fla.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\n\"The most urgent need for innovative strategies to control blood pressure is in low- and middle-income countries,\" Webster said.\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\nThe pill contains low doses of the three medications -- telmisartan, amlodipine and chlorthalidone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t say how much the triple pill costs, or how that cost compares with \u201cusual care.\u201d\nOn GoodRx, 30 tablets of a telmisartan/amlodipine combination runs around $60, while 30 tabets of cholorthalidone is about $17. However, all of the dosages available online were twice what was used in the study.\nAccording to a news release, the researchers are evaluating whether the combination pill is cost-effective solution for blood pressure control.", "answer": 0}, {"article": "\"In health as elsewhere, if something looks too good to be true, it should be treated with great caution,\" says an editorial published this week in the medical journal BMJ.\nBut before you pour your next cocktail, beer or glass of wine, you should know this: the science suggesting a benefit has never been conclusive.\nThe idea that alcohol might be good for our hearts and blood vessels is a popular one, right up there with the notion that chocolate is a health food.\n\"There may be some evidence that perhaps one glass with a meal is OK,\" says Demetrius Lopes, a neurological surgeon at Rush University Medical Center, Chicago, and another spokesperson the heart association.\nThere's no evidence drinking in your 20s or 30s has any health benefits.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was not an issue here. People generally know what a bottle of wine or other alcohol costs.", "answer": 2}, {"article": "\"Do I believe that teenage girls should be immunized?\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\n\"I want to make sure that every family, every young girl, has the information about the vaccine, about the potential risks of not having it,\" Jakobssen says.\nEven though Ken Alexander still likes to think of 14-year-old Audrey as his little girl, he's already had her vaccinated against a very grown-up disease: the sexually transmitted human papillomavirus, or HPV, that can cause cervical cancer.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of the vaccine. The story should have compared this cost to the alternative \u2013 regular pap smears. This is important information given that women will still need regular pap smears even if they are vaccinated.", "answer": 1}, {"article": "If it does, Orlistat (xenical) -- currently sold only by prescription -- could be available over-the-counter (OTC) later this year.\n\"It's very exciting,\" Klein says.\n\"None of these [weight loss] medications are.\"\nWhen fat that's eaten isn't absorbed, it must be eliminated.\nNor is Orlistat a quick fix for unwanted pounds.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Estimates cost to be $2-3 /day.", "answer": 1}, {"article": "But such drugs tend to be extremely expensive.\nScaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d\n\nThe research is still in its early stages, and many questions remain.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\nHerv\u00e9 Hoppenot, the president of Novartis Oncology, called the research \u201cfantastic\u201d and said it had the potential \u2014 if the early results held up \u2014 to revolutionize the treatment of leukemia and related blood cancers.\nThe altered T-cells \u2014 called chimeric antigen receptor cells \u2014 are then dripped back into the patient\u2019s veins, and if all goes well they multiply and start destroying the cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study addresses costs nicely,\u00a0noting that any commercial treatment resulting from this research will probably be very expensive. It notes that other targeted\u00a0cancer treatments cost more than $5,000 a month. And it provides the estimate of experimental cost ($20K per patient).", "answer": 1}, {"article": "Pregnant women are generally advised to limit their consumption of certain types of fish like swordfish and tuna because they contain mercury.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nMore than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nBut many other types are considered safe, especially smaller fish like sardines that are not at the top of the food chain and therefore not likely to accumulate mercury and other contaminants from eating other fish.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss cost. There are dozens of fish oil supplements on the market and their cost varies widely. The story could have given some sense of the financial impact that this regimen would have.", "answer": 0}, {"article": "\"The consistency among the results lead to the unequivocal conclusion that there is no clinical benefit of the use of folic acid and vitamin B12 (with or without the addition of vitamin B6) in patients\" with heart disease, wrote Joseph Loscalzo of the Brigham and Women's Hospital in Boston in an editorial that will be published with the studies.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nInstead, they looked at whether B vitamins can treat or reverse heart disease in people who already have it.\n\"These studies did not test whether B vitamins used by healthy people can help keep them healthy.\nThe findings, released yesterday, are the latest in a series of recent studies that have found vitamins and other dietary supplements fail to have the health benefits they are touted for.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this story doesn\u2019t make claims about efficacy, costs don\u2019t seem applicable. ", "answer": 2}, {"article": "\u201cUsually everything is developed first for adults,\u201d he noted recently, \u201cand children are an afterthought.\u201d\n\n\u2018This is not the end\u2019: Using immunotherapy and a genetic glitch to give cancer patients hope\n\nThis 8-year-old is free of cancer \u2014 for now \u2014 after a \u2018breakthrough\u2019 treatment\n\nFor a 6-year-old with cancer, a future staked on medicine\u2019s hottest field\nThe other major worry is neurotoxicity, which can result in temporary confusion or potentially fatal brain swelling.\nThat study and a Kite trial have shown that the treatment can put about one-third of adults with advanced disease \u2014 those who have exhausted all options \u2014 into remission.\nNovartis has not disclosed the price for its therapy, but analysts are predicting $300,000 to $600,000 for a one-time infusion.\nThe checkpoint inhibitors are targeted at solid tumors, such as advanced melanoma and lung and bladder cancer, while CAR T-cell therapy has been aimed at blood disorders.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tackles this issue head on, as here: \u201cNovartis has not disclosed the price for its therapy, but analysts are predicting $300,000 to $600,000 for a one-time infusion.\u201d", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nIn animal studies, a lack of vitamin D has been linked to several diseases, such as multiple sclerosis and some types of cancer.\nAt the end of the study, men who exercised had higher bone density than those who had supplemented their diet with 1000 milligrams of calcium and 800 international units (IU) of vitamin D per day.\nMore than 40 million people in the US are affected by osteoporosis.\nIt\u2019s most common in older women, but about seven percent of white men and five percent of black men are affected, according to the American College of Physicians.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is rare to see a story include costs of what might be viewed as inexpensive supplements, but this story included the costs \u2013 at least \u2013 of vitamin D supplements.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\nFor example, a separate Spark gene therapy for a rare type of childhood blindness, which is on track for Food and Drug Administration clearance soon, could cost $1 million per patient for infusions in both eyes, according to some Wall Street analysts.\nSo far, with a full year, it doesn\u2019t look like that is happening.\u201d\n\nLindsey George, the lead investigator and a hematologist at Children's Hospital of Philadelphia, said that nine of the 10 men in the trial didn't experience any bleeding episodes after the gene therapy treatment.\nFor the current trial, which is being funded by Spark and Pfizer, researchers used a clotting factor that is 8 to 10 times as strong as the normal version.\n\u201cOne man who came in a wheelchair is now out of a wheelchair and is coaching Little League.\u201d\n\nPeople with hemophilia B inherit a gene mutation on the X chromosome that interferes with their ability to produce normal levels of blood-clotting factor IX.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this therapy is not yet available for patient use, the story makes a point of noting that the cost may well be \u201cstratospheric,\u201d should it make it to market.\nIf approved, such treatments are expected to command stratospheric prices. For example, a separate Spark gene therapy for a rare type of childhood blindness, which is on track for Food and Drug Administration clearance soon, could cost $1 million per patient for infusions in both eyes, according to some Wall Street analysts.\nStill, the therapies can produce at least some offsetting savings. Porteus noted in his editorial that the hemophilia therapy resulted in\u00a0savings of about $200,000 a year per patient because of the elimination of clotting-factor infusions.", "answer": 1}, {"article": "Thourani V, Jensen H, Babaliaros V, Kodali S, Rajeswaran J, Ehrlinger J, Blackstone E, Suri R, Don C, Aldea G, Williams M, Makkar R, Svensson L, McCabe J, Dean L, Kapadia S, Cohen D, Pichard A, Szeto W, Herrmann H, Devireddy C, Leshnower B, Ailawadi G, Maniar H, Hahn R, Leon M, Mack M. Outcomes in Nonagenarians Undergoing Transcatheter Aortic Valve Replacement in the PARTNER-I Trial.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\nHowever, with the advent of TAVR technology, we can now offer these extreme elderly patients a treatment option that otherwise would have been high-risk or prohibitive.\"\nIn the largest series published to date, between April 2007 and February 2012, 531 nonagenarians underwent TAVR: 329 with TF-TAVR and 202 with TA-TAVR.\n\u2022 Both transfemoral and transapical approaches to TAVR appear to be safe and effective for treatment of aortic stenosis in select patients age 90 years and older.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost or that this requires hospitalization. The article highlights that patients spent on average 5 days in the hospital.", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There aren\u2019t specifics on cost. The story states that the various individual medications that might go in a polypill are \u201ccheap,\u201d but we have no evidence that a combined pill would also be cheap. The story links to a \u201cless comprehensive\u201d polypill available online by prescription, but doesn\u2019t tell us how much it costs.\u00a0", "answer": 0}, {"article": "Alzheimer's: New test aids early diagnosis, but worth it to know?\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nAnd some patients may question whether they would want to know that the source of their mental troubles is Alzheimer's disease, said Weiner.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nUntil recently, the diagnosis of Alzheimer's disease could be made only after a patient's death, when a pathologist could find physical evidence of amyloid plaques and neurofibrillary tangles.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story calls the test \u201ccostly\u201d but does not quantify it. The cost of the agent itself, the associated PET scanning, and the interpretation of the test are not mentioned. The story does state that the test is not covered by Medicare or major insurers at this time, but readers have no idea what they would be on the hook for if they decide to pay for the test out of pocket.", "answer": 0}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nThe procedure is performed by an interventional radiologist on patients coping with metastasized lung tumors, the researchers noted.\nNone of the patients was deemed eligible for standard surgical interventions.\nRather, they said that for certain patients who may not be eligible for more standard surgical approaches, the therapy has potential as an alternative means for offering an improved quality of life for a longer period of time.\nTypically, patients were able to return home the following day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost of cryoablation nor of cost for stereotactic radiosurgery which was mentioned as an alternative.", "answer": 0}, {"article": "The results are interesting but need to be duplicated in larger, more ethnically diverse populations, said Dr. Laura Svetkey, director of Duke University's Hypertension Center.\nEvery day for 18 weeks, the volunteers were instructed to eat one-square portions of a 16-square Ritter Sport bar, or a similar portion of white chocolate.\nThe research involved just 44 people aged 56 through 73, but the results echo other small studies of cocoa-containing foods.\n\"I would be as happy as the next person if I got to eat more chocolate,\" she said.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss costs, but most people know the cost of chocolate products, even ballpark costs of more expensive imports. ", "answer": 2}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of long-acting methods (IUDs, implants, and long-acting injections) compared to alternatives such as the birth control pill, patch, or ring, although there is acknowledgement that insurance may not cover long-acting methods.\u00a0 It only briefly addresses IUDs and implants with this line: \u201ccan cost patients several hundred dollars if not paid for by insurance.\u201d", "answer": 0}, {"article": "LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test will enable women with ovarian cancer to be referred to gynaecological surgeons who specialize in the care of women with ovarian cancer, while patients with a benign tumor will not have to travel to specialist centers.\n\u201cThe vision is that a woman who has been diagnosed with having an abnormal pelvic mass will have a simple blood test and from that we will deduce whether or not she has cancer and if she does which drug would be most suitable for her,\u201d he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed here.\u00a0Cost is always a consideration when discussing a new testing method. The existing blood tests (CA-125 and OVA-1) are relatively inexpensive ($60 and $650 respectively). \u00a0Although this new method may be more sensitive and specific, its cost effectiveness is uncertain at the moment.", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs and we always think there should be \u2013 even if inconsequential. ", "answer": 0}, {"article": "LONDON (Reuters) - A 15-minute brain scan could in future be used to test for autism, helping doctors diagnose the complex condition more cheaply and accurately.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\nThe next goal is to test it in children.\nAutism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\n\u201cAlthough this method is not ready for normal diagnostic situations, any step to easier diagnosis is welcome,\u201d said Terry Brugha, professor of psychiatry at the University of Leicester.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the two devices discussed each cost around $150,\u00a0a fairly steep price for a device that offers no clear evidence of an improvement in health.", "answer": 1}, {"article": "The electrodes measured actual firings of neurons.\nPaterson says that if the results out of Boston can be confirmed, \"It's very exciting because finding an early sign for autism is really the holy grail.\"\nBut he says by using an electroencephalogram and new, sophisticated computer programs to analyze the EEGs, he and his co-authors were able to correctly identify with 80% accuracy, which babies were at higher risk for autism and which were not.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not address costs. To see why this is such a serious omission, look no further than this comment that was posted below the story online on the CNN website:\n\u201cThis is great, but if your insurance won\u2019t cover any Autism treatments, what\u2019s the point? I have a 3.5 yr old and two year old boys, both on the Autism spectrum. Our insurance covers nothing for them with regard to any treatment. It\u2019s left to us to absorb. Both require intensive speech and behavioral therapy at a cost of roughly $5,000 per month. I barely make $5,000 a month for a family of 4. \u2026I wholeheartedly approve of the advances they are making, but if insurance won\u2019t cover anything, why bother?\u201d", "answer": 0}, {"article": "\"For all practical purposes, the programs all worked about the same,\" said Kelly D. Brownell, director of Yale University's Rudd Center for Food Policy and Obesity and creator of the Lifestyle, Exercise, Attitudes, Relationships and Nutrition (LEARN) program for weight management, one of the diets studied.\nThe findings confirm, he said, that reducing carbohydrates, \"especially those with refined starch and sugar like that found in the U.S. diet, has metabolic benefits.\"\nBut those who ate vegetable forms of protein, such as soy, and fat, such as olive oil, did reduce their risk of heart disease.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nThe extra four pounds lost by the Atkins group are not very meaningful, Brownell said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention the relative costs for following any of the particular diets mentioned.\u00a0 It did not mention the cost of the books nor the costs associated with dietician visits.", "answer": 0}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\nThe next step is to investigate the effects of omega-3s on other forms of breast cancer.\nEPA and DHA are found in marine life, such as fish, algae and phytoplankton.\n\"It seems EPA and DHA are more effective at this.\nHowever, higher doses of the plant-based fatty acid were required to deliver the same impact as the marine-based omega-3s.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The additional cost of adding fish and seafood to the diet aren\u2019t discussed.\u00a0  ", "answer": 0}, {"article": "For more information, visit www.idri.org.\n\"While previous attempts have used vaccines primarily developed for other diseases, this is the first totally defined vaccine candidate developed specifically for leprosy, using the latest technologies and offering no less than those exposed to leprosy deserve,\" said Steven Reed, Ph.D., IDRI President, CEO & Founder.\n\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\n\"The vision and support of American Leprosy Missions has been tremendous as we've worked with them throughout the years, moving from our work in developing a leprosy diagnostic to our current focus on a successful leprosy vaccine,\" he said.\n\"We are thrilled that after 15 years and an investment of over $5.1 million, made possible by our faithful donors and partners, a leprosy-specific vaccine is beginning a Phase I clinical trial,\" says Bill Simmons, President and CEO of American Leprosy Missions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned. We know that it is far too soon to put a specific price tag on the treatment, but the release could have discussed the feasibility of scaling up manufacturing, whether the process is costly or time-consuming, etc. How much could the vaccine, which the release tells us is the first \u201cdeveloped specifically for leprosy\u201d and \u201cproduced by totally synthetic methods,\u201d cost patients? Based on the information in the release, it\u2019s anyone\u2019s guess.", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nThe study focused on more than 3,000 women \u2014 average age 53 \u2014 who had been treated successfully for early-stage breast cancer.\n\"I went into the study expecting to see a difference between the two groups,\" he said.\n\"We always assumed we're not eating enough fruits and vegetables and that the more we ate, the better,\" Jones said.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion about the costs associated with including fruits and vegetables in the diet, although it\u2019s reasonable to assume that the reader could figure out the costs.", "answer": 2}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that Botox treatment costs $500 to $600 per \"session\" when provided by one Palm Springs-based, housecall-making doctor. \nThe cost of Botox varies geographically, and the terms \"injection,\" \"treatment\" and \"session\" mean different thing to different practitioners. Actual price paid to get a certain result can vary widely. The article should at least have implied this.\u00a0 ", "answer": 0}, {"article": "Adding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\n\"Some patients have now been treated for up to a year, and the effect is as good as it was at the beginning,\" Dandona said at a news conference webcast from Boston.\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\nJune 7, 2011 - People with well-controlled type 1 diabetes had even better sugar control, used less insulin, and lost an average of 10 pounds in six months when taking the type 2 diabetes drug Victoza in a small clinical study.\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. Adding Victoza to a diabetic\u2019s treatment regimen would cost an additional\u00a0$350 per month, according to coverage of the study by MedPageToday. This is not a trivial sum.", "answer": 0}, {"article": "It worked.\nIt\u2019s not clear why, but viruses can also make tumors more visible to the immune system.\nThe medical team used polio viruses already weakened and altered for use in polio vaccines, and genetically engineered them to carry parts of a common cold virus, called a rhinovirus, known to be attracted to glioma cells.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\n\u201cSimilar to many immunotherapies, it appears that some patients don\u2019t respond for one reason or another, but if they respond, they often become long-term survivors,\u201d Desjardins said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much this might cost, but we\u2019ll rate this N/A since the story makes it clear that this concept still requires more research.", "answer": 2}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes the manufacturer of the device estimating a cost between $20,000 and $30,000 for the procedure. The story further notes that the intervention is not yet covered by private insurers or Medicare, but that the company is negotiating for coverage. The results of those negotiations will play a major role in the availability of the procedure.\nThis is sufficient for a satisfactory rating. We\u2019d add that given the widespread use of cost sharing in today\u2019s health insurance products, a procedure of this type will be quite costly to many by way of deductibles and co-insurance. A middle of the road estimate of these out of pocket costs would have been informative.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story mentions costs, the story does not meet this criteria because it fails to provide cost estimates of the alternative treatments.", "answer": 0}, {"article": "For more information, visit http://www.aaojournal.org.\nParticipants answered a food questionnaire to track the intake of vitamin C and other nutrients, including vitamins A, B, D, E, copper, manganese and zinc.\nAfter 10 years, researchers found that women who reported consuming more vitamin C-rich foods had a 33 percent risk reduction of cataract progression.\nThe fluid inside the eye is normally high in vitamin C, which helps prevents oxidation that clouds the lens.\nThe team examined data from more than 1,000 pairs of female twins from the United Kingdom.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the cost of adding more Vitamin C rich foods into the diet, but that would be tough to do, since the cost of foods rich in Vitamin C varies widely across the world.", "answer": 2}, {"article": "Ingelfinger, who wrote an editorial published with the study, echoed Montgomery's cautious optimism.\nWEDNESDAY, Aug. 2, 2017 (HealthDay News) -- A new treatment might open the door for more patients with advanced kidney disease to get a transplant, a preliminary study suggests.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\n\"The desensitization protocols now in use are time-consuming, and they don't always work,\" she said, noting that they can leave dangerous antibodies behind.\nThe enzyme is derived from a strain of Streptococcus bacteria, and it essentially chops up the antibodies that would attack the organ.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the article notes that current desensitization efforts involving time-consuming immune system drug infusions to stifle rejection antibodies add up to $30,000 to the cost of a transplant, it does not make any estimate of the cost of the enzyme infusion that was the subject of the \u201cnovel\u201d approach described in the new study. Based on later comments, it is presumed to cost about $65,000.", "answer": 0}, {"article": "The research was funded by the National Institute for Health Research Imperial Biomedical Research Centre and the Biotechnology and Biological Sciences Research Council\nDr Tony Goldstone, co-senior author of the study from the Department of Medicine added: \"This study adds to our previous brain imaging studies in people who have had gastric bypass surgery for obesity.\nIn a previous research study by the same team, published in 2013, they found that overweight volunteers who added the inulin-propionate ester supplement to their food every day, gained less weight over six months compared to volunteers who added only inulin to their meals.\nAfter drinking the milkshakes, the participants in the current study underwent an MRI scan, where they were shown pictures of various low or high calorie foods such as salad, fish and vegetables or chocolate, cake and pizza.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Granted, the study is preliminary but the release could have included an estimated cost for the supplement, particularly since a form of inulin powder is already available commercially in supplement shops and online.", "answer": 0}, {"article": "She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n\u201cThese patients have lost hundreds of pounds over and over again,\u201d Dr. Twells said.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\nAnd the reason is not a lack of willpower.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells readers that the bariatric surgery has a \u201ctypical\u201d price tag of $30,000 \u2014 and that some medical insurers, including Medicaid programs in many states, are reluctant to cover the cost of bariatric surgery. That\u2019s good.", "answer": 1}, {"article": "Allowing more basic emergency medical service (EMS) staff to administer naloxone could reduce drug overdose deaths that involve opioids, according to a Centers for Disease Control and Prevention (CDC) study, \u201cDisparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in Rural Communities,\u201d published in the American Journal of Public Health.\nThe findings indicate naloxone was most likely to be administered to women, people between the ages of 20 and 29, and people living in suburban areas.\nIn general, the rate of opioid overdose death was 45 percent higher in rural areas compared with urban areas.\nNaloxone is a prescription drug that can reverse the effects of prescription opioid and heroin overdose, and can be life-saving if administered in time.\nAccording to the study findings, advanced EMS staff were more likely than basic EMS staff to administer naloxone.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs, either of the drug itself or of providing more training to basic EMTs to achieve certification to administer it.", "answer": 0}, {"article": "Now two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nCurrent practice guidelines for treating kids' mild middle-ear infections -- or acute otitis media -- call for watchful waiting, to be followed by antibiotics only if symptoms worsen or don't cease.\nOne of the studies noted that while antibiotics -- specifically, amoxicillin paired with clavulanate -- shortened the duration of symptoms, half the children on placebo eventually got better without the aid of those drugs.\nBoth of the studies, in contrast to earlier research on which the \"watchful waiting\" approach has been based, are considered well-designed, even if they are on the small side.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the cost of antibiotics to treat an ear infection may not be a significant\u00a0issue for most families, we think costs always should be addressed.\u00a0 We found an estimate on Drugstore.com of $76 for a 10 day course of treatment. \u00a0 There, that wasn\u2019t difficult, was it?", "answer": 0}, {"article": "So which effect dominates?\nJogging even 5 to 10 minutes per day can reduce the risk of death from all causes I also learned about some of the incredible health benefits of going fast: Even five to 10 minutes per day of jogging at around 6 miles per hour can reduce the risk of death from cardiovascular disease and other causes.\nAnd for those who don't like running, he noted, \"Fast walking, not slow, also prolongs life.\nRunning has greater health benefits than walking (Sarah is super fit), but it also carries a much bigger risk of injury (see Sarah\u2019s foot brace).\nThe main running-related injuries include tibia stress syndrome, Achilles tendon injuries, and plantar fasciitis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs,\u00a0but both walking and running are inexpensive and widely accessible, so we\u2019ll rate this N/A.\nHowever, cost does play a role here, albeit minor, so\u00a0we think the story would have been stronger if it had included a couple points: Most running experts acknowledge that wearing cheap (often lower-quality) running shoes increases the likelihood of injury, and even those who are walking for exercise need shoes that provide good arch and ankle support. Also, many people do not live in neighborhoods conducive to outdoor exercise (from high traffic and/or pollution, or safety issues), and end up spending money at a gym or on buying a treadmill.", "answer": 2}, {"article": "This practice isn't totally harmless.\nThe recommended dietary allowance works out to three or four servings each day of \"fortified\" foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week, according to Manson's commentary.\n\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nYou should be consuming 600 international units daily if you're between the ages of 1 and 70, and 800 IU each day if you're 71 or older, according to the Institute of Medicine, the health arm of the National Academcy of Sciences.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the price of vitamin D supplements (a quick online search indicates that supplements can range in price from less than $4 to more than $80 for 180 capsules). The story also says that the recommended dietary allowance of vitamin D can be met by eating \u201cthree or four servings each day of \u2018fortified\u2019 foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week.\u201d Probably not an issue for most readers, but those aren\u2019t necessarily low-cost foods for people on a budget \u2014 and some of those foods may be unavailable to people who live in \u201cfood deserts.\u201d", "answer": 0}, {"article": "Utilizing IceCure Medical's innovative IceSense3\u2122 cryoablation system, the multi-center trial is examining cryoablation of certain types of breast cancer.\nWe are excited to be participating in this trial where some breast cancer patients can be treated without surgery,\" adds Richard Fine, MD, The West Comprehensive Breast Center, Memphis, TN, another surgeon active in the cryoablation trial.\nThe procedure is typically performed in a physician's office under ultrasound guidance in less than 30 minutes.\nIt involves a small incision and placement of an IceSense3\u2122 nitrogen-cooled probe into the center of a tumor to freeze it from the inside out.\nFor thousands of women, this may soon replace surgery as a treatment for breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There isn\u2019t a dollar sign anywhere in this release, but other cryoablative therapies cost about $11,000 to $12,000 per session and multiple sessions are sometimes necessary.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of a Tdap vaccine for mothers isn\u2019t noted, and it should be: It\u2019s free under any insurance plan, per the Affordable Care Act (sometimes called \u201cObamacare\u201d). For anyone paying out of pocket, though, it\u2019s about $64 per dose.", "answer": 0}, {"article": "Massage therapy increases the activity level of the body's white blood cells that work to combat viruses.\nThe immune changes included increased white blood cells knowns as natural killer (NK) cells, which provide rapid responses to viral-infected cells.ii\n\nAn additional randomized study found women with stage 1 and 2 breast cancer may benefit from massage therapy for enhancing dopamine and serotonin while also increasing NK cell number and lymphocytes.\n\"Researchers working with patients with compromised immune systems have found massage therapy can improve how the immune system functions,\" said Jeff Smoot, President of the American Massage Therapy Association (AMTA).\nThe American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\nTo find a massage therapist near you, the American Massage Therapy Association (AMTA), the most trusted name in massage therapy, offers a free professional massage therapist locator service at www.findamassagetherapist.org.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since there was no mention of costs in this news release, we rate it Not Satisfactory. It would have been helpful to readers to discuss the approximate cost of a massage session, which can vary widely depending on the region, therapist and setting. The Center for Spirituality & Healing at the University of Minnesota estimates the national average for an hour-long massage to be about $60. Many people may wonder if their insurance policy would cover a massage therapy session. Insurance companies rarely pay for massage therapy, particularly for indications that aren\u2019t backed by science or evidence.", "answer": 0}, {"article": "Feb. 4, 2016.\nWe are very interested in clarifying the best ways to prevent these infections, reducing the burden on the patients, on their infants and on the health-care system as a whole.\u201d\n\nAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries.\nBut based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\n\nThis work was supported by a Women\u2019s Reproductive Health Research Career Development grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health (NIH), grant number 1K12HD063086-01; and by the Department of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.\nTuuli and his colleagues also pointed out that the superiority of the chlorhexidine-alcohol combination was consistent whether the C-section was scheduled or unscheduled, whether or not the patient was obese, whether staples or sutures were used to close the wound and whether the patient had chronic medical conditions, including diabetes.\nThe study appears online Feb. 4 in The New England Journal of Medicine and coincides with a presentation at the Society for Maternal-Fetal Medicine\u2019s Annual Meeting in Atlanta.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We gave the release a passing grade on cost for including context on the cost of an infection.\n\u201cAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries. The average cost of treating those cesarean-related infections in the hospital is $3,500 and may be much higher for severe infections.\u201d\nOur wish list for this release might include whether chlorhexidine is any more expensive (or cheaper) than the standard of care and what the cost is for treating an infection outpatient. These are details that would have added to the quality of the release. However, infections are costs that can be prevented, and that is the main issue which the release covers well.", "answer": 1}, {"article": "It may also prevent infections and exacerbations of Chronic Obstructive Pulmonary Disease (COPD) like emphysema.\nThe falls were lower in those given smaller doses rather than higher monthly doses of vitamin D.\n\nThe clinical trial, the first to examine vitamin D's impact on respiratory infections in nursing home residents, looked at 107 patients with an average age of 84 over a 12 month period.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\nAURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\n\"If our results are confirmed by a larger trial, high dose vitamin D, ideally using daily dosing to minimize fall risk, has the potential for substantial public health benefit through ARI prevention for the large and growing population of long term care residents,\" Ginde said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release. Even though we are talking about vitamin D, which can be found at any drugstore for around $20 a bottle, we estimate that it could cost about $10 \u2013 $15 for a 30-day supply.", "answer": 0}, {"article": "This research was supported by Gilead Sciences.\nDaily treatment with the antiviral drug tenofovir during the third trimester of pregnancy reduced the mother-to-child transmission rate of hepatitis B (HBV) from 18 percent to 5 percent, according to the findings of a clinical trial led by researchers from NYU Langone Medical Center and published on June 16 in the New England Journal of Medicine.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\n\u201cThis study provides strong evidence on how best to care for women infected with hepatitis B during pregnancy and reduce the rate of disease transmission,\u201d says Mark Pochapin, MD, the Sholtz/Leeds Professor of Gastroenterology and director of the Division of Gastroenterology and Hepatology at NYU Langone.\n\u201cPreventing mother-to-child transmission is the most effective way to reduce the global burden of chronic hepatitis B infection and liver cancer,\u201d says Calvin Pan, MD, lead author of the study and a clinical professor of medicine at NYU Langone.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost of the drug in question, Tenofovir.\u00a0 A web search found that the cost for a month\u2019s supply of the antiviral drug averages just over $1,000.\u00a0For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines.", "answer": 0}, {"article": "\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed.\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nThe results, published in the Journal of Addiction Research & Therapy, show that 66 per cent of respondents reported an improvement in respiratory symptoms, 29 per cent reported no change and 5 per cent reported worsening.\nThe on-line survey of 941 respondents assessed subjective changes in respiratory symptoms in smokers who switched to vaping for at least two months.\nSenior author Professor Peter Hajek from QMUL said: \"There is no doubt that e-cigarettes are much safer than conventional cigarettes, but smokers are still led to believe that they're dangerous.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Vaping is a lot cheaper than smoking, but it still isn\u2019t cheap, running into the hundreds or even thousands of dollars per year. The cost of vaping isn\u2019t mentioned. Nor is the cost of other smoking cessation methods. The health costs of e-cigarettes are still unknown.", "answer": 0}, {"article": "Children in high-income households tend to perform better on behavioral and cognitive tests -- which could mask some possible harms from their mothers' light drinking during pregnancy.\n\"What we tell women is that we don't know of a safe threshold for drinking alcohol during pregnancy.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\nThe children were last given a battery of behavioral and cognitive tests when they were 5 years of age.\nMothers were first asked about their alcohol use when the kids were 9 months old.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This does not seem to apply.", "answer": 2}, {"article": "\"Any study like this is hypothesis-generating,\" he said.\n\"We think it [angiotensin] is one of the most important factors determining healthy blood vessels and also acts in the brain to help neurons to be a little more resilient,\" said Dr. Benjamin Wolozin, a professor of pharmacology and neurology at Boston University and senior author of a report on the findings, published online Jan. 13 in BMJ.\nTUESDAY, Jan. 12, 2010 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds.\nBut the evidence is not sufficient to support routine use of angiotensin receptor blockers to prevent Alzheimer's disease, Wolozin said.\nOn the other hand, such randomized trials usually include people who are close to having Alzheimer's disease, and \"it could be different if you gave the drugs earlier,\" Lipton said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the drugs was not mentioned.\u00a0 And the possible cost-effectiveness ramifications of the research were not mentioned.\u00a0 As is often the case with 70% of the stories we review, cost just doesn\u2019t seem to matter.\u00a0 But we all know it does. ", "answer": 0}, {"article": "\u201cHospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nProduced by Abbott, the CardioMEMS\u00d4 HF System is approved in the United States by the Food & Drug Administration (FDA) and is currently awaiting approval by Health Canada.\n\u201cNever before have we had the ability to obtain a patient\u2019s accurate lung pressure data while they are outside the hospital,\u201d said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre.\nWith this device, we can see warning signs days in advance, and adjust treatment accordingly.\u201d\n\nThe most rapidly rising cardiovascular disease in Canada, heart failure affects close to one million Canadians, and an estimated 26 million people globally.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this implant was a first in Canada, the news release could have cited costs of existing alternatives and given a ballpark estimate of the new intervention.\nFor example, an implantable cardioverter defibrillator (ICD) is a battery-powered device placed under the skin to keep track of heart rate. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat. ICDs alone range from $25,000-$32,000, but costs vary widely depending on insurance or financial assistance. Procedure costs depend on the physician and medical facility.\nLike ICDs, it\u2019s probable that CardioMEMS will also cost tens of thousands of dollars for US patients. Since there is no discussion of costs in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 There was no discussion of costs but that is understandable at this early stage.", "answer": 2}, {"article": "CHICAGO - A minimally invasive procedure in which pulses of energy from a probe are applied directly to nerve roots near the spine is safe and effective in people with acute lower back pain that has not responded to conservative treatment, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\n\nEditor's note: The data in these releases may differ from those in the published abstract and those actually presented at the meeting, as researchers continue to update their data right up until the meeting.\nThe probability of perceived recovery after one year of follow-up was 95 percent in the pRF group, compared with 61 percent in the injection only group.\n\"We learned that when pulsed radiofrequency is followed by steroid injection, the result is longer lasting and more efficacious than injection only,\" Dr. Napoli said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not included.\nComparing the cost of the three treatment options mentioned in the release \u2014 CT-guided pRF, CT-guided steroid injections, and lumbar disk surgery \u2014 would have been appropriate and helpful.\nAn assumption is made that the cost of this procedure is less than a surgical intervention. This is often not the case, and \u201cminimally\u201d invasive approaches can cost more.", "answer": 0}, {"article": "Newswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\nThetreatment involves patients swallowing a capsule that quicklydissolves in the stomach to reveal a deflated gastric balloon inside.With a thin catheter attached to the device, but long enough toremain outside the patient\u2019s mouth, a physician fills the balloonwith fluid (550 mL) to about the size of a grapefruit.\n\u201cFor many struggling with theirweight, procedureless gastric balloon devices may serve as atreatment option that bridges the gap between weight-loss drugs andsurgery.\u201d\n\nTheU.S.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\niv The risk of death is about 0.1 percent v and the overall likelihood of major complications is about 4percent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t suggest what the procedure might cost. It could be more than the gastric balloons already on the market due to the use of new technology or it could be less since it is less invasive than surgery. It would be useful to provide readers with some idea of how the procedure will be priced in comparison to similar procedures. A web search found prices for gastric balloon procedures ranging from $6,000 to $10,000 across the United States.\nWhereas the Eprise gastric balloon pill would be available to those with a BMI of 27 and above, according to the release, it is not a permanent weight-loss solution. Not exactly a bargain then?", "answer": 0}, {"article": "So mystery and grief hung heavy when he collapsed from a cardiac arrest Jan. 6 inside the Teutonia M??\nThere are now calls for paramedics to use the cooling procedure in the field en route to the hospital.\nFor 24 hours, his body temperature was kept at 91 degrees Fahrenheit, which put him in a state of hibernation.\n\"We consider this to be a standard of care and should be a standard of care to return people to circulation.\"\nThe ambulance service was close by and transported him without delay to AGH only blocks away.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not include any information about the expense of this treatment; it also does not indicate whether hospitals need to purchase special equipment in order to provide this treatment.", "answer": 0}, {"article": "This press release contains forward-looking statements.\nAs a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor.\nAs featured in the ASTRO Scientific Session poster titled \"High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer,\" key data points and findings from the presentation include the following:\n\u2022 The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University).\n\"The data presented at the 2017 ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs of the\u00a0MRIdian on-table adaptive radiotherapy in comparison to conventional radiotherapy are not discussed. Given that it is new and more personalized than current treatment options it\u2019s likely to be correspondingly more expensive. Certainly, more frequent MRIs would be very costly.", "answer": 0}, {"article": "TRENTON, N.J. (AP) - GlaxoSmithKline PLC on Wednesday applied for approval in the U.S. and Europe to sell an existing breast-cancer drug as a first-line treatment.\nAbout two-thirds of breast cancers are hormone sensitive.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\nIt's also been approved for that use in the 27 European Union countries and several others.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost \u2013 and Tykerb is a VERY expensive drug \u2013 thousands of dollars each month. ", "answer": 0}, {"article": "Petersen and his team wanted to develop a test that any physician can administer to patients, without the need for any new technology or expensive equipment.\n\u201cIf we had a simple blood test, a cholesterol test for Alzheimer\u2019s disease, that would help,\u201d says Dr. Ronald Petersen, director of the Alzheimer\u2019s Disease Research Center at the Mayo Clinic, \u201cbut we don\u2019t.\u201d But Petersen has a potential solution, and according to a new paper released Wednesday in the journal , his Alzheimer\u2019s test has promise.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nOnly if they show such changes \u2014 a slower walk, for example, or worsening signs of depression or memory issues \u2014 should they move on to the third phase of the test, which is a blood analysis.\nIn the first phase of the test, his researchers simply collected information from 1,500 patients\u2019 medical charts\u2014their age, family history of Alzheimer\u2019s, factors such as diabetes or smoking that have been linked to Alzheimer\u2019s, and whether the patient had ever reported problems with memory.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does note that current, more sophisticated methods of testing are expensive. But it doesn\u2019t really address the cost of new test, except to imply that it would be cheaper. That may well be true, but the cost of adding a\u00a0separate battery of tests to every patient 65 years and older, as the story suggests, could be enormous.\u00a0The \u201csimple\u201d tests defined in the research involve a detailed medical and social history as well as standardized testing for anxiety and depression and gait. \u00a0This testing along with interpretation takes time, and in today\u2019s environment, time is money.", "answer": 0}, {"article": "The ACC leads in the formation of health policy, standards and guidelines.\nThe study, \"Digital Mammography: Screening for Coronary Artery Disease?,\" will be presented on April 3, 2016, at 9:45 a.m. CT/10:45 a.m. ET/3:45 p.m. UTC at the American College of Cardiology's 65th Annual Scientific Session in Chicago.\nIn an accompanying editorial in JACC: Cardiovascular Imaging, Khurram Nasir, M.D., M.P.H., and John McEvoy, from the Center for Healthcare Advancement and Outcomes at Baptist Health South Florida, said that the report provides impetus to document breast arterial calcification in mammography reports, to improve education of primary care and radiology providers on the link with heart disease, and other actions to establish best practices for incorporating this research into care.\n\"Even by the conservative estimate of 10 percent, approximately 4 million women nationwide undergoing screening mammography will exhibit breast arterial calcification; with 2 to 3 million of them likely to have signs of premature coronary atherosclerotic disease,\" the authors said.\nEarlier research had shown a link between breast arterial calcification and atherosclerotic disease--even heart attack, stroke and other cardiovascular disease events, but researchers said these data provide a more direct relationship between the extent of calcified plaque in the mammary and coronary arteries, as well as a comparison to standard risk evaluation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release discusses cost in terms of it being a no-cost screen, since the information would be gleaned from a woman\u2019s mammogram for breast cancer. This is not the whole story. The study authors suggested that identification of calcification on breast screening would indicate the need for additional coronary artery screening. And if some 40 percent of women undergoing mammography have breast artery calcification, this will mean a lot of additional coronary imaging tests and possibly additional medications and surgery, all at unknown cost.", "answer": 0}, {"article": "This post has been updated.\nThe results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain.\nIn some of the test groups, overall success rates were fairly low, Lerman noted, but the study was conducted during the Great Recession, a time when financial stress may have depressed the chances of succeeding for everyone, regardless of which approach was used.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nBut the patch costs less and has fewer side-effects than varenicline (including nausea, difficulty sleeping and abnormal dreams), so the researchers concluded that slow metabolizers should be put on the patch.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Applause for mentioning cost, but we would have liked some actual numbers. A 56-tablet bottle of Chantix, which is discussed in the story, costs around $250 this week according to an easy-to-use online price comparison tool. A direct comparison is not quite fair, since different smokers use these medications at different rates, but a possibly comparable amount of patches that provide medication through the skin is around $50. The story also could have asked the study author to estimate the potential savings in some way. In addition, the story does not acknowledge that adding a blood test to identify slow vs. normal metabolizers will add cost to smoking cessation efforts. How much is unclear.", "answer": 0}, {"article": "Plus, surgical techniques have improved.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nWhen minimal work is done, it can be four to six weeks; when FAI is corrected, it can be more like three to four months.\nWhile that is still done, restorative techniques have been introduced that allow for the preservation of the labrum instead of its removal.\nThis means that a bone deformity causes the ball and socket to rub against each other in a way that pinches the labrum.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n \nThe story does not mention the cost of hip arthroscopy or other methods to treat labral tears and femoroacetabular impingement (FAI).", "answer": 0}, {"article": "Japanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\nA Japanese drug company is offering up a big claim: Shionogi & Co. says it has an experimental pill that can kill the flu virus within a single day, according to news reports.\nOnce inside a cell, it hijacks the cell's machinery, forcing the cell to make copies of the virus.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are discussed. Given the millions already sickened or at risk of the flu, knowing the cost of the new drug from Shionogi and Co. is a critical piece of information for health care budgets already stretched to the breakpoint for many families and communities.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of Plavix is included in the story. ", "answer": 1}, {"article": "Patsalis\u2019 method takes advantage of differences in the DNA methylation patterns \u2014 which are important to control levels of genes \u2014 between mother and fetus.\nThe risk of having a baby with Down\u2019s \u2014 which occurs when a child has three copies of chromosome 21 instead of the normal two \u2014 increases sharply as women get older.\n\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\nIt involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost. If a story can claim that something \u201cmay soon be\u201d available, it ought to be able to project cost.\u00a0 Of course, it\u2019s probably way too early to project anything meaningful on either count, but therein lies the weakness in such story framing.", "answer": 0}, {"article": "There are substantial risks.\nThe modified virus retains the ability to infect and kill brain tumor cells, and also appears to trigger the patient's own immune system cells to attack the tumors, the researchers say.\nThe scientists removed one of the virus's genes to prevent it from causing polio and replaced that gene with one from a harmless virus known as a rhinovirus, which ordinarily causes the common cold.\n\"We believe we are going to be able to increase the results even more significantly,\" Bigner says.\nIn addition, the researchers are planning to try the approach on children with brain cancer, as well as other types of cancer, including melanoma and breast cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much this might cost, but we\u2019ll rate this N/A since the story makes it clear that this is early research.", "answer": 2}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nThe new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.\nThat approval seems likely, given the results of a new clinical trial that compared Plavix to Brilinta in patients with acute coronary syndromes who had stents placed in their arteries to improve blood flow.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, although the story did mention that the twice a day dosing of the drug would be required. \u00a0If the drug is as close to FDA approval as indicated in the story, it would suggest that the company has some idea about its pricing.", "answer": 0}, {"article": "Barua is with the Kansas City (Mo.)\n\"It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels,\" Barua and his coauthors wrote.\nThe study team looked at national data on more than 83,000 men with documented low testosterone, all age 50 or above, who received care in VA between 1999 and 2014.\nFor example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease.\n... None of the FDA-approved testosterone products are approved for use in men with low testosterone levels who lack an associated medical condition.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned in this document. Generic testosterone is relatively inexpensive, which suggests that if these results reflect a real benefit, the treatment might actually be cost saving.", "answer": 0}, {"article": "Nov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish is not in question.\n ", "answer": 2}, {"article": "Please visit http://www.\nWhile there were fewer cases and less detailed data collected in the physicians' study, the score was similar in both populations, indicating the potential benefit of healthy lifestyle habits in warding off lethal prostate cancer, said the authors.\n\"This study underscores the ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population,\" said senior author June M. Chan, ScD, from the departments of Urology, and Epidemiology and Biostatistics at UCSF.\n\"We estimated that 47 percent of lethal prostate cancer cases would be prevented in the United States if men over 60 had five or more of these healthy habits,\" said Kenfield, assistant professor in the Department of Urology at UCSF Medical Center, and formerly of the Department of Medicine at Harvard Medical School in Boston, where the study was initiated.\nIn contrast, the population-attributed risk for smoking was 3 percent, largely because the majority of older American men are long-term nonsmokers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study evaluated the combined effect of six lifestyle habits on prostate cancer mortality. Those six factors were, as described in the journal article: \u201cnot currently smoking or quit 10 or more years ago, body mass index under 30 kg/m2, high vigorous physical activity, high intake of tomatoes and fatty fish, and low intake of processed meat.\u201d It\u2019s tough to put a price tag on those lifestyle choices. How much does \u201chigh vigorous physical activity\u201d cost? How much does it cost to avoid eating processed meat? It would be easy to say this category doesn\u2019t apply. But the release does address the issue, saying the study findings underscore \u201cthe ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population\u2026.It takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults\u2019 working day.\u201d Recognizing the need for policies that support these lifestyle changes is important \u2014 and addresses the cost issue in a meaningful way.", "answer": 1}, {"article": "EWING, N.J., March 14, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive results from the Phase 3 trial of VYXEOS\u2122 (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\nEven with current treatment, overall survival for AML is poor.\nAn archived webcast will be available on Celator's website beginning approximately two hours after the event.\nThe Company is seeking research and development collaborations with other biotechnology/pharmaceutical companies where its proprietary technology may provide benefit.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the costs of the treatment.", "answer": 0}, {"article": "But testimonials are not scientific proof.\nFor now, here\u2019s what consumers should know:\n\nPhysical therapists say it is not, \u201cthough superficially, it may look the same,\u201d says Justin Elliott, vice president of government affairs for the American Physical Therapy Association.\nIn rare cases, deep needling can lead to a punctured lung or injuries to nerves and blood vessels, and acupuncturists fear non-specialists will be more likely to make such mistakes, Burgoon says.\nFor one thing, he says, dry needling as performed by a physical therapist is not rooted in ancient Chinese medicine \u2014 there\u2019s no talk about redirecting the body\u2019s energy flow by placing needles at certain points in the body.\nMark Crislip, an infectious-disease doctor in Portland, Ore., who recently wrote about dry needling for Science-Based Medicine \u2014 a website critical of alternative medicine \u2014 says the version practiced by physical therapists doesn\u2019t \u201ccome with the mystical baggage that accompanies acupuncture.\u201d But he says it may well be a \u201ctheatrical placebo.\u201d\n\nWhat do published studies say?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story nicely calls out different questions that readers might have, including whether insurance will pay for the therapy. It answers, \u201cMany will not. Charges for patients can range from $10 to $75 per session, says Edo Zylstra, CEO of KinetaCore, a company that offers intensive three-day weekend courses in dry needling to physical therapists.\u201d", "answer": 1}, {"article": "2017.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of the proposed genetic testing for MAF amplification (MAF is a gene expressed in certain cancers and used as a biomarker for bone metastasis) nor any mention of the cost of treatment with a bisphosphonate. Treatment with a bisphosphonate is often recommended for 5 years so this cost should be included.\nAs is the case with many new genetic tests when they become available, there\u2019s a lag between when a test is approved and when insurance will actually cover the cost.", "answer": 0}, {"article": "The patients were selected at random from a national database.\nWithin a year of the blood test, the team found that cancer was more common among those who had thrombocytosis: 11.6% of men and 6.2% of women were found to have cancer compared to 4.1% of men and 2.2% of women without a raised platelet count.\nPrevious studies have suggested a link between thrombocytosis and various cancers, with recent guidelines from the National Institute for Health and Care Excellence advising high platelet counts could be a sign of cancer of the oesophageal, stomach, lung or uterus.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\nWhile many different types of cancer were present in both groups, the team found that breast and prostate cancers were less common among those with thrombocytosis than in the general population, while lung and colorectal cancers were more common.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Blood testing costs vary widely, but can run to hundreds of dollars, even for those covered by national or private health insurance. Moreover, there are likely even heavier costs associated with follow up cancer screenings and tests for those considered at risk because of thrombocytosis. The article makes no mention of potential or actual costs, and one suspects that a quote from a UK health information officer may have had costs in mind when she said \u201cmeasuring platelet count in patients who don\u2019t otherwise warrant a blood test is not necessarily a good idea. But if a patient has a blood test for another reason and a high platelet count is found, then one of the possible diagnoses doctors should consider is cancer.\u201d", "answer": 0}, {"article": "\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\n\u201cTo me, it is a nightmare,\u201d Dr. Albertsen said.\n\u201cI think that makes sense,\u201d said Dr. Howard Sandler, a professor of radiation oncology at the University of Michigan and a spokesman for the American Society of Clinical Oncology.\nThat led to their finding that each of the five variants independently predicted prostate cancer risk.\nThe next step, Dr. Isaacs said, is to look in other populations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included a cost for the test.", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\nAlthough HT is the most effective treatment for managing most menopause symptoms, some women have turned to herbal medicine because they are either not candidates for HT or are concerned about the negative publicity surrounding potential side effects.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Fennel supplements are sold in brick and mortar stores and online. Costs are easily established and should have been addressed in the release along with equivalent doses used in the pilot study.\nWe found 100 mg fennel seed capsules selling on Amazon.com for $9.58 for 100 capsules.\nIt\u2019s not clear that there is a standard way to assess fennel potency. Is the fennel simply ground up and made into a 100 mg tablet? What should a consumer look for when trying to buy it? The release doesn\u2019t offer any guidance.  ", "answer": 0}, {"article": "Rydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\nIf the FLT3 mutation is detected in blood or bone marrow samples using the LeukoStrat CDx FLT3 Mutation Assay, the patient may be eligible for treatment with Rydapt in combination with chemotherapy.\nThe U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy.\nCommon side effects of Rydapt in patients with AML include low levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\n\u201cThe ability to detect the gene mutation with a diagnostic test means doctors can identify specific patients who may benefit from this treatment.\u201d\n\nRydapt is a kinase inhibitor that works by blocking several enzymes that promote cell growth.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this new drug, Rydapt (midostaurin), or of the cost of the diagnostic tool, the\u00a0LeukoStrat CDx FLT3 Mutation Assay, which the FDA approved for use in determining the appropriateness of using this drug. Many patients will need to be tested for this mutation in order to find the individuals who have it and thus may benefit from this new drug.\nHowever, the FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. We rate this one Not Applicable.", "answer": 2}, {"article": "But the procedure had never been done in people.\nThe microscopic bubbles \u2014 roughly the size of red blood cells \u2014 had previously been injected into a vein, along with a chemotherapy drug called liposomal doxorubicin and a tracing molecule.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\nBut it\u2019s just one of many.\n\u201cI want to be a normal housewife \u2026 a normal grandma.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article doesn\u2019t mention costs at all. It\u2019s likely a very expensive procedure since interventional radiologists are involved.", "answer": 0}, {"article": "Half tolerated even twice that amount: a four-peanut dose.\nThe risk paid off: Two-thirds of the kids in the study were able to eat the equivalent of two peanuts without any symptoms after following the months-long experimental treatment regimen, the researchers found.\nStill, if it had taken twice the amount of time, she would have done it: \"It's peace of mind.\"\n\"It's intuitive that that process would trigger some allergic symptoms in many patients,\" Vickery said.\n\"The purpose is not to get them to be no longer peanut allergic and allow them to eat whatever they want.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2014 particularly important since the treatment might have to be taken for life. It\u2019s reportedly due to come on the market next year. ", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention projected costs for the new drug. The story could have provided some insight into the costs of available drugs to treat Type 2 diabetes. The likelihood of this new drug in combination with metformin being less exepnsive than available drugs is very low. ", "answer": 0}, {"article": "Patient care guided by CURATE.AI is currently ongoing.\nRemarkably, CURATE.AI subsequently identified a ZEN-3694 dose that was 50 per cent lower than the patient's starting dose of the drug prior to CURATE.AI analysis.\n\"No two patients' profiles are alike, and as a patient's body and the cancer itself evolve during treatment, the CURATE.AI profile evolves as well, enabling the clinical and engineering teams to optimise care for the entire duration of treatment, an unprecedented advance for combination therapy,\" Prof Ho explained.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\nTo overcome the challenges of conventional combination therapy, the NUS team of engineers developed the CURATE.AI platform, which uses the patient's own clinical data - such as their drug doses and corresponding changes to tumour sizes or levels of cancer biomarkers in the blood - to calibrate his or her unique response to treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The AI used in this case is called the \u201cCURATE.AI\u201d platform. It\u2019s not clear if the platform is proprietary. If it is, it is not clear what the cost would be for health care providers to access and make use of the platform. It is also not clear what level of training, and associated costs, would be needed for health care providers to be able to use the platform in a clinical setting. Given that the AI platform appears to be designed to create personalized treatments for each patient, the cost could be considerable. It\u2019s hard to estimate, since the release does not address cost in any way.", "answer": 0}, {"article": "New investigation advises doctors to recommend cranberry products as first line of defense against repeated urinary tract infections (UTIs)\n\nCARVER, Mass., September 19, 2017 - A thorough review of dozens of studies led scientists to conclude that healthcare professionals should be telling their patients to have cranberry products as a first step in reducing recurrent UTIs.\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\nThe industry appreciates the efforts of these researchers and takes pride in the healthy attributes that cranberry products provide to consumers around the world,\" comments Terry Humfeld, executive director of the non-profit research and education-focused organization, The Cranberry Institute.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\nThe comprehensive meta-analysis and assessment of human clinical trials, published in the official journal of the American Urological Association, The Journal of Urology\u00ae, assures practitioners and their patients that cranberry products are a low cost, low risk and effective way to help prevent recurrent UTIs.1\n\nTo answer the question, \"Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections?\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that \u201ccranberry products are low cost,\u201d which is fair enough and is sufficient to earn this a satisfactory rating. The issue of cost is, however, complicated by the fact that the release offers no information on what sort of cranberry products a patient may use. Is one glass of cranberry juice per day sufficient? Does one need to consume the whole berries? Or should patients take over-the-counter cranberry-based supplements? Costs would vary depending on how one chooses to pursue the vague directions discussed in the release.", "answer": 1}, {"article": "June 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nIt is effective for up to five days after unprotected sex.\nSurgery is often the only way to treat painful, bleeding fibroids, but surgery too can sometimes compromise fertility.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not describe costs of the drug.", "answer": 0}, {"article": "The Canadian Institutes of Health Research funded the study with reagent support from Abbott Laboratories and Roche Diagnostics.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nA positive (or high-risk) clinical chemistry score also identified about 75% of patients at high risk of heart attack or death when positive compared with a low of 40% detected when the high-sensitivity cardiac troponin test alone was positive.\n\"We have developed a simple lab score that is superior to using cardiac troponin alone for the identification of patients at low and high risk for heart attack or death at emergency department presentation,\" say Dr. Peter Kavsak, McMaster University, Hamilton, Ontario.\n\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release characterizes the chemistry tests that make up the scoring system as \u201ccommon,\u201d it offers no information about the cost of each or the likely cost of aggregating them into the recommended scoring system.", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided several estimates for the cost of gastric banding; it also discussed insurance coverage, i.e. that the procedure was not always covered by insurance.", "answer": 1}, {"article": "\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\nBut because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\nPut another way, the risk of cancer returning in the original or the opposite breast was 34 percent lower in women on 10 years of letrozole compared with those who stopped after five.\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions costs. Letrozole, the aromatase inhibitor used in the trial, is available as a generic for less than $100 a month.", "answer": 1}, {"article": "Dr. P. Murali Doraiswamy, a biological psychiatrist at Duke who had helped recruit patients for the study, called the results among \u201c the most highly anticipated data from the entire meeting.\u201d\n\nTo compare the scans with autopsy results, the company scanned the brains of 35 people in hospices who were expected to die within six months.\nIn one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\n\u201cThat was very reassuring,\u201d said Dr. Michael W. Weiner, an Alzheimer\u2019s expert at the University of California, San Francisco.\nIn addition, the company scanned the brains of 76 younger people who would not be expected to have plaque in their brains.\nIn 34 of the 35 patients, the PET scan, the pathologists\u2019 report and the computerized pathology report agreed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about the potential costs of this test.\u00a0 This at least could have been estimated.\u00a0 PET scans are extraordinarily expensive.\u00a0 ", "answer": 0}, {"article": "(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\n\"I was amazed,\" she wrote.\nAnd while I was willing, part of me dreaded it.\n\"I should be able to choose whether the side effects are worth the benefit,\" she wrote.\nThings are wonderful,'\" Streicher said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost information, whatsoever.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although costs weren\u2019t mentioned, most people know the costs of the foods and daily multivitamins mentioned in the story as sources of folate. ", "answer": 2}, {"article": "For more industry information, health research and recipe ideas, visit =.\nColorectal cancer is the third most common type of cancer worldwide and is second to only lung cancer as the leading cause of death in Western Countries.1 Diet has been shown to be a modifiable risk factor in preventing many types of cancer, including colorectal cancer.\nIt is estimated that 30-50 percent of colorectal cancer in men and 20 percent in women can be prevented by diet and other lifestyle changes.2\n\nAn article detailing these findings, \"Dietary Walnut Suppression of Colorectal Cancer in mice: mediation by miRNA patterns and fatty acid incorporation\" has been published in the Journal of Nutritional Biochemistry.3\n\nThis study was supported from a grant by the American Institute for Cancer Research and the California Walnut Commission.\n\"While future studies are needed, we're optimistic of the role of miRNAs as biomarkers of disease and prognosis, and may demonstrate a potential therapeutic target for colorectal cancer treatment.\"\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "In this very narrow discussion of a small study in mice, the suggestion is that someday maybe walnuts (or some nutritional element of walnuts) could help people by slowing the growth of colon cancer. But while the study doesn\u2019t mention how much (or how little) such a therapy might cost, we think this criterion is Not Applicable here for two reasons: 1. the cost of walnuts is generally well known, and 2. the research is at early enough stage \u2014 and the release establishes the preliminary nature of the study \u2014 that it\u2019s hard to know what any walnut-related therapy might cost.\nFurthermore, while the criteria of cost is integral to what we all agree is good reporting about health outcomes, incorporating information about the potential cost of walnuts \u2014 or any other foodstuffs \u2014 in a release about a study that\u2019s so preliminary might actually reinforce the suggestion of a useful therapy. Including that info wouldn\u2019t improve anyone\u2019s understanding of the importance of the research.", "answer": 2}, {"article": "\"I never expected apple consumption to reduce bad cholesterol to this extent while increasing HDL cholesterol or good cholesterol by about 4 percent,\" Bahram Arjmandi, chair of the department of nutrition, food and exercise sciences at Florida State University in Tallahassee, said in a statement.\n\"A large reason apples are so good is the fiber.\nIn fact, they lost an average of 3.3 pounds.\nInsoluble is found more in the skin, and the pulp is more soluble fiber.\"\nIt's kind of like nature's toothbrush, and it's brushing the bad stuff out,\" she explained.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of apples is not in question.", "answer": 2}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story clearly states near the top that this treatment is \u201cvery expensive.\u201d It reports that crizotinib treatment costs about $9,600 per month and that patients may continue to be treated until the cancer resumes spreading. There is also a reference to an assistance plan offered by Pfizer. The story also reports that tumors \u201cshrank or stopped growing in just over half of patients for nearly two years on average.\u201d From this information, careful readers could calculate that the drug cost (not including associated medical care and tests) would routinely approach a quarter of a million dollars per patient. It would have been helpful if the story had provided this calculation. The story also reports that the test needed to identify appropriate patients costs $250.", "answer": 1}, {"article": "And it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nThe skin still has to be able to breathe through this stuff.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n\u201cA lot of what happens when we age and skin starts wrinkling and sagging is loss of elastic recoil,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss costs of the would-be product, even though the story emphasizes that the technology is in private product development and data is being gathered for future FDA approval consideration.", "answer": 0}, {"article": "William E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nIn an interview in the summer, the study\u2019s director, Dr. L. Eugene Arnold, an emeritus professor of psychiatry at Ohio State, noted that there had been \u201cquite a bit of improvement\u201d in many of the children\u2019s behavior, as reported by parents and teachers.\n\u201cHe still has some symptoms, but he is much more manageable.\u201d\n\nWhether such results can be achieved with other children is a matter of debate.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\nThese issues, they say, can be represented on a \u201cbrain map,\u201d the initial EEG readings that serve as a guide for treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story provided cost estimates for a couple of neurofeedback treatment regimens. \u00a0It also indicated euphemistically that it is not paid for by insurance companies.", "answer": 1}, {"article": "Previous research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\nThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\nThe St. Jude Medical Neuromodulation company, which has provided consulting fees to Mayberg and some of the other study authors, is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression, Mayberg said.\nStill, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\nAfter two years, of the 12 patients still in the study, seven patients (58 percent) were in remission.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We would have liked to have seen a little more information on costs, but we are glad that costs are mentioned up high. In the third sentence, the story says, \u201cThe surgery necessary to allow deep brain stimulation is extremely expensive\u201d Later it says, \u201cThe cost of the surgery is about $50,000\u201d. It would have been interesting to note whether deep brain stimulation is covered by Medicare or any insurance companies for treatment of any disorders, including Parkinson\u2019s.", "answer": 1}, {"article": "Body temperature, heart and breathing rate normalize more quickly.\nIt's not just that mother and baby are together, Gray says, but also that the mother is in some way \"programming the baby, the breathing, temperature and heart rate.\"\nThe benefits are many, according to Dr. Lydia Kyung-Min Lee, an ob-gyn at UCLA.\nThis was a \"serendipitous magical finding,\" says Gray, suggesting that skin-to-skin contact acted something like a \"natural incubator.\"\nHe found that when healthy newborns had kangaroo care, there was less facial grimacing and crying suggesting pain, compared to babies who had been swaddled and had the procedure in their bassinets, \"sort of alone.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no cost associated with this practice, especially for healthy full-term babies where less parental training is needed. However, it would have been useful to discuss the high costs of NICU care, and how kangaroo care might affect those costs.", "answer": 2}, {"article": "\u201cYou saw less foreign body response.\n\u201cOur goal is to bring that kind of biological cure across the spectrum of type 1 diabetes.\u201d\n\nThe potential of the approach has attracted interest from both small startups and large biopharmaceutical companies that are looking at stem cell-based therapies for diabetes.\nThe human beta cells survived exquisitely well.\u201d\n\nThe studies show \u201cyou can take stem cells and make a limitless supply of [human beta cells] and put them in a device and cure an entirely different species of animal,\u201d Anderson said.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\n\u201cThis is really the first demonstration of the ability of these novel materials in combination with a stem-cell derived beta cell to reverse diabetes in an animal model,\u201d said Julia Greenstein, vice president of discovery research at JDRF, an organization trying to end type 1 diabetes that provided some funding for the studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Part of the caution in this story is not linking the research too closely to a potential on-the-shelf treatment. The story says in several ways that a drug therapy would be a good distance away. So we don\u2019t think it appropriate to talk about costs at this point. We rate it Not Applicable.", "answer": 2}, {"article": "What to do?\nThe result: Osteoporosis screening rates jumped sharply at age 50, despite guidelines suggesting that screening only begin at age 65, unless a woman has certain risk factors.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nThe researchers looked at whether or not women were getting a dual-energy X-ray absorptiometry (DXA) test, which measures bone mineral density.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study makes no mention of the cost of the screening test or whether it\u2019s typically covered by insurance. That\u2019s what we\u2019d look for here to warrant a bare-minimum Satisfactory grade. We also wonder how much money is being wasted on tests for women who don\u2019t need them, or how much money could be saved by screening more smartly.", "answer": 0}, {"article": "Trials of medications for treating mental illness typically don\u2019t include people younger than 18, Amminger noted, while starting minors on these medications is \u201calways very difficult, and always quite controversial.\u201d\n\nBut if future research bears out the current findings, he added, fish oil promises to offer a safe way to help prevent psychosis in at-risk people, and could also potentially be used to prevent or delay the onset of chronic depression, bipolar illness, and substance abuse disorder \u2014 all of which are far more common than psychotic illness.\n\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nFurthermore, only about a third of people at high risk for psychotic disorders will go on to develop full-fledged mental illness in a given year.\nThe researchers included people who met at least one of the following three criteria: having low-level psychotic symptoms; having transient psychotic symptoms; or having a schizophrenia-like personality disorder or a close relative with schizophrenia, along with a sharp decline in mental function within the past year.\nThey are also key to the proper function of two brain chemical signaling systems, dopamine and serotonin, which have been implicated in schizophrenia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.\u00a0 Fish oil supplements are relatively inexpensive and can cost as little as $0.25 per day for the amount given in the study.", "answer": 0}, {"article": "This version has been corrected.\nHe called the technology \"a canary in the coal mine\" for lung cancer, which kills about 160,000 people in the United States each year.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nCorrection: The original version of this post incorrectly named the company that is distributing the Bronchial Genomic Classifier.\n\"There will still be a small number of biopsies,\" Spira said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes that traditional means of diagnosing suspected lung cancer are costly, often involving invasive procedures and resulting complications. That\u2019s good. But it doesn\u2019t cite any range of costs, information easily available from groups like the American Thoracic Society. More significantly, perhaps, is the lack of any estimated cost for the new genomic classifier test, which was apparently readily available because it was reported elsewhere. (A Reuters story, for one, had this info.)", "answer": 0}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology.\nIn a small study, MRI brain scans predicted with 89 percent accuracy who would go on to develop dementia within three years, according to research at Washington University School of Medicine in St. Louis and the University of California San Francisco.\n\"We could tell that the individuals who went on to develop dementia have these differences on diffusion MRI, compared with scans of cognitively normal people whose memory and thinking skills remained intact,\" Raji said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost. A brain MRI can be expected to run anywhere from $826 to $4,780, including both physician and imaging fees, according to the web site Healthcare Bluebook. The information in the news release suggests MRIs would have to be repeated every two years or so in order to detect brain changes before the onset of symptoms.", "answer": 0}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is particularly important when many patients may have to pay out of pocket for weight loss drugs. The\u00a0story does\u00a0not provide any information about the\u00a0cost of orlistat, the\u00a0cost of the food\u00a0in the\u00a0study diets, or the cost of the counseling provided to study participants.\u00a0\u00a0\nA quotation from one of the study researchers suggests\u00a0that\u00a0a low-carb diet might be a\u00a0cheaper alternative to a low-fat diet plus medication.\u00a0While this is certainly\u00a0possible, it also seems possible that low-carb eating,\u00a0with its emphasis on protein from\u00a0meat,\u00a0would be more expensive than low-fat eating, and that this would cancel out any savings on medication. In any case,\u00a0making any kind of judgment in this area would require\u00a0more hard data, but\u00a0the story provides only speculation.", "answer": 0}, {"article": "This clinical trial was funded by Merck.\nPublished in the New England Journal of Medicine, the study found that, among uninfected women, Gardasil 9 was 97 per cent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective as the current Gardasil vaccine in preventing diseases caused by HPV 6, 11, 16 and 18.\nThe UK currently uses Gardasil which protects against four HPV types and offers about 70 per cent protection against cervical cancer, and also significantly reduces the risk of other types of cancer and genital warts.\nThe findings indicate that if uninfected populations are vaccinated with Gardasil 9, approximately 90 per cent of all cervical cancers worldwide could be prevented.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release is from the UK and likely written for a UK audience, which would expect the cost of the vaccine to be covered under the NHS vaccination program. (The release mentions that the current vaccine is covered by NHS.) However, the release does not provide any detail on what the vaccine costs per person or what the vaccination program costs NHS \u2014 which is something we think even readers in the UK would be interested in and deserve to know. For our U.S. readers, we\u2019d note that\u00a0the vaccine requires three doses and therefore three different office visits. The costs of the visits and the vaccines ($130-140 per dose) bring the total immunization cost to approximately $500. Insurance usually covers a portion of the costs, but patients may have copayments.", "answer": 2}, {"article": "The new study, however, draws from the population.\nJan. 9, 2012 -- Nicotine replacement therapies such as gums or patches may not help smokers kick the habit long-term, a new study shows.\n\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\n\"In the short term, what it is designed for is treatment of withdrawal,\" he says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story discussed costs in the context of overall sales figures. \u201cDeciding how best to get smokers to quit for good is a public health challenge. Sales of the nicotine replacement products have risen, Connolly says. Sales totaled $45 million in 1984, when nicotine gum was introduced. Since 1997, sales have totaled more than $800 million annually.\u201d We wish the story had included some examples of the costs of the individual products compared to cigarettes.\nThe cost of 8 weeks of the nicotine patch is approximately $160-200.", "answer": 1}, {"article": "For more information about Pitt Public Health, visit the school's Web site at http://www.\nThe analysis, published today in the journal Stroke, determined that resuming anticoagulation therapy after a person suffers a major bleeding event was associated with a higher likelihood of stroke-free survival than discontinuing anticoagulation.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\nPeople take anticoagulants to avoid blood clots when they have a risk for stroke or heart attack, but the downside is that these medications increase a person's risk of severe bleeding--such as in the brain or gut--because the blood isn't clotting as well as it otherwise might.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the significant cost difference between the two anticoagulants. A one-month supply for the highest recommended dosage runs about $400 for dabigatran, marketed as Pradaxa, versus $11 for warfarin, which has additional monitoring costs.", "answer": 0}, {"article": "Correction: February 16, 2006, Thursday A front-page article on Feb. 8 about a new study finding that low-fat diets have no effect on the risk of cancer or heart disease misstated the incidence of breast cancer among women in the study.\n\"People are always thinking it's what they ate.\nNot everyone was convinced.\n(The difference was deemed statistically insignificant.)\nDr. Rossouw said the observational studies that led to the hypothesis about colon cancer and dietary fat included men and women.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 2}, {"article": "AUGUSTA, Ga. (March 9, 2017) - The first year of free lung cancer screening in the Augusta, Georgia area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this number one cancer killer.\nAfter 15 years of not smoking, the lung cancer risk tends to diminish but never vanishes.\n\"We want to reach as many people as we can as early as we can,\" he said.\n\"If we catch it in the early stages, ideally before symptoms surface, we can operate and patients can have an overall survival rate of 90 percent.\"\nThey may follow up on smaller nodules in six months, then if the nodule is stable, go back to annual reviews.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release clearly states that the relevant screening technique would normally cost between $100 and $250, but was free as part of the initiative.", "answer": 1}, {"article": "New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\nAny insult to the skin -- be it a cut or wound or the rapid stretching that drives the formation of stretch marks -- is accompanied by inflammation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that a 5.29-ounce tube of the product retails for $39.99 at drugstores.", "answer": 1}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story devotes a few sentences to costs, without actually providing dollar figures. Still, the effort is far stronger than in most stories about colonoscopies or other procedures. This sentence was especially nice to see: \"An alternative to colonoscopy is flexible sigmoidoscopy, a shorter, less expensive exam which looks only at the bottom portion of the colon, combined with a fecal occult blood test, which looks for blood in the stool.\"", "answer": 1}, {"article": "AMD, the No.\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\nAccording to national statistics, the average age at which individuals are given L-DOPA is 67; the average age of AMD diagnosis is 71.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\n\"Results suggest a new path forward in our fight against AMD that may even include a strategy to prevent those at risk of the disease from ever developing it,\" said Brian McKay, Ph.D., associate professor, Department of Ophthalmology and Vision Science, University of Arizona.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release is relatively cautious, it fails to mention the costs of its suggested treatment in any way. One assumes from the release that patients would be taking L-DOPA for a considerable length of time, which could represent a substantial expense. L-DOPA has been prescribed for patients with Parkinson\u2019s disease and other maladies for years and offering an estimate of yearly costs of the drug should have been easy, and would have helped readers gauge the value of this research in terms of patient care. Levodopa is generally prescribed in combination with another drug or drugs but the treatment cost of L-DOPA alone is several thousand dollars annually.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Coffee, tea, or decaf-no matter what your choice, drinking any of these beverages may reduce your risk of diabetes, according to a new analysis of 18 studies including hundreds of thousands of people.\nClinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\nIn the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\nAnd in seven studies that examined tea drinking and diabetes risk, people who drank more than three or four cups daily were at 18 percent lower diabetes risk.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, but most people know what coffee and tea costs.", "answer": 2}, {"article": "Alexander Technique is a series of posture lessons, devised by a 19th century Australian actor named F.M.\n\"We look at what you are doing that causes that problem in the first place, so how you sit at the computer or how you pick up your child or what you do when you're driving,\" says Gray.\n\"The fact of having your arms up and carrying the weight of this instrument and pushing the instrument toward you and so you have this stress, this wall you're pushing against,\" says Rodriguez.\n\"The people who had 24 lessons had gone down from about 21 days of pain that the usual care group reported to about 3 days in pain,\" says Little.\n\"The whole point is that you understand the process so that you can arrive there yourself,\" says Gray.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss the costs of Alexander Therapy. The clinical trial mentioned in the article involved up to 24 sessions with an Alexander therapist, so this treatment can be expensive. \nA systematic review conducted for the British National Health Service found instruction in the Alexander Technique to be significantly less cost-effective than a simple exercise program (See Nice, 2009; p. 97). So costs are an issue with this therapy and they should have been discussed in the article.\n", "answer": 0}, {"article": "On the other hand, Vorona says, \"The last thing I want readers to think is that Dr. Vorona thinks we're facing this obesity epidemic because we're sleep deprived.\nMake sure the room temperature is comfortable.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\n-- Practice good sleep hygiene.\nInstead, choose whole-wheat crackers, which can control insulin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not directly relevant to the dynamics of sleep and weight, nor to the interventions described in the story.", "answer": 2}, {"article": "Malmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\nIt also suggests that women aged 40 to 49 at average risk discuss the pros and cons with their doctors and decide on an individual basis if and when to start screening.\nAmong them, according to the 2009 guidelines, are false-positives, which can lead to anxiety and unnecessary biopsies.\nWhen the researchers looked only at invasive cancers, 92 percent of the women whose cancer was found on mammogram survived without recurrence at five years; 88 percent of the other group did.\nWomen whose cancers were detected by mammograms were more likely than the doctor- or patient-detected cancers to have lumpectomy or other breast-conserving surgery: 67 percent vs. 48 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs regarding mammograms. \u00a0Stories should not assume that every woman in the 40s who chooses to get a mammogram will have this covered by their insurance.", "answer": 0}, {"article": "MONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\nA newer version, one coated with zotarolimus, fell short, the study found.\nThe trial was partially funded by Medtronic, maker of the zotarolimus-eluting stent.\nFonarow said the study results can help cardiologists arrive at treatment decisions.\nFor more information on stents, visit the U.S. National Library of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed.", "answer": 0}, {"article": "By eating bread containing 4% of dried seaweed the overweight men ingested more dietary fiber (4.5 g more fiber per.\nBut the responsibility should also be shared by society, argues University of Southern Denmark professor of biophysics, Ole G. Mouritsen, who has authored several books on seaweed as food.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\nIt is also possible to add seaweed to meat products and thereby provide the consumer with an increased intake of dietary fiber and antioxidants - or maybe the aim is lower cholesterol levels.\nFor example, dried and granulated seaweed can replace some of the flour when producing dry pasta, bread, pizza, snack bars, etc.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in this piece. This is odd for two reasons: 1. Seaweed of certain varieties is readily available in grocery stores and a staple of sushi bars and other restaurants. 2. The authors are advocating that seaweed become a regular part of baking and cooking, which means that costs need to be considered.", "answer": 0}, {"article": "TUESDAY, March 8, 2011 (HealthDay News) -- Acupuncture may help reduce the severity of hot flashes and other symptoms of menopause, according to a small study.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\nThe beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe findings were published online March 7 in Acupuncture in Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 Women in the study were treated for 10 weeks.\u00a0 How much would that cost?\u00a0 Not a trivial issue.", "answer": 0}, {"article": "Bernstein and her colleagues saw an overall 16 percent lower risk of breast cancer in women who reported using low-dose aspirin at least three times per week.\n\"We already knew that aspirin is a weak aromatase inhibitor and we treat women with breast cancer with stronger aromatase inhibitors since they reduce the amount of estrogen postmenopausal women have circulating in their blood,\" said Bernstein.\n\"We did not by and large find associations with the other pain medications like ibuprofen and acetaminophen.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\n\"We thought that if aspirin can inhibit aromatase, it ought to reduce the likelihood that breast cancer would develop and it could also be an effective way to improve breast cancer patients' prognosis once they no longer take the more potent aromatase inhibitors.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes, near the bottom, that low-dose aspirin is inexpensive. That\u2019s enough to earn it a satisfactory rating here since low-dose aspirin is indeed inexpensive. Costs for a bottle of 300 tablets currently range from $3.47 to $12.49 according to an online search.", "answer": 1}, {"article": "Records covered the use of both low- and high-dose aspirin (ranging from 75 milligrams to 500 milligrams), so-called \"nonselective\" NSAIDs (such as ibuprofen [Advil] and naproxen [Aleve]), and both older and newer types of COX-2 inhibitors.\nOver-the-counter NSAIDs are used to control pain, fever and swelling.\nThe study appears in the May 29 online issue of the journal Cancer.\nIn turn, prescription histories were gathered for both the cancer patient group and almost 179,000 healthy Danes.\nFor more on NSAIDs and cancer, visit the U.S. National Cancer Institute.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of NSAIDs is not in question.", "answer": 2}, {"article": "For more information about the American Academy of Neurology, visit http://www.\nMINNEAPOLIS - People who eat vegetables, fruit and whole grains may have lower rates of depression over time, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018.\nIn addition to fruit and vegetables, the DASH diet recommends fat-free or low-fat dairy products and limits foods that are high in saturated fats and sugar.\nOn the other hand, the more closely people followed a Western diet--a diet that is high in saturated fats and red meats and low in fruits and vegetables--the more likely they were to develop depression.\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. However, the \u201ctreatment\u201d at issue is not a drug or medical technology with clearly defined costs. Rather, the DASH diet focuses on an individual\u2019s food choices. While there are cost constraints associated with any diet, and many people do not have easy access to the fruit and vegetables that are at the heart of the DASH diet, it would be challenging to address those issues in any meaningful way in the context of a news release like this one. That being the case, we\u2019ll rate this as \u201cnot applicable.\u201d", "answer": 2}, {"article": "Previous reports22,23 of the overall randomized clinical trial found locoregional control and survival advantages associated with the addition of cetuximab to radiotherapy.\nFurthermore, there were greater severe acute toxic effects from the chemoradiotherapy treatments compared with radiotherapy alone,13 but no significant differences in severe late toxic effects were noted in the comparison of the 3 treatment arms.14 Unfortunately, the concomitant chemoradiotherapy arm had an increase in deaths not attributable to cancer compared with the other 2 arms; this finding needs to be explored further to determine whether undetected fatal late treatment toxic effects are greater with concomitant regimens.\nThe TREMPLIN (Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation) trial compared the efficacy and safety of induction chemotherapy using docetaxel, cisplatin, and fluorouracil, followed by chemoradiotherapy with cisplatin (n = 60) or cetuximab (n = 56), for laryngeal preservation.33 No differences were found in laryngeal preservation, laryngeal function preservation, or overall survival between the 2 regimens.\nHistorically, locoregionally advanced squamous cell cancers of the larynx or hypopharynx have been treated with surgical resection, usually involving laryngectomy with or without postoperative radiotherapy.1 Although laryngectomy is an effective treatment, investigators have sought therapeutic strategies that result in voice preservation.\nVarious modifications of surgical techniques have been explored.2-5 Alternatively, in the early 1980s, investigators evaluated curative primary radiotherapy with salvage surgery as an option for these patients.6,7 Retrospective studies8,9 that compared primary radiotherapy with salvage surgery to initial surgery with postoperative radiotherapy found similar rates of survival in patients with advanced laryngeal or hypopharyngeal cancers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss costs at all. Given that the relevant study compared radiation therapy to the use of radiation therapy in conjunction with cetuximab, that\u2019s particularly problematic. Cetuximab is already on the market (under the trade name Erbitux) for use in treating various cancers. The drug has been the subject of public debate regarding its cost relative to its therapeutic value (e.g., see these articles in the Wall Street Journal and USA Today). Regardless of where one stands on that debate, treatment with cetuximab can cost tens of thousands of dollars, which is worth mentioning. And the likelihood that the combo therapy won\u2019t be covered by insurance (given its nonsignificant results) should have been discussed.", "answer": 0}, {"article": "* Drug being developed by Pfizer, Elan and Johnson & Johnson\n\nLONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nThe treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling.\nThe effect was similar with three different doses of the drug, they reported in the journal Lancet Neurology.\nMost advanced drugs, like bapineuzumab, have focused on removing clumps of amyloid plaques, which are thought to stop brain cells from functioning properly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, nor was there even any mention that the drug needed to be administered via an injection \u2013 which will impact cost of delivery. \u00a0", "answer": 0}, {"article": "The Menlo Park, California-based company\u2019s shares were up 3 percent at $33.00 in extended trading on Wednesday.\nBased on the most recent estimates, about 7.8 million Americans have some form of excessive sweating including palms, feet, underarms or head, and about half of this population suffer from the underarm form, said Dermira spokeswoman Erica Jefferson, in an interview ahead of the data readout.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\nWhile the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The product is not yet on the market, and is defined as experimental, so we\u2019ll rate this as N/A. But readers would still benefit from seeing the\u00a0projected steps\u00a0needed to get on the market, which isn\u2019t made clear here.", "answer": 2}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn't discuss the cost of the drug. ", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nIt didn\u2019t include a comparison group, which would offer the best evidence, but it \u201chelps build the evidence base for the importance of getting in for early treatment,\u201d said Dr. Donna Arnett, dean of public health at the University of Kentucky and past president of the American Heart Association.\nThe findings, reported in the New England Journal of Medicine, are more evidence of the benefits of sending someone to a hospital even if muscle weakness or slurred speech has only lasted for a few seconds, lead author Dr. Pierre Amarenco of Bichat Hospital in Paris told Reuters Health by phone.\nBut in the new study, Amarenco and his colleagues found stroke risks of 1.5 percent at two days, 2.1 percent at seven days and 3.7 percent at 90 days when mini-strokes were treated aggressively.\nThe researchers also found that the one-year stroke risk doubled when multiple blood vessel clogs were seen with brain imaging, a large artery was narrowed by heart disease and the patient scored a 6 or 7 on a seven-point scale that assesses stroke risk factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t addressed. Emergency room costs can be expensive, particularly for uninsured patients. And the costs associated with TIA treatment can vary widely, because treatment options can vary depending on the diagnosis. For example, a patient may be given drugs to \u201cbust\u201d a blood clot, or the patient may need to perform a surgical procedure. A 2014 study found that the average hospitalization for stroke in the U.S. cost approximately\u00a0$20,396 \u00b1 $23,256.\nThat\u2019s a lot of variability, and covers all types of stroke \u2014 not TIAs per se. In other words, it\u2019s tricky to nail down any firm numbers for a relatively concise news story. But the costs associated with treatment in a TIA unit could still be discussed (or at least mentioned).", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nThe test correctly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\nThe diseases typically progress for years before symptoms appear, and once they do, distinguishing one disease from another can be difficult.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nEarly and accurate diagnoses of these brain disorders is essential for developing treatments and identifying patients eligible for clinical trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost. The study itself says having quicker results \u201cmarkedly enhances the cost effectiveness and practicality\u201d of these tests.", "answer": 0}, {"article": "\"For high-risk people, those with heart disease or [who] have had a stroke who are taking a standard dose of a statin, further reduction in LDL cholesterol will give them extra benefit,\" said Dr. Colin Baigent of the Clinical Trial Service Unit and Epidemiological Studies Unit at University of Oxford in the United Kingdom, who was involved in both studies.\nThe researchers found that in trials comparing statin doses, taking high-dose statins reduced the odds of having a stroke by an additional 15 percent, compared to the usual doses of statins.\n\"But if you are at risk from those diseases, you would need intensive treatment to lower LDL cholesterol, even if your LDL cholesterol level is not very high,\" he added.\nThe researchers noted that the higher dose of Zocor (simvastatin) did result in a risk of a muscle disease 10 times higher than that associated with the lower dose.\nIn addition, there were no significant effects of statins on deaths due to cancer or other non-vascular causes, and no excess risk of cancer, even at low LDL cholesterol concentrations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of these drugs or the cost ramifications of the increased dosages.\u00a0This ought to have included the simple increase in costs due to the increased dosage of the medication and also at least a nod to the costs associated with the increase in adverse events.", "answer": 0}, {"article": "Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\nThese risks and uncertainties include, but are not limited to: the ability of test results to change treatment decisions; the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended March 31, 2015.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release never mentions the cost of the test and there is some concern that insurance carriers may not cover costs for tests of DCIS. Insurance coverage is variable and appeals do not always result in reversal of the denial.", "answer": 0}, {"article": "The study did not detect a difference in the length of time patients lived without their disease getting worse.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\nIn addition to Tecentriq\u2019s approval for bladder cancer patients whose disease has stopped responding to chemotherapy, the FDA last month approved the Roche drug as an initial treatment for people with a specific type of advanced bladder cancer and in people whose cancer progressed despite at least one prior platinum-containing chemotherapy.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nThe agency has also granted contingent approval to AstraZeneca Plc\u2019s Imfinzi, Bristol-Myers Squibb\u2019s Opdivo and Bavencio, developed by Pfizer Inc and Merck KGaA, as second-line bladder cancer treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the drug is not discussed, and this is a significant oversight. As we\u2019ve noted in another review of a story on Keytruda, \u201cthe cost is about $150,000 a year.\u201d\nInsurance coverage and high out-of-pocket costs are another issue that could have been addressed.", "answer": 0}, {"article": "CHICAGO (Reuters) - A new analysis of evidence used by a U.S. advisory panel to roll back breast cancer screening guidelines suggests it may have ignored evidence that more frequent mammograms save more lives, U.S. researchers said on Tuesday.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\nIn the new analysis, the team found that annual mammograms starting at age 40 save 65,000 more women from breast cancer than mammograms done every other year in women 50 and older.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The piece does not include any discussion of the financial, physical, or emotional costs of beginning routine mammography screening at age 40, which the authors of the new analysis see as necessary.\u00a0 The financial costs of overdiagnosis are significant for both the individual diagnosed and for society.\u00a0 The article does not include information about the increased number of false positives that will result from annual screening beginning at age 40 or about the significant physical and emotional costs of false positives.\u00a0 The article\u00a0is dismissive of these harms.\u00a0 From the article it is not clear whether the new analysis considered any of these harms or was solely based on breast cancer mortality.", "answer": 0}, {"article": "By comparison, the only approved long-term prescription weight loss medication available on the market today, Xenical, is associated with a seven-pound weight loss when combined with diet and exercise.\nThe drugs, phentermine and Topamax, in combination with lifestyle and weight-loss counseling were associated with a 18-22 pound weight loss in trial participants, compared with a three-pound weight loss in patients who received counseling alone.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nFen-phen was removed from the market in 1997 amid concerns about the drug's heart risk, but phentermine has been used successfully for short-term appetite suppression since then with no major safety concerns.\nThe drug could be a good option for some people, but it's most likely not a silver bullet, said Dr. Melina Jampolis, CNNHealth's physician nutrition expert, who is not connected with the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The story didn\u2019t discuss cost, but the story was clear that is a drug that has been slowed in its path to marketing approval so that is understandable.", "answer": 2}, {"article": "Women in the acupressure group also used less pain medication than women in the control group and reported lower levels of pain overall.\nHowever, the women who were involved during the planning stages, all of whom were affected by menstrual pain, wanted an app,\" reports the study's principal investigator, Prof. Dr. Claudia Witt of the Institute of Social Medicine, Epidemiology and Health Economics.\nSo far, research into the clinical effectiveness of apps has been limited, and only a few have been tested using randomized controlled trials,\" says Dr. Daniel Pach of the Institute of Social Medicine, Epidemiology and Health Economics.\nThese questions addressed in a new study by researchers from Charit\u00e9 - Universit\u00e4tsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.\nOne advantage of an app-based intervention is its ability to provide visual descriptions of the pressure points users need to target in order to achieve the desired effect.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release did not mention it, but the app is \u201cgratis\u201d according to the Luna app website (in German). Most apps of this kind are sponsored and free, and even those that are not free of charge are mostly very inexpensive.", "answer": 0}, {"article": "Reuters - A nicotine addiction pill can help smokers quit gradually when they can\u2019t go cold turkey, a study finds, suggesting that it may be time to revisit practice guidelines that focus primarily on immediate cessation.\nTen years after quitting, the risk of lung cancer drops by half, according to the CDC.\nPrevious research has linked Chantix to side effects including suicidal thoughts, erratic behavior and drowsiness.\nBy the last ten weeks of treatment, weeks 15 to 24, the group taking the pill had significantly higher abstinence rates than the group on placebo.\nPeople with a history of major depressive or anxiety disorder, suicidal behavior, panic disorder, post-traumatic stress disorder, schizophrenia, or psychosis were excluded from the study, published in the American Medical Association\u2019s journal JAMA.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not tell us how much the smoking cessation drug costs or whether insurance companies will pay for it.", "answer": 0}, {"article": "Johnston says the fight against obesity needs creative solutions that help people manage their weight, appetite and hunger by offering socially acceptable food choices.\nAt the end of the period, those students who received the snack more regularly experienced a decrease in their overall BMI (-.7kg/m2) compared to those who did not receive the regular peanut snack (-.3kg/m2).\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\n\"We'd like to think it's preventable, but from where I sit right now, there hasn't been a lot shown to be very effective on a large scale.\"\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release didn\u2019t address costs, but we won\u2019t penalize it because peanuts cost, well, peanuts.\nThat being said, the release could have been improved by the addition of some context about the high costs of eating well, especially in urban food deserts and among families without the time, transport, and resources to buy, cook, and eat fresh food.", "answer": 2}, {"article": "Recipients were at most seven years older or younger than the donors.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nOld age is not necessarily a barrier to kidney donation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss costs. Couldn\u2019t the transplant surgery be more expensive for older donors due to increased rate of complications? And just in general, cost is almost always an issue with surgery, and this needed at least a brief mention.", "answer": 0}, {"article": "THURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\nThe findings were published online May 23 in Neurology.\nThirty-five study participants had this form of vertigo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While this story focused on what researchers believed is a new form of vertigo, they did mention that it could be treated by an unnamed medication.\u00a0 The story should have named the medication, and the cost.", "answer": 0}, {"article": "The researchers found that overall 30-day mortality decreased from 1.6 percent (84 of 5,275 patients) to 0.7 percent (26 of 3,878 patients) after FSI implementation.\nAs the U.S. population ages, the number of operations performed on elderly patients will likely increase.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nFor more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned.", "answer": 0}, {"article": "Funding came from the National Institutes of Health and the American Heart Association.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nAt the end of the two-year study, those who had exercised showed an 18 percent improvement in their maximum oxygen intake during exercise and a more than 25 percent improvement in compliance, or elasticity, of the left ventricular muscle of the heart, Dr. Levine noted.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The intervention proposed is at least a half-hour of exercise 4-5 times per week. With the exception of a recommended 1 or 2 sessions involving weights or exercise machines (which would involve some cost) this intervention would require minimal financial investment. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\n\u201cMost clinicians or surgeons feel like if you take the time to do a big operation on someone, you know the area operated on, how the operations went, if there were complications,\u201d lead author Dr. Benjamin S. Brooke of the University of Utah School of Medicine in Salt Lake City told Reuters Health by phone.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\n\u201cA lot of readmissions are patients who have time to be transferred or triaged, if they are not bleeding to death or having a heart attack,\u201d he said.\nMore than nine million patients underwent one of 12 such surgeries during the study period, and between six and 22 percent, depending on the surgery, were readmitted to the hospital within a month.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Alas, though the story contains some interesting information, it does not explore or speculate as to what the cost would be of returning most patients to an index hospital. It\u2019s possible there would be downstream savings.\nInterestingly, in the U.S. hospitals may face a penalty from Medicare if they have high readmission rates. In that sense, they could have an incentive to discourage patients from coming back to the same institution.", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention costs of estrogen.", "answer": 0}, {"article": "There were also big improvements in their parenting style.\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\nWithin a year, more than half of the women in a control group (58%) were still depressed, whereas only a quarter of the mothers who had been treated with CBT reported depression.\nThe international research project into the impact of depression on pregnant mothers and their babies, led by Professor Sonia Bhalotra from the Institute for Social and Economic Research at the University of Essex, could have major implications for public policy.\nThe study, one of the largest randomised control trials to be held in the developing world, followed women diagnosed with depression mid-pregnancy in 40 communities in rural Pakistan.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were glad that this short story mentioned the societal cost estimate for depression but still find it lacks any \u201ccost\u201d for the therapy under discussion.\nFor the clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, so the cost would be whatever it cost to add this training and time to their work. (Likely minimal.)\nSo, we think the story should have added a line or two acknowledging that it was a relatively affordable intervention where it was implemented\u2013in Pakistan\u2013but is likely to be of widely varying costs depending on where it\u2019s used. In the U.S., for example,\u00a0cognitive behavioral therapy typically requires 8-12 weeks of visits to a professional who charges between $180 and $250 per hour in the United States, according to Consumer Reports. Some of this might be covered by some insurance.", "answer": 0}, {"article": "Awair is the first smart air quality device that monitors, analyzes and provides feedback to improve the air you breathe.\nIt analyzes the data in real-time and gives an Awair score on a 0 to 100 color-coded scale, 0 being the worst air quality.\nAs soon as you see other colored (amber and red) dots show up on top of the green dots, your environment is getting off the healthy ranges whether it being temperature, humidity, CO2, VOCs, and dust,\u201d Ronald Ro, the CEO and co-founder of Bitfinder Inc., the makers of Awair, told FoxNews.com.\nWhile breathing fresh, clean air can boost productivity, sleep and overall health, not everyone can live in the great outdoors and it\u2019s difficult to know just how clean the indoor air in your home or office is.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the Awair app is free, but that each air monitoring device costs $199 dollars. Presumably, one would need multiple devices to monitor air quality throughout a residence.", "answer": 1}, {"article": "Overall, the study found, measures of spasticity dropped an average of three points \u2014about 30 percent \u2014 on a 24-point scale when patients smoked marijuana, but didn\u2019t change after they smoked the placebo.\n\u201cIt\u2019s pretty clear that the patients were not really blinded,\u201d LaRocca said.\n\u201cWe can\u2019t say anything about long-term effects,\u201d Corey-Bloom told Reuters Health.\nFor now, LaRocca recommended that people with spasticity see a doctor experienced in treating MS. And if you\u2019re on an anti-spasticity medication and it\u2019s not working well enough, or the side effects are too much, tell your doctor, he said.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Somebody had to pay for the marijuana used in the study.\u00a0 And somebody would have to pay something if it were used therapeutically.\u00a0 A cost estimate would have helped.\u00a0 Not everybody knows this stuff.", "answer": 0}, {"article": "Taking prenatal vitamins was found even more protective for mothers and children who had a high-risk genetic makeup .\n\"Overall, it does look like there are at least a couple of genes here, either the mother's genotype or the child's genotype, that show this interaction ... magnifying the size of the effect from not taking the vitamins,\" Hertz-Picciotto says.\n\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nOverall, Hertz-Picciotto says, \"For the women who didn't take prenatal vitamins, there was about a 60% higher risk of having a child with autism.\"\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs, which is unfortunate considering that\u00a0there can be\u00a0big differences in the\u00a0price of prescription prenatal vitamins vs.\u00a0OTC brands.\u00a0Some women may also do fine with a basic\u00a0store-brand multivitamin. Costs can also vary depending on insurance coverage, since some plans may cover the cost of prescription vitamins but not OTC\u00a0products.\u00a0At a minimum, the story should have mentioned the range of costs for a month\u2019s supply\u00a0in order to satisfy the criterion. Some discussion of the other tradeoffs between prescription and OTC brands (varying formulations, tolerability, etc) would also have been helpful.", "answer": 0}, {"article": "LOS ANGELES -- Researchers have demonstrated for the first time that the progression of Type-1 diabetes can be halted -- and possibly reversed -- by a stem cell transplant that preserves the body's diminishing ability to make insulin, according to a study published today.\nIn the interim, they were given antibiotics to protect against infections.\nThe idea is to wipe out the faulty immune system and replace it .\nIt was funded by the Brazilian Ministry of Health and other sources.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any costs of the experimental procedure.\u00a0 ", "answer": 0}, {"article": "Media Advisory: To contact corresponding author Susan L. McElroy, M.D., call Jennifer Pierson at 513-536-0316 or email jennifer.pierson@lindnercenter.org\n\"In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11.\nAt some doses, the medication lisdexamfetamine dimesylate, a drug approved to treat attention-deficit/hyperactivity disorder, was effective compared with placebo in decreasing binge-eating (BE) days in patients with binge-eating disorder (BED), a public health problem associated symptoms of mental illness and obesity and for which there are no approved medications, according to a study published online by JAMA Psychiatry.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss costs for drug, lisdexamfetamine (Vyvanse), that is still under patent. All drugs of the amphetamine class suppress appetite, and those that are generically available might potentially give similar results. The companies that market those generic drugs, however, have little incentive to undertake the expensive testing involved to achieve an FDA approval, since many companies make the generics. That said, lisdexamfetamine is different from the other amphetamines in that it is released more slowly into the blood. Tests show the main neurotransmitter affected by these drugs, dopamine, is released more slowly and doesn\u2019t get to as high a level, so this drug may have\u00a0less potential for abuse and addiction problems.", "answer": 0}, {"article": "Researchers then rated them using a well-validated scale that measures aggression and agitation.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\nDextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is always an important factor that should be considered in a story about a potential new use for an existing prescription drug. \u00a0This is a glaring drawback of this piece, since the drug, Nuedextra, is already marketed and currently approved for \u00a0\u201cpseudo-bulbar affect\u201d \u2014 an unrelated neuralgic condition. (Pseudo-bulbar affect refers to uncontrollable laughing or crying, even though the person doesn\u2019t necessarily feel the emotions of happiness or sadness) . A look at Costco, considered one of the least expensive places to buy drugs, came up with a price of $2,222 for 180 capsules. At 2 capsules daily, this would last 3 months. Citalopram, also helpful for agitation in randomized trials as the authors noted, is one of those $4 prescriptions available at Costco, Target.", "answer": 0}, {"article": "Newswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\nNancy Angelino, the very first patient to undergo the procedure, feels fortunate.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs were mentioned.", "answer": 0}, {"article": "Two experts agreed that early intervention is key.\n\"Research has shown that subtle markers of autism are identifiable in the first year of life,\" explained Dr. Ron Marino, associate chair of pediatrics at Winthrop-University Hospital in Mineola, N.Y. \"Video feedback seems like a natural and potentially very potent extension of intervention when it can be most effective,\" he added.\nTHURSDAY, Jan. 22, 2015 (HealthDay News) -- A therapy involving \"video feedback\" -- where parents watch videos of their interactions with their baby -- might help prevent infants at risk for autism from developing the disorder, a new study suggests.\nUsing the therapy during the baby's first year of life may \"modify the emergence of autism-related behaviors and symptoms,\" lead author Jonathan Green, a professor of child and adolescent psychiatry at the University of Manchester in England, said in a journal news release.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss costs of the video intervention. However, other high-end, intensive therapies now in use add substantially to the cost of caring for a child with autism. For example, after only a brief online search, we found information suggesting that the Early Start Denver Model (ESDM), a behavioral therapy, costs around $5,560 per month. It is our belief that anything that is judged to be good enough to be headlined as \u201cmay curb autism\u201d is also worthy of a cost estimate, even by estimating the cost of something somewhat comparable.", "answer": 0}, {"article": "The George Institute is now looking at strategies to maximise uptake of the study results.\nThe Triple Pill, consisted of the blood pressure medications telmisartan (20 mg), amlodipine (2.5 mg), and chlorthalidone (12.5 mg).\nThe researchers tested an entirely new way of treating hypertension by giving patients three drugs, each at half dose, in a single pill for early treatment of high blood pressure.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nDr Webster added: \"Patients are brought back at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the three-in-one pill is not mentioned.\nTwo similar pills already on the market (Tribenzor and Exforge HCT). They\u2019re also once-daily pills combining an angiotensin II receptor blocker + calcium channel blocker + thiazide diuretic. They both have a retail price of approximately $10 a pill, or $300 per month [Source: Drugs.com].", "answer": 0}, {"article": "Antioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\nThe best thing is that we have clean air because then we don\u2019t need any prophylactic treatment.\nA version of the product for use in nebulisers will be available this year in Germany and Poland, while an ectoine-based nasal spray for allergy relief is already available.\nThe impact of air pollution costs $5tn a year, according to a World Bank report published last week.\nIt is expected to be available as an inexpensive, over-the-counter product.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The expected cost to UK\u00a0consumers is noted ($17 pounds/month).", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "These were not\u00a0\u201ctreatment\u201d studies so discussing costs is not relevant. However, the way the story is written could make readers think they should start buying more wine and coffee, which isn\u2019t what the findings\u00a0showed.", "answer": 2}, {"article": "Feb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nIt also appeared to prevent colds in people who used it over the course of about five months.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs in this story. What the Reuters Health story did was mention the actual costs for the lozenges and also the cost in lost productivity of people calling in sick from colds. Both would have been nice to see in this story.", "answer": 0}, {"article": "MONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nThe treatment was effective for at least six months.\nThe procedure is safe as well as effective, the study authors said.\nAll the patients suffered from drug-resistant hypertension.\n\"There's lifestyle and diet, there is getting to the right doses of medications, there are adherence issues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 This approach is not going to be cheap.", "answer": 0}, {"article": "She noted that glitazones -- a separate class of newer drugs such as Rezulin, Avandia and Actos that also target insulin resistance -- have all shown initial promise in clinical trials before worrisome side effects began to surface in users (due to concerns around heart risks, Avandia remains on the U.S. market but under limited distribution).\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\nA similar reduction occurred in patients taking glimepiride.\nThe new drug, called TAK-875, is a pill designed to enhance the secretion of insulin in response to such changes, which means that it has no effect on insulin secretion when blood sugar levels are normal -- potentially reducing the risk for hypoglycemia.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too early to discuss costs for this specific drug, although some mention of the costs of competing drugs would have been helpful.", "answer": 2}, {"article": "For more information, visit http://www.\n\"While older patients represent a large and growing population of medical cannabis users, few studies have addressed how it affects this particular group, which also suffers from dementia, frequent falls, mobility problems, and hearing and visual impairments,\" says Prof. Victor Novack, M.D., a professor of medicine in the BGU Faculty of Health Sciences (FOHS), and head of the Soroka Cannabis Clinical Research Institute.\nThe researchers in the study also include, Ran Abuhasira, a BGU Ph.D. candidate working in the Soroka Clinical Research Center, Lihi Bar-Lev Schleider of \"Tikun Olam,\" and Prof. Raphael Mechoulam of Hebrew University.\nMedical Cannabis Significantly Safer for Elderly With Chronic Pain Than Opioids, According to Ben-Gurion University of the Negev Researchers\n\nBEER-SHEVA, Israel...February 13 - Medical cannabis therapy can significantly reduce chronic pain in patients age 65 and older without adverse effects, according to researchers at Ben-Gurion University of the Negev (BGU) and the Cannabis Clinical Research Institute at Soroka University Medical Center.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned in this news release. The study involves several different methods of taking cannabis (smoking, infused oils, vaporization) which all involve a wide range of pricing. Moreover, it isn\u2019t clear whether insurance pays for this or whether it represents out-of-pocket payments by patients.", "answer": 0}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\n\u201cThere are a lot of questions.\nThe authors report that the dead tissue required surgical removal.\nThe procedure involves using a tiny catheter that is threaded through arteries near the groin to reach the vessels that supply the prostate with blood.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nHowever, recent research suggests colic may linked to an immature immune system struggling with bacterial imbalances in the gastrointestinal tract, and that high levels of E. coli bacteria in particular may contribute to colic symptoms.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nTo test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention how much treatment with this probiotic costs. A month\u2019s supply costs about $40 according to one Internet retailer\u2013information that easily could have been included\u00a0in the piece. \u00a0", "answer": 0}, {"article": "Surgery isn't the answer for all older lung cancer patients, according to Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\nAnd it is mainly a disease of older people.\nLike many patients his age, he didn't expect there would be any effective treatment.\nAnd he found that a surprising number of these older patients did quite well.\nSo they are referred for supportive care to control symptoms, rather than surgery to remove the cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs associated with the surgery.", "answer": 0}, {"article": "It\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nEach case was compared to 10 matched controls who did not develop the disease.\nOverall, 18,532 cases of skin cancer were included in the study.\nThe longer people took the drugs, and the higher the dose, the greater the anticancer benefit.\nThe drugs are thought to counter cancer growth by suppressing inflammatory pathways and stimulating tumors\u2019 ability to expand and develop blood supplies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin and other NSAIDs is not in question.", "answer": 2}, {"article": "Chronic neck pain is a leading cause of disability.\nBoth acupuncture and Alexander Technique prove effective for long-term relief of chronic neck pain\n\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone.\nAcupuncture is a procedure in which patients have thin needles inserted into specific points on the body to relieve pain and the Alexander Technique is an educational process that teaches people how to avoid unnecessary muscular and mental tension in everyday activities.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\nTo speak with the lead author, Dr. Hugh MacPherson, please contact David Garner at david.garner@york.ac.uk or +44 (0) 1904 322153.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention the costs of either acupuncture or the Alexander Technique. This is important to include since both therapies probably require the patient to pay out of pocket, at least in the United States. A quick web search found that the median cost of an acupuncture session\u00a0 nationwide is $100. Alexander Technique sessions cost about the same as massage therapy \u2014 around $70 to $100 per 45-minute session. In this study, 12 acupuncture sessions and 20 Alexander Technique sessions were required.", "answer": 0}, {"article": "During the study, Sweden did not fortify foods, nor did kids use a lot of supplements.\nWhen all their grades from ten core classes were added up, there was a clear difference between teens who got the most and the least folic acid in their diets.\n\u201cIf you\u2019re already sufficient, there is not a lot of evidence that taking more supplements will help.\u201d\n\nShe said the teens in the study might have been deficient in folic acid, with levels a few times lower than what\u2019s typically seen in North American kids.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nThe new study is among the first to examine whether folate is tied to school achievements, according to Dr. Torbjorn Nilsson of Orebro University Hospital and his colleagues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs weren\u2019t mentioned, but we didn\u2019t think that was a necessity in this case.", "answer": 2}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nIn most cases, the lump or lesion is benign or noncancerous and does not require further treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the individual or general health care cost of the different types of biopsies, or if the core needle biopsy guided by x-rays or ultrasound will ultimately cost less than surgical biopsy. The story also was silent on (unaware of?) the big tug of war between surgeons (who get paid for open biopsies) and radiologists (who get paid for the stereotactic biopsies).\u00a0 ", "answer": 0}, {"article": "The patients either had AML \u2013 a cancer of the bone marrow \u2013 or myelodysplastic syndrome (MDS), a group of blood cancers that often progresses to AML.\nThe results of the current trial, he said, point to the inevitable need to replace large cancer clinical trials evaluating homogeneous drug treatments with smaller trials that involve subgroups of patients, with treatments targeted to their specific mutations.\nNewswise \u2014 Patients with the most lethal form of acute myeloid leukemia (AML) \u2013 based on genetic profiles of their cancers \u2013 typically survive for only four to six months after diagnosis, even with aggressive chemotherapy.\nThis information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations.\u201d\n\nFirst author John Welch, MD, PhD, an assistant professor of medicine, added: \u201cIt\u2019s important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging.\nAmong patients in the study with such mutations, median survival was 12.7 months \u2013 which is not significantly different from the 15.4 months\u2019 survival seen in patients without the mutations \u2013 and is longer than the typical four- to six-month survival observed in such patients treated with more aggressive therapies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost in this story. Decitabine is an FDA-approved drug and costs are readily available, but nothing is said of the costs or the relative costs of other treatments.\u00a0  ", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nTo determine an alternate but effective therapy, the researchers enrolled 100 patients age 45-78 with significant stroke risk and coupled with diligent pulse monitoring -- manually or by using a smartphone - twice a day with \"as needed\" anticoagulants for the treatment of AF.\nOral anticoagulation therapy is recommended in patients with infrequent AF and high risk of stroke, however, prolonged use of blood thinners is associated with a higher bleeding risk.\nFollowing this procedure, patients are often prescribed long-term, daily oral anticoagulation medications -- also known as blood thinners.\nPHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since we don\u2019t know which drugs were used in the study we don\u2019t really have an idea what the costs, or costs savings would have been. Obviously if patients start taking their novel anticoagulants on an \u2018as needed\u2019 basis then a lot of money could be saved. These drugs, it should be noted, are typically a lot more expensive than warfarin, the current standard of care in AF.", "answer": 0}, {"article": "The other new drug, ipilimumab (pronounced ip-ee-LIM-yoo-mab), when combined with dacarbazine, extended median survival to 11.2 months compared with 9.1 months for those who received dacarbazine alone.\nIn the latest trial, a big one was liver damage.\nBecause of that, researchers do not yet know the median survival.\nDoctors are eager to try the two drugs together.\nAfter three years, 20.8 percent of those who got that new drug were alive, compared with 12.2 percent of those in the control group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The significant costs of both drugs were mentioned.\u00a0 Nice job.", "answer": 1}, {"article": "Turner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\nThe resveratrol group also showed smaller brain volume, which in the case of Alzheimer\u2019s is a positive sign, as the disease can cause inflammation and swelling that can interfere with nerve connections.\nThat\u2019s likely because experts believe that as Alzheimer\u2019s progresses, more of the protein plaques form in the brain, and less of the protein is released to the rest of the body.\nPlus, he says, resveratrol supplements currently available over the counter are \u201cunregulated and we don\u2019t know how much is in it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost at all. But in this case we\u2019ll rule this Not Applicable since the story clearly indicates that the supplements studied are not on the market.", "answer": 2}, {"article": "Still, little is known about its cause.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While it\u2019s obvious that breastfeeding is free of charge, readers might not appreciate what an advantage this is compared with prepared formulas. This is an especially important consideration in the developing world where a desire for westernization has caused a significant bump in infant formula sales. The average annual cost of a brand-name infant formula is approximately $1200 in the US. Then again, there\u2019s potentially a cost to breastfeeding in terms of work/career advancement for the mother and the labor value of time spent breastfeeding/pumping. Breast pumps can be expensive, too. The news release didn\u2019t need to explore all of this, but some acknowledgment of the issues at play would have been welcome.", "answer": 0}, {"article": "Marji McCullough, strategic director of nutritional epidemiology at the American Cancer Society, expressed interest in the findings.\n\"Many supplements have biologic activity, but before I recommend that people take isolated supplements they need to be tested in humans.\"\n\"The results of this laboratory study are intriguing,\" McCullough said.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\n\"But before recommending bitter melon extract supplements for cancer prevention, we need appropriate clinical trials to establish its safety and efficacy in humans.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs weren\u2019t mentioned.\u00a0 It took us only a few seconds to find out how much this stuff is sold for online. ", "answer": 0}, {"article": "Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity.\nWhile this can reduce the pain, it makes patients drowsy and tired, and they report feeling drunk.\nThe team plans to analyze the impact of other treatment options and carry out a cost-based analysis to establish the best treatment options for TN.\nThe researchers analyzed patients' answers before treatment and at each follow-up appointment, and found that patients reported an improved quality of life and lower rates of depression after radiosurgery.\nAccording to the new study, radiosurgery, which is normally a second line treatment to be used following the medication, helps improve quality of life and reduce depression in patients with TN.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We know surgery has many costs involved but none of them are discussed in this news release. The release mentions performing a \u201ccost-based analysis\u201d at the end but this is insufficient to give credit here.", "answer": 0}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\nWhile heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\nNow it's time to do a larger-scale study, particularly in high-risk populations, and follow participants' progress for longer periods, Dong and Raed say.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release responsibly notes that obtaining more vitamin D is a potentially simple endeavor for most individuals. They can drink more milk, for example, or purchase a relatively inexpensive supplement.", "answer": 1}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions potential cost savings for women who take the new birth control pill, which is intended to eliminate monthly menstrual-like bleeding, but the cost of the drug itself is not noted. The basis for a claim that the drug may also improve women\u2019s work productivity is not clear either. ", "answer": 0}, {"article": "For more information, go to http://www.\nOakland, CA (January 3, 2017) - A new study by researchers from the UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) shows that a modest 4 milligrams of extra zinc a day in the diet can have a profound, positive impact on cellular health that helps fight infections and diseases.\nUCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\n\"We were pleasantly surprised to see that just a small increase in dietary zinc can have such a significant impact on how metabolism is carried out throughout the body,\" says King.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although zinc can be found in everyday foods such as oysters and red meat, the mineral can also be taken as a dietary supplement. A bottle of 100 zinc tablets goes for about $4 to $6 at the local drug store.\nSince there is no discussion of costs in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "BOSTON (Sept. 14, 2016) -- Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\nIn new research that could suggest a road to cure, scientists at Dana-Farber Cancer Institute and Boston Children's Hospital have found that CML stem cells die in response to inhibition of a protein called Ezh2.\n\"The vast majority of patients with CML do remarkably well on imatinib [Gleevec] and similar drugs: The disease is well controlled and side effects are tolerable,\" says Stuart Orkin, MD, the study's senior author and a pediatric hematologist/oncologist at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.\nIn laboratory experiments, the Dana-Farber/Boston Children's researchers found not only that Ezh2 is overabundant in leukemia stem cells but that it helps them survive and give rise to full-fledged CML cells.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Oddly, the release includes a quote from the study\u2019s leader about how \u201cthe cost savings of such an approach could \u2026 be significant\u201d \u2014 yet treatment cost estimates are completely absent in the release.\nCost deserved more than the nod given in this release. The release mentions the treatment will be a \u201cGleevec-like\u201d drug so it\u2019s notable that the costs may also be \u201cGleevec-like\u201d to start.\u00a0 A 2016 Washington Post article noted that the wholesale cost of Gleevec had risen from $26,400 to $120,000 annually over the 15 years it has been on the market. Even with insurance, a patient might have paid $500-$800 month out-of-pocket for the drug, the Washington Post found. The introduction of generics after the patent on Gleevec expires this year will bring the cost down dramatically.\nIn the chronic phase of the disease, where remission isn\u2019t likely, the average cost for brand-name imatinib per year is $79,000 a year, or $92,000 by a more recent estimate. A large group of physicians wrote in a 2013 cost analysis study in the journal Blood: \u201cWe believe the unsustainable drug prices in CML and cancer may be causing harm to patients.\u201d Fortunately, a generic drug should cost $46,000 a year as Gleevec loses patent exclusivity in 2016, according to a recent study in the Journal of the National Cancer Institute.\nBut that\u2019s just imatinib. Although the release mentions an Epizyme-made Ezh2 inhibitor drug in an unrelated Phase 1 clinical trial, it doesn\u2019t name it.", "answer": 0}, {"article": "The trial uses a cream containing beneficial bacteria to fight harmful bacteria on the skin.\n\"What the cream does is help the skin gain back its natural balance and create that barrier needed to keep it healthy.\"\n\"Ideally, we want to eliminate all staph aureus from the skin of eczema patients,\" said Leung.\nIt is then applied to eczema patients' skin as a lotion twice a day for a week.\n\"There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This lotion is still in clinical trials. Pricing is most likely unavailable.", "answer": 2}, {"article": "NEW YORK (Reuters Health) - Botox injections may provide some relief from arm tremors caused by multiple sclerosis, according to a small study published Monday.\nAccording to van der Walt, the cost could range from $500 to $1,000 Australian dollars, which are roughly equal to U.S. dollars.\nThe new study, published in the journal Neurology, tested the effects of Botox injections on MS-related arm tremors, which affect up to two-thirds of people with MS.\nIn real life, the injections would have to be repeated every few months, or possibly every six months for some people, according to van der Walt.\nOn average, the patients\u2019 tremor \u201cscores\u201d had gone from a 5 to a 3 six weeks after Botox treatment \u2014 which essentially means moving from \u201cmoderate\u201d to \u201cmild,\u201d LaRocca said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains: \u201cthe cost could range from $500 to $1,000 Australian dollars, which are roughly equal to U.S. dollars. In the U.S., Botox treatments can cost $455-$575 per injection site.\u201d", "answer": 1}, {"article": "\u2022 The demonstration of a fully automated calculation quantifying retinal autofluorescence that showed a 2.1-fold increase in patients with Alzheimer's, compared with controls.\nHere are several highlights:\n\u2022 The first histologic quantitative analysis of retinal plaque clusters, or \"hot spots,\" containing the most toxic forms of beta-amyloid with specific distribution patterns in superior peripheral regions that were previously unexplored.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\n\"As a developmental outgrowth of the central nervous system that shares many of the brain's characteristics, the retina may offer a unique opportunity for us to easily and conveniently detect and monitor Alzheimer's disease,\" said Keith L. Black, M.D., chairman of NeuroVision, chair of the Department of Neurosurgery and director of the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai.\nFindings from this study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimer's disease,\" said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai, and a co-founder, inventor and scientist at NeuroVision.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "High up in the release it says:\n\u201cAccumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\u201d\nWe love this kind of comparison but we expect those comparisons to be backed up. What makes these other diagnostic tools \u201cinvasive, inconvenient, and costly\u201d? How much do they cost? How much does this type of diagnostic cost? Remember, the study was done on deceased people\u2019s brains and retinas. So you can\u2019t get much more invasive than that.", "answer": 0}, {"article": "Researchers in Turkey conducted experiments with 53 postmenopausal women.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nHalf of them received traditional acupuncture treatment.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 10 weeks of acupuncture treatment \u2013 the course given in the study \u2013 ain\u2019t chump change.", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains the cost of $294,000 a year for this drug.\u00a0 And it describes the drug company\u2019s financial assistance plan.", "answer": 1}, {"article": "In another study released during the Wednesday press conference, researchers from M.D.\nThat recommendation met with outrage from breast cancer specialists, while other organizations, including the American Cancer Society, continued to recommend annual mammograms for women in their 40s.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\nLast year, the U.S. Preventive Services Task Force recommended that women in their 40s not at high risk for breast cancer could forego mammograms until they turned 50 and, even then, it said they only needed to undergo screening once every two years.\nSpeaking at the teleconference, Dr. Jennifer Obel, chair of the American Society of Clinical Oncology's communications committee, said: \"This study adds to our knowledge of mammogram performance in this age group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of annual mammography screening, or even provide a range of costs.\u00a0 The story does not discuss any health care policy cost repercussions of breast cancer screening recommendations.\u00a0 The story does not discuss the cost of unnecessary biopsies or other treatments for women who have a false positive diagnosis via mammography (greater in women 40-49). ", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story deserves high marks for bringing costs into the discussion right in the lead. \u201cIn more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\u201d The story also says, \u201cICDs, which can cost north of $30,000, monitor the rhythm of the heart and produce a shock to bring irregular beating back to normal.\u201d But just as with the Times story, the cost of the device and hospitalizations is only a piece of the economic picture. Additional costs of maintaining the device and battery replacement drive the costs higher. In reality however the overall economic impact of the devices is just about the same as treatment of high blood pressure and elevated cholesterol when life years (a commonly applied economic marker) is considered.", "answer": 1}, {"article": "THIS STUDY randomly assigned 60 adults with mild cognitive impairment or mild to moderate Alzheimer\u2019s disease to be given, via nasal spray, 20- or 40-milligram doses of insulin detemir (Levemir), a man-made insulin that is longer acting than natural insulin, or a placebo daily for three weeks.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nMemory loss is often the first sign of dementia, which in later stages can interfere with such things as the ability to solve problems, control emotions or do such daily tasks as eating and dressing.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nStandardized tests given at the start and end of the study showed that working memory, sometimes thought of as short-term memory, improved for those given 40 milligrams of insulin but not for those given the smaller dose or the placebo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Neither this story nor a competing story by Fox News discussed costs. The product being studied, Levemir delivered through Kurve Technology\u2019s ViaNase, has been written about for about a decade, and so cost information could have been found and reported.", "answer": 0}, {"article": "May 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nThe National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nThe new study was presented at the annual meeting of the American Pain Society.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the regimen used in narcolepsy are discussed.", "answer": 1}, {"article": "The trials lasted anywhere from three months to three years.\nEven though the effectiveness is less than that of allergy shots, the convenience of an at-home version of immunotherapy is a plus, and the sublingual therapy tends to have fewer side effects than shots, according to Nelson.\nThe researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nThe ultimate cost-effectiveness of sublingual immunotherapy has also yet to be determined; in the UK, for example, Grazax treatment costs about 2.25 pounds ($3.50) per day.\nThe most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n \nThe story concedes that the \u201cultimate cost-effectiveness of sublingual immunotherapy has\u2026yet to be determined.\u201d Based on cost in the U.K., the story reports that treatment may be $3.50 per day, adding that it should be \u201ctaken daily, starting several months before the start of the next grass-pollen allergy season and continuing for three years thereafter.\u201d\u00a0 \u00a0\u00a0\n", "answer": 1}, {"article": "MS is an autoimmune neurodegenerative disorder that affects nearly 2.5 million people worldwide.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\nTo enhance the power of their study, the researchers used a \"crossover\" design: they divided the patient population in two and gave the drug, blinded to both participant and researcher, to one group, and a placebo to the other for 90 days; then they switched between the two groups, giving a placebo to the first group and the drug to the other for the next 60 days.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Clemastine fumarate, also known by its brand name Tavist, is an antihistamine that can currently be bought over the counter. According to GoodRx.com, 60 tablets of 2.68mg Clemastine go for $33.33. If patients take the clinical trial\u2019s dose of 2 tablets per day, this supply should last 30 days.\nSince costs are not discussed in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no dollar figures at all in this story. The story touts \u201clower costs\u201d of repairing a torn shoulder \u201cearlier rather than later\u201d but never delivers the data. The story should have\u00a0compared costs of\u00a0surgery to non-surgical alternatives and factored in the possible six-months of rehabilitation following surgery. From the available evidence, it appears the only reference to costs in the story is at best an overstatement. It says \u201cthat repairing a tear earlier rather than later may result in better patient outcomes, earlier return to work and lower costs.\u201d", "answer": 0}, {"article": "Ware and his colleagues recruited 21 adults who were suffering from chronic neuropathic pain after an injury or surgery.\n\u201cA lot of the treatments that are used for neuropathic pain ...might also be associated with disruptions in sleep,\u201d Dr. Andrea Hohmann, who studies marijuana and pain at the University of Georgia and was not involved with the current study, told Reuters Health.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\nThe pain reduction was \u201cmodest\u201d - less than 1 point on an 11-point scale for the strongest marijuana - and patients reported no overall difference in their quality of life based on what they smoked.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is less surprising that neither story discussed costs, given that so few stories do. But sample costs could have been obtained by calling any of the numerous medical marijuana outlets in states where it is legal.", "answer": 0}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\n\u201cI believe for the first time that we have treatments that are effective enough to make it possible to eradicate multiple myeloma definitively in a substantial proportion of patients, along with having the technology to detect that the disease has been targeted and that treatment can be stopped,\u201d said Luciano Costa, M.D., Ph.D., scientist at the UAB Comprehensive Cancer Center, lead of the Hematologic-Malignancy Working Group, and principal investigator of the MASTER study.\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\nHowever, researchers at the University of Alabama at Birmingham Division of Hematology and Oncology are leading and currently recruiting for a Phase II clinical trial that intends to provide newly diagonosed multiple myeloma patients an innovative treatment plan.\nThe clinical trial Monoclonal Antibody Sequential Therapy for Deep Remission in Multiple Myeloma, also known as MASTER, utilizes next generation sequencing technology to detect minimal residual disease down to a level of one cancer cell in 100,000 \u2014 or 100- to 1,000-fold more sensitive than traditional methods to evaluate response.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "In some experiments, it may be too early to discuss treatment costs, but this trial involves drugs that are all already approved for other uses, which means their prices are known. Also, while trial participants typically are not charged for experimental drugs, in this case it appears they will be billed for many treatment costs\u2026 and there would likely be costs for some (including travel and\u00a0 lodging) that insurance would not cover. In fact, the lead investigator acknowledged the costs when asked in an interview about what patients should know about the trial:\n\u201c[T]he study, like any other clinical trials, that our components are considered standard of care and they are charged to the patient or to the insurance. For example, the costs of seeing the doctor, the cost of doing the main test for a traditional disease assessment, the cost of stem cell transplant, but there are components that are considered experimental and are covered by the study, in this case, the daratumumab, the carfilzomib and the MRD testing by itself.\u201d\nThe release should have also noted these costs.", "answer": 0}, {"article": "Currently, an early Alzheimer's diagnosis requires complex brain scans.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nBrain scans and spinal taps are helpful but they're not certain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Potential costs not addressed.\u00a0 However, this is not a commercially available test or even available in most research labs so costs are very difficult to predict.\u00a0 But a story like this also could have touched on the whole issue of the downstream costs associated with testing everyone with some memory loss \u2013 which could be enormous \u2013 and the costs of providing what are now relatively ineffective current drug treaments.\u00a0\u00a0 ", "answer": 2}, {"article": "For more information visit http://www.\nMore than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial, published today (Sunday) in the New England Journal of Medicine.\nToday, together with its academic partner, The Institute of Cancer Research (ICR), it is the largest and most comprehensive cancer centre in Europe treating over 50,000 NHS and private patients every year.\nOf the 361 patients in the trial, 240 with relapsed or metastatic head and neck cancer were allocated to receive nivolumab and 121 to one of three different chemotherapies.\nImportantly, fewer patients experienced serious side-effects from taking nivolumab than with conventional treatment - only 13 per cent compared with 35 per cent of patients who received chemotherapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. This may be because the study was done in the U.K., where public health care mitigates the cost for patients. However, it is definitely an issue for patients in the U.S. In an NEJM piece published last year, one doctor stated that, when used for treating metastatic renal-cell cancer, nivolumab costs, \u201cby my estimate, around $65,000 for Medicare beneficiaries and up to twice that for commercially insured patients.\u201d Other estimates are that nivolumab treatment \u2014 again, for cancers other than head and neck cancer \u2014 could cost more than $100,000 per patient. That is a huge factor in making treatment decisions, and needs to be addressed.", "answer": 0}, {"article": "Visual analog pain scores at 6 weeks after the injections improved by a mean 3.8 points or 61.47 percent in patients who had the PRP injections compared to the autologous blood group, a mean 2.5 points or 41.6 percent improvement.\nNEW YORK (Reuters) - Blood injections, especially of platelet-rich blood, into the affected area help relieve the pain associated with \u201ctennis elbow\u201d where other treatment methods have failed, according to a Greek study.\nAnalogous blood injections, in which the patient\u2019s own blood is taken and then injected into a specific area of the body, is used to help harness the healing power of blood to treat the degeneration of tendons.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\nThanasas added that further studies are needed to see how and when the PRP therapy is most effective, adding that he and his colleagues are about to start trials of PRP therapy in which different concentrations of white blood cells are used to see how this affects the regeneration of tendons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story made no mention of costs. Given that platelet-rich plasma already is being used for a variety of conditions, including tennis elbow, it would not have been difficult to get a range of costs. A basic Google search reveals a number of sources declaring that insurance plans do not typically cover plasma injections. This all would have been good information for the story.", "answer": 0}, {"article": "The research findings published by PLOS ONE help support their objective.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\nThe goal was to identify OVRT performance metrics that differentiated between mTBI and control groups and to create a model that could accurately evaluate mTBI neurologic status in patients.\nSince the development of the goggle, researchers have hoped that the technology used by the goggle in a research setting could be translated to the sidelines of all sports - from professional leagues to amateur and little leagues.\nA team of researchers from the University of Miami Miller School of Medicine has shown that the I-Portal Neuro Otologic Test, which uses the head-mounted goggle that gauged eye movement through video cameras and computers, can successfully diagnose concussion with 95 percent specificity and 89 percent sensitivity.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release mentions that researchers made diagnoses by running tests with the I-Portal goggle, which gauges eye movement through video cameras and computers. But there is no discussion on what the costs for a session with the I-Portal goggle may be.\nThis sounds like a new technology, and it would have been helpful to know the ballpark range of what it may cost for consumers.\nFor this reason, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not report the cost of the drugs. \nWhile price is not essential in a story like this, as a rule costs should be reported.\u00a0 ", "answer": 2}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study makes no mention of costs or insurance coverage. Because insurance coverage for acupuncture varies widely, out-of-pocket expenses for the 12-session regimen could be a substantial barrier to many women getting the treatment.", "answer": 0}, {"article": "\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nPeople who drank three to four cups per day had about a 25% lower risk than those who drank two or fewer cups per day.\nIn the study, researchers analyzed information from 18 studies on coffee and diabetes and another 13 studies that included data on decaffeinated coffee and tea drinking and diabetes.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Costs weren\u2019t discussed, but most people know what coffee and tea costs. ", "answer": 2}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\nThe device will not be suitable for a significant number of heart patients, particularly those who require units that also include a pacemaker, which regulates a heart that is beating too fast or too slowly.\nIn recent years, the safety of defibrillator wires has come in particular focus because a model made by Medtronic has been prone to fracturing.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe story notes that the cost of the device would be similar to that of existing devices, but that implantation is simpler, which might make those costs lower. It would have been helpful to specify the estimated cost of existing implantable defibrillators.", "answer": 1}, {"article": "MONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe U.S. National Heart, Lung, and Blood Institute has more about heart failure.\nDanish researchers analyzed data from more than 31,000 patients hospitalized with heart attack between 2000 and 2005 and divided the patients into four groups: two groups with heart failure (one that received Plavix and one that did not) and two groups without heart failure (one that received Plavix and one that did not).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about the cost of this drug.", "answer": 0}, {"article": "(CNN) A new blood test may be as accurate as a test requiring a painful spinal tap for differentiating Parkinson's disease from similar disorders, according to a study published Wednesday in Neurology, the medical journal of the American Academy of Neurology.\n\"A lot of time, people come in and say they or a family member has a tremor, and they believe it's Parkinson's disease,\" said Wright, who also was not involved in the study.\nBecause spinal fluid is not easily obtained by a primary care doctor, this diagnostic test is not very useful, so Hansson developed a blood test and investigated its accuracy in the new study.\nThis protein is a component of nerve cells, and when these cells die, it can be detected in both spinal fluid and blood.\n\"Disease-specific therapies are now in trials, so accurate diagnosis is essential in determining if these new treatments work,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not included. Presumably a blood test would be cheaper than a test of spinal fluid, which requires a lumbar puncture.", "answer": 0}, {"article": "For more information, recipes and facts about pasta, please visit http://www.\nCertain grain foods, like pasta, are a great complement to a healthy well-balanced meal and provide plenty of opportunities for improving the diet,\" explains registered dietitian Diane Welland, Nutrition Communications Manager for the National Pasta Association.\nFrom the analysis, researchers identified a number of key positive nutritional dietary patterns associated with children and adolescents who eat pasta as part of their diet compared to those who don't eat pasta.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThey are:\n\n-Better overall diet quality (as measured by USDA's Healthy Eating Index-2010 scale) -Greater intake of key shortfall nutrients like dietary fiber, folate, iron, magnesium and vitamin E -No significant associations were seen with body weight, waist circumference and body mass index\n\nPasta has long been celebrated as one of America's favorite foods and is advocated by nutritionists for its good nutrition.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the cost of including pasta in meal preparation but it\u2019s generally known to anyone who buys food that a box of dry noodles can be purchased for less than $1.", "answer": 2}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the cost of the BRCA test, which according to the National Cancer Institute can range from several hundred\u00a0to several thousand dollars.", "answer": 0}, {"article": "That's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nIt's not clear whether the fish oil pills help people with established psychosis.\nThe study appears in the February issue of Archives of General Psychiatry.\nThere's also evidence that fatty acids interact with chemical signaling in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of dietary fish oil supplements.\u00a0 ", "answer": 0}, {"article": "Soy may keep breast cancer from coming back\nThose who ate the most were about 11 percent less likely to die.\nThere are many never-smokers with lung cancer,\u201d she said.\nThe women had all filled out questionnaires that included details of what they normally ate.\nThe benefits may go beyond cardiac health,\u201d Patel said in a telephone interview.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of soy foods is not in question.", "answer": 2}, {"article": "For more information, visit www.aao.org.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\n\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nAbout Ophthalmology \n\nOphthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed, clinically-applicable research.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention costs, despite the fact that investors would need to recoup the enormous cost of developing a device and winning Food and Drug Administration approval. It might be too early to estimate the market price of the ring, but the news release could have helped readers understand financial implications by mentioning the typical high cost of new medical devices as well as what it might cost to pay a clinician to insert, monitor and replace a medicated ring at regular intervals. It could have also mentioned costs for existing treatment options, and in more rare cases, the cost of surgeries that are performed when patients fail to adhere to treatment plans.", "answer": 0}, {"article": "gov.\nCAVEATS Most participants were white.\nAnyone considering changing or beginning treatment of any kind should consult with a physician.\nExcept for trout, freshwater fish usually are lower in omega-3s.\nThose with the lowest levels of omega-3s showed signs of accelerated aging.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish is not in question.", "answer": 2}, {"article": "NEW YORK (Reuters Health) - A large waistline more than doubles the risk that people in their 40s will develop precancerous cells in the colon, according to Korean researchers.\n\u201cThe idea that you\u2019re tailoring screening to age and some combination of risk factors is entirely reasonable,\u201d said Robert Smith, the director of cancer screening at the American Cancer Society.\nThe chances of finding abnormal cells during a screening test were just as good in younger men with too much belly fat as in slimmer men over 50.\n\u201cYou want to make sure that the advantages are going to outweigh the harms,\u201d said the American Cancer Society\u2019s Smith.\n\u201cFrom a task force perspective, this article alone would not prompt us to look at the screening guidelines.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of screening colonoscopy. Costs of screening a younger population is especially important given that more people would need to be screened to find one case of cancer.", "answer": 0}, {"article": "Two clinical trials examined by Khandaker focused on another drug blocking the action of a different cytokine, and both studies showed it improved symptoms of depression.\nAnti-cytokine drugs \"dampen down inflammation by blocking the actions of specific inflammatory cytokines ... with 'surgical precision' and are now routinely used for treating patients who respond inadequately to standard treatments for inflammatory conditions such as rheumatoid arthritis, psoriasis and Crohn's disease both in the US and Europe,\" explained Dr. Golam Khandaker, a clinical lecturer in Cambridge's department of psychiatry and lead author of the new study.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\nThe immune system acts like a thermostat, turned down low most of the time but cranked up when we have an infection, according to Khandaker.\nThese trials form the basis of the Cambridge research that was published Tuesday in the journal Molecular Psychiatry\n\nBased on previous findings about depression, the team looked at the side effects experienced by patients given anti-cytokine drugs in 20 separate studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Information on the steep costs of some of these drugs is readily available, along with data on whether insurers will pay for them. There is no discussion of costs in the story about this, nor does the story mention a single one of the drugs by name\u2013adalimubab and etanercept are two\u2013so that readers can look for themselves.\nIt is particularly important to mention cost in this case because biologics (the drug class in question) are notoriously expensive (adalimubab is estimated around $1,600 a month) while most first-line generic treatments for depression, like SSRIs, are much more affordable (often less than $20/month).", "answer": 0}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This work is early in its development and the story makes that clear.\nHowever, it would still be worthwhile to raise some questions: Who would pay for the development of future modeling tools? Who would pay for the training necessary to make these tools useful to health care providers? Who would pay for the time that health care providers would have to put into the work? None of these things would happen in a vacuum, and it would be useful to raise these issues.", "answer": 2}, {"article": "Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nThe results, published in the latest American Journal of Geriatric Psychiatry, provide preliminary evidence suggesting ketamine's effectiveness as an antidepressant when delivered in repeated intravenous doses.\nRepeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\n\"These results are a promising early piece of the puzzle, but the risks of ketamine use are still not wholly understood.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release didn\u2019t mention the cost of ketamine infusion therapy. Another way to address costs in the release would have been to include a discussion of the medical and social costs of depression.", "answer": 0}, {"article": "Last Wednesday, the F.D.A.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll award a Satisfactory here with some reservations. Although the article addresses the cost of the procedure, and in particular of the valve, readers should have been told how the cost compares to conventional surgery, rather than just the bottom line risks for hospitals. Here\u2019s how the story presents it: \u201cIt\u2019s a hard proposition when $32,500 goes right out the door to Edwards,\u201d the valve manufacturer, he said. The hospital gets about $40,000 from Medicare, which is fine if there are no complications. But older patients, in their late 80s and 90s, often end up with four-, five- or even seven-day hospital stays. \u201cWe could lose $25,000,\u201d he said.\u201d\nAccording to the Healthcare Blue Book, a reasonable charge to the consumer for heart valve surgery is $50,000.", "answer": 1}, {"article": "Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, agreed.\nDuring the study, the patients consumed an average of 18.8 grams of margarine per day, which meant ingestion of an average of 226 milligrams of EPA combined with 150 milligrams of DHA omega-3 fatty acids and/or 1.9 grams of ALA.\n\nBy the study's end, almost 14 percent of the heart attack patients had experienced another \"major cardiovascular event,\" with some cases ending in death.\nIn fact, neither low doses of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, nor of alpha-linolenic acid (ALA), derived from nuts and several vegetable oils, provided any benefit to the vast majority of heart patients, the study showed.\nOne exception appeared to be among women ingesting ALA; researchers saw a 27 percent reduction in the risk for further cardiac complications, although that reduction did not quite reach statistical significance.\nAt the study's start, the patients were instructed to consume (over a period lasting a little over three years) one of four different types of margarines: one supplemented with omega-3 fatty acids; one supplemented with the plant-derived ALA; one supplemented with both omega-3 fatty acids and ALA; and one with no supplements.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The margarines used in the study are not commercially available, so we can understand why cost of these formulations wasn\u2019t given (even if the story didn\u2019t disclose that the these were special non-commercially-available products). \nIt would have been interesting to learn how the costs of omega-3 fatty acid fortified margarine compares to a comparable, unfortified product.", "answer": 2}, {"article": "This research was designed to explore recovery in acute stroke, or the period immediately following stroke - in mice, that is five days; in humans, that is two months.\nThe study was supported by funds from the National Institutes of Health.\nThe gel was eventually absorbed by the body, leaving behind only new tissue.\nThe brain has a limited capacity for recovery after stroke and other diseases.\nAfter 16 weeks, stroke cavities in mice contained regenerated brain tissue, including new neural networks - a result that had not been seen before.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The featured treatment is a gel in developmental phase. The price is likely unknown, and not including it seems reasonable.", "answer": 2}, {"article": "Panel Says Aspirin Lowers Heart Attack Risk For Some\n\nMillions of Americans take baby aspirin every day to prevent a heart attack or stroke.\nSeveral groups including the American Heart Association offer online calculators to help people figure out their risk, which, along with discussion with a health care provider, can help determine whether daily aspirin might be useful.\nFor example, uncontrolled high blood pressure, or high cholesterol, obesity, age and diabetes can all increase heart disease risk.\n\"It's just not prudent or safe,\" he says, noting that bleeding in the abdomen or brain is extremely dangerous and can be fatal.\nThese new recommendations aren't final, and are open to public comment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a component of this story, but it does not appear to be as relevant an issue to this piece compared with other stories.", "answer": 2}, {"article": "That study was funded by the device\u2019s manufacturer, Neuronetics, a company based in Malvern, Pa.\nThe procedure, which is more widely used than rTMS, requires two to three treatments a week for three to four weeks and is effective for many patients.\nFor patients who don\u2019t respond to prescription drugs and talk therapy, the other major option is electroconvulsive therapy, or ECT, in which an electrical current is sent through the brain to deliberately cause a seizure.\nThe use of rTMS for altering mood or affecting the brain has been studied since at least the early 1990s.\nOne 2010 study of 199 \u201cmoderately treatment resistent\u201d patients funded by the National Institute of Mental Health found that rTMS was four times as likely to get patients symptom-free as was a sham procedure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of rTMS, and the market forces that work to encourage or restrain use of this technology, are well described.", "answer": 1}, {"article": "TUESDAY, Jan. 19, 2010 (HealthDay News) -- DNA testing for the human papillomavirus should replace the Pap smear as the main way to screen women for cervical cancer, according to Italian researchers.\nDNA testing for HPV, though, does have drawbacks -- namely that it is less specific, meaning it is likely to pick up more false-positives, than a Pap smear.\nWe're behind in the U.S.\"\n\nThe strategy makes particular sense in less-developed countries, where women could do an HPV test themselves with a \"self swab\" and then send the swab in for analysis, Einstein said.\nTheir recommendation is based on a study that found that the human papillomavirus (HPV) test prevented more cases of cervical cancer than the conventional Pap smear.\nScreening for HPV DNA appeared more effective in older women, but the testing in younger women led to over-diagnosis of a particular type of cervical lesion, the study found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of the tests or mention the costs of the additional colposcopies that result from the higher callback rate from HPV testing. Although the story claims that the HPV testing strategy is \"cost-effective\", it provides no evidence to support this claim.", "answer": 0}, {"article": "The journal that published the new paper, Science, promoted the finding in a news release, but added a \u201cspecial note\u201d citing the Schiavo case and warning that the finding \u201cshould not be used to generalize about all other patients in a vegetative state, particularly since each case may involve a different type of injury.\u201d\n\nThe brain researchers, led by Adrian Owen at the Medical Research Council Cognition and Brain Sciences Unit in Cambridge, England, performed scans on the patient\u2019s brain five months after her accident.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\nAn estimated 100,000 Americans exist in this state of partial consciousness, and some of them eventually regain full awareness.\nOnly 15 percent of people who suffer brain damage from oxygen deprivation recover some awareness within the first three months.\nAnd when the researchers asked the woman to imagine playing tennis or walking through her house, they saw peaks of activity in the premotor cortex and other areas of her brain that mimicked those of healthy volunteers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of the imaging test.", "answer": 0}, {"article": "\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cThis was far greater than expected.\nCurrently, 42 million American women are living with heart disease.\nIt is the leading killer of women in the United States, claiming more women each year than men.\nMen got a good result but women got a fantastic result,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. These things are not cheap.", "answer": 0}, {"article": "The first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works.\nThat's when I get them,\u201d he said.\nThe hope was that the immature adult stem cells would turn into heart muscle, replacing the scar tissue.\nI had my heart attack 11 years ago in the fall.\nThe reduction in swelling increases the heart's ability to pump blood, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this treatment is not available, a discussion of costs is not warranted.\n", "answer": 2}, {"article": "Giving school children access to chilled, self-serve water may help chip away at childhood obesity, a new study of more than one million New York City school students suggests.\n\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\nThe large, clear, electrically cooled jugs with a push lever for fast dispensing were placed in 483 school cafeterias, about 40 percent of schools during the 2008-2009 and the 2012-2013 school years.\nSchools with water dispensers saw a modest weight drop among students, according to the study by researchers from NYU Langone Medical Center, New York University's Institute for Education and Social Policy, and the Center for Policy Research at Syracuse University's Maxwell School of Citizenship and Public Affairs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The CBS article does not mention any costs associated with the installation of a water dispenser. The JAMA Pediatrics article states that water jets are \u201crelatively low-cost\u201d interventions, with a one-time cost of about $1,000 per machine. There are also ongoing maintenance expenses, as well as additional costs for disposable cups. In addition,\u00a0if the jets affect sales of milk and other beverages on school grounds, the costs would actually be higher still.\nWe believe the water jet cost should have been covered in the story, since researchers in the original journal article emphasized the association between a \u201crelatively low-cost water availability intervention and decreased student weight.\u201d That\u2019s why we give the CBS article an Not Satisfactory rating here.", "answer": 0}, {"article": "\"If [Livia] gets more women to know about TENS, then great,\" she said.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\n\"The idea is the nerve system cannot work with two types of signals at the same time,\" Nachum explained, \"so what Livia does is transmit frequency to the nerve system that it is very similar to the body's frequency, but it's not something the body knows.\"\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\nWhen I asked Nachum about the device's frequency, he said, \"We can't share this information at this point.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were pleased to\u00a0see cost discussed\u00a0in the story. The story points out that the projected retail cost of the Livia device ($149) and the pre-order price ($85) is more than\u00a0similar devices (as low as $30 on Amazon).", "answer": 1}, {"article": "Coffee or tea?\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThere's a growing body of research to suggest that both are probably good for you.\nWe've heard a lot about the health benefits of tea, especially green tea.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no costs mentioned with the type of tea recommended in the article (gyokuro or matcha) though the article suggests vendors of these types of tea. If the story can suggest sellers, it can cover costs, which can vary widely with these products. ", "answer": 0}, {"article": "After three months the results were promising, the company said.\n(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nThe medical device maker said it completed an initial feasibility study of 30 men, average age of 60, who suffered from erectile dysfunction (ED).\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\nThe stent \u2014 a tiny wire mesh tube similar to those used to prop open heart arteries \u2014 was placed in the internal pudendal artery, which supplies blood to the penis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Sure, it\u2019s early in development.\nBut just as surely, some estimate could have been made of what the stent, the surgery, and followup care would cost.\nIf it\u2019s not too early to report on \u201cpromising\u201d results after ann initial feasibility study, then it\u2019s not too early to start projecting costs \u2013 even in \u2013 or perhaps especially in \u2013 a business story.", "answer": 0}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\n\"Our hope ... is you might be able to give a single dose of a chemotherapy agent and within a day or two figure out whether the tumor is going to respond,\" says Dr. Michael Graham of the University of Iowa.\nBut researchers are exploring a new use for medical imaging that could shorten the stay in purgatory, possibly revealing within a few days whether chemo is working.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of PET scans under the proposed use. In this case in particular\u2013where the costs and benefits of PET scans are in hot dispute\u2013this is inexplicable. \nConventional PET scan cost is estimated at $3,000 to $5,000. ", "answer": 0}, {"article": "or \"Have you taken your medications yet today?\nWhile there are more than 100,000 health-related apps on the market, the evidence to date is lacking as to whether many of those apps are safe or effective, according to Zubin Eapen, a cardiologist and assistant professor of medicine at Duke University School of Medicine.\n\"We [as physicians] are always looking for evidence to make sure that we are recommending the right things for our patients, whether it's a drug, a device or a digital product, like an app,\" says Eapen, who is also medical director of the Duke Heart Failure Same-Day Access Clinic.\nWhile almost two-thirds of American adults own a smartphone, that number rises even higher when you're talking about plain old cell phones \u2013 a full nine out of 10 American adults own some kind of cell phone.\nIn a randomized clinical trial, more than 700 patients with coronary heart disease were split into two groups: half received four text messages per week for six months plus usual care, while the other half received just usual care.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a tricky one. The story does not explicitly address cost, except to call text messaging \u201ca scalable and affordable approach.\u201d For many (or most) patients, the cost of receiving four text messages a week would likely be negligible \u2014 covered by an individual\u2019s phone plan or by nominal text rates. However, not everyone owns a mobile phone, a fact that makes access (and cost) a more significant issue.\u00a0However, the story does deliver on this point. The story discusses both the number of U.S. adults who own mobile phones (90 percent) and the fact that text messages are more accessible than other forms of mobile health communication (such as apps, which require patients to own smartphones or other smart devices). So, while we\u2019d prefer a more in-depth discussion here, we\u2019ll award\u00a0a Satisfactory rating for the story\u2019s nod in this direction.", "answer": 1}, {"article": "Ideally, the order goes the other way around: We test the idea, and then we implement.\u201d\n\nThese states have the fattest pets \u2014 and they might surprise you\n\nLong before they conquered the Internet, cats took over the world\n\nA kitten nursery saves tiny lives in a city aiming to become \u2018no kill\u2019\n\nBear breaks into house, plays the piano but not very well\nIn 2012, the Department of Veterans Affairs said it would not cover costs of service dogs for veterans with post-traumatic stress disorder, citing \u201ca lack of evidence to support a finding of mental health service dog efficacy.\u201d The department is now in the midst of a multiyear study on the topic, which could lead to government funding for these pooches.\nEarlier this year in the Journal of Applied Developmental Science, an introduction to a series of articles on \u201canimal-assisted intervention\u201d said research into its efficacy \u201cremains in its infancy.\u201d A recent literature review by Molly Crossman, a Yale University doctoral candidate who recently wrapped up one study involving an 8-year-old dog named Pardner, cited a \u201cmurky body of evidence\u201d that sometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nStill, they cautioned that \u201cthis study does not answer whether pet dogs have direct effects on children\u2019s mental health or whether other factors associated with acquisition of a pet dog benefit their mental health.\u201d\n\nIt was a classic case of conflating correlation and causation, which Herzog says is common.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, but this is an important factor to consider when evaluating any intervention\u2013and especially one that can be expensive. For example, Autism Service Dogs of America (a group that promotes the use of service dogs for patients with autism) estimates that \u201cthe full cost to breed, raise and train an ASDA service dog is over $20,000.\u201d Another organization that trains dogs to work with autism patients estimates the cost at $30,000 (though it does not charge the client \u2014 the expense is paid through fundraising initiatives). We don\u2019t claim that these are costs that individual patients would necessarily be responsible for, but they do offer some insight into the potential expenses associated with the care, training and upkeep of therapy animals. It\u2019s not negligible, and it\u2019s worth mentioning.", "answer": 0}, {"article": "We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\nWhen asthma symptoms occur, the number of white blood cells rises, and this measurement is used to define how severe the condition is.\nThe Lancet Respiratory Medicine, 2016.\nFor people with asthma, a sputum eosinophil reading will typically be around five percent, compared to people without asthma, who have readings that are lower than one percent.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address how much fevipiprant might cost or the cost of currently available treatments.", "answer": 0}, {"article": "\"But isn't there some benefit to getting tested earlier, like needing fewer lymph nodes removed and not needing chemotherapy?\nStill, \"the observations are consistent with what we have seen with the value of early detection.\n\"There are multiple benefits of mammography in terms of early detection.\nThey were also 32 percent more likely to need surgery to remove the whole breast (mastectomy), and 66 percent more likely to need lymph nodes removed.\nAlso, because of the nature of the study and the small sample size in the young age group sub-analysis, Lichtenfeld said that \"this cannot be interpreted as a study telling us what age to start mammograms.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss costs. Screening mammograms impose a significant cost on the U.S. health care system and insurers, particularly Medicare.", "answer": 0}, {"article": "Cole's own research deals with fish oil, which is relevant because fish is a component in the Mediterranean diet.\nParticipants were asked about their diet and then, about six years later, underwent an MRI.\nFor example, other research has found that higher adherence to the diet seems to protect against hypertension, also associated with these brain problems.\nIt is complicated in general to compare the benefits of a particular diet with the benefits of not following a different food regimen.\nThe risk factors for vascular disease overlap with those of Alzheimer's disease, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Another not applicable criterion for this story.\u00a0 Costs not mentioned, but also hard to pin down costs of this diet. ", "answer": 2}, {"article": "But there\u2019s a problem with a low-FODMAP diet.\nThey may assume that they have gluten sensitivity, but some researchers believe that it\u2019s not the gluten they\u2019re sensitive to.\nInstead, it\u2019s fermentable oligosaccharides, disaccharides, monosaccharides and polyols, or FODMAPS.\nThe fermentation that is painful to that 10 percent is good for your gut because it stimulates growth of the kind of bacteria associated with digestive health.\nInstead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is really not a consideration in this story. The foods listed are found in the average grocery store and are not esoteric.", "answer": 2}, {"article": "Common warning signs include snoring and excessive daytime sleepiness.\n\"Quality of life is one of the most vital outcomes for patients and often one of the primary reasons to seek medical attention,\" said lead author and principal investigator Dr. Harneet Walia, assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and staff at the Cleveland Clinic's Sleep Disorders Center.\nThe monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nThe study was funded by a scholar award from the Cleveland Clinic Neurological Institute-Center of Research Outcomes and Evaluation and by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).\nFor a copy of the study, \"Impact of Sleep-Disordered Breathing Treatment on Quality of Life Measures in a Large Clinic-Based Cohort,\" or to arrange an interview with a study author or an AASM spokesperson, please contact the AASM at 630-737-9700 or media@aasm.org.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Despite touting the benefits of CPAP, the news release made no mention of the costs of CPAP home machines. These machines aren\u2019t cheap\u2013a quick internet search shows that they can run anywhere from $500 to over $1,000, not including other necessary equipment such as face masks and cleaning supplies. While the National Sleep Foundation says that most insurance policies cover CPAP machines, it is likely that someone buying a machine will still have to pay a hefty out-of-pocket sum. This could prove to be an obstacle to many seeking treatment, especially people from lower socio-economic backgrounds.", "answer": 0}, {"article": "\"If five types of the disease exist, how does this change popular medical opinion on prostate cancer screening?\nWhat they found was more than minimal differences among the tumors.\nIt is much rarer for men younger than 40 years old to develop prostate cancer.\n\u2022 The average age of diagnosis is about 66 years old.\nThis may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost for an additional genetic test.", "answer": 0}, {"article": "People who had sleeve gastrectomy lost about 18 percent and those with gastric banding lost about 11 percent, the researchers found.\n\"This study suggests that patients interested in bariatric surgery, especially gastric bypass surgery, should be able to lose a significant amount of weight and keep that weight off for a very long time,\" said study researcher Matt Maciejewski.\nBased on the new study findings, Gould said, \"I think a patient who is young and who has a long way to go may want to think about these results, and all other things being equal, might pick a gastric bypass for the long-term weight loss.\"\nThe study \"shows that the gastric bypass procedure compared to sleeve gastrectomy or adjustable gastric banding produces more weight loss and it was sustained over the long term,\" Gould said.\nThe new finding, he added, validates his belief that the gastric bypass could be a \"durable procedure.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a component of this story.\u00a0 That is an issue, as the story compares three weight-loss surgical options for morbidly obese individuals, and readers might well be interested in the economics. Also, it would be useful to discuss the costs of\u00a0not having surgery in the matched population.", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0This story is particularly complete, if brief, on the subject of costs. The story explains that previously, a single genetic test might cost anywhere from $500 to $1,000. The company\u2019s new test, which covers approximately 100 different genetic conditions, costs about $350. The story also points out that most insurance plans will cover the fee. That has not been the case with previous tests.\u00a0 The does not address the down stream costs. For example, if one of the tests is positive, does it need confirmation or is the specificity of the test adequate? If a patient is really at high risk based upon her/his family history, is a negative test sufficiently sensitive to be sure that person does not have the genetic defect?", "answer": 1}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article gave a bare-bones estimate about the costs of Botox. However, it didn\u2019t provide any real-world estimates of the total long-term costs of the injections and any ancillary services from specialists.\nSince chronic migraines can be a life-long complaint, the total costs may be jaw-dropping. The article also did not address the cost-effectiveness of Botox for chronic migraines. Will patients and insurers be interested in paying steep prices for meager clinical results?\n\n \n", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not address the cost of obtaining CPR training, nor the cost of providing it. While some training events are free, courses available from the American Red Cross in the Portland, Maine area range from $70 to $110.", "answer": 0}, {"article": "The study's primary endpoint was OS.\nThe findings are the final results of the single institution, Phase II study and represent the longest follow-up to date of stage 3 lung cancer patients who have received proton therapy, said Joe Y. Chang, M.D., professor, Radiation Oncology and the study's corresponding author.\n\"With our study, we hypothesized that proton therapy would offer a survival benefit to patients and reduce treatment-associated toxicities, which can be very serious,\" he said.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nHOUSTON - For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy, offers improved survival compared to historical data for standard of care, according to a new study from The University of Texas MD Anderson Cancer Center.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We\u2019re not talking about a few pills a day here. We are talking about ongoing expensive treatment for five years. The costs needed to be explained as well as whether those costs are typically covered by insurance, especially in the kind of political climate we are in now, where health care coverage is the subject of hot debate. It is important for studies such as this to begin addressing the cost of care.", "answer": 0}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nCarol Peterson, an IT manager at Xerox, drives almost two hours each month to her favorite farm in upstate New York for her unpasteurized supply.\nSusan Mueller, a mother of two in Ithaca, N.Y., bought shares in a dairy farm so she could pick up her raw milk and yogurt at a drop-off point closer to home.\nAnd they consider themselves lucky.\nNo biggie--just zip to your local supermarket and pick up a carton.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story did not contain specific price details, it did mention that the farmers can sell raw-milk and raw-milk products at a \u2018thick premium\u2019 from which the reader could gather that the costs would be more than milk which has been pasteurized.\n\u00a0", "answer": 2}, {"article": "\u201cThe No.\n\u201cIt would be incorporated into these dreams where I was tied up, like in the movie \u2018Alien.\u2019 It was more difficult to sleep with that thing on than to just get through the night with the apnea.\u201d\n\nMr. Bleck got rid of the machine after he discovered Provent.\nFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing.\n\u201cAll sleep apnea is not created equal.\u201d\n\nSome people, for example, breathe through the mouth at night, not the nostrils.\nIts manufacturer, Ventus Medical, says it has shipped one million of the devices in the past 12 months, up from a half million total in the two years prior.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offered one of the most thorough discussions of costs we have seen in a description of an emerging device. It provides a price for a 30-day supply of the patches and for a 10-day trial pack. It also points out, helpfully, that \u201cUnlike C.P.A.P., Provent is not covered by Medicare and most major insurers, though some doctors say they expect that will change in the near future.\u201d", "answer": 1}, {"article": "TNT technology has two major components: First is a nanotechnology-based chip designed to deliver cargo to adult cells in the live body.\nIn lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nThe chip does not stay with you, and the reprogramming of the cell starts.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are no discussions of cost, but because this is a technology already being touted as a \u201cbreakthrough\u201d with wide applications costs should have been broached as part of the description.", "answer": 0}, {"article": "D'Onofrio is also a co-author of several studies based on patient data from Sweden that found similarly lower risk for substance abuse and transport accidents in people with ADHD who used medication.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\n-- The use of medication to treat attention deficient hyperactivity disorder is linked to significantly lower risk for substance use problems in adolescents and adults with ADHD, according to a study led by researchers at Indiana University.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\nThe larger number of people in the two more recent studies -- as well as the use of U.S. patients in the new analyses -- strengthens this earlier evidence.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. It would have been helpful to include the average cost of ADHD drugs with and without insurance. A 30-day supply of generic Adderall averages $25, according to GoodRx.", "answer": 0}, {"article": "So, the investigators asked, could a scan identify those whose actual risk is lower than what was calculated?\nBut if that person has a calcium score of zero, the actual risk turned out to be 4 percent, below the 7.5 percent threshold for recommending a statin according to the guidelines and below the 5 percent risk for considering a statin.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nDr. Krumholz and Dr. Khurram Nasir, a preventive cardiologist at Baptist Health South Florida, who conceived the new study, reasoned that research on heart scans had not been designed to help doctors make treatment decisions they face today.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that a CT scan looking for calcium in coronary arteries \u201ctypically costs between $75 and $100. Still, it is generally not covered by insurance and so is not often used to assess risk.\u201d That\u2019s enough information to clear our bar handily, although we\u2019d note that such scans can also turn up lung nodules that require additional follow-up and related costs.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mentioned the proposed cost of lapatinib.", "answer": 0}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\n\"Among women in the screening group, there was a 28 percent reduction in mortality from breast cancer during the same period.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\nResearchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nCompared with oral medication, he says, \u201cthe odds of success are better with the laser; plus, there\u2019s no side effects.\u201d\n\nThe most common oral treatment, Lamisil, works for about two out of three patients, according to Lamisil\u2019s FDA-approved prescribing information, but it has been associated with rare cases of serious liver problems.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn one small study about laser treatment for toenail fungus, which appeared last year in the Journal of the American Podiatric Medical Association, \u201c26 eligible toes (ten mild, seven moderate, and nine severe)\u201d were treated with a laser produced by Nomir Medical Technologies, which is still seeking FDA approval.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did a good job on this point. It noted that one treatment \u201ccosts about $1,000 and is not covered by insurance.\u201d It put this into a larger context by saying, \u201cLast year, Americans spent $354 million on prescription and over-the-counter treatments for toenail fungus, according to IMS Health, a health-care information company.\u201d And it described at the end of\u00a0the story how one patient\u00a0has tried to fend off reinfection by buying a $130\u00a0sterilization kit for his shoes.", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells readers the scans cost about $200-$400 and are generally not covered by insurance.\u00a0 ", "answer": 1}, {"article": "He was not involved in the research.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\n\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nRecently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. At the very least, what does it cost to train dogs?\u00a0If you can let someone call this the \u201choly grail,\u201d you can tell people how much the search for the grail costs.", "answer": 0}, {"article": "\"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer,\" Mercedes Lopez, of the National Polytechnic Institute in Guanajuato, said in the news release.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nBut drinking tequila won't help, the study authors noted.\nCompared to other mice, those fed agave fructans absorbed more calcium from food, excreted less calcium in their feces, and had a 50 percent increase in levels of a protein associated with the build-up of new bone tissue.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost not discussed but there is no product yet to cost estimate. ", "answer": 2}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions what Medicare pays for the pacemaker InterStim device and treatment.\nBut no cost estimate was given for Solesta.\u00a0 One site states: \u201cThe average wholesale price of Solesta\u00ae is $1,107 per 1 ml injection or $4,428 per treatment session.\u201d\nIn order to give readers a more complete sense of the cost of alternative options, we think cost estimates should have been given for both of the newer options mentioned.\nSome of the other treatment options mentioned in the story can be both effective and less expensive in appropriate patients.\u00a0 Cost is an important issue in this arena.", "answer": 0}, {"article": "But therapies have been improving steadily.\n``The proof of the pudding is always what happens when you give it to people and look at what the potency of the antiviral effect is,\" said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.\n``We can, once again, get control of virus replication in patients with the most advanced disease who are resistant to other drugs and really have a major impact on the course of disease and on survival in these patients,\" said Kuritzkes, who is a paid consultant to Panacos.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\n``We desperately need new compounds with novel mechanisms of action,\" said Eric Freed, chief of the virus-cell interaction section of the HIV Drug Resistance Program of the National Cancer Institute.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide any projections of what the drug might cost. But the story was able to estimate annual sales of the drug for Panacos Pharmaceuticals. If you can give the latter, you should be able to provide the former. ", "answer": 0}, {"article": "Jan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\nWhen that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed, as this is an investigational procedure.", "answer": 2}, {"article": "Paul J.D.\nIn 2016, the Office of Technology Management and Industry Relations reported that Mizzou received $14.9 million in revenue from more than 40 technology licenses.\n\u201cThis new technology may also provide physicians with a safer, more controllable option for treating patients.\u201d\n\nThe team co-authored the paper, \u201cUltrasonic modulation of tissue optical properties in ex vivo porcine skin to improve transmitted transdermal laser intensity,\u201d which recently was accepted for publication by the society\u2019s journal, Lasers in Surgery and Medicine.\nOpen-air transmission, in which the clinician holds the laser at a distance from the patient, is typical during normal dermatological procedures and presents a hazard to both the patients\u2019 and doctors\u2019 eyes.\n\u201cWe\u2019ve named the technique \u2018sonoillumination,\u2019 and we\u2019re hopeful that the procedure will be available widely in the near future.\u201d\n\nWhiteside and his team, including adviser, Heather K. Hunt, an assistant professor of bioengineering in the MU College of Engineering, tested the sonoillumination system on porcine skin tissue samples.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While it could be argued that the work on this combination laser-ultrasound device is at too early a stage to demand a comparison to the cost of existing laser devices, a quote in the release claims, \u201cwe\u2019re hopeful that the procedure will be available widely in the near future,\u201d which implies the developers must have some sense of how much their device might cost when they achieve their stated goal of commercialization.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\nAbout the National Heart, Lung, and Blood Institute (NHLBI): NHLBI, a part of the National Institutes of Health (NIH), plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs associated with the differing strategies. It states that hypertensive elderly patients receive medication to lower their systolic blood pressure to either 140 mm of mercury or 120 mm of mercury, and that, on average, the patients who had a lower targeted blood pressure required an added medication. But no specific drugs are mentioned, so readers cannot judge whether there would be cost differences between this recommended regimen and their current therapy.", "answer": 0}, {"article": "The researchers went one step further and gave contact lenses to the patients.\nAs for side effects, Griffith said the patients didn't report any pain or discomfort, and there were no signs that their bodies tried to reject the corneas, a risk that people face when they get transplanted organs.\nAs for cost, Griffith said the biosynthetic corneas \"in theory\" should be cheaper than donated corneas.\n\"We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation,\" said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.\n\"We believe that sutures used in this study resulted in roughness on the surface,\" Griffith said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is the only story of the three reviewed to discuss costs. As for cost, Griffith said the biosynthetic corneas \"in theory\" should be cheaper than donated corneas. Griffith said a German study recently found that donated corneas cost about $2,500.", "answer": 1}, {"article": "Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer\u2019s and Parkinson\u2019s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\n\u201cFollow up testing showed some of the patients going from abnormal to normal.\u201d\n\nOne of the more striking cases involved a 66-year old professional man whose neuropsychological testing was compatible with a diagnoses of MCI and whose PET scan showed reduced glucose utilization indicative of AD.\nThe study, which comes jointly from the Buck Institute for Research on Aging and the UCLA Easton Laboratories for Neurodegenerative Disease Research is the first to objectively show that memory loss in patients can be reversed, and improvement sustained, using a complex, 36-point therapeutic personalized program that involves comprehensive changes in diet, brain stimulation, exercise, optimization of sleep, specific pharmaceuticals and vitamins, and multiple additional steps that affect brain chemistry.\n\u201cEven though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites.\u201d Plans for larger studies are underway.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss the cost of this complex intervention or the cost of genetic testing for Alzheimer\u2019s. The costs for adhering to this protocol would quickly add up, but the descriptions are so vague that it\u2019s impossible to make informed projections. It cites \u201cdiet, brain stimulation, exercise, pharmaceuticals, optimization of sleep, specific pharmaceuticals and vitamins,and multiple additional steps that affect brain chemistry.\u201d", "answer": 0}, {"article": "The therapy continued with the parents for the next six months with less intensity.\nThe absence of any hope, as well as the very sudden regression in children\u2019s behaviour, led many parents to believe in the discredited theory of Andrew Wakefield that the MMR (measles, mumps and rubella) vaccine was the cause of autism.\nThere are no drugs to treat the condition, which typically sets in around the age of two, and many families have tried intensive training of their children by therapists, with mixed results.\nAutistic children might not interact with their parents at all, but when eventually a child did offer a toy or made a noise that could be interpreted as a request, the incident was rerun on video and the parent encouraged to respond.\nThe lifetime costs to the UK, which include health, social care and education costs as well as productivity losses, are estimated at \u00a31m to \u00a31.5m per child and between $1.4m and $2.4m in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does a good job of noting the social, health, lost productivity and educational costs of autism in the UK and the United States,\u00a0but it did not note the cost of the interventional program itself, and the time challenges that caregivers of autistic children face in pursuing this kind of intervention.", "answer": 0}, {"article": "A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nSpecifically, the group recommends that adults 50 to 59 years old who have a 10 percent or greater 10-year cardiovascular disease risk, are not at an increased risk for bleeding, and have a life expectancy of at least 10 years take a daily low-dose aspirin to prevent heart attack, stroke, and colorectal cancer.\nAdults in their 60s can also benefit from regular use of low-dose aspirin, but the bleeding risk is higher in this age group, so doctors should help these patients decide whether or not aspirin therapy is right for them on a case-by-case basis.\n\"The benefits of aspirin outweigh the harms for most people in their 50's who are at risk of cardiovascular disease but not at increased risk of bleeding.\nWhile taking low-dose aspirin daily can help prevent heart troubles, doctors note that it also increases the risk of bleeding in the stomach and intestines, and strokes caused by bleeding in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is universally known that aspirin is cheap, sold widely and in a manner where its cost will not be a barrier to consumption, so the cost information is not necessary to reiterate in this report.", "answer": 2}, {"article": "\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nThis work and these data, however, are the intellectual property of the individual group members and their sponsoring institutions.\nThe median age was 75 years (range 41to 94).\nTheir collective experience is among the largest multinational series of patients treated with image-guided SBRT to date.\n\"Older patients are often not considered for radiation therapy due to concerns about their ability to tolerate treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are no costs mentioned in the release. There have been a number of studies on the cost-effectiveness of different radiation therapies, including SBRT.  ", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.", "answer": 0}, {"article": "The development of olaparib, which is now owned by AstraZeneca, was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research (ICR) and the University of Cambridge, and clinical trials led by the ICR and The Royal Marsden, and other institutions in the UK and overseas.\nIt is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.\nMost of these men, who all had terminal prostate cancer with limited treatment options, had disease control lasting much longer than expected in this group of patients.\n\"We are excited about this pioneering study because it demonstrates the tremendous crossover and wider applications in the research on these diseases.\"\nIt provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release provides no cost information on the drug and the additional testing and additional radiographic work that would be part of this treatment.", "answer": 0}, {"article": "The study, \"Survival Outcomes in Men Undergoing Radical Prostatectomy after Primary Radiation Treatment for Adenocarcinoma of the Prostate,\" recently was published by Clinical Genitourinary Cancer, a peer-reviewed journal on the detection, diagnosis, prevention and treatment of genitourinary cancers.\n\"However, this study shows that it is a viable treatment option.\nRadiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.\nDuring a salvage radical prostatectomy, the prostate gland and surrounding tissue are surgically removed to keep the cancer from spreading.\nThis can bring a renewed hope and peace of mind to men living with prostate cancer.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention costs.", "answer": 0}, {"article": "Investigators in the Netherlands report the results of a three-year follow-up of a randomized controlled trial that compared three noninvasive treatments that included imiquimod and fluorouracil cream.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\n\"Throughout the last two decades there has been a growing interest in these non-surgical therapies, which offer the possibility of avoiding surgery and reducing demands on busy medical practices.\"\n\"Based on our findings, both imiquimod and fluorouracil are effective noninvasive treatments in most primary, low-risk superficial BCC, but the data provide no definite evidence for superiority of imiquimod to fluorouracil,\" commented Dr. Roozeboom.\n\"When choosing a treatment for an individual patient with a superficial BCC, other factors like age, compliance, and patient preferences should always be taken into account.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release notes that \u201cFluorouracil has the advantage of being less expensive than imiquimod,\u201d a statement for which we rank this satisfactory. But it would have been more complete if we had been told how much cheaper, and how the topical treatments compare with the cost of surgical removal or photo-dynamic therapy.", "answer": 1}, {"article": "The American Botanical council took issue with the findings, however.\n\"Measuring the effect of ginkgo in a big trial in older people, we didn't see any effect of the drug on slowing down or delaying normal age-related changes of cognition,\" said lead researcher Dr. Steven T. DeKosky, vice president and dean of the University of Virginia School of Medicine in Charlottesville.\nTo test ginkgo's effect on cognitive decline, DeKosky's group looked at results from the ginkgo Evaluation of Memory study, which included 3,069 community-dwelling adults 72 to 96 years of age.\nIn a statement, Douglas MacKay, CRN's vice president of scientific and regulatory affairs, said that \"there is a large body of previously published evidence, as well as ongoing trials, which suggest that ginkgo biloba is effective for helping to improve cognitive impairment in older adults.\"\n\"Regardless of whether people say 'I take it and I feel better,' you just don't see an effect,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of how much ginkgo biloba products cost.\u00a0 Even an NBC story, with limited broadcast time, mentioned that Americans spend more than $100 million on a year on these products. A USA Today story said US sales were $99 million in 2008.\u00a0 But what does it cost the individual?\u00a0 ", "answer": 0}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story reports the cost of scanning carotid arteries to be about $70, it does not discuss the cost of surgery. One analysis of Medicare reimbursements done a few years ago reported hospitals were paid about $11,000 for each patient getting a carotid endarterectomy. An earlier report estimated that in 2008 hospitals charged about $35,000 for the surgery and associated treatment, though the ultimate reimbursements by Medicare were much lower.", "answer": 0}, {"article": "Sandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nOn Friday, Moffitt Cancer Center and MD Anderson reported test results of 101 patients with advanced lymphoma who had failed previous therapy and were treated with CAR-T.\n\n\u201cIt puts a GPS navigation on the front of the cell so that when they\u2019re infused back in they know where to go and kill the lymphoma,\u201d said Dr. Frederick Locke, who helped lead the trial.\nNormally, our immune cells are good at killing invaders like bacteria but bad at fighting cancer.\nWith CAR-T, a patient\u2019s own immune cells are removed from the body, reprogrammed to find and destroy cancer cells, then put back into the bloodstream.\nThe FDA will review these results and could make a decision on approval by the end of the year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was not discussed and this was a major oversight.\u00a0Industry analysts and trade stories predict that axicabtagene ciloleucel will cost $250,000 to $300,000 and that the treatment could bring in about $8 billion a year within five years.", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\nThe study was funded by Radius Health, Inc.\n\nEndocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers.\nThe authors found that the risk of new vertebral or nonvertebral fractures dropped consistently among the participants taking abaloparatide-SC, irrespective of their baseline risk factors; and they found an increase in bone mineral density by abaloparatide in each of the baseline risk subgroups.\nThe drug also reduced major osteoporotic fractures by 55% compared with teriparatide and increased bone density to a greater extent in the hip region compared with teriparatide.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t include any discussion of the financial burden of the disease or estimated costs of treating it. This is a big market for drug makers and there are plenty of data available. Forteo, a similar drug to abaloparatide-SC, a human parathyroid hormone, is already on the market. It is reasonable to assume that the cost structure will be similar. GoodRx.com notes that a 28 day supply costs about $2,400.", "answer": 0}, {"article": "But \"the line between disease and the disability baggage that accompanies aging is sort of arbitrary,\" he said, pointing out that many interventions, such as prescribing glasses, have been developed to counteract the effects of aging.\nUsing growth hormone for non-approved purposes is controversial, he said, and some question whether doctors should try to intervene in the aging process.\nAnother researcher who presented a different study at the conference also emphasized the importance of staying active and maintaining a proper diet.\nThe government has approved use of growth hormone for a limited array of conditions in adults and children, Dr. Merriam said.\nA tablet that stimulates the production of growth hormone may help older adults improve their physical functioning and lower their body fat percentage, a researcher said yesterday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide the cost of growth hormone for the purpose of improved physical functioning in the elderly. ", "answer": 0}, {"article": "Scientists from the University of Gothenburg\u2019s Sahlgrenska Academy have developed a portable pocket-sized vestibular, or balance, stimulation device in a bid to improve the lives of Parkinson\u2019s sufferers.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nThe effectiveness of oral levodopa reduces as Parkinson\u2019s disease progresses in the patient and can lead to involuntary movements, or dyskinesia.\nBut this may not be restricted to Parkinson\u2019s disease, so there may be other conditions with poor balance where you could use electrical stimulation of the vestibular organs, the balance organs to improve balance and gait,\u201d he said.\nThe difference is that we use a particular current profile which you can stimulate the balance organs with without creating a balance disturbance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though the device remains experimental, the story says it is similar to other TENS (Transcutaneous Electrical Nerve Stimulation)\u00a0devices. A typical cost for TENS according to an internet search varies from $40 to $200 \u2014 a figure that the story could easily have provided. Some insurers may cover this cost, but possibly not for conditions where there is not a clearly demonstrated benefit.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not contain any information about the costs of the various statin medications.\u00a0 Although not entirely germane to the main topic, since individuals might make choices about which specific statin to take based on claims of enhanced LDL lowering, it would seem that cost information should have been included.", "answer": 0}, {"article": "In late July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA saying that there are no new safety concerns and that \"the [FDA advisory] committee's concerns appear to have been based on cost-effectiveness.\"\nThat's sad.\"\nPolicies get reviewed whenever there is additional information.\"\n\"Until just recently, I didn't know it was so precarious.\"\nSince then, it has also been approved as a treatment for certain types of lung, kidney and brain cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 1}, {"article": "I\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nAt one point, I couldn\u2019t even hold a spoon and feed myself.\u201d\n\nWithin a few days of the transplant, he was able to move his toes, and after four months could stand unaided, although he still needs a wheelchair.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\n\u201cI was in a dire place, but now I can swim and cycle and I am determined to walk.\u201d\n\nHolly Drewry was 21 when she was diagnosed with MS, and her condition deteriorated after she gave birth to her daughter, Isla.\n\u201cIt is important to stress, however, that this treatment is only suitable for patients with relapsing remitting multiple sclerosis disease who have had two or more significant relapses in the past 12 months, failed to respond to standard drug treatment and who have had the illness for at least 10 years.\u201d\n\nOne patient who has undergone the treatment, known as autologous haematopoietic stem cell transplant (HSCT), told the BBC\u2019s Panorama programme that he had made incredible progress.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Low in the story, one patient is identified as having spent \u00a330,000 (approximately $42,500) on the treatment. We\u2019ll give credit for this nod in the direction of cost, but it would be hard for a reader to generalize from that.\u00a0It isn\u2019t clear whether this is covered by insurance or not. It also isn\u2019t clear whether the price paid by this one patient is also the cost for the others. At the least, some context for that reference would have been helpful.\u00a0 We don\u2019t think of UK patients as paying out of pocket for health care. And since this is the U.S. edition of the Guardian, the info should be tailored for a U.S. audience.", "answer": 1}, {"article": "The main reason to take a multivitamin is to correct or prevent a deficiency, \"but there may be a modest benefit in reducing the risk of cancer in older men,\" Gaziano said.\n\"At least this doesn't suggest a harm\" as some previous studies on single vitamins have, he said.\n\u2014 Ask your doctor before taking any.\nSide effects were fairly similar except for more rashes among vitamin users.\nAbout one-third of U.S. adults and as many as half of those over 50 take them.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Most people know that multivitamins are inexpensive.", "answer": 2}, {"article": "A study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nIt aims to screen 1,700 men for five years, but results from the first 300 men were published in the British Journal of Urology International.\nProstate cancer is the second most common cancer in men worldwide and kills 254,000 men a year.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of the costs of the test, associated follow-up procedures or the tests for BRCA mutations.", "answer": 0}, {"article": "However this does not help them to overcome their fear in the long term.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nCBT provides a way of reducing the need for sedation in people with a phobia, but there will still be those who need sedation because they require urgent dental treatment or they are having particularly invasive treatments.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\nThe primary goal of our CBT service is to enable patients to receive dental treatment without the need for sedation, by working with each individual patient to set goals according to their priorities.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. This is not entirely surprising, since the study was done in the United Kingdom, which has a universal health care system. However, the journal article on which the release is based does address cost, at least in terms of the cost to the health care system itself. The article says that the CBT sessions to address dental fears had \u201can average cost of \u00a3810 per patient.\u201d (The cost in British pounds converts to about $1,212.) The article also says, \u201cWhile initially expensive the evidence suggests that patients can then receive dental treatment without sedation thus potentially reducing long-term costs.\u201d For patients in the United States, the cost would likely be significant \u2014 particularly since the researchers report that patients needed an average of five CBT sessions before being able to receive dental care without sedation (and it\u2019s not clear whether health insurance would cover such sessions).", "answer": 0}, {"article": "Still, some researchers not involved in the study said the topic required more work.\nThe smoking rate has declined substantially since the 1960s, but the pace of decline has slowed in recent years and health experts are trying to figure out how to get more smokers to quit.\nWe need more studies, funded by someone other than the company that makes the product.\u201d\n\nSmoking is the largest cause of preventable death in the United States, killing more than 480,000 Americans a year.\n\u201cThe approach taken here is a very reasonable one that appears to have been successful,\u201d said Gary A. Giovino, a professor of health behavior at the State University of New York at Buffalo.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear that Chantix costs approximately $250 per month. The story also notes that some insurance companies would not cover the cost of smoking cessation drugs if an individual has not set a quit date. However, it\u2019s not clear how many insurance companies will pay for smoking cessation drugs at all, or how many would pay for the drugs without a quit date.", "answer": 1}, {"article": "An HIV vaccine has long been elusive.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nResearchers from the National Institutes of Health and Johnson & Johnson at the International AIDS Society conference in Paris Monday morning presented data on a clinical trial of what\u2019s called the \u201cAd26-env mosaic vaccine.\u201d\n\nThe mosaic vaccine was developed using a computer algorithm to analyze HIV data from around the world and select a range of HIV sequences to include in a shot.\n\u201cIt\u2019s a step forward toward getting another candidate into trial that could have some promise.\u201d It\u2019s too soon to say if and when the mosaic vaccine might work to prevent the virus from spreading in humans, he added.\n(Some of that access is now in jeopardy, however, given that President Donald Trump has proposed cutting $800 million from a key US government AIDS program called PEPFAR in the 2018 budget.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While it might be premature to speculate about the exact costs of an experimental vaccine, offering no discussion at all is a major flaw in this story.\u00a0Cost is a central, vital part to this narrative because any health technology developed to be used in the world\u2019s poorest countries are only going to matter to those people if it is affordable.", "answer": 0}, {"article": "SUNDAY, Sept. 19, 2010 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nPatients stayed on each regiment for 14 weeks.\nIn addition, the combination of an inhaled steroid and Spiriva was not less effective than using an inhaled steroid plus Serevent, they said.\nThese included: Spiriva plus an inhaled steroid; a double dose of the inhaled steroid; and an inhaled steroid plus Serevent, a long-acting beta agonist that relaxes the muscles in the airway.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed and should be.", "answer": 0}, {"article": "But after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nLONDON (Reuters) - Exposure to bright light can raise testosterone levels and lead to greater sexual satisfaction in men with low sexual desire, according to the results of a small scientific trial.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\nScientists at the University of Siena in Italy found that regular, early-morning use of a light box \u2013 similar to those used to combat Seasonal Affective Disorder or SAD - helped men increase testosterone and improved their sex lives.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "How much does a light therapy box cost? The story doesn\u2019t say. Using an online search, we found models ranging from $40 to $300, depending on size and features. It would be helpful to know the duration and intensity of light treatment in the study as well, as this can influence cost.", "answer": 0}, {"article": "\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\n\"There should be no argument that finding invasive cancers at a smaller size and earlier stage is beneficial,\" he said, as they are more likely to be cured.\nOne limitation of the study, he said, is that the researchers cannot say for sure it was the computer-aided detection that made the difference.\nHowever, among the women who did have invasive cancer, computer-aided detection was linked with a greater likelihood of finding the cancer while it was stage 1 or 2 compared to stage 3 or 4, they found.\nFor one thing, computer-aided detection (CAD) increases the amount of diagnostic testing among women who turn out not to have breast cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story points out that Medicare pays an additional $11 for mammography readings that use CAD. \u00a0It would also be useful for readers to know that women can\u2019t choose whether to have their mammograms read using CAD or not using CAD.", "answer": 1}, {"article": "News releases can also be found at http://www.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\nThe air pressure in the treadmill can be adjusted to take the patient from 100 per cent of their body weight to only 20 per cent, the same feeling as walking on the moon, and reducing the impact and pressure on joints during the run.\nIn a report titled Return to running following knee osteochondral repair using an anti-gravity treadmill, published in the journal Physical Therapy in Sport, Dr Hambly demonstrates how a graduated return to running using an anti-gravity treadmill can help to reduce fears about re-injury and increase self-belief in being able to run on the injured knee.\nDevices like the anti-gravity treadmill, enable walking or running without the full weight of the body so reducing the load on the joints in the lower limbs and bridging the gap between rehabilitation and return to sport.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs of the \u201cspace age\u201d treadmill device. We found at least one anti-gravity treadmill has been around since 2005. The machines sell for between $24,500 and $70,000. Most people who would want to use them would be referred to a rehabilitation clinic where it may cost about $80 to run on one for 55 minutes.", "answer": 0}, {"article": "The results were published in January in Nature Medicine.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nThe drug, known as 10-1074, may also offer a new way to prevent viral infection in people who are at high risk to acquire HIV, the virus that causes AIDS.\nAlthough it has been a lifesaver for people infected with the virus, antiretroviral medications have significant drawbacks: they can cause severe side effects, and patients have to take them for life.\nCurrently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This new process sounds very expensive but the release doesn\u2019t give us any clues as to how costly it might be. Biologic therapies used for other indications are very expensive. It would be helpful if the release had at least mentioned cost, even to say that they are as yet unknown.", "answer": 0}, {"article": "The program Saint helped develop -- called the \"bladder bundle\" -- includes protocols, checklists, training and information-sharing that help doctors and nurses reduce catheter use and prevent infections.\nThe researchers found that catheter infection rates in the new program dropped 14 percent overall in general wards (non-ICU).\nThe findings were published June 2 in the New England Journal of Medicine.\nAlthough about 20 percent of hospitalized patients get a urinary catheter, one-third of the time they aren't needed, Saint said.\nVisit the U.S. Centers for Disease Control and Prevention for more on urinary tract infections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told that, each year, catheters in hospitals cause 250,000 infections and cost $250 million to treat. That\u2019s important to note and we\u2019re glad it was included. However, the story didn\u2019t tell us how much the intervention costs to implement. But, because this is an intervention that doesn\u2019t have direct consumer costs (unlike, say, a new cancer drug or surgery), we\u2019ll rate this is as N/A.", "answer": 2}, {"article": "\u201cPrior to the Crest trial, we really did not have the best evidence, but these results indicate that we have two very safe and effective methods to prevent stroke.\u201d\n\nThough there are differences in risk between the two procedures and individual variations, he said, \u201cthe results from stenting are very comparable to those for carotid surgery.\u201d\n\nBut Dr. Martin M. Brown, chief investigator for the European trial, the International Carotid Stenting Study, said that although differences in the groups studied might explain the disparate results, \u201cnobody has really shown stenting is better than surgery, so why choose a stent?\u201d\n\nDr. Brown added, \u201cEven if Crest shows little difference between the two, there are three other trials that suggest surgery is safer.\u201d\n\nStrokes are the third leading cause of death in the United States and a major cause of disability among adults.\nAlthough many patients take drugs like statins and medicine to reduce their risk of stroke, surgical treatment of severe blockages in the carotid artery has been shown to be more effective than medical therapy alone in preventing ischemic strokes caused by a buildup of plaque in the arteries.\nBut surgery patients were at higher risk for , with 2.3 percent suffering a heart attack in the first 30 days compared with 1.1 percent of stent patients.\nIt included 2,502 patients at more than 100 in the United States and Canada, who were randomly assigned to receive either surgery or stenting over a period of nine years.\nAmong the possible explanations offered for the disparities are that the European study included only symptomatic patients, who may have had more advanced disease, and that the North American trial carefully screened the doctors doing the stenting procedure, including only highly skilled physicians with a lot of experience.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it hints at potential implications of expanded Medicare coverage for stents, this story doesn\u2019t make any explicit reference to costs.", "answer": 0}, {"article": "\u201cKangaroo mother care is care of preterm infants carried skin-to-skin with the mother.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\n\u201cIt is a gentle, effective method that avoids the agitation routinely experienced in a busy ward with preterm infants.\u201d\n\nAnd it\u2019s safe, WHO added.\n\u201cOur long-term findings should support the decision to introduce kangaroo mother care to reduce medical and psychological disorders attributable to prematurity and low birth weight,\u201d they wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of this intervention or of the control, a neonatal minimal care unit in which infants remain in an incubator while they gain weight, aren\u2019t mentioned.", "answer": 0}, {"article": "\"This study does not indicate that distance runners are any more likely to get osteoarthritis than any other person,\" Seeley said.\nIn other words, it appears running can reduce joint inflammation.\n\"This idea that long-distance running is bad for your knees might be a myth.\"\n\"Instead, this study suggests exercise can be a type of medicine.\"\nWhen the same fluids were extracted before and after a non-running condition, the inflammation markers stayed at similar levels.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no cost mentioned, but typically, running does not have any cost requirement except for good shoes. This category is not applicable for this research.", "answer": 2}, {"article": "I'll Be Me ,\" Saturday, November 7, at 8 p.m.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\nNow, the first study in people with Alzheimer's suggests that the compound, when taken in concentrated doses, may actually have benefit in slowing progression of this disease.\nThe researchers looked at several biomarkers of Alzheimer's, and found that people who took up to four pills a day for a year had higher levels of amyloid-beta proteins in their spinal fluid than those who took a placebo (control) pill.\n\"To really get a better feel of how effective this could be you really need to do larger studies for longer periods of time (such as several years),\" said James A. Hendrix, director of global science initiatives at the Alzheimer's Association, a research and advocacy organization.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address cost at all.\u00a0But as with the competing Time coverage, we\u2019ll rule this Not Applicable since the story clearly indicates that the supplements studied are not on the market.", "answer": 2}, {"article": "MONDAY, July 11, 2011 (HealthDay News) -- Teens who have high levels of folic acid appear to do better in school than those with lower levels, Swedish researchers report.\n\"It's one of those things that's no harm, no foul.\nFolic acid is one of the B vitamins and is a key component in making DNA and RNA.\nAmong the elderly, folic acid consumption appears to affect mental ability, and low levels of this vitamin have been associated with dementia and Alzheimer's disease, according to several studies.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs but we don\u2019t think that\u2019s a big issue in this case.", "answer": 2}, {"article": "The research, supported by the European Research Council and titled Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells, is published by PNAS.\nThis can lead to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.\u201d\n\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\n\n\u2022 Effectiveness shown in tests on ovarian and bowel cancer\n\u2022 Developed by researchers at the University of Warwick\u2019s Warwick Cancer Research Centre\n\u2022 New drug could be cheaper to produce and less harmful to healthy cells\n\nTests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin.\nIn the absence of FY26, cancer cells switch from using their defective mitochondria to using metabolic activity in their cytoplasm to generate energy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release speculates that FY26 could be cheaper to produce than platinum-based chemotherapy drugs. That may well be true, but the release didn\u2019t provide any evidence or reasoning as to why this would be the case. Nor does it explain that cheaper \u201cproduction\u201d might not mean cheaper pricing for patients. We know that platinum is expensive, but then again new drugs are typically far more expensive than existing generic treatments. We\u2019d need more than a general claim that the drug \u201ccould be cheaper\u201d to award a Satisfactory rating here.", "answer": 0}, {"article": "Lehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nIn the study, 119 people (37%) reported no pain at six months.\nThis condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though this is still an experimental approach, it would have been appropriate to discuss the costs in terms of the closest similar treatment \u2013 an epidural steroid injection. Since the story claims the experimental approach has been used thousands of times in Europe, some cost frame of reference was possible.", "answer": 0}, {"article": "\u201cWhat does it mean, to improve metabolic health?\nMost of them have no scientific basis, and you don\u2019t know what you are getting.\u201d\n\nGuarente was involved in several other efforts to develop antiaging medicines that did not pan out.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\n\u201cIt is not quite clear to me what they want to target with this pill,\u201d said Pere Puigserver, a biology professor at Harvard Medical School.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells us early on in the story that a month\u2019s supply of the pill, called Basis, costs $50-60. So consumers will pay up to $700 a year for the privilege of helping the company test its pills.", "answer": 1}, {"article": "Why are so few women being treated?\n\u201cThe management of menopause has been relatively similar in the UK, the USA and in Australia.\u201d\n\nUp to half of women in menopause experience so-called vasomotor symptoms, such as hot flashes and night sweats.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nBut after the initial findings of the Women\u2019s Health Initiative study showed that HRT can increase the risk of breast cancer, stroke and other serious problems, many women stopped using it.\n(Reuters Health) - Many women with severe menopausal symptoms are not being treated for them even though safe, effective remedies are available, a study from Australia suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of therapies for menopausal symptoms is not discussed.\u00a0Prempro\u00a0(the common oral estrogen/progesterone tablet) is $1.65\u00a0per pill on an online pharmacy price checker, and must be taken daily \u2014 so the cost implications of some options are significant.", "answer": 0}, {"article": "Alzheimer's & dementia: The Journal of the Alzheimer's Association.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\nThe American Journal of Neuroradiology (AJNR) is published monthly by the American Society of Neuroradiology (ASNR), a professional association of more than 5,000 members who specialize in diagnostic radiology of the central nervous system, brain, head and neck through the use of X-ray, MRI, CT and angiography.\n\"I believe neuroradiology, and especially quantitative MRI technology, will have a huge impact in the future of diagnosis and treatment of Alzheimer's disease, since there is compelling evidence for the baseline size of hippocampus as a key determinant of risk for future cognitive decline, and since many lifestyle factors can cause atrophy or expansion in the volume of this critical brain structure,\" says neurologist Majid Fotuhi, M.D., Ph.D., of Johns Hopkins University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release, but overuse of medical technology such as MRI scanning is one major reason for soaring health care costs. According to personal finance website Nerdwallet.com, median prices of a brain MRI range from $525 in Atlanta to a whopping $3,310 in Milwaukee.", "answer": 0}, {"article": "Loading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\n\u201cOur diet and deteriorated microbiota are really a major piece of the puzzle in trying to understand why Western diseases are rising like crazy.\u201d\n\nSonnenburg says that when researchers try on mice what many of us do on a regular basis\u2014eat food depleted of dietary fiber\u2014their gut microbes behave erratically.\n\u201cWe discovered that the patients who exhibited higher amounts of were the patients who had a very strong improvement in cholesterol, in glycemia, in waist to hip ratio and also a reduction in different parameters in both cardiovascular disease and risk factors.\u201d\n\nHigher levels of , the findings suggest, seem to have favorable effects on health.\nBoth groups of people lost the same amount of weight, but the high- group had a stronger decrease in visceral fat than the others, says study author Patrice D. Cani, PhD, professor and group leader of the Metabolism and Nutrition Research Group at Universit\u00e9 Catholique de Louvain in Belgium.\n\u201cThey turn and start eating the mucus lining of the intestine,\u201d says Sonnenburg, \u201cbecause that\u2019s also a carbohydrate source and it\u2019s kind of a fallback food for them.\u201d In mice on a low-fiber diet, the mucus lining thins to about half of its normal width, he says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost. However, the intervention being discussed here is increasing one\u2019s dietary fiber intake. And the cost of high-fiber foods is widely variable. While some high-fiber foods may be costly (e.g., fresh vegetables are not readily available for those in urban \u201cfood deserts\u201d), others \u2014 such as beans \u2014 are not. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The results showed no differences in IQ.\nLorch also pointed out that this study involved a mostly homogenous population in a country outside the U.S.\n\n\"We should see whether similar effects are seen in higher-risk populations, such as the low socioeconomic population, racial and ethnic minorities and those at higher risk for neurodevelopmental delay,\" Lorch said.\n\"There is growing evidence from a number of studies that all infants, those born at term and those born early, benefit from receiving extra blood from the placenta at birth,\" said Dr. Heike Rabe, a neonatologist at Brighton & Sussex Medical School in the United Kingdom.\n\"The extra blood at birth helps the baby to cope better with the transition from life in the womb, where everything is provided for them by the placenta and the mother, to the outside world,\" Rabe said.\n\"We don't know exactly why, but speculate that girls receive extra protection through higher estrogen levels whilst being in the womb,\" Rabe said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The difference of slowing down the clamping of the newborn\u2019s umbilical cord does not seem to add any cost to care for a delivery. The story might have talked about potential \u201csavings\u201d if widespread use of this new technique made iron-deficiency for babies less common in US. But any benefit would be difficult to quantify. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "He reviewed the findings for WebMD.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\n\"The idea is that all the surgeon will have to do is remove the pieces with a vacuum,\" says researcher Mark Packer, MD, of Oregon Health and Sciences University in Portland.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that cost is an important barrier\u00a0to wider use of the\u00a0laser procedure, since the\u00a0equipment\u00a0carries a price tag of\u00a0$400,000 and insurers currently won\u2019t cover the extra cost. We\u2019ll call this satisfactory, but to make the information\u00a0more meaningful to\u00a0readers, the story should have broken down how the cost of an individual laser procedure compares with that of the\u00a0standard procedure.", "answer": 1}, {"article": "A University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\n\u201cThere is a critical need for improved therapies for this specific cancer type.\u201d\n\nMost cells use the energy of glucose (sugar).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\nHowever, there are many steps involved in lipid metabolism and researchers have been working to break prostate cancer\u2019s ability to harness this energy source.\n\u201cWe had to find a way to block this pathway so that the cancer would not be able to burn lipid in the mitochondria to acquire energy to resist therapy,\u201d explains Schlaepfer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The drug in question, enzalutamide, is advertised and sold as Xtandi. The cost of the drug could easily have been included in the news release. According to GoodRx, the out-of-pocket cost for 120 capsules of 40 mg Xtandi is roughly $11,000.\nRanolazine (marketed as Ranexa), the other drug discussed, is priced at about $350 for a 60 day supply of 500-mg tablets.", "answer": 0}, {"article": "San Francisco--A new study, presented today at the Society of NeuroInterventional Surgery's (SNIS) 15th Annual Meeting, found that new stroke imaging technology could decrease delays in care by up to 60 minutes, giving patients a better chance at making a full recovery.\nThe time required to transfer a patient from their CT scan to the operating room could delay EVT by as long as 60 minutes.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nThe imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed, either of this form of CT imaging compared to standard, or to the overall cost of care for acute stroke management. Nor does the release outline any factors that may influence potential cost. Is software the only thing new here? Or is new hardware also needed? This part is confusing. The release tells readers that the relevant study is titled \u201cNew Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?\u201d This indicates that the software relies on CT scans. The release further states that \u201crecent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient [with a particular type of stroke]. This study suggests that in the future, stroke patients can bypass the CT scan\u2026\u201d But, if they are bypassing the CT scan, what images is the software working with?", "answer": 0}, {"article": "Newswise \u2014 Fresh thyme and oregano offer a savory touch to a tasty dish, but a University of Iowa researcher recently discovered natural compounds in the herbs that may offer a treatment for cachexia or \u201cwasting syndrome\u201d as it is more commonly known.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs for the compounds referred to in this release. Nor are the compounds themselves identified which might give some idea of the cost of acquiring them.\u00a0 The release suggests an over-the-counter drug was being developed but no information was provided on what the cost might be to patients.\nGiven that this is pre-clinical research, we have no idea about what the process of isolating the active compounds would be, which would impact cost.", "answer": 0}, {"article": "Feb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nThe study appears online in the Journal of Clinical Investigation.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. There are no established ways to increase brown fat.", "answer": 2}, {"article": "\u201cThere\u2019s definitely a major need for a permanent, total artificial heart,\u201d Laman A.\nThe United States Food and Drug Administration has designated the AbioCor as a \u201chumanitarian use device,\u201d meaning its use is restricted to people who are ineligible for transplants and would otherwise be facing imminent death.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nThe Lasker Foundation, which is based in New York, praised their work in the development of artificial heart valves, saying they had \u201cprolonged and enhanced the lives of millions of people with heart disease.\u201d\n\nIn the November 2009 bulletin of the Acad\u00e9mie Nationale de M\u00e9decine, Dr. Carpentier wrote that, instead of picking up from older models of artificial hearts built on animal research, the developers of the new device had sought to use the tools of the digital revolution, namely computer-assisted design, hemodynamic modeling, regulation algorithms and simulations.\nSynCardia, based in Tucson, currently makes the only approved temporary artificial heart, having continued development of the groundbreaking Jarvik-7, which Dr. William C. DeVries implanted in a retired dentist named Barney B. Clark in 1982.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that the company \"estimates its device will cost $176,000 to $226,000. When all expenses are considered, including hospital and surgical expenses, it says it will cost just over $315,000, about the same as a transplant.\"", "answer": 1}, {"article": "WEDNESDAY, April 4, 2012 (HealthDay News) -- Regularly consumption of food and drink rich in substances called flavonoids, such as berries, apples, tea and red wine, can lower a man's risk of developing Parkinson's disease by 40 percent, new research suggests.\nAnthocyanins are a type of flavonoid plentiful in such berries as strawberries and blueberries.\nThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\" Gao added.\n\"For total flavonoids, the beneficial result was only in men.\nResults of the study are published online April 4 in the journal Neurology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of berries and other foods rich in antioxidants is not in question.", "answer": 2}, {"article": "But they are most often used in patients who have a blocked artery and chest pain that occurs, for example, walking up a hill or going up stairs.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\nOther estimates are far higher.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the procedure to insert stents costs from $11,000 to $41,000 in the U.S.", "answer": 1}, {"article": "Johnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested pharmaceutical bio-identical hormones that are made by drug companies and approved by the Food and Drug Administration.\nSuch custom compounds are not FDA-approved.\nFor one thing, the conclusions of the study have been discredited by subsequent studies.\nOnce a woman is educated, then she knows what to go in and ask for.\n\u201cWe also learned that we see fewer strokes and heart attacks from non-oral methods like a patch or a cream,\u201d she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the article.", "answer": 0}, {"article": "Seventy-four subjects with type 2 diabetes were randomly assigned to follow either a vegetarian diet or a conventional anti-diabetic diet.\nThe vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There may be cost implications in maintaining a balanced vegan or vegetarian diet. This is especially true for people whose conventional meat-based diet currently includes a lot of processed foods and they find they need to shop for expensive veggie burgers and soy-based meals at the Whole Foods or Trader Joe\u2019s to round out their vegetarian diet. It would have been good if the release had at least mentioned there may a cost consideration.", "answer": 2}, {"article": "MONDAY, Jan. 11, 2010 (HealthDay News) -- As a major organization of pediatricians considers revising its recommendations on circumcision of newborn boys, two new reviews of existing research offer conflicting conclusions about the bitterly debated procedure.\nFor now, he said, when it comes to circumcision, \"we know it's pretty safe, and we have a lot of evidence for some benefit.\"\nIt says that risks of complications from circumcision are less than 1 percent, and \"serious long-term complications are extremely rare.\"\n\"There are some clear benefits to circumcision,\" he said.\n\"There are some risks to circumcision, although the significant ones appear to be rare.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss the cost of circumcision or its coverage by insurance companies. Currently, some state Medicaid programs do not cover its cost. ", "answer": 0}, {"article": "In this study, the average age was about 59 years old - six years younger than the age at which the U.S. Preventive Services Task Force, a government-backed panel, recommends all women begin being screened for osteoporosis.\nThat may spare the patients from additional testing and additional costs.\nThe disease affects over 12 million Americans over 50.\nThe researchers then found that their ability to accurately diagnose those same patients with osteoporosis from a CT scan depended on what threshold for bone density they used.\n\u201cI don\u2019t think at this point this one test is going to prevent further testing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained the cost of DXA tests and CT scans.", "answer": 1}, {"article": "A video in which Professor Probert explains how the machine works can be found here\n'The use of a gas chromatography (GC)-sensor system combined with advanced statistical methods towards the diagnosis of urological malignancies', published today in the Journal of Breath Research, describes a diagnostic test using a special tool to 'smell' the cancer in men's urine.\nThe results of the pilot study using the GC sensor system indicate that it is able to successfully identify different patterns of volatile compounds that allow classification of urine samples from patients with urological cancers.\nProfessor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nProfessor Probert said: \"There is an urgent need to identify these cancers at an earlier stage when they are more treatable as the earlier a person is diagnosed the better.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this diagnostic test aside from the implication that it would be inexpensive. A lead researcher of the device states, \u201cWith help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient\u2019s bedside, in a doctor\u2019s surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results.\u201d\nThe release is clear that this was a pilot study and that the system is not yet available for mass use. That\u2019s good. But the release does speculate that the\u00a0test might mean that \u201cinvasive diagnostic procedures that men currently undergo eventually become a thing of the past.\u201d\nWe think that if it\u2019s not too soon to speculate about these kinds of benefits, it\u2019s not too soon to provide some idea of what the test might cost.", "answer": 0}, {"article": "Natural-birth advocates cite a \"cascade of interventions\" caused by hospitals' practice of using the drug Pitocin to stimulate labor.\nCaesareans impede this process.\n\"There are certainly women who want timed, elective delivery surgically.\"\n\"One of the knowledge gaps is a clear understanding of the indications for C-sections,\" she says.\nIf something does go wrong, in the eyes of the courts \"a normal birth is a risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the note that \"Caesarean can cost three times as much as normal birth.\"", "answer": 1}, {"article": "\u201cThis isn\u2019t a magic bullet.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nWe\u2019re just learning how to do this treatment.\u201d\n\nMagic mushrooms grow worldwide and have been used since ancient times, both for recreation and for religious rites.\nThe World Health Organization estimates that some 350 million people worldwide are affected by depression, a common mental disorder characterized by sadness, loss of interest or pleasure, tiredness, feelings of guilt or low self-worth, disturbed sleep and appetite, and poor concentration.\nBlood pressure, heart rate and the self-reported intensity of the effects of psilocybin were monitored during each session, and the patients were seen by a psychiatrist the next day and one, two, three and five weeks after the second dose.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not broached in this story. The story signals an\u00a0early phase of research with phrases like \u201cpilot study,\u201d but this is overshadowed by the headline and the lead sentences, which create an expectation of benefit.\nEven at a very high level, for example, the story could have told us whether this is something that could be patented and commercialized by a drug company. The price tag for such a treatment would likely be much greater than if the compound were in the public domain.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs associated with liver transplantation were not provided beyond the sense that they were out of reach for a family of modest means without medical insurance.\nThe costs associated with the recommendation that pediatricians include liver testing as a routine part of patient care was also not discussed.\u00a0\nLastly \u2013 there was no discussion of the costs for behavioral treatment programs designed to better enable children and their families lose weight.\u00a0\nAll of these approaches have costs; no such costs were explained. \u00a0", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs, although the story does mention that insurance coverage varies.", "answer": 0}, {"article": "The study comes a month after Gov.\nThe scans are sometimes criticized as an example of expensive new technologies being adopted before proof is established that they're better than cheaper existing methods \u2014 an issue at the heart of the health care reform debate.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\n\u201cDoctors and patients need to think about the cancer risk when ordering this test.\u201d\n\nThe study, published in the new edition of Archives of Internal Medicine, found a small but real risk from the average radiation \u2014 for every 100,000 men between 45 and 75 undergoing the test every five years, there would be 42 cancers; for every 100,000 women ages 55 to 75, there would be 62.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n \nThe story not only mentions the cost of a scan to individuals ($100 to $500), it also notes that about $50 million dollars was spent on this type of scanning nationwide in 2008. A longer story could have also reported on the costs of additional testing and treatments triggered by screening apparently healthy individuals.", "answer": 1}, {"article": "The current study sets the stage for clinical trials in humans.\n\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\nBoth Nichols and Margaritis agreed: \"The table is now set to propose clinical trials that would treat people who suffer from FVII deficiency.\"\nResearchers at CHOP and elsewhere have bioengineered an adeno-associated virus (AAV), which does not cause disease, as a vector to deliver DNA into cells where it can express enough factor to make the blood clot normally.\n\"These dogs have the type of mutation found in the majority of patients with this disorder, so this approach could lead to a sustained gene therapy in people.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not bring up costs, but we\u2019ll rate this Not Applicable since the release is clear that this is early-stage work that is not yet ready for use in humans. Some mention of costs would have been valuable nonetheless. Gene therapy is known to be extremely costly, and when a disease is rare, as this is, that raises questions about what company would find it profitable to pursue the potential treatment. The University of Utah provides some excellent background on the \u201ccommercial viability\u201d of gene therapy.", "answer": 2}, {"article": "D'Amico noted that new studies using up-to-date high-dose radiation also found that the addition of short-term hormone therapy improved outcomes at five years for men with intermediate risk prostate cancer, compared with radiation alone.\nIn October 2010, the U.S. Food and Drug Administration asked manufacturers to add a warning that certain drugs used in hormone therapy (including the one used in the study) were linked to a small but increased risk of diabetes, heart attack, stroke and sudden death in men.\n\"This study, in conjunction with what we know about hormonal therapy, really nails home the conclusion that hormonal therapy should not be used in men with low-risk disease because the risks outweigh any conceivable benefit,\" commented Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston and author of an accompanying journal editorial.\n\"We decreased the risk of dying from prostate cancer in those patients from 10 percent to 3 percent, at 10 years,\" Jones said.\n\"We can give 15 to 20 percent higher doses of radiation now than we could then, and we can do it more safely and more accurately,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.\u00a0 Over and over again \u2013 more than 70& of >1,500 stories we\u2019ve reviewed fail to adequately discuss costs.\u00a0 This has to change.", "answer": 0}, {"article": "That's why they compared ketamine patients with patients taking other pain medications.\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\n\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\nFor financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating depression in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not specify cost, but says ketamine is \u201crelatively inexpensive and is covered by most health insurance plans if three other antidepressants fail.\u201d If prescribed it is done so \u201coff-label\u201d since ketamine is not FDA approved for depression, and thus not covered by health insurance. At least one ketamine treatment center says the drug is not covered by insurance.\nThe release also doesn\u2019t specify which ketamine formulation it assessed. When given by infusion, which is how depression is treated clinically with the drug, it can cost several hundred dollars per treatment.", "answer": 0}, {"article": "The researchers, Drs.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\nThe benefit was primarily seen among men younger than 65 and the authors estimated that seven men under the age of 65 and 8 over the age of 65 would need to be treated to save one life.\nAfter an average follow-up of about 13 years, 14.6 percent of the men who had undergone surgery had died, versus 20.7 percent in the watchful waiting group, a 38 percent reduced risk.\n\"This is relatively early stage disease, and it shows what we would expect it to show: that those who have more years [to live] have better survival if treated aggressively,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Costs would include treating the double digit rates of incontinence and erectile dysfunction in these younger men who do have surgery. The surgery may help them live longer, but many, especially since younger at time of surgery, live decades with these potential harms and folllowup costs of the surgical choice.\u00a0 This should get at least a line in such stories.", "answer": 0}, {"article": "This was a phase 2 trial.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\n\"The whole field is still preliminary and we have to be careful not to overhype the results [as] we're waiting on the results of the phase 3 trial,\" she said.\nWEDNESDAY, Jan. 5, 2011 (HealthDay News) -- Researchers have taken another step in the hunt to find a treatment for an aggressive, likely-to-recur form of breast cancer.\nIniparib inhibits a pathway that helps repair DNA; researchers call it the poly(ADP-ribose) polymerase (PARP) pathway.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the potential cost of the drug.\u00a0 Since the story briefly discusses \u201ca similar drug\u201d it could have at least given the cost of that drug.\u00a0 As it is, cost is unaddressed \u2013 a huge vacuum.", "answer": 0}, {"article": "Tecentriq is marketed by Genentech based in San Francisco, California.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nWhile patients who received Tecentriq experienced a tumor response across the study, the greater effect in those who were classified as \"positive\" for PD-L1 expression suggests that the level of PD-L1 expression in tumor-infiltrating immune cells may help identify patients who are more likely to respond to treatment with Tecentriq.\nFor more information:\n\nFDA: Office of Hematology and Oncology Products \n\nFDA: Approved Drugs: Questions and Answers \n\nFDA: Companion Diagnostics \n\nNCI: Bladder Cancer\n\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n\"Tecentriq provides these patients with a new therapy targeting the PD-L1 pathway,\" said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost. The FDA evaluates drugs without consideration of cost, so it\u2019s understandable that they wouldn\u2019t comment on it \u2014 and that\u2019s why we\u2019re rating this Not Applicable. But let\u2019s be real here: The value of a new drug is a function not just of how well it works, but its cost-effectiveness. So we look forward to the day when any news release about a new drug \u2014 even one from the FDA \u2014 will include some mention of cost in its message.", "answer": 2}, {"article": "ACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nIn those studies using smaller doses, the reduction in preeclampsia risk hovered around 10 percent, he said, but the higher dose in this latest study was linked to a 62 percent reduction in risk.\nThe exact cause of the disorder is unknown, but certain risk factors make it more likely to occur, including:\n\u2022 Being pregnant with more than one baby,\n\u2022 Having chronic conditions, such as type 1 or type 2 diabetes, autoimmune disease and kidney problems.\nIt can affect all of the organs in a woman's body, according to the American College of Obstetricians and Gynecologists (ACOG).\n\"Preeclampsia is one of the most serious complications of pregnancy, with a high risk of death for the mother and baby,\" said senior study author Dr. Kypros Nicolaides.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll consider this N/A since generic aspirin is very affordable. Still, we never think it\u2019s a bad idea to acknowledge the cost of a treatment. Also, there is the potential for significant cost savings to individuals and society by reducing the financial burden of treating pregnancy and childbirth complications using only a very affordable medication. We\u2019d be curious to see an estimate.", "answer": 2}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The exact cost of an IUD wasn\u2019t mentioned in the story, but it did allude to the low cost of the product. The story also missed an opportunity to articulate the economic issues associated with HPV vaccine availability, namely the manufacturing cost of the vaccines and the profitability focus of the pharmaceutical industry.", "answer": 0}, {"article": "MONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nBut what will need is a very carefully controlled study that accounts for all the variables that might have an impact on the outcome of this approach.\"\n\"But I will say that I don't know of any study looking at acupuncture and vision.\nFor the latter group, doctors will often place a patch over the \"good\" eye temporarily in addition to eyeglasses, and treatment success is typically achieved in two-thirds of cases.\n\"And no question patients will gravitate towards treatments that are covered by their insurance even if it's not the best treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that acupuncture\u00a0may not be\u00a0be covered by many insurers, but it never provides even a ballpark\u00a0estimate of what a typical office visit for acupuncture would cost.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not address costs at all, even though one half of the drug combination \u2013vemurafenib \u2014 is already being used in treatment and costs $11,000 per month of treatment. \u00a0The combination treatment is reportedly going to cost $17,600 per month,\u00a0and it is not clear whether payers will cover it.", "answer": 0}, {"article": "STAR was a retrospective analysis of IRE performed on 200 consecutive patients diagnosed with locally advanced (Stage III) pancreatic cancer (LAPC) at six centers in the U.S.\nThe centers that collaborated on the study included University of Louisville, Louisville, KY; Henry Ford Hospital, Detroit, MI; Cleveland Clinic, Cleveland, OH; Piedmont Hospital, Atlanta, GA; Swedish Medical Center, Denver, CO; and Cancer Treatment Centers of America, Atlanta, GA.\n\nFrom July 2010 to October 2014, patients with radiographic Stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nAs part of the region's leading academic, research and teaching health center, the cancer center provides the latest medical advances to patients, often long before they become available in non-teaching settings.\nSAN DIEGO, April 24, 2015 /PRNewswire/ -- University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife\u00ae System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed, but secondary sources suggest each NanoKnife machine (which can be used over and over again) costs between $200,000\u2013$300,000. The one-use needles, which are used to\u00a0zap or ablate cancerous pancreatic tissue, cost about $2,000 each\u2013but it\u2019s not said how many sessions are required. Nor is the cost\u00a0of\u00a0doctors, hospital stay, etc. discussed. Plus, it\u2019s unknown if insurance will cover this.", "answer": 0}, {"article": "For more information, visit http://www.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nIn fact, typical mammography sensitivity, which is 75 to 85 percent accurate, decreases to 30 to 50 percent in dense tissue.\nNEW YORK April 25, 2018 - A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.\n\"Breast cancer survival is strongly tied to the sensitivity of tumor detection; accurate methods for detecting smaller, earlier tumors remains a priority,\" says Prof. Yehuda Zeiri, a member of Ben-Gurion University's Department of Biomedical Engineering.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release never gives readers an estimate for the cost of a combination breath and urine screening test for breast cancer. The release does state that the technologies used for both urine and breath are \u201cinexpensive\u201d but doesn\u2019t give us a concrete number to justify that claim.", "answer": 0}, {"article": "Although tenecteplase appears to be more effective for stroke patients, it's not approved for that use in the United States, according to Dr. Rohan Arora, director of stroke at Long Island Jewish Hospital in Forest Hills, N.Y.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nIn the United States, tenecteplase costs about $5,800, versus alteplase, which costs $8,000, Arora said.\nIn 2000, the U.S. Food and Drug Administration approved tenecteplase for use after a heart attack, Arora said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained that tenecteplase costs about $5,800 in the U.S. compared with about $8,000 for alteplase.", "answer": 1}, {"article": "The study enrolled 119 participants.\nThe biggest risk factor for developing Alzheimer's is aging, and studies with animals found that most age-related diseases--including Alzheimer's--can be prevented or delayed by long-term caloric restriction (consuming two-thirds the normal caloric intake).\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\nWASHINGTON (Sept. 11, 2015) -- The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer's disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.\nThe Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although resveratrol is found in some foods, it was tested here as an investigational new drug. This means that it is not available commercially in 1-gram pills. The news release points out this fact, which is why we rate this Not Applicable.", "answer": 2}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\nNow that the researchers have validated the test, further studies in larger, more diverse populations will be important to understand how it is best used.\n\u201cThe real key is using this or any test to help drive decisions,\u201d says Jones, who was not involved in the research, \u201cIf it helps me to know who to biopsy or not biopsy, that\u2019s massively valuable information.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story included price estimates for prostate biopsy, it did not include a ball park estimate for the cost to assay for the gene fusion product discussed nor the costs of testing for PCA3, which is currently commercially available.", "answer": 0}, {"article": "Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com\n(June 1, 2016) - A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34 -- a member of a family of proteins that have an impact on vascular-associated tissue -- cells had a significant reduction in angina frequency over patients who received placebo.\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\n\"There are an increasing number of patients with advanced coronary artery disease that are not amenable to surgical or percutaneous revascularization,\" said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs at all. Given that this was a phase II study, meaning it is still at least one step removed from clinical use, we don\u2019t necessarily expect a release to give a precise cost to the treatment. However, we do expect cost to be addressed in at least some capacity. For example, is there an expectation that this treatment would be comparable in cost to other treatment options for angina? Given that this was industry-funded study, the release could have addressed this in at least broad terms.\nAs the release appears to be comparing this procedure to bypass surgery, it would be helpful to know exactly what is involved in obtaining \u201cautologous\u201d (self donated) cells and \u201cintramyocardial delivery into the ischemic zone\u201d later referred to as \u201cinjected.\u201d\u00a0 It is unclear if this is a surgical procedure, inpatient hospital treatment or clinic visit, all of which would influence the final cost.", "answer": 0}, {"article": "Yet most people who have this operation do not get skinny.\nIt used to be that roughly one in 100 people died from this operation.\nA big reason the operation works is because it seems to suppress appetite.\nIt's about one-tenth of cardiac surgery,\" he explains.\nIt can force type 2 diabetes into almost instant remission and it appears to reduce the risk of cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The segment reports that the surgery costs about $25,000 and is not always covered by insurance. ", "answer": 1}, {"article": "\u201cI couldn\u2019t wear a brassiere for three months,\u201d she recalled.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nAmong the 65- to 74-year-olds getting CT scans in the national trial, moreover, many had other serious health problems \u2014 heart disease, diabetes, hypertension, pulmonary disease \u2014 which probably contributed to only 55 percent surviving five years, compared with 64 percent among those under age 65.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story describes the case of one patient who paid $95 out of pocket for a lung cancer screen in 2013. But while the story does\u00a0attempt to at least provide some cost perspective with the coverage,\u00a0we\u2019d note that under the Affordable Care Act, approved preventive tests do not carry copayments, so the cost of the initial scan is not really an issue for eligible patients. And in any case, the real costs to individuals and society are not really addressed by the cost of one scan. The story notes high up that the number of Americans who would be eligible for Medicare-funded scans would be in the millions. So the cost to Medicare and private insurers to fund this program will be, well, gargantuan at that scale. There is the cost of the initial test, annual testing if negative, and potentially more testing if an abnormality is found. This is not going to be a cheap program.", "answer": 0}, {"article": "This benefit was independent of other heart risk factors such as advancing age, high blood pressure, family history of heart attack, body mass index, exercise, smoking, and caffeine and alcohol intake.\nBesides flavonoids, berries also are loaded with other nutrients, including vitamin C, potassium and folate.\nDuring the study period, 405 participants had heart attacks.\nOne serving of blueberries or strawberries equals about one cup.\nThe study included nearly 94,000 young and middle-aged women who took part in the Nurses' Health Study II.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not mentioned but we think most readers know the ballpark costs of berries.", "answer": 2}, {"article": "\"I think we need to pause and think about whether the extra information [from CT scans] really helps us make a diagnosis,\" Smith-Bindman says.\n\"That means we're doing fewer scans per person,\" he says.\n\"In most cases it does, and we should be using CT scanning in those cases.\nA low score indicates the test is unlikely to be necessary.\nNearly 15,000 of those cancers could be fatal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of CT scans, which are substantial. ", "answer": 0}, {"article": "You should go through six to eight weeks of conservative management.\u2019 \u201d\n\nAt the Partners Healthcare System in Boston, spine experts have the same struggle to convince patients that an M.R.I.\nThe patients who knew recovered no faster than those who did not know.\nThey tended to occur along with arthritis and were a part of the disease process itself.\nAnd he was becoming concerned about their findings.\nAnd surgeons use symptoms and a physical examination to identify patients who would be helped by operations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story adequately describes what insurers pay for the scans.", "answer": 1}, {"article": "So why do routine lab tests that doctors order often come back negative or not informative in ME/CFS patients?\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\nThe multidisciplinary Stanford team is now working on developing a panel that could be used commercially, that would test for around five of the 17 cytokines and would likely involve the doctor first classifying patients by severity in order to interpret the results.\nThe symptoms can range from mild to extremely severe, with about a quarter of patients so ill they're mostly or completely confined to bed.\nResearch findings from Stanford University released Monday could point the way to a long-sought diagnostic laboratory test for the condition, and possibly a first-ever treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story talks about work to develop a commercially available test, but there is no discussion of what such a test might cost. A story needs to at a minimum discuss what is known about the costs of diagnosing and potentially treating a cytokine-based condition.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A less common form of obesity surgery may spur more weight loss than its far more popular cousin, gastric bypass \u2014 but at the price of greater long-term risks, researchers reported Tuesday.\nThat begs the question, he said, of whether the extra weight loss \u201cactually accomplished anything.\u201d\n\nIn the U.S., where about 220,000 people underwent weight-loss surgery in 2009, gastric bypass is the most common form chosen.\nBut the risks of nutrient deficiencies are greater with duodenal switch, and include some not seen with gastric bypass, Livingston pointed out.\nThe technique is often reserved for \u201csuperobese\u201d patients with a body mass index (BMI) of 50 or higher \u2014 though some surgeons perform it with less severely obese patients too, explained Dr. Torgeir T. Sovik of Oslo University in Norway, the lead researcher on the new study.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention in this lengthy story of the costs of the two procedures or insurance coverage. Readers need this information, and the fact that the duodenal switch may not be covered by most insurance. The total cost of gastric bypass is about $20,000.", "answer": 0}, {"article": "Other studies are further along.\nThe message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nHowever, experts cautioned that while the results are encouraging, there's a lot of work left ahead before stem cells can be used to treat heart failure.\nSo it's possible, Gorodeski explained, that the \"modest\" symptom improvements would have happened anyway.\nIn an early study of 27 patients, Japanese researchers used patients' own muscle stem cells to create a \"patch\" that was placed on the heart.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed. This is a tricky one, given that this work is still so far removed from being used in clinical practice (and therefore having an established cost). However, stem cell therapies in general are notoriously expensive, so it\u2019s certainly an issue worth noting. If it\u2019s not too early to talk about benefits, it\u2019s not too early to talk about costs.", "answer": 0}, {"article": "As expected, this process is often inaccurate.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nIn rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release reports that the device would probably cost less than $50 to manufacture. However, the cost of a lab device is only part of the cost of infectious disease testing. What sort of training is needed to accurately interpret results? Would the device be able to replace conventional lab tests or would it be used as a preliminary test, that would then be checked by conventional tests? It is possible that in real world circumstances, the device could lead many more people into testing, potentially increasing the total cost of testing programs. The health benefit could be worthwhile, but the news release should not claim that a device would reduce costs without evidence of total costs in real world use.", "answer": 0}, {"article": "One recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nBut what about Alzheimer\u2019s?\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the cost of treatment, though, again, knowledge about this product, including its cost, is widespread.", "answer": 2}, {"article": "For more information about our products and organization, visit http://www.\nApril 29, 2016 - A modified surgical technique may provide a simpler approach to the surgical treatment for one type of chronic headache, according to an \"Ideas and Innovations\" paper in the May issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\nThe official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.\nHe comments, \"This is a straightforward technique and effective procedure that may make it easier for plastic surgeons to adopt and offer surgical options for patients with this debilitating condition.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the news release. Surgery to treat chronic severe headaches could prove to be expensive (ie. thousands of dollars), since the intervention may also require anesthesia, operating room facilities and a hospital stay.\u00a0 Although costs may vary widely depending on the hospital and region, we believe a ballpark estimate would have been helpful.", "answer": 0}, {"article": "One expert agreed that the results were encouraging.\nThese drugs can be safely combined, and the survival was significantly improved without untoward side effects,\" said Dr. Michele Green, a dermatologist at Lenox Hill Hospital in New York City.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\nThe study was scheduled for presentation Saturday at the European Society for Medical Oncology meeting in Vienna and simultaneous publication in the New England Journal of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed. Neither of these drugs is approved for\u00a0sale, so it may be hard to offer a concrete figure. But\u00a0new drugs targeting melanoma via similar pathways are very expensive \u2014 in the neighborhood of $9,000/month, or $56,000 for a course of treatment.\u00a0The story should have mentioned this, even if the drug combo is only available under a research protocol.", "answer": 0}, {"article": "April 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\n\"I personally think foods [containing soy] are better.\"\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"What this study shows is that ingesting soy isoflavones will help you,\" she says.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.", "answer": 0}, {"article": "\u201cWill these peptides actually induce tolerance in people?\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nIt\u2019s rational, but we won\u2019t know until we get it into people,\u201d says Coetzee, who was not involved in the research.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nWhen researchers attach specific proteins to the particles, they say they're able to teach the body not to attack its own tissues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have done what the competing MSNBC story reported:\nMSNBC quoted a researcher saying that one stage of the research\u2026\u201dwas hideously expensive.\u201d \u2026 \u201cIt cost probably about a million dollars to treat 10 patients using live cells,\u201d he said.", "answer": 0}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\n\u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have the liver effects,\u201d he said.\n\u201cPIK3CA mutations are present in many other tumor types,\u201d Hirawat said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although\u00a0BYL719/alpelisib has not been approved by the FDA, it\u2019s safe to assume that the drug will be costly, and there should have been some discussion of this. The only PI3K inhibitor approved as a cancer treatment, for certain types of lymphoma, is an injection and retails for about $4,700 per vial.\u00a0Many vials may be given over the course of treatment.", "answer": 0}, {"article": "While the value of CT scans for screening remains the focus of debate, no one questions the value of the tests for allowing doctors to quickly diagnose a wide variety of health problems, including head injuries, heart problems, cancer, appendicitis, fractures and gallstones.\nAnd patients also can take more responsibility for reducing the number of unnecessary scans.\nYou can't get that kind of information any other way.\nThe individual risk varies depending on the age of the patient and the type of scan.\nAlthough that overall risk is relatively small, the large number of scans being performed could translate into a significant number of cancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of the scans.", "answer": 0}, {"article": "The oral drug targets an enzyme called Syk.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nWeinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\nBut there's an overabundance of Syk in the fluid of arthritic joints, and the enzyme is part of the runaway immune machinery that increases joint inflammation.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs, which is a shame. Arthritis is a chronic condition, meaning that any drug that gives people significant relief likley will become a lifelong medication. Even if a per-pill cost is low, the cost per year can be huge. Without this information, it is difficult to gauge the true value of the drug.", "answer": 0}, {"article": "Restless legs syndrome causes a person to feel a powerful urge to move his or her legs.\nThe first two drugs raise dopamine levels in the body, and the last two drugs reduce the amount of calcium reaching brain cells and trigger the production of other chemicals that help reduce pain.\nThe researchers found that 61 percent of those taking dopamine agonists showed at least a 50 percent improvement in their symptoms, compared with 41 percent of those taking an inactive placebo.\nThere are generic versions of Requip that cost far less, running between $11 and $22 a month.\n\"Physicians and patients now have better information on the effectiveness and harms of two types of drug treatments for patients with at least moderately severe restless legs symptoms in which to guide treatment choices,\" said review author Dr. Timothy Wilt, core investigator at the Minneapolis VA Health Care System.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides monthly cost information for the drugs discussed, and notes that out of pocket expenses will\u00a0vary depending upon insurance coverage. One note is that neurontin is available generically and is less costly than the brand name described.", "answer": 1}, {"article": "\"I wasn't interested in going as far as getting an amniocentesis because of the risk associated with that,\" she explains, \"and so when I heard about this test, that was part of the reason that I was most interested in it.\"\nSome babies with these conditions grow up into adulthood and never know they have them, unless they face a symptom like infertility.\nInsurance coverage varies, and doctors often only offer this testing to women at higher risk because of things like advanced maternal age.\nThis can reveal if there's an increased risk of certain disorders, but it's not very accurate and produces a lot of false alarms.\nBut she had recently moved to Alabama, and the clinic she went to there wasn't as familiar with it \u2014 although when she talked to her doctor, she learned the clinic had just had a visit from a company's sales representative.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that insurance coverage of the new tests varies, but no indication of an actual dollar amount was given.", "answer": 0}, {"article": "\"My basic message is that, overall, there may be some slight risks associated with the medication, but in balancing risks and benefits for most women, I would suggest they stay on their medication,\" she said.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nResearchers at Brigham and Women's Hospital in Boston looked at 3.8 million pregnant women nationwide and found that those taking popular antidepressants, called SSRIs, did not appear to be at significantly increased risk of having a baby with pulmonary hypertension.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned. These costs for these medications vary widely depending on the SSRI, the manufacturer (i.e. brand-name vs. generic), and dosage \u2013 between $20 and $1,000 a month, according to Consumer Reports.", "answer": 0}, {"article": "Following bacterial therapy, cancer stabilized in 21 patients.\n\"If that happens, it actually helps to increase the presence of tumor-specific antigens, which are proteins that make a tumor more obvious to the immune system,\" Janku said.\nThe potential for Clostridium novyi-NT to prompt an immune response against cancer is intriguing, said Sacha Gnjatic, who is associate director of the Human Immune Monitoring Center at Mount Sinai in New York City.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\n\"That didn't result in clostridium seeding anywhere else outside the injected region, but it's a theoretical possibility since we were able to detect it in the blood culture of one or two patients,\" Janku said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the potential cost of this therapy. Although it is probably too early in the process to discuss precise numbers, it would\u00a0have been helpful if the story had discussed the big picture. While bacterial therapies may be cheap to develop, the cost of clinical trials and bringing a new product to market tend to be very high. Also, an ongoing trial pairs this therapy with immunotherapy drug pembrolizumab, which can cost about $13,500 per month, according to published reports.", "answer": 0}, {"article": "Russo says, \"One of our main findings is that there was no overall relationship between most types of physical activity and the likelihood of becoming pregnant for women who had already had one or two pregnancy losses, except for walking, which was associated with higher likelihood of becoming pregnant among women who were overweight or obese.\"\nWalking has great potential as a lifestyle change because of its low cost and availability.\"\nWhat we eat and what we do are potential factors we can change to shape our health.\nResults are in the current online issue of Human Reproduction.\nRusso says, \"We did our best to try to account for the differences and to address them statistically.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release states:\nWalking has great potential as a lifestyle change because of its low cost and availability\nFair enough.", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This technology seems to still be in the experimental stage.", "answer": 2}, {"article": "Canadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\n\u201cTherefore, it is important to study the factors associated with the diagnosis of colon cancer occurring after colonoscopy.\u201d\n\nDuring a colonoscopy, a flexible camera is passed through the colon in search of abnormal growths known as polyps and other warning signs of early tumors.\nIt is one of a few screening tests for colon cancer, the second-leading cancer killer in the U.S., according the Centers for Disease Control and Prevention.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs and should have. If colonscopy is not providing that value that people once thought, it should be examined from a cost basis as well.\u00a0 Since fecal occult blood stool slide testing is so much cheaper (something referenced in the story but without cost estimates given), this is an even more important issue. ", "answer": 0}, {"article": "RotaTeq \"generally appears to have a better safety profile than the earlier vaccine,\" said Umesh D. Parashar, a medical epidemiologist at the CDC.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\nMany people have never heard of rotavirus, but it is one of the most common causes of childhood illness -- many ailments that parents or pediatricians describe as \"stomach flu\" are caused by rotavirus infection.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\nRotaTeq is expected to be one of the most expensive vaccines ever marketed, with Merck listing it at $187.50 wholesale for the three-dose series.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The author states that the vaccine will cost $187.50 for the three-dose series, making it one of the most expensive vaccines ever marketed. Although the author does say that this cost will put a strain on state-sponsored vaccination programs, there is no attempt to try to quantify the magnitude of this strain or comment on the potential cost-effectiveness of this new vaccination program.", "answer": 0}, {"article": "So which one is right for you?\nIt\u2019s similar to [the exposure from cosmic radiation] you might get on a long airplane flight.\u201d\n\nWhile a growing body of data suggest that virtual colonoscopy is as sensitive as colonoscopy in picking up potential tumors, not all cancer experts agree that it\u2019s a good alternative to the gold-standard scope.\nWhile the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nThe prep for both the virtual and actual colonoscopy is the same \u2014 the dreaded \u201ccolon cleanse\u201d that many patients find is the worst part of the procedure.\nThe virtual scan does involve radiation exposure, and if doctors find an abnormality that needs to be removed, you\u2019ll have to undergo a colonoscopy anyway (to avoid another colon cleanse, consider scheduling a colonoscopy on the same day in case tumors need to be removed).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost except a vague line about \u201cthe relatively low cost of investing in the software and other equipment.\u201d But nothing on the patient charges.\u00a0 For a story headlined, \u201cIs It Right For You?\u201d this would seem to be important.\nAnd the discussion of Medicare coverage is wrong when it says that the US Preventive Services Task Force concluded the evidence \u201cwasn\u2019t strong enough to justify Medicare coverage.\u201d\u00a0 The USPSTF concluded\u00a0 that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer.\u201d What Medicare chooses to do is its decision \u2013 not that of the USPSTF.", "answer": 0}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs, and this was a missed opportunity. Cigarette smoking creates a huge burden on our health care system. The cost of the gum \u2013 $50 to $70 for a box of 100 pieces \u2013 may be a drop in the bucket compared to the costs of people developing cancer and other disorders from smoking.\u00a0 A study mentioned in the story has a nice section on costs that we wish the story had quoted: \u201c\u2026the incremental cost of extended versus standard therapy was $2482 per additional quitter at 24 weeks.\u201d", "answer": 0}, {"article": "An accompanying editorial in the journal was skeptical about the results, arguing that the design of the initiative, which is skewed toward older women and stopped all forms of hormone treatment after several years of use, does not match the way doctors typically prescribe treatment to women in their 50s at the onset of menopause.\nThe women with hysterectomies who used estrogen alone had a 23 percent lower risk for breast cancer compared with those who had taken a placebo.\n\u201cWe need to look closely at these findings to see if we can learn more about ways to prevent breast cancer in women,\u201d said Dr. JoAnn Manson, a Women\u2019s Health Initiative investigator and an author of the study who is chief of preventive medicine at Brigham and Women\u2019s Hospital in Boston.\nThe most surprising new finding relates to breast cancer.\nNationwide, about one-third of women in their 50s have had a hysterectomy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not touch on costs.", "answer": 0}, {"article": "Lap-banding, introduced in 2001, involves separating the stomach into two sections with a band so, simply speaking, eating too much becomes more difficult.\nThere are various theories to explain why gastric bypass may be superior, including one that attributes the success to changes in hormones that control the metabolism of blood sugar.\nThe average cost of a bariatric surgery is nearly $30,000, according to a recent study from Johns Hopkins University.\nIn the bypass group, patients lost an average of 64 percent of their excess weight, vs. 36 percent for those in the lap-banding group.\nThe second study, conducted in Taiwan and led by Dr. Wei-Jei Lee of the Min-Sheng General Hospital, involved randomly assigning 60 obese (but not morbidly obese) patients with type 2 diabetes to receive gastric bypass surgery or sleeve gastrectomy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the average cost of weight loss\u00a0surgery is about $30,000. It would have been helpful to include a comparison of the different procedures discussed in the story, but this is good enough.", "answer": 1}, {"article": "\u201cWhy would we?\nBut when it comes to science and rigorous studies, he added, \u201ccomparatively, there isn\u2019t a whole lot of evidence out there.\u201d\n\nIn his studies, he found there was no way to predict the effect of a given orthotic.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\nYour injury is probably linked to these poor-fitting orthotics.\u201d\n\nSo he tried different orthotic styles, different materials, different orthotics labs with every new doctor.\nThe only indication seems to be that a comfortable orthotic might be better than none at all, at least for the activities of people in the military.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It would have been useful to discuss the relative costs of off-the-shelf and custom shoe inserts. The former are generally less than $50 while the latter can run into many hundreds of dollars. The article mentions the expensive price-tag of custom-made orthotics. It didn\u2019t, however, discuss the overall costs of off-the-shelf shoe inserts, which have to be replaced with regularity.\n\n \n", "answer": 0}, {"article": "Was this research necessary -- and ethical?\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\n\"One of the things ALS has going for it is, since it has no effective treatment or cure, you throw anything you can at it,\" he said.\n\"Ethical review happens at several levels: at the NIH, at the Food and Drug Administration and most importantly at University Institutional Review Boards at each institution where a faculty member is participating in a trial,\" Glass explained.\nThese early stages may be painful for some of the \"medical heroes\" involved, but the goal is clear: providing an effective and safe treatment for future patients who suffer from a devastating condition.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention\u00a0of how much this procedure costs. Though this is still in its earliest stages, one could simply mention this issue, as it\u2019s likely to be very expensive.", "answer": 0}, {"article": "The rest of the men used a placebo spray.\nNot all men with premature ejaculation suffer to the same degree as the men in the study, says researcher Ira Sharlip, MD, clinical professor of urology at the University of California, San Francisco.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that \"No price has been set.\"\u00a0 We give it credit for thinking about cost and addressing it \u2013 even if the answer is uncertain at this point.\u00a0 70 percent of the stories we review fail to adequately address costs. ", "answer": 1}, {"article": "Equally important, the response was long-lasting for most patients.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nTo date, the response to this drug seems to be durable in most patients,\" said Dr. Laetsch, who investigates the use of tumor molecular profiling to guide therapy in UT Southwestern's Pediatric Hematology and Oncology Division.\nThe institution's faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t offer any cost projections.\nAlthough larotrectinib is not yet FDA approved and therefore not available for sale in the US, its ultimate approval seems likely. In fact, the company that makes larotrectinib, Loxo Oncology, has pursued a partnership agreement with Bayer Pharmaceuticals to market the new drug in the US.\nGene-targeted oncology drugs that have already hit the market, some of which are now available in generic form, have remained very expensive therapeutic options.\u00a0 An added expense with larotrectinib is that genetic testing for the oncogenic mutations NTK1, NTK2, and NTK3 is not yet commonplace.\u00a0 All of these factors suggest that larotrectinib will be an expensive treatment.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nBut the five people who got inactive stimulation on the first visit, and active tDCS at the brain target on the second visit, consumed an average of 700 fewer calories and lost an average of 0.8 pounds on the second visit.\nNext, the researchers will compare a group getting only active tDCS with a separate group getting only sham stimulation.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\nThe four people who got the sham stimulation during both visits consumed the same number of calories from the vending machines on each visit and did not lose weight.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not provide any information on what the experimental therapy, known as transcranial direct current stimulation, might cost if and when it is available to the public. We\u2019ll rate this Not Applicable because it\u2019s too early to know what it might cost and the release doesn\u2019t make it sound like the technology will be available imminently. However, we\u2019d note that a close cousin of this method, transcranial magnetic stimulation, is FDA approved for major depression and migraine. Sessions cost about $300 each and may include 20 or more sessions and run several thousand dollars. The release could have mentioned this.\u00a0", "answer": 2}, {"article": "We need to look at dietary patterns rather than individual nutrients or individual food components.\u201d\n\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\n\u201cWhat happened is that in the 1960s all polyunsaturated fats were considered the same.\n\u201cOne of the things we learned is that we need to look at the whole picture,\u201d says Lichtenstein.\nThe other half were not told to change their diet in any way.\nSaturated fats are more likely to build up within artery walls and form plaques that can trigger heart attacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of vegetable oil with linoleic acid is not in question.", "answer": 2}, {"article": "The study found that, among the women treated with the hormones, there was an increased risk of heart attacks, strokes, blood clots and, most frightening of all to many women, a slightly higher risk of breast cancer among those randomized to take the leading H.R.T.\n\u2014 to counter them.\n\u201cThe pendulum has swung too far,\u201d she said.\nAmong these older women, it found no such effect.\nfor women in their 50s and for those experiencing earlier menopause as a result of medical treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail costs associated with estrogen and progesterone hormone therapies. For example, are low-dose estrogen pills or transdermal estrogen patches comparable in price?", "answer": 0}, {"article": "Study Limitations: Imbalances caused by matching groups of obese patients for comparison based on age, sex, body mass index and diagnoses of diabetes.\nThe following related elements from this issue of JAMA are also available on the For The Media website:\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity\n\n-- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity\n\n-- Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A , LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study\n\n-- Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities\n\n-- Editorial: Comparing the Outcomes of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for Severe Obesity\n\nFor more details and to read the full study, please visit the For The Media website.\nResults: The rate of death from any cause over about 4.5 years was lower among obese patients who underwent bariatric surgery compared with patients who managed their obesity with nonsurgical care.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Three types of bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy) are the primary interventions evaluated in this study. The costs for these common weight loss procedures are not mentioned in the news release.\nSome information \u2014 even broad cost ranges of bariatric surgery compared to nonsurgical care \u2014 is warranted.", "answer": 0}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Excellent job here. The costs of treatment are a core aspect of the story. The opening paragraph describes how the blood test in question could help determine whether patients should receive \u201ccostly new-generation drugs or rely on much cheaper traditional chemotherapy,\u201d and the specific costs of different therapies are detailed early in the article.\nMuch less information is given about the cost of the blood test itself, though the writer does make it clear that the price is not yet determined. It would have been\u00a0useful to note the costs of\u00a0any\u00a0comparable\u00a0tests already in clinical use, and to\u00a0let the reader know how insurance companies deal with\u00a0new diagnostic tests.", "answer": 1}, {"article": "The only once-and-be-done-with-it option for women has been tubal ligation (\"tying the tubes\") -- surgery that renders a woman sterile.\nUntil then, the patient must use another form of birth control.\nEven the IUD can't stay in place for more than 10 years.\nNow a procedure called Essure, recently approved by the Food and Drug Administration, gives women an alternative.\nThere is the risk of infection or a puncture of the vagina or uterus while inserting the hysteroscope.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of Essure compared to tubal ligation.", "answer": 0}, {"article": "Researchers collected data on occurrence and severity of respiratory symptoms, breastfeeding status and genotyping was performed.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nThe study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are two aspects to this release: a genetic mutation which predisposes to asthma and the potential value of breastfeeding in reducing that risk. The release makes no mention of costs in explaining this research. While on the surface breastfeeding carries no economic burden, genetic testing does. The release does not provide any information (as we will note later) about the availability of genetic testing or whether insurance coverage is available.\nIt\u2019s difficult to quantify, but breastfeeding can have financial costs. There is growing awareness that breastfeeding does exact a toll in time and related earning potential, as explained in this New York Times article.", "answer": 0}, {"article": "But the supplement has largely failed to show benefits in human athletes.\nFor that, at least, the beer can be full-potency.\nTwo hundred seventy-seven men agreed, even when told that the beverage would be nonalcoholic.\n\u201cWe do not know whether the side effects of alcoholic beer would cancel out the positive effects caused by the polyphenols,\u201d he wrote.\nOnly half of the group received the alcohol-free beer, however; the other half got a similarly flavored placebo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Discussion of costs is relatively unimportant as most individuals would know how much beer costs.", "answer": 2}, {"article": "The nitrate-free beetroot juice was the basis of the placebo group.\nCommenting on the findings, Prof. Ahluwalia says:\n\nShe says that one reason the findings are exciting is that they open up the potential for people with high blood pressure to increase dietary nitrate in a way that can be easily worked into their daily lives while still providing a positive benefit.\n\"It is hugely beneficial for people to be able to take steps in controlling their blood pressure through non-clinical means, such as eating vegetables,\" Prof. Ahluwalia adds.\nTo put the importance of these findings in context: The authors note that large-scale observational studies show that for every 2 mmHg increase in blood pressure, the risk of death from heart disease goes up 7 percent and the risk of stroke by 10 percent.\n\"The possibility of using a natural product, rather than another pill, to help lower blood pressure, is very appealing,\" adds Dr. Amoils.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention costs. The cost of typical hypertension drugs is relatively well-known and the cost of beets\u00a0from the neighborhood grocer, from which beetroot juice can be derived, is equally available. A well known online supplement supplier sells beet root juice for about $6 a bottle, suggesting a potential cost for the daily regimen studied here of about $3 a day, or possibly $90 a month.", "answer": 0}, {"article": "Flibanserin is taken nightly at bedtime.\nBut the difference was important to the women, says study researcher Michael L. Krychman, MD, medical director of sexual medicine at Hoag Hospital in Newport Beach, Calif.\n\n\"The absolute number of women who had remission of sexual distress was clinically significant, but equally important to them was how it improved their lives,\" Krychman tells WebMD.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost data for flibanserin is not provided.\u00a0 Some projection of cost should be available for any drug this far along in Phase III trials \u2013 and for which the company has already begun marketing campaigns.\u00a0 If not from the company, then from stock analysts. ", "answer": 0}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of emphasizing that health benefits are more likely with chocolate that has a higher concentration of cocoa solids. However, these premium chocolates\u00a0come with\u00a0a corresponding increase in\u00a0price compared with your average Hershey Bar\u2013 something the story could have explained.\u00a0 Nonetheless, we\u2019ll rule this not applicable as most people probably have a general idea about the cost of chocolate.", "answer": 2}, {"article": "Replacement, by contrast, preserves some range of motion.\nOccasionally, other conditions must be addressed in addition to joint damage.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\nSurgeons replace the raw bone ends with smooth, artificial surfaces that restore at least some of the joint's normal function.\nShe wore a cast for two months, a splint for another two and continued physical therapy through July.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article fails to mention the cost of treatment or whether it is covered by Medicare or other insurers.", "answer": 0}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nThat was after accounting for other factors, such as smoking.\nGood overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\nThose who drank between one-third and 1 drink per day five to seven days a week were almost 50 percent more likely to be in good health when they got older compared with those who did not imbibe.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of alcoholic beverages isn\u2019t in question.", "answer": 2}, {"article": "By MARILYNN MARCHIONE\n\n The Associated Press\n\n Monday, February 28, 2011; 9:39 PM \n\n\n\n-- In a bold new approach ultimately aimed at trying to cure AIDS, scientists used genetic engineering in six patients to develop blood cells that are resistant to HIV, the virus that causes the disease.\nThe gene-snipping compound was added in the lab, and about one-fourth of the cells were successfully modified.\nThree others received about 5 billion.\nCertain types of the virus can use a second protein receptor, though this is less common and usually when AIDS is advanced.\nSome people (about 1 percent of whites; fewer of minorities) lack both copies of the CCR5 gene and are naturally resistant to HIV.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We like this story\u2019s approach.\u00a0 The story could have easily stated that it\u2019s just too early to know \u2013 end of story.\u00a0 Instead, it stated:", "answer": 1}, {"article": "Many food studies simply lump brown and white rice together.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\n\u201cThe bottom line is we showed evidence that increased consumption of white rice \u2013 even at this low level of intake \u2014 is still associated with increased risk,\u201d said Dr. Sun, who was at the Harvard School of Public Health when the study was done.\nThe researchers tried to control for the fact that Americans who eat brown rice tend to be more healthy overall \u2014 they eat more fruits and vegetables and less red meat and trans fats, and they also tend to be thinner, more active and less likely to smoke than those who don\u2019t eat brown rice.\nAnd correlation does not necessarily mean a cause-and-effect relationship, since factors other than brown rice consumption may have accounted for the decreased diabetes risk that was observed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this not applicable, because, while there was no discussion of how the cost of white rice and brown rice compare, most people probably have a sense of the price ballpark.\u00a0 However, we have seen Chinese restaurants that charge extra for brown rice. ", "answer": 2}, {"article": "Cowen & Co estimates that use of DNA blood tests for cancer screening will exceed $10 billion a year by the end of the decade.\nThe test represents a first in the rapidly developing field of \u201cliquid biopsies,\u201d which use gene sequencing technology to screen blood samples for trace amounts of DNA associated with different cancers.\nBut the move by Pathway, a privately owned maker of genetic tests ranging from cancer risk and heart health to drug response, underscores a growing debate over how much genetic information should be made available to healthy people if it is not yet clear how it can improve their health.\n\u201cFor any given test, the rate of false positives causing unnecessary alarm and false negatives that provide false security should be known,\u201d said Dr. Keith Stewart, an oncologist who heads Mayo Clinic\u2019s Center for Individualized Medicine.\nCHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned the cost of the test, but the competing Bloomberg story gave a more detailed breakdown of costs. There was\u00a0no mention of insurance coverage, or of total costs of work ups of positive tests and the need for continual testing.", "answer": 1}, {"article": "With 25 years of specializing in natural phospholipid research, development and production, Lipogen guarantees its customers ingredient systems that are supported by the highest level of scientific data, technical quality and safety to meet the growing demand for natural cognitive health solutions.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\nPMS is a combination of physical and emotional symptoms linked to the menstrual cycle.\nUp to 80% of women report having some symptoms prior to menstruation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release points out the\u00a0high costs of selective serotonin re-uptake inhibitors (SSRIs) and other drug treatments for PMS cost $60 to $535 per month, it fails to mention that a 30-day supply of its product costs $54.95.\nAccording to a website showing the product patent application,\u00a0 it appears to be a combination of\u00a0phosphatidylserine (PS) as the active ingredient along with phosphatidic\u00a0acid\u00a0(PA) and magnesium. These products are available from other manufacturers for purchase on the internet for varying costs.\nOf interest, the patent application (but not the news release) states that various formulations were given \u201cfour times a day\u201d\u2026\u201dfrom three weeks before the expected monthly menstruation until the commencement of menstruation.\u201d\u00a0 That would amount to more than 80 pills or tablets per cycle, which would be quite expensive compared to daily dosing of other medications.", "answer": 0}, {"article": "Locke said about 13 percent of patients in the trial had a severe side effect known as cytokine release syndrome, which produces high fevers, low blood pressure and other flulike symptoms.\n\u201cIt raises the potential that a cure can be possible.\u201d Some of the first patients who underwent treatment now have been in remission for three to five years, he said, although he cautioned that it's still too early to know whether those patients are cured.\n\u201cToday, marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases,\u201d FDA Commissioner Scott Gottlieb said in a statement, adding that the approval demonstrates \u201cthe continued momentum of this promising new area of medicine.\u201d\n\nA CAR T-cell therapy involves a complicated and customized procedure in which T cells \u2014 sometimes called the foot soldiers of the immune system \u2014 are removed from the patient.\nThe one-time infusion, known as CAR T-cell therapy, is made by Kite Pharma, which is based in Santa Monica, Calif., and recently was bought by Gilead Sciences for $11.9 billion.\nThe treatment is for adults with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment, such as chemotherapy and bone-marrow transplants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states the cost of this new therapy. It also contrasts it to the other approved drug for CAR T-cell therapy. However, it would have been helpful to know if this cost includes all the related hospital care and services, or is simply the cost of the drug itself. It also would have been useful to compare it to other treatments for this form of cancer, such as chemotherapy or transplantation.", "answer": 1}, {"article": "Participants in the study familiarized themselves with the workstations during one visit.\n\u201cExercise is a good way to counteract the negative effects of sitting, but just incorporating physical activity into one part of our day may not be enough to overcome the damage caused by prolonged sitting and an otherwise sedentary lifestyle.\u201d\n\nBecause the workday is a major contributor to sedentary behavior, with more than 20 percent of workers in the U.S. reporting more than 8 hours each day, tactics that promote workstation activity have emerged in recent years, including standing desks, as well as dynamic pedal and treadmill workstations.\n\u201cWe expected to see the metabolic rate increase with each progressive stage, but instead found that metabolic rates from movement while seated were either equal to or higher than rates while standing.\u201d\n\nHorswill says the study needs to be further validated, but that the findings should be especially applicable to individuals poised to benefit from NEAT but unable to access popular standing desks because of injury, disability or discomfort.\nThe device, which is commercially available, was a movable footrest, suspended from the underside of the desk, which enabled the feet to swing, twist or teeter.\nThe researchers found that modest movement while seated elevated the metabolic rate more than sitting and more than standing, by 17 and 7 percent respectively, and had no detrimental effect on cognitive function.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "According to the study, the \u201ccommercially available\u201d device referenced in the news release is called the HOVR (the company that makes the HOVR funded the research). While the news release didn\u2019t mention the cost of the device, a quick Google search shows that these devices are available for purchase online and cost between $75 and $150.", "answer": 0}, {"article": "While the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\nAt least five years would need to pass before such a declaration would be considered.\nFifteen other patients who got the same treatment died.\nResponse by others in the field was positive but not effusive.\nThey are alive, with no evidence of cancer, 18 months later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no estimate of the costs for this kind of individualized cancer treatment.", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nThe task force and other groups concluded previously that it was unclear whether the benefits of the prostate-specific antigen, or PSA, test outweigh the risks.\nThe guidelines address perhaps the most important and contentious issue in men's health, and were praised by officials at several leading medical groups, including the National Cancer Institute and the American Cancer Society.\n\"The benefit of screening at this time is uncertain, and if there is a benefit, it's likely to be small,\" said Ned Calonge, who chairs the 16-member U.S. Preventive Services Task Force.\n\"We have seen a dramatic drop in mortality,\" said J. Brantley Thrasher, chairman of the urology department at the University of Kansas and a spokesman for the American Urological Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the costs associated with prostate cancer screening. \u00a0However, as the cessation of routine prostate cancer screening for men over the age of 75 was the new recommendation by the task force, cost is not really germane to the discussion.\nIt might have been helpful to include some mention of the potential costs to screening older men and/or cost saving with cessation of screening older men. \u00a0There are those that are going to interpret the recommendation against routine screening as a cost saving effort.\u00a0", "answer": 2}, {"article": "The U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nIn a 2012 study, researchers estimated that in 2008, approximately 20 percent of all HIV-positive people in the United State were undiagnosed.\nThe British test will probably make it easier for people to be screened for the first time and will allow people to re-screen themselves more frequently.\nIn the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story lists the test cost of $45. However, the story would have offered a more complete picture of cost if it had estimated the annual cost of regular screening and provided costs for other tests.", "answer": 1}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not cite costs. This is unfortunate because hydroxyurea treatment would likely be less costly than standard treatment with blood transfusion.", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention in this story of costs, which is a shame. CTs are the preferred diagnostic tool right now and, apparently, are widely used. A switch to MRIs would not only mean the purchasing of a lot of new equipment but also staff training, new protocols and new drugs and dyes to be administered. Are we talking about an extra $1,000 per person? $5,000? More? The reporter spoke with two local medical institutions and could have asked both of them what it costs to buy both sets of equipment and what it costs to administer the exams.", "answer": 0}, {"article": "Zhang said his group may consider moving into another trial using only electroacupuncture on patients suffering milder depression.\nHONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nLed by Zhang Zhang-jin at the School of Chinese Medicine, University of Hong Kong, the researchers used electroacupuncture to stimulate seven spots on the heads of 73 participants, who had suffered several bouts of depression in the last 7 years.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No estimate was provided of what electroacupuncture for depression \u2013 nine times over 3 weeks as in the study \u2013 would cost.\nAcupuncture is almost never covered by insurance. \u00a0Each session costs > $100 in the U.S. \u00a0So a 9 session course is likely >$1,000.\nIn contrast, generic SSRI drugs are $4/month and if the patient responds well \u2013 about $50 of medication + doctor visits (we could estimate $400) that is covered by insurance.\u00a0 So out of pocket costs might be < $100.", "answer": 0}, {"article": "But this is where it gets more complicated.\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\nKenneth Lin, a family physician at Georgetown University who worked on developing the task force\u2019s SERM guidelines, notes that while SERMs may have reduced new cases, they \u201chave not been shown to reduce breast cancer mortality in any study or meta-analysis.\u201d One possible explanation, he says, is that \u201cthese drugs are effective at preventing nonlethal cancers rather than the more serious ones.\u201d\n\nNot used enough?\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\ncould reduce their risks for invasive cancer by approximately 30 to 50 percent.\u201d On the other hand, these drugs don\u2019t suit everyone, and they are not without risks of their own.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that these drugs are \u201ccovered\u201d by the Affordable Care Act, and that \u201cwomen with a high risk for breast cancer and a low risk for side effects who try this therapy will not incur out-of-pocket costs.\u201d We\u2019ll call this nod in the direction of costs sufficient for a satisfactory rating, but the story does not discuss these drugs\u2019\u00a0prices or the cost of repeated office visits to monitor their side effects. There was an opportunity here for a rich discussion about incurring some upfront cost for a potential for downstream cost savings in terms of lower cancer rates and reduced need for treatment.", "answer": 1}, {"article": "The findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\n\"It was known that green tea polyphenols are more effective and offer more health benefits than black tea polyphenols since green tea chemicals are absorbed into the blood and tissue,\" said Susanne Henning, the study's lead author and an adjunct professor at the UCLA Center for Human Nutrition, which is part of the David Geffen School of Medicine at UCLA.\nHowever, only the mice that consumed black tea extract had an increase in a type of bacteria called Pseudobutyrivibrio, which could help explain the difference between how black tea and green tea change energy metabolism.\n\"The results suggest that both green and black teas are prebiotics, substances that induce the growth of good microorganisms that contribute to a person's well-being,\" she said.\nAccording to Henning, the molecules in green tea are smaller and can more readily be absorbed into the body and reach the liver directly, while black tea molecules are larger and stay in the intestine rather than being absorbed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of black, decaffeinated tea.\nWhile one might argue that the cost of tea is relatively well known, remember that this was an animal study. We don\u2019t know how much a person would have to drink in order to achieve the equivalent dosage for humans. The release could have clarified this point.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - When symptom-free people have heart scans to look for clogged arteries, they can end up with overtreatment and side effects, researchers said Monday.\nPeople who got scans also had more additional tests and major heart procedures.\n\u201cWith these new imaging techniques, we are left with the dilemma of what to do with the results,\u201d he said.\nBut after another 18 months, there was no such difference.\nIf they get big enough, such buildups may cut the blood flow and cause a heart attack.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were reported.", "answer": 1}, {"article": "\"Amazing,\" said Campbell with a smile.\n(CNN) -- As a thick, gray haze began to descend over the words in her schoolbooks, and eventually the faces of loved ones, Barbara Campbell barely grasped that she was going blind.\n\"This is really the first step toward a really bionic eye,\" said Aries Arditi, a senior fellow in vision science at Lighthouse International, a nonprofit advocacy group for the blind and one of the study sites for the artificial retina.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"Being able to repair, in some way, a function that has been lost is a very exciting thing,\" Del Priore said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention the cost of the technology being used in the research, a figure that is certainly available. \nFor example, the New York Times \u2013 when it reported on this work 3 months ago \u2013 simply asked the manufacturer, who said the device \"would cost up to $100,000.\"\u00a0 \nAt a time of debates about controlling the costs of health care, reporters can play an important role by reminding the public that every breakthrough has a price tag.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost of calcium and vitamin D supplements was provided.", "answer": 0}, {"article": "TUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\n\"Because supplements are not regulated as drugs, they can be put on the market with no safety or efficacy testing.\n\"Just because it might cause weight loss doesn't mean it's healthy,\" she warned.\nA follow-up study involving 60 patients is now in the planning stages.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u201cGreen coffee-bean extracts are sold online at prices ranging from about $10 to $20 for 60 capsules,\u201d according to the story.", "answer": 1}, {"article": "The findings were presented Monday at the American Heart Association (AHA) annual meeting in Orlando, Fla.\n\"There are still plenty of people who can't achieve adequate LDL levels with existing drugs, including statins,\" he noted.\n\"This new shot may provide a more long-lasting approach, especially if it could be given once a month,\" Sacco said.\nThe study was funded by AMG145 manufacturer Amgen Inc.\n\nHigh cholesterol is a major risk factor for heart disease.\n\"Even though statins are so effective at lowering cholesterol and reducing risk for heart disease and stroke, they do need to be taken every day and they can have certain side effects in some people,\" said Sacco, who is also chairman of neurology at the University of Miami.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention\u00a0costs. This is an important deficiency,\u00a0since\u00a0drugs like AMG 145, which are called\u00a0monoclonal antibodies, are typically among the most expensive drugs in the world and are an important source of rising health care expenditures.", "answer": 0}, {"article": "For now, he suggested that people choose olive oil and other unsaturated fats over saturated fats (found largely in meat and dairy) and trans fats (found in some processed foods, like crackers, cookies and chips).\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nThe findings, reported in the journal Neurology, hint that the well-known connection between olive oil and heart disease might extend to stroke as well.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nThe current study included 7,625 French adults age 65 and older who reported on their diets and other lifestyle factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of olive oil is not in question.", "answer": 2}, {"article": "\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nStill, he adds, \u201cit\u2019s an important step forward.\u201d\n\nThe technology is likely prohibitively expensive and time-consuming at this point, he says.\nWhile the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\n\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\n\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give the story the benefit of the doubt for again leaning on an independent expert who says the technology is likely prohibitively expensive.\u00a0 While no dollar estimate is given, we think this is good enough for now.", "answer": 1}, {"article": "[Added June 10] So Gokhale studied findings from anthropologists, such as Noelle Perez-Christiaens, who analyzed postures of indigenous populations.\nIn fact, if you look at drawings from Leonardo da Vinci \u2014 or a Gray's Anatomy book from 1901 \u2014 the spine isn't shaped like a sharp, curvy S. It's much flatter, all the way down the back.\nIf you look at an American's spine from the side, or profile, it's shaped like the letter S. It curves at the top and then back again at the bottom.\nAnd people who are thinner probably have less curvature\" \u2014 and thus a spine shaped more like J than than an S.\n\nAmericans are also much less active than people in traditional cultures, Mummaneni says.\nNow she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost at all. And cost could be a significant factor for anyone interested in pursuing the Gokhale Method. According to the Gokhale Method website, a 45-minute initial consultation (in person or via online video) costs $165. For maximum value, the story could have provided some discussion of the Gokhlae method cost vs. comparison of other strengthening programs \u2014 e.g. physical therapy, Pilates, yoga, working with athletic trainer.", "answer": 0}, {"article": "Tomei, a self-proclaimed animal lover, expressed that the effort is close to her heart.\nSometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nTo raise awareness about CDE and help other people find relief, the \u201cMy Cousin Vinny\u201d and \u201cThe Wrestler\u201d star has teamed up with pharmaceutical company Allergan and Guide Dogs for the Blind, an organization that trains dogs and pairs them with visually impaired individuals.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned in this story. A quick internet search shows that two packets of 30 vials of Restasis costs more than\u00a0$300. For comparison purposes, a bottle of generic artificial tear drops costs about $10. Also, there is no mention of the issue of insurance coverage for the cost of Restasis. Some insurers limit coverage for topical cyclosporine or require cumbersome prior authorization to approve coverage.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations and health insurance providers are available at http://www.\nPrevious separate studies have shown that a Mediterranean diet reduces certain risk factors for cardiovascular disease, as does a vegetarian diet; however, this was the first study to compare effects of the two distinct eating patterns\n\nCurrent study authors said they wanted to evaluate whether switching to a lacto-ovo-vegetarian diet would also be heart-healthy in people who were used to eating both meat and fish.\nThe study included 107 healthy but overweight participants, ages 18-75, who were randomly assigned to follow for three months either a low-calorie vegetarian diet, which included dairy and eggs, or a low-calorie Mediterranean diet for three months.\nThe vegetarian diet was more effective at reducing LDL (the \"bad\") cholesterol, while the Mediterranean diet resulted greater reductions in triglycerides, high levels of which increase the risk for heart attack and stroke.\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At first glance it might seem appropriate that costs are not mentioned. However, the comparative costs of these two diets could vary considerably depending on what part of the world you live in (ie. in some locations, a Mediterranean diet is either not feasible or prohibitively expensive).\nAlso, the subjects in this study received both nutritional counseling and diet plans which, may not only have influenced the outcomes of this study, but also would carry a price tag in the real world.", "answer": 0}, {"article": "Researchers reintroduced the drug to 32 patients who were initially treated as part of a study of 634 patients.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nEight of the 32 got ipilimumab alone, 23 got ipilimumab plus a vaccine called gp100, and one got the vaccine alone.\nThe team found that in patients whose cancer initially progressed while on ipilimumab, whose who were reintroduced to the drug had a disease control rate of 65 to 75 percent, compared to zero in the patient who got the vaccine only.\nIpilimumab is a monoclonal antibody, an engineered human immune system protein that boosts the body\u2019s immune response by interfering with another immune compound called CTLA-4, which acts as a sort of brake on immune system cells.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAlthough the cost of this experimental therapy may not be known, it would have been useful to point out whether this drug is similar to other drugs that carry extremely high price tags (some are thousands of dollars per dose) or might be something that might be offered at a lower cost. \u00a0", "answer": 2}, {"article": "But for now this category is useful only to researchers.\nRather, the goal in creating this category is to see if scientists can define when the disease starts, and track it through biomarker tests, brain imaging, or other yet-to-be-invented tests.\nThe guidelines say, for instance, that newly developed \"biomarker\" tests, such as assays for proteins in spinal fluid, and some specialized brain scans can be used for early diagnosis of Alzheimer's.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\nBut, the guidelines say, the tests are to be used only for research, and not for diagnosing Alzheimer's in the general public.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story clearly points out that brain scans and biomarker tests are \u201care to be used only for research, and not for diagnosing Alzheimer\u2019s in the general public.\u201d Since there are no recommended changes that directly affect readers today, and since it is not known which diagnostic tests may eventually prove useful, it is reasonable to put off discussions of cost.", "answer": 2}, {"article": "\"This is hugely promising and very significant research,\" he tells WebMD.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If this technology\u00a0is as close to reality as this story suggests, then it\u2019s\u00a0appropriate to discuss costs. This\u00a0story didn\u2019t.\u00a0 The story could have at least nodded in the direction of financial impact of new technologies.\u00a0\u00a0 Many patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices.\u00a0It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology.", "answer": 0}, {"article": "\u201cNow it\u2019s, like, \u2018When do we get this here?\nTeichner asked Brad and Amy Price, \u201cYou keep using the word \u2018miracle.\u2019 In what way is all of this a miracle?\u201d\n\n\u201cOur son\u2019s still with us, and Cecilia as well,\u201d they replied.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\nTell me what you need me to do.\u2019\u201d\n\nUntil then, she continues to fight her battles one cupcake at a time -- the Price children, Giovanni and Cecilia, proof to her the war can be won.\nAmy recalled: \u201cShe\u2019s sitting on the bed in her tutu and her colorful sweater, and they\u2019re telling me she\u2019s gonna die.\u201d\n\nMany children with the disorder are dead by the age of 6.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Gene therapies are astronomically expensive; Glybera, the only approved gene therapy in the world, costs around $1 million and has only been used once.\nNowhere\u00a0is the potential cost of the treatment mentioned by the reporter, despite\u00a0interviewing a woman financially supporting families to get their children into the clinical trial.\nAlthough it is impossible to say how much the experimental treatment would cost if approved, the likelihood of an extremely high price tag\u00a0should have been mentioned.", "answer": 0}, {"article": "What would that look / sound / smell like?\nLed by Dr Linda Solbrig from the School of Psychology, the research involved 141 participants, who were allocated either to FIT or Motivational Interviewing (MI) - a technique that sees a counsellor support someone to develop, highlight and verbalise their need or motivation for change, and their reasons for wanting to change.\nProfessor Jackie Andrade, Professor in Psychology at the University of Plymouth, is one of the co-creators of FIT, and she explains: \"FIT is based on two decades of research showing that mental imagery is more strongly emotionally charged than other types of thought.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\nAfter 12 months - six months after the intervention had finished - the FIT group continued to lose weight, with an average of 6.44kg lost compared with 0.67kg in the MI group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Both MI and FIT rely on patients engaging in multiple sessions with a trained therapist. Whether done in a for-profit country like the United States or a country that partially or fully subsidizes health care, there are cost considerations. The cost of those sessions, and follow-up consultations, was not mentioned.", "answer": 0}, {"article": "We showed that the islets [cells] can start to work again,\" said Dr. Yong Zhao, an assistant professor in the section of endocrinology, diabetes and metabolism at the University of Illinois at Chicago.\n\"That means if you stop the autoimmune reaction, you may see beta cell regeneration, or there might be other precursor cells in the pancreas.\nThe treatment, which combines a patient's immune system cells with stem cells from a donor's cord blood, even worked in people with long-standing diabetes who were believed to have no insulin-producing ability.\nThe average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\n\"The follow-up is long, up to 40 weeks, but it's not long enough to declare victory against diabetes yet,\" said Inverardi.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this Not Applicable. The research into this potential treatment is so preliminary that it is difficult to estimate cost figures in the story. That said, the story gives readers the impression that the research is much farther along, at a point where we would normally expect some discussion of costs. The error here is the over-stretch on the effectiveness not the omission of cost data.", "answer": 2}, {"article": "The drug was also granted a priority review.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nIn clinical trials, the most common side effects reported by participants taking Nuplazid were: swelling, usually of the ankles, legs, and feet due to the accumulation of excessive fluid in the tissue (peripheral edema); nausea; and abnormal state of mind (confused state).\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nAs the disease progresses, the shaking, or tremor, which affects the majority of people with Parkinson\u2019s disease, may begin to interfere with daily activities.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of Nuplazid\u2019s cost. An online search for the anticipated cost of the drug revealed only that market analysts predict the drug will reach blockbuster status \u2014 meaning it will have sales of at least $1 billion. The drug will no doubt be much costlier than competing generic anti-psychotics.", "answer": 0}, {"article": "Both methods have their limits and, \"while this study is very preliminary, if this radiotracer technology can prove to detect very early recurrence or metastasis in human patients, it could become extremely useful in either the pre- or post-treatment setting in selecting a treatment algorithm,\" Schwartz said.\nThe U.S. National Cancer Institute provides more information on prostate cancer.\nThe findings were to be presented Saturday at the American Association for Cancer Research annual meeting in Chicago, and are also being published in Cancer Discovery.\nIf a treatment showed a marked change, it could continue to be used in that patient, hence \"personalized\" medicine.\nThe imaging tool, known as a prostate cancer-specific radiotracer, has so far only been tested successfully in mice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Certainly an estimate of the cost of the radiotracer and PET scan could have been provided.\u00a0 PET scans are already in use in a number of applications \u2013 and their use is not inexpensive", "answer": 0}, {"article": "Why so few?\n\"You have a lot of gun-shy patients because of a lot of bad experiences,\" says Michael John Coleman, founder of the patient group MAGNUM, also known as the National Migraine Association.\nMedicines backed by the strongest evidence include anti-seizure drugs (divalproex sodium, sodium valproate and topiramate), blood pressure drugs (metoprolol, propranolol and timolol) and, for menstrual-related migraines, a medicine called frovatriptan, the guidelines say.\nOne reason is that it's hard to persuade people to take medicines on days when they feel fine, says Elizabeth Loder, a neurologist at Brigham and Women's Hospital in Boston.\n\"The life toll that poorly controlled headaches take is really underappreciated,\" she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed. As the guidelines state, \u201coverall cost is a consideration when prescribing medications; cost may influence compliance, especially long-term.\u201d", "answer": 0}, {"article": "Women who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\nBut researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nThough the findings are correlational, walnuts are uniquely high in omega-3 and omega-6 fatty acids, which may be of particular value in Type 2 diabetes prevention.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of walnuts is not addressed.\u00a0 When we checked the comments left on the New York Times blog appended to this story, cost was mentioned in 4 of the first 10 comments left.\u00a0 So you may think our criterion is too strict, but apparently some readers don\u2019t think so \u2013 one writing, \u201cWalnuts are an EXPENSIVE luxury.\u201d", "answer": 0}, {"article": "\u201cThere is a great deal of interest in developing other uses of bimatoprost,\u201d Heather Katt, a spokeswoman for Allergan, wrote in an e-mail message, \u201cand Allergan is exploring ways to pursue that pathway through the F.D.A.\napproval process.\u201d\n\nFor those too impatient to wait, there is also the bold and fashionable solution of shaving one\u2019s head.\nAside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\nThis may sound like a long time to wait, but \u201cit\u2019s important to remember that baldness is unlike other conditions where you can progress past the point of being helped,\u201d Dr. Bernstein said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story\u00a0provided a more\u00a0thorough discussion of costs than we have seen in many stories about cosmetic products.\u00a0It says, \u201cIt is, however, expensive: a month\u2019s supply of Latisse can cost up to $150, and that is in amounts appropriate for use merely on the eyelashes. Rogaine, which is also available over the counter now, costs about $25 a month, and a month\u2019s supply of Propecia runs about $75.\u201d", "answer": 1}, {"article": "Folic acid -- a synthetic version of folate found in many supplements and multivitamins -- has been shown to lower homocysteine in previous studies, but its effect on disease risk is disputed.\n\"A healthy diet likely remains important,\" Seshadri says.\n\"The role of supplementation remains unclear.\"\n\"Good nutrition should minimize the risk of Alzheimer's disease, but we can't say that any specific food has been proven to reduce this risk.\"\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "Newby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\nThe findings were similar when it came to changes in symptoms during follow-up.\nConversely, knowing the cause of your symptoms is due to coronary heart disease and patients undergo treatment for it, is also very helpful,\u201d he said by email.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\n\u201cMuch like screening tests for cancer, being told you have heart disease does not make the patient feel better,\u201d he added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of computed tomography coronary angiography (CTCA), which can be a few hundred dollars.", "answer": 0}, {"article": "Taiwanese scientists say a blood thinner drug based on venom from the Wagler's pit viper was effective in mice, and might prove safer than current anti-clotting meds for humans one day.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nIn fact, \"many current blood thinners are based on initial experiments from proteins found in snake venom,\" he added.\nAlso, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs, but our rule of thumb is: If it\u2019s not too early to speculate about benefits, it\u2019s not too early to talk about what the cost might be.", "answer": 0}, {"article": "Lozano acknowledges that retrieving childhood memories, which he says has occurred in about one-third of his patents \u2014 requires lofty voltages that he would be uncomfortable sending patients home on.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\nRight now, deep brain stimulation is used primarily to treat Parkinson's disease and tremor, for which it's approved by the Food and Drug Administration.\nAs Alzheimer's progresses, not only does the hypothalamus atrophy, but electrical communication between neurons in the region also gradually becomes impaired.\n\"We also know that in patients who receive stimulation there is an increase in glucose utilization in memory areas of the brain,\" he says, a finding that could mean there's a way to overcome some of the damage from Alzheimer's.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss what this treatment might cost, even though DBS is widely used for other conditions. A DBS surgery for Parkinson\u2019s, for example, can cost a minimum of $35,000, including hospital and physician fees, according to the National Parkinson Foundation.", "answer": 0}, {"article": "You know your cholesterol, your blood pressure ... your heart gene score?\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nIf the approach pans out and doctors adopt it, a bad score wouldn't mean that you'd get a disease, just that your genetic makeup increases the chance \u2014 one more piece of information in deciding on care.\nOther scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nFor example, when the researchers tested the system using a DNA database from Britain, less than 1 percent of people with the lowest risk scores were diagnosed with coronary artery disease, compared with 11 percent of people with the highest risk score.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does say that the new approach \u201cdoesn\u2019t require the most sophisticated type of genetic testing\u201d \u2014 which is considerably expensive \u2014 adding that they (the researchers) can calculate \u201crisk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe,\u201d\u00a0an at-home genetic test kit currently available. But it fails to point out that such kits themselves can be relatively expensive and currently wouldn\u2019t be covered by most medical insurance plans.", "answer": 0}, {"article": "But such evidence often does not pan out in human studies.\n\u201cIf we can even slightly lower their average blood sugar with metformin,\u201d Wilkin said, \u201cI believe we can have a big benefit on their risk of developing Type 1.\u201d\n\nDespite all these potential benefits of metformin \u2014 and despite a recommendation from the American Diabetes Association that it be tried before any other drug for newly diagnosed Type 2 diabetics \u2014 a recent study found that only about half of all such people get metformin as their first prescribed medication.\n\u201cPlain old metformin given in the same dose as we do for Type 2 diabetes doesn\u2019t seem to be a breakthrough for cancer, at least for pancreatic cancer.\u201d\n\nMany other metformin clinical trials are underway for breast, colorectal, endometrial and other cancers.\nThere needs to be more work in this area with all drugs for diabetes.\u201d\n\nFor Type 1 diabetes, researchers at the University of Colorado Denver School of Medicine published a study in May in which they added either a low dose of metformin or placebo pills to the insulin regimen of 74 adolescents.\nIn 2013, Whitmer presented the results of a study of about 15,000 people newly prescribed a medication for Type 2 diabetes: By the end of the five-year study, those who received metformin had a 40 percent lower risk of having developed dementia than those prescribed sulfonylureas, another common type of diabetes drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Part of why this topic is exciting is that metformin is relatively cheap, but the story doesn\u2019t put a price tag on the drug. The story calls the drug \u201ccheap\u201d in the first sentence, and one\u00a0could argue that cost lurks\u00a0beneath the surface of one brief mention of a study that found only about half of newly diagnosed type 2 diabetics were prescribed metformin right off the bat. Other patients, experts speculate in the story, may be taking newer drugs being touted in advertising. One can infer that these newer drugs are\u00a0more costly than metformin, but we think it would have been easy enough to provide some actual numbers that would have illustrated the meaningful difference.", "answer": 0}, {"article": "A downloadable photo of Dr. Mark Loeb is available here\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nFor the study, Loeb's team conducted a three-year trial in a Hutterite colony, where people live communally and are relatively isolated from cities and towns, to determine whether vaccinating children and adolescents with the flu nasal spray provided better direct and community protection than the standard flu shot.\n\"Our study is the first blinded randomized controlled trial to compare the direct and indirect effect of the live vaccine versus the inactivated vaccine,\" said Loeb, a professor in McMaster's Department of Pathology and Molecular Medicine.\nPrevious recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release doesn\u2019t discuss\u00a0costs in its comparison of influenza shots versus nasal sprays, although both modes of immunization have been around for a long while and the costs for both are easily known. \u00a0While\u00a0flu immunizations are often free through public health clinics and such, some\u00a0people receive their immunizations from their family physicians and carry a specific cost.\u00a0 Knowing the difference in costs between the two types\u00a0is useful information both for people and public health officials.", "answer": 0}, {"article": "Cancer patients and their supporting family and friends may again find comfort in enjoying a meal together. \"\n\"The underlying molecular mechanisms of TSA are not well-understood,\" said Duncan, associate director of the Virginia Agricultural Experiment Station and a professor in the Department of Food Science and Technology.\n\"Our research shows that daily lactoferrin supplementation elicits changes in the salivary protein profiles in cancer patients - changes that may be influential in helping to protect taste buds and odor perception,\" said Duncan.\nThe substance is well-known as a first-line defense, aiding the body's immune response, but little is known about its ability to impact salivary proteins.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of lactoferrin supplements is not mentioned.\nThe 250 mg capsules used in this study were supplied by Jarrrow Formulas who list the capsule price as 50 cents. Therefore, three-a-day dosing \u2014 as tested in the study \u2014 would cost $1.50.", "answer": 0}, {"article": "Researchers say breast cancer survivors often experience side effects from cancer treatments that can persist months or years after completion of treatment.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nFor example, because many treatments designed to prevent breast cancer recurrence inhibit the body's production or use of estrogen, the hormone that can fuel breast cancer growth, breast cancer patients often experience hot flashes and night sweats, among other side effects.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nWhether the reduction in symptoms accounts for longtime use of soy and cruciferous vegetables needs further investigation, says the study's senior author, Judy Huei-yu Wang, PhD, of Georgetown Lombardi's Cancer Prevention and Control Program.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While dietary interventions often are considered inexpensive, they are not free. The cost of adding cruciferous veggies and soy products to the shopping lists of potentially millions of women is worthy of a mention.", "answer": 0}, {"article": "\"We do need something,\" he said.\n\"I wouldn't want to be telling people your kid has autism when the problem is that they're dyslexic,\" Young said.\n\"If we could use this with other markers, we could probably identify people early on and, if we could do that, we'd have a much better chance of helping to make sure that their language development is normal.\"\nIn the youngest children, the activation was about equal in both the right and left hemisphere, while in the older children, activity became more pronounced on the left side, which is similar to adult patterns and to be expected, Eyler explained.\n\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At a minimum, the reporter could have found out what a typical fMRI scan costs for someone without insurance and for someone with basic insurance. It also could have found out what one of the machines costs a hospital to purchase and, perhaps, how many are acutally in use nationwide.", "answer": 0}, {"article": "All participants slept in the sleep laboratory and were closely monitored with all-night sleep recordings during the treatment period.\n\"Although eight hours of CPAP per night can be difficult to achieve in real-life, our results should provide a strong incentive for anyone with sleep apnea, especially prediabetic individuals, to improve adherence to their treatment for cardio-metabolic risk reduction,\" she said.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n\"Despite the demonstrated efficacy of lifestyle interventions and the availability of many drug treatments, the economic and public health burden of diabetes remains enormous,\" said Esra Tasali, MD, assistant professor of medicine at the University of Chicago and senior author of the study.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. This is a significant oversight, since testing to see if a person with diabetes has sleep apnea and, if so, should use a CPAP machine to treat it,\u00a0can cost from hundreds to thousands of dollars.", "answer": 0}, {"article": "Although we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\nIn the test, the participants closed one eye and placed the other against the RETeval device, which flashed 10 to 20 white or colored lights of various intensity against a white or colored background.\nThe participants were tested in normal light and after sitting in the dark for 10 minutes to assess activity in different types of retinal cells.\n\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the cost of this device (or the cost of a test using the device). One news release put the cost at \u201cless than $15,000.\u201d", "answer": 0}, {"article": "Wu recommended that women who are thinking about becoming pregnant should \"start prenatal vitamins and DHA supplements about three months before pregnancy and then continue them throughout the pregnancy.\nMONDAY, Aug. 1, 2011 (HealthDay News) -- When women take a supplement of the omega 3 fatty acid DHA during pregnancy, their babies have fewer cold symptoms and shorter illnesses, new research indicates.\nAlso at 1 month, babies whose mothers had gotten the DHA supplement had 26 percent shorter duration of cough, 15 percent less time with phlegm and 30 percent shorter duration of wheezing.\nDr. Jennifer Wu, an obstetrician and gynecologist at Lenox Hill Hospital in New York City, said, \"We've been recommending DHA intake in pregnant women for brain and nervous system development, and this study suggests another good reason to take DHA.\"\nThe effects seemed to be strongest early on after birth,\" said study senior author Usha Ramakrishnan, an associate professor in the Hubert Department of Global Health at the Rollins School of Public Health at Emory University in Atlanta.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the cost of DHA supplementation. We easily found many websites selling plant-source (from algae) DHA. One site had a bottle of 60 (only 200 mg tabs, so the mother would need to take 2 to reach the 400 mg in the study) for $19.67.", "answer": 0}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe FDA estimates that setting such a standard would help 5 million smokers quit within a year and prevent more than 33 million teens and young adults from becoming regular smokers by the year 2100.\nWASHINGTON (Reuters) - The U.S. Food and Drug Administration took a fresh step on Thursday towards setting a maximum nicotine level for tobacco products in a bid to lower tobacco-related deaths across the country, saying it would collect public comment and scientific research over the next three months.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe FDA will continue to take enforcement actions against companies that inappropriately target children, including through the promotion of e-cigarettes, Gottlieb said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a proposal for reformulating a product already on the market. Also the cost is not closely tied to their contents \u2014 cigarettes are among the most highly taxed products in the US.\nIt\u2019s too early to know if cigarette costs would be altered by this proposal, so we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "Aug. 12, 2012 -- Daily aspirin use, long recommended for people at high risk of heart attack, may also reduce the risk of dying from cancer, according to new research.\nHe found an association, not cause and effect.\nThe new analysis is published in the Journal of the National Cancer Institute.\nHe describes that reduction as modest.\nMany other strategies will also reduce the risk of cancer, he says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin is not in question.", "answer": 2}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nThe prototype pill\u2014dimethandrolone undecanoate (DMAU)\u2014is somewhat similar to the combined female pill, which contains estrogen and a steroid hormone.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\nThe \u201cundecanoate\u201d in DMAU, however, is a long-chain fatty acid that can slow the drug\u2019s journey out of the body, Page said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. We understand that the pill is not close to coming to market, but there should be some discussion of costs \u2014 even if it is only to mention the costs of birth control pills for women and the fact that the costs of the male pill are not yet clear.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions some specific brands and prices.", "answer": 1}, {"article": "Still, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nRegeneron\u2019s drug, which is called VEGF Trap-Eye, \u201cgives us the opportunity to not have to see them monthly,\u201d said Dr. Jeffrey Heier of Boston, an investigator in one of the trials and a consultant to Regeneron.\nMeanwhile, Advanced Cell Technology, of Marlborough, Mass., said it would test its stem cell therapy on 12 adults with severe vision loss caused by Stargardt\u2019s, an inherited disease.\nAfter a year, roughly 95 percent of the patients in all the arms of the trial maintained their vision, meaning their ability to read an eye chart declined by no more than 15 letters, or three lines.\nThere is no treatment for Stargardt\u2019s, which affects more than 25,000 people in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does\u00a0mention the cost per dose of two competing drugs, Lucentis and Avastin (which are\u00a0actually two\u00a0different\u00a0formulations of the same drug that are made by the same company, Genentech).\u00a0Lucentis is the version of the drug meant for the eye, whereas Avastin is approved and sold as a cancer treatment.\u00a0However, doctors can use Avastin off-label in the eye\u00a0with much smaller doses than cancer patients need.\u00a0The result is that the cost per dose is vastly lower for Avastin than it is for Lucentis. A head-to-head trial of Avastin and Lucentis is now underway that will probably have important implications for pricing and prescribing of these drugs. (If Avastin works just as well as Lucentis, more doctors will presumably switch to it at much lower cost to patients.)\u00a0Moreover, allegations have surfaced recently that Genentech is providing questionable\u00a0financial inducements for doctors to use the more costly Lucentis instead of Avastin. Given the significance of these developments for anyone who needs or may need treatment for AMD,\u00a0we feel the\u00a0story could have and probably should have gone into\u00a0a bit more detail about why these two drugs have\u00a0such wildly different costs.\nWe also think that if the story is interviewing a company about its plans to seek marketing approval in just a few months, they certainly could get some kind of pricing estimate from them. Nevertheless, by at least mentioning costs, the story accomplishes\u00a0more than most other\u00a0health articles that we review\u00a0and does enough to satisfy the\u00a0minimum for this criterion. We\u2019ll award a satisfactory.", "answer": 1}, {"article": "TUESDAY, Aug. 25, 2015 (HealthDay News) -- Needles beat pills for treating hot flashes in breast cancer survivors, according to a new trial that compared acupuncture, \"sham\" acupuncture, the medication gabapentin and a placebo pill.\nThe drug is typically used to treat seizures and nerve pain.\nThe women were enduring hot flashes at least twice a day.\nSome women undergoing natural menopause still might have that option available.\nVisit the U.S. National Center for Complementary and Integrative Health for more on acupuncture.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs of any of the treatments studied.", "answer": 0}, {"article": "Studies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nIn the past, these benefits have been hard to test scientifically, largely because study participants who volunteered for meditation programs may have been biased to see them succeed.\nAnd while the participants in both groups exercised more and cut back on alcohol during the study, they did so at similar rates, making these changes unlikely to be responsible for the differences in health outcomes either.\nThe meditating group enjoyed an average drop of 4.9 mm Hg in systolic blood pressure compared to the control group and also reported less stress and less anger.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not attempt to put a price tag on meditation therapy, which as HealthDay pointed out can be expensive.\u00a0 It could also be pointed out that the mean household income of the participants was less than $18,000 annually.\n\u00a0", "answer": 0}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Like its counterparts, this story fails to say a word about costs of the two procedures.\u00a0 Based on our calculations, the two procedures have about a $44,000 price difference and with a Number Needed to Treat of 23, the costs of avoiding a death in this patient population at 4 years exceeds $1 Million.\u00a0 We think that is an important health policy consideration.", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nCollaborating with Dr. Kuhl were Kevin Strobel, M.D., Heribert Bieling, M.Sc., Claudia Leutner, M.D., Hans H. Schild, M.D., Ph.D., and Simone Schrading, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://radiology. )\n\"This suggests that MRI finds breast cancers that also mammography would find, but MRI detects them earlier, and it finds the cancers which, if MRI had not been done, would have progressed to interval cancers.\"\n\"The faster a cancer grows and the better it is in seeding metastases, the better will it be picked up early by MRI,\" Dr. Kuhl said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the news release does not specify the exact price tag, it makes the reader aware that MRI screening is often avoided due to higher cost than other screening options:\n\u201cMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\u201d\nIt would have been helpful if the release had stated whether or not this rapid MRI will have a lower cost than traditional breast MRI.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is an essential part of the story, since cost is presented as one of the most significant benefits of performing bilateral knee replacement. The story cites a 2013 study that \u201cestimated the cost of bilateral surgery at $43,401 compared with $72,233 for two separate surgeries staged over time.\u201d One addition that would have made the story a bit stronger: since many patients requiring knee replacement surgery are older adults, it might have been useful for readers to know the extent to which Medicare might defray related costs. Still, the story tackles cost head on, and gets a solid Satisfactory here.", "answer": 1}, {"article": "By six months, almost all had disappeared.\nAfter surgery to remove the bulk of the brain tumor, Badie and his colleagues directly injected the site with the modified immune cells (called chimeric antigen receptor T cells, or CAR T cells) six times, and the remaining part of this tumor stopped growing.\nIt\u2019s possible that the immune cells had destroyed most of the cancer cells expressing the original protein, so other cancer cells with other proteins began to proliferate and survive.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\n\u201cIf we can do the same for other patients, that would be an amazing accomplishment that many decades of work and research on glioblastoma have never done,\u201d says Badie, whose own father passed away a decade ago from glioblastoma.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there may not yet be any accurate prediction of the cost of the particular therapy described for this single patient, it is generally well established and well documented that immunotherapies\u2013particularly those that involve modifying a patient\u2019s own immune cells\u2013 are many times more expensive than standard treatments, sometimes running to annualized costs in the hundreds of thousands of dollars. This story says nothing about this.", "answer": 0}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nThe present study now documents the prognostic importance of the comprehensive assessment provided by hybrid imaging.\"\nThe approach has shown promise in studies focusing on short-term observations, but information is lacking on long-term outcomes.\nThe research team looked at 428 patients who underwent hybrid imaging.\nNo additional imaging would be necessary if the results were normal.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of the hybrid imaging approach compared with the standard approach.", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a toss-up, since the story tells readers that the wearable device (named Alex) costs $99, but doesn\u2019t tell readers how much the app (named the Text Neck Indicator) costs. A look online tells us the app costs $2.99. For what is essentially a product review, it was an unusual oversight not to include the cost of the app. However, in the event of a toss-up, we try to give the story the benefit of the doubt, so this gets a Satisfactory rating.", "answer": 1}, {"article": "The key to making the therapy work?\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThe disease strikes about one in 20,000 boys; symptoms first occur at an average age of 7.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tackles this issue head on, though what they report may not be comforting for those affected. Here\u2019s how they address the issue: \u201cThe results of the new study also give rise to a concern that is becoming a regular feature of gene therapy work and other new biotech therapies: How much will this treatment cost? Bluebird Bio is not saying\u2026[but one scientist involved in the study] expects the price to be similar to the hundreds of thousands of dollars it costs for a bone-marrow transplant.\u201d", "answer": 1}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nEven More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\nThe study did find negative effects in children whose mothers drank moderately: this was defined as not having more than 3 to 6 British units of alcohol per week or more than 3 to 5 units on a single occasion.\nIf women who say they are drinking at \u201clight\u201d levels are actually drinking at moderately or heavily, that might make the data on light drinking look more dangerous than they are.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This does not seem to apply.", "answer": 2}, {"article": "WEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\nThey measured the scrotum-anus distance as well as the penis length of 117 infertile and 56 fertile men visiting an andrology clinic.\nOne expert who's done her own research in this area applauded the study.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n\"First, this could represent a noninvasive way to test testicular function and reproductive potential in adult men,\" he said in a Baylor news release.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of such an approach is not in question.", "answer": 2}, {"article": "Have a question?\nFor example, patients with kidney, gastric, cardiovascular, or bleeding problems may need to avoid NSAIDS like ibuprofen, so doctors might suggest Tylenol in these cases.\nNow, Moore was referring here to acute pain that strikes after a specific event, like a surgery, a cut, or a burn, but his message was simple: Ibuprofen seems to work best, followed by acetaminophen, and then aspirin.\n\"We always thought [acetaminophen] was safe, but there are increasing signals of accidental overdose in people who are regularly using it for chronic pain, and some liver toxicity,\" explained Conaghan, who has studied adverse events data related to this popular drug.\nBut a final caveat here: If your child is older than 6 months, it's not all that clear that acetaminophen outperforms ibuprofen for reducing fevers, and the same is true for adults.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention costs but since these over-the-counter medications have been widely available for a long time it doesn\u2019t seem like an important omission. Because aspirin has been available the longest and is manufactured by literally hundreds of companies, it is by far the cheaper of the three.", "answer": 2}, {"article": "So why does acupuncture seem to work?\nThe result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\n\"Anyone who treats breast cancer struggles with this problem in their practice, because the hot flashes that some women experience with anti-hormonal treatment can be profound,\" she said.\nThe second group, of 85, was offered the same advice in the same time frame along with 10 half-hour weekly sessions of \"traditional\" acupuncture.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does address cost, but doesn\u2019t say how much that cost might be. As the story states: \u201c[the researcher] didn\u2019t know how much American patients might have to pay for such treatment, but added, \u2018Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.'\u201d\nWhile we always try to give the benefit of the doubt in cases where the story at least attempts to address cost, the characterization here seems debatable enough to merit a Not Satisfactory rating.\nA quick internet search finds that acupuncture therapy costs anywhere from $50 to more than $120 per session. That\u2019s not insignificant (and it wasn\u2019t hard to look up). Given that the study in the story had patients go through 10 acupuncture sessions, this could cost a patient at least $500, and possibly more than $1,200.\nAlso, while other methods for treating hot flashes, such as medication, are covered by health insurance, acupuncture is not necessarily covered.", "answer": 0}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of a Mediterranean diet is not in question.", "answer": 2}, {"article": "MIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nThe numbers were similar when rechecked at 52 weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address costs for any of the treatment options discussed. Is MBSR comparable to CBT? Does insurance cover either treatment option?", "answer": 0}, {"article": "The games are based on the work of Japanese neuroscientist Ryuta Kawashima, M.D.\n\"Functional MRI allows you to study which brain areas are simultaneously active and gives information on the participation of certain areas with specific brain circuits,\" Dr. De Giglio said.\n\"This increased connectivity reflects the fact that video gaming experience changed the mode of operation of certain brain structures,\" Dr. De Giglio said.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nDamage to the thalamus, a structure in the middle of the brain that acts as a kind of information hub, and its connections with other parts of the brain play an important role in the cognitive dysfunction many MS patients experience.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost of this video game/training program although that would be a key immediate question in the minds of both MS patients and their families. Moreover, this cost may not be covered by health insurance whereas other forms of cognitive training, for example performed by occupational therapist, may be. The release also fails to mention the cost of other equipment required to play the video game. Together, the game and player can cost hundreds of dollars, depending on the model purchased, and while that cost may not be overly prohibitive, readers deserve to know it when considering the value of this study\u2019s information.", "answer": 0}, {"article": "\"Our results suggest that the unique polyphenol mixture in tart cherries may help positively shape the gut microbiome, which could potentially have far-reaching health implications.\"\nMontmorency tart cherry juice concentrate can be mixed with water or other juices.\nHowever, when concentrated juices were fermented, this bifidogenic effect appeared to be leveled out by the larger increase of polysaccharides utilizing bacteria.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\n\"Montmorency tart cherries were a logical food to study due to their unique composition of polyphenols, including chlorogenic acids,\" said principal investigator Franck Carbonero, PhD, assistant professor in the Department of Food Science at the University of Arkansas.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of Montmorency tart cherry juice is not mentioned.\nWalmart sells a quart of concentrate for about $16.", "answer": 0}, {"article": "Their editorial accompanies the Marban report in the Feb. 14 advance online issue of The Lancet.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\nIf so, this could change the nature of medicine.\nAll that's needed is a little help from one's own heart stem cells.\nHe invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The treatment is too experimental, and there are no comparable treatments to allow for a meaningful discussion of costs.", "answer": 2}, {"article": "The problem is that over the years the stomach stretches, and when that happens, Watson says, \"Patients are able to eat more at one sitting and they feel hungrier more often.\"\nIf the stomach pouch has stretched, new sutures are put in place to once again reduce the size of the stomach.\nBut then to her dismay she started to gain it back.\n\"It was the first time in my life that I've ever lost a lot of weight and was able to maintain it.\"\nThere are no significant side effects to the surgery, and patients can return to work the day after they have the procedure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story clearly provides the reader with an estimate of the costs of the procedure and highlights issues related to insurance coverage. A strong point in this story.", "answer": 1}, {"article": "There\u2019s no reason why women should be caught unaware in the late stages of a pre-eclampsia\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nThere is currently no test to predict which women will develop pre-eclampsia, which is marked by high blood pressure and high protein levels in urine.\n\u201cA high caliber predictive test would allow women who are identified at high-risk for pre-eclampsia to seek obstetric care by specialists and to be monitored more vigilantly,\u201d Eleni Tsigas, executive director of the Pre-eclampsia Foundation, said in a statement.\n\u201cIf we can bring the rates of maternal deaths in undeveloped countries down to the rates in developed countries, by being able to determine which women are at the greatest risk for developing pre-eclampsia, then it has that potential to save thousands of lives,\u201d Baker said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned in this story. This is partially excusable because\u00a0the diagnostic test is still under development, but, given the possibility of applying this test in low-resource settings, it would have been important for the reporter to ask the researchers for a cost range to show whether it is going to make any sense for most of the world. Many tests like this are too expensive to be applied widely, and there would be comparable tests that could be mentioned as a cost comparison.", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear that the test is expensive and that Medicare and some other insurance plans cover it.", "answer": 1}, {"article": "Eckel said obesity is by far the largest issue responsible for the metabolic syndrome.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\n\"I think the health professional needs to recognize that people that meet the criteria for the metabolic syndrome are at higher risk [for heart disease and diabetes] and we strongly recommend that lifestyle intervention is used to prevent the syndrome and also to modify its prevalence,\" he said.\nIn addition, waist size is a risk factor- a waist more than 35 inches for women and 40 inches for men is of concern.\nTake this test to see how well you're managing your diabetes\n\nThe researchers looked at over half a million people from 50 previous studies on the Mediterranean diet, which included people in Spain, Greece, the U.S., France, Sweden, Italy and Australia, among other countries.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\n\n \nNot applicable. There was no discussion of costs, i.e. how consumption of a \u2018Mediterranean diet\u2019 compared to more typical diets compare in terms of cost to the consumer. But we think most people would have a pretty good grasp of the general costs of the types of foods involved.\u00a0 But where this becomes an issue, for example, is with what the cost of fresh fish can do to a food budget.\n \n\u00a0", "answer": 2}, {"article": "Professor Vieta was not involved in this work, it is an independent comment.\nA total of 133 participants were randomly assigned to take a combination of nutraceuticals (compounds derived from foods such as vitamins or minerals that treat or prevent a disease or disorder) including the anti-inflammatory amino acid n-acetylcysteine (NAC), or NAC alone, or a placebo (a dummy pill) for 16 weeks.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study investigated three interventions: 1) A combination treatment of over a dozen \u201cmitochondrial enhancing agents\u201d (including N-acetylcysteine, or NAC); 2) NAC alone; 3) placebo.\nNAC is the only intervention that is routinely used as a treatment. Its cost is not included. According to Amazon.com a 600 mg tablet costs roughly $0.10 \u2013 $0.30 (but the dosage used in the study is not mentioned).", "answer": 0}, {"article": "For more information, visit http://www.\nIn the accompanying editorial titled, \"Can a Toothpaste Reduce Heart Attacks and Strokes?,\" Joseph S. Alpert, M.D., an internationally renowned cardiologist, noted the importance and timeliness of these findings and commented on how his father, a dentist, had told him even before he went to medical school, that dental health may affect heart attacks and strokes.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nIn addition, the product's proprietary formulation contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject visualize and more effectively remove the plaque.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Plaque HD toothpaste is very expensive: $16.95 plus $5.75 shipping for a single 4.1-ounce tube, according to the manufacturer\u2019s website, compared to less than $5 for a similar amount of conventional toothpaste. Also, plaque disclosing tablets can be bought for about 10 to 25 cents each. These don\u2019t have to be used every day, just on a periodic basis to determine effectiveness of brushing.\nConsidering the big price difference, consumers would want to see strong evidence that this brand of toothpaste really provides health benefits over other toothpastes and other ways of showing plaque on teeth.", "answer": 0}, {"article": "Vericel shares were down $2.01, or 33 percent, at $4.02 on Nasdaq.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\n\u201cPeople were looking for downside and they had one.\u201d\n\nThe data compared Vericel\u2019s bone marrow-derived ixmyelocel-T stem cells with placebo in 109 well-treated patients with advanced heart failure who had exhausted medical and device therapies.\nThe result was primarily driven by the difference in deaths of 13.7 percent in the placebo group, or 7 deaths, compared with 3.4 percent, or 2 deaths, for the ixmyelocel-T group.\n\u201cIt\u2019s a little baffling that you\u2019re keeping patients alive, but not having any effect on those secondary endpoints,\u201d said Needham & Co analyst Chad Messer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Stem cell therapy is assumed to be quite expensive, yet there is no mention of potential cost to the patient or health care system. If the new approach is comparable to other approaches\u00a0then the cost of the alternative methods could be cited. Our rule of thumb: If it\u2019s not too early to talk about how well something might work, then it\u2019\u2019s not too early to start discussing what it may cost.", "answer": 0}, {"article": "So what's a patient to do?\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nThe average American's total radiation exposure has nearly doubled since 1980, largely because of CT, or computed tomography, scans.\n\"The CT scan is a wonderful tool for examining internal organs, organs that are below the depth of where a poking finger or a listening stethoscope can hear, and yet don't show up on routine X-rays,\" Dr. Michael Brant-Zawadzki, a clinical professor of radiology at Stanford University tells CBS News.\nThe dose depends on the type of machine and the person - obese people require more radiation than slim ones - and the risk accumulates over a lifetime.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that CT scans are faster and better at diagnosing certain problems than are other types of imaging.\u00a0 It did not, however, provide information about the costs of various types of imaging or whether there were differences in terms of costs covered by insurance.", "answer": 0}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nIt makes sense that the probiotics may enhance the immunotherapy\u2019s effect, since probiotics are beneficial bacteria in the gut, where food allergens are processed.\n\u201cI think there is certainly a suggestion, but not hard proof, that the probiotics make a difference,\u201d says Nowak-Wegrzyn.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. Would this be a relatively inexpensive treatment? A costly one? Is it too early to tell? Readers won\u2019t be informed of this.", "answer": 0}, {"article": "Such screening is increasingly used in research.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nData from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "One of the quoted researchers noted that the scans are expensive and not covered by insurance. The latter means they are not ready for clinical use to any large degree, so we\u2019ll give the story a pass. We\u2019d add\u00a0that if either of these amyloid screening methods \u2014 PET scans or cerebral spinal fluid testing \u2014 becomes adopted as a preventative practice, it could involve many millions of people and be very costly to an already overburdened public health system.", "answer": 1}, {"article": "protection.\u201d\n\nAlgenist literature touts alguronic acid\u2019s superiority to hyaluronic acid, retinol and vitamin C, among other anti-aging ingredients, in encouraging elastin synthesis and cell regeneration.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\n\u201cWe want to give it a lot of visibility all at the same time.\u201d But Mr. Burke knows that marketing has its limits.\n\u201cIt was a brand nobody has ever heard of,\u201d said Allen Burke, the senior adviser for beauty strategy and development at QVC.\nAfter reviewing press materials and Solazyme\u2019s 84-page patent application, Dr. David McDaniel, a dermatologist and the director of the Institute of Anti-Aging Research in Virginia Beach, Va., said he was impressed by the in-vitro testing of alguronic acid.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that these products retail for $65 to $95. We would have liked to have seen how long one of those products would last with typical daily use. Is it $95 a month? Every three months?", "answer": 1}, {"article": "(http://www.p-cure.com).\nThe P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nThe P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We were pleased to see the potential economic impacts of this therapy raised in the release. The release says, \u201cIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\u201d However, the cost savings refer to the reduced capital investment for the proton beam center, not the cost for patients. The release is basically arguing that the device will decrease the cost for the center per patient treated, and will accomplish this by making it easier to get treatment done and make it more accessible, affording extra time to bring in more patients. This is not exactly the cost that the patient is thinking about.\nWe give the release credit for raising the financial issue but at least one cost-related number is needed here.", "answer": 0}, {"article": "The study was funded in part by National Cancer Institute grant P01 CA021239.\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\nIn July 2015, MGH returned into the number one spot on the 2015-16 U.S. News & World Report list of \"America's Best Hospitals.\"\nThe cognitive effects of proton therapy - primarily affecting verbal comprehension and processing speed - were also less serious than what has been reported with photon radiotherapy, and those effects were primarily seen in children who were under the age of 8 when treated.\nIn contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the costs of the therapy. This is especially important to include in any discussion of proton therapy because its costs are astronomically high \u2014 often twice as much as standard therapy.\nWe\u2019ve previously described some of the issues with costs in other reviews and blog posts\u00a0focusing on proton therapy. You can search the HealthNewsReview.org site for many others.", "answer": 0}, {"article": "By the fifth visit, he was completely out of pain,\u201d Fuh said.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe space agency noticed astronauts, who did not have gravity compressing their spines in space, reporting the disappearance of neck and back pain.\nThe back is gently stretched over a number of treatments, allowing the disc to rehydrate and heal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of the treatment, which is not covered by insurance. The story should have compared the cost to other available treatments. Nonetheless we\u2019ll give it the benefit of the doubt and score it satisfactory. ", "answer": 1}, {"article": "EMBARGOED FOR RELEASE: 11 A.M. (ET) TUESDAY, AUGUST 16, 2016\n\nMedia Advisory: To contact Paul D. Miller, M.D., call 303-925-4514 or email millerccbr@aol.com.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.\nThe trial was conducted at 28 sites in 10 countries.\nOverall, there were no differences in serious adverse events between the treatment groups.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release. At a minimum it could have mentioned the cost of the existing FDA-approved comparator drug.", "answer": 0}, {"article": "These conditions included generalized, social, and separation anxiety disorder as well as having a parent with bipolar disorder.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\n\"This raises the possibility that treatment-related increases in brain activity during emotional processing may improve emotional processing in anxious youth who are at risk for developing bipolar disorder,\u201d said fellow co-author Dr. Jeffrey Strawn, a professor in UC's Department of Psychiatry and Behavioral Neuroscience, as well as director of the Anxiety Disorders Research Program, in a statement.\nOver the course of 12 weeks, each participant underwent functional magnetic resonance imaging (fMRI) scans while they practiced mindfulness-based cognitive therapy, a wide range of theraputic techiniques that include meditation, yoga, and learning how to pay nonjudgmental attention to one's life.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed at all. How much does cognitive therapy cost for children with anxiety disorders? Does it require long-term treatment with multiple sessions? Is it usually covered by health insurance providers? These are all important questions for families who have a child experiencing an anxiety disorder \u2014 and this story doesn\u2019t address them.", "answer": 0}, {"article": "Cooper and his colleagues looked at 29,507 births to women covered by Medicaid in Tennessee between 1985 and 2000.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\nThe fraction of babies with defects was 7.1 percent in the ACE-inhibitor group; 1.7 percent in the other anti-hypertensive group; and 2.6 percent in the group taking no blood-pressure medication.\n\"It would be important for a pregnant woman and her health-care provider to be aware of this, so they can identify an alternative medicine to treat her hypertension,\" said William O. Cooper, a pediatrician at Vanderbilt Children's Hospital who headed the study, published in today's New England Journal of Medicine.\n\"I think it is safe to say that not a lot is known about the options for women in pregnancy,\" said Sandra L. Kweder of the FDA's Center for Drug Evaluation and Research.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost comparison for ACE inhibitors and the other medications that might be used in the management of hypertension. However, since the point of the story was to point out risks, not to promote further use, costs are less of an issue in this story. ", "answer": 2}, {"article": "THURSDAY, May 9, 2013 (HealthDay News) -- Scientists report positive results in early testing of a wireless pacemaker that's placed in the heart instead of being connected to it via wires from the upper chest.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\nIn the new study, researchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that this is in the \u201cearly testing\u201d phase, so it\u2019s understandable that a cost estimate might not be given.\nIn the second paragraph, the story states that the cost is unknown.\nAnd an independent expert postulated that \u201cthe new device will probably be more expensive than other pacemakers.\u201d", "answer": 1}, {"article": "Studies have shown that the intimate association between the gut microbiome and GI tissue has a significant effect on the GBA.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\nThe GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThere is also mounting evidence linking imbalances in the microbial species that make up the gut microbiome to a number of health problems including allergies, autoimmune disorders, and psychiatric mood disorders.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Neither the cost, composition, or dosing of the intervention \u2014 a probiotic preparation of strains of a Lactobacillus and Bifidobacterium \u2014 is provided.", "answer": 0}, {"article": "She said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\nThose with the BRCA1 mutation also have a 36 to 63 percent higher risk of ovarian cancer and those with the BRCA2 mutation have a 10 to 27 percent higher risk of ovarian cancer.\nWomen with mutations in the BRCA1 or BRCA2 genes have a 56 to 84 percent higher risk of developing breast cancer during their lifetimes.\n\u201cAnd you can save the majority of women who would have died of their breast cancer,\u201d she added.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention the costs of testing, surveillance or treatment.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of the IUD or implantation.", "answer": 0}, {"article": "To take a trial that involves people at high risk for lung cancer and to extrapolate it and say it\u2019s good for people with intermediate or low risk is not appropriate.\u201d\n\nThe study, called the National Lung Screening Trial, focused on a specific high-risk group: 53,000 current and former heavy smokers, aged 55 to 74, who had smoked for at least 30 pack-years.\nWe know from our own anecdotes that we have saved a lot of lives.\u201d\n\nDr. Lepor said that he had just met a woman who had smoked for 50 years and was concerned about her risk.\nThe wording of the ad seemed to be aimed at a broad group, ranging from heavy smokers to women who had never smoked, Dr. Brawley said.\nThe study was stopped when it was found that the scanning group had a 20 percent lower risk of dying from lung cancer than those being screened with X-rays.\nCompared with conventional X-rays, the CT, or computed tomography, scans create a detailed three-dimensional image of the lungs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Good job on this.\u00a0 The story stated:\n\u00a0However, it could have also included at least a line about the costs of following testing and possible treatment of false positives.", "answer": 1}, {"article": "She agreed to the memory testing for the study.\nThe team then statistically analyzed the results and found that people scored slightly higher than usual on words when stimulation arrived during a low or foggy state \u2014 and worse, when the pulse arrived in a high state.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nThis study used data from 150 patients, and had 20 collaborators from institutions around the country, including Emory University, the University of Washington, the Mayo Clinic and the University of California, San Francisco.\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have noted how much it typically costs to implant electrodes in the brain of a patient. According to the University of Michigan, deep brain stimulation implants and surgery can cost \u201cabout $30,000 plus physician and MRI fees.\u201d Meanwhile, the National Parkinson Foundation states the all-in cost can reach $50,000 and sometimes up to $100,000 (e.g. for implants on both sides of the brain).", "answer": 0}, {"article": "Beaumont's center is one of just 28 proton therapy centers in the U.S.\nThe facilities are impressive, clean and welcoming, but the difference is the people \u2013 best hospital staff I've ever encountered.\nBeaumont proton team 'second to none'\n\n\"I realize I'm extremely fortunate to have been able to consider traveling to another state for treatment and live there for two and a half months,\" said Tracy.\nIn his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nThe results supported the use of high-dose definitive radiation therapy, via proton beam therapy, for selected patients with unresected spine and sacral chordomas.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned. A visit to the website of the organization that issued the release offered little additional information about cost, noting only that \u201cmany insurance plans will cover\u201d proton beam therapy.\u00a0 And many will not. Finding cost information online was surprisingly difficult. According to a 2017 story on MedPage Today, the cost of proton beam therapy can range from $30,000 to $120,000. Those are significant numbers, and the failure to address cost in the release is a significant oversight.\nSince these multi-million dollar machines (which can cost in excess of $200 million) are available in a very limited number of locations, many patients, including the one profiled in the release, have to travel for proton therapy treatment so prospective patients would need to add travel expenses to overall treatments costs.", "answer": 0}, {"article": "Age-related macular degeneration affects upward of 15 million Americans.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nCedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At no time during the release is the potential cost of a possible treatment ever mentioned.\u00a0 That\u2019s understandable since the work is only being done in animal models and far-removed from eventual clinical use.\u00a0 But the release suggests that\u00a0human use is close at hand.\u00a0 If the procedure were ready for clinical use in humans, it would involve costly eye surgery as well as the very costly and complicated manipulation of human skin cells so that they become stem cells.\u00a0 While the cost of these processes will inevitably\u00a0fall,\u00a0it\u2019s likely to remain substantive.", "answer": 0}, {"article": "The California Walnut Commission (CWC) prohibits discrimination in all programs and activities on the basis of race, color, national origin, age, disability, sex, marital status, familial status, parental status, religion, sexual orientation, genetic information, political beliefs, reprisal, or because all or part of an individual's income is derived from any public assistance programs.\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\nIn addition to providing omega-3s, walnuts also deliver a convenient source of fiber (2 grams per ounce) and protein (4 grams per ounce).\nThe dose of nuts varied from 5 to 100g/day and most participants followed their typical diet.\n\"Our study results further support the growing body of research that tree nuts, such as walnuts, can reduce the risk of cardiovascular diseases,\" said Dr. Falk.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We won\u2019t ding the story for not mentioning costs, although walnuts certainly are expensive. Each one of us passes by bags of walnuts every time we go to the grocery store and probably have at least a vague idea of what they cost.", "answer": 2}, {"article": "\"Are there people gaming the system?\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\n(The same thing happened with tonsils, which doctors no longer remove just to get rid of the chance of infection later on.)\n\"The risk for complications increases as people get older, and the duration of disability after the operation gets longer as people get older,\" says oral surgeon Dr. Thomas Dodson.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article talks about the overall costs of removing wisdom teeth \u2014 $3 billion annually, according to the American Public Health Association (which opposes preventative extraction) \u2014 as well as the costs of removing a single molar. A single extraction can range from $230 to $400 according the story source, the Healthcare Bluebook.\nThe story would have added more value if it had mentioned a range of costs associated with surgical complications or treatment for infections following surgery.", "answer": 1}, {"article": "So what is it about tai chi that works?\nThey became very happy.\n\"You could see them change every week.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\nThe controlled breathing and movements may promote \"mental tranquility,\" according to the study, which could help with pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story does not mention costs.\u00a0", "answer": 0}, {"article": "Note: Around 220,000 people have been diagnosed as having schizophrenia in England and Wales (https:/ )\nThe researchers found that 34.6% of the patients being treated by TMS showed a significant response, whereas only 9.1% of patients in the sham group responded ('significant response' was defined as a more than 30% decrease in the Total Auditory Hallucinations Rating Scale score).\nUsing magnetic resonance imaging (MRI), the pulses were targeted at a specific brain area in the temporal lobe, which is associated with language (the exact area is the crossing of the projection of the ascending branch of the left lateral sulcus and the left superior temporal sulcus)\n\nAfter 2 weeks, the patients were re-evaluated.\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\nThe French research team worked with 26 patients who received active TMS treatment, and 33 as a control group, who received sham (placebo) treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. TMS therapy is already available for the treatment of other mental health conditions, including depression, so cost estimates should not have been difficult to come by. And since costs can reach into the thousands of dollars, depending on the length of treatment, it is not an insignificant issue for patients and their families.", "answer": 0}, {"article": "Pooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nShe said in a statement: \u201cTaking antidepressants is frequently portrayed as a negative thing or something done only when other therapies are not available or have failed, but this in itself can add to the unfortunate stigma that sometimes exists around people with mental health conditions.\u201d\n\nBut she also urged caution.\nRead more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\n\nIn the U.S., the National Institute of Mental Health estimates 16.2 million adults experienced at least one major depressive episode in 2016.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Without mentioning any numbers, the story does say that the costs of antidepressant drugs tend to be lower than the other major treatment approach for depression, which is talk therapy.\nThe story would have been stronger with cost data. For example, the four drugs found most effective\u00a0 in the analysis\u2013 mirtazapine, escitalopram, venlafaxine, and sertraline \u2014 cost $8 to $12 for 30 tablets, according to the web site GoodRx. The study says, \u201cAll of the most effective antidepressants are now off patent and available in generic form.\u201d\nIt also doesn\u2019t mention that talk therapy may have more value for some patients because it can equip people with tools for life, and severe depression needs to be treated by a combination of drugs and talk therapy.", "answer": 1}, {"article": "\u201cOur study essentially shows that what happens in the real world is very different\u201d from what happens in clinical trials, said Hillel R. Alpert of Harvard, a co-author with Dr. Connolly and Lois Biener of the , .\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nThe researchers argue that while nicotine replacement appears to help people quit, it is not enough to prevent relapse in the longer run.\nThe products have been controversial since at least 2002, when researchers at the , reported from a large survey that they appeared to offer no benefit.\nThey interviewed the participants three times, about once every two years during the 2000s, asking the smokers and quitters about their use of gum, patches and other such products, their periods of not and their relapses.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "All three stories at least mentioned the total amount of money being spent on nicotine replacement products or the growth in that spending. None of the stories actually explained how much these products cost or compared them to the costs of cigarettes. The cost of an 8-week regimen of nicotine patches is $160-200.", "answer": 1}, {"article": "He is a leading expert on MCC and a pioneer of immunotherapy for the disease.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nNewswise \u2014 SEATTLE (March 24, 2017) \u2013 The U.S. Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.\nHis team foundational work on the role of immune cells in MCC paved the way for immunotherapy trials in the disease, including one he leads of another immunotherapy drug with a similar mechanism of action (Merck\u2019s Keytruda), whose results were published last year and changed the field overnight.\nAn independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation\u2019s first and largest cancer prevention research program, as well as the clinical coordinating center of the Women\u2019s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this piece. Even though it calls out the drug avelumab (marketed as Bavencio) by name, the release does not talk about what a typical regimen of that drug or any other would be.\nBloomberg reports that avelumab will be priced at $13,000 a month, or $156,000 for a year of treatment.", "answer": 0}, {"article": "Reduction in high blood pressure has added health benefits because it can potentially reduce the likelihood of heart attacks, strokes, chronic heart failure and kidney disease.\nThe randomized, double-blind study included 264 participants with an average age of 58, of whom 58 percent were women.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nThese tools were carefully chosen to increase in knowledge about and motivation to maintain a heart-healthy lifestyle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention the estimated cost; we think that would have been a useful detail to both patients and healthcare providers interested in offering this program.", "answer": 0}, {"article": "People who were given Flublok Quadrivalent were over 40% less likely to develop culture-confirmed influenza.\n\"This study shows that Flublok\u00ae Quadrivalent, produced with modern recombinant technology can provide better protection against confirmed influenza-like illness among older adults than standard-dose quadrivalent influenza vaccine produced with traditional technology,\" said Lisa Dunkle MD, Chief Medical Officer of Protein Sciences.\nFurthermore, Flublok Quadrivalent is the first and only high antigen-content quadrivalent flu vaccine that with its high efficacy makes it ideal for older adults and those with a compromised immune system.\nFlublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus, antibiotics or harsh chemicals (e.g., formaldehyde) in manufacturing.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed at all. Given that this release comes from the manufacturer, and that the drug was approved by the FDA in October 2016, it\u2019s not clear why this information isn\u2019t available.", "answer": 0}, {"article": "The signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nResearchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention direct costs or potential financial consequences of such a test.", "answer": 0}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article reports the costs of surgery ($10,000-12,000) though it does not mention the cost of nonoperative care or compare the costs of the two treatment regimens. It\u2019s unclear from the article whether the surgery costs encompass all aspects of surgery, from surgeon fees through hospitalization.", "answer": 1}, {"article": "The Lung EpiCheck blood test detects changes in DNA methylation in 6 markers in cfDNA associated with lung cancer.\nThe reason for the high mortality rate is that currently most cases are detected when the patient becomes symptomatic, which is usually at late stages of the disease.\nThe results will be presented in a poster presentation titled Lung EpiCheck \u2122 - Results of the Training and Test Sets of a Methylation-Based Blood Test for Early Detection of Lung Cancer at the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, to take place on September 22-26, 2018 in Toronto, Canada.\nIt is estimated that there are about 1.8 million new cases of lung cancer annually worldwide and about 1.55 million die from the disease each year.\nEarly detection of lung cancer can be a game-changer in the fight against this devastating disease, and we are looking forward to begin extensive clinical trials in the US, Europe and China next year, in order to get the test to the market as soon as possible at an affordable price.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of cost. While we understand that this news release is touting a product in the early stage of development, it would still be beneficial to give readers some idea of the projected cost.", "answer": 0}, {"article": "Portions of this study were supported by National Institutes of Health grants (CA140933, CA104825, CA109298, P50CA083639, U54CA151688, U54CA96300, U54CA96297, and CA016672), an Ovarian Cancer Research Fund program Project Development Grant, the Department of Defense (grants OC073399, W81XWJ-10-0158, and OC100237), the Betty Ann Asche Murray Distinguished Professorship, the RGK Foundation, the Gilder Foundation, the Blanton-Davis Ovarian Cancer Research Program, and a Gynecologic Cancer Foundation-St. Louis Ovarian Cancer Awareness grant.\nAmong the 269 patients who received beta-blockers, 193 (71.7 percent) received beta-1-adrenergic receptor selective agents (SBBs) and the remaining patients received nonselective beta antagonists (NSBBs).\nThe research team found:\n\u2022 For patients receiving any beta-blocker, the median overall survival was 47.8 months versus 42 months for nonusers.\nAccording to The University of Texas MD Anderson Cancer Center investigators, the drugs block the effects of stress pathways involved in tumor growth and spread.\nAll these factors were associated with decreased survival, yet those who received beta-blockers had either equivalent or improved overall survival.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost at all. Beta-blockers are currently available, and a monthly prescription can run patients from 10 to hundreds of dollars. The non-selective beta-blockers mentioned in the release are all available as a generic product and are relatively inexpensive as compared to the selective agents", "answer": 0}, {"article": "However, the current non-invasive alternative \u2014 an ultrasound done at the end of the first trimester \u2014 isn\u2019t always good at spotting a baby\u2019s sex, Bianchi\u2019s team reported in the Journal of the American Medical Association.\n\u201cIf parents are using it to determine gender and then terminate the pregnancy based on that, that could be a problem,\u201d she told Reuters Health.\nBecause such disorders mostly strike boys, knowing that the baby is a girl could spare the mother diagnostic procedures, such as amniocentesis, that carry a small risk of miscarriage.\nBut other researchers voiced concerns, saying it could be misused to terminate a pregnancy if the baby isn\u2019t of the desired sex.\n\u201cIt could reduce the number of invasive procedures that are being performed for specific genetic conditions,\u201d said Dr. Diana Bianchi of Tufts University School of Medicine, who worked on the new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions the estimated cost of test, but does not note that consumers can get the test without a doctor\u2019s involvement in the US.", "answer": 1}, {"article": "The majority of cases are caught at around 66.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nAlthough prostate cancer is the second leading cause of cancer death in the U.S. after lung, few risk factors have been found, and it is difficult to accurately diagnose.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no cost data. While this test isn\u2019t on the market \u2014 and might never be \u2014 there are plenty of saliva-based genetic tests that are.\nSays the U.S. National Library of Medicine: \u201cThe cost of genetic testing can range from under $100 to more than $2,000, depending on the nature and complexity of the test.\u201d", "answer": 0}, {"article": "Again, Merck disputes the connection.\nBut the \"absolute risk\" of these unusual fractures is still pretty low \u2014 13 fractures per year for every 10,000 people taking bisphosphonates for five years or longer.\nAmid all the debate, many specialists are wondering if women on bisphosphonates should take a \"holiday\" from the drug from time to time.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\nMoreover, the study verified that long-term use of bisphosphonate drugs reduces the risk of typical osteoporosis fractures by 24 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story gives no cost information. We wish the story had given the yearly cost of at least one of these therapies, and even some comment on the high cost of recovery from a typical hip fracture for the thousands of elderly women who suffer them.", "answer": 0}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of red wine is not in question.", "answer": 2}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nIf you have the time to learn only one technique, this is the one to try.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\n\u201cThe findings were exciting,\u201d she said.\nOne group was instructed to do two sets of 10-minute breathing exercises, while the other group was told to read a text of their choice for 20 minutes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since deep breathing is free, no discussion of costs is warranted.", "answer": 2}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to discuss costs. Given that this drug is apparently meant to be taken in addition to other drugs, it likely will result in an increased cost to patients who already are on medication.\nThe commercially available humanized monoclonal antibodies used to treat other diseases like rheumatoid arthritis can cost thousands of dollars per month and are frequently singled out by insurance companies for large copays.\nThis is important context that was left out.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of the scan, an important piece of information for the consumer given that insurance is unlikely to cover it.", "answer": 0}, {"article": "For advice, information and support, visit http://www.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\nDr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nAs part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate - making it extremely difficult to pay attention to walking.\nIt affects 127,000 people in the UK - which is around one in 500 of the population.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention the drug\u2019s cost but we won\u2019t dock points for that omission since the release is from the UK where cost would be less of a concern for readers than it is in the U.S. This drug is common enough in the United States and is available in generic form.", "answer": 2}, {"article": "Many older adults prefer psychotherapy to medication for the treatment of anxiety.\nEditorial: Solving the Geriatric Mental Health Crisis in the 21st Century\n\nIn a related editorial, Eric J. Lenze, M.D., of the Washington University School of Medicine, St. Louis, writes: \u201cTherefore, we are in the midst of the following two unprecedented trends: the aging of the population and the transformation of everything in our lives by mobile technology.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nThe clinical trial demonstrated both treatments reduced symptoms of worry, depression and GAD, but telephone CBT was superior to telephone NST and resulted in a greater reduction of symptoms.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At no point in the release was cost mentioned.\u00a0 Psychotherapy and counseling can be costly, especially for the elderly on fixed incomes.\u00a0 Readers would be well-served with some estimate of the costs of the services provided through this trial.\u00a0 Also, a mention of a comparison between the costs of office visits for such therapy versus that delivered via telephone would be useful to give readers a fuller picture of the practical potential for this approach.\u00a0Medicare requires in person contact for payment. \u00a0That\u2019s why the cost issue is important in this case. We think news releases can and should address these matters.", "answer": 0}, {"article": "Most of the women had a personal history of breast or ovarian cancer already.\n\u201cThe interpretation of these tests is not a simple color-by-numbers thing.\u201d The vast majority of uncertain genes will be benign, but a misinterpretation could lead a patient to a drastic, unnecessary surgical procedure, he said.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\nFor 15 years, at-risk women have only been tested for BRCA1 and 2, but many companies now offer multi-gene panels for 20, 25 or 30 other genes, Ellisen told Reuters Health.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article mentions that the tests themselves \u201care not more expensive than testing for the BRCA mutations alone,\u201d but it doesn\u2019t state what those BRCA-only panels cost. In addition, insurance coverage for panel testing is not as uniform as it is for BRCA 1/2 testing. There are established guidelines for BRCA 1/2 testing from the National Comprehensive Cancer Network that most insurance companies honor. There are not yet established guidelines for panel testing.\u00a0We appreciate the nod to cost, but we thought a little bit more detail was needed here for a Satisfactory rating.", "answer": 0}, {"article": "\u201cWe found that patients generally can resume normal activities the following day with typical side effects.\u201d\n\nThe study, which appeared in the Red Journal\u2019s January 2017 issue, presented the results of a nonrandomized, prospective clinical trial of 58 patients with low- or intermediate-risk (non-metastatic) prostate cancer, with a median follow-up period of 2.9 years.\nTypically, HDR brachytherapy is administered in four to as many as nine treatment sessions, which generally requires multiple invasive procedures to insert the implants.\nThe median patient age was 63 years (range 43-73), and 91 percent of the patients presented with stage T1 disease.\nIn contrast to low-dose-rate (LDR) brachytherapy, where radioactive seed implants are placed permanently in the body and gradually deposit low levels of radiation over a period of months, HDR treatments deposit the dose in one treatment, after which the radioactive implant is removed from the patient.\nWith brachytherapy, also known as internal radiation therapy (RT), implants are surgically inserted in or near cancerous tissue to deliver a curative radiation dose directly to the tumor while limiting exposure for surrounding healthy tissue.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was zero mention of cost, which is unfortunate because presumably a single treatment would entail fewer costs than one that involved multiple procedures.", "answer": 0}, {"article": "The most effective screening tests currently available are based on a single biomarker called prostate specific antigen (PSA).\nScientists from the Cancer Research UK Cambridge Research Institute and the Institute of Cancer Research (ICR) said the protein, called microseminoprotein-beta or MSMB, is found at reduced levels in men diagnosed with the disease and are also lower in men with more aggressive forms of the cancer.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nThe results, published in the Public Library of Science (PLoS) ONE journal, showed that MSMB is found at significantly lower levels in the urine of men diagnosed with prostate cancer than those without the disease.\nProstate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Not applicable. There was no discussion of cost but since this test is investigational, information about pricing is not expected at this time.", "answer": 2}, {"article": "The human collagen used to develop the corneas was provided by biotechnology company FibroGen Inc.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\nA shortage of human donor tissue coupled with the threat of graft rejection from donor corneal transplants has driven the search for other ways of treating corneal damage.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nAlthough synthetic corneal replacements made from plastic are available, they have many drawbacks and are considered an option for only a small percentage of people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "One of the few ways this story fell down. Because donor corneas and plastic corneas are already on the market, at least a range of costs for those treatments and assessment of whether this would be a more or less expensive treatment would have been important information to include.", "answer": 0}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of this treatment. If it\u2019s not too early to send a news release touting a potential new treatment \u2014 even one that is in the earliest stages of development \u2014 it\u2019s not too early to address cost.\nChloroquine, the unnamed substance in the release, when used to treat malaria costs about $4 a tablet. The release doesn\u2019t say whether the drug would be given as an injection or tablet when used to stop early contractions.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study does not discuss the costs of any of the products mentioned.\u00a0 You could say, \u201cwell it doesn\u2019t amount to very much,\u201d we suppose.\u00a0 But 70% of the nearly 1,900 stories we\u2019ve reviewed fail to adequately discuss cost.\u00a0 It all adds up.\u00a0 We think it\u2019s an important item to include in any story about claims for health care interventions.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nIn study results to be presented next week at an annual meeting of cancer doctors, Hassenbusch's treatment \u2014 chemotherapy and a new vaccine \u2014 significantly prolonged survival of patients with glioblastoma, the most common and aggressive brain cancer.\nLate Houston surgeon's work may fight cancer that killed him Surgeon's trial study on cancer is hailed\n\nBrain tumor took his life, but his pioneering therapy now may give others hope\n\nThe death of Houston neurosurgeon Samuel Hassenbusch from the brain cancer he treated has been one of 2008's sadder stories.\nThe time of survival was also up significantly from the previous average of 14 months, said Sampson, who declined to reveal the exact number until he presents the data June 2 at the American Society of Clinical Oncology meeting in Chicago.\nBecause chemotherapy kills patients' white blood cells, it is usually considered incompatible with vaccines or, as they're also known, immunotherapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs associated with the two additions to current glioblastoma treatment strategies.\u00a0 How much does Temodar cost?\u00a0 How much does Avastin cost?\u00a0 Would insurance cover it?\u00a0 And why didn\u2019t the story at least include a projection of how much the vaccine would cost?\u00a0 These are increasingly important issues in cancer treatment. ", "answer": 0}, {"article": "The study had some limitations, the authors acknowledged.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood.\nHowever, the risk reduction was modest and may have been due to chance, the authors said, noting that more research is warranted, especially because statins can cause adverse side effects.\nFor example, only about 70 percent of people who were taking drugs to lower cholesterol were actually on statins at the study's start.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the story. At least a mention of the typical price for a statin would have been nice, given that they are lifelong drugs that add up to a considerable amount over time.", "answer": 0}, {"article": "Early lab-based tests of ICEC0942 were successful in targeting resistant breast cancers and indicated minimal side effects.\nProfessor Charles Coombes, from the Department of Surgery & Cancer, said: \"Treatment-resistant tumours represent a significant threat for patients, as once a cancer stops responding to treatments there is increasingly little clinicians can do.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nDr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nLicensing of the technology to Carrick Therapeutics was led by Cancer Research UK's Commercial Partnerships Team and Imperial Innovations, the Technology Transfer Office of Imperial, with support from Emory University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs here, either of initial research funded by the charity Cancer Research UK or of the potential cost to patients and payers if this drug ever goes on the market. While an exact price isn\u2019t something we\u2019d expect, the news release could have described the financial arrangement under which Carrick obtained the license to this therapy and mentioned the high costs that new cancer drugs typically command.", "answer": 0}, {"article": "The American Academy of Family Physicians has more about cholesterol-lowering drugs.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this drug is still experimental, the story should have told readers that some analysts predict that this sort of drug, known as a biologic, will cost at least $10,000 a year, compared to less $200 a year for a generic statin. Many observers predict that the extremely high cost of this new type of cholesterol-lowering treatment is likely to mean it would be used only when statins don\u2019t do the job, which means this line of research may never be relevant to most people.", "answer": 0}, {"article": "Nov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\nAnd nearly 19% of women and 14% of men age 45 and older have joint pain, stiffness, and other symptoms of knee osteoarthritis, according to a large 2007 study.\nIn people with osteoarthritis, the cartilage in a joint wears away in some areas.\nIn a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs. Presumably, since this drug is already sold\u00a0outside of the U.S., the story could have provided at least a ballpark estimate.", "answer": 0}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article omits mention of costs, an important public health issue.\u00a0A flu shot costs about $11, whereas FluMist costs about $20.\u00a0Even though equally effective in preventing the onset of flu, FluMist is less efficient than the flu shot.\u00a0", "answer": 0}, {"article": "Six months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nThree management options exist for floaters: patient education and observation; surgery; and the laser procedure, YAG vitreolysis, of which there are limited published studies on its effectiveness for treating floaters.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\nNo differences in adverse events between groups were identified.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost does not make an appearance.\u00a0 Given the ubiquity of these floaters, some reflection on cost is warranted, as laser treatment of both eyes can run into the thousands of dollars.", "answer": 0}, {"article": "Newswise \u2014 An international team led by researchers at the Austrian Institute of Molecular Biotechnology (IMBA) in Vienna and the University of Maryland School of Medicine in Baltimore discovered that genetically determined breast cancer can be largely prevented by blocking a bone gene.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nOne door for breast cancer prevention has now been opened and this can be tested very fast.\u201d\n\nThe present work is the result of international collaboration.\n\"Our finding is so exciting because there is already an approved drug against RANKL called \u201eDenosumab\u201d.\nAn already approved drug could be quickly available and would then be the first breast cancer prevention drug.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the treatment in question, denosumab, (trade name: Prolia) is not mentioned.", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The website reveals that the materials for this diet plan cost almost $50, including shipping. This price should have been included in the release.\nThe news release says that the diet is based on common food items, implying the food cost wouldn\u201dt be substantially more expensive than the dieter\u2019s regular diet. However, this impression cannot be checked without reviewing the plan materials.", "answer": 0}, {"article": "Johnson & Johnson and Bavarian Nordic have a vaccine in early-stage clinical tests.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nHowever, the antibody response was weaker than was found in a trial of the same Ebola vaccine in macaque monkeys, in which the animals were also found to be protected.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although accurate cost information is unlikely to be available at this point, cost will undoubtedly become an issue for successful deployment of any vaccine in one of the lowest-resource geographical areas in the world. We think that could have been mentioned, even at this early stage of development.", "answer": 0}, {"article": "Decipher was developed in partnership with the Mayo Clinic.\nThe Decipher results increased agreement in treatment recommendations between urologists and radiation oncologists, as the odds of a recommendation for adjuvant treatment by urologists vs radiation oncologists increased from 0.27 (95% CI, 0.17-0.44) to 0.46 (95% CI, 0.29-0.75) after results of the Decipher test were made available.\nIn addition, the 19% of the patients with the highest risk based on Decipher had a nearly 10-fold higher risk of distant metastases by 5 years.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There isn\u2019t a dollar sign in this release, and we could find no reliable figure for how much each Decipher test costs. (A New York Times article suggests similar genomic tests for prostate cancer cost roughly $3,000, if not more.) We\u2019ve reached out to the company\u2019s PR agency for an average per-test cost, but haven\u2019t received a response in time for the publication of this review.", "answer": 0}, {"article": "This data can be sent to a mobile phone.\n\"This gives us confidence that our new technology could potentially solve many mysteries of the gut and help the large portion of the population who have not been able to find a useful diagnosis or treatment for their symptoms,\" Kalantar-zadeh said.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\nStudy lead and capsule co-inventor Professor Kourosh Kalantar-zadeh said the results showed high sensitivity and signal-to-noise ratio in measuring the concentration of intestinal hydrogen, providing valuable information at the site of intestinal gas production.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes many bold claims about the accuracy and clinical utility of this device. And if it\u2019s not too early to make such claims,\u00a0it\u2019s not too early to give readers some idea of what this type of technology might cost.", "answer": 0}, {"article": "This trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nThe effect of yoga was measured by participants' responses to a series of questions that assess overall quality-of-life, cancer-related fatigue, and prevalence of sexual and erectile dysfunction and urinary incontinence.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not say how much the yoga classes cost, but that is not a fatal flaw, given that the classes are offered daily to millions of downward dog fans in health centers, living rooms and parks around the world. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Dr Ishwar Singh, a specialist in novel drug design and development from the University of Lincoln's School of Pharmacy, is leading the research team.\nImportantly, the two new simplified forms of teixobactin have also proven to have identical potency against superbugs as the natural form of teixobactin.\nWith this new knowledge, synthesised versions of teixobactin can be more easily developed, taking the process from up to 30 hours to just ten minutes for a single coupling step - a significant step towards turning teixobactin into a viable new drug.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\nEach amino acid sits at a specific place in teixobactin's structure, and the Lincoln team has now successfully replaced enduracididine - which holds position ten - with two alternative amino acids which are not positively charged.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "A key point of the release is that the researchers have developed a form of the teixobactin antibiotic that could be commercially viable. This statement implies that they made some rough calculations of the potential cost of manufacturing the drug. Even though it may be too early to guess at a market price (which depends on many factors other than actual manufacturing cost), it would have been nice to see some comparison to the production costs of other antibiotics.", "answer": 0}, {"article": "Those T-cells pick up melanoma cells\u2019 molecular scent and hunt them down before going off in search of tumor cells hiding elsewhere in the body.\n\u201cBut short of that, this might be like diabetes, where we can control it and people live normal lives.\u201d\n\nImlygic is based on a form of the herpes simplex virus that commonly causes cold sores.\n\u201cThe field is exploding, and this would be another arrow in the quiver that oncologists use.\u201d\n\nImlygic is part of a new group of immune-stimulating viral therapies that could change how cancer is treated and managed.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\n\u201cIt\u2019s a low-toxicity treatment, and for the right patients you see quite stunning results,\u201d said Robert Coffin, a virologist who created Imlygic at BioVex, the Woburn-based company he founded.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story nods to costs when it says the company will charge the patient $65,000 for a treatment. But they actually will be trying to charge insurance companies this amount.\u00a0\u00a0How widely will it be covered and when? How many courses of treatment will be necessary? We\u2019ll give the benefit of the doubt here but the story could have done more to clarify.", "answer": 1}, {"article": "Cassandra Quave, an Emory University scientist who studies how indigenous people use plants in healing practices, said researchers pulled apart the chemical ingredients of the berries and tested them in mice infected with these superbug strains.\nFighting bacteria with drugs designed to kill them helps fuel the problem of antibiotic resistance if stronger bacteria can survive and evolve to become \u201csuperbugs.\u201d\n\n\u201cBut instead of always setting a bomb off to kill an infection, there are situations where using an anti-virulence method may be just as effective, while also helping to restore balance to the health of the patient,\u201d said Quave.\n\u201cWe\u2019re trying to answer the question: Does this work against bacteria, and how does it work, and is it safe to use?\u201d\n\nThe Brazilian peppertree, a shrubby tree native to South America, is an invasive species throughout the southern United States, particularly in Florida, where it\u2019s sometimes called the Florida holly or broad-leaf peppertree, and is considered a noxious weed.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\nResearchers from Emory University and the University of Iowa found that extracts from the Brazilian peppertree, which traditional healers in the Amazon have used for hundreds of years to treat skin and soft-tissue infections, have the power to stop methicillin-resistant Staphylococcus aureus (MRSA) infections in mice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss costs. But if\u2019s not too early to state that the plant extracts \u201ccould help fight deadly superbug,\u201d then it\u2019s not too early to discuss costs of said extracts.\nLess savvy readers may think that treatment with this plant involves crushing up some\u00a0berries and putting them on your skin rash, a very inexpensive process. However, more thorough reporting would have said something about the need for\u00a0complex and expensive clinical trials, which would drive up the price of any final drug.", "answer": 0}, {"article": "Participants had an average starting cholesterol of about 230 milligrams per deciliter of blood.\n\u201cIn a sense it\u2019s a necessary micronutrient and we need it, but we might be (in) a situation where we have enough \u2014 we might even have too much.\u201d\n\nSelenium is found in meat, bread, and some nuts.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nLast week, a review of prior studies suggested that selenium probably doesn\u2019t help prevent cancer, but might be linked to an increased diabetes risk at high doses (see Reuters Health story of May 11, 2011.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says a month\u2019s supply of selenium costs about $2. But many people may be getting selenium in\u00a0their daily multivitamin,\u00a0and may not\u00a0need to buy\u00a0more.", "answer": 1}, {"article": "He was not part of the study.\nIt is a real testament to how far we\u2019ve come in the treatment of patients with suspected coronary disease,\" said Dr. Steven Nissen, department chair of cardiovascular medicine at the Cleveland Clinic.\nIn both test groups, only about 3 percent of the people had heart attacks, suffered \"major\" complications, needed hospitalization for chest pain or died during two years of tracking, researchers found.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\nCTAs, the study found, result in fewer instances of patients with suspected heart issues undergoing unneeded catheterization procedures \u2014 only to later learn they had no artery problems.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs do not surface in this story.\u00a0 Since one would assume that a CT scan would be considerably more expensive than traditional stress tests, this seems to be an important omission. \u00a0A bit of digging would have made apparent another type of cost between the two kinds of tests: A 2011 observational comparison of these two modalities among Medicare patients (published in the Journal of the American Medical Association) found that heart-related health-care spending was substantially higher among patients who received coronary CT angiography compared with traditional stress testing.", "answer": 0}, {"article": "The proprietary formulations support long product patent lives.\n\"Joint pain associated with normal aging and over-exercising is extremely common,\" said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Biopharmaceutical.\n\"We demonstrated superior treatment outcomes with our acne product in a head-to-head clinical trial against the market-leader, and now we've done the same with OsteoRx\u2122.\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\n\"Research funded by U.S. National Academy of Medicine shows that 70 million adults suffer from joint pain, making it the most prevalent source of pain.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not contain any cost information of interest to people suffering from joint pain. The chief financial officer, Frank Parise, mentions money only in relation to his company\u2019s fundraising efforts:\n\u201cWe are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\u201d\nA bottle of 120 tablets of Osteo-Rx sells for $19.99 on the company\u2019s website.", "answer": 0}, {"article": "WEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nThe study included 15 healthy participants who took part in six sessions.\nChantix costs roughly $3 per pill.\nRecently, the drug was linked to a small but significant risk of heart attack and stroke among people with pre-existing heart disease.\n\"We need a lot more options in terms of medicines to help curb drinking,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that Chantix costs about $3 per pill.", "answer": 1}, {"article": "\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nMarch 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story merely quoted one hepatitis C specialist saying, \u201cThis is a very expensive drug, and I would imagine some insurance companies would not pay for it.\u201d\u00a0 But why not give specific cost estimates?\u00a0 Even a framework for what \u201cvery expensive\u201d\u00a0means.\nAs we wrote on our blog (a piece that commented on how inconsistently some journalists deal with drug cost information), \u201cIt\u2019s probably safe to say that the cost will be in the thousands per month. The costs of existing treatment is about $70,000 for 48 weeks of treatment.\u201d\nYou better believe that any company that expects drug approval within a month knows what its pricing will be.\nAlso, the story could have mentioned the specific cost of erythropoietin, since the trials found that many participants require it to combat the anemia that often results from the treatment.\n", "answer": 0}, {"article": "\u201cIf you\u2019re a busy surgeon, you have a volume to maintain,\u201d Bollinger says, \u201cand it\u2019s hard to go from doing three a day to one during the learning period.\u201d\n\nChristopher Chen, a surgeon who uses the anterior approach at Alta Bates Summit, adds that most doctors \u201cstill use the posterior approach because it\u2019s the one they were taught.\u201d And, he says, the majority of younger surgeons learn the older approach because established surgeons are typically the ones who staff the residency training programs and demonstrate the method they know best.\nOthers say it took about 50 cases.\nBesides his study, there have only been a few others.\nUnger performed both surgeries.\nAnd this creates economic issues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs.", "answer": 0}, {"article": "Source: Stewart RAH, Wallentin L, Benatar J, et al.\nThis classic diet does not exclude a dinnertime glass of wine, however, sugary drinks, fried food, and sweets are not on the menu.\nParticipants eating a Mediterranean diet showed a lower risk of heart attack and stroke, the researchers discovered; yet, eating healthy food appeared to be more important than avoiding unhealthy foods identified as typical of a so-called Western diet, such as French fries, fatty red meats, and, yes, even cake.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nLook at it this way: if 100 people ate the highest proportion of Mediterranean foods and 100 ate the least, there would be three fewer heart attacks, strokes, or deaths among those who ate more foods from the Mediterranean diet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not talk about costs. Eating fresh fruits and vegetables\u2013and fresh seafood, especially\u2013is associated with higher costs in many countries.", "answer": 0}, {"article": "Arterburn and Simon's coauthors are GHRI Senior Investigator Denise M. Boudreau, PhD, Research Project Management Director Emily O. Westbrook , Programmer Analyst Mary Kay Theis, and Andy Bogart; Tamar Sofer, PhD, a biostatistician at the UW School of Public Health and post-doctoral research fellow at Harvard University; and Sebastien Haneuse, PhD, an associate professor of biostatistics at the Harvard T.H.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\n\"We found that bupropion is the only antidepressant that tends to be linked to weight loss over two years,\" Dr. Arterburn said.\n\"So it makes sense for doctors and patients to choose antidepressants on the basis of their side effects, costs, and patients' preferences--and, now, on whether patients are overweight or obese.\"\nAfter two years, nonsmokers lost an average of 2.4 pounds on bupropion--compared with gaining an average of 4.6 pounds on fluoxetine (Prozac).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "A quote from one of the study\u2019s co-authors\u00a0mentions \u201ccosts\u201d and \u201cpatient preferences\u201d as sensible considerations in first choice of antidepressant therapy, but the release offers no information about the comparative costs of the drugs that were studied or even the estimated average annual cost of such therapy. The release would have been strengthened by such data.", "answer": 0}, {"article": "In this new study, researchers found an increased amount of the protein CCL11 in patients previously diagnosed with CTE.\nWhile it is hoped that this will be one avenue to help detect the disease in the living, McKee believes that it will just be one part of a larger process.\nHowever, there is a potential bias in that study, as relatives of these players may have submitted their brains for diagnosis due to clinical symptoms noticed while the players were alive.\n\"This is an inflammatory marker that may be non-specific and may not be diagnostic of CTE,\" he said.\nIn addition, the number of reported concussions tend to be an unreliable indicator in general, because they are usually self reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The relevant research finding is so far removed from a clinical diagnostic tool \u2014 and the story makes that clear \u2014 that it\u2019s tough to expect much from the story in regard to cost.", "answer": 2}, {"article": "Funding for the study was provided by F. Hoffmann-La Roche and Biogen Idec.\nTUESDAY, Nov. 1, 2011 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.\nThe result: at week 24, all of the patients receiving either dose of ocrelizumab fared better in terms of lesion count than either the placebo or standard treatment groups.\nBut initial indications suggest that the new antibody drug, called ocrelizumab, successfully targets these renegade cells with hopeful results: a significant reduction in disease-related inflammatory brain lesions.\nThe patients were divided into four groups, treated with: a low dose of ocrelizumab (600 milligrams); a high dose of ocrelizumab (2,000 mg); a well-known MS inflammation treatment known as \"intramuscular interferon beta-1a\"; or a sugar pill (placebo).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It may have been understandable that costs wouldn\u2019t be discussed at this early stage of research.\u00a0 However, when the Mayo expert weighed in at the end about a comparable drug, this provided the perfect and easy opportunity for the story to include ballpark costs of drugs in this category. And a ballpark cost of the comparable drug is somewhere around $20,000.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of Lucentis, which is substantial, up to $2000 per injection. Since the injections need to be\u00a0given monthly for an indefinite amount of time, cost is a huge issue and has the potential to be a signficant barrier to obtaining the drug. The story does mention that Avastin is a much cheaper alternative, but this is not enough information on the cost of treatment.", "answer": 0}, {"article": "The latest trial success follows Roche\u2019s announcement last week about a separate study in which Tecentriq mixed with chemotherapies carboplatin and Abraxane boosted progression-free survival, compared with chemotherapy alone, in first-line treatment of patients with advanced squamous non-small cell lung cancer.\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\n\u201cWe are pleased the IMpower150 study demonstrated a clinically meaningful survival benefit for people receiving their initial treatment for this type of advanced lung cancer,\u201d said Sandra Horning, Roche\u2019s chief medical officer.\n\u201cFacing biosimilar competition... we see Tecentriq sales coming timely to support Roche\u2019s profitability going forward.\u201d\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not discussion of costs. Some estimates have put the monthly cost of Tecentriq alone at $12,500. Adding the three other drugs brings it to about", "answer": 0}, {"article": "\u201cIf used perfectly, how much HIV protection could there be?\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\nIn the ring, the drug is used as \u201cpre-exposure prophylaxis,\u201d or PrEP, slowly leaching out in the vagina and preventing the virus from taking hold in nearby cells.\nMuch like the contraceptive NuvaRing, the dapivirine ring should be kept in every day and replaced once a month for maximum effectiveness.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story would have benefited by spending even one sentence on cost, since HIV is especially prevalent in countries with few resources. Will the ring be cheaper or more expensive than the pill? If the ring must be replaced monthly, what does that mean for the cost, and will people be more likely to fail to buy the replacements because of cost?\nThere was a lost opportunity here to compare the cost of the vaginal ring versus Truvada, the currently available option for pre-exposure prophylaxis.", "answer": 0}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there was no specific price mentioned, the medication was described as \u2018a cheap generic\u2019. \u00a0Further \u2013 there was discussion about a goal being to see it remain inexpensive. \u00a0That said \u2013 it still would have been helpful to include the price since it is a currently available product.", "answer": 1}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We give the story high marks here for at least addressing the costs at a couple of centers. It says, \u201cAt Memorial Sloan-Kettering, treatment for inpatients is available at no extra charge; outpatients pay $90 to $110 a session. At Norris Cotton, trained volunteers administer treatments free of charge\u2014often while patients are at the hospital receiving intravenous chemotherapy treatments. Insurance typically doesn\u2019t pay for Reiki.\u201d That last sentence is crucial. The reporter might have asked an insurance company for what other sorts of pain relief or anxiety relief treatments insurance does cover and why Reiki didn\u2019t meet the same bar.", "answer": 1}, {"article": "The ChemMedChem study is available at http://dx.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nThe study is funded by the National Institutes of Health and Georgia State's Center for Biotechnology and Drug Design and Molecular Basis of Diseases Program.\nThe RB analogs inhibited the ATPase activities of two SecA isoforms identified in S. aureus, SaSecA1 and SaSecA2, as well as the SaSecA1-dependent protein-conducting channel.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though it\u2019s \u201cearly days\u201d for this strategy we\u2019d like to see some mention of costs, if not for the proposed therapy then a related one, or the societal costs of combating MRSA. The release didn\u2019t shy away from forecasting potential treatment benefits based on this early research \u2014 so we\u2019d like to see the same approach applied to costs.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article mentions that the cost of cupping \u201cvaries widely, from $40 to $100 or more for a half-hour session.\u201d", "answer": 1}, {"article": "\"If this does very well, other drug companies will say, 'I want a piece of this action.'\"\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nWith a patch, you \"put [it] on and forget about it, rather than having to remember to take pills,\" Dombrowski said.\nAnd, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. At CVS.com, a box of five patches costs $7.99. This isn\u2019t high for short-term use, but if you are a chronic pain sufferer (a category not addressed in this story) you might run through a box or two per day. Regardless, costs should have been mentioned.", "answer": 0}, {"article": "\"This is the largest clinical study done in the world on conventional electrodes and will have major implications for doctors and their patients who need their long-term hearing restored,\" said the study's lead investigator, George Wanna, MD, Site Chair, Department of Otolaryngology-Head and Neck Surgery at New York Eye and Ear Infirmary of Mount Sinai (NYEE) and Mount Sinai Beth Israel; Chief, Division of Otology-Neurotology and Director of the Center for Hearing and Balance and Ear Institute at Mount Sinai Health System.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\nThe study found that the actual brand of the electrode did not make a difference; the presence or absence of wire was the only distinguishing factor.\nThey reported that patients who had the round window approach had a much better chance of keeping their residual hearing in the long term.\n\"This is an exciting time in this field, and the advancement in hearing technology and continued improvements in techniques and outcomes will benefit patients and their families.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Surgery can be costly itself as well as all the related expenses that follow from it so knowing the overall costs is very important. No costs are mentioned.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - There may be a seed of truth amidst the many health claims for pomegranate juice, researchers from Israel said Thursday, at least for kidney patients on dialysis.\n\u201cWe found significant reductions in hospitalization due to infections, with more than 40 percent reduction in the first hospitalization and 80 percent in the second,\u201d said Kristal.\nA 16-oz bottle of POM Wonderful sells for about $4.\n\u201cThe effects of juice were compared to a placebo, not to any other kind of juice that might have exactly the same effect.\u201d\n\n\u201cThe pomegranate people are spending millions to prove what I could have told them in the first place,\u201d she added.\nThe findings were presented at the American Society of Nephrology\u2019s meeting in Denver \u2014 aka Renal Week \u2014 and have not yet been vetted by independent experts.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included a price estimate for one brand of pomegranate juice \u2013 about $4 for a 16 oz. bottle.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Statins are described as \u201ccheap,\u201d but actual figures are not provided.\u00a0The price of statins varies considerably and some are not cheap. ", "answer": 0}, {"article": "Feb. 1, 2012 -- A new drug appears to be effective for shrinking uterine fibroids and controlling the heavy menstrual bleeding they often cause, according to new research from Europe.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs.\u00a0 If the drug is awaiting marketing approval in Europe, some estimate could have been obtained.\u00a0 And, since the drug has the active chemical of the Ella contraceptive drug \u2013 only in smaller doses \u2013 at least the cost of Ella could have been cited.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\n\"There are patients who would like to get better in a 'fix me' approach\" and surgery may be best for them, said Elena Losina, another study leader from Brigham and Women's Hospital.\nAbout one-third of people over 50 have a tear in one, and arthritis makes this more likely.\nYet they ended up the same as those who got surgery right away, as well as the rest of the physical therapy group who stuck with it and averted an operation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included researcher estimates: \u201cSurgery costs about $5,000, compared with $1,000 to $2,000 for a typical course of physical therapy.\u201d", "answer": 1}, {"article": "\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems.\n\u201cTransplants are working for people with other gastrointestinal problems,\u201d lead study author Ann Gregory, a microbiology graduate student at The Ohio state University, said in a news release.\nThe children ranged from 7 to 16 years old.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The short story does not discuss the costs of the experimental fecal transplant. In some patients, the donor stool material is introduced using a colonoscopy or other mechanical procedure, which can cost $2,000. This story does not explain how the stool was given to the children, so the costs are further confused by that.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Applause all around for this fast and efficient cost comparison. \u201cSmaller veins can often be treated with sclerotherapy, which involves injecting a chemical solution into the vein to destroy it, and costs $250 to $500 per treatment. For larger veins, doctors may recommend endovascular procedures, which range in price from $2,500 to $3,000. These involve threading a catheter into the vein and directing a heat source such as a laser or radio-frequency device into the vein to incinerate it.\u201d There was no price put on the \u201cstripping\u201d option of pulling out the veins entirely, but we still give the story a satisfactory score here.", "answer": 1}, {"article": "He will run Islexa with Michael Bennet from CGT and Anne Lewendon from Aberdeen University.\nIt is a lifelong condition that occurs when the pancreas does not produce any insulin, while type 2 diabetes \u2013 far more common, especially as obesity rises around the world \u2013 is a condition where the pancreas does not produce enough insulin or the body\u2019s cells do not react to it.\nHaving a hugely expanded supply of lab-grown islets will enable us to significantly extend this established clinical treatment.\u201d\n\nCGT was set up in 2012 and is based on the 12th floor of Guy\u2019s hospital in London.\nThe promising early results have given them the confidence to form a wider consortium with the Scottish Islet Transplant Programme, the University of Edinburgh and the Scottish National Blood Transfusion Service.\nJohn Casey, consultant transplant surgeon at the Royal Infirmary of Edinburgh and lead clinician for the islet transplantation programme in Scotland, said: \u201cIslet transplantation can transform the lives of patients with type 1 diabetes, and in some cases can result in long-term freedom from insulin injections with excellent glucose control.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the premise of the piece is about pre-clinical efforts, it\u2019s too early to discuss specific costs, so we\u2019ll rate this N/A. However, the article could have been enhanced by noting the cost of other cell-based therapies, islet cell transplants, insulin treatment and the amount of investment being sought.", "answer": 2}, {"article": "+ Total fat loss was much greater when participants combined diet plus walking (about 16 pounds) and diet plus weight training (about 17 pounds).\nThe findings, \"Effect of Exercise Type During Intentional Weight Loss on Body Composition in Older Adults with Obesity,\" appear in the November issue of the journal Obesity.\nPut another way, the percentage of weight loss coming from muscle mass was 20% in the weight loss plus walking group, 16% in the weight loss alone group, and 10% in the weight loss plus weight training group.\nThese results may be even more important for older adults who gain and lose weight with frequency, because seniors typically don't regain muscle - they regain fat mass - which is \"all the more reason for older adults to try and preserve muscle mass during weight loss,\" Beavers said.\nThe participants were randomly assigned to one of three groups: a weight-loss-only group, who followed a calorie-restricted diet with no exercise regimen; a weight loss plus cardio (i.e., walking) group; and a weight loss plus weight-training group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not make any mention of costs. Although weight training isn\u2019t like a medication with a certain price, the release could have added information about the cost of local weight training classes at senior centers, YMCA classes, etc. There are also many articles online that discuss tips on weight training for seniors for free.", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost. It\u2019s a missed opportunity to discuss the costs associated with whole brain radiation and the savings that could be had by avoiding it.\nBut since the story is focused entirely on not pursuing a course of action \u2014 and there\u2019s no additional treatment specified in place of whole-brain radiation that would involve costs \u2014 we won\u2019t dock points for this omission. We\u2019ll rule it Not Applicable.", "answer": 2}, {"article": "Previous studies have examined how exercise, brain games and an active social life may boost cognitive capacity and possibly stem cognitive decline associated with aging.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe study was too short to reveal any long-term effects so the researchers plan to follow the participants as they age to provide additional evidence of whether college studies may reduce the risk or delay the onset of dementia.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe control group was significantly older than the college studies group, but there were no significant differences in baseline cognitive capacity scores, the study noted.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned in the article and we think that they should have been. Although costs for tuition in Australia are fixed,\u00a0the lowest tier is approximately $5,000 US dollars annually. That is a considerable sum for elderly retirees.", "answer": 0}, {"article": "Now, a groundbreaking study suggests that not all C-sections are equally risky.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nThe step is just one of a cascade of physiological changes that take place in mother and baby during the labor process, including surges in stress hormones and reproductive hormones like oxytocin that may help the fetus adapt during labor, preserve blood flow to the organs, and keep the baby alert and prepared for breast-feeding.\nSurprisingly, the data showed more health problems among babies born by planned C-section than among those delivered by emergency C-section or vaginal birth, even though the planned surgery is done under more controlled conditions.\nDr. Mairead Black, the University of Aberdeen obstetrician who led the study, said that as cesarean births had increased in Scotland and worldwide, the researchers wondered what, if anything, children born by C-section \u201care missing out on.\u201d\n\n\u201cOur thinking was: If a baby is born naturally, it comes into contact with bacteria from the mother, which might help with immune system development,\u201d Dr. Black said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not include any discussion of costs. We believe that information could have added a further dimension to the topic.\nCesarean delivery is estimated to cost 50% more than vaginal delivery, in an analysis from 2013 of US births. [http://www.medscape.com/viewarticle/803426_2]\nAt a time when health-care costs are important drivers of policy, this is not a small factor. Health insurers, including the government\u2019s Medicaid program, could adjust policies to discourage elective C-sections.\nThe story could have added this dimension to the discussion of impact.\u00a0Unwarranted variation in procedures of any kind that carry risk and may not always improve care should raise questions.", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n\"Our findings show that women who are more vulnerable benefit from the care of a midwife, likely because they receive more time, counselling and education on how to care for themselves,\" said the study's lead author Daphne McRae, a post-doctoral research fellow at the UBC school of population and public health who conducted the study while she was a PhD student at the University of Saskatchewan.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\nThe study was co-authored by Patricia Janssen, Saraswathi Vedam, Maureen Mayhew at the University of British Columbia, and Deborah Mpofu and Ulrich Teucher at the University of Saskatchewan.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how much it costs to use midwives in Canada or who pays for their services. The release did note that all of the 57,872 women included in the study had received medical insurance premium assistance.\nIn general, midwifery care is less costly than that provided by specialists in obstetrics and gynecology and general practitioners.", "answer": 0}, {"article": "But another experiment got the researchers more excited.\nWASHINGTON (Reuters) - Researchers have identified a group of genes that are especially active in lung cancer patients \u2014 even in healthy tissue \u2014 and said they may be used to predict which smokers will eventually develop lung cancer.\nIt is sort of a window into the lung.\u201d\n\nCigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nThe main gene is called PI3K and it affects a pathway of other genes, Bild, Avrum Spira of Boston University and colleagues reported.\nAnd it can be found in the windpipes of smokers, meaning they do not need more dangerous and uncomfortable lung tests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "     \n This test is not yet available, so a discussion of its cost is perhaps not warranted. The story states that myo-inositol is \u201ccheap,\u201d but that\u2019s a relative term.\u00a0 Nonetheless, because of the early stage of the research, we\u2019ll rule this not applicable. ", "answer": 2}, {"article": "(Reuters) - Tiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial.\nOramed uses a protective coating and a high-enough dose of insulin so that most of it can be destroyed and still deliver a clinically beneficial amount of the hormone.\nA safe and effective oral insulin, if approved, is expected to become a multibillion-dollar product.\nThey were dosed before bed time and had their overnight glucose levels continuously monitored.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A comparison of cost to currently available long-acting insulin would have been informative, but the report is on a trial for safety and efficacy, so this is preliminary.", "answer": 2}, {"article": "The F.D.A.\nTimothy Anderson, pharmaceutical analyst at Sanford C. Bernstein & Company, said in a recent note that Entresto was \u201clikely to become a mega-brand over time\u201d but that the initial uptake was \u201clikely to be on the slower side given the entrenched nature of off-patent ACE inhibitors.\u201d He said it was highly unusual that there were no major competitors for Entresto on the way, giving it a \u201clong runway.\u201d\n\nIn a clinical trial with more than 8,400 participants, patients were randomly assigned to take either Entresto or enalapril, an ACE inhibitor.\nThe other ingredient, sacubitril, inhibits an enzyme known as neprilysin, a new mechanism of action for a heart failure drug.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does an excellent job here. Not only does it provide the predicted daily and annual cost of the drug ($12.50 and $4,500, respectively), but explains why some health plans may balk at the price (given that competing drugs are significantly less expensive).", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nCHICAGO -- Among women with dense breast tissue, for whom traditional mammograms are less effective at detecting cancer, who request additional screening after a negative mammogram, abbreviated breast MRI (AB-MR) may be a valuable cancer detection tool.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\nIn a study of 195 asymptomatic women with dense breast tissue who had a negative mammogram within the previous 11 months, AB-MR detected five additional cancers after a negative screening mammography, according to preliminary findings from a Penn Medicine team presented this week at the Radiological Society of North America meeting in Chicago.\nAmerican Cancer Society guidelines currently recommend a full breast MRI, not an AB-MR, in women who, based on family history of breast or ovarian cancer and/or previous treatment for Hodgkin disease, have a 20 to 25 percent or greater lifetime risk of breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs of the abbreviated breast MRI and it was unclear if this type of procedure is commonly covered by insurance for asymptomatic women.\nThe release also refers to women who \u201c\u2026request additional screening after a negative mammogram\u2026.\u201d \u00a0Requesting additional costly screening adds to overall healthcare costs and may also lead to over-diagnosis.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the peer-reviewed study on which this story seems to have been based on makes the point that text messages could offer a low-cost strategy for reducing the chances of subsequent heart attacks, the story does not reflect on cost.", "answer": 0}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nThe findings are the result of a combination of experimental studies, computational studies and human studies, Rimer said.\nThey often recommend taking citrate (CA), in the form of potassium citrate, a supplement that can slow crystal growth, but some people are unable to tolerate the side effects.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release could have mentioned the price of the supplement used by researchers. The product is sold as a weight loss aid. The manufacturer\u2019s recommended dose of two capsules taken three times a day costs about $17 per month.", "answer": 0}, {"article": "Infection rates dropped by 90% in patients who consistently used PrEP.\n\"We now have findings from two studies showing that PrEP can work for heterosexuals, the population hardest hit by HIV worldwide,\" Fenton said.\n\"Developing and deploying proven HIV prevention methods \u2013 including PrEP, microbicides, vaginal gels, clean needles, medical male circumcision, early treatment, counseling, testing, condoms and suppressive therapy for pregnant women will all be key to slowing the global epidemic,\" he said.\nAn earlier PrEP trial, the iPrEx study, looked at treatment in men who have sex with men.\nThe news comes at the same time a second study looking at PrEP in heterosexual couples in Kenya and Uganda also found significant reductions in infection rates.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although these drugs are available cheaply in developing countries\u00a0(less than $1 per pill according to some estimates), even these modest costs can put\u00a0them out of reach in the poorest countries where they are most needed. In the United States, the cost of daily treatment with Truvada (one of the medications studied which contains a\u00a0combination of\u00a0emtricitabine and tenofovir)\u00a0can add up to some $13,000 annually. The story should have referenced cost as one of the obstacles to any large-scale new prevention effort", "answer": 0}, {"article": "STOCKHOLM (Reuters) - Giving patients with a history of heart attacks a margarine enriched with omega-3 oils in addition to standard drugs appears to make no difference to their chances of having a repeat attack.\n\u201cThis may also be why the rate of major cardiovascular events during follow-up was no lower in the fatty acid groups than in the placebo group.\u201d\n\nAll the men and women in the Dutch study were aged between 60 and 80 and had suffered a heart attack roughly four years previously.\nFish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\n\u201cIt will be viewed as a largely negative study and people who are enthusiasts for omega fatty acids will continue to be enthusiasts and people who are skeptics will continue to be skeptics,\u201d said Scott Wright of the Mayo Clinic in the United States, who was not involved in the research.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable; the product in question is not commercially available. But why didn\u2019t the story give us some range for comparison by giving us the price of Unilever\u2019s existing omega-3 margarine brands? ", "answer": 2}, {"article": "Unlike traditional stents that remain in place after implantation, Absorb is designed to disappear fully within three years of the procedure.\n\u201cNo metal may also reduce the potential of future blockages that occur with permanent metallic stents.\u201d\n\nData released in October concluded Absorb was comparable to Abbott\u2019s own Xience drug-coated metal stent in safety and effectiveness but showed a higher risk of heart attacks and blood clots.\n\u201cNo metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities,\u201d said Gregg Stone of Columbia University Medical Center, who led clinical trials for Absorb.\nThe stent, called Absorb, is made of a plastic similar to dissolving sutures and offers patients an alternative to metal stents currently used to prop open arteries cleared of blockages.\nThe approach holds particular promise for patients whose coronary artery disease could require multiple implants over the course of several decades, said Mitchell Krucoff, a professor at Duke University Medical Center who has advised Abbott on Absorb.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A reader would be hard-pressed to determine the cost of this new stent.\u00a0 The only cost information provided sits in the last paragraph of the story, where it notes that the dissolvable stent will apparently cost more than Abbott Lab\u2019s drug-coated metal stent, marketed under the name Xience. (See our review of the AP story to see how much more in-depth they covered costs.)", "answer": 0}, {"article": "For more information, please visit: www.medimetriks.com\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\n\"The results of the Phase 2 study suggest that MM36 represents a potentially safe, effective and well-tolerated non-steroidal treatment for mild-to-moderate atopic dermatitis,\" said Linda Stein Gold, MD, director of clinical research, Department of Dermatology at Henry Ford Hospital and co-author of the article.\n\"We believe these Phase 2 results demonstrate compelling evidence of MM36's capacity to be a leading topical PDE4 inhibitor and are aggressively developing MM36 for atopic dermatitis in the US.\nThe randomized, double-blind, vehicle-controlled study in 121 patients showed that MM36 demonstrates a statistically significant effect on the primary endpoints versus vehicle as measured by improvement in IGA score (Investigators Global Assessment) and percentage change in EASI score (Eczema Area and Severity Index).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release discloses the total 2015 sales of Otsuka, the drug maker, but offers not a penny\u2019s worth of information about the costs of current therapies or whether the new product would be more or less expensive. Although there is no pricing for an investigational new drug still in clinical trials and not yet FDA-approved for sale, it would be helpful to consumers to know if part of the novelty of the product will be its availability and cost.", "answer": 0}, {"article": "At the top of the list?\n\"The good news is that we now understand which foods we need to target to prevent Americans from dying prematurely from cardiometabolic diseases,\" says lead study author Renata Micha, a public health nutritionist and epidemiologist at the Friedman School at Tufts University.\n\"Our research suggests that nearly half of the risk can be reduced [by] eating a healthy diet,\" Mozaffarian says.\n\"This is a remarkable burden, nearly 1,000 deaths each day\" linked to dietary habits, says senior study author Dariush Mozaffarian, dean of the Friedman School at Tufts.\nHe says the bigger point is this: \"Whether poor diet is causing 1,000 cardiovascular and diabetes deaths per day, or 500, it remains among the leading causes of preventable suffering.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story addresses cost at both the individual and societal level, noting that poor diets are \u201clinked to billions of dollars in healthcare spending. For instance, diabetes costs the U.S. $245 billion a year. In the U.S., a women with diabetes incurs, on average, about $283,000 in lifetime health care costs. (Many cost studies don\u2019t separate Type 1 and Type 2 diabetes.).\u201d That\u2019s helpful context..\u00a0", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offers clear information on the cost of the genetic tests by saying,\u201dThe various genomics tests, which have a list price between $3,800 and $5,000, generally are covered by Medicare and some private insurers.\u201d\u00a0 To its credit, it mentions the costs fairly early in the story.", "answer": 1}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\nIt now needs to be taken over by some diagnostic corporation before it can launch into something for widespread use.\u201d\n\nWhat needs to be determined is \u201cwhat the sensitivity and specificity would be in a screening population of 100,000 people,\u201d said Dr. Brian Wolpin, of the Dana Farber Cancer Institute.\n\u201cIt kills people and it kills them quickly.\u201d\n\nA screening test could have a huge effect, said Dr. Timothy Donahue, an associate professor of surgery and molecular and medical pharmacology and chief of pancreas and gastrointestinal surgery at the University of California, Los Angeles.\n\u201cUsing this test we were 100 percent accurate at identifying all cancer patients.\u201d\n\nIn 2015 48,960 Americans will be diagnosed with pancreatic cancer, according to estimates by the National Cancer Institute.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this story. No costs for the test. No costs for the downstream treatments and surgeries. If a researcher is going to be quoted as saying a clinical test could be on the market in a year, there should be some mention of costs.", "answer": 0}, {"article": "\"Might this be a good application to help that person recover or prevent this decay from advancing?\n\"An alternative could simply be brushing better in a certain location and not drinking Coca-Cola all day long,\" says Mark Wolff, a professor of dentistry at New York University who specializes in cariology, or the study of tooth decay.\nSo, we are actually waiting until the lesion grows bigger and bigger and becomes deep enough and worthy to be drilled out and be filled,\" Phark says.\n\"When you take a sugar cube and you put it into your coffee, you will see that it is soaked up with the coffee,\" Paris says.\n\"But if you put your sugar cube into honey, you can imagine that it will take ages to soak into the sugar cube.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nOddly, while the story says this product is cheaper than drilling and filling a cavity\u2026 and it includes a comment from an expert saying this product is more expensive than other approaches to preventing cavities, it does not say how much this product costs.", "answer": 0}, {"article": "About Camurus\n\nCamurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.\n\"We were pleased to be involved in the development of CAM2038 and are hopeful that it will serve as another safe and effective therapeutic option for patients with opioid use disorder.\nThe ability of CAM2038 to produce a long-lasting and robust blockade of hydromorphone-induced Drug Liking is especially encouraging,\" said Sandra D. Comer, Ph.D, Professor of Neurobiology, Columbia University.\n\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence.\n\"The study results show that CAM2038 provides rapid and extended blockade of opioid effects,\" said Fredrik Tiberg, President and CEO of Camurus.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the projected cost of the treatment and it is likely to be significant. In addition to the cost of the medication, if it requires a health care professional to administer it \u2014 that will add to the cost. It is also not clear how long the treatment might last. If the treatment is successful, the cost/benefit may be fine, but who pays for the treatment will be an issue.", "answer": 0}, {"article": "The panel that issues those guidelines is currently reviewing its recommendations, he said.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe five-year \"disease-free\" survival rate was 83.9 percent in those who did not have the more aggressive surgery compared with 82.2 in those who did, the researchers reported.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn the new study, Armando Giuliano of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, Calif., and colleagues analyzed data collected from 445 women who had their nodes removed and 446 who did not, along with radiation and chemotherapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.\u00a0 The article does refer to an editorial that accompanied the paper.\u00a0 The editorial observed that women would be spared \u201cunnecessary surgery.\u201d\u00a0 Less surgery should result in lower costs for the patient.", "answer": 0}, {"article": "For their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills.\nThe findings, he added, \u201craise other questions that need to be followed up (including), what\u2019s going on in the elderly?\u201d\n\nBoth types of Effexor, or venlafaxine, also seemed to help adults with mild to severe depression, with slightly more patients responding to the immediate-release dose.\n\u201cClearly the efficacy of antidepressants is age-dependent, (and) largest, most interestingly, in youth, which I don\u2019t think would be the mainstream view in psychiatry,\u201d Gibbons told Reuters Health.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\nOne recent study suggested that up to a fifth of patients on the antidepressant Cymbalta (duloxetine) might actually benefit more from placebo pills (see Reuters Health story of December 9, 2011.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of antidepressants weren\u2019t discussed, but perhaps that is understandable in this kind of broad overview of a meta-analysis. Fluoxetine (prozac) and venalfaxine (effexor) are now both generic. \u00a0So costs are pretty low.", "answer": 2}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\nProfessor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: \"Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment.\"\nA research team from the University of Adelaide and Griffith University have been studying the interactions between the toxin and an abnormal glycan (sugar) expressed on the surface of human cancer cells and released into the blood.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned and, according to the published study, the high costs of the sensors used in detecting the cancer have proven to be a major drawback.", "answer": 0}, {"article": "The report, he added, might quell the craze.\nAfter reviewing the data, the committee concluded that the evidence for the benefits of high levels of vitamin D was \u201cinconsistent and/or conflicting and did not demonstrate causality.\u201d\n\nEvidence also suggests that high levels of vitamin D can increase the risks for fractures and the overall death rate and can raise the risk for other diseases.\nBut Andrew Shao, an executive vice president at the Council for Responsible Nutrition, a trade group, said the panel was being overly cautious, especially in its recommendations about vitamin D. He said there was no convincing evidence that people were being harmed by taking supplements, and he said higher levels of vitamin D, in particular, could be beneficial.\nWhile those studies are not conclusive, any risk looms large when there is no demonstrable benefit.\nIn general, most people are not getting enough vitamin D from their diets, but they have enough of the vitamin in their blood, probably because they are also making it naturally after being out in the sun and storing it in their bodies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Most people know roughly what a bottle of vitamin D supplements might cost them, so the lack of information on cost is not a significant gap. We appreciate that the story provided\u00a0data showing the large and growing amount our society is spending on vitamin D\u00a0supplements ($430 million in 2009), with apparently little health benefit to show for it.", "answer": 1}, {"article": "Despite all the headlines about swine flu, which has become the main influenza strain circulating in the world, doctors do expect some garden-variety flu to hit this fall too \u2013 the kind that every year kills 36,000 Americans and hospitalizes 200,000.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nHealth officials say influenza is circulating unusually early this year with cases in every state \u2013 and nearly all the infections are swine flu.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nBut different manufacturers make different formulations of the vaccine, so more evidence was needed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story should have mentioned the typical range of charges for seasonal flu and whether there would be any difference in the price of the H1N1 flu shots.", "answer": 0}, {"article": "Subsequent actions by PGC1-alpha then stimulate cells to produce more mitochondria.\nNoting that he is a scientific advisor to Sirtris, a company developing drugs that activate the sirtuins, Dr. Kahn said, \u201cCertainly, drugs that act on this class of proteins have the potential to have major effects on human disease.\u201d\n\nDr. Auwerx\u2019s study complements one published earlier this month by Dr. David Sinclair of the Harvard Medical School, who found that much more moderate doses of resveratrol protected mice from the metabolic effects of a high-calorie diet.\nDr. Evans described the study as \u201cvery important, because it is rare that we identify orally active molecules, especially natural molecules, that have such a broad-based, positive effect on a problem as widespread in society as metabolic disease.\u201d\n\nDr. Ronald Kahn, director of the Joslin Diabetes Center in Boston, said the research would focus attention on the sirtuins, a recently discovered group of enzymes that resveratrol is believed to affect.\nThe two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company.\nThe principal theory developed by Dr. Guarente and others is that the sirtuins somehow sense the level of energy expenditure in living cells and switch the body\u2019s resources from reproduction to tissue maintenance when food is low.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no\u00a0estimate of costs for any reservatrol product \u2013 real or imagined.\u00a0 However, the web site of the company mentioned as selling reservatrol, states that a 30 day supply (which is actually much less reservatrol than was fed to the mice in the study) is $34.95.", "answer": 0}, {"article": "Abstract 375: Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n\"Image-guided treatments have expanded the options available for patients with liver cancer from innovative approaches to biopsies to resections to chemo,\" said Raman.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nInjection volume was based on lesion size.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of how much this therapy might cost. The reported cost of T-VEC for a round of melanoma therapy has been $65,000.", "answer": 0}, {"article": "But it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about direct costs for this test.", "answer": 0}, {"article": "General.\nCritics have gone so far as to send letters to newspapers that covered her work apologizing to patients \u201con behalf of Dr. Faustman\u201d for \u201chaving their expectations cruelly raised.\u201d She has also struggled for funding, receiving much of her research support from the private Iacocca Family Foundation, rather than in federal grants.\nIt alters the immune system so as to increase levels of T regulatory cells; T regs keep other immune cells in check, including those that attack the pancreas\u2019s insulin-making cells \u2014 the root cause of type 1 diabetes.\n(The standard of care is a continuous glucose monitor, in which a probe is inserted into the abdomen, plus an insulin pump.)\nAlthough many studies of BCG are underway around the world in diabetes and other autoimmune diseases, including multiple sclerosis, there has been little interest among U.S. researchers outside Faustman\u2019s lab.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the BCG vaccine costs less than $1 per dose, though it remains to be seen if the cost will remain the same if it\u2019s approved for diabetes. The story does acknowledge\u00a0that treatment with the BCG vaccine did not eliminate the study patients\u2019 need for insulin.", "answer": 1}, {"article": "\u201cMentally, people feel calmer, sharper, maybe more content.\nWe thought it\u2019s time to see if we could pull all [the literature] together \u2026 to see if there\u2019s enough evidence that the benefits individual people notice can be used to help people with mental illness.\u201d\n\nTheir findings suggest that yoga does in fact have positive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\nIf a large national study were done, it could turn out that yoga is just as good and may be a low cost alternative to people with unmet needs.\u201d In the meantime, he says it doesn\u2019t hurt to add yoga to existing treatments so patients can take advantage of any potential benefits.\nFor instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\n\u201cYoga has also become such a cultural phenomenon that it has become difficult for physicians and consumers to differentiate legitimate claims from hype,\u201d researchers from Duke University Medical Center write in their study, published in the journal Frontiers in Psychiatry.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs. Yoga is relatively cheap (roughly $10 to $20 per class in the Northeast city where one of our reviewers lives)\u00a0compared with other forms of treatment,\u00a0but it isn\u2019t covered by insurance. So the costs can still add up, especially for those with limited incomes who are already paying for other medical care.", "answer": 0}, {"article": "But a 23 percent reduction is not a cure.\n\"The injectables aren't going to go away,\" commented Dr. Scott S. Zamvil, a professor of neurology and faculty member in the program in immunology at the University of California, San Francisco.\nMONDAY, April 11, 2011 (HealthDay News) -- A new oral medication for the treatment of multiple sclerosis (MS) shows promise in slowing disease progression, limiting brain atrophy and reducing MS relapses, a recently completed two-year clinical trial demonstrates.\n\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nThe findings concern the experimental drug laquinimod, and stem from work with over 1,100 MS patients at 139 medical facilities in 24 countries.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Multiple sclerosis is a chronic illness requiring ongoing treatment. So, cost of treatment is an important consideration. This story did not include cost information,in part because the drug in question is not on the market. Acccording to this Bloomberg story, it costs $4,000 a month, and searches on Drugstore.com and other sites back this up.\nTip:\u00a0 we\u2019ve added a new resource for journalists to help them track down costs of medical interventions.", "answer": 0}, {"article": "(Reuters) - Vanda Pharmaceuticals Inc said its experimental drug for a rare sleep disorder proved effective in a second late-stage trial, and the company now plans to apply for a U.S. approval for the drug in mid-2013.\nThey have gained nearly 8 percent since December 18.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nThe second trial showed that patients treated by the drug maintained their clinical benefits while placebo-treated patients showed significant deterioration in measures of night-time sleep, daytime naps and timing of sleep.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No cost estimate given but this is still an experimental approach.", "answer": 2}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cIt is also important that teenagers undergoing this surgery have access to an experienced surgeon as part of a multidisciplinary paediatric team of doctors and Health professionals to ensure there is long-term regular follow-up.\u201d\n\nPaediatric surgeon Mr Sanjeev Khurana, who did all the lap band surgeries between 2009 and 2013, says lap band surgery is a reversible surgical procedure that can be safely used in teens with severe obesity.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of this surgical procedure is missing in action in this release. This is a problem, because costs in the US, as of 2015, average more than $14,000.", "answer": 0}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story included a calculation that suggested that the intervention was as cost effective as strategies screening for elevated LDL, the story failed to indicate the actual cost to the consumer. \n\u00a0", "answer": 0}, {"article": "A Marine veteran who ran the New York City Marathon the year he turned 40, Carver has scheduled a similar procedure on his left knee in May, early enough \u201cto be ready for golf season.\u201d\n\nFor those who are still working at physically demanding jobs, there are other considerations.\n\u201cMy goal is to get back to an hour \u2014 30 minutes on the elliptical and some back exercises,\u201d he said.\n\u201cThey\u2019re aging, they\u2019ve had some injuries, and they want to continue to be active into their 60s, 70s, and 80s.\nBecause of improvements in materials and the way they\u2019re treated and sterilized, implants \u2014 which include polyethylene and titanium alloys \u2014 don\u2019t wear down as fast as they once did.\nGrowing up, he was \u201ca jumper and a rebounder,\u201d he said, scooping basketballs off the rim during Roxbury pickup games and later playing in high school and college.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states: \u201cThe procedures can cost up to $50,000 for knees and $40,000 for hips, though the prices vary widely among Medicare and private insurers, which typically bear the bulk of the cost.\u201d", "answer": 1}, {"article": "The simple answer is yes!\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\n\"I eat normal foods though I eat less than I used to, and I enjoy takeaways and chocolate but not on a regular basis so I have maintained my lower weight, it has been a total lifestyle change.\n\"The bottom line is that if a person really wants to get rid of their Type 2 diabetes, they can lose weight, keep it off and return to normal.\n\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of cost and while the diet changes, including diet shakes and vegetables, may not exceed the cost of a regular diet, the individualized weight management program for a half-year could represent additional costs for people not in the study, something of which readers should be reminded.", "answer": 0}, {"article": "The Cochrane reviewers selected 15 studies that enrolled a combined 1,360 participants.\n\u201cBut there still needs to be consensus about the dose.\u201d\n\nZinc experts say that many over-the-counter zinc products may not be as effective as those studied by researchers because commercial lozenges and syrups often are made with different formulations of zinc and various flavors and binders that can alter the effectiveness of the treatment.\nWhile it\u2019s not certain how the mineral curbs colds, it appears to have antiviral properties that prevent the cold virus from replicating or attaching to nasal membranes.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nThe review found that not only did zinc reduce the duration and severity of common cold symptoms, but regular zinc use also worked to prevent colds, leading to fewer school absences and less antibiotic use in children.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although researchers have not reached a consensus about the optimal dose or formulation, the story could have provided cost information for the various over-the-counter zinc products. In addition, this story could have been enhanced by a brief discussion of the general costs of treatment and the cost of lost work days, school absenteeism, and physician visits.\n", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the cost of night milk is\u00a0not discussed directly, the reader is given a hyperlink\u00a0to the company website of\u00a0Milchkristalle GmbH, a producer of night milk, where the price of night milk may be found. (Though we\u00a0find it strange that a hyperlink of night milk should direct the reader to a specific company selling a night milk product.)", "answer": 1}, {"article": "In clinical trials, a plant-based diet lowers total cholesterol by 12.5 mg/dL.\n\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\n\"The first place to start is by building meals around nutrient-packed, plant-based foods, which fit into nearly every cultural template, taste preference, and budget.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives a brief nod to costs, acknowledging that the diet would fit into \u201cnearly every\u201d budget. But we\u2019d like to see a bit more. The costs of adhering to a plant-based vegetarian diet could be prohibitive for some, particularly those without easy access to fresh produce markets. While it would take some effort to estimate the annual cost of eating this way for a person or family, the cost consideration could at least be acknowledged.", "answer": 0}, {"article": "\"It was really bad,\" she says.\nPrior to the study, O'Brien-Murphy says she had found herself increasingly debilitated by back pain.\nFor O'Brien-Murphy, the massage-therapy experience has been life-changing: She has traveled to China, where she walked all over without problems, and she's already planning her next trips.\nResearchers say future studies should look more closely at the benefits of massage and focus on cost-benefit analysis.\n\"But it may also be there are simply more generalized effects of relaxation \u2014 in the caring and attention and someone laying hands on \u2014 that may all be important.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Massage, too, has a cost, and could have been ballparked at the very least.\u00a0 What do 10 sessions of massage therapy cost?\nThe study reported that the massage treatments \u201cwould have cost about $540 in the community.\u201d The study goes on to state, \u201cThere is no evidence that these treatments reducted costs of back pain-lreated health care services during the 1-year posttreatment period.\u201d This information could have been easily conveyed.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A company official declines to estimate how much the test will cost. This information is in the last line of the story.\u00a0\nIt\u2019s tempting to assign a satisfactory rating for at least asking the question.\u00a0 \nBut a more complete story would have asked the official to estimate a price compared to the company\u2019s similar breast cancer test now on the market. \nIn fact, one did: A Bloomberg story reported that the company\u2019s breast cancer test costs about $3,800. \nAn even more complete story, from the Associated Press, mentioned that despite their price insurers often pay for some tests like this because they may be able to avoid spending $30,000 to $40,000 for chemotherapy on patients who do not benefit.\u00a0 \nReporting costs is important for at least two reasons:\u00a0 ", "answer": 0}, {"article": "The study received no funding from private industry.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\nThe participants all underwent a session of \"image-guided therapy,\" in which a spaghetti-sized catheter was inserted through a nostril and into the nasal passage to deliver a dose of lidocaine to a nerve center known as the sphenopalatine ganglion.\nThe day after the procedure, average migraine pain levels had dropped from about 8 to just over 4.\n\"Of course, it remains to be seen if the demonstrated benefit already seen holds up over a longer period of time, and with a bigger group of patients.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in the article. A search of 4 percent lidocaine yielded a price tag of $524.25 for 100 mL, suggesting that the costs of the lidocaine itself (they used 2 mL for each nostril, or 4 mL total) would not be significant. The main cost would be the imaging and procedure fees for the interventional radiologist. It\u2019s not clear what those would amount to, but it wouldn\u2019t be a trivial sum.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this drug is not yet available, we can understand that cost information was not included. But since the story points out that Merck is acquiring boceprevir for $41.1 billion, couldn\u2019t it at least have mentioned the\u00a0 high cost of current hepatitis C treatment, as well as the high cost of its complications?", "answer": 2}, {"article": "Of course, the chips have limitations.\nThough there still aren\u2019t enough data to prove the chips are reliable enough to put rodents out of a job, Ingber says it\u2019s only a matter of time; they hope to have them tested and ready for market in two years.\nThe sophisticated architecture of these organs-on-chips\u2014which are about the size of a thumb drive\u2014has also earned the Wyss Institute recognition in the art world with a Design of the Year award from the Design Museum and placement in the Museum of Modern Art\u2019s permanent collection.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The Newsweek report generally addresses the costs to put a new drug on the market, and it states that \u201cIncorporating the chips into drug testing could save millions of dollars and years of time on research.\u201d\nWe\u2019ll reward the story\u2019s impulse to address cost with a Satisfactory rating, but we\u2019d note that the issue is more complicated than readers may appreciate based on the coverage.\u00a0The article starts by projecting benefits \u2013 cost of drug development and time to FDA approval. And only later does it imply that the new technology initially will add to the cost because it will be done along with the old technology (animal studies). Only if it is as good or better may it be a substitute. Then the question is whether it will indeed be cheaper. It may be cheaper if the chips are less expensive than animal studies or if they better identify agents that do or don\u2019t work in humans. But\u00a0costs are difficult to predict and the totals can add up quickly \u2014 for example, a vial of human lung cells costs over $700. This all seems very speculative at this point.", "answer": 1}, {"article": "The IVC required cross-clamping in 24 cases.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nRobotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes and reproducibility when performed by surgeons with adequate robotic experience, according to first multi-institutional report, published in the journal of urology\n\nNew York, NY, Feb. 7, 2016 - Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nRenal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the cost of the robotic procedure, nor is there any mention of how much the open procedure costs. As we\u2019ve noted in previous reviews and posts, robotic surgery can be very expensive compared to traditional laparoscopic minimally invasive surgery. In some cases, the costs of the robot and the disposables used during a surgical procedure can be in excess of the reimbursement to the sponsoring hospital and those costs are eventually passed on to the consumer. The cost-effectiveness of robotic-assisted minimally invasive surgery is still an open question that we think deserved some discussion in the release.", "answer": 0}, {"article": "Lauren Pestikas sits as she receives an infusion of the drug ketamine during a 45-minute session at an outpatient clinic in Chicago on July 25, 2018.\nIts potential effects on depression were discovered in animal experiments in the late 1980s and early 1990s showing that glutamate, a brain chemical messenger, might play a role in depression, and that drugs including ketamine that target the glutamate pathway might work as antidepressants.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nKhare reached up with a syringe to inject a small dose of ketamine into an IV bag hanging above the chair, then dimmed the lights, pulled the window curtains and asked if she had questions and was feeling OK.\n\nPestikas listened to music on her iPhone and watched psychedelic videos.\n(AP Photo/Teresa Crawford)\n\nCHICAGO (AP) \u2014 It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K.\n\nNow the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story said one woman paid $3,000 \u201cso far\u201d for her treatments and \u201cscrambles to find a way to pay for another one\u201d as the effects wear off.\nIt also reported that a \u201ctypical\u201d treatment at one clinic \u201cinvolves six 45-minute sessions over about two weeks, costing $550 each. Some insurers will pay about half of that\u2026.\u201d", "answer": 1}, {"article": "\"It's difficult to predict what will happen next, but they are on the right track,\" Mironov said.\nAll of the vessels were implanted into patients' upper arms, to connect them to dialysis machines.\nBut because dialysis is done so regularly, kidney patients often run out of healthy vessels and need an artificial one, often made out of gortex.\nIn the five remaining patients, the vessels worked for at least 6 to 20 months after they were implanted.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included an estimate that tissue-engineered blood vessels could cost more than $15,000, perhaps making them too expensive for wide use.", "answer": 1}, {"article": "PCA3 is found only in the prostate.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nAt a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, researchers presented results of the largest study to date of the PCA3 test.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\n\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, which might be explained by the fact that the test is not yet available in the US. \u00a0However, since it is commercially available in several European countries, those costs should have been mentioned at the very least. ", "answer": 0}, {"article": "Researchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nThe results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy.\nOral immunotherapy, swallowing small amounts of the allergen, has shown to be more effective than sublingual therapy, which involves putting even tinier quantities of milk under the person's tongue.\nDo not try the immunotherapy technique at home; these experiments are conducted under medical supervision.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There wasn\u2019t any estimate given of the cost of oral immunotherapy, nor of the drug mentioned at the end of the article that is being studied for use against food allergies.", "answer": 0}, {"article": "Keytruda thereby met its main goal of the study.\nThe U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer.\n(Reuters) - Merck & Co\u2019s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost at all. Given that this is as much a business story as a health story, and that Keytruda has already been approved for use by regulators, this is a significant oversight. Previous news coverage of Keytruda in other news outlets says that Keytruda will cost $12,500 per month, and that median use of the drug is 6.2 months \u2014 or $77,500. If a patient takes it for a year, that comes to $150,000. That\u2019s worth noting.\nIt would also have been worth noting what the estimated costs of\u00a0docetaxel are, for comparison purposes.", "answer": 0}, {"article": "There was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nLater studies have continued to yield positive results, although some scientists say there are still gaps in knowledge.\nBut over-the-counter preparations of fish oil have much less rigorous quality control and are often blends of the two fish oils know to be beneficial in heart disease with other less useful fatty acids.\nApproval from the agency for the use of the drug in heart disease is not expected soon.\nIt seems natural for Italy to be at the forefront of the fish oil trend and home to the largest clinical trials.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss the costs of any of the means to increase dietary omega-3 fatty acid intake. ", "answer": 0}, {"article": "Click for more from The Sun.\nDr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nBritish AI expert Prof Noel Sharkey, from the University of Sheffield, said of the findings: \"This is exactly the sort of task that deep learning is cut out for - finding high-level patterns in data.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n\"Although the sample sizes and test sets were relatively small, the results are so promising that a much larger study would be worthwhile.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned. Nor that the type of scan was specifically a PET scan.\nAccording to this survey of six Veteran Affairs hospitals, the cost of a PET scan using FDG is approximately $1,900.\nWithout insurance (and without the FDG tracer) CostHelper lists the cost of a brain PET scan as $6,700.\nUsing the AI would presumably add additional costs.", "answer": 0}, {"article": "During the last three months of 2008 \u2014 the most recent data available that allowed a comparison among robotic, open and laparoscopic surgeries \u2014 more than half of all prostate removals involved robot-assisted surgery.\nThe results were similar for people who had kidneys removed.\nWe were going to get patients out of the hospital quicker, have better potency and incontinence outcomes,\u201d he told Reuters Health.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\nOpen and laparoscopic surgeries were still more common than robotic surgeries for kidney repairs and removals.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Much of the focus of the piece was on costs.", "answer": 1}, {"article": "WASHINGTON (Reuters) - A urine test can help doctors better spot prostate cancer than either the current blood test or a rectal exam alone, U.S. researchers reported on Tuesday.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nIt is a string of RNA that does not appear to have any function but that is overexpressed, or overactive, in prostate cancer.\nBiopsies are difficult and painful to do and may take a portion of healthy prostate, missing any tumors entirely.\nLightly touching the prostate can cause its release and it can then be detected in the urine using the test.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Although this product is used elsewhere in the world, there was no estimate of its cost.", "answer": 0}, {"article": "But the triggers are different for different people.\nThen the center works with patients to try to identify what triggers their headaches and how they can avoid those triggers in the future.\n\"I write an exercise prescription probably as often as I write a prescription for medication,\" Bernstein says.\nOn top of that, exposure to radiation in tests like CT scans adds up over time and can increase the risk of certain cancers.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed in any way, either for the treatments that the woman at the heart of this story ostensibly underwent or the handful of alternatives tossed in at the end of the story.", "answer": 0}, {"article": "\"There are a lot of pundits who remain skeptical or feel we need to research this ad infinitum before it's ready, which doesn't make sense to me,\" Feifel says.\n\"If there was even a 1 percent chance that this worked, it would have been worth it to me,\" he says.\n\"I remember I was in my bathroom and I literally fell to my knees crying because I had no anxiety, I had no depression,\" he says\n\nFor the past year, Paul has been getting ketamine every four to six weeks.\n\"It became clear to me that the future of psychiatry was going to include ketamine or derivatives of ketamine,\" says David Feifel, a professor of psychiatry at the University of California, San Diego, who began administering the drug to patients in 2010.\nEven so, ketamine clinics are popping up around the country and they have already treated thousands of patients willing and able to pay out of pocket.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nice detail here. The story reports that each treatment can cost $500 to $1000 and it is usually repeated every few weeks. The story also reports the treatment is generally not covered by insurance.", "answer": 1}, {"article": "Fibromyalgia patients have chronic widespread pain, which is associated with fatigue, poor sleep patterns and depression.\n\"Both acupuncture and traditional medicine have a place in treating fibromyalgia,\" said Dr. Alexander Rances, an acupuncturist, pain management specialist and attending physician at North Shore University Hospital in Manhasset, N.Y.\n\n\"A combination of Western as well as traditional Chinese medicine probably offers these patients the best possible therapy,\" he said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\nFor more on fibromyalgia, visit the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offers an estimate of the cost of an acupuncture session at $125. The study participants received nine separate sessions, which would, by this estimate, total $1,125. The story also mentions that some insurance carriers will pay for acupuncture treatments.", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nAlpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nNot applicable. Costs weren\u2019t discussed, but the costs of these common foods are well known.", "answer": 2}, {"article": "According to Hegde, yoga may curb oxidative stress because it stimulates the parasympathetic nervous system \u2014 the part of the nervous system that basically acts as a brake against the gas pedal of the sympathetic nervous system.\nIn the U.S., hospitals and local community centers are increasingly offering such classes.\nSome are vigorous work-outs involving complicated poses that would not be appropriate for older adults with chronic health conditions.\nA BMI between 25 and 30 is considered overweight.\nIn the real world, yoga classes vary widely.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of class costs. How much do yoga classes \u2013 several times a week \u2013 cost?", "answer": 0}, {"article": "\"Unfortunately, that is not the case.\n\"These are very delicate operations and a sophisticated image guidance system has been developed to help the surgeons, but they don't trust the system because sometimes it is spot on and other times it is off the mark,\" said Robert Webster, associate professor of mechanical engineering and otolaryngology, who is developing a surgical robot designed specifically for endonasal surgery.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how switching to the coffee-filled cap might affect costs. A silicone swim cap and six cups of coffee grounds run less than 20 bucks. But it\u2019s safe to say this device will cost much more given the need for a potential investor to recoup the cost of clinical trials and other expenses related to getting a medical device to market. The news release suggests the cap may save time or prevent errors during surgery, which could reduce some health care costs.", "answer": 0}, {"article": "When it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\nAnd many of the studies were short in duration, comparing sleep duration in snapshots before and after a school made a switch.\nBecause if later school start times can truly help students sleep better, the research suggests that better sleep would lead to major improvements to their health and well-being.\nBecause if later school start times can truly help students sleep better, the research suggests that better sleep would lead to major improvements to their health and well-being.\nWhen your body clock is off from society\u2019s, scientists call it \u201csocial jet lag.\u201d And like the jet lag from a long journey, it messes with your body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although specific, numerical costs are not mentioned, the story does a good job of reflecting on the kinds of costs that school districts would incur if they went to a later start time.", "answer": 1}, {"article": "The National Institutes of Health, as well as the Michael J.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\n\"Depression is a very frequent condition associated with Parkinson's, so we became interested in whether an antidepressant could modify how the disease progresses,\" said Tim Collier, lead author of the federally funded study and a neuroscientist at MSU.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\n\"By using a test tube model, we found that by adding nortriptyline to the alpha-synuclein proteins, they began to move and change shape much faster, preventing the proteins from clumping together.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story is about a proof-of-concept study, which is the very earliest step in research. But if it\u2019s not too soon to issue a news release, it\u2019s not too soon to address cost impacts. The release could have mentioned the cost of the medication, nortryptiline, or alternatively, the economic burden of Parkinson\u2019s.", "answer": 0}, {"article": "Ulf Ekelund at the Norwegian School of Sport Sciences in Oslo said the study emphasised what researchers have found time and again: that even a small amount of regular exercise wards off death.\nNearly 9,000 of the study participants died in the period.\n\u201cMy take home message is that the greatest risk reduction and the greatest gain for the individual and for public health is if those who are physically inactive take up some activity,\u201d he added.\nIn the study, those who exercised a little had a 29% lower risk of death than those who did no exercise at all.\n\u201cThe novel finding is that it appears the duration, and possibly the intensity, of leisure time physical activity is more important than the frequency,\u201d Ekelund said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We don\u2019t think that cost is relevant here.", "answer": 2}, {"article": "About UABKnown for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama\u2019s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation\u2019s top 50.\nIn all four studies, eye dryness was significantly reduced, with two of the studies showing improvements at week two.\n\u201cDry eye is a common complaint to eye care professionals, with millions of U.S. adults experiencing the symptoms of this often chronic disease,\u201d Nichols said.\nSigns and symptoms were assessed at baseline and at weeks two, six and 12.\nEDITOR\u2019S NOTE: The University of Alabama at Birmingham is a separate, independent institution from the University of Alabama, which is located in Tuscaloosa.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention cost. We were unable to find any cost information online after a brief Google search. ", "answer": 0}, {"article": "But some pain experts defend the value of the diagnostic tests.\nDr. Nikolai Bogdu at the Newcastle Bone & Joint Institute in Australia told Reuters that further cost analysis is needed to account for millions of patients who might not get pain relief from the radiofrequency treatment.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nDoctors may not change their approach anytime soon, however.\nPatients don't care much about the finer points of diagnostic accuracy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story said that \"skipping diagnostic nerve blocks can save $10,000 in medical costs.\" ", "answer": 1}, {"article": "More News at Northwestern Now\nThis can lead to increased positive affect in the face of stress \n\n7) Understanding small acts of kindness can have a big impact on positive emotion and practicing a small act of kindness each day \n\n8) Practicing mindfulness with a daily 10-minute breathing exercise, concentrating on the breath\n\nFifteen months after the interventions, 91 percent of the intervention group had a suppressed viral load compared to 76 percent of the control group.\nThe research was supported by grants R01 MH084723 and K24 MH093225 from the National Institute of Mental Health and grant P30 AI117943 from the Third Coast Center for AIDS Research, all of the National Institutes of Health.\nLearning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\n\"Even in the midst of this stressful experience of testing positive for HIV, coaching people to feel happy, calm and satisfied -- what we call positive affect -- appears to influence important health outcomes,\" said lead author Judith Moskowitz, professor of medical social sciences and director of research at the Osher Center for Integrative Medicine at Northwestern University Feinberg School of Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We did not find any discussion of the cost of bringing patients in for five sessions of what is called \u201cpositive skills intervention.\u201d While it may be low-cost, we need some mention of that to help evaluate the practicality of this therapy.\nThe study itself devotes space to cost analysis.\n\u201cThe [intervention] was quite time intensive for both the study team and the participants which lessens the likelihood that it can go to scale in this format.\u201d\n\u201cWe have begun work on translating the intervention to a self-guided online format that would significantly reduce the cost.\u201d\nIf the news release had included these details, it would have added some practical context for readers.", "answer": 0}, {"article": "\"Although there appear to be some benefit of an overall lower death rate in both groups, the [special panel] recommended stopping the trial,\" Nabel said.\nMany earlier studies had shown that tightly controlling blood sugar significantly reduced the risk of many complications.\nLetters were mailed to all participants Monday notifying them of the results so they could consult with their doctors about switching to the less intensive therapy.\nOver about four years, about half of the patients getting intensive treatment achieved blood sugar levels close to normal, and about half the patients in the standard treatment group achieved levels close to the average diabetic.\nAbout half the excess deaths were from heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost information provided; it is both relevant and available. \u00a0The medications used to more tightly control sugar levels are expensive.", "answer": 0}, {"article": "Atrial fibrillation affects more than 2.6 million people in the United States.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\n\"The benefits of apixaban are preserved, regardless of the risk score used and regardless of the patient risk category,\" study author and cardiologist Dr. Renato Lopes said in a Duke news release.\nThe findings suggest that the current risk scoring systems for tailoring anti-clotting (anticoagulant) treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke, according to the Duke University Medical Center researchers.\nMONDAY, Oct. 1, 2012 (HealthDay News) -- A new anti-clotting drug called apixaban was better than warfarin at preventing stroke in patients with the heart rhythm disorder atrial fibrillation, a new study found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this story, even though apixaban has been found to be quite costly. A study in Nature Cardiology, for example, found that apixaban cost $3,545 per patient compared to $1,805 for patients treated with aspirin.", "answer": 0}, {"article": "\u201cIt\u2019s a bit like with mobile phones.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\nThe Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.\nI see the same thing with this system.\u201d\n\nThe Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson\u2019s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If we\u2019re far enough along to determine that that the \"artificial pancreas\" was better than conventional techniques at managing glucose,\u00a0we\u2019re far enough along to\u00a0start talking about what this approach may cost.\u00a0 \nMany patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices.\u00a0It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology. \n\u00a0", "answer": 0}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of Actos or other diabetes drugs.", "answer": 0}, {"article": "Franks says thalidomide can help an additional 75% of patients achieve remission.\nThe majority of the patients (60%) had the most common subtype of lupus-related skin disease, known as discoid lupus erythematosus, which is characterized by red, scaly patches that can scar.\nIn more recent years it has been brought back to the market to treat a number of serious conditions, but its use is monitored closely to ensure that it is not taken by women who are pregnant or who might become pregnant.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Brief discussion of costs at the end of the story; however, costs were mentioned in relation to conditions for which lenalidomide\u00a0is currently approved to treat (and the costs were taken from the manufacturer\u2019s website). \u00a0If patients use lenalidomide\u00a0for treatment of lupus skin conditions, which at the moment is off-label use, the patient could be responsible for total cost.", "answer": 1}, {"article": "March 5, 2012 (Orlando, Fla.) -- A traditional Chinese herbal remedy known as kampo helped to relieve daily asthma symptoms in nearly all of more than 200 people studied, Japanese researchers report.\nThe study did not look at possible side effects of kampo herbs.\nThe number of people in the U.S. with asthma is growing.\nIn kampo medicine, most herbs are taken as a fixed formula.\nOf those, 52 were given standard treatment (typically an inhaled steroid and a bronchodilator), and 226 were treated with kampo herbs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of the cost of kampo, nor of any comparison with current asthma medications.", "answer": 0}, {"article": "Disease-free survival and overall survival three years after treatment were 48.3% and 55.8%, respectively.\nResearchers say surgical removal of tumors is the standard treatment for early-stage lung cancer, but some people are not candidates for surgery due to other coexisting illnesses such as emphysema and heart disease.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nIn these situations, the lung cancer tumor is deemed inoperable and conventional radiation therapy or observation without cancer treatment is offered.\nMore than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs or insurance coverage. Likely given how experimental the treatment is, insurance will not cover the procedure. Given that it is not an approved treatment, a simple statement about its cost relative to current therapy could have been helpful. For desperate patients and families struggling with the treatment options, uNPRoven treatments that are likely not to be covered by insurance would require out of pocket coverage.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Readers have to get deep into the story, but they are eventually told about \u201cKeytruda\u2019s $100,000-per-year price tag.\u201d", "answer": 1}, {"article": "That's left women who can't take hormones at a disadvantage.\nFor example, the drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients, studies indicate.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\n\"Because of this, we can take advantage of the 'side effect' and decrease involuntary sweating associated with hot flashes, and decrease the hot flashes as well,\" he explained.\nAnd oxybutynin doesn't interfere with the metabolism of tamoxifen, Leon-Ferre said, calling that an important consideration for breast cancer survivors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Using the lead researcher as a source, the article states that most insurers cover oxybutynin; that a month\u2019s supply can range from $21 to $42; and that the cost could be less, depending on the type of insurance a patient has.\nKudos to HealthDay for explicitly addressing cost.", "answer": 1}, {"article": "\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story cites the product\u2019s cost: $25 for the introduction kit and and $20 for the maintenance kit, which lasts for about three weeks. The story does not indicate how many weeks that proper use entails, but the randomized trial cited by the AAP in forming their recommendations (the\u00a0Learning Early about Peanut Allergy (LEAP) study) continued peanut exposure until age 5. If Hello, Peanut! was used for the same duration, the total tab would be just over $1,900, a not-insignificant expense. Other less costly alternatives to include mixing smooth peanut butter into pureed fruits and vegetables \u2013 which is suggested by the AAP in the new guidelines. Yet, this alternative is not mentioned by the NYT.", "answer": 1}, {"article": "Cleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\nA person\u2019s breath contains a variety of chemical compounds, and it has long been recognized that certain illnesses can affect how the breath smells.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nPeople with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned, but since this test is in an early stage of development, it would be difficult to provide an accurate cost figure. That figure would have to include both the cost of the test and any unnecessary follow-up tests and procedures due to false-positive results.\u00a0 We\u2019ll rule it not applicable.", "answer": 2}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story gives pricing information for some of the supplements mentioned \u2014 $3.79 for a month\u2019s supply of one ketone\u00a0capsule product, and\u00a0$68 for a month\u2019s supply of ketone/coffee bean extract combo.", "answer": 1}, {"article": "Natural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\nThe Science: For decades, parents looking for an over-the-counter medicine to cure a child\u2019s sickness and coughing have turned to syrupy medicines containing dextromethorphan, a popular cough suppressant found in products like Children\u2019s Dimetapp DM and Robitussin DM.\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nThe subjects were randomly divided into three groups: one that received no treatment, another that received one or two teaspoons of buckwheat honey, and a third that received a dose of honey-flavored dextromethorphan.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. We also would have liked to have seen some explanation of whether it mattered if a parent used the cheapest honey or the pricey organic stuff.", "answer": 0}, {"article": "Wall Street sees denosumab as a potential blockbuster crucial to Amgen.\n\"It'll find a particular niche where it'll be used, but I don't see it as taking over the market,\" said Dr. Sundeep Khosla, a professor and osteoporosis researcher at the Mayo Clinic.\nThe second study included 1,468 men with prostate cancer at increased fracture risk due to cancer hormone therapy, although 556 dropped out for reasons from side effects and cancer progression to the study being extended from two to three years.\nIn this case, it targets a molecule in bones that drives formation of cells called osteoclasts that break down bone, a strategy that greatly reduces bone loss.\nBut another injection given intravenously is only needed once a year, and estrogen, while out of fashion due to its link to breast cancer, is available in skin patches changed once or twice a week.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Pricing for this drug is not yet available; however, the story suggests that it could be expensive, with similarly engineered drugs costing more than $10,000 a year.\u00a0 In addition, the costs of currently prescribed osteoporosis medications are provided.\u00a0 \u00a0\u00a0\u00a0", "answer": 1}, {"article": "That's why the device requires training every time Burkhart uses it.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nThe study builds on previous work in which humans have been able to move computer cursors and robotic arms using their own brain signals, and a study in which monkeys with paralysed arms were able to move them again thanks to a similar intervention.\n\"The recordings we get from these electrodes in the brain can be quite unstable from day to day,\" Jackson said.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is too early in the development of this experimental technology to begin talking about what the price of such a system might be. But readers would have gotten a clearer idea of the preliminary state of this work if the story had noted that the brain mapping, device implantation, sophisticated equipment and hundreds of hours of training probably cost hundreds of thousands of dollars.", "answer": 2}, {"article": "Hundreds of laboratories are now offering genetic testing for more than 1,200 conditions.\n\"There is concern about the validity of many genetic tests that are being offered,\" said Joan Scott, deputy director of the Center for Genetics and Public Policy at Johns Hopkins University.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nSome questioned its reliability, while others worried that the results could either lull women into a false sense of complacency or needlessly alarm them, prompting them to take unnecessary tests or even undergo unneeded surgery.\nA biotech company today will begin offering the first genetic test to assess a woman's risk for the most common forms of breast cancer, reigniting debate about the growing number of unregulated genetic tests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the cost of this test $1,625 and mentions that insurance companies currently don\u2019t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO\u2019s speculation that insurance companies will eventually cover the test because it\u2019s easy to perform and \"any doctor can order the test\" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. ", "answer": 1}, {"article": "In five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nFeb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story doesn\u2019t mention specific costs, although it at least makes a passing reference to expense: \u201cIt can be time consuming and more expensive than other diets, experts say.\u201d The story explains that if parents are to embark on this diet, they will need to have their kids monitored by \u201cexperts\u201d or by \u201ca primary care doctor and, if possible, a dietician.\u201d If so, that would make this diet extremely expensive and would require significant out-of-pocket spending given that insurance companies are not currently paying parents to see their doctor for ADHD-related diet monitoring.", "answer": 0}, {"article": "New clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\n\"This is the first randomized clinical trial looking at the effect of magnesium supplementation on symptoms of depression in U.S. adults,\" says Tarleton.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Despite claiming the low cost of magnesium supplements as a benefit, the release doesn\u2019t include the cost. A quick google search shows that magnesium tablets can be bought online or in stores for less than $15 per bottle.", "answer": 0}, {"article": "Obesity-related health conditions include high blood pressure, type 2 diabetes and high cholesterol.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nIt takes about eight minutes to place the balloons, and about 14 minutes to remove them, according to Dr. Jaime Ponce, medical director of the bariatric surgery program at Hamilton Medical Center in Dalton, Ga. Ponce was the principal investigator of the clinical trial on the ReShape system.\nThe device is available to obese people who often don't qualify for surgical weight-loss procedures, according to the FDA.\nThe balloons have been available in Europe since 2011, where their average price is about $6,200, according to the manufacturer, ReShape Medical Inc. in California.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does discuss costs. The discussion would be better if it included the cost of implanting the device. The story only told the price of the device in Europe \u201caverage price is about $6,200, according to the manufacturer.\u201d But it was not clear whether that price includes fees to the doctor and clinic for insertion and removal. And readers/consumers should also think about this: given the high likelihood of \u201cintolerable\u201d nausea, what is the impact this might have on lost work time?\nWe are not given context of prices for other procedures related to this one \u2013 such as bariatric surgeries.\n\u00a0", "answer": 1}, {"article": "PROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\nThe greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption).\nIn addition to Lin and Liu, the study's other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women's Hospital.\nThe authors therefore concluded, \"Our study highlights the urgent need for large, long-term RCTs that improve our understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release. We didn\u2019t expect to see chocolate bar prices. But there are existing dietary cocoa flavanol products on the market that could easily have been referenced.\nOnly 7% of the releases we\u2019ve reviewed so far adequately address cost. It has to start somewhere. Each news release writer can say to him/herself, \u2018Not in this case.\u2019 And in 93% of cases so far, cost is inadequately discussed.", "answer": 0}, {"article": "MONDAY, March 21, 2011 (HealthDay News) -- While the majority of morbidly obese patients who undergo gastric banding say they are generally satisfied years later, almost 40 percent are saddled with major complications, while about half have to have their bands removed, a small, new Belgian study reveals.\nOn average, excess weight loss had been maintained at a level approaching nearly 43 percent, and quality of life appeared to be equal to that of patients who had not undergone the surgery.\nLAGB creates a small pouch by placing a constricting ring, or band, around the top portion of the stomach; the smaller stomach size allows patients to feel full more quickly.\nThe finding comes on the heels of a recent study out of the University of California, San Francisco that suggested gastric bypass surgery is superior to alternative surgical methods (such as gastric banding) for promoting weight loss and/or eliminating type 2 diabetes.\nIt is also been reported that LAGB patients are likely to regain much of their lost weight years down the road.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although not discussed in the study precipitating the story, the costs for gastric banding and appropriate follow-up care are readily available.", "answer": 0}, {"article": "[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\nA new test can accurately predict within minutes if an individual has Ebola Virus Disease (EVD), according to new research published in The Lancet.\n106 suspected Ebola patients admitted to two treatment centres in Sierra Leone (run by the Ministry of Health and Sanitation of Sierra Leone and supported by the non-governmental organisation Partners In Health) during February 2015 were tested by both RDT (performed on a fingerstick blood sample at the point-of-care) and by standard RT-PCR (performed on plasma in the laboratory).\nAccording to co-author Dr Jana Broadhurst from Partners In Health, Boston, USA, \"This test could have an immediate impact on patient care and infection control by reliably detecting patients well into their illness who are likely to be highly infectious.\nThe altona RT-PCR assay failed to detect a small number of EVD cases that tested positive by both RDT and by an alternative RT-PCR test (Trombley), all with relatively low amounts of virus.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We don\u2019t see any dollar signs in this release, either for the new test or RT-PCR. According to a New York Times blog post, they cost $60-$200 each.", "answer": 0}, {"article": "Noonan says the small trial helped her and her colleagues learn more about which patients may benefit from MILs therapy.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\n\"What we learned in this small trial is that large numbers of activated MILs can selectively target and kill myeloma cells,\" says Johns Hopkins immunologist Ivan Borrello, M.D., who led the clinical trial.\nIn nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release, while loaded with information about the research, fails to mention costs related to this new approach at any point. This is in spite of the fact that the paper provides what\u2019s necessary\u00a0to fulfill this criterion. The study authors wrote: \u201cThe easy access to the tumor site, the absence of the need for surgical removal of the tissue containing the T cells, the numbers of cells obtained with the harvest, and the ability to expand products in all patients with a relatively short process at a reasonable cost contrast sharply with several limitations of TIL ACT\u201d (a current therapeutic approach to the disease).", "answer": 0}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\nThat mark, which also appears on the back label, explains in fine print that \u201cno crash means no sugar crash.\u201d\n\nThat is hardly surprising, because 5-Hour Energy does not contain sugar.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\nThe study found that test subjects given 5-Hour Energy experienced \u201cenergy\u201d for about 40 minutes longer than when given Red Bull or Monster Energy, though it was not clear from court papers whether that difference reflected the energy shot\u2019s higher levels of caffeine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that energy drinks are expensive compared with other sources of caffeine, such as coffee or caffeine tablets. A 16-oz can of monster sells for $2.99.", "answer": 1}, {"article": "Half ate 22 grams of freeze-dried blueberry powder (equivalent to a cup of blueberries) daily for eight weeks.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe study, in The Journal of the Academy of Nutrition and Dietetics, found that those who ate the blueberry preparation saw an average 5.1 percent decrease in systolic blood pressure (the top number) and a 6.3 percent decrease in diastolic pressure.\nResearchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Blueberries are expensive, and the featured study utilizes \u201cfreeze-dried blueberry powder,\u201d which is more of a supplement than something you\u2019d find in a grocery store. Some back-of-the-envelope calculations based on prices from this supplier suggest that the daily powdered blueberry regimen could cost as much as $50 a month.", "answer": 0}, {"article": "Vincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\nThe study of acupuncture as a remedy for hot flashes was sparked by reports from women who had undergone the ancient Chinese therapy for other problems and reported that their hot flashes seemed to moderate.\nSome herbs and supplements seem to work, she added, but improvement has proven to be temporary.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\nThat requirement has hobbled other alternative treatments, including the herb red clover and vitamin E supplements.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not include any information on the cost of acupuncture or on whether insurers cover this for any indications. ", "answer": 0}, {"article": "Another conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nEvidence points to the regeneration of brain cells as a critical mechanism for the relief of depression, as published in peer-reviewed journal Neural Regeneration Research, February 2016 issue.\nKetamine is a dissociative anesthetic in use since 1970's.\n\"Activation of brain-derived neurotrophic factor (BDNF) appears to have an important role in the antidepressant effects of ketamine.\nKetamine appears to potently induce mechanisms which reverse these neuro-degenerative processes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of the cost of the infusions, nor does it say whether insurance pays for them. Given that they are not approved as safe and effective by the U.S. Food and Drug Administration (FDA), any cost would likely be borne by the patient.\nThe only person cited in the release, Dr.\u00a0Theodore Henderson, is co-founder of Neuro-Luminance Ketamine Infusion Centers. The center\u2019s website states that infusions start at $745 each, with discounted rates available for multiple-infusion packages.", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention costs of the screening tool, should one be developed. Costs for screening tests vary widely.", "answer": 0}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The $20,000 procedure cost is in the first sentence. Many stories never get there at all.", "answer": 1}, {"article": "She worked with a group of mice that are genetically bred to have healthy ratios of omega 3 fatty acids.\nWhat she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article includes no discussion of the cost of adding either omega 3 supplements or foods high in omega 3 fats to an individual\u2019s diet. Omega 3 supplements may not be especially\u00a0expensive,\u00a0but the story doesn\u2019t address this issue either.", "answer": 0}, {"article": "Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide [2].\nAmsterdam, The Netherlands: A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the European Cancer Congress 2017 [1].\nThe trial was based on the results of previous research that suggested differences in the levels of specific chemicals (butyric, pentanoic and hexanoic acids, butanal, and decanal) between patients with stomach or oesophageal cancer and patients with upper gastrointestinal symptoms without cancer.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nBoth tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15%.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This research is only at its earliest stages, so is it too early to expect cost information? If it\u2019s not too early to promote a technique in a news release it\u2019s not too early to provide a ballpark cost. The release does tout potential savings from avoiding \u201cunnecessary\u201d endoscopies but without also considering that an easy test could send many healthy into further testing or even treatment they didn\u2019t need.\nA 20% false positive rate, which this test apparently offers, could translate into a huge number of expensive endoscopies.", "answer": 0}, {"article": "Saturated fats can remain a part of a healthy diet, in limited amounts \u2013 but there are two easy ways to help:\n\u2022 Saturated fats should make up 10 percent of total caloric intake daily.\nAll that is known is the participants had a normal cholesterol levels and normal blood pressure.\nFollow her on Twitter @drfernstrom.\nA new study suggests the answer may be no.\nBut even when their cholesterol levels were lowered by the switch from saturated fats, there was no longevity benefit.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this is about affordable and widely available cooking oils, this is N/A.", "answer": 2}, {"article": "But are they benefiting from acupuncture itself, or just getting a placebo effect?\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nIt lasts, and the placebo effect doesn\u2019t last once you stop a treatment.\u201d\n\nBut acupuncture believers say it doesn\u2019t really matter whether Western scientific studies find that the treatment has a strong placebo effect.\nBut the real lesson, acupuncture supporters say, is how difficult it can be to apply Western research standards to an ancient healing art.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "      \n\n\n \n\n \nThe article didn\u2019t address costs or reimbursement issues.\n If acupuncture could be shown to be efficacious for common health conditions, its relatively low cost could be viewed as a major selling point in a world of spiraling treatment expenditures.\n ", "answer": 0}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nCephalon soldiered on, giving FDA more data.\nWell, the Food and Drug Administration.\nBut today the company said its response fell short.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost, which we wish had been included.", "answer": 0}, {"article": "[3]\n\nWriting in a linked Comment, Professor Avan Aihie Sayer from the University of Southampton, Southampton, UK, and Professor Thomas Kirkwood from Newcastle University, Newcastle upon Tyne, UK discuss whether grip strength could be a new biomarker of ageing, writing that, \"This is not a new idea, but findings from PURE add support.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThe findings show that every 5kg decline in grip strength [2] was associated with a 16% increased risk of death from any cause; a 17% greater risk of cardiovascular death; a 17% higher risk of non-cardiovascular mortality; and more modest increases in the risk of having a heart attack (7%) or a stroke (9%).\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release says that grip strength is low-cost, but a dynamometer is not something used routinely in clinical practice.\u00a0Why not provide a cost estimate for both the dynamometers, the cost of administering the test in the clinical setting, and the cost of potential widespread risk-stratifying use? \u00a0Would this still be low-cost? Maybe so, but some projections are possible IF you deal with real numbers, not just the researchers\u2019 value judgment that it is \u201clow-cost.\u201d", "answer": 0}, {"article": "Blitz said debate should be aired publicly, and he is not rattled by opposition to plans for a regional approach.\nDespite often heroic efforts to save cardiac arrest victims with CPR and defibrillation, two out of three who regain a pulse but don't wake up don't survive to hospital discharge.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\nIn 2007, UH's Blitz, calling the gap in survival rates an embarrassment, pressed Cleveland hospitals and EMS officials to join a national program to track outcomes and improve survival.\nThe therapy is targeted to patients stricken by ventricular fibrillation, an electrical disturbance that causes the heart's pumping chambers to quiver instead of pump.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the costs for the treatment nor the investment in the infrastructure to support the availability of this treatment.\u00a0 Puzzling given the public policy and city/regional planning aspects of the issue. ", "answer": 0}, {"article": "New York, NY, September 22, 2015 - The U.S. Preventive Services Task Force (USPSTF) recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial.\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\nSimilarly, new diagnoses had fallen by 23.0-29.3% among men over age 70 and by 26.0% among infirm men, populations at risk for harms of treatment but unlikely to live long enough to benefit from early detection.\nHowever, the study also identified a drop of 28.1% in diagnoses of intermediate risk disease and 23.1% in high risk prostate cancer one year after the draft guideline, which could result in missing important opportunities to spare men with higher risk cancers from progressive disease and cancer death.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention about the costs of PSA tests or of the resulting low-risk cancers that may be unnecessarily irradiated, surgically extracted, or robotically removed. Similarly, there\u2019s no mention of the costs of treating advanced cancer \u2014\u00a0both for health care (advanced cancer treatments can be extremely expensive\u2013e.g., Provenge) and life years lost.", "answer": 0}, {"article": "The researchers plan to conduct a follow-up study with a larger number of people.\nNewswise \u2014 Lovers of Indian food, give yourselves a second helping: Daily consumption of a certain form of curcumin \u2014 the substance that gives Indian curry its bright color \u2014 improved memory and mood in people with mild, age-related memory loss, according to the results of a study conducted by UCLA researchers.\nThe paper\u2019s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.\nThe study was supported by the Ahmanson Foundation, the Marshall and Margherite McComb Foundation, the McMahan Foundation, Bob and Marion Wilson, the Fran and Ray Stark Foundation Fund for Alzheimer\u2019s Disease Research, the U.S. Department of Energy and the National Institutes of Health.\nIt also has been suggested as a possible reason that senior citizens in India, where curcumin is a dietary staple, have a lower prevalence of Alzheimer\u2019s disease and better cognitive performance.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs in the news release. A quick google search for Theracurmin capsules reveals that \u2014 at the dosages used in the study \u2014 a month\u2019s supply would cost somewhere between $75-$100 dollars.", "answer": 0}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\n\"These findings are interesting, and show that vitamin D may have a role in improving outcomes in cancer care.\"\nAfter adjusting for prognosis and healthy behaviors, the researchers found that patients in the group with the highest levels of vitamin D lived about eight months longer on average than those in the group with the lowest levels.\n\"That is interesting because that's more of a cancer-specific endpoint as opposed to overall survival, which could be influenced by other factors like heart health,\" Krishnamurthi said.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss cost. However, most people generally understand that vitamin supplements are affordable, so we\u2019ll rate it not applicable.", "answer": 2}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story was more precise on costs than the LA Times, saying, \u201cThe devices cost up to $35,000, versus the roughly $25,000 cost of a standard defibrillator. Hospital and doctor fees can raise the total cost over $50,000.\u201d Both stories said, vaguely, that \u201cthe cost\u201d of the disease every year is $40 billion. This is confusing to readers for two reasons. One, there is no single payer shelling out $40 billion every year to treat heart failure, and so that number is likely not much more than a very good guess. Two, it leads people to believe that the device, at $50,000 per person, may be a bargain if heart failure right now costs $40 billion to treat. We applaud the Journal for at least raising this issue high in the story. The story cites\u00a0Eric J. Topol, cardiologist and chief academic officer at Scripps Health, saying, the reduced rate of hospitalizations in the study \u201cmay actually present a net reduction in costs from a societal standpoint.\u201d That\u2019s a big what if.", "answer": 1}, {"article": "Language, for example, requires coordination across the auditory, visual, and motor brain regions, as well as the participation of the prefrontal cortex, she said.\nIn the new study, Dr. Frank Duffy and Dr. Heidelise Als compared EEG measurements of nearly 1,000 children with and without autism.\nThe use of EEG-based testing may help diagnose autism in children and may improve early detection in infants, leading to more effective treatments and coping strategies, the researchers said.\n\"What was unique about this study is the very large number of children studied,\" Dawson noted.\nShe said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the study, even though EEGs have been in use for more than 60 years.", "answer": 0}, {"article": "\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\nThe study showed that the time window could be expanded to 16 hours.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nTraditional guidelines have set a limit of six hours after stroke symptoms begin, and said after that it would be too late to help.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much the special imaging and surgical procedure will cost patients.", "answer": 0}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The original Associated Press story mentions the cost of of Pneumovax $30, and the original AP story also had questions about cost effectiveness of vaccinating younger, otherwise healthy college-age smokers.\nBut both points were cut out in the version published by the NY Daily News.\u00a0 ", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\nThroughout the study, patients remained in intensive or less intensive therapy, although as their clinical conditions changed, they could change forms of therapy, Dr. Palevsky said.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nThere was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was not explicit information in this story about costs to the individual undergoing care, though one could surmise that less intense treatment would cost less. \u00a0The story included estimates of the impact from the results of the study on costs to the health care system.", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\nThe study led by researchers at the Perelman School of Medicine at the University of Pennsylvania is the first to show that lisdexamfetamine (LDX) improved subjective and objective measures of cognitive decline commonly experienced in menopausal women.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention in the release as to the cost of LDX although, since it is routinely prescribed for ADHD, the cost for users should be easy to provide.\u00a0 A cursory search of the internet suggests that a 30-day supply could cost between $100 and $300, depending on the provider and insurance coverage.\u00a0 Nor is it clear from the release how long women would need to take the drug to ward off any cognitive decline, since the trial the release reports on only continued for several weeks.\u00a0 Providing that information would allow readers to accurately gauge the value of the treatment.", "answer": 0}, {"article": "\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\nThe third new drug is Orexigen Therapeutic's Contrave, which is a combination of the antidepressant Wellbutrin and the addiction drug naltrexone.\nAlso, it does not have the same problems as the previous weight-loss drugs, Fen-Phen (Phentermine), Acomplia (rimonabant) or Meridia (sibutramine), which had been associated with heart problems, he said.\n\"If weight-loss drugs are tailor-made to hit only the right receptor, based on physiological knowledge, it seems to be possible to develop weight-loss medications that do not possess any serious adverse effects,\" Astrup added.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is a passing reference to costs, which is more than the other two stories provided. But it would not have taken much effort to gather some basic cost ranges for a drug that has to be taken twice a day for at least a year to see results.", "answer": 0}, {"article": "Feb. 17, 2011 (Orlando, Fla.) -- Taking a pomegranate pill a day may help slow the progression of prostate cancer, preliminary research suggests.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\nCarducci credits antioxidants in the pomegranate for its anticancer effect.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs for pomegranate-containing products.", "answer": 0}, {"article": "An estimated 104,000 Americans quit smoking for good as a result of the 2014 campaign.\n\u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\n\nThe most recent Surgeon General\u2019s Report, The Health Consequences of Smoking\u201450 Years of Progress, called for airing effective messages such as the Tips ads with high frequency and exposure for 12 months a year for a decade or more.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We give the release credit for providing some detail on the costs of smoking-related illnesses. However, the intervention here was a national anti-smoking campaign and the cost of that campaign was described in obscure terms:\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health. \u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\nOne can deduce based on the numbers given that the campaign costs less than $72 million ($1 million an hour for three days), but why spin it to this extent when it would have been easy to give us an actual number?", "answer": 0}, {"article": "About 10 percent of the students had an abnormal EKG.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n\nThe story cites unnamed experts who make the vague claim that EKG screening would be \u201ctoo costly.\u201d However, an estimate of the cost of the equipment and the cost per test would have been easy to include and would have provided valuable context to the discussion. Notably, the authors of the study discussed in this article have suggested that the cost of an EKG is as low as $3 under the research protocol they used.\u00a0 However, the cost skyrockets to over $100 if the customary physician billing process is used. The story presents this tension in a one-sided and biased fashion without ever discussing the cost implications sufficiently.\u00a0\n", "answer": 0}, {"article": "This new approach to drug discovery is a promising technology that is rapidly moving in the translational research space , .\nAmong these, the abstract \"Tivanisiran a new treatment for Dry Eye Disease, that improved signs and symptoms in clinical trials\" (Posterboard number: 925 - B0103) is highlighted, the compound improving the ocular inflammatory parameters, tear quality and a reduction in ocular pain associated with dry eye disease is also underlined1.\nDry eye can be treated with cyclosporin drops or autologous serum, but there is as yet no specific product for chronic treatment of the ocular pain related to dry eye syndrome; oral analgesics or anaesthetics are used in general.\nThe novel mechanism of action of tivanisiran, based on genetic silencing through RNA interference (RNAi), is targeted at the treatment of the signs and symptoms of this pathology, making it a firm candidate for the treatment of dry eye disease.\nIn this respect, Jim\u00e9nez points out that \"this is a significant step forward in the development of innovative drugs in different therapeutic areas through a novel technology of genetic silencing based on the RNA.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the potential cost of this new medication, tivanisiran. We do know, however, that current other treatments for dry eyes can be expensive. Cyclosporine A drops, for example, may run as high as $400 a month. There is no indication that tivanisiran might be more affordable to patients, or if insurers might cover the cost of this news drug.", "answer": 0}, {"article": "A limitation of the study was the modest number of participants.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nPresently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).\nPersonal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the prescription hearing aid used in the study is noted ($1,910), as is the cost range of five different PSAPs tested (ranging from $30 to $350).", "answer": 1}, {"article": "This is the experience many women have.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\nFamily-centered cesareans are a relatively new idea in the U.S., and many doctors and hospitals have no experience with them.\nThe techniques are relatively easy and the main goals simple: Let moms see their babies being born if they want and put newborns immediately on the mother's chest for skin-to-skin contact.\n\"It is the first time we have really done anything innovative or creative with changing the C-section procedure in years,\" she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story said hospitals aren\u2019t charging more for the family-centered cesarean. We\u2019ll judge this nod in the direction of costs to be sufficient for a satisfactory rating, but ideally we\u2019d like to see a dollar estimate for what a traditional cesarean costs. In addition, we\u2019d note that the family-centered cesarean does involve some additional resource costs \u2014 for example,\u00a0extra nursing staff and the logistics of getting the neonatal team into the operating room \u2014 that should be considered, even if these are not currently reflected in typical hospital charges.", "answer": 1}, {"article": "Those deaths were related to the transplants, Saccardi said.\nMONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nTo see how patients did over the long term after stem cell transplants, Saccardi and colleagues followed 281 patients from 13 countries who received stem cell transplants between 1995 and 2006.\nHowever, it can be considered a concrete option for patients showing aggressive MS who have not responded to approved treatments,\" said study co-author Dr. Riccardo Saccardi.\n\"There may be a population of MS patients that could be identified that might do well with transplant,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed. And that\u2019s particularly problematic, given the potential costs associated with stem cell treatment. While we\u2019re not aware of any clinically-available stem cell treatments for MS, we can get a rough idea of costs from the stem cell treatments currently available for treating some cancers \u2014 and those costs can reach into the hundreds of thousands of dollars.", "answer": 0}, {"article": "What if you could lose weight and reduce your risk of life-threatening disease without any changes in what you eat -- other than a five-day special diet once every few months?\n\"This study provides evidence that people can experience significant health benefits through a periodic, fasting-mimicking diet that is designed to act on the aging process,\" said Valter Longo, director of the USC Longevity Institute and a professor of biological sciences for USC Davis and Dornsife.\nThe diet, which was designed to mimic the results of a water-only fast, allowed for participants to consume between 750 and 1,100 calories per day.\nThe next step for researchers is a large, FDA phase III clinical trial to test the FMD on patients diagnosed with age-related diseases or at high risk for them.\nThe work was funded by the USC Edna M. Jones Chair in Gerontology fund, as well as through a National Institutes of Health grant to co-author Wendy Mack at the Keck School of Medicine of USC, through the Southern California Clinical and Translational Science Institute.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release discloses that meals during the low-calorie diet periods were provided by a nutrition company, there is no discussion of the cost of following this special diet. We thoroughly scoured L-Nutra\u2019s pages describing the ProLon meal kits containing \u201cproprietary plant-based soups, bars, drinks, snacks, herbal teas, vitamins, and supplements\u201d but no costs were to be found despite the site claiming the meal kits are available. The site invites potential customers to create an account and request more information.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says Lynparza \u201cwill cost $13,886 per month without insurance, according to AstraZeneca.\u201d It mentions that the manufacturer is offering financial assistance to pay for it.\nHowever, the story does not compare the cost to other treatments or address the question of whether insurance companies are expected to cover it, which are important questions now that the drug has been approved for use in breast cancer patients.\u00a0Many patients with metastatic disease worry about reaching their lifetime insurance caps.\nAstraZeneca also does not specify whether the financial assistance that will be provided will cover the full cost or some percentage of the cost, and how the degree of financial assistance provided will be determined.", "answer": 1}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story mentions that stem cell treatments are often not covered by insurance, they should have said how much these treatments typically cost.", "answer": 0}, {"article": "It would be, they report in the Journal of the American Medical Association.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\nIn 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nBut in the new report, Dr. Thomas Gaziano of the Harvard School of Public Health and colleagues say they\u2019re in fact simpler than the old guidelines, which advised people to aim for a total cholesterol level of less than 200, keeping \u201cbad\u201d LDL cholesterol to 130 for average people and under 100 for those considered at risk of a heart attack.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the New York Times skipped the cost question, NBC gave readers the numbers they needed to know. It said that \u201cStatins, which include Lipitor, Mevacor, Crestor and Zocor, are extremely popular. They\u2019re prescribed to about 15 percent of U.S. adults, at a cost ranging from about $4 a month for the cheapest generic version to $600 for a pricey name-brand.\u201d That\u2019s a huge cost range and, multiplied out for the millions more Americans who are being encouraged to take statins, represents a significant potential increase in health care spending. To inform readers even more fully, the story could have looked at what those global costs would add up to for the entire country. It also could have explained what researchers mean when they say that the drugs are \u201cworth it\u201d and how the value of treatment was calculated in the study.", "answer": 1}, {"article": "Pereira wrote about blood pressure reductions in a patient getting deep brain stimulation in the January 2010 issue of the Journal of Clinical Neuroscience.\nWhile the case study is only an example of the phenomenon occurring in a single person, previous reports have observed the same kinds of reductions in blood pressure in people getting deep brain stimulation for pain, though researchers had believed that the blood pressure benefit was directly tied to the degree of pain relief the person experienced.\nJan. 24, 2011 -- Using electrical pulses to stimulate nerve centers deep within the brain may reduce high blood pressure that can\u2019t be controlled with medication, a case report shows.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\nThough his pain eventually returned after four months, his doctors report that their patient\u2019s previously uncontrolled blood pressure has remained normal for nearly three years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2013 a major omission. According to one estimate our reviewer accessed within minutes, costs for the device and procedure may be upward of $150,000 per patient. Any discussion of costs should also include the costs required to monitor the device over time.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this article\u00a0mentioned that rub-on testosterone products are readily available, it did not explicitly mention the cost of those products, or compare them to existing, approved treatment for anemia and low bone density in men.", "answer": 0}, {"article": "COLUMBUS, Ohio - Results from an international, randomized study show that an implanted nerve stimulator significantly improves symptoms in those with central sleep apnea, without causing serious side effects.\nOnly eight (11 percent) of those in the control group achieved the same reduction.\nDuring the first six months of evaluation, 68 devices were activated for treatment, while 73 were left inactive as the control group.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nPositive airway pressure devices have been used, but many patients don't tolerate them well and a recent study showed them to be harmful.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost. Surgery to implant a device is likely to be quite costly and it will require maintenance.", "answer": 0}, {"article": "\"If a cell phone company told you they tested all the models and their model came out the best, would you believe it?\nOne of the most prominent claims, that POM can decrease arterial plaque by 30 percent, was taken from a single pilot study that included just 19 people and was funded by the makers of POM.\nHealth.com: 25 diet-busting foods you should never eat\n\nNot all of the products were drinks, but \"the beverage category stands out,\" says Bruce Silverglade, director of legal affairs at the Center for Science in the Public Interest, a consumer advocacy group based in Washington, D.C. \"At first blush it seems that beverage products are certainly a large proportion of food products that make bogus health-related claims.\"\nThe federal government doesn't require companies to vet health claims with the agency before plastering them on product packaging (as long as the claims are accompanied by a disclaimer about their uncertainty).\nAnother claim, that POM drinkers experience a 17 percent improvement in blood flow, was taken from another POM-funded study that included just 45 people and only lasted for three months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says a bottle of POM costs $4, meeting our standard for a satisfactory. It could have specified that\u00a0the $4 cost refers to 16 oz bottle and not a larger package.\u00a0There also is no information about how often you\u2019d need to drink the juice to obtain the claimed benefits, so we don\u2019t know if people\u00a0are supposed to drink a\u00a0bottle a day or a bottle a week \u2014 which would make a big difference on the\u00a0cost front. (The latter problem may not be the\u00a0fault of the article, as a quick perusal\u00a0of the POM website turned up no specific information about serving recommendations from the manufacturer.) .", "answer": 1}, {"article": "\u201cSo this is a possible fringe benefit.\u201d\n\nResearchers studied 2,447 men over 12 years, examining them every other year.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n\u201cWe were pretty surprised by the strong association with objective things like the 49 percent reduction,\u201d he said.\nAfter adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nOther nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention any costs of these medications if taken on a daily basis or per dose. ", "answer": 0}, {"article": "March 15, 2012 -- A new prescription gel may quickly treat a common precancerous skin condition called actinic keratosis, a new study shows.\nThe new gel, Picato (ingenol mebutate), is applied once daily for two or three days, depending on the area being treated.\nAt the end of the two-month study, 42% of people in the first group and 34% of those in the second group who got the new gel showed complete clearance of their lesions.\nThe short duration also makes people more likely to stay the course, another advantage, according to the study's authors.\nBy contrast, only 4% and 5%, respectively, of the people who received the placebo had complete clearance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of the gel. We quickly found online estimates of $699 for one tube at .05% dosage.", "answer": 0}, {"article": "So far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nA separate study a few months later showed no such benefit, however.\nThose findings appear in a separate report in the journal Menopause.\nBut no one knows if altering serotonin levels actually does affect women\u2019s hot flashes.\nBut there is little evidence that they work, according to the North American Menopause Society.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does discuss how much Lexapro \u2013 the antidepressant mentioned in the article \u2013 costs.", "answer": 1}, {"article": "NEW ORLEANS \u2014 Eighty-year-olds with clogged arteries or leaky heart valves used to be sent home with a pat on the arm from their doctors and pills to ease their symptoms.\nThis improved dramatically as the study went on, from 85 percent in the early years to 98 percent by its end.\nBut today \u201cwe have elderly folks who are extremely viable\u201d who want to decide for themselves whether to take the risk, he said.\nThat led more doctors to operate on older patients for everything from bum knees to bad backs.\nThe answer: Average survival was roughly six years \u2014 almost the same as similarly aged people who do not have heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion about the costs of the procedures discussed or whether there were additional costs associated with treating the older patient.", "answer": 0}, {"article": "Wilmington, DE, December 17, 2018 - The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or \"knocking out\" a gene in cancer tumors that helps the tumors develop resistance to the drugs.\n\"We believe that finding ways to use CRISPR to improve existing treatments will lead to some of the first benefits for patients while we tackle the vital ethical issues around the use of CRISPR for edits that can be passed on through DNA.\n\"We think it's best to start with CRISPR therapies that involve relatively conservative uses of this powerful tool,\" Dr. Kmiec said.\nBut he said some patients with non-small-cell lung cancer, the most common form of lung cancer, are resistant to chemotherapy agents used to treat the disease or develop resistance after being exposed to the drugs.\n\"This approach can also hopefully help contain costs and provide a level of safety and reliability that is reassuring for patients and increases the chance that insurance companies will provide coverage.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release mentioned this as a potential \u201caffordable\u201d way of making lung cancer treatment more effective, and that it can \u201chopefully help contain costs\u201d and provide reliability that \u201cincreases the chance that insurance companies will provide coverage.\u201d\nHowever, it doesn\u2019t mention the cost of either gene editing or chemo.", "answer": 0}, {"article": "Doctors used MRI and mapping biopsies to locate the cancerous tissues.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\nIf the technology holds up, it could also work for other cell-based cancers like breast, thyroid, pancreas and liver, Ahmed said.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quoted another news source quoting the researcher, who claimed \u201cthat HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100. Fewer side effects would also lower other health care costs, he said.\u201d\nBut that quote from the researcher may have been an incomplete assessment of costs.\nIt\u2019s unknown if cancers are more likely to recur following HIFU.\u00a0 If they were, then ultimate costs would be higher.\u00a0 In fact, the Lancet article noted that 4 men required retreatment within one year.\u00a0 Additionally, 39 of 41 men had repeat MRI/biopsy after 6 months.\u00a0 While that may have been just part of the research protocol, the extent to which repeat MRI/biopsy are part of clinical practice would also contribute to costs.", "answer": 0}, {"article": "The woman died a year later.\n\"If you are a patient and someone says, 'There is an 85% chance of you spending $120,000 on a drug, and spending four months of your life being sick, with no benefit,' you're not going to be so excited.\"\nThe Food and Drug Administration approved two new melanoma drugs in 2011 \u2014 the first new therapy for the disease in more than a decade \u2014 and approved two from GlaxoSmithKline on Wednesday.\nBut after decades of failure, the spate of new drugs is helping more patients than ever before, giving people like Herry more time and better quality of life, Schuchter says.\n\"The reason we're seeing these breakthroughs is because we did the basic science research to help us understand how this cancer happens, how it escapes therapy and how it progresses,\" Turnham says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Ballpark costs are mentioned in the final take home quote from the executive director of the Melanoma Research Foundation: \u201c\u201dIf you are a patient and someone says, \u2018There is an 85% chance of you spending $120,000 on a drug, and spending four months of your life being sick, with no benefit,\u2019 you\u2019re not going to be so excited.\u201d", "answer": 1}, {"article": "Lung cancer is the No.\n\u201cHowever, unique to this study, we have been able to report less advanced cancer in those who do develop cancer, a decreased frequency of squamous cell and small cell carcinomas, and improved survival, when controlled for stage, in people taking metformin and/or TZDs.\u201d\n\nThe team reviewed the medical records of 157 lung cancer survivors with diabetes.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\nWASHINGTON (Reuters) - Commonly used diabetes drugs such as metformin may help control lung cancer, and may help prevent it, U.S. researchers reported on Tuesday.\nPatients who had taken the drugs to control diabetes were much less likely to have lung cancer spread \u2014 which is when it becomes most deadly \u2014 the researchers told a meeting of the American College of Chest Physicians.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t quite relevant as there are no regimens to compare yet. In other words, this was not a prospective study comparing different methods to prevent or treat cancer. However, we give a nod because we\u2019re told that generic metformin is cheaper than TZDs.", "answer": 1}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\n\"This is the single most effective drug we've had in psoriasis, ever,\" says Kenneth B. Gordon, MD, a dermatologist and clinical associate professor at the University of Chicago's Pritzker School of Medicine.\nThe result: The thick, red, flaking skin lesions that are characteristic of psoriasis cleared up in about three times as many patients who got briakinumab as those who got methotrexate.\nAt that time, the company said it wanted to evaluate the \"next steps\" for briakinumab and might try for approval again at a later date.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At this stage of development, the cost of briakinumab is impossible to determine. However if the costs will be anything like other biologics such as Stelara \u2013 which the story mentioned \u2013 then the cost could be as much as $1,500 to 2,000/month.\u00a0 So some attempt could have been made to address the important cost issue in this field of drug development.", "answer": 0}, {"article": "Taking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\nThe 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this story, but statins are not free, nor is heart surgery. A quick note about how much they cost would have been helpful.", "answer": 0}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\n\"The potential to use such simple treatments to enhance the longer-term benefits of other behavioural, educational and technology-based therapies is very exciting,\" he said.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\nThe next step in the research is to understand exactly how oxytocin changes brain circuitry to improve social behavior, and to document how related treatments might be used to boost established social learning interventions.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention the cost of the oxytocin nasal spray sold as a generic, or under the brand names Pitocin and Syntocinon. Medical-grade oxytocin shouldn\u2019t be confused with the numerous brands of non-medical grade oxytocin sprays that are sold over-the-counter and online.", "answer": 0}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.\nIn the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.\nIn particular, the researchers compared the ability of all three NAD+ precursor vitamins - NR, niacin, and nicotinamide - to boost NAD+ metabolism and stimulate the activity of certain enzymes, which have been linked to longevity and health benefits.\nIn addition to Brenner, the research team included lead study author Samuel Trammell, Mark Schmidt, Benjamin Weidemann, Zhonggang Li, and E. Dale Abel at the UI Carver College of Medicine; Philip Redpath and Marie Migaud at Queens University Belfast; Frank Jaksch at ChromaDex in Irvine, Calif, and Ryan Dellinger, formerly at ChromaDex.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss costs. A 30-day supply, consisting of 60 125-mg tablets, is available on Amazon for $45.99, or $1.53 per day. There is just one manufacturer \u2014 ChromaDex \u2014 licensing the patented product to various companies, which package and sell it under their own labels. As a result, there is no real price competition.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story excels in this criteria where so many others fail. The story says, \"The program costs about $1,600 for 12 weeks,\" and then it goes on to make an\u00a0important comparison. \"Compare that to the $19,000 to $29,000 cost of bariatric surgery, which is often reimbursed by insurers.\" This helps readers understand that dieting is a far cheaper approach to weight loss, and that the burden of expensive weight-loss surgeries is actually passed onto all of us in the form of higher insurance premiums. We wish the story had driven home the point more emphatically \u2013 as it alluded to in the headline and in one line in the story \u2013 that people in the trial got the intervention for free.\u00a0 That\u2019s a big leap from reality. ", "answer": 1}, {"article": "Another method involves a specially designed treadmill tank.\nIt\u2019s also an easy-on-the joints form of exercise for seniors and others who suffer from arthritis, and a recent study shows it can speed recovery from stroke faster than using a traditional treadmill.\n\u201cThe study proposes a different, very innovative approach\u201d to rehabilitation after stroke, said Dr. Gisele Wolf-Klein, director of geriatric education at Northwell Health in Great Neck, New York.\nAt chest height, it\u2019s about 30 percent of body weight,\u201d Johnson said, noting, for example, that a person with an injured knee who weighs 100 pounds who is running in waist-high water would only feel like 50 pounds on the bad knee.\nFor those without access to a water treadmill, you can purchase a foam vest specifically designed for water jogging or use foam barbells to help keep you afloat.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, which is a significant oversight. At least some idea of what the out-of-pocket costs are for this kind of therapy is important.\nWhile we wouldn\u2019t expect the story to necessarily address all the following issues, these are the kinds of questions people have when considering what kind of therapy to receive.\nFirst, the treadmill systems: It is difficult for consumers to find a cost for underwater treadmills, as most of the companies that sell them tell potential customers to contact the company for a quote. However, the treadmill company mentioned by name in the article quotes $65,000 in the example on how its leasing program works. And a 2013 story in USA Today says that underwater treadmill systems range in price from $33,000 to $270,000. A 2014 story in Runner\u2019s World says that insurance may cover the use of such a treadmill system at a physical therapist\u2019s office, if the system is being used for injury recovery. The CBS story doesn\u2019t even give us that much information.\nSecond, this story also mentions pools that have a \u201cwater flow system you can work against.\u201d Again, it\u2019s not clear what the costs of such a system would be, but one such company notes that its least expensive therapy pool options start at $7,400 (yet, the same company notes that its standard system \u201cstarts at $22,900\u201d).\nThird, the story also refers to simply exercising in a pool with a foam vest or foam handbells. This is, of course, far more affordable for most people.\u00a0But it\u2019s not clear, at all, how comparable the benefits of this sort of activity are to the use of the high-end systems discussed in the rest of the article.\nLastly, for a story like this, it would be great to know how water-based physical therapy compares in cost to standard PT. It may not be covered by a patient\u2019s insurance and result in higher out of pocket costs, for example.", "answer": 0}, {"article": "But researchers say the preliminary findings could one day lead to diabetes treatments.\nWhen researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nMost of the research has focused on changes in gut hormones, but we have shown that a decline in specific circulating amino acids also occurs.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there was an acknowledgment that it simply wasn\u2019t possible to offer gastric bypass surgery to everyone with type II diabetes, there was no discussion about the costs of gastric bypass surgery.", "answer": 0}, {"article": "To book an interview, please contact: \n\nTucker Wilson \n\nMedia Relations \n\nFaculty of Health Sciences \n\nMcMaster University \n\n(905) 525-9140, ext.\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nIn a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Because the release is presented as if the study were conducted in humans, we would expect to see some explanation of what the vaccine might cost.\nA better news release might have commented on the potential costs (and time)\u00a0required for\u00a0testing a new vaccine and bringing it to market.", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story stated, \u201cInsurance often doesn\u2019t cover the 3-D portion so doctors say you often need to pay about $50 out of pocket.\u201d However, would have preferred a quote from an insurance company instead of doctors to be sure that this cost is reflective of true out-of-pocket expenses.", "answer": 1}, {"article": "The frequency of screening mammograms -- and the appropriate age to begin them -- has been debated since the U.S. Preventive Services Task Force in 2009 recommended that women routinely get screening mammograms every other year starting at age 50.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nAnd 7% to 9% will be told they should have a biopsy because of something suspicious that turns out not to be cancer, the researchers concluded.\nIts main message, Hubbard says, is that call-backs (or recalls) for false-positive results are common, so women shouldn't panic when they occur.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the financial costs of screening mammography & false-positive recalls & biopsies were not included in the study, readers would benefit from being reminded that recall mammography & biopsies increase patient financial costs.", "answer": 0}, {"article": "That\u2019s Stage IV cancer and it\u2019s almost always deadly at that stage.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\nThat doesn\u2019t mean a cure \u2014 it\u2019s too soon to say that \u2014 but it does mean months or years of cancer-free life that they otherwise could not have hoped for.\nThe drug works far better in patients whose tumors express more PD-1, meaning they have a lot of PD-1 activity, so the drug will optimally be used jointly with a test for PD-1.\nThe drug, called Keytruda, takes a new approach to treating cancer by stopping tumor cells from cloaking themselves against the normal, healthy immune system response.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The video claims the cost is about $150,000 a year and is \u201ccovered by insurance.\u201d The text story notes how pricey it is and states \u201cKeytruda costs about $12,500 a month, or $150,000 a year.\u201d", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the LVAD device costs $80,000, and that the total cost, including implant surgery, is over $150,000. ", "answer": 1}, {"article": "The study was published online June 27 in The Lancet.\nBut millions of Americans suffer from type 2 diabetes, so \"cost issues favoring sulfonylureas may be the only reason for preferring continued sulfonylurea use,\" he added.\nThe new study provides more evidence that drugs like linagliptin \"are just as good as the old standby sulfonylurea therapies, with the added benefits of inducing fewer hypoglycemic events, causing less weight gain, along with a likely decrease in cardiovascular events,\" said Dr. Stuart Weiss, an endocrinologist at NYU Langone Medical Center and clinical assistant professor at the NYU School of Medicine, New York City.\nTo compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were glad to see the story at least mentioned the cost issues, although we would have preferred some actual dollar figures. It says, \u201cOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\u201d And later it says, \u201cmillions of Americans suffer from type 2 diabetes, so \u2018cost issues favoring sulfonylureas may be the only reason for preferring continued sulfonylurea use,\u2019 he added.\u201d\u00a0 Barely satisfactory.", "answer": 1}, {"article": "It was published Tuesday in JAMA, the journal of the American Medical Association.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\nFor the problem-solving therapy, people were asked to create a list of the things that matter most to them in their lives and brainstorm on how to incorporate those things into daily life.\nStill, Buntrock seems pleased with the results, especially since the German insurance company BARMER GEK that sponsored the trial is now providing it to its customers.\nIt took the trainers about 30 minutes to provide feedback for each session, and they also stayed in touch with participants via instant messaging, Buntrock says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed in a meaningful way. The story simply refers to online programs for mental health problems as \u201clow cost.\u201d Given that the online programs used in the study involved generating feedback from online trainers for each session and for each patient, the cost may not be negligible. And it\u2019s not clear whether insurers in the U.S. would be willing to pay for preventive mental health treatment. The research was done in Germany, which has a different health care system than the U.S., but the issue of cost should have been addressed more fully.", "answer": 0}, {"article": "The other 10 received a fake treatment.\nThe tests also measured activities of daily living affected by neglect, such as dialing numbers on a phone, reading a menu, and sorting coins.\nThis condition often occurs after a stroke on the right side of the brain and is typically treated with a combination of physical therapy and brain retraining or mental tasks using a pen and paper or computer.\nResearcher Giacomo Koch, MD, PhD, of the Santa Lucia Foundation in Rome, Italy, and colleagues point out that the changes could be the combined effects of the mental tasks and the TMS.\nThey can\u2019t see or recognize anything on one side of their body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that TMS equipment is expensive and requires specialized training. However, this story didn\u2019t put a dollar figure on the cost of the machine as Reuters did. And neither\u00a0this story nor its Reuters counterpart attempted\u00a0to quantify the costs of treatment for\u00a0patients and insurers.", "answer": 0}, {"article": "Actuarial five-year OS was 95.6 percent for the entire cohort.\nOur trial confirms that SBRT may be preferable to other treatment approaches for newly-diagnosed cases of prostate cancer, including more aggressive disease.\u201d\n\nThe abstract, \u201cFive-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer,\u201d will be presented in detail during a scientific session at ASTRO\u2019s 58th Annual Meeting at 7:45 a.m. Eastern time on Monday, September 26, 2016.\nSpecifically in the low-risk group, the five-year RFS rate was 97.3 percent, which is superior to the 93 percent historical comparison DFS control rate (p = 0.014).\nAlthough prostate tumors generally respond well to radiation therapy (RT), the possibility of radiation exposure to healthy tissue in the genitourinary (GU) and gastrointestinal (GI) systems can be of concern.\n\u201cOur study is the first to contribute multi-center data that support the use of SBRT as front-line therapy for men with prostate cancer.\u201d\n\nA total of 309 men with newly diagnosed prostate cancer were enrolled in the trial at 21 community, regional and academic hospitals across the U.S.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release quotes lead researcher Robert Meier, MD, saying previous studies have shown SBRT to be \u201ca cost-effective and faster alternative to IMRT\u201d but does not provide any detail as to the specific costs of either procedure. In fact, the difference is substantial. A 2014 study in the Journal of Clinical Oncology examined Medicare claims data showed a mean treatment cost of $13,645 for SBRT versus $21,023 for IMRT. And a 2012 study in the Journal of Oncology Practice concluded that SRBT has \u201cgreat potential cost savings\u201d for the health care system, with an average cost of $22,152 versus $35,431 for IMRT.\nOne could also consider the cost of side effects as well as need for future treatments.", "answer": 0}, {"article": "On average, they spoke about three times.\n\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\n\u201cA lot of first-time moms wonder what\u2019s normal, what\u2019s depression, and what to do with the fact that they feel overwhelmed and alone and like their experience looks nothing like the happy moms they see smiling in all of the baby food and diaper commercials.\u201d\n\nBecause postpartum depression is the most common complication of childbirth, it makes sense to explore peer counseling and other interventions that can reach women in rural or suburban areas where access to mental health professionals may be limited, said Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the Center for Women\u2019s Mood Disorders at the University of North Carolina at Chapel Hill.\nTo assess the effectiveness of phone counseling for easing these symptoms, Letourneau and colleagues identified 64 mothers with symptoms of major depression within 24 months after delivery and offered them up to 12 weekly peer support calls.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We want to rule this satisfactory. The story notes that the peer phone counseling is run by volunteers with nurses on call, and is thus cheaper than professional counseling, which is \u201cexpensive.\u201d But we need some kind of quantification to know what the story means by \u201clow-cost\u201d vs. \u201cexpensive.\u201d", "answer": 0}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The intervention, rest, does not have any obvious costs. (Unless one is working, wherein prescribed rest can result in loss of income.) The tool used to track activity and symptoms could presumably cost\u00a0money if it\u2019s ever made publicly available.", "answer": 2}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost. \u00a0The cost implications are important. \u00a0The results of the study question the routine use of a costly drug, and cautions that the PPI only be used in select patients and not those who are on Plavix. \u00a0\nIt would been of interest to note that the alternative medications for the treatment of \u2018heartburn and certain stomach problems\u2019 are less costly than the PPI that appears to be problematic.", "answer": 0}, {"article": "\"Guidelines changed based on this study,\" Jolly noted.\nThe results of the study were published online March 16 in the New England Journal of Medicine to coincide with a planned presentation of the findings at the American College of Cardiology's annual meeting in San Diego.\nFor the study, Jolly and colleagues randomly assigned 10,732 patients undergoing an angioplasty after a heart attack to have clots manually removed or to not have them removed.\nMONDAY, March 16, 2015 (HealthDay News) -- A new study calls into question the value of removing blood clots from a patient's heart arteries during angioplasty, a procedure to open blocked arteries.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the cost of angioplasty, or whether that cost would be affected if routine practice regarding clot removal is changed. While there are many ways that costs might change that would be difficult or impossible to predict (for example, the impact of differing stroke rates and the related follow-up care), it should have been possible to estimate the direct costs of the procedure with or without clot removal.", "answer": 0}, {"article": "Of 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nIn it, the research team randomly assigned six patients to receive either sham or active rTMS one week and the other treatment the next, measuring pain scores before and after each session.\nIn addition to the potential of rTMS in pain relief, there has been growing research into noninvasive stimulation to augment progress in physical rehabilitation soon after stroke.\nHowever, Kobayashi and colleagues point out in their peer-reviewed online publication of this study, \u201cRepetitive Transcranial Magnetic Stimulation Once a Week Induces Sustainable Long-Term Relief of Central Poststroke Pain\u201d (Neuromodulation: Technology at the Neural Interface: April 23, 2015)[1] that there has still been controversy about the efficacy of rTMS in post-stroke pain.\nKobayashi said that some patients really hoped to continue rTMS after the study because their pain worsened after rTMS treatment sessions were over, and almost all the patients said that after the study ended, their pain increased to the level before rTMS.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA approved the use of rTMS for chronic depression several years ago, so it should have been easy to approximate the costs of a 12-week \u00a0course of therapy. The usual cost of the use of rTMS for depression is $6,000 to $10,000 for 4 sessions per week for 5 weeks. So, continuing with treatment weekly for an ongoing basis (the approach advocated here) would appear to be relatively costly.", "answer": 0}, {"article": "Then last year, in a sharp turnaround, the CDC recommended that it not be used during the 2016-17 flu season after a study found it had not been very effective in the previous year, particularly among kids.\nThe company says its flu vaccine \"starter kit,\" which can vaccinate 500 people, costs $900.\nThe patch, about the size of a small square bandage, has tiny, dissolvable needles filled with a dose of flu vaccine.\nSome of these technologies are already available on the market, while others are still being tested.\nAnd the patch can be administered by people who aren't trained health professionals.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article provides information about the cost of both the flu vaccine patch and the jet-injector. The cost of giving flu vaccine by nasal spray isn\u2019t provided.", "answer": 1}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\nAbout 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost was made in the report about this device.\u00a0 As medications exist for treatment of migraine during aura, the comparative cost is important. Speculation as to whether this device would be covered by insurance would have also been helpful. \u00a0\u00a0 ", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the cost of some of the products in question.", "answer": 1}, {"article": "But the limit is tricky to impose.\nSher's ethics board said OK.\n\n\"And she went ahead and had a baby at 57 years of age without any problems whatsoever,\" Sher says.\n\"My best friend and I made a pact together that at age 38, if we were both still single, we were going to have a child on our own,\" says Robyn Ross.\nAnd the uterus doesn't decline like eggs do; in some cases, it can actually be coaxed back into working order.\n\"I guess there's a big assumption that most women that need to do this [are] career, successful, rich women,\" she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the high price tag for freezing eggs and the possibility that a family may need more than a single \u201cfreezing.\u201d\u00a0The story quotes about $40,000 for a safe number of eggs in storage and seems to imply that price includes the in- vitro fertilization required. But we wish they had done a better itemizing more ofl the costs of a high-tech pregnancy, including the possible higher risk of twins and pre-term delivery.", "answer": 1}, {"article": "Repatha, with a list price of more than $14,000 a year, was approved based on its ability to dramatically lower \u201cbad\u201d LDL cholesterol in patients who require more intensive therapy on top of widely-used statins, such as Lipitor, or who are unable to tolerate statins.\nThe data should pave the way for greater acceptance by health insurers and pharmacy benefit managers, who have been rejecting about 75 percent of prescriptions written for the expensive medicine despite multiple appeals by physicians.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\n(Reuters) - Amgen Inc said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease, according to initial results of a large, eagerly-anticipated trial released on Thursday.\nAt the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "To its credit, the story mentions the high cost of the drug Repatha \u2014 $14,000 per year \u2014 and cites reluctance on the part of some insurers to cover that cost without more substantive data on its efficacy. \u00a0The news release issued by the drug\u2019s manufacturer, Amgen, didn\u2019t include either point.", "answer": 1}, {"article": "Tumor cells make PD-L1 turn on PD-1 when immune cells approach.\n\"I suspect the findings were significant enough that this will be a practice-changing finding,\" Dr. Pasi Janne, lung cancer specialist at Harvard Medical School and the Dana-Farber Cancer Institute, told NBC News.\nLung cancer is the top cancer killer in the U.S. It\u2019s diagnosed in more than 220,000 people a year and it killed nearly 160,000 people last year, according to the National Cancer Institute.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes the costs and puts the costs in perspective, too. It says, \u201cKeytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey \u2013 costing about $150,000 a year for a course of treatment. It\u2019s approved for use with a specific test for PD-L1 activity.\u201d", "answer": 1}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nPeople who took Xarelto -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found.\nXarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring.\n\"Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks.\"\nXarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs. Various estimates we found quickly online showed a cost of $7 \u2013 9 per pill \u2013 not a trivial issue!", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains the cost of the glasses and lenses and that the lens costs could be recurring.\u00a0 It did not explain if insurance covers this approach.", "answer": 1}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nA recent study from the Center for BrainHealth at The University of Texas at Dallas shows that a certain type of instructor-led brain training protocol can stimulate structural changes in the brain and neural connections even years after a traumatic brain injury (TBI).\n\"People who showed the greatest change in cortical thickness and connectivity, showed the greatest performance increases in our cognitive tasks.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nThese findings provide hope for people who thought, 'This is as good as my recovery is going to get' and for the medical community who have yet to find a way to objectively measure a patient's recovery,\" he said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention how much the brain training costs. The release could have stated that the cost of cognitive training usually includes repeat visits to a therapist.", "answer": 0}, {"article": "The device has gas sensors that detect various odorous molecules in sweat.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\nStill, that means that 11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn't.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\nThe researchers are now testing more than 1,000 patients and trying to identify the odorous molecules unique to heart failure patients, Kechagias says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. Because the research is in its infancy and there does not appear to be a comparable device, we don\u2019t think the cost question applies here.", "answer": 2}, {"article": "Additional information is available at http://abstract.asco.org/176/AbstView_176_165870.html.\nDr. Mehnert, who is also a medical oncologist in the Melanoma and Soft Tissue Oncology Program at Rutgers Cancer Institute, shares more about the research:\n\nQ: How was the study structured?A: At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites.\nNewswise \u2014 New Brunswick, N.J. \u2013 June 2, 2016 \u2013 According to the American Cancer Society, the chance of being diagnosed with thyroid cancer has risen rapidly in the United States in recent years.\nThe clinical benefit of pembrolizumab in advanced thyroid cancer will be further studied in a follow-up phase II clinical trial that is now ongoing to try to discover biomarkers which predict response to treatment with pembrolizumab.\nQ: How are immunotherapy drugs changing the landscape of cancer treatment?A: Although many patients treated do not respond, when immunotherapy does induce responses in patients with advanced cancers, these responses may be very long lasting in terms of disease control.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost. Immunotherapy drugs like Keytruda that are already on the market have received wide attention specifically because of their high prices..The cost of Keytruda is easily obtainable and is approximately $5,000 per 50mg single use vial. Although the dose was 10mg every two weeks, that would require two vials at approximately $10,000 per month drug costs or $240,000 for the two-year treatment program.", "answer": 0}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss costs. Screening mammograms impose a significant cost on the U.S. health care system and insurers, particularly Medicare. Some critics of those suggesting less frequent screening for some groups of women argue that such efforts want to cut costs at the expense of women\u2019s health and lives. Evidence-based guidelines are winning over some hearts and minds, but hardly all.\nIn any case, it behooves news organizations to at least acknowledge the financial\u00a0cost issue and put it in perspective. This article did not and although it noted the improvement in data collection wrought by digital mammograms in recent years, it also did not note the increased cost of digital (and now 3D) mammography over conventional screening methods.", "answer": 0}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs. The author should have mentioned that the cost of installing a digital system is substantial and the cost-effectiveness of digital mammography as a screening program has not yet been evaluated.", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\nFor further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress \n\nPress Office in Room 5B of Fiera Roma during EULAR 2015 or on: \n\nEmail: eularpressoffice@cohnwolfe.com \n\nOnsite tel: +44 (0) 7738 890 799 / +44 (0) 20 7331 5442 \n\nTwitter: @EULAR_Press \n\nYoutube: Eular Pressoffice\n\nThe European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nReducing the TNFi dose by two-thirds resulted in more flares (exacerbations of symptoms and signs) but these subsided when the higher dose of TNFi was restarted, and did not adversely affect subsequent progression of any disability.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release includes a quote from the lead author, Dr. James Galloway, saying that his study findings offer \u201ca more cost-effective option\u00a0by substantially reducing the high drug costs associated with TNFi maintenance therapy.\u201d\u00a0But it does not specify how much the drug costs or how much might be saved with the new strategy.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of treatment is provided in a side bar: raloxifene is about $75 for a month\u2019s supply, while tamoxifen is about $100. Story notes that medication is taken daily for 5 years. ", "answer": 1}, {"article": "GW Pharmaceuticals funded the clinical trial.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\n\"Cannabidiol should not be viewed as a panacea for epilepsy, but for patients with especially severe forms who have not responded to numerous medications, these results provide hope that we may soon have another treatment option,\" says lead investigator Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center at NYU Langone Medical Center.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nIn addition to Dr. Devinsky, the co-authors in this study were: J. Helen Cross, PhD, FRCPCH, Linda Laux, MD, Eric Marsh, MD, Ian Miller, MD, Rima Nabbout, MD, Ingrid E Scheffer, MD, PhD , Elizabeth Thiele, MD, and Stephen Wright, MD on behalf of The Cannabidiol in Dravet Syndrome Study Group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of the drug but the NYT reported last year that Epidiolex could cost from $2,500 to $5,000 per month. Since the drug isn\u2019t FDA approved, it\u2019s too soon to know whether its cost will be covered by health insurance.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides no information about costs, in part because the patient who is the focus of the story was participating in a clinical trial and likely received the treatment at no cost. Even if that was the case, however, the story should have discussed how much this type of treatment would cost, if it became available outside the context of a clinical trial.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of stent insertion, which can run into the tens of thousands of dollars.", "answer": 0}, {"article": "Both drugs have been used for impulsive conditions, including ADHD.\nIn the paper Pharmacological manipulation of impulsivity: A randomized controlled trial published in Personality and Individual Differences, the scientists conducted a series of trials on 60 men aged between 19 and 32, with 20 taking a placebo, 20 Atomoxetine and 20 Modafinil.\n\"We found Modafinil, which is already on the market, did reduce people's impulsive behaviour,\" said Professor Vlaev.\nWhen we eat food that tastes good we get a powerful release of dopamine in the pleasure/reward section of the brain, but food addicts have been found to have a deficiency in a certain type of dopamine so that their sense of reward and pleasure is diminished, thus they have to eat more to reach the same level of pleasure as anybody else.\nThe tests revealed that those who had taken Modafinil had a significantly reduced level of impulsiveness, whereas Atomoxetine produced no difference compared to the placebo group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of Modafinil. According to GoodRx, a supply of 30 tablets containing 200 mg ranged from $86 at Safeway to $141 at Target on the day of our web search.", "answer": 0}, {"article": "\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\nAfter controlling for factors including smoking and education level, they found that women who breast-fed for 1 to 12 months reduced their risk of arthritis by 25 percent, and that those who breast-fed for more than a year cut their risk in half.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not mentioned but also not terribly important.\u00a0 ", "answer": 2}, {"article": "For the study, researchers looked at data on 27,347 women ages 50 to 79 who joined two WHI trials between 1993 and 1998 and were followed through 2014.\nThey took hormones or a placebo for five to seven years and were followed for a total of 18 years altogether.\nWomen were 63 years old on average when they joined the trials and had already gone through menopause.\nYounger women in the study appeared to have better survival odds with HRT.\nOne trial tested estrogen alone against a placebo, or dummy pill, while the other trial tested estrogen taken in combination with progestin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information is given on the cost of a typical course of treatment.", "answer": 0}, {"article": "Children who took vitamin D had a significantly lower BMI, the researchers found.\nDr. Evangelia Charmandari, associate professor pediatric and adolescent endocrinology at at the Medical School of the National and Kapodistrian University of Athens and lead author of the study, said: \"These findings suggest that simple vitamin D supplementation may reduce the risk of overweight and obese children developing serious heart and metabolic complications in later life.\u201d\n\nThe findings are set to be presented at the 57th Annual European Society for Pediatric Endocrinology Meeting, and have therefore not yet been reviewed.\nAccording to findings presented at the European Society of Endocrinology annual meeting in Barcelona, individuals with higher levels of total body and abdominal fat appeared to have lower levels of vitamin D.\n\nRachida Rafiq, the lead author of the study told Newsweek at the time: \"Our results are significant as vitamin D deficiency and obesity are very common problems in our society nowadays,\" she told Newsweek, and argued that it is an important potential relationship to explore.\nRelated: Household cleaning products might be making your children fat\n\nIn what is believed to be the first study to investigate the links between vitamin D supplementation and the weight and health of obese children and adolescents, researchers from University of Athens Medical School and Aghia Sophia Children's Hospital, Athens, recruited 232 particpants.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of Vitamin D is not mentioned, but the cost is so low we\u2019ll rate this N/A. (The study says about 100 of the 200 participants were given 50,000 IU of the vitamin per week, which works out to about 20 cents per month.)", "answer": 2}, {"article": "strongly supports the basic rationale being pursued at Sirtris, which focuses on the development of small-molecule compounds that directly activate the enzymatic activity of SIRT1 as a new therapeutic approach to many diseases of aging,\" Vlasuk wrote in an email to the journal.\nThe study in rodents found that when mice had a particular gene -- SIRT1 -- knocked out, or turned off, resveratrol had no effect on them.\nSeveral studies, including work with yeast, worms and flies, have found that resveratrol acts on a class of seven genes known as sirtuins and, in human cells, SIRT1 in particular.\nA decrease in mitochondrial energy production has been linked to a variety of diseases, including diabetes and Alzheimer's disease, as well as to the aging process itself, said senior study author David Sinclair, a professor of genetics at Harvard Medical School in Boston.\nMitochondria provide the energy that cells need to function.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 It\u2019s understandable that costs were not discussed at this early animal-model stage of research.", "answer": 2}, {"article": "Larsson and her colleagues combed through research databases spanning the last 45 years to find studies that tracked how much magnesium people took and how many of them had a stroke over time.\n\"It's again the diet per se, not any one individual component of the diet.\"\nBut Larsson told Reuters Health in an email that she could not say whether other aspects of what the people ate partially or entirely explained the finding.\nThose are things that have low sodium, high potassium and high magnesium,\u201d said Larry Goldstein, director of the stroke center at the Duke University Medical Center in Durham, North Carolina.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of such a diet is not in question.", "answer": 2}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy may work slightly better than soy at reducing menopausal hot flashes, a new study says.\nThe researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo.\nThey compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nA month\u2019s supply costs about $12, while a month of hormone tablets runs between $40 and $60.\nIt\u2019s thought to have similar effects to estrogen on the brain, bones, and blood vessels, Bolanos-Diaz told Reuters Health by email.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were pleased to see that the story included cost estimates of both soy supplements and of hormone replacement therapy pills.", "answer": 1}, {"article": "What's the point of a runny nose?]\n\u201cIt's almost symbiotic,\u201d Navarro said, \u201cbecause in order for it to survive and thrive, it needs its host to be happy and healthy.\u201d\n\nPerhaps the adaptations that help the parasites stay hidden also benefit their host by reining in overactive immune systems.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThis suggests that AIP-2 might also help humans, since dendritic cells have the same function in us that they do in mice.\nThe researchers also noticed that AIP-2 seemed to have a calming effect on the body's dendritic cells \u2014 a part of the immune system responsible for processing threats.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story speculates at length about potential benefits of this treatment, before ever establishing that this is preliminary research. Our guideline is \u201cif it\u2019s not too early to talk about benefits, then it\u2019s not too early to talk about costs.\u201d This story didn\u2019t\u00a0do so.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story suggests that competition in the marketplace for new sunscreen formulations is vigorous, it makes no mention of costs.", "answer": 0}, {"article": "\"If a health care provider wants to target blood pressure in a patient with traditional heart disease risk factors and above-normal blood pressure, he or she can look at coronary artery calcium to help with tiebreakerlike decisions,\" says J. William McEvoy, M.B.B.Ch., M.H.S., assistant professor of medicine and member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins University School of Medicine.\nThe researchers say this demonstrates that calcium scores may only be useful in guiding more personalized blood pressure treatment for patients with mild high blood pressure -- the gray zone -- not those with high blood pressure.\nParticipants with high systolic blood pressure between 160 and 179 millimeters of mercury had high event rates ranging from 20 to 40 heart disease events per 1,000 person-years regardless of their calcium scores.\nAnd the risk factor equations that determine whether certain people are at higher risk and should be treated more intensively with blood pressure medications may have inaccuracies on the individual level, says McEvoy.\nLow heart disease risk was classified as a less than 15 percent chance of a heart disease event over the next 10 years, and high risk was 15 percent or greater risk of a heart disease event.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release says that coronary artery calcium scans \u201caren\u2019t usually covered by insurance and can range in cost from $100 to $400.\u201d", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nIn the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\nCollectively known as the genitourinary syndrome of menopause (GSM), the various genital and urinary problems associated with menopause have created a market for new therapies and treatments to help women regain sexual function and bladder control.\nIt further demonstrated that four or five laser therapies may be superior in lowering the intensity of GSM symptoms compared with three laser therapies in both short- and long-term follow-up.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of CO2 laser therapy is not mentioned.\nMuch of the CO2 laser treatment in the US is applied to skin \u2014 often for wrinkles, scars, discolorations, or people who want to look younger. According to WebMD such \u201claser skin resurfacing\u201d cost an average of $2,330 in 2016.\nHowever, it\u2019s unclear if vaginal laser therapy would be comparable in terms of duration, equipment involved, or cost.", "answer": 0}, {"article": "\"By wearing the brace, I could get back to sports and was able to call my physician and say 'why didn't we try this first?'\"\nTheir quality of life improved, and their activity level went from one that did not permit recreational sports to one that did.\n\"It absolutely gave me almost immediate relief,\" he says.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no mention of costs which can be signficant.", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told that \"each visit runs a little over $800, and Dr. Sister recommends follow-up visits every four to six months.\"", "answer": 1}, {"article": "For more information about NIH and its programs, visit http://www.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nTo assess the impact of acetaminophen use on children's asthma, AsthmaNet investigators studied 300 children, aged 1 to 5 years old, who had mild, persistent asthma, defined as symptoms on more than 2 days out of a week but not daily.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Like the Boston Children\u2019s Hospital news release, the University Hospitals Case Medical Center news release does not address costs. The acetaminophen medication used in the study, Little Remedies, costs about 50 percent more than Children\u2019s Advil \u2014 $8.86 for 4 fluid ounces versus $4.96, respectively \u2014 at Walmart. It would have been helpful to include the costs of the generic versions of these drugs which could be significantly lower than brand name drugs.\nSince costs are not mentioned in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "The company said high levels of the protein might spur the immune system to attach the body\u2019s own tissues.\n\u201cThe question was, \u2018Can you prove in a very large trial what we\u2019ve proven here?\u2019 \u201d\n\nThe 865 patients in the trial, who were mainly in Asia, South America and Eastern Europe, received either Benlysta or a placebo in addition to the drugs they were already taking.\nIf Benlysta gets to market, it will be the first drug from the company, and one of the first in the industry, to result from genomics.\nOne recent study estimated that 322,000 Americans definitely or probably have systemic lupus erythematosus, the most common form of the disease and the one against which Benlysta was tested.\nBecause the disease\u2019s symptoms wax and wane on their own and vary considerably from one patient to another, it has been hard to demonstrate the efficacy of drugs in clinical trials.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article comments that Benlysta will be far more expensive than current treatments but doesn\u2019t give an order of magnitude. Nonetheless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "For the work, a cohort of 541 9- to 11-year-olds in China, 54 percent boys and 46 percent girls, completed a questionnaire about how often they consumed fish in the past month, with options ranging from \"never\" to \"at least once per week.\"\n\"It really has to be a concerted effort, especially in a culture where fish is not as commonly served or smelled.\n\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nPrevious studies showed a relationship between omega-3s, the fatty acids in many types of fish, and improved intelligence, as well as omega-3s and better sleep.\n\"Here we look at omega-3s coming from our food instead of from supplements.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No details are provided that would let a reader estimate the cost of including more fish in a diet such as type of fish or the amount to be consumed.", "answer": 0}, {"article": "Manuka is proving to be a moneymaker for many companies that market it online as \"nature's miracle\" and \"nature's greatest secret,\" claiming it can relieve everything from stomach ulcers to bedsores and sinus infections.\nThe picture has not always been so bright for manuka, or its manufacturers.\nAfter four weeks, seven of those 10 wounds no longer showed the bacteria's presence.\nThey find it difficult to accept anything that has an ancient lineage, whatever the scientific evidence,\" he says.\nThe dressings should be available this fall.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of one jar of manuka that can be bought over the internet.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nBut no cause-and-effect relationship has been established.\nCompared with the control group, the children scheduled for adenotonsillectomy were more likely to be hyperactive by their parents' estimates and more likely to experience behavior problems and sleepiness at school.\nThe rest have the operation to relieve breathing difficulty or nighttime sleep apnea, a serious disorder in which the sleeping child briefly stops breathing during the night.\nTwenty-two of the adenotonsillectomy patients, but only 2 of the controls, had a diagnosis of attention-deficit hyperactivity disorder.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs.", "answer": 0}, {"article": "\u2022 Surgery should be followed by intraperitoneal, or localized, chemotherapy delivered to the abdomen.\n\"For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced-stage ovarian cancer, but there are many survivors as well,\" said Dr. Narod, senior scientist at Women's College Research Institute.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\nUp to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss cost at all. This may be due to the fact that the researcher who wrote the opinion piece, and the institution that wrote the news release, are based in Canada, which has socialized health insurance plans. However, given the expense associated with surgery and chemotherapy, and the fact that the release was promoted through a U.S.-based online science news service (and thus, theoretically, aimed at least in part at U.S. audiences), there should have been at least some effort to address the cost. Even if the cost of the proposed standard of care is comparable to other treatment options for advanced stage ovarian cancer, it could have said that.", "answer": 0}, {"article": "; Karen L. Margolis, M.D., M.P.H.\nThe study was also limited by the relatively small number of strokes that occurred during the follow-up period (just 3.4 percent of the women experienced a stroke during the study period and 1.6 percent reported having had a stroke prior to the study) and by the Women's Health Initiative's exclusion of women who had already had severe strokes at the time of recruitment.\nBecause the study was observational, it couldn't establish a cause-and-effect relationship between breastfeeding and lower stroke risk, meaning that it is possible some other characteristic that distinguishes between women who breastfeed and those who don't is the factor changing the stroke risk.\nFor babies health, the American Heart Association recommends breastfeeding for 12 months with transition to other additional sources of nutrients beginning at about four - six months of age to ensure sufficient micronutrients in the diet.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Breastfeeding is not an option for all mothers, whether because of medical/physical limitations or because of socioeconomic ones. However, breastfeeding is also not a medical intervention that one can easily place a price tag on. As such, we rate this criterion as not applicable.", "answer": 2}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\n\"While I recognize there is no place like home, should there be the need for urgent or medical care the question is will that be available to the patient when they're in the setting of their own home,\" Padgett said.\n\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\nAccording to research done by the American Academy of Orthopaedic Surgeons, there are no significant differences between either approach in recovery outcomes six months after surgery.\nBut it's not the surgical approach alone that allows some of his patients to go home the same day -- it's a combination of what happens before, during and after surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of hip replacement, even though it is a common procedure and its costs are widely discussed. For example, a Blue Cross Blue Shield report noted an average cost of about $30,000, but with wide variations, ranging between \u201c$11,327 in Birmingham, Alabama, and $73,987 in Boston.\u201d", "answer": 0}, {"article": "Wolf notes, however, that chemoradiation often severely damages the larynx, which may cause problems with eating or swallowing years later.\nThe non-responders can be referred immediately for surgery.\n\"This approach allows us to enhance quality of life for all of our patients.\nAll three must be involved to assess the patient and refer to the appropriate therapy.\nMany patients can spare their voice box by having chemotherapy and radiation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This is the one area the release fails to address at all. Cost is simply not addressed.", "answer": 0}, {"article": "For more information, please visit http://www.\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\nThe first study, published in the journal Hypertension in 2012, found cognitive and cardiometabolic benefits of habitual cocoa flavanol consumption in older adults who had been diagnosed with mild cognitive impairment (MCI).\nDr. Kwik-Uribe went on to speak about Mars' flavanol research program that has spanned over two decades: \"The amount of research showing the beneficial effects of cocoa flavanol consumption is growing and Mars is proud to be a partner in important research like this that highlights the positive role cocoa flavanols may play in supporting healthy aging.\"\nThe high- and intermediate-flavanol cocoa drinks were produced using Mars' patented Cocoapro\u00ae process, while the low-flavanol drink was made with a highly processed, alkalized cocoa powder.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "One might say that everyone knows what a piece of chocolate costs. But this study isn\u2019t about chocolate. It\u2019s about a special concoction made out of the flavanols found in cocoa beans. As the release says, \u201cthe nutritionally matched drinks were specially prepared\u201d using either \u201cMars\u2019 patented Cocoapro process\u201d or \u201ca highly processed alkalized cocoa powder.\u201d We have no idea what that would cost for a typical U.S. consumer to replicate in the kitchen, but if the cognitive benefits of this concoction are to be believed, then it would make sense to mention the possible costs.", "answer": 0}, {"article": "If you'd like to find out more about this procedure, please click here\n\"It was like a miracle to me.\n\"I had a guilty feeling.\nLook what I've given her.\"\nIn less than a week, she was starting back to her regular routine, including exercise.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost estimate provided for this medical device.\u00a0 \n\u00a0", "answer": 0}, {"article": "WEDNESDAY, March 2, 2011 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.\nThe most common side effects in both groups were fatigue and depletion of white blood cells.\nThis drug shows much promise, and it should certainly be included in additional trials to fully establish its benefit.\"\nCommenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"The findings of this trial are exciting because they will propel eribulin into wider use.\nDr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost in the article.", "answer": 0}, {"article": "London, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nYou could stockpile the vaccine and wouldn't have this wait to make a new pandemic-specific vaccine,\" she said.\n\"With this type of vaccine, you would at least be able to start using the vaccine as soon as you knew a new pandemic was starting.\nNormally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this vaccine is not yet available, a discussion of costs is not necessary.\u00a0\u00a0\u00a0", "answer": 2}, {"article": "\u201cThis is a very different model for how we treat depression.\n\u201cWith our latest results, we believe that brexanolone, if approved, could provide relief for women with a range of postpartum severity.\u201d\n\nThe paper, published in The Lancet, includes a new integrated analysis of results from three double-blind, placebo-controlled trials that took place at 30 sites in the U.S., including UNC\u2019s Perinatal Psychiatry Unit.\nThe most common (\u226510% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.\nAt the end of the 60-hour infusion, the average reduction in patients\u2019 Hamilton Rating Scale for Depression (HAM-D or depression severity score) was 17.0 points for women in the brexanolone injection 90 \u00b5g/kg/hr group, versus 12.8 in the placebo group (p<0.0001).\nIn the brexanolone trials, we saw patients starting to feel better within days,\u201d said the trial\u2019s academic principal investigator, Samantha Meltzer-Brody, MD, MPH, director of Perinatal Psychiatry Program at the UNC School of Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention costs. While a new therapy may not have an established price, the release could have stated \u201cno price is available for this drug.\u201d What would be even better is some context for what women suffering from postpartum pay typically for counseling and medications.", "answer": 0}, {"article": "Has he had any use of prescription painkillers since he started the study?\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\nSuboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\n\"They make you feel great; I'm not going to lie, you take a couple pills, you feel relaxed, you don't feel nervous, you have the weight of the world off your shoulders,\" said one young man named Brian who would not letreveal his identity.\nHere's how it works: When people are addicted, new receptors are created in the brain, which crave opioids.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The focus of the segment is, properly, the high costs of addiction to painkillers. Still, it fails to state how much Suboxone costs. ", "answer": 0}, {"article": "For more information about the AACR, visit http://www.\nHowever, our results suggest that risk might differ by smoking history, with metformin decreasing risk among nonsmokers and increasing risk among current smokers.\nMetformin use for five or more years was associated with a 31 percent decrease in the risk for adenocarcinoma, the most common type of lung cancer diagnosed in nonsmokers, and an 82 percent increase in the risk for small-cell carcinoma, a type of lung cancer often diagnosed in smokers, but neither of these findings were statistically significant.\nThe AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with over 18,000 attendees.\nIn addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of metformin, which is available as a generic and is comparatively cheap. Nevertheless, since diabetes often requires a lifetime of drug use, costs of metformin versus other drugs would be useful to readers, especially in cases such as this when the drug under study is suspected of providing additional benefits or bringing negative side effects.", "answer": 0}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n\"Vaccinations cause acute distress for both infants and their parents, contributing to vaccination avoidance,\" states Dr. Anna Taddio, a pharmacist and senior associate scientist at The Hospital for Sick Children (SickKids) and professor, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario.\n\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No dollar signs here, though an over-the-counter tube of lidocaine cream usually costs under $10. We\u2019re not sure from the release if an OTC cream was used or one of the proprietary, prescription-only products.", "answer": 0}, {"article": "For more information, visit http://www.\n(Embargoed until 12:30 p.m., June 8, 2015) - A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).\n\"Prostate cancer still represents one of the main causes for cancer-related deaths among men,\" said Matthias Eder, PhD, co-author of the study and a researcher in the division of radiopharmaceutical chemistry at the German Cancer Research Center in Heidelberg, Germany.\nThe PSMA-inhibiting theranostic agent, called PSMA-617, is still in its initial stages, but it could be ideal for the treatment of patients with hormone-refractory prostate cancers, which are notoriously difficult to control and linked to poor prognosis.\nTo be clear, other PSMA-based theranostics have reached the research bench, but previous contenders had too many limitations in terms of instability in live subjects, a lack of imaging contrast between targeted tissue and background signal and increased PSMA-associated binding to normal organs such as the kidneys.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Nothing at all is said about the cost of this treatment either for imaging or treatment. Granted, the drug is in the very early stages of development, but that didn\u2019t stop the release from claiming that the approach \u201cpersonalizes cancer imaging and therapy,\u201d \u201coffers new hope for advanced prostate cancer,\u201d and may have \u201ca major impact.\u201d If it\u2019s not too early to make such bold statements, then it\u2019s not too early, in our view, to give some idea of what this treatment might cost.", "answer": 0}, {"article": "See the Cartoons of the Week.\nThe question of how soon children should be screened for high cholesterol is becoming increasingly important in the U.S., with its rate of child obesity topping 20%.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nBut because West Virginia has one of the nation's highest rates of death from heart disease, since 2000, the state has offered free, universal cholesterol screening to all fifth-graders enrolled in public schools.\nRather than calling for all youngsters to have their cholesterol tested, which would entail considerable expense on the national level, Dr. Ralph Sacco, president of the American Heart Association (AHA), suggests looking more critically at current screening guidelines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes one comment that national screening would be expensive, but it does not provide a dollar figure. It also does not mention the potential cost of treatments. Cost is clearly relevant to the story. The researchers blame the lack of health care insurance for the high proportion of parents and grandparents of these children who have never had a cholesterol test. The story does not address the issue of how families would pay for ongoing treatment.", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the cost of several of the products mentioned.", "answer": 1}, {"article": "For more information about the AACR, visit http://www.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nAmong the 36 patients with hormone receptor-positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease.\nBackground: In February 2015, the U.S. Food and Drug Administration (FDA) approved the CDK4/6 inhibitor palbociclib (Ibrance) for use in combination with the aromatase inhibitor letrozole for treating postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer.\nThe oral CDK4/6 inhibitor abemaciclib is a very different molecule from palbociclib, with distinct attributes that contribute to its discrete therapeutic effects, in particular, its single-agent activity, according to Shapiro.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While one could say it is far too soon to start talking about the cost of a drug that is only beginning to be tested in people, the release compared abemaciclib to a somewhat similar drug, palbociclib (brand name: Ibrance) that is listed at approximately $10,000/month. The release could have referred to the costs of similar drugs\u2026 and perhaps included some mention of how long researchers anticipate patients would be treated with this sort of drug. As an aside, the Wall Street Journal reported a fascinating story on how Pfizer set the (just under) $10,000/month list price of Ibrance.", "answer": 0}, {"article": "Co-authors are Evgeny Pokushalov, M.D.\n\"About a third of all patients undergoing bypass surgery will develop atrial fibrillation, putting them at higher risk for cardiovascular complications,\" said Jonathan S. Steinberg, M.D., senior study author and Adjunct Professor of Medicine at the University of Rochester and Director of the Arrhythmia Institute in the Valley Health System in Ridgewood, New Jersey.\n\u2022 In the 30 days following surgery, those who received Botox injections during heart bypass surgery had a 7 percent chance of developing AF, compared to 30 percent chance in patients who received saline.\n\u2022 One year after surgery, none of the patients who received Botox had AF, compared to 27 percent of the patients who received saline.\nAtrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story rightly points out that the development of atrial fibrillation after coronary artery bypass surgery has significant financial implications: \u201cAtrial fibrillation is also always associated with lengthened hospitalization and that means increased healthcare costs.\u201d But we would have liked to have seen some attention paid to the cost of the intervention, namely multiple injections of botulinum toxin.\u00a0 We calculate the cost of one 4mls vial of Xeomin (incobotulinumtoxinA) to be approximately $1000. This cost is likely to be rather small in comparison to the cost of extended hospitalizations, antiarrhythmic therapies and lost productivity from atrial fibrillation.", "answer": 0}, {"article": "Likewise with the hormonal IUDs.\nMegan L. Kavanaugh, a senior research scientist at the Guttmacher Institute, which studies reproductive health, said in an interview that \u201call new insurance plans obtained through the act\u2019s exchanges fully cover all contraceptive methods without any co-payments or other out-of-pocket costs.\u201d Title X family planning clinics and Planned Parenthood clinics are more likely than other sources to offer LARC methods, she said.\nOnly about half of obstetrician-gynecologists offer the implant, the committee said, and many physicians use \u201coverly restrictive criteria\u201d when deciding whether to recommend an IUD, especially for adolescents and women who have not yet been pregnant.\nIn a paper published two years ago, European experts predicted that \u201cafter decades of dominance by \u2018the Pill,\u2019 it is likely that in the future, long-acting reversible contraceptives will become the first-line contraceptive option, owing to their superior contraceptive effectiveness in real-life use, cost effectiveness as well as their established safety profile.\u201d\n\nHere is a summary of the advantages of LARCs, listed by the committee:\n\n\u25a0 They are independent of the sex act and do not depend on the user\u2019s motivation and reliability.\nThere are few contraindications; nearly all women are eligible for an implant or IUD, according to guidelines from the Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We applaud the way this story examines what may be the \u201cunder use\u201d of devices and clearly explains some of the nuance about up-front costs versus the long-term cost of contraception. Bravo for pointing out that the Affordable Care Act now covers these devices, which at one time may have seemed \u201ctoo expensive\u201d for some patients.\nWe think it would have been even better if the story had a few actual figures in it \u2013 to demonstrate this. For example, one website from Planned Parenthood explains the cost for the copper IUD this way:\n\u201cThe cost for the medical exam, the IUD, the insertion of the IUD and follow-up visits to your health care provider can range from $500 to $900. That cost pays for protection that can last more than a decade.\u201d\nAs the story points out \u2013 that cost will not fall to an individual patient who is covered under the ACA. But the old prejudices about cost may be part of the reason for the gap in popularity.", "answer": 1}, {"article": "The last update, in 2005, put more emphasis on chest pushes by alternating 30 presses with two quick breaths; those \"unable or unwilling\" to do the breaths could do presses alone.\nHands-only will be added to CPR training.\nOnly about 6 percent of those who are stricken outside a hospital survive, although rates vary by location.\n\"I was lucky,\" he said.\n\"It's a second lease on life,\" he added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not associated with this treatment. ", "answer": 2}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\nThe potential of irisin as a meaningful drug target in PCOS is very promising,\" said Dr Bacopoulou.\nIn this study, Greek researchers from Aghia Sophia Children's Hospital in Athens compared the hormones of 23 teenagers with PCOS with 17 healthy teenagers of the same age and BMI.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. Given how far this is removed from widespread clinical applications, that\u2019s somewhat understandable. Then again, if a clinical application is so far away, it\u2019s hard to understand why one would claim in the headline that this test \u201cmay reduce teenagers wrongly diagnosed with PCOS.\u201d\nThe researchers presumably know the general cost of measuring irisin levels in a blood test. Is it relatively inexpensive? Even a modest indication of general cost would have been welcome. The release could have acknowledged that the cost of the test in a research setting might be quite different from the cost of a clinical test.", "answer": 0}, {"article": "2014;311(24):2499-2507.\nWomen with heterogeneously dense breasts make up about 40 percent of the U.S. screening population (women ages 40-74) \u2014 approximately 25 million women in the U.S.\n\n\"Utilizing Genius\u2122 3D MAMMOGRAPHY\u2122 exams for breast cancer screening will reduce the need for subsequent unnecessary testing, and decrease the number of unnecessary breast biopsies\u2014 addressing concerns that were previously raised as limitations of conventional mammography while also reducing costs for health systems,\" said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions.\nThis study brought together the principal investigators from the groundbreaking 2014 study on 3D MAMMOGRAPHY\u2122 exams, also published in JAMA, this time led by Elizabeth Rafferty, MD, a co-author on the prior study.3 A total of 452,320 examinations (278,906 conventional mammograms compared to 173,414 Genius\u2122 3D MAMMOGRAPHY\u2122 exams), were analyzed.\n\"Density creates challenges for conventional mammography by obscuring the images, which often results in additional visits and exams for women,\" said Edward Evantash, MD, board certified OB/GYN and Medical Director for Hologic.\nMARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius\u2122 3D MAMMOGRAPHY\u2122) exams reduce recall rates, and increase invasive cancer detection in women with both dense and nondense breasts.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No discussion of costs or whether the addition of the 3D mammography\u00a0is covered by insurance policies. This is a huge oversight considering the release touts the potential for significant cost savings. For example, the release states:\n\u201cThis has the potential to provide health systems and insurance companies with significant cost savings, reduce patient stress and expenses, and alleviate challenges for referring physicians who are tasked with relaying mammography results to their patients.\u201d\nA quick online scan of the cost for this newer technology finds that although the 3D test is FDA-approved, it still isn\u2019t covered by most insurance plans.\u00a0 At least one large clinic using the 3D technology asks patients for an an out-of-pocket payment of $60 and then the 2D portion of the imaging test is billed to insurance. The patient is liable for any outstanding balance after insurance has paid.", "answer": 0}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nKrystexxa, which is made by Savient Pharmaceuticals Inc. of East Brunswick, N.J., is an enzyme that lowers uric acid levels by metabolizing it into a chemical that does not cause bodily damage and is then passed through the urine.\nThe condition is associated with obesity, high blood pressure, high cholesterol, and diabetes.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nGout is more common among men and postmenopausal women, and people with kidney disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs.\u00a0 Why not?\u00a0 And, since the drug must be administered every two weeks as an intravenous infusion, cost of delivery could be another substantial issue. (Our medical editor on this story says such biologic infusions tend to cost more than $1,000 per infusion.) How could this be excluded from such a story? ", "answer": 0}, {"article": "For every one point increase in processed foods consumption, they lost 1.67 points in IQ.\nThe researchers identified three basic diets: \"processed,\" crammed with fats, sugar and convenience foods; a \"traditional\" diet high in meats and vegetables; and a \"health conscious\" diet with lots of fruit, vegetables, salads, fish, rice and pasta.\nThe key seemed to be the diet at age 3, since diet at 4 and 7 seemed to have no effect on IQ, the research team noted.\n\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\n\"This can have a series of deleterious effects, including decreased cognitive ability, poor behavior and social skills,\" she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is some research suggesting that diets with a lot of junk food cost less than diets that are rich in fresh fruits and vegetables. This might be a factor that explains why low-income families tend to eat more junk food than families that are well off. Frozen vegetables (and fruits) are also healthy choices and may be a better alternative for low-income families. The story could have brought this factor into the discussion.", "answer": 0}, {"article": "To study the relationship between berry consumption and heart disease, Cassidy and her collaborators at the Harvard School of Public Health analyzed findings from the Nurses Health Study 2 which includes more than 90,000 nurses in the U.S.\n\"They have effects on blood pressure in animal models,\" says Cassidy.\nWould the protective effect hold up for older women?\nEckel says it's not clear.\n\"Having a heart attack when you're a woman between ages of 45 and 60 is distinctly unusual,\" says Eckel.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not mentioned but we think most people know the ballpark cost of berries.", "answer": 2}, {"article": "He cites clinical data showing stroke and death rates of more than 10 percent within one year among those getting stents -- not much different from the results in the same study for surgery.\n\"My memory and energy levels are better now,\" she said.\nDr. Alberts and some other doctors say that both procedures are done too often and that the advent of carotid stenting seems to be making the problem of over-treatment worse.\nThen there are the interventional radiologists, who have extensive experience with stenting in arteries not near the heart, and neurologists, who specialize in treating brain diseases.\nMeanwhile, patient demand for stents is growing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of stenting procedure put at $10 -15K; later mention of \nMedicare restriction of coverage criteria.", "answer": 1}, {"article": "To contact Editor's Note author Mitchell H. Katz, M.D., email mediarelations@jamanetwork.org\nThe authors note a number of limitations in their study including that breast cancer was not the primary end point of the trial for which the women were recruited; the number of observed breast cancer cases was low; the authors do not have information on an individual basis on whether and when women in the trial underwent mammography; and the study cannot establish whether the observed beneficial effect was attributable mainly to the EVOO or to its consumption within the context of the Mediterranean diet.\nThe authors report that women eating a Mediterranean diet supplemented with EVOO showed a 68 percent (multivariable-adjusted hazard ratio of 0.32) relatively lower risk of malignant breast cancer than those allocated to the control diet.\nThis one has a small number of outcomes (only 35 incident cases of breast cancer), the women were not all screened for breast cancer with mammography, they were not blinded to the type of diet they were receiving, and all were white, postmenopausal and at high risk for cardiovascular disease.\nThe women were an average age of 67.7 years old, had an average body mass index of 30.4, most of them had undergone menopause before the age of 55 and less than 3 percent used hormone therapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost of the supplemented diets compared to what might be expected for a normal daily diet.\u00a0 Some brands of extra-virgin olive oil can cost considerably more, comparatively,\u00a0than other available cooking oils. \u00a0And you\u2019d have to buy lot of olive oil to match this diet \u2014 participants received a whopping 1 L per week per family. Other foods in the Mediterranean diet (e.g. fish and nuts) are also relatively expensive. So the release fails at this category, although it is a minor failure in this case considering the relative strength of the rest of the release.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is not enough discussion of costs in the story \u00a0The costs one needs to consider \u2014 in addition to the cost of the initial bone scan \u2014 are any treatment-related costs (e.g. drug therapy), as well as follow-up care, monitoring, etc. These would be offset by potential savings in terms of less need for future treatments for a new fracture. The story does mention that hip surgeries cost\u00a0$25,000 or more, which may help explain why hospitals are not clamoring to set up screening programs for men to prevent fractures.", "answer": 0}, {"article": "JACC is ranked No.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\nIn addition, as many as 20 percent of people hospitalized with a heart attack report symptoms of depression, while patients with heart disease have three times the risk of developing depression compared to the general population.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\nThe Journal of the American College of Cardiology, which publishes peer-reviewed research on all aspects of cardiovascular disease, is the most widely read cardiovascular journal worldwide.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It\u2019s hard to put a price tag on regular exercise as there are so many ways to get your physical activity on and many of them are free. So we\u2019ll say this category doesn\u2019t apply.", "answer": 2}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In a piece that found room to tell us how much the operating tables cost, there is no excuse for not telling us how much the competing procedures cost.", "answer": 0}, {"article": "This post has been updated.\nPart of the problem is the common perception that women deserve free mammogram coverage and that the scientific community is basing its decision on cost or rationing, said Lawrence Gostin, a Georgetown University law professor and expert on public health.\nThe American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nThe U.S. Preventive Services Task Force, an independent panel of experts whose members are appointed by the federal government, issued a final set of recommendations late Monday saying that women between the ages of 50 and 74 should get routine screening once every two years.\nThe task force's guidelines are important because insurers and government programs often follow the panel's recommendations in deciding whether to cover certain preventive services.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does address how the USPSTF recommendations may affect insurance coverage of mammography screening, as well as related congressional action mandating that insurers cover such screening. However, the story does not tell readers the bottom line: how much would a mammogram cost if it were not covered by insurance? While we found varying estimates, a 2011 paper stated that the overall cost of a mammogram was $266 \u2014 a considerable sum, and likely out of reach for many women. This was a shortcoming of both the Washington Post and New York Times stories.", "answer": 0}, {"article": "The study appears in the September issue of the journal PLoS Medicine.\nThe regular use of statins was associated with a 42% reduction in rheumatoid arthritis (RA) risk in a newly reported study of patients enrolled in one of Israel's largest health plans .\n\"It would certainly be premature to suggest taking statins to prevent rheumatoid arthritis ,\" he tells WebMD.\nThe analysis revealed that patients who took statins for at least eight years during the decade-long study period were roughly 40% less likely to develop rheumatoid arthritis than people who did not take statins at all or who took them less persistently.\nThe most widely prescribed class of drugs in the world, statins such as Crestor, Lescol, Lipitor, Pravachol, and Zocor reduce cholesterol in the blood by blocking an enzyme in the liver associated with its production.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story does not mention the costs of statin therapy, which include not only the drug itself but also ongoing testing and other monitoring. For some patients, statins are part of a lifelong treatment regimen. In those cases in particular, the costs can really add up.", "answer": 0}, {"article": "She's a breast surgery fellow at Massachusetts General Hospital and Brigham and Women's Hospital in Boston.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThat includes 39 percent who met the ACS criteria for above-average risk for breast cancer, and an additional 11 percent who met the American Society of Breast Surgeons' criteria.\n\"We believe formal risk assessment is essential for women ages 40 to 44 in order to identify those who require screening mammography to start at the age of 40, and those who would qualify for screening MRIs and genetic testing,\" Plichta said.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed in the story. It is not clear if such a breast cancer risk assessment would be covered under insurance if they asked their doctor for such an assessment.", "answer": 0}, {"article": "Walnuts are the only nuts with appreciable levels of omega-3 fatty acids, which some studies of male infertility have linked to better sperm quality, says researcher Wendie Robbins, PhD, of the UCLA Fielding School of Public Health.\nBefore and after the experiment, the men\u2019s semen quality was analyzed by a researcher who did not know which ones had eaten walnuts.\nThe other men were told to continue their regular diet but not to eat any tree nuts.\nHalf the men were randomly assigned to eat 2.5 ounces of walnuts a day, along with their usual diet.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned, but the price of walnuts\u00a0isn\u2019t\u00a0a major concern.", "answer": 2}, {"article": "Results of the vaccine were not as good in the other 25 patients.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nNov. 8, 2011 -- A vaccine for breast and ovarian cancer that has spread to other parts of the body shows promise, according to a preliminary study of 26 patients.\n\"In January, it will be four years [for her],\" he tells WebMD.\n\"It gives us encouragement that we may be on to something here.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does discuss costs, but the framing is problematic. The story, based on a conversation with one source, the study\u2019s lead investigator, says, \u201cIt\u2019s difficult at this point to predict costs. However, he expects costs will not approach those for Provenge, the pricey treatment vaccine for prostate cancer approved by the FDA in 2010. Provenge costs $93,000 for the one-month, three-dose treatment. Medicare covers it.\u201d This tells readers that, no matter what the drug costs, Medicare likely will cover it. We appreciate the effort to bring cost information into the story, but this type of information is misleading.", "answer": 1}, {"article": "Ribas' research is funded by the Parker Institute for Cancer Immunotherapy and the National Institutes of Health.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\n\"This particular combination has been especially gratifying because not only does the SD-101 therapy drug induce tumor shrinkage at the actual site where it's injected, but it's working in conjunction with pembrolizumab to shrink tumors outside of the ones we're directly injecting.\"\n\"We have found that the reason patients with metastatic melanoma do not initially respond to immunotherapy with an anti-PD-1 is that their immune system was not ready,\" said Dr. Antoni Ribas, the study's lead author, a professor of medicine at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The experimental drug does not yet have a cost.\nThe news release does not state that Keytruda costs about $12,500 a month (it is given intravenously every three weeks) or $150,000 a year. It would have been relevant to discuss\u2013since this new drug would be in addition to this very expensive treatment.", "answer": 0}, {"article": "Partial replacements are also cheaper, say researchers from Oxford University.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\n\u201cThe main strength of this study is that we were able to use real data, from very large numbers of people, about their actual operations, their GP visit, and their own reported quality of life outcomes in a way that is not always possible,\u201d said Dr Rafael Pinedo-Villanueva, the co-lead researcher and NDORMS senior health economist, who is funded by the National Institute of Health Research Oxford Biomedical Research Centre and the Medical Research Council.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\nAbout half of all patients should be suitable for a partial replacement, but an analysis of data routinely collected by the National Joint Registry showed that of 98,147 knee replacements undertaken in 2016, only 9% were partial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story ran in the U.S. edition of the Guardian. Generally, we expect those stories to acknowledge that the U.S. patients have to pay for their healthcare, and what those costs might be. However, in this case, because the research is looking at some benefits specific to the UK\u2019s National Health Service, we\u2019ll rate this N/A. It does include a small mention on this topic: \u201cPartial replacements are also cheaper, say researchers from Oxford University.\u201d", "answer": 2}, {"article": "It was surprising to see only 29 percent of patients received the recommended combination therapies, and as many as 20 percent are not getting any treatment six months after their diagnosis,\" said Dr. Lu-Yao.\nIt's not just the risk of side effects.For some men, especially those who are not fit enough for the surgery, prostatectomy is not an option.\nSeveral large clinical trials are nearing completion that should validate these retrospective findings of the benefits of primary radical prostatectomy followed by additional therapies such as adjuvant radiation,\" said Leonard Gomella, Chair of the Department of Urology at Jefferson (Philadelphia University + Thomas Jefferson University), who was not involved in this research.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\nOr, as a second option, to spare the prostate and treat it using radiation therapy plus hormone-blocking therapy,\" said senior author Grace Lu-Yao, PhD, Associate Director of Population Science at the Sidney Kimmel Cancer Center - Jefferson Health, one of only eight NCI-designated cancer centers nationwide with a prostate cancer program of excellence.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the cost of any of these treatments. One survey\u00a0from 2014 found uninsured patients were charged an average of $34,720 for prostate removal surgery, plus an average of $8,280 for physician costs. Some hospitals provided discounts for prompt payment.\nAny comparison between these options\u00a0could consider not only the costs of the initial treatment but also any subsequent costs associated with side effects or progressive disease.\nIt\u2019s also worth noting that Jefferson Health offers robotic surgery, which is substantially more expensive.", "answer": 0}, {"article": "Medtronic has also noted such effects in Infuse\u2019s warning label.\nThe products\u2019 use in cervical fusion procedures is a small component of their total sales, which reached an estimated $760.3 million in 2008, with Medtronic\u2019s share the larger one, according to Millennium Research Group, a consulting firm in Toronto.\nThe use of a bioengineered protein should be \u201cdiscontinued either permanently or until further information becomes available regarding how to use it safely,\u201d said Dr. Thomas A. Einhorn, chairman of orthopedic surgery at Boston University.\nThe high complication rate was seen in 2006 data..\n\n\u201cI would have hoped that this sort of surveillance would be a routine part of F.D.A practice,\u201d Dr. Deyo said.\nThe research team based its report on records collected through a database known as the Nationwide Inpatient Sample, which gathers information from 20 percent of the nation\u2019s hospitals.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nWhile this story reported that one manufacturer of bone-growth proteins had an estimated $760 million dollars worth of sales of the products in 2008, it did not include the higher hospital charges highlighted in the study published in the Journal of the American Medical Association. According to the study authors, the median hospital charges for spinal fusion procedures using the bone-growth proteins was $46,112, about 40 percent higher than the $31,179 median charge for procedures that did not include the proteins.", "answer": 0}, {"article": "He was fascinated by certain powerful cells of the immune system \u2014 T cells.\n\"It's a new modality for treating cancer,\" Dr. Samuel Broder, a former director of the National Cancer Institute, says now of Allison's pioneering research.\nA clinical trial to study the drug \u2014 now called ipilimumab, or Ippy for short \u2014 was set up at Memorial Sloan Kettering Cancer Center in New York City.\nIt might be too early to say we're going to cure cancer, Allison says, \"but we're going to cure certain types of cancers.\nStill, the approach offers promise to some people that other therapies can't, and has transformed the way doctors think about cancer treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost. Given that ipilimumab treatment can cost $120,000 (according to this 2012 paper in the journal Pharmacy & Therapeutics), and is not necessarily covered by insurance, that\u2019s a significant oversight. A\u00a0quick acknowledgement of the steep price tag would have made helped readers more fully understand what this treatment involves.", "answer": 0}, {"article": "In years past, \"the message was that chocolate consumption might be associated with higher LDL [bad] cholesterol or perhaps higher incidence of cardiovascular disease,\" he said.\nBoth are good for heart health,\" he said.\nThe National Stroke Association has more on stroke.\n\"Today, we know that all chocolates are not the same.\"\nAntioxidants are thought to prevent cell damage.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of chocolate is not in question.", "answer": 2}, {"article": "Stent sales fell roughly 30 percent to $4.1 billion in 2014 from 2006 levels, according to Evercore.\nExperts describe Abbott's device as an important step in finding a better approach to treating the leading cause of death in the U.S.\n\n\"This is presumably a better technology going forward, at least that's the theory, but it will take years to prove,\" said Dr. George Vetrovec, professor emeritus at Virginia Commonwealth University.\n\"The key for the stent market will be whether pricing returns to rational levels and the success of the new bio-absorbable stent platforms,\" states Evercore ISI analyst Vijay Kumar, in an investment note.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\nThe Food and Drug Administration approved the device Tuesday for patients with coronary artery disease, the artery-narrowing condition that causes about 370,000 U.S. deaths each year, according to government figures.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This piece does an admirable job of providing cost information in the face of reluctance by Abbott Labs, the stent\u2019s designer, to disclose such information. The reporter, instead, offers readers a sense of the typical hospital bill for \u201cstenting procedures.\u201d \u00a0You will not be surprised to learn that such surgery is not cheap at about $30,000.", "answer": 1}, {"article": "HIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\n\"The approaches we have taken pave the way for identifying drug candidates for other proteins that have traditionally been considered undruggable.\"\nTexas has the fifth highest rate of this cancer in the U.S.\n\nHIFs or hypoxia-inducible factors, like HIF-2, allow the body's cells to adjust to low-oxygen environments.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs mentioned. If a release claims that a drug is \u201cmore effective and better tolerated than the standard of care drug,\u201d it should also be prepared to give some cost specifics.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nPast research showed the sooner that a clot-busting tPA drug is given after an ischemic stroke - one in which a clot is blocking blood flow - the better patients fare.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\nThis preliminary study showed that three months after stroke, 182 out of every 1,000 patients treated before arriving at hospital were less disabled, including 58 patients who had zero disability, compared to people who received treatment after reaching the hospital.\nNour's team used data from Berlin's PHANTOM-S study, which took place from 2011 to 2015 and included 427 participants (median age 72) which were compared to 505 patients who received conventional care with in-hospital clot busting.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release briefly mentions the issue of costs with this statement: \u201cIts better outcomes could offset the increased costs of a mobile stroke unit.\u201d\nWe thought the release would have been better if it had noted the nominal cost of clot busting drugs as well as the cost of a CT scanner and additional personnel essential to mobile stroke units, which would be considerable.", "answer": 0}, {"article": "\u201cBut it\u2019s piecemeal,\u201d she said.\nAlthough the study could not determine why the patients lived longer, the authors and other experts had several theories: depression is known to shorten life, and patients whose pain is treated often sleep better, eat better and talk more with relatives.\nBut the National Institutes of Health is under budget pressure, and the other major source of money for medical research, the pharmaceutical industry, has little incentive to study palliative care.\nBut it also includes how much suffering a patient wishes to bear, effects on the family, and legal, insurance and religious issues.\nDuring the debate over President Obama\u2019s 2009 health care bill, provisions to have Medicare and insurers pay for optional consultations with doctors on palliative and hospice care led to rumors, spread by talk-show hosts like Rush Limbaugh and Glenn Beck and by the former vice-presidential candidate Sarah Palin, that the bill empowered \u201cdeath panels\u201d that would \u201ceuthanize\u201d elderly Americans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it touches on reimbursement, this story never addresses the key issues that most readers will be interested in \u2014 how much do palliative care consultations typically cost, does insurance cover it,\u00a0and does this approach\u00a0stand to increase or decrease the overall cost burden on our health care system?", "answer": 0}, {"article": "SpermCheck, which is approved by the U.S. Food and Drug Administration, assesses sperm count with 98% accuracy in 10 minutes and does away with the unpleasantness of conjuring up a sperm sample in a doctor\u2019s office.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\nStores will begin stocking the $39.99 test in April; until then, men \u2014 or their partners \u2014 can find it online at www.Walgreens.com and www.CVS.com.\nThe test reveals whether sperm count appears normal, at 20 million or more sperm per ml; lower than that indicates a trip to the doctor is pretty much unavoidable.\n\u201cIn our society, the woman carries the burden of trying to determine the issues surrounding infertility,\u201d Ray Lopez, CEO of SpermCheck, told Bloomberg News.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the cost of the test will be $39.99.\nAlthough the story does provide information about the cost of the test (which may have come directly from a news release), it fails to note that the standard approach requires two separate tests as established by the World Health Organization.\u00a0 At a minimum then the real cost of the test is $80.", "answer": 0}, {"article": "The new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\n''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodriguez Jr. T, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, DeVore B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Davila-Roman V and Eby CS for the GIFT investigators.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nNow, a new study led by Washington University School of Medicine in St. Louis shows that dosing warfarin (Coumadin and others) is safer -- producing fewer adverse events such as hemorrhage -- when key elements of a patient's genetic makeup are considered.\nThe School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked seventh in the nation by U.S. News & World Report.\n\"It's a widely used anticoagulant, but it causes more major adverse events than any other oral drug.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release doesn\u2019t give actual costs of warfarin versus some of the newer drugs, or factor in the cost of the usual monthly blood testing required of those taking the drug, it does note the cost of the gene testing used for the study, and that the $200 price tag is now less than a month\u2019s prescription of one of the newer anti-coagulants on the market.", "answer": 1}, {"article": "The scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not compare the prices between a six-month supply of anticholinergic drugs and a single botox injection.", "answer": 0}, {"article": "Founder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\nDue to increasing concern about antibiotic overuse and its links to obesity, celiac disease, and Superbugs, the American Academy of Pediatrics now recommends against the use of antibiotics to treat routine ear infections in children over 2.\n\"Eardrops don't work,\" says Dr. Scott Morehouse, founder of ClearPop, \"because the Eustachian tube, where the pain occurs, is connected to the mouth, not the outer ear.\"\nIn light of this, Morehouse developed a lollipop with a patented shape optimized to pull congestion out of the middle ear and into the mouth.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release\u00a0does not discuss costs, which is surprising. On Amazon, the cost is\u00a0$12 for two ClearPop lollipops, more than you might pay out of pocket if you have insurance that covers antibiotics but still relatively cheap.", "answer": 0}, {"article": "Amgen said Aimovig trial patients also had statistically and clinically meaningful improvements in secondary trial goals including fewer monthly migraine days and better physical function.\nSimilar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\nAmgen has partnered with Novartis AG to co-commercialize Aimovig in the United States, while Amgen has rights to the drug in Japan and Novartis has rights to commercialize in rest of world.\nLOS ANGELES (Reuters) - A late-stage trial of Amgen Inc\u2019s experimental drug Aimovig found that it reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments, while 14 percent of placebo patients achieved that goal, the company said on Tuesday.\nAimovig has the \u201cpotential to help fill treatment gaps in more difficult patient populations whose migraine has not been adequately managed with current therapies,\u201d Sean Harper, executive vice president of research and development at Amgen, said in a statement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs except to mention a $4 billion sales estimate. This doesn\u2019t help consumers. According to some estimates, pricing for the drug will start around $8,500/year. That\u2019s not chump change.", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not report how much the laparoscopic surgery costs, either directly or over time due to fewer complications or more treatments. \nOne assumes that robot-assisted surgeries are more expensive, though again the story should have specified. Given the possibility of economic self-interest by proponents of laparoscopic surgery, this information would have been very useful. \nA daVinci machine reportedly costs over a million dollars, with signficant annual maintenance costs in addition.\u00a0", "answer": 0}, {"article": "Researchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\nSince the optimal extended dose schedule is not known, researchers chose to look at the data in multiple ways, with the primary definition looking at extended dose history in the last 18 months, the secondary definition looking at extended dose occurring at any time in the dosing history, and for tertiary definition looking primarily at how extended dose history affects PML risk.\n\"Our safety findings are clinically and statistically significant, and we believe that extending the dosing schedule of natalizumab is practice changing and may save lives.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of infusing natalizumab is not mentioned, but this study found the 2-year cost to be $72,120.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There were no estimates for the costs of either treatment.", "answer": 0}, {"article": "This is relatively new thinking.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nWhen babies eat certain foods early in life\u2014the kinds so many end up allergic to, like eggs and peanuts\u2014they\u2019re less likely to develop allergies to those foods later on, finds a new analysis published in the ( ).\nBut, as an editorial published in the same issue of points out, in the next decade, food allergy prevalence nearly doubled in the United States.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost does not apply to in this example of eating habits. However, the story would have been stronger with some context about how much money is spent on treating child food allergies.", "answer": 2}, {"article": "Participants who slept for six hours each night did only slightly better -- they were 4.2 times more likely to develop a cold than the seven-hour-a-night folks.\nTo conduct the study, the researchers asked 164 healthy participants with an average age of 30 to wear a wrist actigraph \u2014 a device that monitors sleep \u2014 for one week to establish their baseline sleep habits.\n\"Sleep is part of our own nature's defense against illness,\" says Dr. M. Safwan Badr, former president of the American Academy of Sleep Medicine and chief of the division of pulmonary, critical care and sleep medicine at Wayne State University School of Medicine in Detroit.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\n\"It's almost alarming how strong the effects are,\" says Aric Prather, an assistant professor in the department of psychiatry at the University of California, San Francisco and lead author of the study, published Monday in the journal Sleep.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs, but there is no obvious commercial product involvement here, so we\u2019ll rate it Not Applicable. Although in theory there may be a cost to more sleep \u2014 \u00a0people often give up sleep for work or other activities.", "answer": 2}, {"article": "Others have such high cholesterol that taking statins alone is not enough.\n\"It seems that the group that takes them, compared to the group that doesn't, has half the rate of cardiovascular events and mortality as those that don't,\" Dr. Seth S. Martin of the Johns Hopkins School of Medicine told CBS News.\nOne in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\nThe antibodies target the cholesterol-regulating protein PCSK9 and lower the levels of LDL, the so-called \"bad\" cholesterol, by 60 percent.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2014 and antibody-based drugs are typically on the more expensive end of the drug-price spectrum. Some experts estimate that these drugs may cost in the $10,000-per-year range, which, extended over the lifespan of millions of patients, may be a tremendous burden for the system.\nIn addition, the difference in costs with statin medications is going to be striking. For those at very high risk in whom statins aren\u2019t enough, adding this medication may be appropriate. The challenge is defining use in those who cannot tolerate statins, since \u201ctolerate\u201d is a relative term. Many patients can be successfully switched from one statin to another. Having the new agent may result in providers and patients trying less hard to find the right medicine. Given the number of individuals who have elevated cholesterol, the cost implications could be staggering.", "answer": 0}, {"article": "\"When we say 'eat more fresh fruit,' we stick to the tried-and-true or anything that is handheld and peeled, but these findings suggest that a kiwi can be part of a heart-healthy diet,\" he said.\nA blood pressure reading that is less than 120/80 is considered ideal.\nIn addition, the study looked at the whole fruit, not individual nutrients.\n\"Don't count on this to be the complete answer to high blood pressure,\" he said.\nSystolic blood pressure is the upper number in a blood pressure measurement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs.\u00a0 Shoppers probably have a ballpark idea.", "answer": 2}, {"article": "This story has been updated with additional information.\nInterestingly, none of the patients who took the drug reported psychiatric side effects, such as abnormal dreams, insomnia, and anxiety \u2014 but 5 of the 11 women on the placebo reported such symptoms.\nThe drug has a \u201cvery, very short half-life\u201d in the body, Jonas said, meaning that it can be metabolized quickly.\nSage Therapeutics, based in Cambridge, Mass., reported on Tuesday that 7 of the 10 women who took the drug in the trial experienced significant improvement in their depression within 60 hours of the injection.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The drug is still in early experiments, but it would have been nice to give readers some indication of how the eventual price of this drug might compare to available antidepressants.", "answer": 2}, {"article": "Oppenheimer analyst Leland Gershell said he expects Amphora, the company\u2019s lead product, to bring in sales of up to $415 million by 2032.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\nAn estimated 16.5 million women in the United States do not use any method of contraception, according to the company, on fear of side effects, leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention what the cost might be for the new birth control gel. It\u2019s a useful bit of information in the birth control market with products ranging from a couple dollars for a condom and hundreds of dollars for an IUD. Reporters can ask for estimates or cost-comparisons even for products that are not yet approved or on the market.", "answer": 0}, {"article": "Sha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\n\u201cWe need to do the next steps to understand what is in the young plasma.\u201d\n\nPlasma is the liquid part of blood, with the red cells and immune cells removed.\nLater, because it was taking so much time and effort, they cut the trial to just nine people and all nine knew they were getting the real thing \u2013 a unit of plasma, once a week for a month, from healthy young men under the age of 30.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\n\u201cThere are things you can do but right now there is no drug that is actually going to slow down the progression of the brain disease in Alzheimer\u2019s,\u201d said Keith Fargo, director of scientific programs for the Alzheimer\u2019s Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this new approach in this story.\u00a0 The story does state that whatever product is potentially developed, it will not be whole plasma.\u00a0 Since we know what the cost to patients would be for current whole plasma transfusions, and for whole blood transfusions as well, it seems\u00a0plausible for some estimate to be made based on what patients are now charged for either plasma or whole blood transfusions.", "answer": 0}, {"article": "The results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\nThe drug has no street value or abuse potential.\nHe now suggests the medication to other addicts.\nYet addiction is stubborn.\nThe 30-year-old was back at work and seemed proud of his recovery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The high cost of these regular injections is front and center in this story.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Testing women for human papillomavirus (HPV) may catch more pre-cancerous growths than standard cervical cancer screening does \u2014 but more evidence is needed before the newer tests become routine, a study published Monday concludes.\nIt may not even be the doctor\u2019s \u2014 but may instead depend on whatever health system he or she is part of.\nIt has not been clear exactly how HPV testing, or liquid-based Pap tests, measure up against standard Pap tests.\n(The tests are not approved for younger women because they give doctors little information; younger women commonly have HPV infections that go away on their own.)\nSeveral other clinical trials in the review looked at HPV testing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not mention the cost of any procedure, nor does it tackle the societal cost of changes in screening frequency or method.", "answer": 0}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- A minimally invasive treatment for enlarged prostate that limits blood supply to the prostate seems to be just as effective as surgery but without the risk of debilitating side effects, such as impotence and urinary incontinence.\nAnother drawback is that few doctors are trained in PAE so far, said Pisco, chair of radiology at Hospital Pulido Valente and professor in the Faculty of Medical Sciences at New University of Lisbon in Portugal.\n\"Because medication is so effective, most of the patients that we treat surgically are in pretty bad shape,\" she added.\nDrugs are used to treat most patients with an enlarged prostate, with only about 10 percent qualifying for surgery to remove the entire gland, said Dr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Why not?\u00a0 You can let a researcher say it\u2019s ready to be used in certain patients, yet you can\u2019t estimate a cost?", "answer": 0}, {"article": "\u201cYou can say, \u2018O.K., let\u2019s dismiss the observational studies because they have all these problems.\u2019 \u201d But, he said, despite the virtues of a randomized controlled clinical trial, such a study \u201cwill never ever be done.\u201d It would be impossible to keep people on a low-sodium diet for years with so much sodium added to prepared foods.\nDr. Alderman said that he once was an unpaid consultant for the Salt Institute but that he now did no consulting for it or for the food industry and did not receive any support or take any money from industry groups.\nBut that study, others say, will never happen.\n\u201cIt\u2019s a problematic study,\u201d Dr. Sacks said.\nDr. Briss adds that it would not be prudent to defer public health actions while researchers wait for results of a clinical trial that might not even be feasible.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 2}, {"article": "Servan-Schreiber offered more words of wisdom to LaPook -- words he says doctors rarely impart to their patients -- and LaPook discussed with co-anchor Harry Smith on The Early Show Friday why he thinks it is that cancer survivors aren't offered more guidance by the medical establishment:\n\nServan-Schreiber appears in the joint CBS, NBC, ABC special \"Standing Up To Cancer\" Friday night.\n\"There's tremendous evidence that physical exercise helps prevent cancer, and also helps people who already have cancer prevent a recurrence,\" he says.\nAccording to Servan-Schreiber, herbs and spices such as garlic, turmeric, rosemary, thyme, mint, and green tea help make the body less fertile for cancer.\nHe has penned the best-selling book, \"Anti-Cancer: A New Way of Life,\" about his past and on-going battle, and offers suggestions to fellow cancer patients.\n\"Help it with the right nutrition, with physical exercise, with managing stress better, and avoiding contaminants that feed cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u00a0is not necessary for the story to discuss the costs of such common items, however it would have been nice if the story had mentioned that eating a diet high in fruits and vegetables could be more expensive than the traditional Western diet.", "answer": 2}, {"article": "Amgen will provide Phase III data on denosumab in advanced cancer patients at a major oncology meeting that begins later this week.\n\u201cIf you have a fracture because of tumor invasion of bone, the last thing you want to have is another one.\u201d\n\nAccording to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, one out of every two women over age 50 will break a bone in their lifetime due to osteoporosis.\nAs Prolia only needs to be taken twice a year, it is likely to be attractive to patients who are not happy with current drugs that must be taken more often or cannot tolerate them.\nNEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nIn a pivotal study that was the basis for the approval, Prolia reduced the incidence of vertebral, non-vertebral, and hip fractures in post-menopausal women with osteoporosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "According to the story, each injection is estimated to cost $825 and people will require two injections\u00a0per year. There is no mention of whether insurance companies will cover the cost, particularly since cheaper drugs for osteoporosis are available.\u00a0", "answer": 1}, {"article": "Arriving in New York, you would be synced to the local time after one day, he said.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nAs for frequent flyers trying this themselves, it is \u201cfar too early \u2013 neither the methodology is available outside research, nor any guidance about safety, nor tests of simulated jet lag in an appropriate \u2018realistic\u2019 protocol,\u201d Wirz-Justice told Reuters Health by email.\n(Reuters Health) - Exposing sleeping people to a series of short flashing lights at night might help them adjust more quickly to time zone changes, according to a new U.S. study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While no costs were discussed, the suggestion that the device might be expensive was made: \u201cThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\u201d We\u2019ll consider this nod in the direction of cost sufficient for a Satisfactory rating, since it would be difficult to say exactly how much such a device would cost at this stage.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of treatment costs.", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nUsing a specialized technique developed at McMaster, scientists collected and analyzed sweat samples from infants in CF clinics at the McMaster Children's Hospital and the Hospital for Sick Children in Toronto.\nResearchers have identified two new biological markers of cystic fibrosis (CF), a genetic disease which affects children and young adults, leaving them with lifelong health complications including digestive problems and persistent lung infections.\n\"CF Canada invests heavily in research that aims to improve the lives of people living with CF, and findings such as those from Dr. Britz-McKibbin are crucial to our understanding of the disease.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study does not address costs. The method used to identify the new biomarkers is described as \u201ca specialized technique developed at McMaster [University]\u201d (where the research was done), making it difficult or impossible to estimate what the cost may be.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no indication of whether the levels of vitamin D in multivitamin preparation had any impact on its price.\u00a0 Not only was the cost of the supplement ignored, so was the cost of monitoring treatment, costs of complications of overdosage, and \u2013 at the other end of the spectrum \u2013 potential savings from improved health.\u00a0\u00a0 Cost is a factor in such stories. ", "answer": 0}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe story cites a cost of ~$40,000 exclusive of hospital costs, and says this is roughly the same as traditional total joint replacement.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are mentioned reasonably\u00a0early in the story, and with specificity. This was good\u00a0to see.", "answer": 1}, {"article": "Give these a click:\n\nPersonalized cancer vaccines have already helped treat three patients\n\nSmartwatches might cause cancer, says article based on \u2018expert\u2019 who pushes holistic breast cancer treatments\n\nSun damage keeps happening even after you go inside, new study says\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nA modified version of the Herpes Simplex 1 virus (known for causing cold sores and some cases of genital herpes) called T-Vec has successfully been used to treat melanoma in a phase III clinical trial.\nBut there's more work to be done to determine just how T-VEC can fit into the cancer-treatment landscape.\nSo in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed -- the tumor.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of this drug. Genetically modified drugs are often extremely expensive and because there is no discussion of alternative therapies, it is difficult to know anything about the cost, actual or comparative.", "answer": 0}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The news story provides no information on the costs of using these drugs or alternative medicines.", "answer": 0}, {"article": "These findings suggest the pills may help protect against death in patients with pneumonia.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\nPatients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\nStatins such as Lipitor, Crestor, and a generic called simvastatin are widely prescribed to lower so-called \u201cbad\u201d or LDL cholesterol \u2014 a risk factor for heart disease \u2014 and are credited with being among the most successful drugs in helping to prevent heart attacks and strokes.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Notwithstanding one researcher\u2019s comment that statins are \u201ccheap\u201d (which might not be the case if we\u2019re talking about drugs that are still on patent),\u00a0there was no specific mention of the cost of treatment with statin drugs. These include the costs of the drug itself as well as ongoing monitoring.", "answer": 0}, {"article": "Abroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\nDr. Abroms has stock in Wellpass Inc. (formerly Voxiva, Inc.) and has licensed Text2quit and Quit4baby to Wellpass.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\nAfter three months, 16 percent of the women who were enrolled in both Text4baby and Quit4baby had quit compared with just 11 percent of women getting just Text4baby.\nQuit4baby is targeted to smoking cessation and sends more text messages--between 1 and 8 per day aimed at bolstering a pregnant woman's resolve to quit.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It is not made clear what costs would accompany this kind of mobile health message strategy, and whether the costs would be absorbed by health plans and health care providers that use the service, or by individual patients.\nWide use presumes thousands of app downloads and significant infrastructure costs on the part of those maintaining the service.\nIt\u2019s assumed there is profit motive, given the licensing agreement.\u00a0 ", "answer": 0}, {"article": "For the study, Lumeng's team collected data on more than 43,700 Michigan preschool-age children between 2005 and 2013.\n\"Head Start programs must adhere to specific dietary guidelines,\" she said.\nMore than 19,000 were in Head Start.\nThe report was published Jan. 12 online in the journal Pediatrics.\nThe program is designed to build stable family relationships, improve children's physical and emotional well-being and develop strong learning skills.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states early in the article that the Head Start Program is free to impoverished children ages 3-5.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re rating this one a cautious \u201cSatisfactory.\u201d\u00a0 The story offers no information about the cost to a patient of a digital therapist, but it does reflect on the cost of creating and maintaining a similar app.", "answer": 1}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The Wall St. Journal article did not discuss the costs or cost-effectiveness of any of the interventions.\n", "answer": 0}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nThat was longer than we expected, and it's great news for this group of women.\"\nResearchers say the 10-year interval is OK because the women\u2019s risk of developing the brittle bone disease osteoporosis in that time is low.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story makes no mention of costs.", "answer": 0}, {"article": "In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\nOther doctors were not so sure.\nThey came from about three dozen countries.\n\u201cIf it can keep the cancer away, I\u2019m all for it,\u201d said Ms. Behrend, 39, a single mother in Tomball, Tex.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Clearly stated.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does a good job of noting the cost of the combing salons, as well as\u00a0cost of the medicinal shampoos and other drug treatments, specifically noting also that insurance may not cover the costs.", "answer": 1}, {"article": "The compound WAY-316606 could therefore be used to treat baldness, without patients suffering the same side effects as they would on CsA.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nIn the U.S., there are around 50 million men and 30 million women affected by hair loss, which U.K.-based researchers said could be a source of \u201cpsychological distress.\u201d\n\nIn a study conducted on human hair follicles, researchers investigated a drug called Cyclosporine A (CsA), which has been prescribed to treat immune disorders and transplant rejection since the 1980s.\nThe research team, led by Dr. Nathan Hawkshaw at the University of Manchester, in the U.K., investigated whether CsA could provide some clues for treating baldness.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Arguably it\u2019s too early to know anything about how much this treatment might cost. But, if it\u2019s not too soon to speculate about a \u201ccure,\u201d it also could be argued that it\u2019s not too soon to address cost impacts. This was a tough call, but we went with N/A because of how early the research is.", "answer": 2}, {"article": "For more information about our products and the organization, visit http://www.\nThe RTSA technique--using an implant in which the natural locations of the shoulder \"ball and socket\" are reversed--uses other muscles to move the shoulder, providing an alternative when the rotator cuff is severely damaged or destroyed.\nAbout The Journal of Bone & Joint Surgery\n\nThe Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field.\nThe average Constant score--a standard assessment accounting for shoulder motion, strength, daily activities, and pain--at the time of final-follow-up improved from 24 to 59 (out of a possible 100).\nThe company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this surgical procedure in this news release.\u00a0 A quick search online reveals that such procedures can range in cost from $7,000 to $21,000 while an average cited by a study from Johns Hopkins placed the typical cost at around $10,000.\u00a0 Joint replacement operations are typically expensive and their costs should be provided in any story or news release promoting their use.", "answer": 0}, {"article": "It found that bariatric surgery:\n\u2022 produced a mean weight loss of more than 100 pounds\n\nCHARLOTTESVILLE, Va., Oct. 1, 2015 - A study evaluating the effects of bariatric surgery on obese women most at risk for cancer has found that the weight-loss surgery slashed participants' weight by a third and eliminated precancerous uterine growths in those that had them.\nThe findings have been published as a lead article in the scientific journal Gynecologic Oncology.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\nA total of 68 participants underwent the procedure; two opted out of the surgery, and another died of a heart condition prior to surgery.\n\"We're talking about small numbers, really tiny numbers\" of study participants, Modesitt said, noting one limitation of the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release (or in the study).", "answer": 0}, {"article": "[On average] \"22 grams (about .78 ounces) of new heart tissue grew,\" which he says is quite remarkable considering this had never been done before and the average weight of the part of the heart that is responsible for pumping the blood through the body is about 150 grams (about 5.3 ounces).\nHeart attack patients often go on to develop heart failure.\nHe says that why this is happening is still unclear.\nThe damaged area also doesn't conduct electric current as well, leading to an abnormal heart rhythm, which can cause more problems.\n\"That doesn't usually happen this way in research.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too early to have a meaningful discussion of costs.\n\u00a0", "answer": 2}, {"article": "\u201cI had to talk to my priest.\nBy contrast, said Dr. Paul Sugarbaker, a surgeon at Washington Hospital Center and the leading proponent of Hipec, \u201cthere are no long-term survivors with systemic chemotherapy \u2014 zero.\u201d\n\nDr. Sugarbaker, who opposed Dr. Ryan in the debate, said that it has long been known that cancerous cells are unable to withstand as much heat as healthy cells.\nWhile proponents contend that the risk of dying from the surgery has been reduced since the Dutch trial, the procedure still lasts eight hours or more and full recovery can take three to six months.\nThe therapy has even been featured on an episode of the TV series \u201cGrey\u2019s Anatomy.\u201d\n\nBut Dr. Ryan, a gastrointestinal oncologist, suggested in an interview that the procedure was being extended to because \u201cyou can\u2019t make a living doing this procedure in appendix cancer patients.\u201d\n\nHe debated the procedure publicly at the recent annual meeting of the American Society of Clinical Oncology.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Good job on this, stating \u201cThe cost of the surgery and Hipec, including hospitalization, ranges from $20,000 to more than $100,000, doctors said. While Medicare and insurers generally pay for the operation, the heated treatment may not be covered. But doctors added it may be if it is described merely as chemotherapy.\u201d", "answer": 1}, {"article": "The main side effects, Vertex said, were headache, upper respiratory tract infections, nasal congestion, rash and dizziness.\nThe long time needed to develop a drug for cystic fibrosis is a lesson for those expecting a quick payout from the sequencing of the human genome, which was completed a decade ago.\nThe saltiness of their sweat \u2014 a measure used to diagnose the disease \u2014 was markedly reduced, suggesting that the drug was having an effect on chloride ion transport.\nThe caveat is that VX-770 is designed to counter one specific genetic mutation that accounts for about 4 percent of cases of cystic fibrosis.\nIt can take years of research to determine how a mutation actually causes a disease and then to design a drug that corrects the problem.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It discusses the drug\u2019s costs, which are expected to be substantial.\u00a0Given the relatively small population that the drug might be of benefit to, price considerations are important. The story briefly notes both aspects.", "answer": 1}, {"article": "This study was presented at a medical conference.\nBut if the findings are confirmed, \"patients who are taking aspirin for other reasons may see an added benefit,\" says study head Kevin Choe, MD, a radiation oncologist at the University of Texas Southwestern Medical School in Dallas.\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nCost was not mentioned in this story. Now you might say that the focus is on aspirin, which readers are likely to already know is relatively inexpensive. However, the story should have highlighted the cost differential between aspirin and some of the other drugs included in the study, such as warfarin and Plavix, since those on the inexpensive aspirin derived the most benefit. And it should be noted that even drugs that cost little for each pill may cost the nation a substantial amount if long-term use is recommended for many millions of individuals", "answer": 0}, {"article": "Lakhan tells WebMD in an email that the extracts were administered orally.\nIn the paper, published in the open access journal BMC Neurology, the researchers write that recently introduced therapies of combined THC and CBD have the potential to relieve symptoms and that past reviews have suggested that cannabinoid therapy is beneficial for people with MS.\n\nGenerally, use of the marijuana extracts were well-tolerated in patients, the researchers write.\nThe reviewed studies included the use of cannabis extracts delta9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, in people with MS.\n\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms,\" Lakhan says in a news release.\nThe reviewed studies were published between 2002 and 2007 and included data from nearly 500 people with MS. Five of the six studies analyzed reported significant improvements in spasticity; one study reported no improvement in spasticity.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If the marijuana extracts are experimental, we could understand why costs might not be mentioned \u2013 which they weren\u2019t.\u00a0 But since the story never explained whether these are available products or not, we have no idea of availability nor of cost.\u00a0 ", "answer": 0}, {"article": "Other expert groups have made similar statements.\nFor example, Walmart sells Equate loratadine tablets (the same active ingredient as Claritin) for about $7 for 60 24-hour doses\n\nAntihistamines make perfect sense for someone who suffers a few sneezy days each season and doesn't want to use a spray for weeks or months, Eghrari-Sabet says.\nIf you are allergic to mold spores or to pollen from trees, grasses or ragweed, that means knowing when levels are high (by checking pollen.com or the National Allergy Bureau) and then taking steps such as these recommended by the American Academy of Allergy, Asthma and & Immunology:\n\u2022 Keep windows closed at home and in your car.\nThe non-prescription steroid nasal sprays are selling for about $17 to $23 for a one-month supply (at the typical two-squirts per nostril adult starting dose).\nThese drugs work by fighting inflammation and they are in the \"single most effective drug class\" for treating nasal allergies, according to the American College of Allergy, Asthma & Immunology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story goes above and beyond our standard here. There is a whole section on costs, which tells consumers to \u201cexpect to pay more.\u201d Insurers will no longer cover the cost, the article says, so expect to shell out $17 to $23 for a one-month supply of non-prescription steroid nasal spray. The story also discusses the costs of antihistamines and says store-brand versions are a cheaper alternative to steroid sprays. An example is Walmart\u2019s Equate loratadine tablets, which cost $7 for 60 24-hour doses.", "answer": 1}, {"article": "He and his colleagues plan to report their findings Tuesday at the Radiological Society of North America annual meeting, in Chicago.\nAnd though surgery safety has \"largely improved,\" Napoli pointed to the risk for bleeding and infection, the need for a minimum two- to three-day hospital stay, the high cost, and the fact that some patients ultimately realize little benefit.\nBy the one-year mark following either treatment, a full \"perceived\" recovery was reported by 95 percent of the pRF patients, compared with just 61 percent of the steroid injection patients.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\nFor the study, the Italian investigators compared 128 lumbar herniation patients who underwent a single 10-minute round of CT-guided pRF with 120 patients who received one to three rounds of steroid injections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says pRF is \u201cfar cheaper\u201d than steroid injections, but there\u2019s no data on its cost.\nWe found one web site, MD Save, offering procedures for $2,500, but it\u2019s unclear whether that\u2019s representative.\nThe story could have helped readers by comparing the cost of CT-guided pRF, CT-guided steroid injections, and lumbar disk surgery.", "answer": 0}, {"article": "The test isn't ready for prime time, however, and it's not foolproof: a study found that it misses some premature births and incorrectly predicts others.\nThe test may cost $150 to $250, Graves said.\nThe test wasn't as effective at 24 weeks of gestation.\nFor more about premature birth, visit the U.S. National Library of Medicine.\nThey tried to find signs in the blood that indicate what kind of birth the women would have.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included an estimate that \u201cThe test may cost $150 to $250.\u201d", "answer": 1}, {"article": "So researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nThe breath of diabetics sometimes smells of rotten apples, experts report; the skin of typhoid patients, like baking bread.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given that all the sources here have a vested interest in seeing these products come to market, clearly there\u2019s investor excitement\u2013aka \u201cprofit potential.\u201d When that\u2019s the case, it\u2019s a good idea to spend some time discussing what these products might cost, especially if they\u2019re not any more precise than current methods, which remains unknown. Healthcare costs in the U.S. are staggering\u2013will these products magnify this problem, or alleviate it?", "answer": 0}, {"article": "Indiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\n\"The five-year survival rate is really low, so that makes prevention and identifying risk factors or predictors associated with pancreatic cancer very important.\"\n\"Pancreatic cancer is really unique and different from other cancers,\" said study co-author Ka He, chair of the Department of Epidemiology and Biostatistics at the IU School of Public Health-Bloomington.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No cost information is provided but there are cost implications to following the recommendations. The release concludes that everyone \u201cshould strive to get the daily recommendations of magnesium through diet\u201d and \u201cadding a magnesium supplement to their diet may prove beneficial in preventing this disease.\u201d", "answer": 0}, {"article": "heart assocIation Mouth-to-mouth not necessary and seen as deterrent\n\nIn a break from decades-old first aid guidelines, the American Heart Association on Monday endorsed \"hands only\" cardio-pulmonary resuscitation - rapid chest compression without mouth-to-mouth resuscitation - to improve the odds for victims of cardiac arrest.\nThe bystander who needs to provide those chest compressions is often a loved one of the victim.\nThe pressure should be applied to the center of the chest, between the two nipples of the victim.\nThe message is, if there is any doubt, provide \"hands only\" CPR.\nThat's a risk well worth taking when the odds of survival without CPR are so slim.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The news story does not mention costs, but a discussion of cost is relatively unimportant in the context of this story.", "answer": 2}, {"article": "\u201cOver the next couple of years, we will find out what it means.\u201d\n\nOn Oct. 23, 2008, Avid and two other companies, and , that are developing fluorine 18-based dyes for amyloid scans, got a pointed question from an advisory committee to the F.D.A.\nOther tests are being studied \u2014 ones that look for amyloid in cerebrospinal fluid that bathes the brain; scans that look for shrinkage of the brain in areas needed for memory and reasoning; PET scans that look for uptake of glucose, a cellular fuel, to show areas where the brain was active and where it was not.\n\u201cSomething bad happens, and now something good happens.\u201d\n\nLate last year, Avid saw the initial results of its hospice study \u2014 data from the first six patients.\n\u201cThe field was taken aback.\u201d\n\nYet there was a problem.\n\u201cThe 20 percent who had amyloid, though they were still statistically in the normal range, did worse on every memory test than the control group.\u201d\n\nWhat, Dr. Skovronsky asked, did that mean?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is one glancing reference to cost. \"The type of scans used in this study, PET scans, are expensive and patients have to go to a scanning center, get injected with a radioactive dye, wait for the dye to reach their brain and then have a scan.\" How expensive? (The average cost\u00a0 of a PET scan is $3-6,000.) And, if this scan is truly the revolution that this story is making people believe it is, every person in America will want to have this scan done when they turn 50, maybe younger. What would that do to health care costs?", "answer": 0}, {"article": "Dr. Senay said another study done in Stockholm, Sweden observed that the decline of patients with a very mild form of Alzheimer's Disease after they began taking supplements that contained two Omega-3 fatty acids.\n\"The reason we talk about it so much is in the 1960s and 70s, researchers discovered people living there had lower blood pressure problems, cholesterol problems so they started to analyze the diet,\" Dr. Senay told The Early Show co-anchor Julie Chen.\nThe Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story advocates a diet of fresh fruits and vegetables, beans, nuts, fish and moderate consumption of wine. Fresh foods may cost more than pre-packaged fast food and may not be readily available to poorer people living in urban areas. These people are at even greater risk of developing health problems from a traditional American diet of processed, high-fat foods. This is not addressed in the news story.", "answer": 0}, {"article": "Roslin said limiting grains and sugars reduces insulin surges, which sparks water loss, curbs hunger and can boost energy.\nYour skin clears up.\nIt's a lifestyle change.\nEfron lasted only four days.\n\"I think 21 days without having solid food is very difficult.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "Duchenne muscular dystrophy affects an estimated one in 3,500 males, according to the National Institutes of Health.\nBecause of the involvement of the X chromosome, boys are far more likely to be affected than girls, who have two copies of the X chromosome and, thus, are likely to have a \u201cspare\u201d copy of the healthy gene.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\nThe team, working with funds from the NIH and non-profit groups, tested Viagra in mice that had heart damage similar to that seen in muscular dystrophy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nEven though this line of research is preliminary, the story should have noted that typical treatment for pulmonary hypertension patients who use the Revatio brand of sildenafil costs more than $15,000 a year and that since the drug does not cure the disease, this sort of treatment might well continue indefinitely. ", "answer": 0}, {"article": "Alzheimer's disease is the most common age-associated neurodegenerative disorder that has no cure.\n\"Taken together, our findings from these people confirm the data obtained with animal models and support, for the first time in human subjects, our notion that calcineurin inhibition has a protective effect on the development and possible progression and even reversal of Alzheimer's disease,\" said senior author Giulio Taglialatela, Professor and Vice Chair for Research in the department of neurology and director of UTMB's Mitchell Center for Neurodegenerative Diseases.\nThe UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the A\u03b2 oligomers and that elevated calcineurin is found in the nervous system of Alzheimer's patients.\nHowever, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The economic and clinical toll taken by Alzheimer\u2019s and other forms of dementia is staggering, so a treatment that could reduce the likelihood of developing the disease would have large consequences. \u00a0Identifying who should receive the treatment is important since not everyone will develop dementia. \u00a0That makes the cost of the intervention an issue from the economic perspective. These are difficult issues to explore in a new release, but the release could have at least signaled the importance of the discussion by mentioning the cost of these drugs. The medications are currently available for use by transplant patients \u2014 so pricing should not be hard to find.", "answer": 0}, {"article": "Kjersti Aagaard, vice chair of obstetrics and gynecology at Baylor College of Medicine and Texas Children's Hospital, is more skeptical.\nIron deficiency occurs in about one in six American babies, and it's more common among those clamped quickly, said Ola Andersson, a neonatologist and pediatrician at Uppsala University in Sweden, who led a study published today in JAMA Pediatrics.\n\"The most important thing for parents to be talking with their provider about is how will we adapt to the delivery as it emerges,\" she said.\nBut those doctors overestimated the benefit to the mother and didn't look at the impact their change had on the babies, said Heike Rabe, a researcher at Brighton and Sussex Medical School and University Hospitals, in the United Kingdom, who wrote an editorial accompanying the study.\nIn the new study, Andersson found that healthy, full-term newborns whose umbilical cords were left attached for three extra minutes had better fine motor control when they reached preschool than those clamped immediately.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The difference of slowing down the clamping of the newborn\u2019s umbilical cord does not seem to add any cost to care for a delivery. The story might have talked about potential \u201csavings\u201d if widespread use of this new technique made iron-deficiency for babies less common in US. But any benefit would be difficult to quantify.", "answer": 2}, {"article": "When she saw them, she said, \u201cI asked my analyst to rerun the data.\u201d\n\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nThe secretions, he added, pour from the base of the appendix into the right side of the colon and are \u201cvery sticky\u201d and can obscure polyps.\n\u201cAfter the prep has been completed, mucus and intestinal secretions start rolling out of the small intestine and colon,\u201d Dr. Rex explained.\nThe tests are \u201chugely expensive,\u201d he said, and insurers may not pay for more frequent colonoscopies.\nAbout a third of the colonoscopies were done by general internists and family practitioners who might not have had the experience to do the test well.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story refers to colonoscopies as being \u201chugely expensive.\"\u00a0 It would have been better to tell readers exactly how much they cost. ", "answer": 0}, {"article": "That\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nMost of the tumors found via CT scans were small, whereas those found through X-ray screening or in patients with symptoms were more often further advanced, according to the findings published in the journal Lung Cancer.\nWhile doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nCT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThere and in Canada, the lung cancer debate has centered around how often to screen smokers, and until what age screening should be done, Roberts said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story emphasizes cost several times, including the estimate of a few hundred dollars per scan.", "answer": 1}, {"article": "Eye and Ear specializes in ophthalmology (eye care) and otolaryngology\u2013head and neck surgery (ear, nose and throat care).\n\u201cThe development of cochlear implants, for example, didn\u2019t really accelerate until someone placed an electrode in the cochlea of a patient and found that the patient heard a frequency of some type.\u201d\n\nSmell loss, or anosmia, has an estimated prevalence of 5 percent of the general population.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\nIn the elderly, of whom there are estimates that greater than 50 percent of the population over the age of 65 has experienced smell loss, it can be difficult to get proper nutrition, as the sensation of flavor is closely tied to the sense of smell, and as flavor diminishes, appetite decreases in this population.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t addressed, but we wouldn\u2019t expect much here in regard to cost. The work is far too preliminary to attach a price tag, and the release highlights just how far off any relevant technology is from becoming a reality. Ideally, some discussion of cost, even in the most general terms (even if, for example, it were simply to say that it is far too early to estimate cost) would have been desirable.", "answer": 2}, {"article": "Lustig and his colleagues think they\u2019ve produced the \u201chard and fast data that sugar is toxic irrespective of its calories and irrespective of weight.\u201d\n\nMORE: FDA Wants Nutrition Labels to Include More Detail on Added Sugars\n\nLustig\u2019s confidence comes from the unique study, described in , of 43 Hispanic or African-American children aged eight to 18 years old.\nBut I worry that people are going to hang everything on this when we still need to reduce consumption.\u201d\n\nLustig hopes that won\u2019t happen as more data emerges that details how sugar is altering the body in unhealthy ways outside of its caloric contribution.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\nThe only difference in the nine-day diet was that most of the sugar the children ate was replaced by starch \u2014 the overall number of calories remained the same.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Many sugar-rich packaged and prepared foods are more expensive than home-made foods.But the study was not designed to compare the costs of diets, and most people know how much different types of food that contain sugar cost. So we\u2019ll rate this Not Applicable. On the other hand, it would have been useful to cite estimates of the cost of treating the disorders\u00a0linked to metabolic syndrome components, such as high blood pressure, as well as the costs of treating the chronic diseases that are a consequence of the syndrome, such as diabetes and heart disease.", "answer": 2}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nThis means their cancer depends on estrogen to grow.\nIn this procedure, just the tumor and some healthy tissue are removed, sparing the rest of the breast.\nAges ranged from 39 to 80.\nAmong the exceptions are those whose cancers are too large, or those who have different cancers in the same breast.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the differences in cost between the two options.", "answer": 0}, {"article": "She tried decongestants, antihistamines and steroid nasal sprays.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\n\"I read an article about people feeling less tired all the time after having had surgery, and I thought, boy, I would really like that,\" she says.\n\"And if we can use those as novel targets for, let's say, nasal sprays or medications, we may be able to treat people like Judy without surgery,\" Metson says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A comment about the overall cost of endoscopic sinus surgery, as well as insurance coverage and likely out-of-pocket expenses for patients, would have been appropriate in this story. In addition, the costs associated with the equipment and upkeep are also important considerations. However, the story didn\u2019t mention costs.", "answer": 0}, {"article": "Zee says that the effectiveness of pink noise is all in the timing.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n\u201cThat\u2019s very much tied to what part of the slow wave the stimulus is hitting on.\u201d\n\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds.\n\u201cWe wanted to see if it would work in older people, too,\u201d says senior author Dr. Phyllis Zee, professor of neurology at Northwestern University Feinberg School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article makes clear that commercial development of a pink noise generator is in the future, so it\u2019s too early to say what such a technology would cost. Indeed, we\u2019re told that the researchers hope to develop an affordable device. Affordable is too vague to be helpful here. We encourage reporters to at least dig up some numbers on existing alternatives. For instance, there are 99-cent apps to generate white noise and presumably higher quality speaker devices that run up to $120. But the pink noise study relied on timing the noise to sleep waves \u2014 so would a commercial product need to include an electroencephalogram device as well? That seems a different price category altogether.", "answer": 0}, {"article": "Elizabeth Williams, from the School of Biomedical Sciences at Queensland University of Technology, tells Newsweek the two studies \u201cdescribe tantalizing complementary and consistent results in Phase 1 trials in melanoma patients using vaccines.\"\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\n\"The vaccines are personalized for each individual\u2019s tumours by harnessing technologies that enable the comprehensive analysis of the molecular fingerprint of the tumour,\u201d she says.\nThe next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.\u201d\nCancer vaccines that are personalized to the patient\u2014designed to help the immune system identify tumors as foreign bodies and destroy them\u2014have been considered as a potential treatment for a number of years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story doesn\u2019t discuss how much the vaccines cost. Therefore, readers can\u2019t compare the affordability of these vaccines to existing treatment options.", "answer": 0}, {"article": "Nature publishes broad review articles, called Primers, that cover global aspects of various diseases and describe all aspects from epidemiology, disease mechanisms, diagnosis, screening and prevention, management and quality of life.\n\"IBS considerably affects quality of life and places an enormous burden on patients, physicians and the health-care system,\" said Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.C.P., F.A.S.G.E., Professor of Medicine in the Gastroenterology Division at the University of South Alabama in Mobile, Ala. \"The results of these studies add to the growing body of medical evidence supporting the utility of IBgard\u00ae, a novel formulation of peppermint oil, in improving the symptoms, patient satisfaction and quality of life of patients with IBS.\nThe lead author of the review article, entitled \"Irritable Bowel Syndrome,\"1 was Paul Enck, M.D., Department of Internal Medicine VI (Psychosomatic Medicine and Psychotherapy), University Hospital T\u00fcbingen, T\u00fcbingen, Germany.\nThe consensus report, entitled \"Irritable Bowel Syndrome: A Global Perspective,\"2 guides health providers in the best management of IBS through recommendations based on the latest evidence and resulting from a global expert consensus process based on best current practice.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release by the maker of IBgard notes that its product is available at \u201cCVS/pharmacy, Walgreens and Rite Aid\u201d and other stores, but it neglected to tell readers that the recommended doses would cost up to four times as much as generic peppermint oil capsules, with a monthly cost that could exceed $100 (6 capsules/day). (CVS lists IBgard at $22.99 for 48 capsules, or 63 cents each vs. 15 cents each for generic capsules.)", "answer": 0}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\n\"They're identifying a group of guys who don't need to be screened, or need to be screened less often,\" said Dr. Otis Brawley, the cancer society's chief medical officer.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not list the costs of all the screenings mentioned, but we give it a passing grade for at least addressing the issue of costs-versus-benefits. The story says, \u201cHPV tests cost $80 to $100 compared to $20 to $40 for Paps.\u201d", "answer": 1}, {"article": "Funding of this work was supported by the Nemours Foundation along with the regional economic development initiative of the Florida High Tech Corridor.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nIn the study, researchers loaded Cerium oxide nanoparticles with curcumin and coated them with dextran to test in cell lines of a high-risk form of neuroblastoma, known as MYCN-amplified, as well as non-amplified neuroblastoma.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release is about a pre-clinical study that looked at the effects of cerium oxide nanoparticles and curcumin in cell culture. It will be a while before this type of technology is studied in living patients.\nWe rate this one Not Applicable.\nWe caution news release writers that if it\u2019s not too early to talk glowingly about the potential life-saving benefits of an intervention in a news release, it\u2019s not too early to give some attention to the costs. However, this research is clearly far too preliminary to make such projections.", "answer": 2}, {"article": "And functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\nAnd I do a little twitch with my muscle in here.\nis functional electrical stimulation.\n\"I had these two implanted electrodes here.\nCenter.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.", "answer": 0}, {"article": "The study was funded by the Veterans Health Administration's Health Services Research and Development Service\nAll 129 patients in the study, most of them men in their 40s and 50s, were receiving outpatient addiction treatment in a CBT-based, non-abstinence setting at the Ann Arbor VA. Half were randomly assigned to ImPAT sessions, the other half to support groups of peers, led by a therapist, where pain and addiction could be discussed.\nJust 10 weekly sessions of the approach, called ImPAT for Improving Pain during Addiction Treatment, had an effect that lasted up to a year in 55 veterans who took part, according to the new results published in the journal Addiction by a team from the VA Ann Arbor Healthcare System's Center for Clinical Management Research and University of Michigan Medical School's Addiction Center.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nAnd while existing prescription guidelines do not explicitly prohibit the use of opioid painkillers in people with pain who have substance use disorders, these guidelines recommend only using opioids sparingly and under close supervision, he says.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed. How much might one ImPAT session cost\u2013given that patients may need as many as 10 sessions (or more) to see benefits? Is it possible that these sessions would be covered by insurance? It\u2019s not clear. However, to the release\u2019s credit, it does note that this treatment \u201chas the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\u201d That\u2019s a positive point. But it doesn\u2019t get at what the costs might be for patients. For example, does\u00a0\u00a0inexpensive adoption by treatment centers guarantee inexpensive treatment sessions?", "answer": 0}, {"article": "THURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\nAll had already undergone at least one failed drug regimen.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nAtrial fibrillation accounts for between 15 percent and 20 percent of all ischemic strokes, with stroke risk rising fivefold among patients with the condition as compared to healthy men and women, the release noted.\nFor more on irregular heartbeats, visit the U.S. National Library of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2013 a recurring and significant oversight. ", "answer": 0}, {"article": "\u201cDr.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cIt is very rewarding as a reconstructive surgeon to continuously refine these procedures for our patients.\u201d\n\nMs. Burt chose the Valley breast surgery team after carefully researching her treatment options for DCIS (ductal carcinoma in situ), a diagnosis that is often debated among clinicians as to whether it should be classified as breast cancer at all.\n\u201cIt\u2019s important to listen to each woman\u2019s needs and then to decide together what is the best approach to treatment, so that in the end the cancer will be gone and the woman can move on with her life,\u201d says Dr. Wilson.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No dollar signs here. However, not including a mastectomy (anywhere from $15,000 to $55,000 or more), tissue-expander breast surgeries typically cost about $40,000 per breast. But if there are any complications, those costs can skyrocket due to additional surgeries and other medical costs.", "answer": 0}, {"article": "The Morr\u00e9's are committed to the premise that understanding cancer is the key to its conquest.\nAlthough the fight against cancer often appears to be an overwhelmingly intransigent problem, significant progress is being made regarding the development of additional tools for cancer detection, such as the ONCOblot Test.\nor e-mail info@oncoblotlabs.com\n\nIf you'd like to read the clinical study, please visit http://clinicalproteomicsjournal.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nSerum samples that were collected from asbestos-exposed individuals prior to the development of mesothelioma as part of a cancer surveillance program were tested for ENOX2 protein presence to determine how long in advance of clinical symptoms that the mesothelioma-specific ENOX2 protein transcript variants could be detected.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It is notable that the company that sells the ONCOblot test (which can be used for early detection of 26 different cancers) doesn\u2019t discuss its price. Some clinics list their test cost at $850 or $1000. It is not known how often testing would need to be repeated, if it is found to be useful for people exposed to asbestos.", "answer": 0}, {"article": "Anderson estimates Jardiance could boost Lilly\u2019s earnings per share by 8 percent on average across 2016 to 2020.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\nThat has not been the case with all things in diabetes,\u201d said David Marrero, president of health care and education at the American Diabetes Association.\nThere was no significant difference in non-fatal heart attacks or non-fatal strokes.\nAbout 26 million Americans have type 2 diabetes, according to federal data for 2014.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The initial version of the story that we reviewed did not address cost.\nAn update to the story, posted after our review, noted the drug costs more than $4,000 annually.", "answer": 0}, {"article": "The results may help family members who are trying to get pregnant make decisions as well.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n\u201cWhen we do pre-implantation genetic screening, we can ensure that the embryos are chromosomally normal before transferring them back to the intended mother\u2019s uterus, and that increases the likelihood of implantation,\u201d Dr. Jared Robbins, an associated professor in obstetrics and gynecology-reproductive endo & infertility at Northwestern University Feinberg School of Medicine, told Fox News.\nAccording to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\n\u201cWe can\u2019t fix the embryos yet, but we can determine which embryos are affected by the disease and which aren\u2019t and only transfer back those that are not affected,\u201d Robbins, who is also a fertility doctor at Northwestern Memorial Hospital, said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost at all, which is a huge oversight in a story about preimplantation genetic screening. First of all, preimplantation genetic screening is only an option for people who are using IVF \u2014 which is expensive and often not covered by insurance. Second, the screenings themselves often cost thousands of dollars.", "answer": 0}, {"article": "\"We wouldn't want to be encouraging people to drink that much [coffee], without people considering the other risks factors,\" Hashibe says.\nIt\u2019s not exactly known why coffee may help prevent these cancers.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\nBut he is concerned that the side effects of coffee are not addressed in this study.\nToo much coffee may make it harder to conceive and can increase the risk of miscarriage.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable \u2013 the cost of coffee is not in question.", "answer": 2}, {"article": "Ankle replacement has been around for three decades, but it has been slow to catch on.\nNow another aging joint is fast becoming a candidate for replacement.\nEven with a successful implantation, patients should not necessarily expect to have the same ankles they did at 18.\nComplications can include slow healing, as well as infection.\nProblems with early devices left surgeons and patients wary.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article does not discuss costs \u2013 a significant oversight.", "answer": 0}, {"article": "Related links:Department of PsychologyCentre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain\u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9alMAB-Mackay Rehabilitation Centre\n\u201cThis cost saving can be both to the individual, and if appropriate, to the insurance companies that may provide individuals with assistive devices.\u201d\n\nPartners in research: This work was supported in part by the Vision Health Research Network, the Fonds de recherche du Qu\u00e9b\u00e9c - Sant\u00e9, the Antoine Turmel Foundation, CRIR, and the MAB-Mackay Foundation.\nBut there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\n\u201cTablet computers offer many of the same benefits while being socially acceptable,\u201d says Aaron Johnson, the study\u2019s senior author, and an associate professor in the psychology department, and a member of the Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal (CRIR).\n\u201cWhat was interesting to note was that it didn\u2019t matter what technology was used to do the magnification: an iPad worked just as well as a traditional device like a closed circuit television system (CCTV),\u201d he says.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We are glad to learn, as the release points out, that there may be a less expensive option for seniors needing vision aids, but we were disappointed that the release did not give any actual costs. The newest iPad models range in cost from about $260 to more than $400, depending on the features. However, people can buy used ones for far less money. Some of popular iPad competitors cost around $100 on Amazon.\nThe release states only this as far as cost: \u201cEnter the iPad: a technological device that\u2019s relatively cheap.\u201d We would have rather seen the release give us the actual cost of one of the \u201cexpensive\u201d devices and then compare it to the typical cost of an iPad. We also think the release could have mentioned other tablet devices, rather than focusing on one brand. For some people, expensive devices may be covered by an insurance provider, while less expensive ones are not. This complicates the cost to an individual. It was good to see a brief mention to reimbursement issues in the release.", "answer": 0}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\n\"The claims that are being made are not evidence-based yet, although they are intellectually appealing,\" said Hepinstall.\n\"The appealing thing about it is instead of going in and resurfacing a damaged joint, you're injecting something to help the bone, but keeping the patient's own anatomy,\" Hepinstall continued.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention any cost-related concerns. The story posits that this procedure is less invasive than the standard joint replacement surgery, which suggests there would be cost savings associated with pursuing a \u201cbone cement\u201d or \u201csubchondroplasty\u201d procedure, but this is not explicitly stated in the story. Also, like any new medical treatment, the cost might be much higher than expected.", "answer": 0}, {"article": "Participants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\nMany Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nThe risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss the cost of daily aspirin intake. Because the cost to individuals is low and well-known, we won\u2019t insist on this point. Nevertheless, were a recommendation made for everyone to begin taking aspirin daily starting at age 45 the national price tag would be substantial. Readers would also benefit from an acknowledgement that such a recommendation would lead to higher spending on treatment of bleeding ulcers and other adverse events that would offset some of the potential cancer-related savings.", "answer": 2}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nWithin a year, 14.4 percent of spironolactone patients and 13.4 percent of antibiotic patients had switched to alternative treatments, suggesting each treatment was working at almost the same rate, despite the fact that tetracycline-class antibiotics are prescribed five times as frequently.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t provide the cost for either antibiotics or spirinolactone. It only suggests that using spirinolactone could be \u201cless expensive\u201d than the antibiotic course.", "answer": 0}, {"article": "The process can take several years.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nThe study was funded by Acorda Therapeutics, the maker of cimaglermin, and the report was published online Dec. 26 in the journal JACC: Basic to Translational Science.\nTUESDAY, Dec. 27, 2016 (HealthDay News) -- Heart failure patients have weakened hearts, but researchers say an experimental drug used for the first time in humans may repair heart cells and improve heart function.\n\"It's a remarkable thing that you could give a drug once and have it affect heart function three months later -- it's really extraordinary,\" she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost for the tested drug, cimaglermin, in this story.\u00a0 The costs for regularly prescribed drugs for the medical condition that\u2019s the focus of the study \u2014 weakened left ventricular function \u2014 are well known and although cimaglermin is an experimental drug, it should be possible to predict whether the new drug would be comparatively priced, cheaper or more expensive.\u00a0 Readers would benefit from that knowledge.", "answer": 0}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. There was no discussion of costs, i.e. how consumption of a \u2018Mediterranean diet\u2019 compared to more typical diets compare in terms of cost to the consumer. But we think most people would have a pretty good grasp of the general costs of the types of foods involved.\u00a0 But where this becomes an issue, for example, is with what the cost of fresh fish can do to a food budget.", "answer": 2}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\nFor people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nOne large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of eggs and cereal is not in question.", "answer": 2}, {"article": "But, MacKay continued, \"it should also be understood that these two treatments actually work very differently.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nThe results: Both M-Y and Tamiflu were effective at eliminating fever, whether administered on their own or in combination.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\nThe M-Y flu preparation is composed of 12 herbs: ephedrae, zhimu, qinghao, shigao, yinhua, huangqin, chaoxingren, lianqiao, bohe, zhebeimu, niubangzi and gancao.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the herb mixture is much less expensive than Tamiflu. But how much does Tamiflu (and the related physician visit) cost?\u00a0Providing an actual\u00a0price tag would have dispelled any uncertainty.", "answer": 0}, {"article": "Doctors say bronchial thermoplasty has given them a new weapon in the battle against severe asthma, and many patients call it life-changing.\n\u201cI\u2019m a language therapist,\u201d she said, \u201cbut I can\u2019t even think of the word to describe how much better this has made my life.\u201d\n\nAcross the country, about 24 million people suffer from asthma.\n\u201cNow I can breathe,\u201d he said, \u201cand I\u2019m saving my insurance company a fortune.\u201d\n\nDr. Charlene McEvoy, a director of an asthma center run by Health Partners, the largest health plan in Minnesota, believed in thermoplasty enough to push the insurer to start covering it.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\n\u201cFor those of us in the field who work with severe asthmatics and see how limited they are, it\u2019s frustrating because we have this new therapy, we\u2019ve seen it work, and the data says it works,\u201d said Dr. Roy St. John, a pulmonary disease specialist at Columbus Pulmonary and Critical Care in Ohio.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story discusses the high price of the procedure and the unwillingness of most insurers to cover it. One could argue that the story is off base when it suggests that the procedure would be highly cost effective, without citing any supporting evidence or allowing a rejoinder from the opposing camp. However, we\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "And studies suggest that fortifying corn masa with folic acid could prevent an additional 40 to 120 cases of neural tube defects among babies born to Hispanic mothers each year.\nThe rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\nInstead, they were consuming corn masa flour products, because that was the staple grain in that diet,\" says Cynthia Pellegrini, senior vice president of public policy and government affairs at the March of Dimes.\nIt all has to do with nixtamalization, the process by which tough corn kernels are softened by soaking in an alkaline solution, usually of slaked lime.\nIt renders the corn more pliable for grinding into masa flour and gives the masa its distinctive aroma and flavor.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not talk about any costs. There are a few places where cost might have been valuable. The story could have discussed whether refining corn flour by a different method would cost more than the existing method. The story might have included whether fortified corn flour would be equal or higher in price for consumers than unfortified.\nWe also would have welcomed some comment on the cost of caring for a baby born with a neural tube defect.", "answer": 0}, {"article": "Newswise \u2014 HOUSTON \u2013 (Nov. 8, 2018) A small clinical trial using gold nanoparticles that act as tumor-seeking missiles on a mission to remove prostate cancer has begun at The University of Texas Health Science Center at Houston (UTHealth).\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\n\u201cIn fact, the first patient in the trial was actually riding a bike within a week of his treatment.\n\u201cThe side effects of traditional treatment were not worth it to me, and I wasn\u2019t afraid to try the most cutting-edge technology.\nIt is the first trial of its kind in the world.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No discussion of cost, but one could imagine that a treatment made from gold is not likely to be inexpensive.", "answer": 0}, {"article": "MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\nThe company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nThe Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although a major aim of the study was to examine societal costs of employing this test, the actual cost of the test to an individual patient is nowhere to be found.\u00a0 It appears to be in the hundreds of dollars, and there is no sign that Medicare is covering it as of yet.\u00a0 The release notes that a number of US-based insurance companies have contracted to use the test.", "answer": 0}, {"article": "Nestor received a research grant for the study from Ulthera, which makes the technology.\nMarch 19, 2012 (San Diego) -- Ultrasound treatment can reduce excessive sweating in the underarms by nearly 80%, according to a new study.\nResearchers used a ''microfocused\" ultrasound to target the sweat glands in 14 men and women, aged 18 to 75, says Mark Nestor, MD, PhD, a dermatologist and voluntary associate professor of dermatology at the University of Miami Miller School of Medicine.\n\"Microfocused ultrasound appears to be effective and safe in the treatment of hyperhidrosis,\" Nestor says.\nThe sweating can occur even when the temperature is cool and the person is at rest.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story seems to excuse itself from this issue by saying the researcher \u201cdid not estimate costs.\u201d\u00a0 Well, that\u2019s not good enough.\nThe story explains that the technology is already approved for eyelid lifts.\u00a0 Even though that\u2019s a totally different ballgame, what does that cost?\u00a0 Use of new technologies is not free \u2013 and stories promoting efficacy claims shouldn\u2019t give researchers a free ride on the cost issue.\nIt took us just seconds to find cost estimates online.\u00a0 One plastic surgeon wrote: \u201d rough pricing guidelines: Axillary treatment: Botox (~6 months): $600-995; Ultrasonic therapy (permanent): $3800 Hands OR Feet: Botox (~6 months): $400-895.\u201d", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address cost at all. The story is focused primarily on childbirth practices in the U.K., which has a significantly different healthcare system from that in the U.S. However, the story does discuss childbirth practices in the U.S., and speaks to U.S. experts on the subject. Home births are often significantly less expensive than hospital or birth center deliveries, but there are still costs involved. The story would have been stronger if it had addressed this, even in broad terms.", "answer": 0}, {"article": "Pancreatic cancer is the fourth leading cause of death from cancer in the United States.\nResearchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nAfter six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nInvestigators concluded that although the FOLFIRINOX did improve survival rates over gemcitabine, the toxicity of the drug combination caused numerous negative side effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\nOne of the online commenters on the CNN website wrote:\n\u201cWhat is the cost for these treatments? How long would the person live with no chemotherapy, just drugs for pain management? If a person wants to pay for these treatments on their own dime that\u2019s one thing. But as a society that shares limited resources for health care can we really afford to spend inordinate amounts to prolong a person\u2019s life a couple months? Not heartless, just pragmatic.\u201d\nAnother wrote, in response:\n\u201cI was one who was fortunate enough to be on Gemcitabine (at $2,000 per prescription for 6 weeks) after a whipple and radiation. That was almost 7 years ago. I have been able to further my education, re-marry, and watch my young son grow into a young adult.\u201d\nYet the story itself was silent on costs.", "answer": 0}, {"article": "As this Lancet study points out, because annual flu shots were recommended for the elderly since the 1960s, it has been unethical to conduct high-quality randomized controlled trials where you give only one group the shot in order to compare it with another group that didn't get the vaccine.\nIt's true that flu vaccines don't work spectacularly well, at least according to the best evidence we have (and most of the evidence on flu vaccines is of poor methodological quality).\nFor children under age 2, the benefits are less clear; the evidence, the researchers found, was scant, and of the research that was available, it seemed the efficacy of the shot was similar to placebo.\nThe flu shot is designed to protect people against three or four strains of the A and B viruses that researchers believe will be most common that year, leading to the nasty fevers, headaches, coughs, and runny noses that make many people miserable in the fall and winter.\nHe continued: \"However, the vaccines provide moderate protection, and can prevent huge numbers of cases of this serious illness.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story only touches on the costs of flu shots in passing, saying that they\u2019re relatively cheap, we\u2019ll give them the benefit of the doubt on this category.\u00a0 At least at two points in the story, the issue of costs are raised.\u00a0 We would have liked it even better had the story mentioned the actual range of possible costs for the flu vaccine.\u00a0 A quick web search shows the prices ranging from $10 to $30, based on information from the CDC.\u00a0 And free shots are regularly available at public health centers as well.", "answer": 1}, {"article": "For more information, visit http://medicine.\nThe study, \"The Impact of Preoperative Statin Therapy on Open and Endovascular Abdominal Aortic Aneurysm Repair Outcomes,\" recently was published in Vascular, the official publication of the International Society for Vascular Surgery.\n\"Our research showed that patients who took statins before either open or minimally invasive interventions had better outcomes compared to those who did not take statin medications,\" Vogel said.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"This information could be beneficial to patients who are about to have elective endovascular abdominal aortic aneurysm repair,\" Vogel said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release, not costs of statins or costs of the surgeries and procedures referenced. If the researchers truly believe that statin medication before, during, and after the procedure are a significant factor in reducing mortality, talking about the medication costs would help make their point as statins are a relatively cheap therapy.", "answer": 0}, {"article": "Newswise \u2014 Baltimore, Md.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\nIt\u2019s this type of innovation that sets MPTC apart from other proton treatment centers.\u201d\n\nAbout the University of Maryland School of Medicine\n\nCommemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\n\u201cWe are very pleased to be able to offer deep-tissue thermal therapy, which can be combined with standard radiation therapy as well as proton-beam therapy to enhance the cancer-killing effects of the radiation,\u201d says Zeljko Vujaskovic, MD, PhD, a professor of radiation oncology and director of the Division of Translational Radiation Sciences (DTRS) in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention the cost of either of the treatments, or whether or not insurance will cover these procedures. We\u2019ve discussed before that proton beam therapy can cost between $30,000 and $120,000. But it is hard to find cost information on the more experimental hyperthermia treatment, and the University of Maryland website doesn\u2019t list any information.", "answer": 0}, {"article": "\"Why is a higher adherence to the MedDiet related to slowing down the rate of cognitive decline?\nThe main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes.\n\"These include reducing inflammatory responses, increasing micronutrients, improving vitamin and mineral imbalances, changing lipid profiles by using olive oils as the main source of dietary fats, maintaining weight and potentially reducing obesity, improving polyphenols in the blood, improving cellular energy metabolism and maybe changing the gut micro-biota, although this has not been examined to a larger extent yet.\"\n\"I would therefore recommend people to try to adhere or switch to a MedDiet, even at an older age,\" Hardman added.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the text clearly identifies the components of the Mediterranean diet, it does not attempt to \u201ccost\u201d them out for the typical American. The costs of adhering to a Mediterranean diet could be prohibitive, especially for older adults living on fixed incomes. While it would be some work to estimate the annual cost of eating this way for a person or family, the cost consideration could at least be acknowledged.", "answer": 0}, {"article": "Patches in the mouse study contained an array of 100 needles, each some 650 microns in length, or about the width of a few strands of human hair.\nHe also said that although initially there will be start-up costs, he thinks the price will be no more than traditional flu vaccines once it is mass-produced.\nIn the study, one group of mice received the influenza vaccine from traditional hypodermic needles; another group received the vaccine through the dissolving microneedles; and a control group received the microneedle patches not containing any vaccine.\nThree months after vaccination, researchers exposed a different group of immunized mice to the flu virus and found that those who received the microneedles did better than those injected by the hypodermic needles.\nInfected with the influenza virus 30 days later, both groups that received the vaccine remained healthy while mice in the control group contracted the flu and died.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story relays a researcher\u2019s guess that the patch technology will be no more expensive than the standard flu vaccine once it is mass-produced. That\u2019s enough for a satisfactory given the early stage of development. At least it\u2019s more than the competing AP story did. ", "answer": 1}, {"article": "MONDAY, Nov. 16, 2015 (HealthDay News) -- Breast-feeding a premature infant may help reduce the risk of a serious eye problem known as retinopathy of prematurity (ROP), new research suggests.\nThe studies included more than 2,200 preterm infants, comparing how often babies had been fed human milk or formula, and whether or not they developed ROP.\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\nExclusive breast-feeding seemed to drop the odds of ROP by 75 percent compared to exclusive formula use.\n\"Human milk feeding potentially plays a strong role in protecting very preterm newborns from any-stage ROP and severe ROP,\" the international team of study authors wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a relevant criterion in this case as the comparison is made between breast milk and formula. Both feeding methods entail costs, both financial and other, that we feel are beyond the scope of the coverage.", "answer": 2}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost not discussed but since the article clearly stated that the methods discussed are \u201cat least years away,\u201d this is understandable.", "answer": 2}, {"article": "The all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\n(Reuters) - Achillion Pharmaceuticals Inc\u2019s experimental hepatitis C drug, when used with Gilead Sciences Inc\u2019s Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.\nThe new-generation hepatitis C regimens use a two- to three-drug combination \u2013 a nucleotide analog inhibitor or \u201cnuke\u201d and a NS5A inhibitor in Gilead\u2019s case \u2013 to achieves a cure in about eight to 12 weeks, making them faster and more effective than older treatment options.\nGilead\u2019s regimen Harvoni, with its own NS5A inhibitor and Sovaldi as the \u201cnuke\u201d, needs to be taken for at least eight weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a business story, and the early post of this story included a lot of financial information, such as company share prices, the size of the market for hepatitis C drugs, and the total sales for the drugs being studied. But it didn\u2019t include costs.\n[Later in the day, the story was updated to include a price for the drug combination being reported on and other available treatments. It estimated a cost for the new drug combination of about $35,000 per patient per year, assuming a 55 percent discount. Other drug combinations were said to cost $83,000 to $93,000. We applaud the addition of extra information, but that wasn\u2019t the story we reviewed.]\nIt\u2019s also possible \u2014 but not discussed \u2014 that these drugs could end up paying for themselves in the long run if they reduce the need for liver transplants. Such benefits haven\u2019t been established.", "answer": 0}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nCombined with annual biopsies, or tissue samples, it was about 70 percent accurate in singling out the aggressive tumors in a small study, John Hopkins University researchers were to report Sunday at the American Association for Cancer Research annual meeting, in Washington, D.C.\n\n\"What we have shown is that using the Prostate Health Index and tissue DNA measurement is informative in separating out patients whose cancers are likely to progress vs. those that are not likely to progress,\" said study leader Robert W. Veltri, an associate professor of urology and oncology at Hopkins.\nIn a study of 2,000 men in the Chicago area, \"we found it to be more accurate than the tests now available, and it also seems to identify the more aggressive prostate cancers,\" he said.\nIt is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.\nMONDAY, April 19, 2010 (HealthDay News) -- An updated version of the standard prostate cancer test can help improve predictions about which men might not require immediate treatment, researchers report.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs for this product. \u00a0\nWhile it is currently not approved for clinical use in the US, the story could have extrapolated from princing in Europe.\u00a0 Would it be expected to double screening costs or inflate them by a factor of 10?", "answer": 0}, {"article": "The study is published in the journal BMJ.\nThey did not study actual people eating actual chocolate.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nSeveral studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study included a cost-effectiveness analysis and the story reported on it.\u00a0 Unfortunately, it didn\u2019t offer any critical analysis of that cost-effectiveness projection.", "answer": 1}, {"article": "He says he has seen dramatic results in patients he has treated with vitamin D supplements for disorders such as fibromyalgia, involving generalized muscular aches and pains, and multiple sclerosis.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\n\"It was believed that megadoses of vitamin E, beta-carotene, selenium, folic acid and the B vitamins would confer a large array of health benefits.\nIn the case of beta-carotene, scientists were surprised to find that when the results of randomized trials were in, those taking the supplement actually had a higher risk of lung cancer.\nDr. Cliff Rosen of Portland, Maine, knows a lot about vitamin D. It's necessary for strong bones, and Rosen is a leading bone specialist.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of testing for vitamin D levels was provided.\u00a0 No information about the costs of vitamin D supplements, but we\u2019ll give the story the benefit of the doubt on this one. ", "answer": 1}, {"article": "So why weren't they all cured?\n\"This study really underscores the fact that children who have other issues with sleep should be looked at for bedwetting because anything that depresses sleep at night can lead to bedwetting,\" said AUA spokesman Dr. Anthony Atala, a urologist at Wake Forest University in Winston-Salem, N.C.\n\n\"If a child has bedwetting, pay close attention to their sleep patterns, and observe them while they are asleep and you can see whether they are breathing at a regular pace, and if not, seek additional help,\" Atala said.\nThe findings were to be presented Monday at the annual meeting of the American Urological Association (AUA), in Washington, D.C. Research presented at medical meetings should be viewed as preliminary until it has been published in a peer-reviewed medical journal.\n\"There are several potential causes of bedwetting, and sleep apnea is clearly one of them,\" said Dr. Lane S. Palmer, chief of pediatric urology at the Cohen Children's Medical Center in New Hyde Park, N.Y.\n\n\"There are secondary positive effects of this tonsil- or adenoid-removing surgery, but I don't know that I would jump to have my child's tonsils or adenoids out as a primary treatment for bedwetting,\" he said.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. Tonsillectomies are not cheap, and the cost definitely should have been factored in here. Also, there is a question about whether insurance would cover a tonsillectomy that was done primarily to resolve a bedwetting problem.", "answer": 0}, {"article": "In a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nTreatment with probiotics also resulted in lower levels of triglycerides, Very Low Density Lipoprotein (VLDL), high-sensitivity C-Reactive Protein (hs-CRP) in the blood of the Alzheimer patients, and likewise a reduction in two common measures (called \"Homeostatic Model Assessment\", HOMA-IR and HOMA-B) of insulin resistance and the activity of the insulin-producing cells in the pancreas.\nBut scientists have long hypothesized that probiotics might also boost cognition, as there is continuous two-way communication between the intestinal microflora, the gastrointestinal tract, and the brain through the nervous system, the immune system, and hormones (along the so-called \"microbiota-gut-brain axis\").\nWalter Lukiw, Professor of Neurology, Neuroscience and Ophthalmology and Bollinger Professor of Alzheimer's disease at Louisiana State University, who reviewed the study but was not involved in the research, said: \"This early study is interesting and important because it provides evidence for gastrointestinal (GI) tract microbiome components playing a role in neurological function, and indicates that probiotics can in principle improve human cognition.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the intervention isn\u2019t mentioned, and there\u2019s no assessment of how the cost might compare with other medications prescribed to treat the cognitive symptoms of Alzheimer\u2019s disease. It should also be noted that this intervention, if it were available to purchase, would likely be a long-term, continual investment. Probiotic bacteria are known to be transient \u201cpassers through\u201d in the gastrointestinal tract, so a person would need to continue to purchase and consume the beverage for as long as they hoped to see results. Probiotics also tend to be relatively expensive, with the capsules now on the market typically costing about 50 cents to $1 per pill.", "answer": 0}, {"article": "Her mother, aunt and grandmother died of cancer.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\nBRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the story focuses on the story of Ms. Jolie Pitt, a woman with financial resources beyond those of most women, we think discussion of costs is particularly relevant. First, there are costs of genetic testing to find out if you carry the BRCA mutation. Those tests may cost hundreds or several thousand dollars, and insurance coverage for the tests varies with different carriers.\u00a0[As noted by a commenter, the costs of BRCA testing are covered under the Affordable Care Act for women at high risk of breast cancer. Here\u2019s a post from the KevinMD blog with more information] As far as the surgery goes, commercial and government insurers consider elective removal of ovaries and bilateral mastectomy to be standard of care for this condition, and provide coverage under a specific set of criteria.", "answer": 0}, {"article": "the bigger issue though is, is the increased costs associated with protons worth it to society?\nHuge magnets direct the beam of radiation the length of a football field into treatment rooms.\nThat's because proton beam radiation is highly targeted - delivering its dose only to the tumor and sparing the surrounding tissue, which is important for certain rare cancers.\nin my opinion it's worth it if we can reduce the initial costs of building proton centers,\" Loeffler said.\nThe massive facility at the University of Pennsylvania - soon to be the world's largest - will cost $140 million.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of describing the problem of the costs of proton beam therapy.", "answer": 1}, {"article": "Quantity surveyor Alex Laws was part of the Newcastle University clinical trial and is delighted with the results of the study.\nHowever, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\nAlex said: \"I was keen to be part of the clinical trial as I know how important research is into helping people with the condition - I previously worked in the medical research field.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs at all, although the unit cost of the drug is both quite low and readily available.\u00a0 Diabetic patients already spend a substantive amount for their medications over their lives and knowing that the addition of this other drug would not be an undue financial burden would be a welcome piece of information. Since the study was done in the UK, one might have expected some comment on the effect of the use of this drug in a large number of type I diabetics on the health care system.", "answer": 0}, {"article": "When left untreated, however, B.P.H.\nand almost died from sepsis one year.\n\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\nMEN, the joke goes, spend the first half of their lives making money and the second making water.\nUrological experts are beginning to rethink treatments, too, based on symptoms and how much a man is bothered by them.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs associated with any of the treatment options mentioned \u2013 a glaring omission given the variation in costs among the approaches discussed. ", "answer": 0}, {"article": "Available from: http://www.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nILC 2017: The study evaluated the use of a direct-acting antiviral treatment in children aged 6 to 11, for whom the standard of care has been pegylated interferon plus ribavirin\n\nApril 21, 2017, Amsterdam, The Netherlands: A study presented today that evaluated an investigational dosage of once-daily ledipasvir 45 mg/sofosbuvir 200 mg (LDV/SOF) in children aged six to 11 years infected with the Hepatitis C virus (HCV), found that 99% of children (n=89/90) had undetectable levels of HCV-RNA 12 weeks after treatment.\nAround 180 million people globally have chronic HCV infection,1 including approximately 15 million people in the EU.2 The prevalence of HCV infection in children varies from 0.05%-0.36% in the United States and Europe and up to 1.8%-5.8% in some developing countries.3 While direct-acting antivirals have been used to treat and cure adult patients with HCV,4-7 until now children have been mainly treated for 24 to 48 weeks with pegylated interferon plus ribavirin (RBV), an older treatment which causes severe side effects.8\n\n\"Direct-acting antivirals have transformed the treatment of adults with chronic HCV, however, studies of these new therapies in children are required,\" said Dr Karen Murray, University of Washington School of Medicine and Seattle Children's, Seattle, United States, and lead author of the study.\nChildren with HCV genotype 1 infection received 12 weeks of treatment (n=85) or 24 weeks of treatment if they had cirrhosis and failed prior treatment with pegylated interferon plus RBV (n=1); genotype 3 patients received LDV/SOF plus RBV for 24 weeks (n=2); genotype 4 patients received LDV/SOF for 12 weeks (n=2).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of costs. The manufacturer, Gilead Sciences, has been charging $94,500 for a 12-week regimen of this combination therapy, marketed to adults as Harvoni. While government and private payers have balked at the cost, the company says the price tag is justified by its effectiveness in eradicating the virus, which will save the cost of treating serious liver disease down the road.", "answer": 0}, {"article": "Cook's primary-care doctor, Sujay Pathak, an internist in Baltimore, first saw her in February.\nFor the past 50 years, hyperbaric therapy has been approved by the Food and Drug Administration as a treatment for non-healing wounds, carbon monoxide poisoning, burns and decompression sickness.\nWhile in the chamber, patients breathe in pure oxygen, typically pressurized to about twice the density of sea-level air; in this environment, the lungs take in about 10 times as much oxygen as under normal conditions.\n\"It's very difficult to get funding for studies on this topic,\" Harch said.\n\"A non-healing wound in the leg and a non-healing wound in the brain,\" he said, \"they are the same basic thing.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that \u201cpatients typically receive between 40 and 60 hour-long hyberbaric treatments spread over two to three months\u201d and that a treatment \u201ctypically cost between $200 and $400 per session and is rarely covered by insurance.\u201d", "answer": 1}, {"article": "\"Great.\n\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor years, all Siravo and her husband, David, wanted was a good night's rest \u2013 and now they're finally getting it.\nA treatment is offering hope for millions of patients with sleep apnea, a disorder that causes people to stop breathing when they're asleep.\n\u2026 And after we activate the device it's perfect,\" Boon explained.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Here\u2019s what the story says in regard to cost: \u201cThe device costs around $20,000 not including the surgery.\u201d\nThis doesn\u2019t adequately address two key points.\nThe first problem here is that an invasive surgery, such as this one, could be extremely expensive. Does it require the patient to be put completely under by anesthesia? Is it out-patient surgery, or would patients have to spend at least one night in a hospital? Details like that can make a huge difference in terms of cost.\nThe second, bigger problem is that the story doesn\u2019t make clear that this is not a one-time cost. Inspire implants can malfunction, and the batteries in the implants will need to be replaced. For example, a 2010 study published in Sleep Medicine Reviews found that, out of eight patients, five experienced device malfunctions more than six months after implantation. There may have been improvements in the technology since that study was published, but there is still no acknowledgment that Inspire\u2019s internal power supply would need to be replaced periodically \u2014 and neither the new battery nor the related medical procedure is likely to be free.", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nFewer studies link coffee to a higher likelihood of dying prematurely, but this classic found a link between 6-plus cups a day and dying of cardiovascular disease, while this 2013 paper, on 43,727 people followed for a median of 17 years, concluded that adults under 55 who averaged more than 4 cups a week had a 56 percent (men) or 130 percent (women) higher risk of dying over the study period than non-coffee drinkers.\nOverall, the heaviest coffee-drinkers (more than five cups a day, regular or decaf) had a tiny 2 percent additional risk of dying compared with coffee abstainers.\nIf you do want to infer causation from this latest study, know that drinking coffee reduced the absolute mortality risk from 6.8 deaths a year per 1,000 people to, at best, 5.8.\nFirst Take: The new research, published in Circulation on Monday and funded by the National Institutes of Health, mined three large, ongoing epidemiological studies (74,890 women in the Nurses\u2019 Health Study, 93,054 women in the Nurses\u2019 Health Study 2, and 40,557 men in the Health Professionals Follow-up Study), following them for at least 20 years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Arguably, most people know how much their java habit costs them every day, and neither this STAT story nor the competing CNN coverage mentioned costs. Like hazelnut cream, some mention of the overall cost of the coffee habit in the U.S. would have added some flavor, but this omission gets a pass.", "answer": 2}, {"article": "The study found none.\nThe number of hot flashes among the women taking Lexapro, which is also known as escitalopram, dropped to about five on average after eight weeks--a 47 percent decrease or about 4.6 fewer hot flashes per day, the researchers reported.\nAmong those taking a placebo, the number of hot flashes dropped to 6.43 per day, a 33 percent decrease of 3.2 fewer hot flashes per day.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not mention costs. Lexapro costs about $110/month and is not available as a generic. Because of this, insurance companies will probably relegate it to 2nd or 3rd\u00a0tier status with higher copays\u00a0for those who wish to use it.", "answer": 0}, {"article": "The researchers also made a secondary discovery.\n\"The finding supports the idea that omega-3s, and specifically DHA, are preferentially protective in obese postmenopausal women,\" Manni said.\nIn the current study, the combination of Lovaza and a half recommended dose of Raloxifene at 30 milligrams, was superior to the individual treatments in reducing triglycerides and LDL -- \u201cbad\u201d -- cholesterol and increasing HDL -- \u201cgood\u201d -- cholesterol.\nThe protection likely comes from the fatty acids' anti-inflammatory effects, said Dr. Andrea Manni, professor and division chief of endocrinology, diabetes and metabolism, Penn State College of Medicine.\nTo tease apart the effects, Manni's team, working alongside researchers from Emory University and Colorado State University, looked at the influence of prescription omega-3 supplementation on breast density in different weight women.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs although omega-3 fatty acid supplements are readily available across the market.\u00a0 A quick web search shows that a month\u2019s supply of Lovaza, the omega-3 fatty acid used in this study, will cost about $280 per month, or $3.360 a year, a hefty price for most Americans.", "answer": 0}, {"article": "\u201cI wouldn\u2019t say it\u2019s a cure.\nAnd Dr. Gloria Yeh, a Beth Israel Deaconess internist and co-author of the editorial, said others \u201cwill say, \u2018It\u2019s too slow, I can\u2019t do that.\u2019 \u201d\n\nBut she said it offered a \u201cgentler option\u201d for patients deterred by other physical activities.\n\u201cI was used to being treated in a condescending manner because they couldn\u2019t diagnose me: \u2018She\u2019s menopausal, she\u2019s crazy.\u2019 \u201d\n\nBefore the study, \u201cI didn\u2019t know tai chi from a sneeze,\u201d said Ms. Petersen, who has diabetes and other conditions.\nSo, that these results were so positive for something that\u2019s very safe is an impressive accomplishment.\u201d\n\nRecent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0At a minimum, the reporter could have found out how much the master used in the study typically charges and how much the DVD costs. Still, unlike most of the stories, this reporter did write, \"Dr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy.\"", "answer": 1}, {"article": "OMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nWhile antibiotic therapy is the current standard of care, the emergence of resistant bacteria is a global threat and provides an incentive to explore adjunct treatments that can improve their efficacy,\" said James Bailey, DO, assistant professor in physical medicine and rehabilitation at Rowan University School of Osteopathic Medicine.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nStudy published in the Journal of the American Osteopathic Association finds OMT plus antibiotics reduces risk of death for the most severely ill patients\n\nCHICAGO--August 29, 2016-- An analysis of multicenter randomized controlled clinical trial found osteopathic manipulative treatment (OMT) for pneumonia reduced length of hospital stay in adults 50 to 74 years old and lowered in-hospital mortality rates for patients 75 and older.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the costs of osteopathic adjunct therapy even in general terms. Readers would have no idea, for example, if medical insurers might cover the cost for in-hospital or post-discharge osteopathic care. And it might have been highly useful to include easy-to-get information about the average cost of an extra day or two in the hospital for pneumonia treatment. Given that payment for patients hospitalized with pneumonia is typically based upon a bundled fee, the costs of providing OMT may be offset if length of stay is reduced.", "answer": 0}, {"article": "There is also another issue.\nAnd the recent data indicating that some women can skip chemotherapy are based on an after-the-fact analysis of selected clinical trials.\nThe results of the analysis, published recently in The Journal of the American Medical Association, were the same even if the cancer had spread to the lymph nodes.\nAnd so, he said, \"a lot of people will take a treatment even if there is a very low statistical chance that they will benefit.\"\nAnd for good reason, many cancer researchers say: a series of large studies has shown that chemotherapy saves lives and that newer and more aggressive regimens are improvements over older ones.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of chemotherapy and no mention of potential cost savings for women who might not benefit as much from treatment; however, this is not very relevant to this story, as there is a suggestion that less treatment might be better, with a cost savings implied. ", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not report the cost of wine or mineral water, but these drinks are so commonplace that it seems reasonable to assume that readers already know what they cost. So we\u2019ll rate this Not Applicable, but we\u2019d note that a\u00a0typical bottle of wine is 750 ml, which is 5 servings of 150 ml (about 5 oz) that were \u2018prescribed\u2019 in the trial. \u00a0Although the cost of a moderately priced bottle (say $10) every 5 days is not huge, this could be a burden for some people on a fixed income. \u00a0A better choice for them might be more fresh vegetables.", "answer": 2}, {"article": "But scientists also realized it could have other uses.\nAnd the population that could be most benefited by this could be post-menopausal women.\u201d\n\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nIt\u2019s a fairly dramatic effect.\u201d Mice also showed increased oxygen consumption, higher levels of physical activity and more heat production in beige fat (which dissipates energy around the body).\nAs a result, they started considering it as a potential treatment for osteoporosis, particularly in post-menopausal women\u2014a period when women lose bone mass fairly quickly.\nSo we thought maybe there was a connection\u2014that FSH could have direct effects on adipose tissue.\u201d\n\nIn the study, published in Nature, scientists injected the antibody into mice that had had their ovaries removed (mimicking menopause) and mice that had been fed on a high-fat diet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. The Nature article notes that \u201cIcahn School of Medicine at Mount Sinai has filed a provisional patent application that covers the application of FSH inhibition to decrease body fat,\u201d so clearly the researchers have considered the possibility of commercializing the relevant antibody. And while it is likely far too early for one to say what a related medical treatment might cost, the story needs to make clear that there will be a cost. Is it easy to produce antibodies like this one? Does it involve esoteric technologies or components that could contribute to cost? Is it something that could be made using existing manufacturing processes? If nothing else, the story could at least say that researchers aren\u2019t sure what any resulting treatments might cost (assuming someone asked the researchers about this).", "answer": 0}, {"article": "But confirmation would be good news for the prevention and control of gonorrhea.\n\u201cGonorrhea rates have been going down in the vaccine group whereas in the non-vaccine group it\u2019s following the rest of the province.\u201d\n\nIt is not clear how long the protection \u2014 if it\u2019s real \u2014 will actually last.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much a gonorrhea vaccine might cost. In the U.S. meningitis B vaccine Bexsero, which contains manufactured by GlaxoSmithKline, costs $99 for a pediatric dose and $106 for an adult dose. Two doses are required.\nA discussion of cost and cost-effectiveness is particularly important when considering a widespread public vaccination campaign.", "answer": 0}, {"article": "In a first, U.S. trial to test Cuban lung-cancer vaccine\nThe studies simultaneously were published by the New England Journal of Medicine on a day that some experts called the \u201cSuper Bowl of lung cancer immunotherapy.\u201d\n\nThe reports underscore the increasingly important first-line role that immunotherapy, which unleashes the immune system to destroy cancer cells, is taking against the deadliest cancer.\n\u201cInstead of chemo being the backbone on which to improve, immunotherapy is now the backbone on which we build.\u201d\n\nLung cancer is the second-most-common malignancy in the United States, after breast cancer.\nH. Jack West, an oncologist at Swedish Medical Center in Seattle, said, \u201cIt is literally practice-changing \u2014 immediately.\u201d\n\nRoy Herbst, an oncologist at Yale Cancer Center said that most lung cancer patients now will be offered immunotherapy in some form much earlier than before.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of these drugs weren\u2019t given. Checkpoint inhibitors run about $150,000 a year, according to some published news reports. With 140,000 people in the U.S. diagnosed annually with non-squamous non-small cell lung cancer \u2014 the type in the Keytruda trial \u2014 the cost of treating people with this drug could easily run into the billions.\nIt\u2019s also worth noting it isn\u2019t clear how long treatment with these drugs should continue, which significantly affects costs.", "answer": 0}, {"article": "On the third and fourth days, researchers switched diets and repeated the process for each person.\n\u201cThere have been several very high-profile studies showing that drinking beet juice can lower blood pressure, but we wanted to show that drinking beet juice also increases perfusion, or blood flow, to the brain,\u201d Daniel Kim-Shapiro, PhD, director of the Translational Science Center at Wake Forest University, says in a news release.\nPrevious studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nOn day one, subjects reported to a laboratory after a 10-hour fast, completed a health status report, and had either a high- or low-nitrate breakfast.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The costs of these veggies was not discussed, but it\u2019s not in question.", "answer": 2}, {"article": "\"Sixty to 80 percent [success] for something that somebody's not going to get guaranteed pain relief -- in my mind, it's not something I would go for,\" Duggal says.\n-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nIn high-impact activities like running, the forces even exceed the actual weight because it's so concentrated in a narrow spot where the fascia attaches to the heel bone.\nIt's the same technology used since the 1980s to blast kidney stones, an application called lithotripsy, but for foot problems doctors use less intense shock waves.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is a major part of the story here and NPR doesn\u2019t gloss over it.\u00a0The cost of shockwave treatment\u00a0can range anywhere from $500 to several thousand dollars, NPR reports, and\u00a0usually is not covered by insurance.\u00a0NPR could have added some useful context\u00a0 by mentioning that\u00a0the shockwave machines themselves can be very expensive to purchase and operate.\u00a0This\u00a0can\u00a0create an incentive for physicians who have bought such a machine to promote\u00a0shockwave treatments to patients who may not need them. In addition, it\u00a0would have been helpful to know how this treatment\u2019s costs differ from those of other common treatments. \u00a0\u00a0", "answer": 1}, {"article": "The work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\nMS patients differ markedly from each other regarding which disability affects them the most.\nThey compared gene expression changes between regions that correspond to different disabilities.\nIn the spinal cord - an area that's critical for walking -- they found a decrease in the expression of cholesterol synthesis genes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss potential costs.", "answer": 0}, {"article": ".\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America.\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nThe findings were to be presented Nov. 30 in Chicago at the annual meeting of the Radiological Society of North America.\nThey found that elastography correctly identified 98 percent of cancerous lesions and 82 percent of benign lesions, and they also determined that elastography was more accurate than ultrasound in gauging the size of the lesions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of the cost of elastography.\u00a0The use of a second additive technology will clearly add to the costs of diagnosis unless the sensitivity and specificity of the test is sufficiently high to reduce unnecessary biopsies. The potential cost implications of this added technology are not noted in the story.\u00a0 Although the true economic impact of the technology is not known at present, the potential cost implications of the method should have been noted.", "answer": 0}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that Vascepa costs about $2,400 per year. However, that price is much lower than indicated by online searches (here and here) that show prices around $3,400 per year at the 4 gram per day dose used in this study.", "answer": 1}, {"article": "\u201cIt\u2019s a survival thing,\u201d she said.\n\u201cIf it\u2019s happening because of fear or the common reason I hear \u2013 \u2018I just want to be done with it\u2019 \u2013 that\u2019s a different situation.\u201d\n\nTuttle\u2019s study found 60 percent of women with breast cancer chose lumpectomies, which remove only the tumors, not the whole breasts.\n\u201cIf I didn\u2019t do as much as possible to eliminate the cancer, I would feel like I was almost waiting for the other shoe to drop.\u201d\n\nWomen removing a single cancerous breast have a 1 percent chance per year of suffering cancer in the other breast.\nIf it shows up on one side, it could come back, so let\u2019s just eliminate it.\u201d\n\nJeremy Olson can be reached at jolson@pioneerpress.com or 651-228-5583.\nThe rising use of magnetic resonance imaging, MRI, is likely contributing to the increase in double mastectomies, said Dr. Joseph Leach, a medical oncologist with Park Nicollet Health Services.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While cost is very unlikely to drive a decision about breast cancer treatment, it\u2019s increasingly important for the media to educate readers about the true underlying costs of medical treatments. In this case, the reporter cites \"higher costs\" as one disadvantage of double mastectomy. This obligates the reporter to specify those costs. \nTo know how the cost of either a single or double mastectomy compares to the costs of lumpectomy plus radiation would have added additional value. ", "answer": 0}, {"article": "So far, however, there is little scientific proof of their effectiveness\u2014many studies of probiotics have involved less-than-rigorous...\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\nProbiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells us that probiotics sales totaled $770 million last year, but it doesn\u2019t break\u00a0that figure\u00a0down as far as what the individual can expect to pay. A quick search on one of the products mentioned showed that a 1-2 month supply will set you back about $68. This is important as many people may not have the resources to pay for their medications prescribed by their physicians.", "answer": 0}, {"article": "The researchers split the participants into two groups, one that received drug treatment and one that took placebo pills.\n\"It's a pessimistic trade-off, the weight gain and other side effects for what looks like a modest delay in the acute psychotic episode,\" said Dr. Steven Hyman, a professor of neurobiology at Harvard.\n\"Unfortunately, the study's numbers are so small that it cannot be decisive on the key issue, which is whether it's prudent to treat people early when there are uncertainties about the diagnosis and given the effect of stigma and adverse effects,\" said Dr. William Carpenter, director of the Psychiatric Research Center at the University of Maryland, who was not involved in the study.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\nSome left the study without explaining why; others moved; and 10 of those on medication quit the study because they felt the drug was not working, could not make the appointments or did not like the side effects, among other reasons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of Zyprexa and no mention of how long this medication would need to be taken to prevent a severe psychotic break in susceptible adults. These drugs cost around $200/month. Add in physician visits and monitoring for onset of diabetes, weight gain, and hyperlipidemia and you can easily come up with $300/month. ", "answer": 0}, {"article": "And, they say, it might not help cure many deadly prostate cancers because those cancers may have already spread outside the prostate, microscopically seeding other organs, long before a P.S.A.\nBut even with this uncertainty, prostate cancer specialists say, most men who are treated would not have died of prostate cancer, and that is especially true for elderly men, in particular those who are frail and have a limited life expectancy.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\nThey note that prostate cancer is a common cancer, found in most men\u2019s prostates on autopsy, although often the men had no idea they had it.\n\u201cI think I am going to live to be 100,\u201d he said, asking that his name be withheld to protect his privacy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs, either in terms of the actual dollar value involved in routine PSA testing or for follow-up biopsy and treatment.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No data comparing costs of c-section vs. vaginal birth is provided. \nThis is surprising, given the fact that one reason experts discourage elective c-sections is high cost. ", "answer": 0}, {"article": "First published on September 5, 2007 at 12:00 am\nThe robots have proven popular for urologic, gynecologic and some general surgery, Pappas said, but few coronary surgeons use them for valve repairs and fewer still do bypass procedures.\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\nWhile surgical robots have been available for most of this decade, few are used to do cardiac bypass surgery, even though that was their focus when the machines were introduced.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter fails to indicate how costs of robot-assisted bypass compare to costs of conventional bypass operations.\u00a0The article\u00a0does not report whether insurance companies pay the additional costs, if any. And since the\u00a0device maker offers a comparison between bypass surgery and stents, the report should\u00a0compare prices\u00a0of stent insertion\u00a0to robot-assisted bypass surgery. ", "answer": 0}, {"article": "Each carries problems.\n\u201cWith an average of one man dying every 45 minutes from prostate cancer in the UK, the need for a more reliable test that can identify dangerous forms of the disease earlier is greater than ever.\u201d\n\nIn the past few years, a number of celebrities have revealed that they had been diagnosed with prostate cancer and have joined campaigns to raise awareness of the disease, including Michael Parkinson, Ian McKellen and most recently Stephen Fry, the comedian and former rector of Dundee University, who this year described how he had surgery to deal with a prostate tumour.\n\u201cOur new method is far more accurate and also allows us to identify the difference between cancerous and benign tissue in the prostate without the need for invasive surgery.\u201d\n\nThe prostate is a small gland in the male reproductive system and is normally about the shape and size of a walnut.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\nPSA results can be unreliable; a DRE is not good at identifying which cancers are benign and which need treatment; MRI scans cannot always give a definitive answer; while a biopsy carries a risk of infection and is expensive.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The only mention of costs in this Guardian story is the following sentence, \u201cThe method is non-invasive and cheaper than current detection techniques.\u201d\u00a0 But the story offers no information to back up that statement. There\u2019s no mention of the current costs for the available screening approaches and there\u2019s no estimate of\u00a0what this new technique might cost patients.", "answer": 0}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Both groups in this study used smoking cessation products, and so it would have been helpful to know how much they cost, even if it was just a quick approximation or discussion of affordability. At the same time, these aren\u2019t high-dollar items, so cost isn\u2019t as important to discuss as say, when reporting\u00a0findings about a new cancer drug or surgery.", "answer": 0}, {"article": "Bangalore said this is critically important because \"compliance is big issue with our patients.\"\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nMost guidelines set forth by the major medical groups suggest starting a patient with an ACE inhibitor first, but the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) considers ACE inhibitors and ARBs to be equal.\nHappiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nThe one difference they found was that ARBs tend to be better tolerated by patients, meaning that they have fewer side effects or result in fewer adverse events.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story could have been a bit more specific, it gets points for stating that most ACE inhibitor drugs, and many ARB drugs, are now available in generic form, which means the cost for the medications would usually be considerably less than their comparative name-brand compounds. We\u2019ll rate this Satisfactory, but we\u2019d add that though more ARBs are generically available, this class of medications continues to be more expensive than ACEIs. For patients struggling to meet the cost of their medications, this is a major consideration, and important information for any news story.", "answer": 1}, {"article": "U.S. experts familiar with the study call it interesting but say the treatment needs more study and wonder if it would catch on in the U.S.\nBut at 25 weeks, the resolution rates were similar in the two groups: 30% of the patched group and 42% of the acupuncture group.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\n''These results suggest that the treatment effect of acupuncture is equivalent to that of patching for anisometropic amblyopia in older children,\" Lam writes.\nSo Dennis Lam, MD, a researcher at the Joint Shantou International Eye Center of Shantou University and Chinese University of Hong Kong, and his colleagues evaluated 88 children, ages 7 to 12, with the condition known as anisometropic amblyopia, in which there is a difference in the degree of nearsightedness or farsightedness between the two eyes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A source in this story cited time and expense as two factors that might decrease the attractiveness and accessibility of acupuncture. However, it never\u00a0attached figures to these concerns. We think the story should at least have mentioned\u00a0the cost of a typical office visit\u00a0to an acupuncturist.", "answer": 0}, {"article": "The volunteers drank a 10-ounce glass of cherry-flavored liquid that contained two and a half ounces of fructose or glucose.\nAnd it is packed with fiber, which helps slow down the absorption of food, which makes you feel full.\u201d\n\n\n\n For more fitness, food and wellness news, \u201clike\u201d our Facebook page.\nThe volunteers were then presented with images of high-calorie foods and asked whether they would like to have the food now, or a monetary award a month later instead.\nThere was no difference in leptin or ghrelin levels between fructose and glucose drinkers.\nIt has a relatively low amount of sugar compared with processed foods and soft drinks \u2014 maybe 5 grams in an orange, compared with 25 grams in a 12-ounce can of soda.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s hard to assess cost in this situation \u2014 there is no specific medication or treatment to put a price tag on. We\u2019ll give this a \u201cNot Applicable.\u201d", "answer": 2}, {"article": "\"Based on the current safety and clinical benefit data, the dose of the vaccine was increased to 40 million dendritic cells per injection and the trial opened to patients who have previously been treated with a HER2-targeted therapeutic, including patients with breast cancer,\" said Berzofsky.\nIn the dose escalation portion of the phase I clinical trial, patients were injected with the vaccine on weeks 0, 4, 8, 16, and 24 after enrollment in the study.\n\"Moving forward, we would like to investigate whether we can increase the proportion of people who benefit from treatment with the vaccine by combining it with checkpoint inhibitor therapy,\" he added.\nThe final product, which is administered intradermally (between the layers of the skin), comprises patient-derived dendritic cells genetically modified with an adenovirus to produce parts of the HER2 protein.\n\"We hope that one day the vaccine will provide a new treatment option for patients with these cancers.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release noted that the vaccines were individually customized using each person\u2019s immune cells. That technology does not sound cheap yet there was no discussion of cost.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even though deep brain stimulation (DBS) is not close to being recommended for diabetes, it is a current therapy for Parkinson\u2019s disease and other movement and psychiatric disorders. Thus, cost information\u00a0could have been included \u2014 we found estimates ranging from $35,000 \u2013 $50,000.\nOf course, the costs associated with the use of this technology for diabetes might differ from the costs with Parkinson\u2019s disease. However, our rule of thumb in these situations is, If it\u2019s not too early to claim this approach \u201cmay offer treatment,\u201d it\u2019s not too early to discuss what that treatment may eventually cost.", "answer": 0}, {"article": "Dr. F. Xavier Castellanos, director of research at the New York University Child Study Center, called assertions that stimulants are neuroprotective \u201cexaggerated,\u201d adding: \u201cThe best inference is that there is no evidence of harm from medications \u2013 normalization is a possibility, but far from demonstrated.\u201d\n\nA.D.H.D.\n\u201cThere might be quite a profound neurological benefit,\u201d he said in an interview.\nKatherine Ellison is an author or co-author of four books about A.D.H.D.\nFor most people with A.D.H.D., stimulants can temporarily boost focus, motivation and self-control by increasing the availability of these chemical messengers.\nThe question is whether these effects can last once the drugs have left the bloodstream.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of ADHD medications and other common therapies are readily available. The story would have been better if it had included at least a brief reference to these costs", "answer": 0}, {"article": "So what if it were possible to know before treatment which men might be more likely to suffer complications?\nPatients were assessed every three to six months for signs of sexual dysfunction for up to five years.\nThe number of men studied was eventually winnowed down to 260 patients with erectile dysfunction and 205 controls.\nIf you see a radiation oncologist he\u2019ll say oncology.\u201d\n\nDetermining what type of treatment a man should receive is only part of the dilemma of prostate cancer.\n\u2022 Pregnant women with cancer on the rise.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not addressed. Genomic analyses, although becoming cheaper, still may cost around $1000.", "answer": 0}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The report states that\u00a0the operation is costly, about $25,000, and that insurance coverage is not guaranteed. It also indicates that at this time surgery\u00a0purely to treat diabetes, not reduce body weight, is\u00a0unlikely to be covered.\nThe report adds useful context by\u00a0stating that\u00a0conventional diabetes care costs $10,000 per year.\u00a0", "answer": 1}, {"article": "The results so far are very promising.\n\"We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren's disease,\" said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\n\"Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren's disease,\" said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a single 40 mg injection of the the anti-TNF (tumor necrosis factor) drug, adalimumab (brand name, Humira) isn\u2019t mentioned.\u00a0Given the level of the research at the moment, the durability of what can best be described as a change in a surrogate marker is unknown. \u00a0Although the cost of 40mg of Humira is around $5,000 for two 40mg/0.8ml pens, according to GoodRx, the true cost of this potential treatment is unknown but likely to be costly.", "answer": 0}, {"article": "A video of him walking with and without aid of the system can be found here: https:/ .\n\"Both guys were taking steps the first time we turned the systems on,\" said Ron Triolo, a professor of orthopaedics and biomedical engineering at Case Western Reserve and executive director of the Advanced Platform Technology (APT) Center.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n\"In both cases, there is a disconnect between the brain and muscles,\" said Stephen Selkirk, MD, a neurologist at the VA's Spinal Cord Injury Division and assistant professor of neurology at Case Western Reserve School of Medicine.\nIn each patient, \"the pulses are sent in a pattern that is close to how normal muscles work,\" said Rudi Kobetic, a principal investigator at the Stokes Cleveland VA and APT Center.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs. While it may not be possible to put an exact price tag on a treatment that is so preliminary, we think some estimate of the costs involved is warranted. One study put the indirect costs of multiple sclerosis at more than $30,000 per person per year, due mainly to impaired mobility. The news release hints at the high cost by mentioning that the researchers are seeking funding to fit one of the patients with a permanent device in a clinical trial.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nThey usually smoke less, are more physically active and have a healthier diet,\u201d the researcher wrote.\nTaking vitamins for 10 or more years cut risk by 41 percent.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nAmong the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no insight about the costs of various multivitamin formulations.", "answer": 0}, {"article": "Singh said there was no evidence of a similar danger from the lozenges or syrups.\nWhile the episodes usually aren\u2019t serious, the resulting visits to the doctor alone cost the U.S. an annual $7.7 billion, according to the new report.\nAlthough the precise estimate is still uncertain, researchers found that people who started taking zinc-loaded lozenges or syrups within 24 hours of showing symptoms \u2014 a sore throat, say, or runny nose \u2014 shortened their cold by one day.\nThe review, published by the Cochrane Collaboration, an international organization that evaluates medical research, also shows that people taking the supplements tended to have milder symptoms.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that the supplements can be bought \u201cfor a few dollars,\u201d which is more than the WebMD story noted. Even better, though, this story talked about the costs in work days missed and lost productivity from the common cold.", "answer": 1}, {"article": "And will they change the quality of sleep in any way?\nUslaner and his colleagues investigated a compound called DORA-22, which has the same mechanism of action as suvorexant, to see how it fared alongside not only Ambien and Lunesta but also diazepam (Valium) in rats and rhesus monkeys.\nThe appeal of orexin antagonists, said Dr. Michael Thorpy, director of the Sleep-Wake Disorders Center at Montefiore Medical Center in New York City, is that they \"target a system that's more specific for sleep.\"\nThese new medications -- known as dual orexin receptor antagonists (DORA) -- target a more specific region of the brain than popular sleep drugs such as Ambien and Lunesta, promoting sleep without affecting learning and memory (also called \"cognition\"), according to the new research.\nThis is the first time in years that scientists have targeted a totally different receptor in the quest to combat insomnia, said Dr. Alexandre Abreu, co-director of the UHealth Sleep Center at the University of Miami Miller School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the cost of the newer sleep aids (in excess of $250/month), the cost of a new drug is an important consideration.\u00a0 While the study in question was conducted in rats, a close relative of DORA-22 is under consideration for approval by the FDA.\u00a0 It is for that reason we think that cost should have been part of the storyline.", "answer": 0}, {"article": "Some of the complaints related to the placement of the device.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nA woman using Essure must do a test to confirm that the device is properly placed within three months of the procedure and until she receives a confirmation from her doctor, she must use alternate birth control methods, Bayer said in a statement on Wednesday.\nIn a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention the cost of a TVU or whether a separate charge will be applied for this procedure. In general, TVUs can be costly if not covered by insurance. Depending on the insurance status, who does it, or where (geographically) it is done, the procedure could cost between $250-1,000. \u00a0It is in interesting to note that the cost of a HSG is typically higher (can be anywhere between $800-3,000).", "answer": 0}, {"article": "This gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\n\u201cThat\u2019s the hope.\u201d\n\nHe said he thinks electronic health records will be key to putting individualized guidelines into practice.\nIf, on the other hand, the number of heart attacks and strokes prevented were kept the same, the individualized guidelines would accomplish that result at a 67 percent cost savings versus the national guidelines.\n\u201cThe general theme is that we can do better, and we may have an opportunity to improve patients\u2019 health outcomes,\u201d Owens said.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Couldn\u2019t Dr. Eddy have commented on the projected cost of implementing his idea?\u00a0 And certainly the projected cost saving impact of his Archimedes system has been the focus of past news coverage. So even a line about cost impact would have been appreciated.", "answer": 0}, {"article": "SUNDAY, Oct. 23, 2011 (HealthDay News) -- Older women who take nonsteroidal anti-inflammatory drugs -- such as aspirin or ibuprofen -- appear to have a lower risk of death from colorectal cancer than women who don't use these medications, a large new study suggests.\nThe researchers confirmed 2,119 cases of colorectal cancer and 492 deaths due to the disease.\nThe U.S. National Cancer Institute has more about colon and rectal cancer.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\nThe findings were slated for presentation on Sunday at the AACR International Conference on Frontiers in Cancer Prevention Research, in Boston.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of over-the-counter drugs like aspirin and ibuprofen are not in question.", "answer": 2}, {"article": "CHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\nThroughout the study, there were no cases of IRE-related incontinence, even when the lower urinary sphincter was included in the treatment field.\nIncontinence is one of the most common adverse side effects of current treatments for localized prostate cancer and can have a substantial impact on the quality of life.\nUnlike other treatment procedures for prostate cancer therapy, image guided or irreversible electroporation (IRE) only destroys cells; vital tissue structures are not affected, making IRE the first tissue-selective form of therapy.\nThe IRE treatment also had very low toxicity on the rectum and bladder, even in cases of advanced cancer infiltrating these structures in patients who were not candidates for surgery or radiation therapy anymore.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs.", "answer": 0}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a strong point of the piece. The story contrasts the much higher cost of eBx relative to standard skin cancer treatments, referencing an editorial in the journal JAMA Dermatology. \u00a0The cost issue is situated high in the story, and the text then devotes space later in the story to a more detailed explanation.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story lists both the costs of the newest drug \u2013 Gilenya \u2013 and the costs of existing injectable treatments. This is a great bonus for the reader.", "answer": 1}, {"article": "Carissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nThe study included only males between the ages of 7 and 28 because they were part of a bigger research project at the University of Utah, which is following males with autism for a longer period.\n(The advocacy group Autism Speaks has posted videos to help parents see the signs of autism)\n\nThe earlier a child has been identified as having autism, the earlier behavioral therapies can be applied to lessen the impact of the disorder later in life.\nBut she cautions that using this method as a true diagnostic tool to detect autism in a child is \"a long way off.\"\nPlus, the research needs to be expanded to many more study participants and tried on younger people with autism and those who are not as high-functioning as the subjects in this first trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Just as Reuters did, CNN ignored costs. MRI scans are a major driver of healthcare costs and the use of this technology as a routine screening instrument could have a significant direct financial impact. The cost of a routine MRI could have been provided.", "answer": 0}, {"article": "Researchers at Georgia State analyzed clinical data from a large cohort of breast cancer patients treated at Northside Hospital in Atlanta from 2005 to 2015.\nThe researchers also found that among early stage patients (noninvasive or minimally invasive breast cancer), African-Americans displayed higher tumor recurrence than European-American patients.\nRecurrent breast cancer has hindered the successful management of this disease for decades and is one of the primary factors for the racial disparity in prognosis and outcomes.\nDifferences in recurrence rates and patterns between the races following various forms of treatment have not been thoroughly investigated.\nWhen breast cancer recurs, it is more challenging to treat regional and distant tumors than local tumors (in the breast), Wright explained.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not discuss costs, but presumably receiving chemo before surgery\u2013instead of after\u2013does not considerably increase costs.", "answer": 2}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned \u2014\u00a0not acceptable\u00a0when the drug is already on\u00a0the market and cost information is\u00a0easily obtained. According to one estimate\u00a0our reviewer found within minutes,\u00a0treatment with Avodart costs about\u00a0$4 per day. Previous analyses of finasteride, which has a similar mechanism of action, estimated that the cost per quality-adjusted life year (QALY) gained from treatment far exceeds $100,000/QALY. An acceptable cost effectiveness for a treatment is considered to be less than $50,000/QALY.", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not talk about the cost of adding a daily dose of ginger to one\u2019s diet. But since that cost can\u2019t be very significant, we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "If media wish to link to the paper once it's published, they can use the following link, which will go live when the embargo lifts: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(16)30179-5/abstract\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThe rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.\nWhen a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\n\"This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a 'game changer' for future treatment.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention the cost of the potential new drug, nor is there any estimate of what the cost might be in comparison to other asthma treatments currently in use including inhalers and corticosteroids. The release would have been more helpful to people with asthma if it had included some cost estimates since new medications tend to be very expensive.\nIf it\u2019s not too early to promote a treatment to a patient audience, it\u2019s not too early to provide a ballpark cost.", "answer": 0}, {"article": "Accessed October 2013 from http://www.hcup-us.ahrq.gov/reports/statbriefs/sb23.jsp [5] Flum, D. R., et al.\n\u201cThe balloon and other technologies may help to fill the therapeutic gaps between diet and exercise and medical therapy, and medical therapy and surgery, where the gaps are quite large.\u201d\n\nPeople with obesity and severe obesity have higher rates of heart disease, diabetes, some cancers, arthritis, sleep apnea, high blood pressure and dozens of other diseases and conditions.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\n\u201cThere is no magic pill for obesity, but this swallowable balloon and other intragastric balloons may offer new hope to people who otherwise would not seek treatment or not have as good a result with diet and exercise alone,\u201d said Raul J. Rosenthal, MD, ASMBS President and Chairman, Department of General Surgery, Cleveland Clinic Florida, who was not involved in the study.\n[3] The risk of death is about 0.1 percent[4] and the overall likelihood of major complications is about 4 percent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs. Although the manufacturer has not revealed the price it plans to charge in the U.S., the Obalon device is on the market in Europe and Mexico, where prices, including office procedures, range from $2,500 to $4,000. It should be noted that prices for medical devices in the US are generally higher than those charged in other countries.", "answer": 0}, {"article": "My entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\nHowever, the price tag could be as much as $10,000 a year.\nShe feels like a different person who no longer has to shy away from social commitments.\nThe aim of the medication is to stop a migraine before it even starts.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells us the drug, if approved, may cost $10,000 a year. This is very useful context.", "answer": 1}, {"article": "May 4, 2010 (New York) -- An experimental weight loss/blood pressure pill may pack a one-two punch against hunger and high blood pressure, one of the main health consequences of obesity, according to new research presented at the American Society of Hypertension\u2019s 25th annual meeting in New York.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nThe FDA is not obligated to follow the advice of its expert panels, but it usually does.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs.", "answer": 0}, {"article": "U.S.\nResults are published in the scientific publication the Journal of Medical Cases, and is authored by USRM Chief Science Officer Dr. Kristin Comella and colleagues Dr. Scott Greenberg of the Magaziner Center for Wellness, and Dr. Laura Ross of Ross Orthopedic.\nFigure 1a shows a tear at baseline on the posterior horn of the medial meniscus, while Figure 1b, taken 9 months after the first injection shows complete resolution of the tear.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nMeniscal injuries are the most common knee injury in the United States with an annual average of incidence of 66 per 100,000, according to a 2014 article in the Journal of Orthopedics.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this proposed procedure to the patient, nor is there any indication that such a procedure might be covered by medical insurance, since this is a very early experimental approach. The procedure involves outpatient liposuction to obtain a small quantity of the patient\u2019s fat tissue, and various complicated separation procedures to obtain the cell mixture ultimately used in the treatment. The cost for each of those procedures should be well-known and the release could have offered a comparison with the typical cost of the current approach to treating meniscus injuries.", "answer": 0}, {"article": "\"The risk of MS among daughters whose mothers consumed four glasses of milk per day was 56% lower than daughters whose mothers consumed less than three glasses of milk per month,\" Harvard researcher Fariba Mirzaei, MD, says in a news release.\nHowever, few foods naturally contain the vitamin.\nThe disease most often strikes adults after age 20, but it can develop in children.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\nVitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A discussion of cost is not necessary on this topic in this context.\u00a0\u00a0\u00a0\u00a0", "answer": 2}, {"article": "Elizabeth Loder, chief of headache at Brigham and Women's Hospital in Boston, points out that because CGRP constricts blood vessels, there may be potential long-term effects on blood pressure or other cardiovascular function.\nBiologic therapies like these are expensive, and treatment could reportedly range anywhere from $8,000 to $18,000 a year.\n\"With Vioxx, it took 10 years before they discovered that it increased the risk of heart problems.\"\nRight now, the longest patients have been on one of these new therapies is one to two years.\nPerhaps in 10 years I'll feel differently.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says these treatments could cost \u201canywhere from $8,000 to $18,000 a year.\u201d", "answer": 1}, {"article": "As a point of reference, the U.S. Food and Drug Administration requires manufacturers who choose to put a \"gluten free\" label on food packaging to meet the same 20 parts per million of gluten standard.\n\"One of the things that we wanted to make sure we distinguish is that we don't see ourselves as a medical device,\" Sundvor told CBS News.\n\"So we do not need FDA clearance for the device because we are not using it to diagnose or manage disease.\nWe had this shared experience; Shireen has several food allergies and I also have several food intolerances.\nSo we started talking about the idea and we researched the market and realized it's something we could make happen.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story clearly states the cost of the \u201cpre-order\u201d version of Nima and the cost of \u201ctest pods.\u201d", "answer": 1}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\n\u201cTo go from being completely blind for many years, to being able to read a few letters and see shapes is an amazing step.\u201d\n\nRetinitis pigmentosa in a genetic eye condition that leads to blindness and affects about 1 in 4,000 people worldwide.\nHe was cautious about possible wider applications, but said that if it was developed further, the device may someday be used to help people with severe cases of age-related macular degeneration, the leading cause of blindness in older people.\nAccording to the study published in the Proceedings of the Royal Society B journal, one blind patient who had the device implanted was able to identify and find objects placed on a table in front of him, and was able to walk around a room independently.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. Instead by saying, \u201ccould be on the market and available for thousands of patients in about five years\u2019 time\u201d it leaves readers with the impression that cost is not an issue. This is exactly the kind of device that an insurance company might put on its \u201cineligible\u201d list.\u00a0A quick review of the business media suggests the cost of the device will exceed $75,000 if it becomes commercially available. according to this Medical Device Technology Alert. It is hard to imagine why this important fact was overlooked in the story.", "answer": 0}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor.\nThe forthcoming trial lead by Shagisultanova will be a multi-center clinical trial with CU Cancer Center as the lead site, testing the combination of three drugs - tucatinib plus the anti-estrogen receptor drug letrozole and the cell cycle inhibitor palbociclib - against breast cancers positive for both HER2 and estrogen receptors.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nThe fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease.\n\"I think this drug has an extremely high likelihood of being approved for women with HER2+ breast cancer for use after previous treatments,\" Borges says.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much tucatinib treatment might cost. If it\u2019s not too soon to promote the potential benefits of a drug it\u2019s not too soon to provide cost estimates.\n[Editor\u2019s note: We had originally rated this criteria Not Applicable since it is an investigational drug in very early trials and it\u2019s plausible costs are unknown. However, the rating has been revised to be consistent with past reviews and to reflect our general position that costs (or cost estimates based on similar drugs or treatments) should be presented.]", "answer": 0}, {"article": "Dr. Lazova is currently the Director of Dermatopathology at California Skin Institute in San Jose, California.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nFor the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\nIn this study, mass spectrometry correlated better than the gold standard of histologic examination to determine if an atypical mole was in fact benign or a melanoma.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not say how much IMS costs or how it compares with using a microscope. According to an article posted by the American Association for Clinical Chemistry, most mass spectrometry methods \u201crequire labor-intensive\u2014and hence costly\u2014sample preparation. Other factors include limited sample counts over which to amortize fixed expenses, and the fact that expertise for maintenance and assay development may be in short supply.\u201d", "answer": 0}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nThe supplements taken by women in the study contained 210 mg of gamma linolenic acid, 175 mg of oleic acid, 345 mg of linoleic acid, 250 mg of other polyunsaturated acids and 20 mg of vitamin E, according to researchers.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nThe researchers do not make any recommendation in their study about whether women who suffer from PMS should increase their intake of essential fatty acids or, instead, consult with their doctor.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of the supplements.\u00a0 As we\u2019ve reported, about 70% of the stories we reviewed don\u2019t discuss costs.\u00a0 It\u2019s a bad trend, easily corrected, and takes only another few words in a story.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": " The rabbits were given a supplement. Is this supplement available and if so, what does it cost? We\u2019re not told. \u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention any costs, including who pays for travel, hospital, physician, or immunosuppresant medication expenses. Also, the kidney swap program entails huge logistical hurdles/challenges, as not every medical center can afford/provide 4 transplant teams working simultaneously; the swap entails 4 hospital rooms, 4 surgical teams, etc.", "answer": 0}, {"article": "Schneider\u2019s team has been following the patient, taking samples from his colon, liver, spinal fluid and brain as he developed various conditions that justified the tests.\nWASHINGTON (Reuters) - German researchers who used a bone marrow transplant to treat a cancer patient with the AIDS virus, have declared him cured of the virus \u2014 a stunning claim in a field where the word \u201ccure\u201d is barely whispered.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\nAll these places are suspected \u201creservoirs\u201d where HIV can hide out for years, to rebound in patients who stop taking drugs that suppress the infection.\n\u201cIt\u2019s not practical and it can kill people,\u201d said Dr. Robert Gallo of the Institute of Human Virology at the University of Maryland, who helped discover the human immunodeficiency virus that causes AIDS.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs.\u00a0With an estimated cost of $150,000 to 200,000, the cost of a allogenic bone marrow transplant is significant enough to be mentioned.", "answer": 0}, {"article": "Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City, agreed.\n\"The prospect of reducing the transmission of influenza and other respiratory viruses using far-UV radiation is very exciting,\" said Dr. Michael Grosso, chief medical officer at Huntington Hospital in Huntington, N.Y.\n\n\"Though hand-washing remains critically important, it does not prevent every instance of transmission,\" Grosso said.\nBut he believes \"the use of overhead, low-level far-UVC light in public locations would be a safe and efficient method for limiting the transmission and spread of airborne-mediated microbial diseases, such as influenza and tuberculosis.\"\nIt appears that low-dose far-UV light is safe and effective, and has the advantage of inactivating a wide range of disease-causing viruses.\"\nMONDAY, Feb. 12, 2018 (HealthDay News) -- As a particularly nasty flu season rages across the United States, scientists have found a powerful new disinfectant that makes \"light\" work of the virus.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s mentioned \u201clamps with this type of UV light currently cost less than $1,000 \u2026 but (according to the study author) that price would likely fall if the lamps were mass-produced.\u201d The article gets credit for addressing this issue, but the tone seemed a bit speculative.", "answer": 1}, {"article": "(Reuters Health) - A system of automated twice-daily texts and the ability to use text messaging to receive answers to questions about treatment helps relieve some of the stress of chemotherapy for women with breast cancer, researchers at the Fox Chase Cancer Center in Philadelphia reported Monday.\nEveryone has different information-seeking behavior\u201d and the system can respond to that, Dr. Wen said.\nTexting did not affect the odds of developing symptoms of depression.\nCompared to 52 women who only received an American Cancer Society pamphlet on chemotherapy, the 48 women in the texting group reported an overall lower level of distress and a higher quality of life during their therapy.\nThey also felt they had better communication with their doctors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "How much would a texting system cost? Who would pay for it? Would it require extra staffing at the doctor\u2019s office? This story left us wondering.", "answer": 0}, {"article": "\u201cI had terrible pangs of sadness and despondency.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\nAfter he died in 2002, she sold the Long Island house they\u2019d loved and shared, finding it too filled with memories, and moved to their country home in upstate New York.\n\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not tell us what it costs to get 16 weeks of complicated grief therapy. The insurance issues for medical care are thorny enough, but mental health coverage often lags behind other categories. The story would have been more useful had it mentioned that most therapy costs upwards of $150 an hour, and that a 16-week set might be more than $2,400 and might not be covered.", "answer": 0}, {"article": "Devenish manufactures pre-mix and special feed for pigs, poultry, cattle, sheep, equine, game, companion animals and aquaculture.\nThe results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the 'omega-3 Index'-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues.\nProfessor Chris Elliott, Founder of the Institute for Global Food Security & Pro Vice Chancellor, Faculty of Medicine, Health & Life Sciences, Queens University Belfast said:\n\n\"The cost to the health service of treating cardiovascular related illness in the UK is \u00a310billion/year.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\nThe findings were presented by Professor Alice Stanton of The Royal College of Surgeons in Ireland:\n\n\"Greater consumption of oily fish has long been linked to a reduced incidence of heart attack, stroke, diabetes and cancer and improved brain health, vision, muscle and joint health,\" said Professor Alice Stanton.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs that might be\u00a0incurred by consumers interested in choosing chicken and eggs that ate this new feed.\u00a0 Will the new feed cost more than conventional feed, which is likely to be passed along to customers?\nThe only mentions of cost are a vague assertion that chicken and eggs are \u201cvery affordable sources of quality protein.\u201d But that doesn\u2019t tell us what the cost will be of chickens that consume the enhanced feed.\nThe release also makes an unsubstantiated claim that nutrient-rich foods such as this feed will help reduce the UK\u2019s and the whole world\u2019s cardiovascular disease burden. It says:\n\u201cThe cost to the health service of treating cardiovascular related illness in the UK is \u00a310billion/year. Having access to sustainably produced nutrient-rich food, with a scientifically proven health claim, offers huge potential to turn this around globally.\u201d\nThere wasn\u2019t any evidence provided to support that claim.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story alluded to the fact that patients would have to pay to have a test done correctly. Even better would have been an actual cost for the test, or range of possible costs.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\n\"The biggest problem we face in preventing stroke in patients with atrial fibrillation is that almost half of patients don't take any blood thinner at all,\" Bernstein said.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\nLOS ANGELES, Feb. 19, 2016 - A new medication reverses the blood-thinning effects of the anticoagulant dabigatran in patients suffering a brain bleed, potentially limiting the extent of bleeding, according to research presented at the American Stroke Association's International Stroke Conference 2016.\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost at all. According to NEJM Journal Watch, the cost is reported to be in the ballpark of $3,500 per use, which we consider to be a very conservative amount.", "answer": 0}, {"article": "Before Starting A Statin, Talk It Over With Your Doctor\n\nA study published Monday is pushing back against the notion that up to 40 percent of Americans should be taking statin drugs to reduce the risk of heart disease.\nThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines.\n\"The elderly do not benefit as much as previous studies might have thought,\" he says.\nAnd it is only useful as a screening test for people who haven't had heart disease.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of cost, even to mention that statins are relatively inexpensive these days and are mostly generically available. To its credit, the article does mention the cost of a calcium scan.", "answer": 0}, {"article": "\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nAll of the women received therapy for eight weeks and were interviewed at the four- and eight-week marks by someone who did not know which treatment they were getting.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\nMany pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nThe researchers say 63% of the women who received depression-specific acupuncture reported a significant reduction in symptoms, compared to 44% of women in the other two groups combined.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion regarding the cost of acupuncture, a particularly important omission since acupuncture is not covered by all insurance companies.\u00a0\u00a0\u00a0\u00a0 ", "answer": 0}, {"article": "Both approaches reduced volunteers\u2019 normal daily caloric intake by about 750 calories.\nAnd like most of the recent studies about the health effects of low-carbohydrate diets, \u201cthese are very short-term results,\u201d said Dr. Dena Bravata, an internist and research associate at the Center for Primary Care and Outcomes Research at Stanford University, who was not involved with this experiment but has conducted dietary studies.\nBut a unique worry raised by these regimens, extending back to the heyday of the original Atkins diet in the 1970s, was that indulging in repeated fatty, glistening meals would lard your arteries and cause heart disease.\n\u201cBut what about in 5 or 10 years, if they remain on the diet?\u201d\n\nThis study also reported on a single marker of cardiovascular health, she continued.\n(In the current study, participants followed a diet based on the New Atkins for Life approach, which includes more vegetables than the original Atkins diet, Dr. Stewart said, adding that he and his colleagues have no ties to and receive no financing from the Atkins diet organization.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about costs but a motivated reader reader could calculate this.\u00a0 However, it\u2019s worth noting that long-term costs of following a restrictive diet are not inconsequential.", "answer": 2}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va.\n\"It may provide (an opportunity for) both physicians and couples to take a closer look at ways for men to step up to the plate and optimize their reproductive potential,\" said Dr. Robert Brannigan, urologist at Northwestern University Feinberg School of Medicine.\nBy detecting that protein, the test indicates whether or not a semen sample contains 20 million sperm per milliliter.\nThe test costs about $40; the average cost of a semen analysis in a doctor's office is about $100.\nWhen a couple is struggling to conceive, it's the woman who is usually the first \u2014 and often the only one \u2014 to be poked, prodded and analyzed, experts say.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says, \u201cThe test costs about $40; the average cost of a semen analysis in a doctor\u2019s office is about $100.\u201d As a comparison, the story says, \u201cThere are also several at-home sperm analysis kits available online. They each include a microscope and cost at least $80.\u201d", "answer": 1}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\n\"The CMA test alone has triple the detection rate of karyotyping or fragile X,\" said co-senior author Bai-Lin Wu, director of the Genetics Diagnostic Laboratory at Children's Hospital Boston.\nBut if the parents don't have the abnormality, geneticists conclude that the deletion or duplication happened by chance, and the parents are probably not at any greater risk of having another child with autism than the general population, Marion said.\n\"In the vast majority of cases, we believe there is at least a genetic predisposition to autism, but the ability to identify a specific genetic cause has been very elusive,\" Marion said.\nMONDAY, March 15, 2010 (HealthDay News) -- A newer type of genetic test is better at detecting abnormalities that predispose a child to autism than standard genetic tests, new research has determined.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention specific costs of the CMA test; however, it did indicate that not all insurance will cover this test. Since the story stated that\u00a0 \"both Children\u2019s Hospital Boston and Montefiore have offered CMA testing for several years,\" some cost estimate could have easily been found. ", "answer": 0}, {"article": "Johansson and her colleagues used data from nationwide Swedish health registries to compare pregnancies between nearly 600 women who had given birth after bariatric surgery and more than 2,300 women who hadn't had the surgery but had the same BMI.\n\"The number of women who are obese in early pregnancy has increased dramatically over the last decades,\" said study author Kari Johansson, a postdoctoral researcher and nutritionist at Karolinska Institute in Stockholm.\nWhile various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines' absorption of calories and nutrients from food.\nWEDNESDAY, Feb. 25, 2015 (HealthDay News) -- After undergoing weight-loss surgery, women are significantly less prone to diabetes during pregnancy but twice as likely to deliver smaller-than-normal infants, a new study suggests.\nBecause obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have addressed the cost of bariatric surgery in several ways. There is the cost of the surgery itself, and then there is the cost of pregnancy/delivery among obese women who have had bariatric surgery or not. The latter issue would seem most relevant to the story at hand, but might also be harder to measure. At least mentioning either issue, with an attempt at quantification, would have earned the story a satisfactory rating here.", "answer": 0}, {"article": "Article reference: R.M.\nBy pooling the data of several studies, Thomas Jefferson University researchers showed that a higher rate of IV fluids not only decreased c-section rates, but also shortened the overall length of labor by one hour, as well as shortened the pushing phase.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost does not make an appearance in this release. The concept may seem trivial when considering the cheap ingredients in saline\u00a0fluid, but little about American medical care is cheap.\nAnother important consideration is the cost of cesarean section compared with that of vaginal delivery, which is not addressed in the release.", "answer": 0}, {"article": "\u201cFollowing a 'healthy diet' emerges as an important strategy for prevention of neurological disease, but remains to be proved.\u201d\n\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cNow, we see it may reduce stroke risk in people older than 65.\"\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of olive oil is not in question.", "answer": 2}, {"article": "Bethany, who manages occupational therapists for a nursing-home chain, and Jay, a rural mail carrier, shuttled between the Twin Cities visiting their daughters.\nIt\u2019s too soon.\u201d\n\nScientists have wanted for decades to marshal the immune system to vanquish cancer, but their attempts have mostly been frustrated.\n\u201cI couldn\u2019t walk up the steps very well.\u201d Almost three years of treatment, including punishing chemotherapy, provided a couple of years of remission.\n\u201cThere\u2019s a lot that still needs to be worked out.\u201d\n\n[Here\u2019s what you need to know about immunotherapy]\n\nComplications can be lethal; one clinical trial was briefly halted in July after three young adults died of brain swelling.\n\u201cThen suddenly it\u2019s over.\u201d\n\nIf his daughter\u2019s cancer returns yet again, \u201cI have no idea what we\u2019ll do,\u201d Jay said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The CAR T-cell therapy is currently available only in clinical trials, where costs presumably aren\u2019t an issue (a point the story might have made for readers who aren\u2019t familiar with clinical trials).\nThat leaves the question of how much this therapy may cost if it becomes more widely available. And this is where the story offers some valuable insight: \u201cIt is also far from clear that such a personalized approach \u2014 possibly costing hundreds of thousands of dollars \u2014 is economically viable on a large scale.\u201d In other words, to quote the story again: \u201cbig questions surround the therapy.\u201d", "answer": 1}, {"article": "(Reuters) - Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nAsterias is looking to show recovery of mobility in four out of every 10 patients treated with OPC-1, compared with two out of 10 achieving the same level of improvement without any treatment, Chief Executive Pedro Lichtinger told Reuters in early August.\nIn an early-stage study conducted by Geron, the therapy showed potential in repairing spinal injury in four of the five patients tested, without any adverse events.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The therapy, AST OPC-1, is in its early developmental stages \u2013 making it difficult to estimate costs in this case.\nSince the story is clear about the early state of the research, we rate this one Not Applicable.", "answer": 2}, {"article": "\"The [brains of] children who received the ESDM looked virtually identical to typical 4-year-olds,\" Dawson says.\nThe treatment, dubbed Early Start Denver Model or ESDM, offers a child 20 hours a week of one-on-one treatment with a trained therapist.\nAs measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\n\"We jump-started and improved the responses of children's brains to social information,\" says Dawson, professor of psychiatry at the University of North Carolina and chief science officer at Autism Speaks.\nIt also calls for many more hours of the treatment, in the form of structured play, with a parent trained in the technique.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. And we can only assume that two years of therapy would be quite expensive for families and, as yet unproven in multiple trials, likely would not be covered by insurance.", "answer": 0}, {"article": "Breaking the diet with so much as a few cookies can cause seizures to flare up.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\nThough its exact mechanism is uncertain, the diet appears to work by throwing the body into ketosis, forcing it to burn fat rather than sugar for energy.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story was not explicit about the costs of the diet. The ketogenic diet may involve inpatient initiation of treatment, lots of lab work and a good deal of involvement from the neurologist and dietician.\u00a0 The price of all of this may be offset by reduced drug costs.\u00a0 The listing of the components of the diet gives the impression of a low cost of care which may not be valid.", "answer": 0}, {"article": "Rosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\nIf the child still has symptoms 3 days later, then they should get the antibiotic and start giving it to their child.\n\"More young children with a certain diagnosis of acute otitis media recover more quickly when they are treated with an appropriate antimicrobial agent,\" Klein wrote.\nThese 2 new studies were designed to provide the research to fill the gap, and clarify treatment recommendations for babies and toddlers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss the costs of antibiotic prescriptions to the individual or costs of policies on our health care system and society. We think it should have.", "answer": 0}, {"article": "\"It's the first time in the history of Type 1 diabetes where people have gone with no treatment whatsoever ... no medications at all, with normal blood sugars,\" said study co-author Dr. Richard Burt of Northwestern University's medical school in Chicago.\nBut it didn't work for two of them.\nOne patient was as young as 14.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\nThe hazards of stem cell transplantation also raise questions about whether the study should have included children.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn't mention costs of this new treatment. ", "answer": 0}, {"article": "Mumford, who's now 30, says he's never felt better.\nCord blood stem cell transplants have the same risks as adult bone marrow transplants: the new blood rejecting the host, called graft-versus-host disease.\nIf collected and stored for private use, the procedure can cost as much as $2,000 or more, plus annual storage fees.\nThe nonprofit, named for his mother, who died of breast cancer while he was being treated, provides emotional and financial assistance to cancer patients.\nIn such transplants, patients have chemotherapy, radiation or both to kill the cancer cells and to suppress the immune system so that the new stem cells are not rejected.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of donation are discussed, but not transplantation \u2014 the treatment discussed. It\u2019s not cheap, and it may not be completely covered by insurance.", "answer": 0}, {"article": "Contrary to earlier reports, giving acetaminophen (Tylenol, etc.)\n\"We found no matter how you slice it, there was absolutely no difference between Tylenol and Motrin,\" says senior investigator and corresponding author Wanda Phipatanakul, MD, MS, of Boston Children's Hospital's Division of Allergy and Immunology.\n\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nSince the study was limited to young children with mild persistent asthma receiving asthma controller therapy, the authors also note that their findings may not apply to other age groups or children with more severe asthma.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed in the Boston Children\u2019s Hospital news release. The acetaminophen medication used in the study, Little Remedies, costs about 50 percent more than Children\u2019s Advil \u2013 $8.86 versus $4.96, respectively \u2013 at Walmart. It would have been helpful to readers to include the less costly generic versions of these drugs.\nSince costs are not mentioned in the news release, we give it an Unsatisfactory rating here.", "answer": 0}, {"article": "Wine rounds out the list of of 10 \"brain healthy\" food groups that help protect against Alzheimer's: green leafy vegetables, other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil and wine.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe study, published in the journal Alzheimer's & Dementia, looked at more than 900 people between the ages of 58 and 98 who filled out food questionnaires and underwent repeated neurological testing.\nThe Mediterranean and DASH diets do not specifically recommend these types of vegetables, but the MIND diet study found that including greens in addition to other veggies made a difference in reducing the risk of Alzheimer's.\nBut the MIND diet helped slow the rate of cognitive decline and protect against Alzheimer's regardless of other risk factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of the diets in this story.\u00a0 Some parts of the diets, including berries out of season and greens year round, can become expensive.\u00a0 The types of foods included in this diet are not necessarily readily available in economically depressed areas of the US. A quick nod to either of those facts would have earned the story a satisfactory rating.", "answer": 0}, {"article": "For example, over 6 years of follow-up, no ovarian cancer cases were seen among BRCA2 mutation carriers who underwent salpingo-oophorectomy, compared with 3 percent of carriers who did not undergo the procedure, the researchers report.\nRoughly half of the women in the study had undergone either mastectomies (surgery to remove their breasts) or salpingo-oophorectomies (surgery to remove the ovaries and fallopian tubes) between 1974 and 2008, in order to proactively lower their risk of cancer.\n\"There really isn't anything else that can reduce a woman's risk by this much.\"\nThe surgery in question is drastic: removal of the breasts or ovaries before any signs of cancer have arisen.\nHe said the surgery today is often done in an outpatient setting, with the use of laparoscopes, which limits scarring and shortens a patient's recovery time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention the costs of genetic testing, increased cancer surveillance or surgery.", "answer": 0}, {"article": "GALVESTON, Texas -Researchers from The University of Texas Medical Branch at Galveston found that testosterone replacement therapy may slow disease progression of chronic obstructive pulmonary disease.\nThe paper is currently available in Chronic Respiratory Disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "This early detection is key because early treatment is more effective.'\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\nThe Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\nWhen inflammation occurs in the body, some proteins are altered in a process called citrullination.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t provide discussion of what the cost of the blood test might be. If the test is promising enough to issue a news release about it, readers should be given some idea of the cost. A related test called the CCP assay, which detects certain peptides that also predict future RA, is already in use and would make a good comparison. Moreover, there would not only be the cost for this test, but also the downstream costs of earlier treatment (and potential benefits). In general, the potential benefits in terms of cost savings are usually offset by higher costs associated with treatment for a longer duration of time (earlier diagnosis = earlier \u201clonger\u201d treatment).", "answer": 0}, {"article": "He hopes to make periodontal treatment a standard part of treating prostate disease, much like cardiac patients are often encouraged to visit their dentist before undergoing heart procedures and a dental checkup is advised for women who are pregnant or considering pregnancy.\nThe men were assessed for symptoms of prostate disease by answering questions on the International-Prostate Symptom Score (IPSS) test about their quality of life and possible urination issues.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\nBut even without prostate treatment, 21 of the 27 men showed decreased levels of PSA.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release and the study both suggest that treating periodontal disease might be a \u201crequired approach\u201d to reducing prostate inflammation and possibly prostate cancer.\u201d So the release probably should have said something about the social and financial costs of untreated gum disease and prostatitis, and the costs of providing dental care to what is likely a substantial percentage of the population. It\u2019s likely that if further studies do in fact demonstrate the value of dental treatment that money might be saved in terms of downstream treatment of prostatitis, prostate cancer, and dental disability. Dental care is not cheap in the United States, and insurance coverage, even where it exists, usually pays for only a fraction of the care.\nAlso, not mentioned anywhere is that PSA testing as a routine cancer screen is not recommended anymore. Unnecessary testing is costly.", "answer": 0}, {"article": "TUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\nThis increase in less-invasive biopsies went along with a decrease in the number of more-invasive biopsies and through-the-skin biopsies where no imaging was used, the researchers found.\n\"In time, I would expect 80 to 90 percent of biopsies will be image-guided biopsies,\" he said.\nDuring that time, the number of biopsies increased from 1,380 per 100,000 in 1997 to 1,945 per 100,000 in 2008.\nIn fact, the use of these minimally invasive biopsies increased from 59 percent to 67 percent of all biopsies between 1997 and 2008, a trend which is likely to continue, one expert noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2013 which is curious in a story describing the growth in use of less invasive biopsies, supposedly allowing for shorter hospital stays. ", "answer": 0}, {"article": "(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co\u2019s diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker\u2019s biggest product.\nIt was undertaken after heart safety concerns were raised over other diabetes medicines.\n\u201cFor the heart failure concern raised by other agents in the class there is no difference (with placebo),\u201d he added.\nThere was also no significant difference between Januvia and placebo in infections, cancer, kidney failure or severe hypoglycemia, which is dangerously low blood sugar, researchers reported.\nPancreatic cancers, also uncommon, were numerically fewer with Januvia, 9 versus 14.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in this story. Cost information is available. It costs about $350 for 30 tablets of 100 mg each.", "answer": 0}, {"article": "She had tried everything.\n\"We have two-thirds of all Americans who are overweight or obese, and the costs are nearing $150 billion a year,\" says Christine Ferguson, a health policy professor at George Washington University.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\n\"When you're talking about a drug where it could go into literally tens of millions of Americans, there has to be attention to safety,\" Woodcock says.\nSome see Qnexa as a test of the FDA trying to recalibrate how it weighs risks and benefits for weight-loss drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of Qnexa\u2019s cost. As the New York Times reported, \u201cThrough a regulatory loophole of sorts, many obesity doctors prescribe two separate drugs that, when taken together, are essentially the same medicine.\u201d So, at least some estimate of the cost of those components could have been given.\u00a0 Or analysts could have helped project what expected Qnexa costs would be.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nThe idea that you can take a medicine one or a few times and become \u201ccured,\u201d or at least significantly helped, conflicts with current standard practices, which often involve taking medications every day for years, or life.\n\u201cThose kinds of changes are not delusional, because blinded interviews with family members, friends and work colleagues [confirm these reports].\u201d\n\nSimilar work has shown psilocybin can help treat anxiety associated with cancer, at UCLA and New York University.\nIn the 1950s through the early \u201970s, research began to show that psychedelics like LSD and psilocybin, the active ingredient in magic mushrooms, could be quite effective at treating mental health disorders like addiction.\nThe same year, Johns Hopkins University physician and researcher Roland Griffiths showed that in healthy volunteers, psilocybin produced lasting benefits like improved mood and peacefulness six months after ingestion.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not discussed at all. Presumably without patentable drugs derived from these substances, they could be very economical, yet we have no idea if the substances used in these experiments underwent substantial processing or packaging which, of course, would all affect cost.", "answer": 0}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nIt did reduce the severity and duration of colds slightly, but the researchers say the difference was so slight it ended up being pretty meaningless, and not worth the effort or expense of taking all that vitamin C.\n\nPeople apparently protected from colds by vitamin C, Senay said, are those who subject their immune systems to extraordinary amounts of physical stress, such as people who run marathons, or do serious trekking in the winter.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nFor the rest of us, the chances of vitamin C warding off colds is so slight, the lead researcher concludes it \"doesn't make sense to take vitamin C 365 days a year to lessen the chance of catching a cold.\"\nAnd the results, just published by The Cochrane Library, are likely to disappoint people who swear by vitamin C.\n\nAccording to their analysis, daily vitamin C basically had no effect on the incidence of the common cold in the general population, except for very specific groups of people, all of them small groups.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Information about how much it would cost to take the\u00a0vitamin prophylactically for a year would have made a useful point\u2013taking vitamin C isn\u2019t just ineffective, it\u2019s costly. It would also have been good to report how much\u00a0money Americans spend on vitamin C products to treat colds\u2013not just the supplements but lozenges, often-expensive vitamin C products marketed for cold treatment, etc.\u00a0 ", "answer": 0}, {"article": "Weiss advises women with advanced breast cancer to have genetic testing.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nThe drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing cancer cells from killing healthy ones.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.\nWhen a drug has not been approved, and thus is not on the market, it can be hard to estimate cost. In this case, however, there is a similar drug on the market: The PARP inhibitor olaparib (Lynparza) is $13,440 per month, without insurance, according to a 2015 report.", "answer": 0}, {"article": "Antioxidants neutralize unstable forms of oxygen called reactive oxygen species that can damage cells throughout the body.\nIt is unlikely that people could get too much vitamin E from food.\nAt that point, they were interviewed about their usual diet habits, which the researchers used to estimate their intake of vitamins C and E and beta-carotene.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nReactive oxygen species are produced naturally in the body, as byproducts of metabolism; because the brain is an area of high metabolic activity, it is thought to be particularly vulnerable to accumulating oxidative damage over a lifetime.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of foods containing vitamin E is not really in question, so we\u2019ll call this one not applicable.", "answer": 2}, {"article": "But that could finally change with the introduction of two simple new blood tests for spotting the disease.\nThe tests, which measure antibodies in the blood, were based on research suggesting that IBS may develop after infection from a bacterial toxin found in food poisoning.\n\"There's always kind of a 'trend of the week' that you had to go and get tested for and rule out, and at the end of the day you don't feel better,\" she said.\n\"I'm not saying the symptoms went away,\" she said, but she \"started to feel more whole.\"\n\"We now have a test to say, you have a disease,\" Pimentel told CBS News.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost, and it\u2019s not clear from the story if the tests are commercially available. Since there\u2019s a consumer website devoted to the tests, we assume they can be purchased, but couldn\u2019t find any cost information on the site. The story could have enlightened us.", "answer": 0}, {"article": "Routledge added that current evidence shows that not smoking, only consuming alcohol within recommended limits, staying active, monitoring cholesterol levels and eating a balanced diet can all help with the health of the heart and brain.\nDementia is an umbrella term used to describe symptoms related to the loss of brain function.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\n\"What's good for the arteries is good for the brain,\" he added in summary of his findings.\nHow you live your life... has a real impact on how quickly your condition can decline.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t discussed. Various online estimates for carotid ultrasounds put them at $200-$800.", "answer": 0}, {"article": "Peer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\nDr. Ashley Brenton, Associate Director of R&D for Proove states, \"This validation study builds on the peer-reviewed evidence supporting Proove Opioid Risk\u00ae and its components as an optimal model to predict opioid abuse risk.\"\nThis study, entitled \"Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre\", is published in the peer-reviewed Journal of Addiction Research and Therapy (Impact Factor: 1.4).\nDistinguished Fellow American Society of Addiction Medicine (ASAM), Diplomate American Board of Addiction Medicine and Fellow American College of Preventive Medicine, J. Ramsay Farah, MD, MPH, MRO, CPE, led a research team that showed Proove Opioid Risk\u00ae identifies patients at risk for Opioid Use Disorder (OUD) with nearly 97% accuracy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the Proove Opioid Risk (POR) system costs. Presumably, this system would be used by health care providers to determine whether it was safe to prescribe opioids to specific patients. However, such providers would have no way of knowing, based on this news release, how much of an investment this would require.", "answer": 0}, {"article": "So what to think of infrared saunas?\nThe existing evidence, though scanty, suggests spending up to 15 minutes a day in one could benefit your heart and ease symptoms associated with chronic pain.\nBut if you\u2019re wondering whether an infrared sauna is worth a try, the evidence suggests you have little to lose and possibly something to gain by checking one out.\nStill, the big questions surrounding sauna bathing\u2019s safety have always centered on its occupant\u2019s (and her heart\u2019s) ability to withstand the heat.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. Standard saunas are generally available at fitness gyms, but it\u2019s unclear where a person finds an \u201cinfrared\u201d sauna, and if they cost more to install and/or use.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states, \u201cTen one-gram capsules of kratom cost $20, while 30 grams of powder is $34.99.\u201d\n(However, it\u2019s not clear how much a person might use per day.)", "answer": 1}, {"article": "\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nMore than 2.2 million men in the U.S. are living with prostate cancer.\nThe patients\u2019 average age at diagnosis was 65.\nMen who took acetaminophen for less than five years saw no protective benefit.\nProstate cancer is the second leading cause of cancer death in men.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost is not much of an issue here.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe standard Medicare per-injection costs of the three anti-VEGF drugs evaluated in the study are about $1960 for aflibercept (Eylea), $1200 for ranibizumab (Lucentis) and $70 for bevacizumab (Avastin).\nNewswise \u2014 BOSTON \u2013 (February 19, 2015) \u2013 In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss.\nThe most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy, which is caused by elevated blood sugar levels damaging the blood vessels of the retina and affects approximately 7.7 million Americans.\nWith the rate of diabetes increasing dramatically worldwide, many individuals will be at risk for vision loss from diabetic eye complications and DME is a major global health concern,\u201d says Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee, and an Investigator in the Section on Vascular Biology, an ophthalmologist in Beetham Eye Institute at Joslin and an Assistant Professor at Harvard Medical School.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The costs of the three anti-VEGF drugs evaluated in the study were listed as about $1960 for aflibercept (Eylea), $1200 for ranibizumab (Lucentis) and $70 for bevacizumab (Avastin), per injection. This is\u00a0satisfactory, although since a treatment course involves multiple injections, we\u2019d like to have seen the total cost of treatment compared without having to do the math ourselves.", "answer": 1}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe protective effect of hormonal therapy may depend on the health status of neurons at baseline and may be lost if therapy starts years after menopause,\" Dr Imtiaz concludes.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\n\"The protective effect of hormone therapy may depend on its timing: it may have cognitive benefits if initiated at the time of menopause when neurons are still healthy and responsive,\" says Bushra Imtiaz, MD, MPH, who presented the results in her doctoral thesis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release. Hormone replacement therapies have been on the market for decades, and their well-known costs should have been included. The cost to an individual may not be very high, but the cost to society of unnecessary, and potentially harmful, hormone prescriptions could be very high.", "answer": 0}, {"article": "Research involving 800 patients ultimately led to the approval of Zecuity.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nMONDAY, Jan. 21 (HealthDay News) -- A skin patch for the treatment of migraines, and the intense waves of nausea that often accompany these debilitating headaches, has been approved by the U.S. Food and Drug Administration.\nIn general, though, \"the more options that are available to migraine headache patients, the better,\" Waltman said.\n\"I've had some patients where the nausea and vomiting was so bad they couldn't even swallow a pill,\" said Nancy Waltman, a nurse practitioner with the University of Nebraska Medical Center College of Nursing, Lincoln Division.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says it\u2019s \u201cnot clear\u201d how much the new patch will cost, which is accurate, but Bloomberg was able to provide a ballpark estimate from a company official, who said it would be in the $95 range. Since this HealthDay piece references the same\u00a0Bloomberg story when discussing the planned launch of the new product, we\u2019re not sure why it didn\u2019t pass along the $95 figure as well.\u00a0We\u2019re pleased that the story at least raised the issue of cost, but we\u2019ll fault it for not providing detail that was easily available. You\u2019d also like to see the cost per migraine episode of this medicine vs. alternatives.", "answer": 0}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This issue\u00a0is alluded to obliquely in the quote that ends the article,\u00a0which\u00a0suggests that\u00a0palliative care\u00a0may help address \"critical concerns regarding the use of health care services at the end of life.\" This is not\u00a0specific enough to satisfy the criterion.", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story states that the protein-containing drink is more expensive than the traditional sports drink, this is insufficient information on costs. How much more expensive? What is the actual price? ", "answer": 0}, {"article": "Drs.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\n\"We discovered that whole brain radiation added to focused radiation in the treatment of brain metastases \u2013 in other words, cancer that travels to the brain- reduces the number of new brain tumors over time; however, patients receiving the whole brain radiation had significantly more difficulties with memory and complex thinking than patients who only had the focused radiation,\" says Dr. Asher.\nAnthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and as well as Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, began their research on this subject over 10 years ago in Charlotte, North Carolina.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since both the focused radiation and whole brain radiation are common treatments for brain tumors, an estimate of typical costs should have been included in the release.\nThere is likely to be a range of costs because of issues with the specific tumor\u00a0target. However, the release could have made note of that.", "answer": 0}, {"article": "Although colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\nPatients must often take time off work and need transportation home from the procedure.\n\"We were pleased by the results of this first clinical study,\" he says.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nOne screening test, the colonoscopy, in which a flexible, lighted tube with a video camera is inserted to examine the colon, requires dietary restriction and preparation of the colon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of possible or projected costs. Other stories estimated in the $300 per test ballpark.", "answer": 0}, {"article": "Related: De Niro says 'find the truth on vaccines'.\nThe scans showed that 70 percent of high-risk toddlers diagnosed with autism at age 2 had an elevated amount of cerebrospinal fluid around their brains at 6 and 12 months, compared to toddlers who were not diagnosed with autism.\nRelated: See the special bond between a boy with autism and a deaf shelter dog\n\nThe study results are \u201cvery exciting,\u201d said Dr. Adriania Di Martino, a professor of child and adolescent psychiatry at NYU Medical School.\nBut if the fluid is not flowing properly, these byproducts hang around and cause inflammation, which could \u201champer brain development\u201d and lead to autism, said Shen.\nIt may be possible to predict autism in infants as young as 6 months who have older siblings with the disorder, according to a new study by a national network of researchers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this article made it clear that parents of children with autism should not rush out and get MRIs of infant siblings, it did not mention the costs of MRIs, which may be prohibitive for parents without good insurance coverage.", "answer": 0}, {"article": "The key asset Pfizer wanted?\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nA few weeks ago, the Food and Drug Administration granted Tesaro\u2019s drug fast-track approval status \u2014 and this new data will support its registration applications to both the FDA and the European Medicines Agency, Tesaro CEO Lonnie Moulder said.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\nAt the European conference this weekend, Tesaro added a few more details to that data:\n\nThe study looked at 553 patients whose cancer responds to a certain type of chemotherapy, known as platinum chemo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t include costs. While the cost to consumers of the three new drugs may still be a question, the cost of the established drug \u2014 Lynparza by AstraZenaca \u2014 is well known and can run around $3,000 or more for a bottle of 112 capsules.\u00a0 And readers would benefit if only by knowing if the new drugs would be cheaper or more expensive than current medications.", "answer": 0}, {"article": "Co-authors on the paper, all from Boston University, are T.A.\n\"The potential of digital UV technology for phototherapy is enormous,\" said Dr. Robert C. Walker, RayVio's CEO.\nRayVio's 293nm LED showed the most significant potential for vitamin D3 production in the shortest amount of time,\" said Dr. Holick, a Professor of Medicine, Physiology and Biophysics at Boston University School of Medicine, and endocrinologist at Boston Medical Center.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Our philosophy: if not too early to talk about a device\u2019s effectiveness, then it\u2019s not too early to start discussing its potential price on the market. And the release claims there \u201cwill be\u201d a new generation of marketable products based on this research.\nThe news release states RayVio\u2019s 293nm UV LED was the most effective out of all the UV LEDs tested in this study. The California-based manufacturer sells its UV LED products online, with unit prices ranging between $6.93 to $68.06 for a single device.\nSince costs are not discussed in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\u201cLithium is a drug with a bad reputation.\nThe paper, co-written by Hayes and four colleagues from UCL and Oxford University, concluded that: \u201cLithium remains an important treatment for individuals with bipolar disorder.\u201d It accepts that \u201cthere is clear evidence that its use is associated with a number of adverse events.\u201d\n\nHowever, it adds: \u201cThese risks need to be offset with the potentially superior effectiveness and anti-suicidal benefits of the drug compared to other treatment options.\u201d\n\nThe researchers studied a nationally representative sample of 6,671 patients across the UK who were treated for bipolar disorder between 1995 and 2013.\nThe very limited use of lithium is despite the National Institute for Health and Care Excellence (Nice) advising in 2014 that it should be the standard treatment for bipolar disorder, which is also known as manic depression and is characterised by manic highs and bouts of depression.\nThere should be more sensible use of it.\u201d\n\nStephen Buckley, head of information at the charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications for people experiencing mental health problems, including bipolar disorder.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not address costs. Because this ran in the U.S. edition of The Guardian, this is important and useful information for readers stateside, who often have substantial out-of-pocket drug costs.", "answer": 0}, {"article": "\"Sure.\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\nSo even though he had been feeling good for awhile, he admitted there was always fear his disease could take a turn for the worse.\nWhen he turned the device on, the temperature went up in that one area where the metal was and nowhere else.\n\"I decided it was time to turn the switch on and try it\u2026Try treating myself,\" he explained.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe device is at a very early stage of experimentation, so it\u2019s understandable that costs wouldn\u2019t be discussed.", "answer": 2}, {"article": "Brooks hopes that more health workers will consider incorporating pets into care plans for people with mental illness.\n\"There's like a chasm, deep chasm between us ... [Other people are] on one side of it, and we're on the other side of it.\n\"That surprised me, you know, the amount of people that stop and talk to him, and that, yeah, it cheers me up with him.\n\"I think it's really hard when you haven't had a mental illness to know what the actual experience is [like],\" said one participant.\n\"When I'm feeling really low they are wonderful because they won't leave my side for two days,\" one study participant with two dogs and two cats, \"They just stay with me until I am ready to come out of it.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed.\u00a0There is the hint that it might be out of reach for some people with this quote in the story:\n\u201cHe feels this study is important because, although there\u2019s a lot of work looking at the benefits of trained therapy animals, they can be expensive and out of the reach of many patients.\u201d", "answer": 0}, {"article": "Get to know how you can help save and improve kids' lives at http://www.\n\"We looked at all of these metabolites in concussed male adolescent patients and in non-concussed male adolescent patients and it turns out that the spectrum is really different,\" explains Daley, who is also Western's Associate Vice-President (Research) and a principal investigator at Western's renowned Brain & Mind Institute.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\n\"This novel approach, to use blood testing of metabolites as a diagnostic tool for concussions, was exploratory and we were extremely pleased with the robustness of our initial results,\" says Dr. Fraser, also an Associate Professor in Western's Departments of Paediatrics, Physiology & Pharmacology and Clinical Neurological Sciences at the Schulich School of Medicine & Dentistry.\n\"There is no one metabolite that we can put a finger on but when we looked at all of them, those profiles are different enough that we could easily distinguish concussed patients from non-concussed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We are told the test is \u201crelatively inexpensive\u201d as would be the drawing of blood, but we\u2019re not given a hint at what the cost is for measuring more than a dozen metabolites. The release might have better addressed the unknowns about this preliminary test by letting readers know that a commercial test is not yet available and its cost remains unclear.", "answer": 0}, {"article": "Taylor discovered that the study participants who received in-person cognitive behavioral treatment for their insomnia reported significantly greater improvements in sleep quality -- as determined by the sleep diaries and activity monitors -- than those who received the Internet therapy.\n\"The online program can also be done from home rather than at a military behavioral health clinic, which some service members may avoid due to concerns about stigma,\" said Pruiksma, an assistant professor of psychiatry at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).\nFor military personnel, internet-delivered cognitive behavioral therapy appears to be an effective alternative to meeting regularly with a therapist, although it is about half as effective as traditional methods, according to results of a study conducted by Daniel Taylor, University of North Texas professor of psychology and director of UNT's Sleep Health Research Laboratory.\nFor deployed military personnel, the side effects such as grogginess, slowed cognitive processing and slowed reaction time can be dangerous,\" Taylor said.\nIn a previous study of civilians with insomnia, Taylor and his research team discovered that cognitive behavioral therapy led to significant improvements in sleep efficiency, with the research subjects' use of sleep medication declining from 87.5 percent before therapy to 54 percent afterward, although the subjects weren't required to stop taking their medication.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Obviously there are likely major differences in costs associated with in-person CBTi versus internet-delivered CBTi so it is unfortunate these were not discussed in this release.\nThe only mention of cost was that of the $1.16 million grant the University received for the 6-week study.", "answer": 0}, {"article": "This barrier works to protect the brain from toxins.\n\"GBM is one of the most aggressive of all cancers and it affects people of all ages,\" said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation.\nStudy funded by Ivy Foundation shows PPF could help treat glioblastomas by sensitizing tumors to chemotherapy and radiation treatments\n\nPHOENIX, Ariz. -- Nov. 12, 2015 -- In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.\nIn addition, TGen laboratory research also found that PPF increases the effectiveness of a standard-of-care chemotherapy drug called temozolomide (TMZ), and radiation, to treat glioblastoma.\nIn a study published today in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM -- the most common primary tumor of the brain and central nervous system -- by targeting a protein called TROY.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though propentofylline, the drug being studied, is not FDA approved for use in people, the release could have easily included some basic price information since the drug is currently sold for use in elderly dogs in many countries. One online pharmacy quotes a price of $67 for sixty 100 mg tablets tablets. Of course, the price would likely be higher for a drug that meets FDA standards for human use.", "answer": 0}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail the costs of the weekly sessions of therapeutic hypnosis, which are likely to be high. But if the woman can learn the technique and use it herself over several years, it may be more cost effective than medication. This is what makes the cost consideration worth mentioning.", "answer": 0}, {"article": "Feb. 7, 2011 -- Giving your sweetie chocolate for Valentine's Day may show you care for their health as well as their heart.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\nDark chocolate generally has a higher percentage of cocoa content than milk chocolate.\nThe seeds are dried and then processed to produce cocoa powder.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story should have pointed out that the dark chocolate associated with health benefits is generally more expensive than other chocolates due to its high cocoa content.", "answer": 0}, {"article": "The cause of atopic dermatitis is a combination of genetic, immune and environmental factors.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\n\u201cFDA\u2019s approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\n\u201cEczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies.\u201d\n\nAtopic dermatitis, a chronic inflammatory skin disease, is often referred to as \u201ceczema,\u201d which is a general term for several types of inflammation of the skin.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. We rate this one Not Applicable. We hope the FDA will also begin commenting on the projected cost of a drug and its cost-effectiveness.\nIn this case, costs are very steep. An NBC.com story on the approval which we also reviewed, predicts the drug will cost $37,000 annually. It\u2019s unknown if Dupixent will be covered by health insurance.", "answer": 2}, {"article": "The worms were getting rave reviews.\nThe bottom line: \"The proportion of patients who improved with the worms was no different than the proportion of patients who were improved with placebo,\" says Dr. Stephen Hanauer at Northwestern University Feinberg School of Medicine, who was involved with one trial.\n\"If you think about it, the worst thing that you want is an immune system that's out of control,\" Loke says.\n\"They basically ride your bloodstream back through your heart, into your lungs,\" where they hang out for a while, Velasquez-Manoff says.\nWhen you first meet Moises Velasquez-Manoff, the first thing you notice is his hair \u2014 or the lack of it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned. Parasites can costs thousands of dollars for a year\u2019s supply, and worms must be replenished because they tend to die off. Since this is a non-approved and non-proven therapy, all costs would likely be\u00a0out of pocket.", "answer": 0}, {"article": "However, the N.Y.U.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nThe test is so simple and inexpensive that any coach or parent potentially could administer it, the study\u2019s authors believe, and any league afford to provide it as a way to help evaluate and safeguard players.\nThe most commonly recommended sideline test is the Standardized Assessment of Concussion, a multipart examination during which athletes are asked to name the date, describe how they feel, memorize and recall lists of words, and do jumping jacks and other tests of coordination.\nIf the time is slower, even by a small amount, he or she probably has a concussion, according to neurologists.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes several times that the cost per player is minimal, but does not offer details. A check at the King-Devick test website revealed that the tests are sold in packages under an annual license for testing from 5 to 1,000 athletes at a cost of $50 to $1,000. With 100,000 public schools in the United States, the test could be a major revenue stream for the test owners if widely adopted. In addition, while the article talks about this being done by volunteer coaches and parents, one could imagine that this could be required for high school athletes. Performing a baseline test in all athletes could fall to teachers and coaches who are paid and may be a significant burden in terms of time required to administer the baseline tests. It is also unclear how often this in-depth baseline testing would need to be repeated.", "answer": 0}, {"article": "Existing treatment options -- diet and lifestyle modification, psychological therapy, and other drugs -- do not help all people with the condition.\nJan. 5, 2011 -- A two-week course of the antibiotic rifaximin (Xifaxan) helps to relieve the symptoms of irritable bowel syndrome (IBS), and the relief lasts up to 10 weeks after stopping the medication, according to new research.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nThe drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story made no mention of costs. This is a shame in a story that is essentially promoting off label use for a costly drug that is only approved for a very narrow range of treatments. The Associated Press story that we also reviewed estimated that the pills cost $21 a pop, resulting in a $910 price tag for a two week supply. Given that IBS sufferers may require long term treatment, this bill could grow exponentially.", "answer": 0}, {"article": "The exams didn\u2019t become more embarrassing or less comfortable, either.\n\u201cFor example, men can\u2019t see the top of their bald heads or the back of their necks or ears,\u201d Robinson said.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\nThe new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although presumably there is\u00a0a cost associated with training people to\u00a0recognize melanomas, having a partner help check for suspicious moles can be assumed to be cost-free.", "answer": 2}, {"article": "It is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\n\"This is quite remarkable because there are no other vaccines that perform nearly so well for people in their 70s and their 80s.\nMany vaccines are made from a weakened form of the virus, but Shingrix is made from just a single protein--known as glycoprotein E--that comes from the outer shell of the herpes zoster virus.\n\"Our research shows that the vaccine stimulates your immune system to produce more antibodies and it generates a 24-fold increase in T cells.\nThe research, published in the Journal of Infectious Diseases, shows that Shingrix offers protection for up to four years, but Professor Cunningham believes it will last much longer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No cost information is provided. According to GoodRx, Shingrix costs about $300 out-of-pocket for a course of two injections.", "answer": 0}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nIt has been shaking for years and they look at it as though, \u2018Hmm, is this really my hand?\u2019 It\u2019s really a remarkable moment.\u201d\n\nFor Samuels, who underwent the procedure on June 29, the recovery has been surprising.\nThe therapy, called focused ultrasound thalamotomy, uses the energy generated by sound waves to burn off certain cells in the thalamus, a region of the brain where the essential tremor is thought to originate.\nIt has been developed by InSightec, which is funding the trial along with the Focused Ultrasound Foundation and the Binational Industrial Research and Development Foundation.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not say how much this new procedure costs or compare it with existing treatments for patients who don\u2019t respond to medication. Deep brain stimulation, the current treatment standard, can run anywhere from $30,000 to $70,000, according to various online cost estimates.\u00a0There also may be additional costs incurred by those patients who have adverse effects.", "answer": 0}, {"article": "\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nMen who had the highest lycopene levels were 59% less likely to have this kind of stroke than men with the lowest levels.\nThe lowered risk was even greater for strokes caused by blood clots in the brain, called ischemic strokes.\nTomatoes are not the only food that is rich in this antioxidant.\nMen who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of tomatoes, or other sources of lycopene, is not in question.", "answer": 2}, {"article": ".\nAlso, the women who took vitamin D reported no need to use nonsteroidal anti-inflammatory drugs (NSAIDS), such as the pain reliever ibuprofen, to manage their pain in the two-month study period, while 40 percent of those assigned to placebo reported using an NSAID at least once.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\n\"From a symptomatic standpoint, it's something to be considered, but more studies are needed to see the risks and benefits,\" Graham said.\n\"It's provocative in the fact that the results are pretty amazing,\" said Dr. Robert Graham, an internist and vitamin D expert at Lenox Hill Hospital in New York City.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did explain that \u201cThe cost of vitamin D supplements would be roughly comparable with (NSAIDS or birth control pills).\u201d\u00a0 It didn\u2019t give a ballpark cost, but we\u2019ll give it the benefit of the doubt for nodding in the direction of addressing cost.\n\u00a0", "answer": 1}, {"article": "SUNDAY, March 21, 2010 (HealthDay News) -- For the first time in humans, scientists have successfully used a gene-manipulation therapy to enter tumor cells and block the production of toxic proteins that are causing cancer, researchers report.\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThe experiment proceeded just as planned, as biopsies later showed.\n\"This is something we've been waiting to see,\" he continued.\n\"This is one step away from getting into the actual DNA.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were discussed, which is understandable at this early stage of research.\u00a0 Not applicable.", "answer": 2}, {"article": "In the first 24 hours, more than 80% of the children in the study needed pain relief at home.\n\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nWidely available ibuprofen is a better choice for pain relief in children who have undergone minor orthopedic outpatient surgery, as it has fewer adverse effects compared with oral morphine, according to results from a clinical trial published in CMAJ (Canadian Medical Association Journal).\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Readers are likely aware that non-prescription strength ibuprofen is readily available at a low price. The release doesn\u2019t mention how much oral morphine costs, however. Thus, readers can\u2019t tell whether ibuprofen might not only save children some unpleasant side effects, but save their parents money as well.", "answer": 0}, {"article": "He'd read about advances in targeted therapies \u2014 drugs that go after cancer cells at the molecular level.\n\"We took a disease where nothing really works for any length of time and we've given her a year of life, and hopefully much more, where she's been much better,\" Hyman, her oncologist, says.\nOur series is produced with member station WNYC, and with Ken Burns Presents: Cancer: The Emperor of All Maladies, which will air on PBS starting March 30.\nShe's been in the clinical trial for a year now, and continues to take Zelboraf (or vemurafenib generically) daily.\nBut in the meantime, patients like Anselmo are grateful to have time they wouldn't have had otherwise.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article generalizes some costs, e.g. \u201cZelboraf is expensive,\u201d but no hard numbers are shared. (E.g. As of 2011, a common, six-month course of Zelboraf costs about $56,000.) With costs varying widely\u2013and astronomically\u2013among treatments, and name-brand vs. generic, this is critical and pertinent information to include. Another missing cost-related discussion regards the oral chemotherapy drug called temozolomide (which was alluded to in the article but never named). Temodar, the name-brand form of the drug, costs about $100,000 a year, while the generic alternative costs less than $10,000 a year\u2013a 10-fold difference. The cost of genetic testing ($4,000 sequencing costs per tumor) was mentioned in the on-air piece but not in the online body copy.", "answer": 0}, {"article": "The study's authors acknowledged that their preliminary data offers \"promise for the use of time-restricted feeding as a weight loss technique in obese adults, but longer-term, large-scale randomized controlled trials [are needed].\"\n\"There are also many studies that either report no overall effect or sometimes the opposite.\nIndividuals who ate between 10 a.m. and 6 p.m. consumed around 350 fewer calories, resulting in a loss of 3 percent body weight, and their blood pressure dropped by around 7mm Hg.\nWe observed that fewer participants dropped out of this study when compared to studies on other fasting diets,\u201d said Varady.\nFurther research is now needed to uncover whether 16:8 works better than other fasting diets in terms of weight loss and health benefits.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no cost associated with following this diet.", "answer": 2}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not talk about costs, which was disappointing. The costs of intensive medical therapy can easily be identified. Using an online pharmacy we calculated the costs to be about $1,500 to $2,000 annually for medical therapy, using generic drugs. Using the Health Care\u00a0Blue Book, we found the average cost of coronary artery bypass sugery and hospitalization to be about $62,000. We think that this is important information for readers that should have been included.", "answer": 0}, {"article": "The surgery she's upset about may be archaic - but it's very common.\nIt's all over in about an hour, and patients are usually home within a day and back to normal within a week or two.\nLike all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\n\"If patients really know that they have options when it comes to hysterectomy, we will start seeing some of the changes that I feel need to happen,\" Warren said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story theorizes that the cost of laparoscopic surgery would be less than\u00a0abdominal hysterectomy because of the reduced hospital stay, no further information is provided. This is not adequate information on costs. Furthermore, there are even cheaper non-surgical alternatives such as medication, IUD, and ablation.", "answer": 0}, {"article": "THURSDAY, Oct. 26, 2017 (HealthDay News) -- Blood thinners may pull double duty for people with the heart rhythm disorder atrial fibrillation: New research suggests they help prevent dementia as well as stroke.\n\"Patients start on oral anticoagulation for stroke prevention but they stop after a few years at an alarmingly high rate,\" he said.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\n\"It is not possible to give placebo to [atrial fibrillation] patients and then wait for dementia or stroke to occur.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs, which is unfortunate because there can be substantial costs associated with anticoagulation, especially with the newer anticoagulants.", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. A web search of programs offered in the U.S. show prices ranging from a $200-1000 for a series of sessions which may last several months and include music instruction. \n", "answer": 0}, {"article": "Remember, Senay urged: Most people can achieve the recommended calcium intake by eating three or four servings of dairy products and other foods that contain calcium per day.\nAdults over 50 need 1,200 milligrams per day.\nCalcium recommendations vary according to age.\nThe maximum recommended intake of calcium is 2,500 milligrams.\nSupplements are an additional tool to be used when needed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned.", "answer": 0}, {"article": "Other New York counties took similar actions after New York City\u2019s measure was enacted.\nFor the new study, the researchers compared data on people hospitalized between 2002 and 2013 for heart attacks or strokes in counties that did or didn\u2019t restrict trans fats.\nWhile admissions for heart attacks and strokes fell after 2002 in all the counties, the drop was more substantial in those that enacted trans fat restrictions, the authors found.\nIn 2006, there were 753 hospital admissions for heart attack or stroke per 100,000 people in counties that never enacted restrictions compared to 726 per 100,000 people in counties that put restrictions in place.\nSimilarly, admissions for strokes were about 4 percent lower in counties with restrictions, but that finding could be due to chance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While there might be an aggregate, societal cost to this change in food ingredients, it is not clear that individuals will incur monetary costs as a result of this change.", "answer": 2}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that beta-blockers are available as generics but doesn\u2019t specifically mention costs. As a class, beta blockers drugs are low cost ($10 to $200 a month according to some estimates).", "answer": 0}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\n\"All bones - spine bones and big leg bones - will respond to pressure from weight by forming more bone.\"\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nAnother 34 million are at risk because they have low bone density.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "not applicable in this case", "answer": 2}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes that the GeneSight test is covered by Medicare if a patient is being treated by a psychiatrist and that some insurance plans also cover the test. It also tells us that the\u00a0Genomind Genecept Assay is covered by Medicare and Medicaid.\nWe aren\u2019t provided out-of-pocket costs for the GeneSight test, though. Nor could we find the full price of Genomind\u2019s \u2018Genecept Assay\u2019 on its website or elsewhere.", "answer": 1}, {"article": "), showing benefits in pivotal phase III trials.\nWhile median progression-free survival appeared similar between treatments (4.6 months and 4.4 months with nivolumab and everolimus, respectively), when researchers explored a delayed progression-free survival benefit at six months, they reported 15.6 months with nivolumab and 11.7 months with everolimus.\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\nEach year, there are 338,000 new cases of RCC diagnosed worldwide; it is the most common type of kidney cancer among adults and approximately 30% of patients present with metastatic disease at diagnosis, according to the scientific literature.\nResearchers at The University of Texas MD Anderson Cancer Center demonstrated a median overall survival benefit of 25 months with nivolumab, a Food and Drug Administration (FDA)-approved immunotherapy agent, compared with 19.6 months for everolimus, a current standard of care for patients with metastatic kidney cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cancer treatments are very (some would same ridiculously) expensive and the two treatments highlighted in this release are no exception.\u00a0 To put it into perspective, we calculate the monthly cost of nivolumab to be in the vicinity of $12,600 (not including administration fees) and of everolimus at $11,500 month.\ncalculation\nnivolumab = 3mg/kg x 70kg = 210mg @$30/mg=$6,300 x 2 = $12,600 everolimus = $11,500 for 30 tablets", "answer": 0}, {"article": "\"The paradigm for the last 20 years for patients like this been: 'Mr.\nThe study is the first large, well-designed comparison of angioplasty to non-surgical care for patients who are not having a heart attack or in imminent danger of having one.\nSome cardiologists who specialize in the procedures, however, argued that the study did not focus on the sickest patients who are most likely to benefit, and that the main purpose of angioplasty in many is to alleviate chest pain, not to prevent heart attacks.\n\"The data are compelling,\" said William E. Boden of the University of Buffalo School of Medicine, whose findings were published yesterday by the New England Journal of Medicine to coincide with a presentation at a meeting of the American College of Cardiology in New Orleans.\n\"I don't think this is going to cause any huge paradigm shift,\" said Gregory J. Dehmer, president of the Society for Cardiovascular Angiography and Interventions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that angioplasty typically costs $50,000.\u00a0 While it would have been helpful to have a sense for the cost of angioplasty in in comparison to medical therapy, the story does give a sense of the cost burden to the healthcare system by providing procedures that don't benefit a significant proportion of patients.\u00a0 ", "answer": 1}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\nIt does this by enhancing the protective neurohormonal systems (Natriuretic Peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).11 Other heart failure medicines only block the harmful effects of the overactive RAAS.12 Entresto contains the neprilysin inhibitor sacubitril, and the angiotensin receptor blocker (ARB) valsartan.11\n\nEntresto is indicated in the US to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.11 Entresto is usually administered in conjunction with other heart failure therapies, in place of an Angiotensin Converting Enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB).11 Entresto film-coated tablets are available in three dosage strengths: 24/26 mg, 49/51 mg, and 97/103 mg (sacubitril/valsartan).11 These doses are referred to as 50 mg, 100 mg, and 200 mg in the clinical trial literature including the New England Journal of Medicine publication of the results of PARADIGM-HF.\nEAST HANOVER, N.J., June 22, 2016 /PRNewswire/ -- A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto\u00ae (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone.1 This analysis, based on an application of the results of PARADIGM-HF to published heart failure statistics, is the first to quantify the possible impact of Entresto's potential benefit in reducing death.1\n\nHeart failure is a chronic condition that contributes to more than 300,000 deaths in the US every year.4 About half of people with heart failure have HFrEF.5 This new analysis estimates that as many as 28,484 deaths in HFrEF patients annually could be prevented or postponed with optimal use of Entresto (with sensitivity analyses demonstrating a range of 18,230 to 41,017).1\n\nFurther, the study suggests that delaying routine use of Entresto in clinical practice could have a substantial negative effect on patients, given the expected risk-benefit profile, as it could result in failure to prevent tens of thousands of deaths.1 These findings demonstrate the significant survival benefits Entresto could offer to those living with HFrEF, if patients in the group defined by the authors were given access to treatment.1 The study authors stated that nearly 84% of HFrEF patients \u2013 2.2 million people \u2013 may be candidates for treatment with Entresto.1\n\nHeart failure is a life-threatening condition and despite available medicines, about half of patients diagnosed with heart failure die within 5 years.4,6,7 According to the study authors, these findings may substantially impact the national health of the HFrEF population, offering significant clinical benefit in preventing or postponing death when applied in clinical practice.1\n\n\"This expert analysis adds to the already compelling case for the treatment of heart failure patients with reduced ejection fraction with Entresto,\" said Fabrice Chouraqui, president of Novartis Pharmaceuticals Corporation.\nIn particular, management's expectations regarding Entresto could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.\n\"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions cost-effectiveness several times but does not give any indication of what the price of therapy with Entresto would be, nor the comparative cost between Entresto and other medications. Nor does it quantify what it means when it says the drug is \u201ccost-effective.\u201d The Institute for Clinical and Economic Review, ICER, warned in a draft report that the drug\u2019s current price was too high and that widespread use could overwhelm the health system. The drug cost was estimated at about $4,600 per year for a typical patient. According to the report:\n\u201cAt the list price of $4,560 per year, Entresto does not save money over the long term but its added costs are well-aligned with the degree of benefit it brings to patients, meaning that Entresto can be judged \u201ccost-effective\u201d in the long-term according to commonly accepted cost-effectiveness thresholds.\u201d\n\u201cHowever, ICER\u2019s analysis predicts that nearly 2 million patients could be prescribed Entresto over the first five years, creating a total budget impact so high that excessive cost burdens would be placed on the overall health care system. In order to keep health care cost growth in line with growth in the national economy, ICER\u2019s value-based price benchmark for Entresto is $3,779 annually, a 17% discount off the list price.\u00a0 Private insurers and Medicaid programs are frequently able to achieve discounts at this level.\u201d\nThe published study did address cost in terms of quality-adjusted life-years (QALYs). It would have been helpful for the release to add at least some costs which would add context.", "answer": 0}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Vaccine pricing is complicated and prices are unknown at this point in development (pre-clinical). The story could have addressed cost as a potential limitation even if price is unknown at this time.", "answer": 0}, {"article": "The fact that even with this bias we see no large benefit \u2014 indeed, seemingly no benefit at all \u2014 to running more rather than running less reinforces the value of moderate running.\nHere is one study that shows large mortality reductions for fast walking even for short periods, and here is another showing that very slow walking has fewer benefits than faster walking.\nThe goal here is to use these METs and their relationship to health to analyze the value of walking compared with jogging or running.\nThere was a time when the optimal exercise speed was however fast you had to run to get away from a saber-tooth tiger.\nA hazard rate of 0.48 \u2014 compared with a sedentary group \u2014 suggests a much larger reduction in the risk of death than a hazard rate of 0.90.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not go into the costs associated with running or moderate jogging, but there are few costs that are explicitly associated with it. While runners often spend significant amounts of money for high-end running shoes, lightweight shorts and tops, or to enter races, none of those things are absolutely necessary. Once could jog for 25 minutes, three times a week, in any old clothes, wearing inexpensive shoes (or no shoes at all). In short, the amount of money that people can choose to spend on running is so widely variable as to make a discussion of costs effectively meaningless. For that reason, we\u2019ll call this n/a.", "answer": 2}, {"article": "[11]\n\nEVZIO (naloxone HCl injection) Auto-injector is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.\nAdditionally, there are nearly two times the number of prescription opioid-related deaths as compared to heroin-related deaths.1 On average, 3,300 children five years old and younger are admitted to emergency departments each year due to accidental opioid exposure.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\nFor example, taking high doses of opioids, taking an opioid in combination with other drugs (e.g., benzodiazepines) or alcohol, or if there is a history of certain medical conditions (e.g., COPD, severe asthma) places individuals at significantly higher risk for life-threatening OIRD.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of cost. That\u2019s an important omission since the cost of even generic naloxone is undergoing steep price increases. According to a report from the American Society of Health-System Pharmacists last year, \u201cWhen Kaleo Inc. launched its Evzio 1-mg/mL naloxone hydrochloride autoinjector in July 2014, the company priced each carton at about four times the invoice price of a box of same-strength 2-mL naloxone syringes, said Matthew Rosenberg, an analyst at FDA.\u201d\nAn online search revealed that Evzio\u2019s retail price was about $700 per kit, according to a MedPage Today article. Prices for standard naloxone kits ranged from around $40 to $60 per kit, with on-going price hikes.\nThere\u2019s a very limited supply of money for drug abuse treatment and a naloxone injection is only the start. Is having an extremely expensive one the\u00a0best use of funds? The release needed to address the cost disparity between this device and less expensive ones on the market.", "answer": 0}, {"article": "The findings were published today in the Journal of Bone and Mineral Research.\n\"Our compound only locks the collagen -degrading CatK activity, preventing the unregulated breakdown of collagen in bones without any other negative impacts.\"\n\"The development of osteoporosis drugs by pharmaceutical companies has focused heavily on blocking CatK in recent years,\" said Dieter Br\u00f6mme, a professor in the faculty of dentistry and a Canada Research Chair in Proteases and Disease.\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\nMost drugs in development have been so called active site-directed inhibitors, which act like master keys and lock the entire enzyme, blocking both its disease-relevant functions such as collagen degradation and its other normal functions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of cost. HealthNewsReview.org found a bottle of 60 capsules of 500-mg red sage online for $19.95. Of course, that could be far from the cost of an actual treatment should one be developed, since we don\u2019t know the cost of processing, marketing, and quality assurance.", "answer": 0}, {"article": "I would be in my 60s when I had to do this again, and who wants to have surgery unnecessarily when you are 60 something?\"\nAlthough the long-term effects of silicone in the body are still uncertain, many plastic surgeons don't see the leaking of modern implants as a health concern.\nIt also turns out that the longer a woman has the implants, the more likely she is to experience these complications.\nBut no one ever told her to get an MRI \u2014 something the FDA now recommends that women with silicone implants get every few years.\nWhat's more, he says few of them follow the recommendations to get routine MRIs to screen for leaks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article sidesteps any issues related to costs of breast implants or the remedies for failures, a glaring omission in light of frequent complications and adverse outcomes.\n", "answer": 0}, {"article": "He recommends trying to incorporate barley into existing recipes, using it as a substitute for rice or even on its own -- just like oatmeal.\nBarley is higher in fibre, has twice the protein and almost half the calories of oats, which are important considerations for those with weight or dietary concerns.\nMeasuring non-HDL and apoB provides a more accurate assessment for cardiovascular risk, as they account for the total 'bad cholesterol' found in the blood.\nCanada is one of the top five world producers of barley -- almost 10 megatonnes per year -- but human consumption accounts for only two per cent of the crop yield, with livestock making up the other 98 per cent.\nBarley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Barley, like oats or other grains are cheap and plentiful. Mentioning their cost in the story is unlikely to be an important factor.", "answer": 2}, {"article": "Both the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\n\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention the cost of pecans. More expensive than some other tree nuts, the ballpark price of pecans should be known to the average reader.", "answer": 0}, {"article": "Scientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in memory and learning.\n\u201cWe need a way of treating the cognitive symptoms of schizophrenia, such as problems with episodic memory, but slow progress is being made toward developing a drug treatment,\u201d said Barbara Sahakian from the department of psychiatry at Cambridge University.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\nThis study, published in the journal Philosophical Transactions of the Royal Society B, found that 22 patients who played the memory game made significantly fewer errors and needed significantly fewer attempts to remember the location of different patterns specific tests.\nWhile some psychotic symptoms can be reasonably well treated with medication, patients often still have debilitating problems with memory and cognitive function, meaning they struggle to get back to work or stay in education.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss cost at all. The relevant iPad game is, presumably, not free. And even if it were, a patient would need to own or have access to an iPad (definitely not free). While these things may be presumed, it\u2019s still worth mentioning. For example, it would be good to know if the game were free, or if it could be accessed on a PC \u2014 in which case patients may have more low-cost options for accessing the game.\nEven if \u2013 or especially if \u2013 it were a low-cost intervention, that would be worth a one-line mention.", "answer": 0}, {"article": "Additional information about clinical trials, including information for potential participants and financial supporters, is available at http://www.\nThe study from a Massachusetts General Hospital (MGH) research team - published in npj Vaccines - also reports that the effects of BCG vaccine on blood sugar control appear to depend on a totally novel metabolic mechanism that increases cellular consumption of glucose.\nMihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nInitial clinical trial results, published in a 2012 PLOS One paper, reported that two doses of BCG spaced four weeks apart led to reductions in autoreactive T cells, an increase in Tregs and what turned out to be a transient increase in insulin production.\nThe lead author of the npj Vaccines paper is Willem M. K\u00fchtreiber, PhD, MGH Immunobiology Laboratories.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the bacillus Calmette-Gu\u00e9rin (BCG) vaccine is not mentioned.\nAlthough the wholesale price is usually less than $1 US dollar, the cost in the United States usually runs between $100 to $200.", "answer": 0}, {"article": "The bad news is that there is no benefit of being less likely to develop heart disease, and any reduction in the risk of hip bone fractures evaporates with time, according to a report in the latest issue of the Journal of the American Medical Association.\nWomen who took a combination of estrogen and progestin face increased risk for breast cancer, previous studies have shown, Chlebowski said.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nAt the same time, the women continued to be at a lower risk for breast cancer.\nBut the increased risk for strokes and blood clots disappeared and the protective effect for breast cancer persisted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe researchers from Verily, formerly known as Google Life Sciences, developed the algorithm in the hope of making accurate assessments of patients\u2019 cardiovascular health more quickly and easily than current methods.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This Newsweek story offers no information on what the cost of such retinal scan might be, nor does it mention whether health insurance would cover such screening, if it is proven to eventually work.\u00a0 There are a number of free cardiovascular risk assessment tools available online.", "answer": 0}, {"article": "So far, the FDA is erring on the side of caution.\nDr. Mina Fazel, child psychiatrist at the Oxford University Children\u2019s Hospital, says, \u201cIt\u2019s complicated, because you\u2019re giving antidepressants when you\u2019re very worried about that young person\u2019s mood.\u201d Essentially, the moment when it seems most necessary to prescribe the drugs may also be the moment when the patient is most at risk of suicide.\n\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nOf course, this is a high-cost intervention in terms of both dollars and time invested, and it may not always be readily available\u2014but the upside is that there is no reason to believe it is harmful.\nGuidelines from the psychiatric associations in most countries recommend that doctors first try psychotherapy, or \u201ctalk therapy,\u201d which is has been shown to work, at least by participants\u2019 own assessment of their depression levels (it\u2019s very hard to test therapy against a placebo, for obvious reasons).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the cost of antidepressants, though does mention that the alternative, cognitive behavioral therapy, \u201cis a high-cost intervention in terms of both dollars and time invested.\u201d A cost comparison would have been useful since the study encourages a shift away from drugs and toward therapy.\u00a0Seeing a therapist for psychotherapy may not be so high a cost if the patient learns some lifetime skills and insights that help lessen and prevent depression, which tends to be recurrent.", "answer": 0}, {"article": "The C.B.T.\nA big part of the difference may be how insomniacs perceive their sleep performance and the negative messages they give themselves about their poor sleep and how it will affect their daily lives.\nDrugs, on the other hand, just treat insomniacs\u2019 symptoms without addressing the underlying cause, which is why the relief they provide may be less durable.\nIn this way, unless exacerbated by physical causes \u2014 like sleep apnea or restless leg syndrome \u2014 insomnia is a condition of the mind that then infects the body.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wish this story comparing effectiveness of different therapies for insomnia had compared costs as well. How often is cognitive behavioral therapy for insomnia covered by insurance? Is there a co-pay per visit? What is a typical number of treatments, and what might it cost? How does that compare to taking some of the common drugs?", "answer": 0}, {"article": "After controlling for several factors, the researchers concluded that \u201c[Women for Sobriety], LifeRing, and SMART are as effective as 12-step groups for those with AUDs.\u201d\n\n\u201cEssentially, that\u2019s the story,\u201d Zemore said.\n\u201cThat\u2019s why you\u2019re seeing these associations between SMART and LifeRing affiliation at baseline and worse recovery outcomes when you control for involvement.\u201d She added, \u201cBut I want to emphasize that these go away when you control for recovery goals.\u201d\n\nAgain, the study is not the final word.\nThis is a big part of the 12 steps, with the final step even invoking \u201ca spiritual awakening.\u201d For people who aren\u2019t religious or spiritual, this can be a big turn-off; that\u2019s one reason SMART and LifeRing exist to begin with \u2014 they\u2019re meant to be secular alternatives to the 12 steps.\nPresumably, you could get those by participating in alternatives to AA.\u201d\n\nIn other words, these alternatives could help the one-third to two-thirds of people who don\u2019t get anything or much out of AA.\nThere\u2019s good research into how AA works, but it\u2019d be good to figure out if SMART, LifeRing, and Women for Sobriety work in a similar way.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs associated with either AA or the alternative addiction treatment groups. That would be useful information for people who may not understand how these groups work. However, since these groups generally don\u2019t charge members for participation (although they may solicit donations or require the purchase of recovery literature), we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are discussed, though the US National Library of Medicine says individual genetic tests \u201ccan range from under $100 to more than $2,000\u201d \u2014 and PapSeek appears to use three genetic tests (on Pap smear, Tao brush, and blood tissues).", "answer": 0}, {"article": "Proprietary Capsimax is made using OmniBead Beadlet Technology to encapsulate the beneficial heat of concentrated highly-active, natural capsicum in a controlled-release coating--delivering effective levels of capsaicinoids without the oral and gastric burning sensation of unprotected red hot peppers.\nThe company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nThe study showed that supplementing with this low dose of Capsimax increased metabolic rate which calculated to an equivalent to burning an extra 116 calories per day.\nWhether looking for a new ingredient to add to a finished product, or technology to enhance an existing ingredient, OmniActive delivers unmatched innovation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of Capsimax (or products containing the Capsimax proprietary supplement) is not mentioned.", "answer": 0}, {"article": "DOI: 10.1371/journal.pone.0177782\n\"The mortality rate of cervical cancer should absolutely be zero percent because we have all the tools to see and treat it,\" said Nimmi Ramanujam, the Robert W. Carr, Jr., Professor of Biomedical Engineering at Duke.\nWhile more than 4,000 American women die of the disease each year, the mortality rate has dropped more than 50 percent in the past four decades, largely due to the advent of well-organized screening and diagnostic programs.\n\"We recruited 15 volunteers on Duke's campus to try out the new integrated speculum-colposcope design,\" said Mercy Asiedu, a graduate student working on the project in Ramanujam's lab.\nCITATION: \"Design and Preliminary Analysis of a Vaginal Inserter for Speculum-Free Cervical Cancer Screening,\" Asiedu MN, Agudogo J, Krieger M, Miros, R, Proeschold-Bell, RJ, Schmitt JW, Ramanujam N. PLOS One, May 31, 2017.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release\u00a0indicates that the pocket colposcope will be much less expensive than current equipment, although no specific numbers are provided. The omission is unfortunate, since the study it\u2019s based on does provide cost estimates, citing a cost of $54 for the camera and $1 for the inserter. This device also requires the availability of a cell phone or laptop, and, at least for the present,\u00a0images must still be read by a trained technician. We don\u2019t know how much savings the device will generate, and it\u2019s difficult to estimate how feasible\u00a0it will be for low-resource clinics domestically or internationally. It\u2019s true the device is at an early stage of testing, but more information would have been helpful.", "answer": 0}, {"article": "LaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\n\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\nBut the link was present in all types of women in the study, including those of all races and ethnicities, women who were obese and those who were not, women with high and low functional abilities and women older and younger than 80.\nAnd recent analyses, compiled from studies in which adults self-reported their levels of physical activity, have suggested that older adults have to log moderate-to-vigorous exercise in order to reduce their risk of early death.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost wasn\u2019t mentioned, but given that this is light activity, we\u2019ll rate this N//A. Still, the story could have explicitly said that the activities that are highlighted in this study probably have no cost associated with them.", "answer": 2}, {"article": "Two patients discontinued therapy because of adverse events related to the drug.\nThe immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\nAt a median follow up of 213 days, 33.3 percent remained on treatment, and 45.6 percent of patients survived for at least one year, which Sharma noted \"is better than anything we've seen in the past.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all, which is particularly problematic given that Opdivo is already on the market for use in treating other forms of cancer. In an NEJM piece published last year, one doctor that, when used for treating metastatic renal-cell cancer, nivolumab costs, \u201cby my estimate, around $65,000 for Medicare beneficiaries and up to twice that for commercially insured patients.\u201d Other estimates are that nivolumab treatment \u2014 again, for cancers other than bladder cancer \u2014 could cost more than $100,000 per patient. That is a huge factor in making treatment decisions, and needs to be addressed.", "answer": 0}, {"article": "The electronic nose detected nearly 90 percent of people with asthma compared to about 70 percent who were accurately diagnosed in the traditional way with lung function tests, according to new research published in the April issue of the journal Chest.\nFENO was able to correctly identify asthma in 79.2 percent of the study volunteers and lung function testing (spirometry) discerned just 70.8 percent of the people with asthma.\nThe Italian researchers wanted to compare the electronic nose to the other commonly used tests -- spirometry and FENO -- to see which test was best at confirming a diagnosis of asthma.\nThis test seems relatively easy for patients and it does have potential, but they've only looked at a very narrow collection of people who have allergic asthma.\"\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this device is\u00a0experimental,\u00a0we can accept the fact that the story didn\u2019t put a specific price tag\u00a0on the technology.\u00a0The story did note that cost might limit initial use of the device.", "answer": 1}, {"article": "Check out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\nShe owns her eggs, no question.\nIf you decide to try egg freezing, don\u2019t wait too long.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Excellent.\u00a0 Estimate of $10,000 or more per procedure and states that insurance usually doesn\u2019t cover it. ", "answer": 1}, {"article": "The first problem we solved was: how do we make the hand move electronically?\n\"His main interest was to create a shocking response from onlookers by pulling it off in the grocery store,\" Falardeau wrote on CNN iReport .\n\"We quickly found out this is much less about fitting in and feeling normal, and much more about expressing yourself,\" Petresky said.\nPetresky says they ask every family about the child's favorite color, superhero and interests, so the new limb can \"not just be a piece of plastic ... but be a part of them.\"\n(CNN) By the time Cynthia Falardeau read about Alex Pring, a little boy who got a battery-powered robotic arm last summer, she had made peace with her son Wyatt's limb difference.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention costs, but in a way that is confusing and incomplete. In one place it says assembling an arm costs $20 to $50, then later it says the materials for an arm cost $350. The sort of 3D printers used can cost many thousands of dollars, but that expense does not seem to be included in this story. There is no mention of the costs of fittings or other expert services, or how long the limbs might last and how often they need to be replaced. Considering that conventional prosthetic arms cost thousands of dollars, the costs listed in this article are hard to believe.", "answer": 0}, {"article": "In another 12%, tumors stopped growing for at least six months.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\n\"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned in the article. As the expense of Herceptin (trastuzumab) alone has come up in public discourse, such as in this Atlantic\u00a0article, it stands to reason that a novel compound including trastuzumab would have economic considerations.", "answer": 0}, {"article": "\"I have successfully raced in 20 triathlons since I started taking sildenafil, including five ultra events that require 10-kilometer swims,\" Calder-Becker said.\nShe coughed up blood and was once hospitalized.\nOften the symptoms dissipate over 24 hours, but the condition can be serious and even fatal and medical attention is recommended.\nMany don't know they are prone to the problem until they are in the water and quickly develop symptoms.\n\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned in the release.", "answer": 0}, {"article": "Most women who get either treatment have insurance that pays, Amundsen said.\n\u201cPregnancy, childbirth, menopause, and the structure of the female urinary tract account for this difference.\u201d\n\nThe researchers at nine medical centers did a head to head comparison of a single Botox injection to the implanted medical device, assigning 381 women to randomly get one or the other treatment.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nExercises to strengthen the pelvic floor muscles can help, as can \u201cbladder training\u201d to accustom the body to urinating at regular times.\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We hear a lot about costs throughout this story, but see no specific numbers or meaningful discussion. And this is a major oversight, since\u2014at least according to a 2015 study that focused on the UK National Health Service\u2014Botox combined with quality supportive care \u201cappears to be a cost-effective use of resources.\u201d\nA neurostimulator for bladder issues costs between $20,000 and $30,000. Meanwhile, one unit (or \u201cU\u201d) of Botox costs roughly\u00a0$10-$28, with a typical cost hovering between $10-$12 per U.\u00a0Since the treatment uses 200 U of Botox, its price is likely about $2,000-$2,500 per 6-month treatment course, but that doesn\u2019t include the cost of administering it, which is likely to be considerable.", "answer": 0}, {"article": "LONDON (Reuters) - Scientists in Canada and Sweden have used laboratory-made biosynthetic corneas to restore vision to patients in a small human trial, and shown for the first time that they can help to repair damaged eye tissue.\n\u201cWith further research, this approach could help restore sight to millions of people who are waiting for a donated human cornea for transplantation.\u201d\n\nThe cornea is a tiny piece of transparent, film-like tissue that covers the surface of our eyes.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\nAlthough the fragile film is easily destroyed by trauma or infection, replacement human corneas can be used to restore vision, although this depends on a steady supply of donors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. Again, charitiable organizations who work in this area could have provided some ballpark figures for human corneal transplants. The researchers claim in another story that this option would be cheaper. At a minimum, a dollar figure would have been good context.", "answer": 0}, {"article": "IntelliCare is a national research study.\nThe preliminary study did not include a control arm, so it's possible that some people who enrolled in the trial would have improved anyway, partly because they may have been motivated to try something new, Mohr said.\nThe IntelliCare algorithm recommends new apps each week to keep the experience fresh, provide new opportunities for learning skills and avoid user boredom.\nSome of the IntelliCare apps include:\n\u2022 Daily Feats: designed to motivate you to add worthwhile and rewarding activities into your day to increase your overall satisfaction in life.\n\"We designed these apps so they fit easily into people's lives and could be used as simply as apps to find a restaurant or directions,\" said lead study author David Mohr, professor of preventive medicine and director of the Center for Behavioral Intervention Technologies at Northwestern University Feinberg School of Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that there is no cost associated with downloading the Intellicare apps. But because Intellicare is part of \u201ca national research study\u201d the researchers request that users provide \u201cconfidential feedback\u201d weekly to help them further develop the system. Some people may not be comfortable sharing personal data over the internet, with good reason.", "answer": 1}, {"article": "The study was recently published in the journal Spine.\n\"With low back pain, there are many reasons people don't get better,\" added Perle, also a professor of clinical sciences in the College of Chiropractic at the University of Bridgeport in Connecticut.\nWEDNESDAY, July 6, 2011 (HealthDay News) -- For the millions of Americans with chronic low back pain, a silver bullet to alleviate the condition has yet to be identified, a new study suggests.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did attempt to offer information on the costs of manipulation by consulting a spokesman for the American Chiropractic Association. However, the article only offered the unsatisfactory observation that costs vary. The journalist could have dug deeper and documented the range of costs per manipulation treatment\u2014and the typical number of visits per back pain episode.\n\nThe costs and cost-effectiveness of manipulation are important issues. If multiple treatments for chronic back pain provide similar benefit, then the value of the treatment modality is really dependent on the cost.\n", "answer": 0}, {"article": "\"They still drank, but they drank less.\"\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nIt is one of the substances known as isoflavones found in kudzu.\nThe study is published in Drug and Alcohol Dependence.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reader is likely to come away confused on this point. The story states that currently available kudzu supplements cost about $6 for 3 weeks of treatment, but it didn\u2019t clearly explain that these are not the same as the standardized extract tested in the study, which is not yet on the market and will likely cost much more if and when it is approved for sale.", "answer": 0}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nIn the year after a heart attack, about 12% of people have a second heart attack or stroke.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 Can\u2019t you give us some ballpark of what it costs to offer \u201cIV infusion of \u2018good\u2019 cholesterol\u201d?\nWe appreciate the fact that CSL 112 is in an early stage of development and that costs are not known at the moment.\u00a0 But shouldn\u2019t some attention be given to the potential impact of a drug that requires IV infusions?", "answer": 0}, {"article": "Cancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nThe advantages of brachytherapy, also called \"accelerated partial breast irradiation,\u201d are shorter treatment time and a smaller area that is exposed to radiation.\nAlthough standards depend somewhat on doctors' preferences, candidates for breast brachytherapy typically have early-stage tumors with a margin of healthy tissue around the tumor site after removal and minimal or no migration of cancer cells to nearby lymph nodes.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nHowever, he said, \"I think it is becoming more popular, both from a physician perspective but also from a patient perspective.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not report how much the procedure costs or how it compares to conventional radiation therapy. While price would not be a driver of this decision, price information is easy and valuable to report. ", "answer": 0}, {"article": "Driscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\n\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Caffeine is already ubiquitous and people consume it daily in coffee, tea, sodas and supplements. A discussion of costs isn\u2019t necessary. ", "answer": 2}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\nHe's exercising at the gym three times a week, lifting weights.\nHis job suffered as a result of his fatigue.\nNoninvasive measures are always the first lines of defense, she says.\nThen, there's surgery to remove blockage in the nasal passage.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs \u2013 not on the robotic surgery, not on CPAP.", "answer": 0}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release mentions both a treatment and a screening test. The treatment is ibuprofen, an over-the-counter, nonsteroidal anti-inflammatory drug that is probably widely known to be quite affordable.\nThe screening test is measuring levels of amyloid beta protein 42 (Abeta42) in the saliva. The cost of that test is not included in the news release.", "answer": 0}, {"article": "About nine years ago, scientists discovered that the tumors of about half of patients with melanoma have a mutation in a gene called BRAF.\nWEDNESDAY, Aug. 25, 2010 (HealthDay News) -- By probing deeper into the biological mechanisms that go awry in melanoma, scientists have come up with an experimental drug that has had an effect in a surprising number of patients with advanced melanoma.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\n\"I don't want to say this is going to change survival rates but they're working with the most ill people, so you can't really generalize [to other patient populations],\" said Dr. Alice Pentland, chair of dermatology at the University of Rochester Medical Center.\nThe average survival time for someone diagnosed with melanoma is nine to 11 months, added Chapman, who is an attending physician in the Melanoma Sarcoma Service at Memorial Sloan-Kettering Cancer Center in New York City.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention costs, which is somewhat understandable given the early phase of research.\u00a0 But the competing USA Today story, while noting that drug pricing hasn\u2019t been set, at least noted that many new cancer therapies \"cost $5,000 to $7,000 a month.\"\u00a0 This story should have done something like that as well. ", "answer": 0}, {"article": "Thus, we foresee an exciting, long term relationship that will benefit cancer patients and cancer research.\u201d\n\nIn December 2007, Hitachi was the first company in the U.S. to clear FDA Premarket Notification Special 510(k) for the \u201cPROBEAT\u201d system with its spot scanning irradiation technology.\nToshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nGiven the growing demand for technical and clinical advancements in the treatment of cancer, interest in proton therapy is on the rise, with more and more hospitals and cancer treatment facilities venturing into this area.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. PBT typically costs twice as much as traditional radiotherapy so it\u2019s definitely relevant to any announcement of a new facility. Several large insurance companies have ruled out coverage of PBT for prostate cancers. Any reliable reporter covering the business, healthcare or technology beats who writes a story based on this news release would be expected to ask about the costs so why not include at least some ballpark figures in the release?", "answer": 0}, {"article": "Other researchers will be analyzing economic data.\nThey include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nThe hope is that the devices, now being tested in clinical trials, will save lives, reduce medical expenses and nudge heart patients toward managing their symptoms much the way people with diabetes manage theirs.\nThere are, for example, more than four million recordings of weights and blood pressures and over 60,000 instances when the defibrillators went off, shocking a patient\u2019s heart.\n\u201cWe think we did not let the people in the remote sensing group get into heart failure.\u201d\n\nStill, the information overload problem looms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Mixed bag. The story explained that the devices \"can cost as much as $30,000.\"\u00a0 And there was one data point from one study on one device that users\u2019 hospital costs were $1,600 less per admission.\u00a0 But the device costs are variable and device performance will be variable.\u00a0 We\u2019ll give the story the benefit of the doubt but it painted the cost picture with really broad strokes. ", "answer": 1}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not project any cost of this new stent; it did provide estimates for the amount of sales revenue generated by those drug-eluting stents that are currently available to consumers. \u00a0(The story also did not provide information about how much these stents cost consumers either.) \u00a0There was no discussion of associated costs for the medications that need to accompany the use of these drug eluting stents.", "answer": 0}, {"article": "By the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\nExperts said the drug is likely to appeal to heavy drinkers who would rather seek help from their own doctors, rather than enter a rehab clinic to dry out.\n\"It's been a miracle to me,\" Wolfe said.\nAt the start of the study, they drank, on average, 11 standard drinks daily.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided an estimate for the cost of the treatment as well as the reminder that the costs for the doctor\u2019s visit also needed to be factored in.", "answer": 1}, {"article": "The blood test, which is not without its own ouch factor, measures levels of circulating IgE.\n\u201cBut Hugh Sampson\u2019s work may turn the tide.\u201d\n\nAs for Sarah Marcus, starting last summer she was weaned from allergy shots so she would no longer need them when she went away to college, at the University of Pennsylvania.\n\u201cAbsolutely.\u201d\n\nSome allergists have made the switch to blood testing \u2014 especially in the area of food allergies, where blood testing is replacing the so-called food challenge test, a two- to six-hour procedure in which patients are given increasing amounts of suspect foods like egg or milk to determine whether they will have an allergic reaction.\nBut skin-testing results can vary from one allergist to the next, and most allergists don\u2019t rely on a prior allergist\u2019s results when a patient switches practices.\nDiagnosing requires a thorough medical history and interpreting the test results within that context; generalists may lack the time to do a complete history, especially under the pressures of managed care.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of the blood test compared to the skin prick test. While it does refer to the contention by some that \"allergists resist blood testing in part to protect their revenue,\" the story does not describe the actual fees surrounding either the blood tests or the skin-prick tests. ", "answer": 0}, {"article": "\u201cThis is a patient population that\u2019s at risk for thrombotic [clotting] issues.\u201d\n\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\nOur intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year.\nWe think the drug must at least diminish the food-seeking drive, which correlates to an increased caloric intake in patients.\u201d\n\nZafgen, founded in 2005, is backed by investors that include venture capital firms Atlas Venture of Cambridge and Third Rock Ventures of Boston.\n\u201cThe efficacy of Beloranib looks very promising,\u201d said Dr. Merlin G. Butler, director of research and genetics at the University of Kansas Medical Center in Kansas City, Kan., and a principal investigator for the clinical trial there.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As the drug is still pending approval from the FDA, the exact cost of the drug is unknown. However, it seems close enough to approval that some cost estimate should have been attempted \u2014 perhaps via a market analyst or company officials. Should it be approved, the drug will most likely be quite expensive.", "answer": 0}, {"article": "And what about colon cancer screening for the elderly?\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\nWEDNESDAY, June 15, 2016 (HealthDay News) -- Reiterating a recommendation last made in 2008, an influential U.S. panel of health experts is advocating that regular colon cancer screening begin at age 50 and continue until at least age 75.\n\"There is only one test -- colonoscopy -- that can both diagnose a polyp/cancer and remove or sample it at the same time,\" said Swaminath, who directs the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Evidence convincingly shows screening for colorectal cancer works, but not enough people are taking advantage of this highly effective service,\" said Owens, a general internist at the Veterans Affairs Palo Alto Health Care System and a professor at Stanford University.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of screening vary dramatically, not only by test but also by the terms of a person\u2019s health care insurance coverage. Insurance may completely cover the cost of screening, but depending on their insurance, people who get follow-up tests to check a suspicious screening test result may get hit with thousands of dollars in medical bills. Especially since the task force highlighted the importance of individuals deciding on the right type of colon cancer screening for themselves, which certainly includes their insurance coverage, the story should have mentioned costs. Also, though not directly addressed in these guidelines, it is worth noting that colon cancer screening is covered under the Affordable Care Act, but that workup of an abnormal screening test may not be.", "answer": 0}, {"article": "That study enrolled just 62 people, but the results were significant enough for NIH to fund new research _ at Pennsylvania, the University of Texas in Houston, Boston University and other sites _ enrolling about 650 cocaine users to see if modafinil really does work.\nResults from the first of three key clinical trials could arrive by year's end.\nIt may help restore proper function of a crucial brain chemical, dopamine, that addiction hijacks.\n\"We didn't expect that at all,\" Dackis says.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of taking modafinil daily. ", "answer": 0}, {"article": "In fact, Dr. Weinstein's findings, released today in the Journal of the American Medical Association, conclude that surgery is only slightly more effective in some cases than a non-surgical approach.\nThe operation was a success and she's been pain-free for four years.\nWhether you have surgery often depends on where you live and what doctor you see.\nHis back pain was excrutiating,reports.\n\"I think that it be important for people to have good information,\" he adds.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of surgery or any of the non-operative options.", "answer": 0}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nA Kythera representative said Wednesday that the new treatment likely won't be available until June, as it must train doctors to administer Kybella, and that the company would not have more details about the potential cost of the drug until after its launch.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that the company would not discuss the \u201cpotential cost\u201d of the drug until after its launch next month, and that the\u00a0sales of the anti-wrinkle drug Botox exceed $2 billion per year. That\u2019s enough for a Satisfactory rating. The story could have further informed readers by noting that insurers won\u2019t pick up the tab.", "answer": 1}, {"article": "Tumors or other abnormalities show up in red.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe most effective screening tool for detecting breast cancer is mammography and for women of all ages to remain breast aware, reporting any changes to their [doctor].\u201d\nThe Manchester team says it is far less effective for younger women, where the detection rate could be as low as 60% for women under the age of 50.\nOct. 28, 2010 -- A University of Manchester, England, engineering professor has invented a portable breast scanner that could lead to more accurate tests for younger women without the need for X-rays.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wouldn\u2019t expect a discussion of cost implications for a technique still in its formative years. But since the article states that \u201ccosts are reduced,\u201d we have to address it. \nFirst of all, costs compared to what? Mammography? The other investigational techniques using RF or microwaves just mentioned?\nLet\u2019s assume the comparator is mammography. It may be that, if and once there\u2019s an available product, costs for each screening visit can be reduced. But the total costs depend on how effective it is. Without knowing how good it is at picking up breast cancer (sensitivity) and excluding signals that aren\u2019t breast cancer (specificity), we don\u2019t know its role. It might be too unreliable to replace mammography. Poor sensitivity leads to missing cancers, which cost life and money. Poor specificity leads to more unnecessary biopsies and treatments; if indeed people would screen themselves at home, poor specificity also means more unnecessary doctor visits. Also, will clinic and home uses be covered by insurance?\n As the independent sources says, we don\u2019t know how the new device will be used. Until trials determine whether it will replace mammography, supplement it, or sink out of memory, we can\u2019t know the total costs. To say vaguely that \u201ccosts are reduced\u201d may not, therefore, be correct.", "answer": 0}, {"article": "Revenues from pharmaceutical and device corporations are available at http://www.\nIn the current analysis of treatment between 6 and 24 hours after symptoms were observed, or after the person was last seen to be well, researchers found:\n\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\n\u2022 treatment remains beneficial through 24 hours, with patients who had their clots removed being 35.5 percent more likely to have minimal or no disability 90 days later, but the overall effect of treatment declines with time.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a thrombectomy procedure isn\u2019t addressed. Even through the study is comparing the procedure within 6 hours vs. within 24 hours, it would help readers if they knew how much this procedure runs.\nFrom a health policy standpoint, expanding the treatment window for more people would certainly cost more, but just what those costs might be is hard to extrapolate.", "answer": 0}, {"article": "The number of children found to have autism has been increasing for reasons that remain mysterious.\n\"If you can find someone who appears to have deficits in oxytocin biology, giving them what you might argue would be replacement oxytocin may be helpful,\" Parker said.\n\"All the data seem to suggest that manipulating the oxytocin system has a powerful effect on the core symptoms of autism,\" said Eric Hollander, director of the compulsive, impulsive and autism spectrum disorders program at the Montefiore Medical Center in New York.\n\"It's possible it can become a cure, if it's given early when the problems are detected in the little kids,\" Sirigu said.\nPrevious U.S. studies found that people with autism who received the hormone intravenously were less likely to engage in repetitive behavior that is another hallmark of autism and were more likely to be able to identify emotions in voices.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If a story is not going to challenge an advocate saying, \"Many families are using it with success and reporting improvement,\" then it certainly can tell us how much it\u2019s costing those families. \n", "answer": 0}, {"article": "The fact that recognizing and acknowledging a familiar person is such...\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No estimates of the cost of this treatment were provided.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of the PSA test itself or of follow-up testing or treatment.", "answer": 0}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\n\u201cThis is not a quick fix, and it doesn\u2019t mean people with peanut allergy will be able to eat peanuts whenever they want,\u201d Jay Lieberman, MD, vice chair of the ACAAI Food Allergy Committee and study co-author, said, according to EurekAlert.\n\u201cWe\u2019re excited about the potential to help children and adolescents with peanut allergy protect themselves against accidentally eating a food with peanut in it,\u201d said allergist Stephen Tilles, MD, ACAAI former president, study co-author and consulting advisor for Aimmune Therapeutics, according to EurekAlert.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2014 particularly important since the treatment might have to be taken for life. Also, it\u2019s expected to be marketed next year.", "answer": 0}, {"article": "Another trial is testing whether a daily supplement of 4,000 IU of vitamin D will prevent Type 2 diabetes.\n\u201cBut keep in mind, there isn\u2019t yet evidence that taking those higher amounts will confer any benefits beyond the recommended daily allotment of 600 to 800 IU.\u201d\n\nSome studies, she noted, have even found evidence that very high levels of vitamin D circulating in the blood might be just as unhealthful as very low levels.\n\u201cThe higher your latitude and the greater your area\u2019s average cloud cover, the higher your rates of cancer.\u201d Since he and his late brother, Frank Garland, published the first study, in 1980, revealing that relationship, hundreds of other studies have explored the link between vitamin D, including supplements, and health \u2014 but none were large enough, long enough or designed well enough to convince the skeptics.\nI just don\u2019t know which one.\u201d\n\nHurley is a science journalist and author of \u201cNatural Causes: Death, Lies and Politics in America\u2019s Vitamin and Herbal Supplement Industry\u201d (Broadway Books, 2007).\nBefore we make a blanket recommendation for the 86 million people in the United States who are at risk for Type 2 diabetes to go out and buy vitamin D supplements, we need to know for sure if they help.\u201d\n\nA third trial, designed to test whether 5,000 IU of vitamin D per day will slow the progression of multiple sclerosis in 172 patients, is being led by Ellen Mowry, an associate professor of neurology at the Johns Hopkins University School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A brief mention of cost would have improved an already strong article.\u00a0While it can be argued that most people have a rough idea of the price of vitamin D supplements, a quick word on the monthly cost of supplements, or the potential cost-effectiveness of supplementation as a prevention strategy, would have been welcome.", "answer": 0}, {"article": "Reavill says he may be proudest of his intention to hire disabled veterans in southern Illinois, a hard-hit region economically.\nIt remains to be seen whether that saved time will result in saved lives.\nIt can be inserted in a nonsterile environment such as an emergency room.\nThe catheter is inserted into the arm and travels to the heart within 20 to 30 seconds via the bloodstream.\nHe plans to bear the cost of any prostheses the veterans need to work on the catheters.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of how much the \u201cbreakthrough\u201d approach will cost.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article discussed that Medicare covers the treatment at $450 for a two-hour session. There wasn\u2019t a discussion about whether other insurance programs covered the treatment. It would have been helpful to know how much the entire treatment plan for the profiled patient cost and whether it was covered by his insurance.", "answer": 1}, {"article": "Side effects from antidepressants can include constipation, diarrhea and dizziness.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\n\"Bringing psychotherapy into discussions of treatment may also enhance coordination of care between primary care and mental health care providers in addition to addressing the issue of patient-centered care,\" Amick said.\nThey found that symptom improvement and rate of remission were similar between the two options, whether used alone or in combination with each other.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives a slight nod to costs without saying very much. It states, \u201cHowever, psychotherapy can be time-consuming and may be substantially more expensive, depending on the patient\u2019s insurance benefits.\u201d Medications and CBT both have costs so it would have been nice to compare them.", "answer": 0}, {"article": "The essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\nNot only did the researchers determine that the procedure was safe and effective, they found that it offered a lasting benefit, reducing shaking for trial participants throughout the 12-month study period.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\n\u201cThe degree of tremor control was very good overall in the study, but the most important aspects were the significant gains in disabilities and quality of life \u2013 that\u2019s what patients really care about,\u201d Elias said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions cost, saying, \u201cBecause the approach is so new, insurance plans will not yet cover the procedure, though that may change in the coming months. The cost at UVA has not yet been determined.\u201d\u00a0 But the procedure is still neurosurgery which is inherently expensive.\u00a0 Readers might benefit from knowing the cost of the current alternative surgical approach to treating this condition, deep-brain stimulation. The fact that other language in the release does come close to marketing this procedure for the medical center is also troubling.", "answer": 1}, {"article": "Handedness (molecular asymmetry) is critical to the function of bio-molecules in the body.\nThe same can be true of molecules, and in some cases, having the wrong handed molecule can have profound biological consequences.\nImportantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.\nIn this case, the osmium compound JPC11, with sodium formate, can selectively produce a molecule of a specific 'handedness' - thus manipulating how cancer cells grow.\nProfessor Martin Wills, catalyst specialist at the University of Warwick, commented:\n\n\"Although asymmetric catalytic hydrogenation processes are well developed in the materials industry, this research provides the first ever example of it being achieved inside cells using a synthetic catalyst.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Given how early this research is in the development process, it would be impossible to place a specific cost on the potential treatment \u2014 or even a range of costs. However, the release could tell readers whether the process used to make JPC11 is expensive, time-consuming, relies on novel technologies, or has the potential to be easily scaled up \u2014 all of which can affect ultimate cost. For example, if it\u2019s a relatively straight-forward process that does not rely on specialized equipment or high-cost components, that\u2019s worth mentioning. If it\u2019s a complex, multi-step process that relies on highly-processed (and expensive) ingredients or technologies, that\u2019s worth mentioning too. The release doesn\u2019t address potential issues related to cost.", "answer": 0}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s little need to discuss costs of a substance as well known as coffee.", "answer": 2}, {"article": "\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\n\u201cBut here every one of those things fails.\u201d One of Dr. Barrett\u2019s papers on echinacea was included in the analysis.\n\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nJ. David Gangemi, director of the Institute for Neutraceutical Research at Clemson University, said he found the study interesting, but added, \u201cI think that many of the people who have dedicated their careers to clinical trials in studying these effects are not at all convinced from this analysis that there is this large reduction in incidence and duration of disease.\u201d\n\nDr. Gangemi is the senior author of a 2005 study, published in The New England Journal of Medicine and included in the review, that found no benefit in the herb.\nThere are several possible reasons that even a carefully devised single study might fail to show an effect that actually exists.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this article is about a treatment whose benefits are disputed,\u00a0it should tell readers how much it costs.\u00a0This would let them\u00a0do a rough cost-vs.-benefit calculation as they consider whether to\u00a0use echinacea.\u00a0 ", "answer": 0}, {"article": ".\nThe results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.\nThe only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.\nAnd, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last,\" he added.\n\"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder,\" Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the story. Although pridopidine is an experimental drug, it may have been useful for the reader to know whether pridopidine could be at least a cheaper alternative to tetrabenazine, the only drug currently approved for Huntington\u2019s disease.", "answer": 0}, {"article": "The American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\nSays Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\n\"We know that people's neurologic outcomes are likely to be better if they get it but we don't completely understand what's happening in the brain for sure when the body is cooled.\"\n\"Anytime you can take someone who comes into the hospital after having cardiac arrest, who may not ever wake up, and you can potentially change that to someone who can wake up and become back the person they were the day before, it's an amazing thing,\" says Dr. David Likosky, a neurologist.\n\"This is ice, and it's a treatment that's very simple, and it's a treatment that makes a big difference: the difference between waking up and not.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although one of the physicians commenting on the treatment contrasted this treatment with the situation in medicine where there are expensive treatments that may make little difference \u2013 and explained this procedure as being just \"ice\"\u00a0 \u2013 the video showed some specialized equipment for controlled lowering of body temperature. The story gave no estimate for the cost of the treatment.", "answer": 0}, {"article": "There\u2019s ample reason for caution.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nAccording to a new study, a medication, ancetrapib, appears to simultaneously raise the level of HDL \u2013 sometimes called \u201cgood\u201d cholesterol- and to lower the level of LDL, or \u201cbad\u201d cholesterol.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThis and other CETP inhibitor drugs are being tested in combination with statins. More than 20 million Americans currently take statins, so an approved drug would be expected to be widely prescribed. Stock market jumps that quickly followed the announcement of these trial results show that market watchers expect a lot of money would be spent. So even though this cholesterol drug is still being tested, if the lead sentence of the story promises people that it may be available \u201csoon\u201d then it is reasonable to expect the story to tell them how much they may soon be paying. Readers would be curious to know if the \u201cjaw-dropping\u201d effects (to quote from an American Heart Association news release) will be accompanied by a jaw-dropping price\u2026 for individuals and for the nation.\n", "answer": 0}, {"article": "Coleman disclosed receiving speaker fees from Novartis; the researchers also received academic grant funding from the drug maker.\nIn addition, there were some troubling side effects among women taking Zometa, including 17 cases of osteonecrosis of the jaw (a severe bone disease that can result in death of the jawbone).\nIn the trial, known as AZURE (Adjuvant Treatment with Zoledronic Acid in State II/III Breast Cancer), Coleman and his colleagues evaluated 3,360 breast cancer patients from 174 participating centers, all with stage II or III cancers but no evidence of metastases (cancer that has spread beyond the original site).\n\"The role of bisphosphonates in preventing cancer recurrence has been less clear,\" she said, noting that multiple studies have had conflicting findings.\n\"There is no overall difference in recurrence rates or survival rates [between patients who got the bone drug and those who did not], except in older patients, defined as more than five years after menopause.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We won\u2019t require a discussion of costs in this story because the use of zoledronic acid for early stage breast cancer is still up in the air. However, since the drug is already being sold for other indications, the story would have been better if it had told readers something about the costs of using the drug for approved indications.", "answer": 1}, {"article": "The Society is based in Oak Brook, Ill. (RSNA.org)\nOAK BROOK, Ill. - An MRI breast imaging technique that requires no contrast agent, combined with sophisticated data analysis, could reduce the number of unnecessary breast biopsies, according to a new study appearing online in the journal Radiology.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nIn an independent test set of 127 women, the radiomics analysis reduced false-positive findings by 70 percent, while detecting 60 of 61 malignant lesions, or 98 percent.\n\"Diffusion kurtosis imaging has been introduced in DWI to provide important information on tissue structures at a microscopic level,\" said study lead author Sebastian Bickelhaupt, M.D., from the German Cancer Research Center in Heidelberg, Germany.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although it seems self-evident that reducing the number of unnecessary biopsies could save on medical costs, the release doesn\u2019t elaborate on the role of MRIs as an adjunct to mammography. In what proportion of cases are MRIs ordered prior to tissue biopsy? Does diffusion kurtosis imaging add to the cost? Cost of this procedure simply isn\u2019t addressed.", "answer": 0}, {"article": "Besides false alarms and unnecessary anxiety, the implant itself can cause problems.\nIt may be the people who fall in the middle -- who have disabling seizures at unpredictable intervals -- who would stand to benefit the most, he said.\nIn this study, the implants revealed that most patients were suffering more seizures than they thought; one patient who reported 11 a month was actually having more than 100.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nAn implanted device like this could also give patients and their doctors more information about their epilepsy, he added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It seems that some cost estimate could have been projected by the device manufacturer which also funded the study.\nBut given the stage of the technology development we\u2019ll give the story the benefit of the doubt and grade this N/A.\nIt would have been appropriate to note that the device requires a neurosurgical procedure along with implantation, both relatively expensive propositions", "answer": 2}, {"article": "\"One of the concerns about taking aspirin remains the potential for intestinal bleeding.\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\nThe study identified five healthy behaviours as being integral to having the best chance of leading a disease-free lifestyle: taking regular exercise, non-smoking, a healthy bodyweight, a healthy diet and a low alcohol intake.\nAs a result, we set out to conduct a systematic search of all the scientific literature.\"\nA mutation - known as PIK3CA - was present in about 20% of patients, and appeared to explain much of the reduction in colon cancer mortality by aspirin.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t touch on cost but because aspirin is so widely available, and its cost so minimal, we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the drugs are not discussed, nor is\u00a0whether they are generally covered by insurance, or how long kids would have to take them (for a few years? into adolescence? into adulthood?).", "answer": 0}, {"article": "April 12, 2012 -- The next new acne treatment may be found in the produce section of your food store.\n\"The problem with treatments containing benzoyl peroxide is the side effects they are associated with,\" namely a burning sensation and skin irritation.\n\"Herbal preparations are less harsh on the skin due to their anti-inflammatory properties, while our results suggest they can be just as, if not more, effective than chemical treatments,\" she says.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of thyme \u2013 or the proposed tincture \u2013 is not in question for the moment.", "answer": 2}, {"article": "The findings appear in the latest Archives of Surgery.\nThe most common drugs before treatment were metformin, a generic taken by about half of patients, followed by the medicines Avandia and Actos, taken by more than one-third of patients.\nThe researchers argue that the findings, drawn from data on four years of claims made in seven states, support coverage of bariatric surgery by insurers because of the savings and improvements in patients' health.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nBut an analysis of insurance claims for more than 2,200 people with Type 2 diabetes who underwent stomach-reducing surgery found that the vast majority of them were able to drop drugs they had been taking to treat the condition beforehand.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n1clip_filelist.xml\"/>\n\n\n\nHealth care spending before and after the surgery is a key point in this story. The story also includes an estimate of the cost of stomach-reduction surgery. However, neither the story nor the study offer a comparison of the spending of these patients to that of people who do not have this type of surgery.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of\nhernia operations, which may play a role in someone opting for watching waiting.", "answer": 0}, {"article": "To find out, they studied 79 adults with chronic insomnia.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nThe key ingredient in the therapy, according to lead researcher Dr. Daniel Buysse of the University of Pittsburgh School of Medicine, was a simple, somewhat counter-intuitive lesson: \u201cWhen you are sleeping poorly, the most important thing you can do is spend less time in bed.\u201d\n\nInsomnia affects about one in every five Americans, rising to one in three among the elderly, and has been linked to a range of physical problems, from accidents to hypertension.\nYet the time and resource-intense strategy \u2014 usually involving between six- and eight hour-long appointments with a clinical psychologist - is not widely available and its cost, generally hundreds of dollars, is prohibitive for many.\nNEW YORK (Reuters Health) - A few short visits and phone calls with a nurse may be enough to help insomniacs get their zzz\u2019s, suggests a new study of sleep-deprived older adults.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nAlthough this trial was a preliminary experiment, the proposed intervention is clearly defined as two office visits and two telephone calls with a nurse, so it should have been possible to estimate the cost. Since one purpose of testing this sort of brief intervention is to offer lower-cost alternatives to established behavioral treatment for insomnia, readers should have been given some estimate of the relative costs of the interventions.", "answer": 0}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nU.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24.\nKeytruda, as a sole agent, was targeted only at patients with high PD-L1, making them more receptive to immunotherapy.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nThe failure of Opdivo to work for \u201call comers\u201d in lung cancer was first announced in August, without any details.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, even though the FDA approved Keytruda for advanced, non-small cell lung cancer treatment in 2015.", "answer": 0}, {"article": "Overall, this is very exciting.\u201d\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nThese promise that patients could become more independent.\u201d\n\nWhen healthy, retinal cells transmit visual information to the brain.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\nThe researchers were unable to determine how well the rats were able to see, if at all, but they noted that the animals\u2019 eyes continued to react to light more than six months after the implant was installed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Both artificial retinas are in the earliest stages of development, still to be tested in humans. Even if there\u2019s no product yet, we\u2019d like to see\u00a0stories make mention of costs. For instance, the cost of implanting the current FDA-approved artificial retina (mentioned in the article) might serve as a benchmark for estimating future cost of the new devices.", "answer": 0}, {"article": "The testing is done under medical supervision.\n\"We found that 14 percent of the patients challenged had mild or moderate allergic reactions,\" explains study author Carla Davis, an allergist and director of the Food Allergy Program at Texas Children's Hospital.\n\"I think [the results] are very encouraging,\" Bruce Lanser, a pediatric allergist who directs the Pediatric Food Allergy Program at National Jewish Health in Denver, told us.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nBut the only way to confirm that it was safe for Jula to eat egg was to take the food challenge test.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of oral food challenges. That\u2019s too bad because the economics of food challenges are part of the overall newsworthiness of the procedure, although it was not a focus of this particular study. Considering that oral food challenges take three to six hours and require multiple staff to provide adequate supervision, families with inadequate or no insurance may not consider looking into the time-consuming procedure. However, families of patients on special diets spend thousands of extra dollars per year on groceries. Prior research suggests that in the end, having a food challenge earlier rather than later could save money for children assessed as low risk.", "answer": 0}, {"article": "Eteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials.\n\u201cHe\u2019s no longer riding the handicap bus to school,\u201d she said.\nAnd the stock had already roughly quadrupled since July, when Sarepta announced some interim results from the study.\n\u201cThat would be the quickest path to insolvency,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The drug is in early stages of development and as such, identifying the potential cost is premature", "answer": 2}, {"article": "\"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels,\" said Salloway.\nThe other study, which involved looking at more than 2,000 MRI scans from 262 patients, found 36 cases of amyloid-related imaging abnormalities (ARIA) may have been linked to the bapineuzumab.\n\"I think it is too early to tell from the data from this small Phase 2 safety trial,\" said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station.\nBut only 8 of those 36 cases involved symptoms, and they were more likely to be found in patients with APOE-e4 who were taking higher doses of the drug.\nAlthough bapineuzumab has shown promise in certain Alzheimer's patients, other research found that patients taking a higher dose of the drug had an increased risk of brain inflammation from water retention.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As the drug is still under development, there was no discussion of costs.\nThis is a humanized monoclonal antibody and the story might have mentioned some of the drugs currently on the market to treat other disorders such as bevacizumab (Avastin) or adalimub (Humira). \u00a0This could have led to some discussion about costs because these are not inexpensive medications.", "answer": 2}, {"article": "For more information please visit http://www.\n\"We've long heard anecdotal evidence that singing in a choir makes people feel good, but this is the first time it's been demonstrated that the immune system can be affected by singing.\n\u2022 Among RCM alumni are composers and performers such as Sir Hubert Parry, Benjamin Britten, Gustav Holst, Sir Colin Davis, David Helfgott, Samuel Coleridge-Taylor, Lord Lloyd Webber, Dame Joan Sutherland, Sir James Galway, Ralph Vaughan Williams and Alfie Boe.\nTo find out more call the Tenovus Cancer Care free Support Line on 0808 808 1010 or visit tenovuscancercare.org.uk\n\nFor more information contact Ruth Taylor, PR and Communications Manager on 07429 103084 / ruth.taylor@tenovuscancercare.org.uk.\nRosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention any costs. While the non-profit Tenovus makes choir singing available to people for free that doesn\u2019t mean such an activity would be free to people everywhere if they wished to access it. If a cancer treatment center needed to establish a new choir program, with a director, that would require resources \u2014 financial and otherwise.", "answer": 0}, {"article": "Though they may suffer from physical and emotional pain as a result of VVA, women may not feel comfortable discussing these symptoms with a healthcare professional, may not recognize the symptoms as treatable, may not fully understand the treatment options available, or if they did receive treatment, found the current prescription treatment options inconvenient, messy, or uncomfortable to use.\nUH is the second largest employer in northern Ohio with 26,000 employees.\nUH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including \"America's Best Hospitals\" from U.S. News & World Report.\nPrevious publications have shown TX004HR to be safe and effective at alleviating symptoms of VVA.\nVVA affects 50 to 70 percent of post-menopausal women, and is characterized by pain with sexual activity, dryness, and discomfort.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the softgels might cost.", "answer": 0}, {"article": "Instead, the chief usefulness of the \"ALVAC-AIDSVAX\" vaccine is likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\nThe vaccine is not licensed or being produced in large amounts.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At this early phase of research it\u2019s understandable that cost wouldn\u2019t be discussed. ", "answer": 2}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story tells readers that solanezumab and aducanumab could generate annual sales of $3 billion and $10 billion respectively, it says nothing about the potential cost of the drugs to consumers or insurance companies. Those billions would likely come largely from Medicare. These drugs are still far removed from the marketplace, but presumably the experts they spoke to were basing their annual sales estimates on more than guesswork. That makes it particularly problematic that the story doesn\u2019t touch on cost at all.", "answer": 0}, {"article": "The controls have had twice the death rate from aging-related diseases like heart failure and diabetes.\nIt was probably preserved by evolution because it saved people from starving to death when food was scarce, but it is the bane of dieters because it means that the more weight they lose, the harder it is to keep reducing.\nAt first, he said, \"I was starving to death, I had headaches, I was grouchy.\"\nThe low-calorie animals weigh about 30 percent less and have 70 percent less body fat than the controls, as well as lower insulin levels.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Everything has a cost. Yet the story gave no cost estimate for the costs associated with consumption of foods \u2018high in nutrients but low in calories.\u2019 ", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article provides prices on both devices:\nBoth the Dechoker, $89.95, and the LifeVac, $69.95, have a plastic mask that provides a seal over the mouth and nose while suction is provided.", "answer": 1}, {"article": "All participants took calcium and vitamin D as well.\n\"These were patients with severe periodontal disease but who were otherwise systemically healthy,\" said study senior author Dr. Laurie K. McCauley, chair of the department of periodontic and oral medicine at the University of Michigan in Ann Arbor.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nIt is much rarer in people who take a lower-dose bisphosphonate (such as Actonel, Boniva or Fosamax) for osteoporosis.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs. Forteo at the doses described costs about $250/week. Given the severity of the osteonecrosis described in the letter of a single case, the costs are relatively nominal since the treatments were of fairly brief duration.", "answer": 0}, {"article": "Years later, on the surface.\n\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\n\"I am in a lot less pain today and now it just feels as though I have a sunburn that is a few days old,\" he said.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nNow he's trying something that might seem shocking: an electrical current applied to his head - part of a clinical trial at Beth Israel Medical Center in New York.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter says \"That\u2019s the hope\u2026whatever the cost.\"\u00a0 No cost was discussed.\u00a0 Granted, this is early research on an experimental approach.\u00a0 But it was given network news time.\u00a0 Our rule of thumb is:\u00a0 if it\u2019s not too early to project possible benefits, it\u2019s not too early to project possible costs. If the story can use words like \"breakthrough, promising, hope\" to describe this very early research and project those words onto an unsubstantiated potential market of 1 in 4 Americans suffering from chronic pain or 1 in 10 having it for over a year, then we suggest it\u2019s time to talk costs. \u00a0 \n\u00a0\n ", "answer": 0}, {"article": "This is one of the first few studies that suggests a different mechanism.\nIt\u2019s a medication that works differently than everything else.\u201d\n\nThe study was funded by a grant from the National Institutes of Mental Health, but the SAMe pills and placebo pills were provided by the dietary supplement maker Pharmavite.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nAs a result, doctors are looking for additional treatments to help these patients, referred to as \u201cnonresponders.\u201d\n\nModern antidepressants essentially work by building up concentrations of neurotransmitters, which amplifies their effect on the brain.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s a nice summary of costs and lack of insurance coverage, citing the editorial.\n However, we were surprised to see in this summary that \u201cthe cost is relatively low\u201d when the cited editorial states \u201cSAMe is relatively expensive.\u201d This mistake may have been unintentional, and while it\u2019s the exact opposite conclusion of the one in the source, we are inclined not to dock the article a point because the rest of the summary provides balance about copays and, most importantly, tells its readers the absolute monthly cost of the supplement.", "answer": 1}, {"article": "Many smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nSome previous studies have suggested that the earlier detection helps, while other research concluded it may do more harm than good by spotting too many benign growths.\nStill, \"a validated approach that can reduce lung cancer mortality by even 20 percent has the potential to spare very significant numbers of people from the ravages of this disease,\" he said.\nThe NCI said it is not clear that all smokers should get the scans, which are not risk-free.\nWhile the spiral CTs emit less radiation than standard CT scans used to diagnose disease, researchers also will analyze whether the radiation exposures from three scans changes a smoker's lifetime risk of other radiation-related cancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story reports that these scans typically cost $300-400 and are not generally covered by insurance. The story would have been better if it had clearly pointed out that the potentially huge cost of such a screening program, because hundreds of smokers had to be scanned to extend one life in this trial and follow-up tests and treatments cost much more than the initial scan. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion. The New York Times never specified the scans\u2019 costs.\n", "answer": 1}, {"article": "The study started in August 2010.\n\u2022 The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon\u00ae adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc. (NASDAQ: AGEN), MPL and liposomes\n\nGSK \u2013 one of the world's leading research-based pharmaceutical and healthcare companies \u2013 is committed to improving the quality of human life by enabling people to do more, feel better and live longer.\nDr Emmanuel Hanon, Senior Vice President, Vaccines Research and Development, GSK, said: \"This is the first time that such high efficacy has been demonstrated in a vaccine candidate for older people and it is remarkable, as we know that these people frequently have an age-related weakening of their immune system.\nVaccine efficacy was maintained across the various age groups included in the study, ranging between 90% in people aged 70-79 years (95% confidence interval: 83-94%) and 89% in those aged 80 years and above1 (95% confidence interval: 74-96%)1.\nThe high efficacy is in line with the results of the ZOE-50 trial, a study in people over 50 years old which was presented and published last year showing a 97% efficacy (95% confidence interval: 93-99%)2.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The vaccine in question has not yet been submitted to the FDA for approval, so we wouldn\u2019t expect to have a specific price for the vaccine. The price GSK will charge for the vaccine will vary by country. Still, GSK ought to have some idea of how much this vaccine would cost in one of the largest global markets. The release never mentions cost at all.", "answer": 0}, {"article": "\"It's protecting against a severe disease, particularly in elderly adults,\" he said, \"so the benefit, I think, is overwhelming that we should be using this because it's recommended.\"\nBut the vaccine can cost a couple of hundred dollars, he said, perhaps making it out of reach for those with limited resources.\nA study of a cross-section of adults enrolled with a health-management organization in southern California shows that the vaccine provides protection for many older adults without many side effects.\nIt usually starts as a rash on one side of the face or body, often causing pain, itching and tingling.\nEven though the vaccine is only about 55 percent effective, \"it's better than nothing,\" she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story reports that the vaccine can cost a couple of hundred dollars and that cost can put the vaccine out of reach for some people and that even people who could afford it may decide it is not as high a priority as other health care items.", "answer": 1}, {"article": "I'm proof.\"\nIf an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nAnd even if the stent does fit, patients often undergo a long, painful recovery.\nThese aneurysms often grow slowly, without symptoms, but some people may notice a pulsating feeling near the belly button, back pain, or nausea \u2014 often signs of impending rupture.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how much this procedure costs or whether it\u2019s covered by insurance, and no comparison with stent procedures that don\u2019t include the 3D printing and customized fit.", "answer": 0}, {"article": "Five immune system autoantibodies have been linked to type 1 diabetes.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nAfter adjusting the data to try to account for the duration of exposure to one of the study formulas, the researchers found that the extensively hydrolyzed formula reduced the risk of having one diabetes autoantibody by 49 percent, and the risk of having two or more autoantibodies by 53 percent.\nWhen Finnish researchers randomly assigned 230 babies at high risk of type 1 diabetes to receive either a regular infant formula, or one that was extensively hydrolyzed -- which means the proteins in the formula are already partially broken down and more readily available for digestion -- they found that the extensively hydrolyzed formula cut the rate of developing diabetes-linked antibodies in the blood by about half.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the extensively hydrolyzed formula is more expensive than standard formula; however, the authors should have indicated how much more expensive hydrolyzed formula is compared to regular formula. Monthly cost comparison of two formulas would have been appropriate as this may be a deciding factor for many families who choose not to breastfeed, or who are weaning.", "answer": 0}, {"article": "\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nThe procedure to implant the device into Ekstadt\u2019s cornea takes less than 5 minutes: The doctor uses a laser to create a tiny pocket in her cornea and two minutes later the Raindrop is inserted and the procedure is finished.\nThey may work quite well for a period of time but a person's lenses will continue to change with age and, ultimately, the patient may need cataract surgery.\nA cataract procedure replaces the lens, improving both near and far vision, and lasts for the rest of the patient\u2019s life.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story gives us the price of $4-5,000 for surgery, which is not likely to be covered by insurance or Medicare.", "answer": 1}, {"article": "\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nThe study was very small, and the procedure is not ready for widespread use.\n\"We now have a unique approach with some positive findings, but it's still early.\nOne patient has gone without insulin injections for 3.5 years.\nEight teens who took part in the study have remained insulin-free for two years, on average.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No estimate was given of the cost of this \u201ccocktail treatment.\u201d", "answer": 0}, {"article": "Erin M. Schumer, MD, MPH, Victor van Berkel, MD, PhD, and colleagues from the University of Louisville analyzed breath samples collected before and after surgery from 31 lung cancer patients and compared their carbonyl VOCs levels with samples from 187 healthy patients.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nOur next step is getting approval from the FDA.\u201d\n\nNote: This work was supported by the Coulter Foundation, V Foundation, National Science Foundation, and Bill and Melinda Gates Foundation.\nThe American Cancer Society (ACS) estimates that more than 224,000 Americans will be diagnosed with lung cancer this year, and more than 158,000 lung cancer patients will die\u2014that translates to 433 lung cancer deaths per day in the United States.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does mention that the cost of materials to conduct the test is \u201caround $20\u201d which is considerably less than the cost of CT scan imaging which is now being used. It is unclear, however, how much patients would be actually charged.\u00a0The release should\u2019ve been clearer about the actual cost to patients.\u00a0", "answer": 1}, {"article": "The medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\nAfter her surgery the difference was dramatic.\nThe surgery could be a glimpse into a new medical frontier.\nManuela could identify 44 letters on an eye chart.\nThe pupil constricts when there is light, as with a healthy eye.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs or insurance coverage.", "answer": 0}, {"article": "So his team designed a randomized controlled clinical trial to see if short-term use of a curcumin supplement could reduce inflammation in people with metabolic syndrome, a cluster of risk factors for heart disease.\n(Reuters Health) \u2013 - Adding spice \u2013 in the form of curcumin supplements \u2013 to the daily diets of people with risk factors for heart disease may lower inflammation, a new study suggests.\n\u201cThe findings of our studies, along with clinical findings reported by other groups, indicate the usefulness of daily use of curcumin supplement for the prevention and treatment of several diseases,\u201d Sahebkar said.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention or discuss cost at all. A quick online search found that the price of curcumin supplements can vary significantly from as little as $8 for 90 one-gram doses (the size of the dose used in the study) to as much as $45 for 60 doses. The story also notes that \u201cmost of the clinical benefits reported for curcumin have been achieved when curcumin was added to a standard drug therapy regimen.\u201d Adding a potentially high-cost supplement to an existing drug routine could tip the scales of any cost-benefit analysis.", "answer": 0}, {"article": "For more information about deep brain stimulation, visit the American Association of Neurological Surgeons\n\"It's a really interesting paper,\" said Dr. Nicholas D. Schiff, director of the Laboratory of Cognitive Neuromodulation at New York-Presbyterian Hospital/Weill Cornell Medical Center.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story speculates that DBS might become a treatment for hard-to-control high blood pressure. But it didn\u2019t offer any estimates as to what it might cost to treat patients with this technology. At the very least, the story could have pressed the authors of the case report\u00a0to discuss the cost of the device and\u00a0the price tag for a typical implantation procedure.\u00a0In this 2008 Chicago Tribune blog post, the cost of\u00a0DBS was estimated at $150,000 or more per patient.\u00a0There would also be additional costs for ongoing monitoring and follow-up once the device\u00a0was\u00a0implanted.", "answer": 0}, {"article": "For more information, please visit http://www.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\n\"We have completed four randomized studies, and they have led us to conclude that Aged Garlic Extract can help slow the progression of atherosclerosis and reverse the early stages of heart disease.\"\nA follow-up screening conducted a year after the initial screening found those who had taken Aged Garlic Extract had slowed total plaque accumulation by 80%, reduced soft plaque and demonstrated regression (less plaque on follow-up) for low-attenuation plaque.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release makes no mention of the cost of this supplement in its discussion, although the supplement and its cost are easily available via the web. It would be nice to know what a year\u2019s worth at the prescribed dose would cost.", "answer": 0}, {"article": "\u201cWe are saying forget about stimulating an immune response.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nLOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While WebMD missed the cost component, Reuters smartly raised this issue and discussed how future research will be funded. \u201cAll of the funding for the University of Pennsylvania\u2019s gene therapy work has come from the academic community, but the work is expensive. \u2018We are looking for corporate partners as we head into Phase II trials,\u2019 Kalos said.\u201d", "answer": 1}, {"article": "Why use the traditional approach if the laparoscopic technique is better in some ways?\nThe study \"confirms what a lot of surgeons who do both procedures know already,\" Brunt said.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nThe procedures are designed to reduce the bulge of the hernia and make a patch so it doesn't protrude again.\n\"It's not one-size-fits-all,\" said Dr. L. Michael Brunt, a professor at Washington University in St. Louis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give credit to the story for attempting to compare the relative costs of the two procedures, but we thought the language used was just too vague to support a satisfactory rating. The story says the costs of the two procedures are \u201ccomparable,\u201d but that \u201cthe laparoscopic procedure may cost more.\u201d Unfortunately, it\u2019s difficult to tell from this description if the procedures cost about the same or whether the laparoscopic procedure is, in fact, more expensive. Attaching a specific dollar figure to each procedure would have made the meaning more explicit.\u00a0 Given the nature of the long-term follow-up presented, one could have discussed both the short-term medical costs of the two procedures and then whether there were differences in care over the ensuing 5 years that may have changed the short-term comparison.", "answer": 0}, {"article": "Visit the Mayo Clinic News Network.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\n\"As a class, these drugs have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels.\"\nThe drug was associated with fewer major bleeding events and fewer recurrent blood clots, compared to low-molecular- weight heparin.\n\"Clotting events can be deadly with pulmonary embolism being the second most common cause of death in cancer patients.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not discuss the costs of apixaban or how it compares to the cost of the injectable medication heparin. According to GoodRx, the average cost of apixaban is $424, while the average cost of heparin is $189 (these costs do not reflect insurance coverage). There is also no generic version of apixaban (sold under the brand name Eliquis) available yet. The release did quote the study author saying that a downside to heparin injections is that they \u201care expensive at nearly $100 per day,\u201d however no information was provided about how apixaban costs compare.\u00a0", "answer": 0}, {"article": "The other groups showed no significant change.\nA third group made no dietary changes.\nEating fewer calories may lead to better memory, a new study says.\nThen they took tests involving memorizing words.\nThe study was small, involving 50 men and women ages 50 to 72 who ranged from normal weight to overweight.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a major issue in this story. ", "answer": 2}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nApril 14, 2010 (Toronto) -- A decades-old drug made from human plasma appears to slow the decline of mental skills in people with Alzheimer's disease, suggest results from a small preliminary study.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\nResearchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The approach is described as \"expensive \u2014 about $2,000 to $3,000 per treatment. And patients in the study received infusions up to twice a month, depending on the dose, for 18 months.\"", "answer": 1}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story covers cost in the very last two lines. ", "answer": 1}, {"article": "The two patients included in the study were treated at MD Anderson between June 2017 and January 2018.\n\u201cWe have a limited amount of time to fix the problem so they can resume ICI treatment, but I feel that we\u2019ve made great progress in this area.\u201d\n\nThe researchers chose to investigate the potential for FMT as an alternative, compassionate-use therapy for patients suffering from refractory, or unresponsive, ICI-associated colitis.\nThe current data further suggests there is the potential for many molecular studies to better understand the role of the microbiome in driving ICI-colitis and immunotherapy response more broadly.\n\u201cBased on these results, this should be evaluated even as a first-line therapy for ICI-associated colitis because it\u2019s safe, quick, and the effect is durable - from one treatment.\u201d\n\nImmune checkpoint inhibitors, which release a block on the immune system to attack cancer, have been successful in providing durable responses for patients with several cancer types.\nFMT has shown promise in treating other types of gastrointestinal diseases, such as recurrent Clostridium difficile infection and inflammatory bowel disease (IBD), which shares many clinical and molecular characteristics with ICI-associated colitis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the use of fecal transplants to soothe severe colitis in cancer patients (caused, in this case, by immunotherapy) has yet to be tested clinically, the treatment itself is increasingly popular for other gastrointestinal issues and typically costs in the $1000 to $2000 range.\u00a0 Alas, we learn nothing about that cost in this release.", "answer": 0}, {"article": "He points to a recent meta-analysis published in the journal Addiction that concluded that naltrexone helped reduce heavy drinking and cravings for alcohol.\n\"The biggest problem we have in the field is that less than 10 percent of individuals with an alcohol use disorder get any treatment whatsoever,\" says George Koob, director of the National Institute on Alcohol Abuse and Alcoholism.\nThe analysis also found that another drug, acamprosate, is effective at helping people who have already stopped drinking to maintain abstinence, perhaps partly by easing the physical and emotional cravings experienced by heavy drinkers who quit.\nAccording to the NIAAA, \"patients can now receive effective alcohol treatment from their primary care doctors or mental health practitioners by combining the newer medications with a series of brief office visits for support.\"\nAs as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a close call. The story mentions that an analysis found the drug \u201ccost effective\u201d for treating alcohol use disorders. But it doesn\u2019t mention any specific numbers, nor if insurance covers it.", "answer": 0}, {"article": "If you are interested in enrolling in a clinical trial, you can find one at clinicaltrials.gov.\nThe study shows the results of a six-month follow-up with patients in 2007, and researchers are presently working with data from the two-year follow-up.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nIn accordance with clinical trial regulations set by the Food and Drug Administration, phase I is meant to show safety, while phase II and phase III trials are done on a larger group of subjects and evaluate how well the drug works.\nThe largest national stem cell study for heart disease, sponsored by Baxter Inc., uses this surgical method, and recently announced success in a 12-month phase II trial for patients with severe angina.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that harvesting enough stem cells for infusion is difficult and costly, though it fails to cite specific costs. \nFor research in Phase I, any comment on cost might be purely speculative. ", "answer": 2}, {"article": "Want to embed a link to this study in your story?\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\nThe combination of ibuprofen and acetaminophen may represent an effective non-opioid alternative.\nDespite the epidemic, opioid analgesics remain a first-line treatment for moderate to severe acute pain in the emergency department.\nWhy The Research Is Interesting: The United States is facing an opioid epidemic with almost 500,000 individuals dying from opioid overdoses since 2000.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. The costs of ibuprofen and acetaminophen are fairly low \u2014 but the relevant opioids are also relatively inexpensive. For the relevant dosages, the costs would be more or less comparable, with the hydrocodone/acetaminophen combination likely being the most expensive.", "answer": 0}, {"article": "Recent tests show the cancerous nodules in Mejia's lungs are shrinking, and she hopes for more good news after scans later this summer.\nAt the time she was 39 and had experienced bleeding she blamed on hemorrhoids.\nThe findings are published in the Journal of the American Medical Association.\n\"I am thankful for every minute I get to spend with them,\" she said.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In such a short piece, discussions of cost are almost always missing, but they were missing as well in the competing WSJ article.", "answer": 0}, {"article": "PARIS (Reuters) - Sanofi-Aventis\u2019 cabazitaxel candidate prostate cancer drug combined with prednisone reduced the risk of death by 28 percent compared with another treatment, the outcome of a final-stage trial showed.\n\u201cThe development of cabazitaxel is one of many investigational compounds we hope to present to the cancer community in the months and years to come,\u201d Debasish Roychowdhury, Sanofi\u2019s oncology senior vice president, said.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\nFiling for approval in the EU has been completed.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story included no discussion of costs. If a drug is this far down the pipeline in the EU and the US, somebody has some cost projections. ", "answer": 0}, {"article": "But a P.P.I.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nSmoking and alcohol can loosen tension of the upper esophageal sphincter and cause symptoms of reflux like hoarseness, postnasal drip and shortness of breath by irritating the mouth, larynx and trachea, Dr. Aviv reports.\nOne characteristic often associated with acid reflux \u2014 being overweight, especially with abdominal obesity \u2014 largely explains why the condition has become so common in Western countries.\nEating big meals, lying down before a meal is digested, and exercising too soon after eating can also trigger symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost, but given that the treatment option the story focuses on broad, non-specific recommendations for lifestyle changes, we\u2019ll give it a pass.\nEating less fatty food and more produce is not a viable option for everyone, particularly those who live in so-called \u201cfood deserts\u201d that have limited access to healthy foods they can afford, but that is a broader discussion \u2014 and not one that we would expect to be addressed in a story like this one. Taking all of that into account, we\u2019ll rate the cost criterion as not applicable here.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story does mention the cost of amniocentesis and chorionic villus sampling, the story does not mention the cost of the new twofold screening protocol. This is important information for consumers given that insurance may not cover the screening yet.", "answer": 0}, {"article": "In one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\nHe generally recommends exercise and an active lifestyle to women who feel bothered by menopause.\nWhile the same pattern was seen in the placebo group, it was less pronounced.\n\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\nBut a U.S. expert wasn\u2019t convinced by the results, which run counter to other published studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Soy supplements are over the counter so the price may vary.\u00a0 Story cites estimate.", "answer": 1}, {"article": "Loyola Medicine offers both open and robotic radical cystectomy and all three bladder replacement techniques.\n\"It is important to conduct these trials before widespread adoption of technology, as has been the case with robotic prostatectomy (removal of the prostate),\" he said.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost in this release. The journal article says several institutions refused to provide their prices. Nevertheless, the high cost of robotic surgery is an important issue. The researchers wrote they were unable to say whether those high costs might be offset [or not] by certain potential benefits (such as shorter hospital stays), but the release should have at least acknowledged the cost issues.", "answer": 0}, {"article": "Predefined analyses showed significant differences between active and control study groups for hippocampal and whole-brain atrophy, and favourable effects for CDR Sum of Boxes and episodic memory (both were most pronounced in patients with high baseline cognition with regular intake).\n\u2022 Academy of Sciences of the - Institute of Physiology\n\nFor further information on the European LipiDiDiet study and consortium, visit: http://www.lipididiet.eu\n\u2022 A Clinical Trial investigating the effects of Fortasyn Connect (Souvenaid) in Prodromal Alzheimer's Disease: Results of the LipiDiDiet study H. Soininen, , M. Kivipelto, T. Hartmann for the LipiDiDiet study group (2016), presentation held at 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy,\n\u2022 The World Alzheimer Report 2015: 'The Global Impact of Dementia'.\nProfessor Hilkka Soininen, Professor in Neurology MD, PhD from the University of Eastern Finland, who headed the clinical trial as part of the LipiDiDiet project, said: \"Today's results are extremely valuable as they bring us closer to understanding the impact of nutritional interventions on very early AD (pre-dementia) which we are now better at diagnosing but unable to treat due to a lack of approved pharmaceutical options.\nIts remit is twofold - the clinical and epidemiological assessment of the value of nutritional support in people at risk of developing AD, and to conduct basic research to better understand and improve the possible therapeutic and preventive effects of nutrition in AD and Vascular Dementia.\n\"This is exciting because it shows that in the absence of effective drug options, we really have found something that can help slow down some of the most distressing symptoms in very early AD (pre-dementia); especially in those who started the intervention early.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Presumably, the aim here is to make an over-the-counter nutritional drink along the lines of Ensure for people to take as they age to stave off memory loss. If that\u2019s the case, the release should explain what something like this costs to make and what it might cost on the shelf.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of tomatoes, or other sources of lycopene, is not in question.", "answer": 2}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis can make a difference to other patients, so I am glad to be the first one helping them with my experience.\u201d\n\nAs soon as the donor kidney was reattached to the patient, it turned ruby-red and started to pour out urine, indicating that it was functioning well.\n\u201cIt behaved like a normal kidney, despite it being an extended criteria donor kidney.\u201d\n\nHe points out blood tests within 48 hours showed that the kidney was removing wastes and excess fluid from the blood normally.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\nKidneys are the most frequently transplanted solid organ, but a continuing shortage of donor kidneys impacts wait times and quality of life of those waiting for a transplant.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. Does the technology used to keep the kidney viable in ex vivo organ perfusion increase costs? Is this something that would be passed on to patients?\nThe economics of improving the viability of kidneys for transplant is an important consideration that isn\u2019t mentioned, either. The estimated first-year cost of a kidney transplant is in the $270,000 range and that of renal dialysis about $70,000 annually, so despite its costs, transplantation is economically as well as clinically preferred over the long run. The techniques described likely will add costs over cold storage but knowing how much would have been an important aspect of the story.", "answer": 0}, {"article": "Pinto launched Innovative Laser Therapy after he successfully quit smoking with a round of laser therapy from a clinic in Florida.\n\u201cWe can hope that this is going to be a method that is going to help people.\u201d But, Daviglus said, \u201cWe need more research and more evidence.\u201d\nThe authors weren\u2019t able to follow most of the 340 participants for more than 6 months after treatment, so they don\u2019t know if those who stopped smoking started up again, or if they really quit for good.\nOne study, no matter how many patients are in it, really needs one or two confirmation studies.\u201d\n\nIf future studies do show its effectiveness, laser treatment would have a leg up over conventional methods of smoking cessation, such as medications including Chantix and Zyban, said Spielholz, who continues to work with Laser Therapeutics on getting FDA approval.\nAnd while the laser device used by clinics including Innovative Laser Therapy has been approved by the Food and Drug Administration for temporary pain relief, the agency has not cleared it to be marketed for smoking cessation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that the company profiled \"charges $350 for a one-time treatment that takes less than an hour, and offers free extra treatments to patients who are still struggling with quitting in the following 6 months. Other companies do a few shorter therapy sessions as part of their regular treatment plan.\"", "answer": 1}, {"article": "\u201cI've responded great.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\nThe researchers tested this vaccine, known as p53MVA, in a 2013 clinical trial and found it to be safe in patients with advanced gastrointestinal cancers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release referred to a combination of a new vaccine targeting the p53 gene and a pembrolizumab biosimilar. Pembrolizumab is currently used as a chemotherapy drug but no mention of costs were given for this drug or the combination treatment of the vaccine\u00a0with pembrolizumab. According to GoodRX, four vials of 50 mg Keytruda cost around $9,000.", "answer": 0}, {"article": "Ziman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\nAntibodies \"are easily accessible in the blood, so it provides a fantastic test to identify an early-stage cancer,\" said project lead Professor Mel Ziman, leader of the university's Melanoma Research Group on Monday.\nThe problem is particularly serious in Australia, where melanomas were the fourth most commonly diagnosed cancer in 2017 and cause about 1,700 deaths a year, according to the university.\nDr. Jodie Moffat, head of early diagnosis at Cancer Research UK, agreed that a test which finds melanoma earlier could help reduce deaths from the disease, adding that \"melanoma can be more than skin deep, and it's much harder to treat when diagnosed at a late stage after it has spread.\"\nIf detected early, skin cancers have a survival rate as high as 95%, the research team said, but it drops to just 50% if diagnosed late.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This test, since it involves ten separate autoantibody antigens is likely to be expensive. \u00a0A test to determine breast cancer recurrence risk, Oncotype DX cost approximately $3,000. \u00a0It is unclear how often a blood test for melanoma would need to be repeated, so the cost will be an important consideration, and should have at least been acknowledged.", "answer": 0}, {"article": "\u201cWhy is my brain coming up with this?\nThe idea is that reliving the memories helps remove the sting and that the urgency of the memories can be reduced as the brain begins to move them from short-term to long-term memory.\nThe sound or the eye movement is supposed to activate both sides of the brain in an imitation of REM sleep, when the brain usually converts short-term memories into long-term recollections.\n\u201cBut I never felt like I was getting over it.\u201d Random memories could send her spiraling into panic and fear.\nHenn, who had been visiting her boyfriend in Chapel Hill, immediately returned home to Raleigh, N.C.\n\n\u201cI didn\u2019t stop for the first week after Nate died,\u201d she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of treatment surfaces only in the context of whether individuals\u2019 health insurance plans will pay for the treatment. Some will and some won\u2019t; regardless, we have no idea what that cost is.", "answer": 0}, {"article": "To explore the therapeutic potential of fish oil supplements, the authors offered 16 cancer patients undergoing an initial 10-week chemotherapy regimen a daily dose of 2.2 grams of a particular omega-3 fatty acid called eicosapentaenoic (EPA).\nFor more on chemotherapy, visit the American Cancer Society.\nTotal fat tissue measurements were unaffected by fish oil supplementation, the team noted, and no side effects were observed.\nThe finding is based on a small study involving just 40 lung cancer patients.\nMazurak and her colleagues report their observations in the Feb. 28 online edition of Cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost for the mega doses of fish oil used in the study.", "answer": 0}, {"article": "Simmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\n\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\nIt suggests hair cortisol levels may provide a marker of trauma exposure in children and identify those at risk of developing psychosocial and behavioural problems, and who may need medical and psychological support, leader of the study and a fellow in child and adolescent mental health at the University of Melbourne, Dr Julian Simmons, said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the hair test is far from ready for any practical, clinical use, the story speculates that it could be a tool to identify children at risk. If it\u2019s not too soon to make such predictions, it\u2019s not too soon to give readers an idea of what the test might cost.", "answer": 0}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n      \n\n \n \nThe story does not discuss the costs of annual mammography screening, or even provide a range of costs.\u00a0 The story does not discuss any health care policy cost repercussions of breast cancer screening recommendations.\u00a0 The story does not discuss the cost of unnecessary biopsies or other treatments for women who have a false positive diagnosis via mammography (greater in women 40-49).\n ", "answer": 0}, {"article": "Doctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\n\u201cWhat\u2019s really important to say is that bipolar disorder is very difficult to treat, the burden is enormous, and these medications help keep people free of mood and anxiety symptoms and allow them to function,\u201d said Andrew A. Nierenberg, medical director of the bipolar clinic and research program at Massachusetts General Hospital.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the average cost of these drugs.\u00a0 This is important information, especially for epileptic and bipolar patients who often take medications for most of their life.\u00a0\u00a0 \nThe drugs under discussion are fairly expensive drugs (approximately. $150-200/month for the newer drugs). There are older, and less expensive medications that might work as well for some people.\u00a0 \n ", "answer": 1}, {"article": "The researchers from Harvard's T.H.\n\"The sexy headline is eat this and you'll have a lower risk of breast cancer, but I'd shift the focus to, eat more fiber because it's better for you and you'll be a healthier person and you're less likely to be obese and have chronic inflammation and other things that will reduce your risk for heart disease and cancer along the way,\" said Attai.\nDr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital, in New York, told CBS News, \"It lends support to the fact that we need to encourage people to start healthy habits earlier on.\"\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nNevertheless, Blackwell said, \"It is reasonable for pediatricians to encourage a high-fiber diet and include decreasing breast cancer risk as one of the potential benefits.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are a lot of foods you can eat to increase your dietary intake of fiber, and the story lists\u00a0apples, pears, raspberries, artichokes, green peas, broccoli, split peas, lentils, beans, whole wheat pasta, whole grain bread, brown rice, bran flakes, and oatmeal. We\u2019ll rate the story Not Applicable since most people are aware of the cost of the foods mentioned. However, we wish the story had discussed the fact that many of these healthy sources of dietary fiber are either unaffordable or unavailable to many young women, particularly those from low-income backgrounds who live in food deserts. As we noted with the NPR story, we recognize that this is a story about breast cancer risk, not about food availability. However, if a story focuses on the importance of a healthy diet, there should ideally be at least a brief acknowledgment that many people do not have access to the foods that make up a healthy diet.", "answer": 2}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the vaccine is not available, a discussion of costs is not warranted. ", "answer": 2}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the shot would cost between 4 and 7 euros. The story should have commented on the greater societal costs of implementing such a vaccination program.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss costs.\u00a0 And cost is a significant issue here.\u00a0 The AP story, by comparison, reported that \u201ccolonoscopy costs vary widely but typically exceed $1,000.\u201d", "answer": 0}, {"article": "\u201cShortly after that he told me I could relax and that I did a good job and they had retrieved the clot and just to relax and I immediately started trying to move my arm.\u201d\n\n\u201cA patient will come in, they can't speak, they can't move half their body,\u201d says neurosurgeon Dr. J Mocco, of Mt.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\n\u201cThe earlier that patients with acute ischemic stroke get to a hospital offering the appropriate treatment, the higher the likelihood is of a good outcome,\u201d said the study\u2019s lead author, Dr. Mayank Goyal of the Hotchkiss Brain Institute at the University of Calgary.\nThe intravenous drug is very effective for smaller clots, but it often fails to break up larger clots and is usually most effective when given within 4.5 hours after the first symptoms.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We found multiple studies that discuss the cost of these types of clot retrieval procedures, including this one. It would have been helpful for the reporter to have asked how much the procedures cost, on average, in the cases studied for the journal article.", "answer": 0}, {"article": "Canakinumab is already approved as Ilaris for rare autoimmune conditions.\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\n\u201cThe modest absolute clinical benefit of canakinumab cannot justify its routine use in patients with previous myocardial infarction until we understand more about the efficacy and safety trade-offs and unless a price restructuring and formal cost-effectiveness evaluation supports it,\u201d wrote Dr. Robert Harrington, chair of the Stanford University School of Medicine, in an editorial in the New England Journal of Medicine.\nZURICH (Reuters) - Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited benefits.\nWhile Narasimhan said it was too early to discuss pricing, he argued so-called PCSK9 cholesterol drugs that cost about $14,000 annually should not be relied on as a yardstick.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article does a great job of noting the cost and pricing issues inherent in the drug company\u2019s efforts to develop, test and market novel biologicals. The headlong rush to \u201cpersonalized\u201d medicine, pharmacogenetic approaches to treatment, limited resources even in wealthy nations with gold-plated insurance policies, and the opacity of drug industry research costs make it imperative to explain to the public the realities of medicine\u2019s pricing system.", "answer": 1}, {"article": "Dr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\nThe head is attached to a spike that is driven into the femur, or thigh bone, to anchor it.\nIn X-rays, many of the squeaking hips appear to be perfectly aligned.\nThat could force patients to undergo the very operation \u2014 a second replacement of the same hip joint \u2014 they had hoped to avoid by choosing ceramics.\nEach combination has known or suspected drawbacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article states that the costs are \u201cgenerally \u2026 close to $45,000.\u201d", "answer": 1}, {"article": "That took about 40 minutes a day, or 3.3 hours a week.\nThe result makes sense, since there's some previous evidence suggesting that higher-intensity exercise is tied to improving how the body processes sugar, said Neal Pire, an exercise physiologist who puts together medically based training programs at HNH Fitness in Oradell, N.J., a program of Holy Name Medical Center.\n\"The take-home message here is that if you're consuming a healthful diet and engaging with exercise consistent with the guidelines, you're going to see a benefit in your waistline and on the bathroom scale,\" said Ross.\nBottom line: All the exercisers improved, but the folks who did the best walked briskly for about 40 minutes five times a week.\nOne group worked out at low intensity, about 50 percent of maximum oxygen uptake (VO max, a measure of cardiovascular fitness), for about 31 minutes per session \u2014 enough to burn 180 calories for women and 300 for men.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Fitting exercise time into a life can be tricky if you are in poverty, working two jobs, or don\u2019t have a safe neighborhood. The story delivers an implicit acknowledgment of such concerns in the first line when it says, \u201cSome people \u2014 who are they? \u2014 have no problem fitting regular aerobic exercise into their lives.\u201d But that\u2019s not quite enough for a satisfactory rating here. The study involved \u201csupervised\u201d training sessions, which we assume means with some kind of trainer. How much would it cost to hire someone like that or join a gym that offers exercise equipment? A quick statement about those costs would\u2019ve earned the story a pass here.", "answer": 0}, {"article": "Moffitt is the No.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nInterestingly, patients who achieved a pCR had a higher immune response within their local sentinel lymph nodes.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nTheir approach involves creating the vaccine from immune cells called dendritic cells that are harvested from each individual patient to create a personalized vaccine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much this treatment costs.", "answer": 0}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nBut the lower doses used in this study (1.5 or 0.75 mcg) \"may help to improve the overall safety profile, particularly for geriatric patients,\" he said.\n\"Nocturia is very common in patients over 50 years old, and can cause significant problems by causing loss of sleep, and injury due to falls,\" said study lead author Dr. Jed Kaminetsky.\nThe researchers also found that those in the higher-dose spray group experienced a \"significant improvement\" in overall quality of life, compared with the untreated group.\nTo assess its potential in adults, the study team enlisted nearly 1,400 men and women, 50 and older, who had a history of nocturia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price or potential price of this drug is not discussed. Since there is mention of the drug already being \u201ccommonly\u201d used in children, we assume there\u2019s some idea of how much it costs\u2013though it\u2019s not made clear.", "answer": 0}, {"article": "MONDAY, Oct. 31, 2011 (HealthDay News) -- Doctors who listen to Mozart while performing colonoscopies may spot more precancerous growths, researchers suggest.\nThis was up from a baseline detection rate of 21 percent before the study began.\n\"Adenoma detection rate is linked to a reduction in colorectal cancer incidence, so it is an important quality indicator for colonoscopy,\" said O'Shea.\n\"Anything we can do to get those rates up has the potential to save lives.\nIn their small study, two doctors performed endoscopies either while listening to Mozart or with no music at all.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no extensive costs associated with listening to Mozart\u2019s music.", "answer": 2}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\n\u201cOur goal is for them to be on the most varied, nutritious diet possible.\u201d\n\nThe trickiest part is avoiding onions and garlic, the dietitians say.\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that health insurance is unlikely to cover the costs of a clinic visit with a dietitian to discuss the proper implementation of the diet, but it fails to offer an estimate of what that out-of-pocket cost might be. The story could have offered an estimate on how other approaches to IBS treatment, such as medications or probiotics, might stack up. And since food manufacturers are apparently already offering low-FODMAP products, the story would have helped readers by indicating whether those products are more costly than their \u201cregular\u201d counterparts.", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job here, noting that a treatment with Rez\u016bm costs around $2,000, and that it is often (but not always) covered by health insurance. In addition, the story notes that patients may need multiple treatments.\nAs a side note, we would like to know how this compares with costs of surgery and with costs of other minimally invasive procedures.", "answer": 1}, {"article": "Newswise \u2014 SAN FRANCISCO, March 16, 2017\u2014-Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented today at the 2017 Multidisciplinary Thoracic Cancers Symposium.\nThis high degree of precision makes SBRT particularly effective at sparing surrounding healthy tissue, which is important for tumor sites near essential organs, such as the heart and lungs.\nRecursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.\nWhile the primary treatment for early stage lung cancer is surgical removal of the tumor, some patients may not be able to tolerate surgery due to health status, advanced age or other factors.\nThe Society\u2019s mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not report the cost of stereotactic body radiation therapy (SBRT) or any alternatives a patient could consider.", "answer": 0}, {"article": "LONDON (Reuters) - In an analysis that set off a fierce debate over the health effects of salt, researchers said on Wednesday they had found no evidence that small cuts to salt intake reduce the risk of developing heart disease or dying prematurely.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\n\u201cThe people in the trials we analyzed only reduced their salt intake by a moderate amount, so the effect on blood pressure and heart disease was not large,\u201d he said.\nThe researchers said they suspected the trials conducted so far were not big enough to show any benefits to heart health, and called for large-scale studies to be carried out soon.\nThe Cochrane review attracted sharp criticism from nutrition experts.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not in question in this context.", "answer": 2}, {"article": "Depression risk was assessed using the Edinburgh Postnatal Depression Scale (EPDS) six weeks after childbirth.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nIt may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a birth with an epidural isn\u2019t mentioned. While it depends on the insurance carrier \u2014 some pass all or part of the costs of anesthesiology during birth onto consumers \u2014 the average epidural in the US\u00a0adds about $1,200\u00a0to a birth bill, with some anesthesiologist practices charging\u00a0more than $2,700\u00a0per epidural.", "answer": 0}, {"article": "The first CT scan was OK.\nA chest X-ray showed nothing suspicious.\n\"So I don't need any chemotherapy, I don't need any radiation.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nI am cancer-free,\" he says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the cost of the scan is about $300 and is generally not covered by insurance.", "answer": 1}, {"article": "What (abnormality) is going to contribute to the overall health versus something that just looks funny?\nIf proved effective, it could become the norm for identifying heart conditions that put one in 10,000 people at risk when doing top-level physical activities, researchers say.\n\"The hope would be that with data, we could get the entire system interested in participating \u2026 get funding to run a clinical trial, locally and maybe nationally.\"\n\"One of our goals is to advance the field \u2026 in areas either untouched or unappreciated as being important,\" Towbin says.\nIn the most complete test of its kind, the institute is using both an electrocardiogram and limited echocardiogram to see the rhythm and structure of the heart.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that this sort of screening would typically cost $2500 and that the cost is a challenge. The story might have made the challenge more obvious by noting that screening all high school athletes would cost $20 billion.", "answer": 1}, {"article": "\u201cI\u2019m thinking, is this the way it\u2019s going to be for the rest of my life?\nDepression is about three times more common in heart attack survivors and those hospitalized with heart problems than the general population, according to the recommendations published in the journal Circulation.\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nShe said she spent most of her time at her Englewood, Ohio, home sitting in her chair, frequently crying for no reason.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t describe the costs of depression screening nor did it mention reimbursement issues as a barrier to providing the screening.", "answer": 0}, {"article": "The designer of that treatment, Dr. Katherine A.\nIf all goes well, a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\n\nIn a trial in 2006, a patient injected with a corrective gene produced his own Factor IX but only for 10 weeks.\nTreating a patient with concentrate costs $300,000 a year, with a possible lifetime cost of $20 million, but the single required injection of the new delivery virus costs just $30,000, Dr. Katherine P. Ponder of the Washington University School of Medicine in St. Louis notes in her commentary in The New England Journal of Medicine, calling the trial \u201ca landmark study.\u201d\n\nThe patients have continued to produce their own Factor IX for up to 22 months, said Dr. Edward G. D. Tuddenham, director of the Hemophilia Center at the Royal Free Hospital in London.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\nThe delivery virus, carrying a good version of the human gene for the clotting agent known as Factor IX, was prepared by researchers at St. Jude Children\u2019s Research Hospital in Memphis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job noting the possible costs of this approach ($30,000 for a single treatment) and places it in the context of current costs ($300,000 annually).\u00a0 With an estimated incidence of hemophilia B at about 5 per 100,000 males, the cost of treating the disease worldwide is a important piece of the story.", "answer": 1}, {"article": "The Novartis pill works in a very precise way to block the action of inflammatory cells called eosinophils.\nThe latest research, published in the journal Lancet Respiratory Medicine, comes at a time of considerable innovation in asthma care, with the recent launch of new injectable drugs for severe asthma that also target eosinophils.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nLONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address how much fevipiprant might cost and how it might compete with currently available treatments. A 2013 story in the New York Times reported that asthma inhalers ranged from $50 per month for one of the oldest drugs to as much as $350, with prices being buoyed in recent years by patent extensions.", "answer": 0}, {"article": "Until today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nThe leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\n(The clip is made by Abbott, which funded the study; outside experts reviewed the trial data.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reported that \u201cthe device itself costs about $30,000, not counting the cost of the hospital and doctors: a surgeon, an interventional cardiologist and an echocardiologist, among others, all in the operating room.\u201d An idea of the total cost would have been useful, since it\u2019s likely to be far higher than $30k.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Monitoring high-risk pregnancies with ultrasound tests may help prevent some fetal and newborn deaths, a new research review finds.\nSome had flaws in their design, while in other cases the researchers failed to provide details on key elements of the study design.\nAbnormal findings indicate that the fetus may be under stress.\nIn some cases, early delivery may be the best course, but it is unclear whether other options \u2014 such as bed rest or tighter blood pressure control in a woman with high blood pressure \u2014 are effective.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not give any estimate of the cost of Doppler ultrasound examinations.", "answer": 0}, {"article": "In some instances, a combination of traditional and alternative options was the most effective.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\nA man\u2019s \u201clatency time\u201d can also become reduced later in his sexual life, and this secondary form is usually defined as ejaculation within three minutes or less.\nTogether, the two acupuncture studies found that the treatment slightly increased intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo.\nIn addition, the authors write, the studies are so different, it\u2019s tough to draw conclusions about the different options.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There were no discussions of cost here, apart from the fact that the products in question would likely be available without a prescription and hence, the costs pertaining to a doctor\u2019s visit would not\u00a0be relevant here.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned. According to the website for the STAR trial, the cost of raloxifene is about $75 per month, while tamoxifen costs about $100 per month. Because these drugs have to be taken for long periods of time, cost is an issue. ", "answer": 0}, {"article": "MONDAY, July 9, 2012 (HealthDay News) -- A daily drink combining several nutrients appears to help people with early Alzheimer's disease improve their memory, a new study suggests.\n\"You're going to be making a decision using your own funds and we would advise anybody to make sure they understand what the product offers and make sure they understand what it's going to cost.\"\n\"I don't think it has any effect on the fundamental diseases process, but we'll see,\" he said.\n\"But they don't have the kind of data we would find for a medication.\"\n\"You are making a judgment without the protections you have when dealing with a medication,\" Thies said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states \u201cThere are no plans to market Souvenaid, so the cost hasn\u2019t been established.\u201d", "answer": 1}, {"article": "WEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\nThe study included 520 youngsters with ear infections.\nAbout three-quarters of children have ear infections in their first year of life.\nThe study was published Dec. 21 in the New England Journal of Medicine.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs was included in the news story.", "answer": 0}, {"article": "We know early intervention is extremely important.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\nTUESDAY, Feb. 22, 2011 (HealthDay News) -- By analyzing patterns in the brain's electrical activity, researchers say they've been able to assess autism risk in children as young as 6 months of age.\n\"In this study, we have taken the first step in showing that there is definitive information in the electrical signals measured by EEG to distinguish normal controls from infants at high risk for developing autism,\" Bosl said.\nAnd unlike MRIs, they require no sedation, so testing could be put to widespread use, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "By saying that EEGs are \u201crelatively inexpensive, painless and safe\u201d the story skirts the entire issue of screening costs both at the individual level and at the population level. Even basic genetic screenings for couples considering having children are not covered by many insurance plans unless the couple is in a very high risk group for a particular disorder. The assumption that people might be able to just stop into a clinic and have their child scanned for very little money is naive and misleading.", "answer": 0}, {"article": "The people who do this are specially trained.\nThe procedure must start within six hours of the onset of a stroke, which means that emergency teams and hospitals will have to move fast, Powers said.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\n\"If you actually deploy or open one in the middle of a clot, it smooshes out and the clot gets caught in the chicken wire, and then you pull the whole thing out back through the artery,\" Powers said.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention, even generally, what removing a clot using these devices might cost. In a broader way, we would have welcomed discussion of how much treating strokes costs the entire health system and how risks versus benefits of different strategies may have large effects throughout the health system. For example, if this new intervention prevents disability for more patients, might it save the system those costs?", "answer": 0}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nThe researchers found that even former heavy smokers appear to have a reduced incidence of lung cancer if their initial LDCT screening is negative, suggesting that less frequent screening might be warranted.\nThey then compared those patients to other CT-scan recipients whose screenings detected an abnormality to assess any differences in lung cancer incidence and lung cancer-specific deaths.\n\"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines,\" Patz said.\nIn the first year after a negative screen and before the scheduled first annual screen, 17 patients (0.09 percent of all initial negative LDCT participants) were diagnosed with lung cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release appropriately mentioned that a changed frequency of screening could save millions of dollars in subsequent screenings and \u201creduced downstream\u201d effects of false positive tests.", "answer": 1}, {"article": "Doctors numbed the lower half of O'Brien's body.\n\"With this kind of surgery we don't cut into the muscle at all,\" Dr. Bergersaid.\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nTraditional knee surgery cuts through muscles and tendons.\nLess than two hours later the operation was over.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs associated with this type of knee replacement nor the expected lifespan for this device.", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\n\"This really fills a need for adults with moderate to severe sensorineural hearing loss,\" Marzo said.\n\"There are little things that I probably heard when I was younger, before my hearing loss, but I don't remember them,\" she said.\n\"When I wore a hearing aid, I turned it off when I got home because all the background noise was so agitating,\" said Merlo, 40.\nUnlike a hearing aid, which amplifies sounds, Esteem is a prosthetic inner-ear stimulator.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs. Cost of any new device is important as is insurance coverage.\u00a0 Neither are addressed in the story, an oversight we find difficult to understand.\u00a0 According to the manufacturers website the cost of the surgery and the device in $33,000.\u00a0 Insurance does not cover the device at the moment.\u00a0 The battery, said to need replacing every 7 years, costs approximately $6,000 and may need to be performed as early as every 3 years depending on usage per day and other factors.\u00a0 Again, these costs are not covered by insurance.", "answer": 0}, {"article": "Dr. Louis Jacques, director of the coverage and analysis group at the Centers for Medicare and Medicaid Services, said cost was not a factor and that the agency had reviewed products approved by the F.D.A.\nThe 10 voting members, mainly doctors and health policy experts, averaged 3.6 on the question of how much confidence they had that there was adequate evidence to conclude that Provenge significantly prolongs survival.\nOne criticism of the drug was filed by a law firm, Willkie Farr & Gallagher, on behalf of a client who the law firm said wanted to remain anonymous because of the \u201cpublic vilification of anyone that questions Provenge.\u201d\nThe drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\n\u201cOne has to wonder if today\u2019s meeting is about something other than science, namely the cost,\u201d Brad Loncar, an investor in Dendreon whose grandfather died of prostate cancer, told the Medicare Coverage Advisory Committee on Wednesday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided the costs for the FDA approved Provenge ($93,000/patient); as XL184 is under study and not available for sale, there was no information about what its costs might be.", "answer": 1}, {"article": "Several of these differences were associated with worse performance months later in cognitive and behavioral tests.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nThe study was part of the ongoing Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) project, through which Mukherjee and study co-author Geoffrey Manley, MD, PhD, vice chairman of neurological surgery at UCSF and chief of neurosurgery at Zuckerberg San Francisco General Hospital, along with collaborators from many other research institutions are leading studies and gathering common data across research sites to more quickly advance TBI research.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Medical imaging studies are known to be expensive, and MRIs are no exception.\u00a0Functional magnetic resonance imaging (fMRI) is a relatively new procedure that uses MRI techniques to measure metabolic changes in an active part of the brain. MRIs focus on a body part\u2019s anatomical structure, while fMRIs mainly concentrate on its metabolic processes.\nConsumer websites estimate an MRI to cost between $400 and $3,500, depending on the type of procedure, body part\u00a0and center location. According to the Healthcare Bluebook, a brain MRI (with or without contrast) should cost around $1,212.\nSince the news release doesn\u2019t discuss these costs, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "The average age was 53 when the study began.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\nAll the women had been successfully treated for early-stage breast cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the cost of fresh fruit and vegetables compared to the typical American diet of largely processed/fast foods.\u00a0 But it\u2019s safe to assume most readers know the costs from their regular grocery shopping. ", "answer": 2}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nFor example, immunotherapy drugs can now tag cancer cells so that it's easier for a patient's own immune system to identify and attack them.\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\n\"Accelerated approval\" means that the FDA has fast-tracked the process of getting drugs to patients before the usual clinical trials are completed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Surprise \u2014 or at least it will be to readers of this Newsweek story: The list price of the drug is nearly $400,000 a year, as a more complete story in Forbes reported. The company marketing the drug said it will help patients pay their share of the cost.", "answer": 0}, {"article": "\"We show that patients taking anticoagulant [blood thinning] medication had better outcomes with regards to prostate cancer death and that this benefit was most prominent in patients who had high-risk disease,\" said study lead author Dr. Kevin Choe, a radiation oncologist with the University of Texas Southwestern Medical School in Dallas.\nAfter an average follow-up of about seven years, only 1 percent of men who had been taking an anticoagulant had died versus 4 percent of those in the control group.\n\"If the figures from the interim analysis are similar to the final analysis, we would expect a 43 percent reduction in the chances of death from prostate cancer in men with this regimen,\" he said.\n\"The standard treatment for localized, high-risk prostate cancer for people who are fit for radiotherapy should be a combination of hormone therapy plus radiotherapy.\"\nIn looking at the records of more than 5,000 men with prostate cancer, 2,000 of whom were taking aspirin or another blood-thinning drug, researchers presenting at the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego report that the risk of dying from the cancer was reduced by more than half.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nA story that says that aspirin seemed to account for more benefit than far more expensive drugs certainly should address the cost differential between the inexpensive \"ubiquitous\u2026pedestrian\" drug and others. Cost was never mentioned. ", "answer": 0}, {"article": "Urba is a co-author of the\n\non ipilimumab published in the New England Journal of Medicine Saturday.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nWhile far from a cure, the treatment is the first to improve survival in people with melanoma that has spread, or metastasized, says Dr. Walter Urba, director of cancer research at the Providence Cancer Center.\nSome patients received ipilimumab alone, others it combined with a cancer vaccine called gp100, and a third group received only the cancer vaccine.\nThe 47-year-old pre-school teacher from Eugene was stunned when her biopsy came back positive for melanoma \u2013the most life-threatening form of skin cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 Is this OK because this is still experimental?\u00a0 We don\u2019t think so, not when the drug company is allowed to project possible approval within a year.\u00a0 Much better to say, as a Wall Street Journal story did, that the company said it was too early to set pricing.\u00a0 But to ignore costs entirely is a mistake in our view. ", "answer": 0}, {"article": "The research was funded by an Incubator grant from MS Research Australia.\n\"This is the first demonstration that micro-RNAs associated with circulating exosomes in blood are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtypes with a high degree of accuracy,\" said Associate Professor Michael Buckland, Head of the Department of Neuropathology at RPA Hospital and the Brain and Mind Centre, University of Sydney.\nGiven exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu.\n\"This, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS.\n\"In studying the blood exosomes of healthy volunteers and patients with MS, the research team identified a 'molecular signature' of MS that not only correctly diagnoses MS, but also discriminates between patients with different stages of disease,\" Associate Professor Buckland said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this research is basic stuff, a source in the release is already talking about its diagnostic value. Claims of that sort should be accompanied by at least cursory information about possible cost.\nIn reality, this test is so far from clinical use that estimating cost would be difficult.", "answer": 0}, {"article": "Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\nBacteria are known to quickly acquire resistance against antibiotics, but to our knowledge, bacteria do not develop resistance against electroceuticals.\u201d To test the experimental design, Roy and a team of scientists developed an animal model to mimic the skin function of a person suffering from metabolic syndrome \u2013 obesity, high blood pressure, high blood sugar - which mirrors the type of patient that typically develops chronic wounds.\n\u201cThe prototype dressing mimics this physiological process, and while it has proven to create an optimal environment where chronic wounds can heal, we are always looking for new ways to keep pathogens under better control.\u201d\n\nRoy notes that chronic wounds are particularly susceptible to infection because bacteria, which at times are free floating within a wound \u2013 can sometimes mobilize, creating colonies covered by a thick sticky coating called a biofilm.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "In general, if a product is\u00a0far from deployment, an\u00a0estimate of its cost\u00a0could seem\u00a0premature. However, this release contains the following statement:\n\u201cThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\u201d\u00a0\nAnd if it\u2019s not too soon to make a declaration like that, it\u2019s not too soon to estimate what the cost might be. The release might have looked to the cost of existing FDA-approved WEDs to suggest an estimate. For example, this 2015 article on WED in Advances in Wound Care journal by Ohio State University researchers suggests a cost-savings over other wound care methods by reducing the number of dressing changes required per week.", "answer": 0}, {"article": "This news release is available in French.\nIn a study recently published in BMJ Open Respiratory Research, experts from Concordia University, the H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and several other institutions* analyzed the exercise habits of 643 participants who had been diagnosed with asthma.\n\"The issue of exercise-induced bronchospasm is real -- but if you use your releaver medication, blue puffer, before you exercise, and then take the time to cool down afterwards, you should be okay,\" he says.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\n\"Those numbers reflect the population in general,\" says Bacon, who is also director of the Centre de r\u00e9adaptation Jean-Jacques-Gauthier at Hopital du Sacr\u00e9-Coeur.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Physical activity was broadly defined in the study and included activities such as walking, dancing and swimming. We rate this Not Applicable, since cost is not a major factor here. But we need to keep in mind that this piece was recommending 30 min per day of activity. That\u2019s 3.5 hours per week. This is time that could be spent doing other things (including paying work) and there may be a cost \u2013 either positive or negative \u2013 associated with it. In theory, if exercise does in fact reduce asthma symptoms, one could argue that patients with asthma who exercised would have lower costs of care for things such as emergency visits. But this, of course, is unproven.", "answer": 2}, {"article": "The study was funded by the Celladon Corp. of La Jolla, Calif.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\n\"The therapy works by replenishing levels of an enzyme necessary for the heart to pump more efficiently by introducing the gene for SERCA2a, which is depressed in these patients.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\nTUESDAY, Nov. 16, 2010 (HealthDay News) -- By substituting a healthy gene for a defective one, scientists were able to partially restore the heart's ability to pump in 39 heart failure patients, researchers report.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this gene therapy has barely begun the long road of clinical trials and so we won\u2019t hold this story to the expectation that it discuss costs, the story could have offered readers at least some general comments about how the costs of this sort of gene therapy might compare with conventional treatments for heart failure.", "answer": 2}, {"article": "Newswise \u2014 Bethesda, Md.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nStatin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no information about the cost of statin therapy. This class of medicines includes a number of generic formulations that are relatively inexpensive. The release refers to statins as cost-effective. This reference to cost probably refers to their use for preventing heart disease. Whether these agents are cost-effective for treating liver disease is unknown.", "answer": 0}, {"article": "When it comes to the most popular type of osteoporosis treatment, bisphosphonates, the question is not so much about how much to take, but whether there are harmful consequences from long-term use.\nIn a statement, the FDA said it is reviewing the data and is considering changing the labeling on bisphosphonates.\nIt also recommended that patients report groin or thigh pain to their physicians, but did not suggest they stop taking the medications unless ordered to do so by their doctors.\nOne of the best studies the panel found focused on healthy women over age 65 and concluded that screenings spaced eight years or less apart did not make much of a difference in identifying which women would be more at risk for fractures.\nIt also called on the US Food and Drug Administration to change medication labeling to alert physicians and patients to the possibility of these unusual fractures, and to urge awareness of possible warning signs: prolonged groin or thigh pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss the costs of various management approaches. A simple statement about the costs of screening and the annual costs of bisphosphonates would have been useful.\n\u00a0\n ", "answer": 0}, {"article": "Castle said there could be a few reasons that doctors opt to screen women more often than is recommended.\nIn those scenarios, a woman age 30 to 60 has had two consecutive normal Pap tests but no HPV tests; two normal Paps and a negative HPV test; or a negative HPV test but no recent Pap tests.\n\u201cA woman should say, \u2018What screening tests are you doing on me?\u2019\u201d\n\nAnd if doctors want women to come back again next year, women should ask them why, Saraiya said.\n\u201cWe need to shift toward the wellness visit as opposed to, \u2018You have to come in here every year for a Pap,\u2019\u201d Castle said.\nWomen should talk to their doctors about screening, especially if they think they are being screened too often, researchers added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story referred to \u201cextra costs women may incur to get childcare and make it to the doctor\u2019s office \u2014 plus the costs to a strained healthcare system of ordering more tests.\u201d", "answer": 1}, {"article": "The other half got a heart health education program.\nThe Chinese developed tai chi thousands of years ago, but it has recently piqued the interest of Western medicine as an alternative mind-body therapy to treat disease.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "How much would it cost to replicate the\u00a0experience of participants in this study who received tai chi training? And would the classes be covered by insurance? These are important questions for people with heart failure, who tend to be older and are\u00a0often living on fixed incomes. But the story doesn\u2019t tell us.\u00a0It wouldn\u2019t have been hard to estimate\u00a0cost ranges for a 12 week course that meets twice weekly as in the intervention.", "answer": 0}, {"article": "Editor's note: To obtain a copy of the Cancer Prevention Research paper, \"Effect of vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial,\" or to arrange an interview with corresponding author Catherine Duggan, please contact: Kristen Woodward in Fred Hutch media relations, kwoodwar@fredhutch.org or 206-667-5095.\nHalf of the study participants were randomly selected to receive 2,000 IU of vitamin D daily for the duration of the year-long trial, and the other half received an identical-appearing placebo, or dummy vitamin.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\nHowever, it has not been known whether combining the two -- weight loss and vitamin D -- would further boost this effect.\n\"Weight loss reduces inflammation, and thus represents another mechanism for reducing cancer risk,\" Duggan said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention\u00a0of the potential costs of screening women for vitamin D levels (as encouraged in the release in a statement from the principal investigator) or the cost of supplementation.", "answer": 0}, {"article": "TUESDAY, June 14, 2011 (HealthDay News) -- Not only do cooler heads prevail, they might also sleep better, according to researchers who say they have developed a cooling cap that, when worn during sleeptime, may help treat insomnia.\n\"It does reduce brain metabolism in the frontal lobes, and it improves sleep.\"\n\"It's in the brain where the chemical changes are occurring that lead to sleep,\" he said.\nThe U.S. National Heart, Lung, and Blood Institute has more on insomnia.\nParticipants slept for two nights in a sleep lab with no cap; two nights with the cap set at a \"neutral\" temperature (about 86 degrees Fahrenheit); two nights at a moderately cool temperature (72 degrees Fahrenheit); and two nights with the coolest temperature (57 degrees Fahrenheit).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs but that\u2019s understandable at this early stage of development.", "answer": 2}, {"article": "Fleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nNot a huge dent, but a significant one.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nThe drug is not for women whose prior premature births were of twins or other multiple births, or who are carrying more than one fetus in their current pregnancy.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs, something we always look for and wish would be provided.", "answer": 0}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis will enable doctors to identify those women who are at greatest risk of having a baby with a birth defect, and ensure they are getting sufficient vitamin B3.\nVitamin B3 is required to make NAD and is typically found in meats and green vegetables as well as vegemite.\nAt the heart of the paramount discovery is the dietary supplement vitamin B3, also known as niacin.\nhttp://www.nejm.org/\n\nThis study would not have been possible without the generous support of the Chain Reaction Foundation, the Key Foundation and the National Health and Medical Research Council.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the supplement (vitamin B3, also known as niacin) is not mentioned. A quick Google search shows that you can buy it online for less than $10. ", "answer": 0}, {"article": "That also was not significantly different.\nOver the past 20 years, studies showed that if a person having a stroke gets a thrombolytic drug within three hours of when the symptoms start (4\u00bd hours for certain patients), the process can be reversed and a lifetime of disability avoided.\n\u201cFor the stroke field, this is a really big deal,\u201d Walter Koroshetz, deputy director of the National Institute of Neurological Disorders and Stroke, said of the findings, which were presented over three days at the International Stroke Conference in Hono\u00adlulu.\nIf flow isn\u2019t restored quickly, brain tissue and the functions it controls \u2014 movement, speech, cognition \u2014 are damaged or can die.\nPractitioners hoped that \u201cendovascular treatment,\u201d in which a catheter is threaded into a blocked artery and the clot pulled out, would do for stroke patients what it has done for heart attack patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nice job on this.\u00a0 The story reported:\n\u201cInsurance companies and Medicare, the health insurer for the elderly, already cover the endovascular procedure. It costs about $23,000 compared with $11,000 for acute stroke treatment using intravenous clot-dissolving drugs, known as thrombolytics.\u201d\n(and)\n\u201cWill it change practice? That\u2019s a good question,\u201d said Koroshetz. \u201cThe payers may look at this and wonder if they should continue paying for these procedures. If it gets to that point, then clearly things will change.\u201d", "answer": 1}, {"article": "The hypotensive effect was dependent on time.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nMoreover, the higher the mean systolic BP was during the first week, the more it dropped on the second week of melatonin administration.\nOver the next 2 weeks, the seniors were administered a low dose of melatonin (1.5 mg) each day by night at 10:30 p.m. On the third week data were monitored again.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost. Melatonin is widely available over-the-counter and a range of costs should be reported. According to GoodRX, a bottle of 100 1mg melatonin tablets cost around $7.\n(We acknowledge that the study was conducted in a country that has a different health system including different price supports. But since the news release is aimed at a U.S. audience, the cost criteria \u2014 as well as availability and alternatives that apply in the US but not elsewhere \u2014 are fair game.)", "answer": 0}, {"article": "The number could double by 2050.\n\u201cThe number of dementia cases could drop by half.\u201d\n\nNov. 20: MRI scan may predict which people will develop Alzheimer's disease\n\nLambracht-Washington said the study marks major progress toward a safe and effective vaccine.\nMore: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nThe vaccine works by prompting the body to produce antibodies inhibiting the buildup of amyloid and tau, two proteins that are hallmarks of the degenerative brain disease.\nThe vaccine is one of several promising treatments aimed at reducing the buildup of those substances before they become deadly plaques and tangles in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs.\nIt might be difficult to estimate the cost of a vaccine that hasn\u2019t yet been tested in humans. However, the story could have pointed out that at least some researchers have begun to consider the financial impact of treatments that are in development to slow or delay Alzheimer\u2019s.\nFor example, British study released in March estimated that a hypothetical vaccine given to everyone over 50 that delayed the onset of Alzheimer\u2019s by five years would yield a savings of about $9,000 in health, social care, and unpaid care costs over a person\u2019s life. It estimated that the justified cost of such a vaccine, if it had to be given every two years, would be $1,175 per dose. However, those figures would drop to a lifetime savings of $2,200 and a justified cost of $293 per dose if the vaccine delayed onset of disease by just one year.", "answer": 0}, {"article": "\u201cThis outcome is more than we hoped for.\nThe bottom line is we now have clear evidence that lowering inflammation through this pathway lowers rates of heart attack and stroke with no change at all in cholesterol.\u201d\n\nAbout a quarter of people who have heart attacks will have another heart event even if they keep their cholesterol at recommended levels.\nThe cancer data is still preliminary, and needs to be confirmed with additional studies, but it\u2019s encouraging, says Dr. Otis Bradley, chief medical officer for the American Cancer Society, who was not involved in the study.\nWhile the connection between heart disease and cancer may not seem obvious, Ridker says that many people who have had heart problems, like those in the study, are former or current smokers, since smoking is a risk factor for heart attacks.\nMORE: Why Inflammation in Your Mouth May Raise Your Risk of Cancer\n\nBut in a new paper published in the and presented at the European Society of Cardiology meeting, scientists say they now have proof that lowering inflammation alone, without affecting cholesterol, also reduces the risk of a heart attack.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear enough that far more must be done at the bench and bedside to bring this drug into first line use, even for subsets of people who already have had heart attacks or who have cancer. One reason is the $200,000 per year price tag already in place for the drug\u2019s use in some rare autoimmune disorders tied to its anti-inflammatory effects. The pricing challenges are a substantial and enlightening part of the Reuters treatment of the study, which we also reviewed, but nowhere to be found in this TIME article.", "answer": 0}, {"article": "CBS News correspondent Kelly Wallace reports Kate Miller's 15-year-old son Cody killed himself just 17 days after starting the drug.\nFDA said it is also reviewing reports of side effects with those drugs.\nIn clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.\nHis mom now believes that Singulair cost him his life.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price of the drug is not reported. ", "answer": 0}, {"article": "For more information, visit http://www.\nThe amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\nIn the trial, the therapeutic reduced MDD symptoms by 42 percent in the experimental group after six weeks compared to 15.7 percent in the control group, which was given a similar task using simple shapes instead of emotions.\nIt's exciting to have the opportunity to test the program within a large health care system such as Mount Sinai.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. The release would have been stronger if it allowed readers to see the economic context of this new therapy.", "answer": 0}, {"article": "Now we can get a diagnosis sooner.\"\n\"In the past, we would have had to wait to diagnose Parkinson's or chosen different medications to test, which might have had different side effects, and this would have delayed the timely diagnosis of Parkinson's,\" Xie said.\n\"I was thrilled there was something that could positively tell me I had Parkinson's because everybody had guessed what I had,\" said Ray Ramas, 56, who in June became the first patient at Central DuPage to undergo the scan.\nThe DaTscan injection was first used in Europe a decade ago, and GE Healthcare made it available to U.S. hospitals in late June.\nDuring an FDA advisory panel meeting, committee members were mostly positive about DaTscan, though one neurologist objected to the average $1,500 cost of a scan versus $150 for a month's supply of carbidopa or levodopa medications for a Parkinson's patient, according to Medscape Medical News.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nYes, the story reports that a DaTscan costs about $1500. Oddly, instead of reporting what the hospitals featured in the story charge for a scan, the story attributes the price estimate to a quote taken from an article by Medscape Medical News. But there is a much higher price listed on the web site of the Michael J. Fox Foundation for Parkinson\u2019s Research, which estimates a DaTscan costs almost $3000. Still, because the story does address cost we will give it credit on this criterion.\n\nMichael J. Fox Foundation for Parkinson\u2019s Research page on DaTscan:\nhttp://www.michaeljfox.org/newsEvents_parkinsonsInTheNews_article.cfm?ID=694", "answer": 1}, {"article": "But as for whether they\u2019ll help a client prepare for an important presentation?\n\u201cThe only difference is it\u2019s kind of a beautiful environment.\u201d\n\nCustomers at Evolved Science shell out anywhere from $325 to $875 for an infusion.\nPatients kick back in cream-colored chairs together while they\u2019re hooked up to IVs in the \u201cinfusion lounge.\u201d\n\n\u201cIt doesn\u2019t look like a doctor\u2019s office.\n\u201cThere is not not substantial evidence that vitamin supplements have a large impact on cognitive function,\u201d said Dr. Francine Grodstein, a public health researcher at Harvard who has studied the subject.\nAnd though the IV lends a medical air to the procedure, the infusions suffer from the same problem as many supplements taken orally \u2014 there isn\u2019t any robust evidence to back up their health claims.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides the retail price for the supplements described in the story.\u00a0 (Between $325 and $875 for an infusion.)\u00a0That\u2019s great, but it would have been even better to know the mark-up. How much the ingredients cost vs. how much is charged to the patient? And does insurance cover this, ever?", "answer": 1}, {"article": "The agreement was to publish no matter the results.\n\"I was surprised to see the added benefit [of the avocado],\" Penny Kris-Etherton, a nutrition scientist at Penn State and the lead author of the study, tells us.\"\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\nThe only difference between the two was the avocado \u2014 the other diet had the same amount of fat from other sources.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Avocados are relatively expensive \u2014 a fact pointed out by several competing stories that covered this study, but not this story. Eating one per day regularly could cost in the ballpark of $30 per month, which may be out of reach for some people.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story does not explicitly note the cost of the two commercially available tests, it does provide substantial context about the rising popularity of the tests among clinicians and pregnant women, as well as cautionary notes about their use from both those involved in the study and an expert who wrote an accompanying editorial to the JAMA article.", "answer": 0}, {"article": "The drug was approved by the FDA in the mid-1990s.\nA second study, this one a randomized controlled trial involving a very small number of humans (23), found that patients with an early form of colorectal cancer who were treated with metformin did see a decrease in possible cancer-related growth, compared with participants not taking the drug.\nMetformin (originally marketed as Glucophage, though it is now available as an inexpensive generic) has been in use for more than two decades and is currently prescribed to 40 million Americans.\n\"All other things being equal, many diabetics face a choice of oral agents, and early evidence that metformin may have an effect on the oncology side may increasingly play a role in decision-making,\" said Dr. Michael Pollack, professor of medicine and oncology at McGill University in Montreal.\nWEDNESDAY, Sept. 1, 2010 (HealthDay News) -- A drug widely used to treat high blood sugar in type 2 diabetics may hold some promise in the prevention of tobacco-induced lung cancer, according to extremely preliminary findings in a mouse study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that \"Metformin (originally marketed as Glucophage, though it is now available as an inexpensive generic) has been in use for more than two decades and is currently prescribed to 40 million Americans.\" Good enough to get a satisfactory score. ", "answer": 1}, {"article": "Tobacco kills one-third to one-half of those who smoke.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\nThe World Health Organization says tobacco is the leading preventable cause of death globally, killing more than 5 million people each year from heart disease, cancer and lung disease.\nOther studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention the cost of metformin, which is relatively cheap as a generic, thus adding to the potential appeal of this approach.\u00a0 This should have been mentioned. ", "answer": 0}, {"article": "\u201cThis study clearly opens the field ...\nAn independent Nordic study, published at ESMO on Sunday, revealed 566 patients who were given Erbitux plus a three-drug chemotherapy regimen called FLOX, in first-line treatment for bowel cancer, did not live longer or gain any significant extra benefit to those on chemotherapy alone.\nErbitux, known generically as cetuximab, also more than doubled the median time before the patients\u2019 disease worsened, to 3.7 months from 1.5 months.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\nAdding Erbitux to cisplatin, a platinum-based chemotherapy, doubled the tumor response rate and the length of time patients lived without their disease worsening, compared with giving cisplatin on its own, in the Phase II trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "According to the story, sales for this drug were $1.7 billion last year; however, we don\u2019t know how much an individual person can expect to pay \u2013 information it would have been easy for Reuters to find and to include in the story.\u00a0 ", "answer": 0}, {"article": "Her team reviewed MRI images from 130 patients treated for clot-caused strokes at Sainte-Anne Hospital in Paris between May 2006 and October 2008.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nThe MRI is \"trying to act as a surrogate clock,\" said Kallmes, who edited Oppenheim's journal article.\nA study in The Lancet Neurology also found that a slight increase in deaths and bleeding in an extended treatment group over a three-month follow-up period underlined the notion that treatment within 3 hours -- although not required -- is still optimal.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs \u2013 not for the individual and not for health planners and society. As we discussed in the \u201cavailability\u201d criterion above, this is an important question.", "answer": 0}, {"article": "New blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\nA multicenter study validating the accuracy of the new blood tests, \"Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects,\" was published this week in the journal PLOS ONE.\n\"Most IBS patients have been told at one time or another that the disease was psychological, all in their head,\" said Pimentel.\nThe tests are marketed under the name IBSchek\u2122 and are produced by Commonwealth Laboratories Inc., in Salem, Massachusetts.\nThe blood tests identified the two antibodies associated with IBS -- anti-Cdtb and anti-vinculin -- with greater than 90 percent certainty.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of the IBS diagnostic tests at all. A consumer website for the tests, which are sold by Commonwealth Laboratories Inc., also did not include information about the cost of the tests.", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \u201cHonor Roll\u201d of best hospitals in America, ranked No.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\n\u201cHealth care utilization is extremely high once cancer progresses, with hospital readmission rates as high as 40 percent and death in the acute care setting ranging from 30-50 percent \u2013 both measures of poor-quality cancer care.\u201d\n\nTo improve the quality of care, researchers at the Icahn School of Medicine developed standardized criteria or \u201ctriggers\u201d for palliative care consultation for patients admitted to the cancer unit at The Mount Sinai Hospital.\n\u201cAs cancer progresses, patients are often at high risk for physical pain and emotional distress,\u201d said Cardinale B. Smith, MD, MSCR, Associate Professor of Medicine (Hematology and Medical Oncology), and of Geriatrics and Palliative Medicine, at the Icahn School of Medicine at Mount Sinai.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes several general statements about the costs of not referring patients early to palliative care.\nIt\u2019s not clear whether the cost savings at a large hospital like Mount Sinai would carry over to smaller hospitals across the country that might not have the requisite staff already in place. Additionally, a\u00a0statement about the implications of costs incurred by patients for early palliative care would improve the release.", "answer": 1}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nRSV is the major cause of hospitalization in young children under age 2 and is an increasingly problematic infection in adults with chronic lung disease, the elderly, and those with weakened immune systems.\nThere is no vaccine or easy, effective treatment for RSV.\nResearchers say that until now, the function of POPG has been unclear.\nPOPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs weren\u2019t discussed and we can understand why with something that is only in the pre-human testing phase. ", "answer": 2}, {"article": "The stent was approved in Europe in January, but will not be widely available there until late next year.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\nDuring the same period, no blood clots were reported among patients who were far enough along in testing to be evaluated in the 101-patient study.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\nHe said Absorb and stents like it will likely be the next generation of stents and ultimately improve outcomes for patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\nThe Wall Street Journal, by comparison, at least reported:\u00a0\u201cAbbott expects to charge more for the Absorb device than the permanent, medicated stents currently available, which cost around $1,500 to $2,000.\u201d", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nThe current treatment is injection with the drug sumatriptan, but frequent use of the drug isn't recommended because of the risk of adverse effects.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\nThis new study included 76 adult patients, aged 18 to 70, with either episodic cluster headache (57) or chronic cluster headache (19).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention costs for either oxygen treatment or the conventional treatment, an injection with sumatriptan. ", "answer": 0}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were discussed, but the counseling component indeed carries a price tag. It\u2019s critical for readers to understand what that would cost, in general terms.", "answer": 0}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Especially in the WSJ, we would expect some mention of the extraordinarily high health care costs that can result from intensive treatment. The decision about which treatment is best in any particular baby\u2019s case should not be driven by costs, of course, but it is important to acknowledge the cost issue for this as well as for other health conditions.", "answer": 0}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no information about the costs of this medication.", "answer": 0}, {"article": "Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A.\nThe F.D.A.\u2019s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work.\nCancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs.\nThe shares were up more than 130 percent for the day, closing at $16.99.\nAnd it had been intended to measure something different \u2014 not whether Provenge prolonged life, but whether it delayed the worsening of cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story anticipates approval and comments on the drug maker\u2019s stock price, it fails to anticipate the drug\u2019s cost or comment on the expense required to extend life by several months. ", "answer": 0}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nPresented at the American Diabetes Association's 77th Scientific Sessions on June 11, 2017, the additional research includes an examination of patients in the Prevencion Dieta Mediterranea (PREDIMED Study), a Randomized Trial of a Low-CHO Diet for Obesity (CHO Study), and The Healthy Weight for Living Study.\nThe study, \"Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials,\" found that fasting blood sugar and/or fasting insulin can be used to select the optimal diet and to predict weight loss, particularly for people with prediabetes or diabetes.\n\"Recognizing fasting plasma glucose as a key biomarker enables a new interpretation of the data from many previous studies, which could potentially lead to a breakthrough in personalized nutrition,\" said Arne Astrup, M.D., Head of Department of Nutrition, Exercise and Sports at University of Copenhagen.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives no indication of how expensive it would be for the average person to use these markers for customizing their weight loss program. There is no mention of how much the testing would cost, (and of importance to US audiences, whether insurance would cover the expense), how often patients would need to be tested in order to ensure efficient weight loss, and what fees would be charged by doctors and dietitians to interpret the results and guide the weight loss effort.", "answer": 0}, {"article": "\"Before, I couldn't even function.\nThere are some promising findings involving rats and one 2014 JAMA study showing that states with medical marijuana laws had nearly 25 percent fewer opioid-related overdose deaths than those without, but even a co-author on that study said it would be wrong to use the findings to make the case for cannabis as a treatment option.\nThe research falls short of concluding marijuana helps wean people off opioids - Vicodin, Oxycontin and related painkillers - and heroin, though.\n\"It's hard to argue against anecdotal evidence when you are in the middle of a crisis,\" said Patricia Hymanson, a York, Maine, neurologist who has taken a leave of absence to serve in the state House.\nTired of feeling \"like a zombie,\" the 37-year-old mother of two decided to quit cold turkey, which she said brought on convulsions and other withdrawal symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does a disservice by not mentioning the costs of medical marijuana, even if it is hard to estimate it. If cannabis becomes a major substitute for opioids, the economic implications of this could be huge both for individuals and society.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions these tests are available for $89, and that a company also charges\u00a0$395 to get the panel of all 92 telomeres.", "answer": 1}, {"article": "The number of deaths caused by the condition dropped only little, however: from 12.3 per 100,000 in 1998 to 11.9 per 100,000 in 2006.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\n\u201cI think doctors should think carefully about the pretest probability of a pulmonary embolism before they order this test,\u201d Wiener told Reuters Health.\nAfter 1998, that number rose to 112 per 100,000.\nIn the years before 1998, when the technique was introduced, 62 per 100,000 Americans were diagnosed with a pulmonary embolism annually.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost \u2013 a signficant issue in the context of alleged overdiagnosis.", "answer": 0}, {"article": "This week, specialty insurance administrator Magellan Behavioral Health Inc. issued medical necessity guidelines for TMS treatment and will provide coverage effective Jan. 1.\n\"Generally speaking, just because a device, procedure or medication has been approved or is deemed to be safe by some entities does not mean that it is automatically covered,\" BlueCross BlueShield spokeswoman Kelly Allen said.\n\"We had several patients who were headed toward the hospital, who had this treatment and were able to avoid that,\" said Dr. Scott West, a psychiatrist who pioneered the treatment in Nashville 2 and one-half years ago.\n\"I have a room in my house in which I had stacked boxes from when we moved 10 years ago that I wanted to get to, but I couldn't do it,\" the Centerville woman said.\n\"When this large magnet pulses repetitively, it causes an electromagnetic field which then passes through the skull and stimulates the brain tissue itself,\" said West, explaining a cascading effect that results in the interior nerve fibers connecting better.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides the reader with information on the cost so it meets the criterion. \u00a0We would have liked a bit more information. \u00a0For example, how durable is the response and will patients need repeated treatments? Based on the literature to date, patients may need to undergo treatment every 2-3 months. \u00a0We are told that each treatment costs about $400 and the total cost is $8-12,000. \u00a0That means each patients receives 20-30 treatments. \u00a0There are ancillary costs associated with each trip that we would have liked to have included. Nonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is an unusual story, not directly about a therapy that patients choose or buy. But we still think the price of the device \u2014 at a minimum \u2014 should be included. The cost of the procedure is also relevant, but not reported on.", "answer": 0}, {"article": "\"The interesting thing about the Safety Planning Intervention is that it is a relatively brief intervention and can be used in a lot of different [health care] settings,\" says Brian Ahmedani, director of behavioral health research at the Henry Ford Health System in Detroit, who wasn't involved in the new study.\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\nThis is the first large-scale study of the Safety Planning Intervention, which Stanley and her group developed in 2008 and which has been adopted at hospitals and clinics around the country.\n\"It is a brief intervention that hospital workers, primary care staff, outpatient behavioral health, can all be trained in to utilize,\" she says.\nFor example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told the intervention takes a few minutes up to two hours for nurses or social workers to administer when a patient comes to the emergency room after a suicide attempt. We assume this counseling is provided at no additional cost, but we\u2019d like to know for certain. One possible additional cost is having a delegated staff person in the ED at all times to\u00a0accommodate these patients. Also, there may be cost savings in not having these patients wait for a full psychiatric evaluation by a psychiatrist or a psychiatric social worker or nurse.", "answer": 0}, {"article": "For starters, Blank says, circumcision helps baby boys pretty much immediately.\nIt's all the same couple of studies that have been regurgitated and reprogrammed.\n\"They act as though there's this huge body of literature.\nTo do that is a human rights violation and an ethical travesty,\" says Georgeanne Chapin of the anti-circumcision group Intact America.\n\"Those families who choose circumcision should have access to circumcision.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was mentioned as a barrier for some people but no actual cost estimates were given in the story.\u00a0 AP\u2019s story gave a CDC estimate of nationwide costs ranging from $200-600.", "answer": 0}, {"article": "The trial was registered at http://www.\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\nAbout the Journal of Orthopaedic & Sports Physical Therapy\n\nThe Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae) publishes scientifically rigorous, clinically relevant content for physical therapists and others in the health care community to advance musculoskeletal and sports-related practice globally.\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\nAs a result, \"the identification of a comparable treatment alternative with minimal side effects, such as dry needling, offers valuable clinical advantages,\" she says.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs for either steroid injections or dry needling. According to costhelper.com, the cost of a steroid injection runs $100 to $300, not including the cost of a doctor\u2019s office visit. Dry needling is considerably less expensive but typically requires more frequent treatments. We found one Kansas physical therapy practice that charges $25 for the first treatment and $20 for additional visits. Both may be covered by insurance.", "answer": 0}, {"article": "Five of the participants met the criteria for clinical response and remission.\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n\"The purpose of our study was to investigate the effects of ketamine for TRD in younger patients for whom this indication for ketamine administration is not well studied,\" Mark Roback, a professor of pediatrics at the University of Minnesota, told Newsweek.\nResearchers from the University of Minnesota (UM) and the nonprofit Mayo Clinic found that ketamine caused an average decrease of 42 percent on the Children\u2019s Depression Rating Scale (CDRS)\u2014the most widely used rating scale in research trials for assessing the severity of depression and change in depressive symptoms among adolescents.\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of ketamine infusions, which can be expensive.\u00a0 A quick internet search yields costs of between $400 to $800 per infusion. Therefore, the six infusions used in this study would cost\u00a0 a family $2,400 to $4,800.\u00a0 And since ketamine is not FDA-approved for treating depression, insurance companies probably wouldn\u2019t cover it.\u00a0 Given the heightened concern that parents feel for their adolescents suffering from depression that doesn\u2019t respond to conventional drug treatments, information on the costs presented by this new approach is warranted.", "answer": 0}, {"article": "Further,Dr.\n\u201cIt\u2019s wonderful to have this option to offer this special set of patients.\u201d About UT Southwestern Medical CenterUT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nFrank Brown of Dallas, grandfather of six and the owner of Frank\u2019s Wrecker Service in Dallas, has familial hypercholesterolemia, an inherited condition that causes high levels of cholesterol, especially low-density lipoprotein (LDL) cholesterol or \u201cbad cholesterol.\u201d High levels of LDL cholesterol are strongly associated with heart disease.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. While the release does not tell us which of the two new drugs the patient took, it does tell us that he took either evolocumab (sold under the trade name Repatha) or alirocumab (sold under the trade name Praluent). Both drugs are given via injection either once or twice a month. According to press materials issued when Repatha was approved by the FDA in August 2015, \u201cThe U.S. Wholesale Acquisition Cost (WAC) price of Repatha is $542.31 for one 140 mg single-use prefilled SureClick autoinjector or prefilled syringe, or $14,100 annually for the every two weeks administration.\u201d That\u2019s not chump change. According to press materials issued when the FDA approved Praluent last July, \u201cThe U.S. WAC price of Praluent is $40 per day ($1,120 every 28 days) for both the 75 mg and 150 mg doses.\u201d Again, that\u2019s not an insignificant expense. The cost to consumers may vary, depending on each patient\u2019s insurance, etc., but failure to address cost is a significant oversight.", "answer": 0}, {"article": "+3582944 54542\n\nIntake of fermented and nonfermented dairy products and risk of incident CHD: the Kuopio Ischaemic Heart Disease Risk Factor Study Timo T. Koskinen, Heli E. K. Virtanen, Sari Voutilainen, Tomi-Pekka Tuomainen, Jaakko Mursu, Jyrki K. Virtanen.\nA very high consumption of non-fermented dairy products, on the other hand, was associated with an increased risk of incident coronary heart disease.\nMilk was the most commonly used product in this category, and a very high consumption was defined as an average daily milk intake of 0.9 litres.\nAll the mechanisms are not understood yet, but they may be linked to compounds forming during the fermentation process.\nThe consumption of high-fat fermented dairy products, such as cheese, was not associated with the risk of incident coronary heart disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned but we\u2019ll let this pass since it\u2019s reasonable to assume the approximate pricing of most of the dairy products tested are widely known.", "answer": 2}, {"article": "What's that like for Mason?\nMason believes the stem cells accelerated his recovery.\nBut it's hard to know what would have happened without them.\nAn experimental procedure aimed at repairing spinal cord injuries is showing promise.\nThe surgery performed by Dr. Arthur Jenkins, took four hours.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of this procedure.", "answer": 0}, {"article": "The U.S. Physicians Health Study II included nearly 50,000 male doctors aged 50 and older and spanned more than 10 years.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\nExcluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\nThe findings were published in the Journal of the American Medical Association and presented on Wednesday at a meeting of the American Association for Cancer Research in Anaheim, California.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The story didn\u2019t mention costs, but most people know that a daily multivitamin isn\u2019t very expensive.", "answer": 2}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story addresses cost in multiple places. One dentist notes that using SDF \u201ccomes out to pennies per tooth.\u201d Elsewhere, the story refers to the overall treatment as costing $25 \u2014 and notes that getting a cavity filled at the same dentist\u2019s office costs $151. We were glad to see the cost of a traditional filling included, since it gives readers useful context. The story also notes that Oregon is, so far, the only state to reimburse Medicaid providers for treating cavities with SDF.\nOne factor not noted is that some cavities may need to be repeatedly treated, raising the cost.", "answer": 1}, {"article": "Up until June 1, LabCorp of America had a product on the market.\nSince 2003, the PreGen-Plus kit could be ordered through a physician or other licensed health care provider for $800, although some insurance and health plans covered the cost partially or in full.\nThat test, which looks at two different DNA markers (instead of the one marker used by PreGen-Plus), is the one with which Markowitz is more familiar.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\nExact Science Corp. is in discussions with the FDA to develop a test that could hit the over-the-counter market sometime in 2009, pending FDA approval, said company president Jeffrey Luber.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that one test that was available through June 1 costs about $800. It also mentioned that some insurance and health plans covered the cost partially or in full.", "answer": 1}, {"article": "\u201cI prescribe them all the time,\u201d she said.\nThere are probably a few reasons for this, including cost, if not covered by insurance, and a perception that these agents are not safe in light of the history with weight loss agents.\u201d\n\nIn fact, a 2017 report that examined the medical records of 2.2 million patients found that fewer than one in 50 patients who were eligible for a diet pill prescription received one.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nSo the challenge is to keep it off long term.\u201d\n\nWhile a 5 percent weight loss may not seem like a lot, \u201cthat is the point where there is a very significant reduction in the risk of diabetes,\u201d said Dr. Louis Aronne, a professor of metabolic research at Weill Cornell Medicine.\nFen-phen scares off a lot of them.\u201d\n\nWhen it comes to dieting, Americans need to reframe how they view weight loss, Surampudi said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned cost and lack of insurance coverage as factors in the low uptake of weight loss drugs, but it doesn\u2019t give data. The drug highlighted in the story, lorcaserin, marketed in the U.S. as Belviq, costs $285 for a 30-day supply if you pay out of pocket, according to web sources. It wasn\u2019t made clear how long people must stay on these drugs, which also affects cost.", "answer": 0}, {"article": "Otto tracked 755 patients who died from breast cancer from 1995 to 2003 and another 3,739 control patients matched by age and other measures.\nNearly 36 percent of these women had never had a mammogram.\n\"This study focuses on survival.\"\nThe study, however, has some limitations, Bernik noted.\nThat could have affected survival, of course.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of mammography.", "answer": 0}, {"article": "To him, diet underpins longevity.\nAccording to Toribio-Mateas, the results confirm earlier theories that \"some hormone-like growth factors that are required during development to grow, then become promoting agents of aging after development and sexual maturity have been reached\".\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\n\"Diet can have a remarkable effect on you,\" says Valter Longo, Professor of Gerontology at USC Davis, who has been long been researching the mechanisms behind human aging and has recently turned his attention to fasting.\nUnlike the 5-2 diet, which requires two days of low calories at any point in the week, Longo's diet involves fasting for five consecutive days, which requires much more willpower.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Fasting to improve your health sounds like a great way to spend less money on food, and it\u2019s tempting to assume this diet would be cheap to follow. But that doesn\u2019t seem to be the case:\u00a0The story indicates study participants were fed a custom-designed meal program that would have to be replicated in the general population to achieve the same benefits. This will presumably cost money\u2013but we\u2019re not given any idea of how much that might cost.", "answer": 0}, {"article": "Therefore, Ulrik Dalgas is not recommending that all multiple sclerosis patients throw themselves into intensive physical training regimes without first seeking professional advice.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\nNew research shows that resistance training protects the brain in persons with multiple sclerosis, which may delay the development of the disease\n\nIn the past, multiple sclerosis patients were advised not to exercise for fear of exacerbating the illness.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\nIt is not yet clear whether all people with multiple sclerosis can benefit from this type of exercise, as it has not been sufficiently tested in the more severely affected patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Patients in the intervention group underwent resistance training twice a week for 6 months. The news release does not specify what types of exercises were included. It\u2019s unclear whether the exercise program would require supervision by a physical therapist or whether it could be adapted to be done at home, perhaps with friend or family help. In any case, there are cost implications that should have been addressed.", "answer": 0}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research.\n\"The goal is to create cells that are missing or defective in people.\n\"It introduces a whole new paradigm for treating disease.\"\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost estimate because there has not actually been a treatment developed yet that makes use of the approach described in the research.", "answer": 2}, {"article": "NEW YORK (Reuters Health) - A small U.S. study suggests daily hormone injections may boost mental agility in older people with and without mild cognitive problems.\nWhat\u2019s more, the hormone, which was provided free by the manufacturer in the study, today costs $700 for a single shot, Baker said.\nAt the end, those who got the drug did better on psychological tests of executive function - whether or not they had mild cognitive impairment.\n\u201cOur work and others\u2019 has shown that exercise really does make a difference.\u201d\n\u201cAll you have to do is supplement that hormone and it then will result in a whole cascade of effects that then restore an aging system to a younger system,\u201d said Baker.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not only did the story estimate cost \u2013 $700 for a single shot \u2013 but it put it up high in the 5th paragraph along with caveats about \u201cjumping the gun.\u201d", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story pulls off a difficult trick: addressing cost in a meaningful way when it\u2019s not clear what the price tag will be. The story tells readers \u201cSonata\u2019s manufacturer declined to say what the procedure might cost once the trials are complete and it is approved.\u201d The story also explains that \u201cbecause it\u2019s still under investigation in the U.S., it\u2019s not covered by insurance.\u201d And the story also quotes an independent expert as saying that \u201cIf insurance doesn\u2019t pay for Sonata, no one is going to get it.\u201d The story also notes that a comparable procedure cost tens of thousands of dollars.", "answer": 1}, {"article": "That\u2019s the most Mr. Skjoth will say about it.\n\u201cThere aren\u2019t a lot of options, and I\u2019d love to be able to say to my patients, \u2018This is something you can try that is worth the money.\u2019 But I can\u2019t do that yet.\u201d\n\nHarklinikken\u2019s formula, refined over 20 years, is derived from plants and cow\u2019s milk.\nIn the 1990s, clients mixed it with Rogaine, Mr. Skjoth said, \u201cand then we took the Rogaine part away and started focusing on the actual liquid.\u201d\n\nSmall studies have shown the efficacy of various plant-derived ingredients, mostly in mice.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nBut during regular follow-up appointments, Harklinikken uses high-tech equipment to photograph and magnify the scalp and count new hairs and active follicles, which motivates users to adhere to the regimen.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story barely rates satisfactory by calling this an \u201c$88-a-month serum.\u201d It would have better served readers by giving the total cost treatment, which well exceeds $1,000 annually and isn\u2019t covered by insurance.\nWhile patients are described seeing results after three or four months, there\u2019s no mention of the fact that the company\u2019s web site recommends \u201ccontinuing application\u201d to maintain results. And while the story says patients \u201cmust also use the company\u2019s shampoo, conditioner and styling products,\u201d it doesn\u2019t say what they cost.\nFurther, when HealthNewsReview.org requested an online consultation via the company\u2019s web site, we were notified of a $49 \u201cstart-up cost\u201d if we qualified for treatment along with $29 for each \u201cfollow-up\u201d consultation. Those costs aren\u2019t mentioned in this article. There\u2019s also no cost comparison with other hair loss treatments. We found a year\u2019s supply of minoxidil on Amazon for as little as $54 for an annual supply.", "answer": 1}, {"article": "Of the increased infections and cancers, Reich said, \"Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug.\"\nBriakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nAfter a year, about 66 percent of those taking briakinumab had a 75 percent improvement in their PASI score compared to almost 24 percent for those on methotrexate, according to the study.\nThere were also two cases of cancer in people taking briakinumab and none in the methotrexate group.\nThe study volunteers had had psoriasis for at least six months, and the condition affected at least 10 percent of their bodies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We also would have liked to have seen some comment on the costs of biologic drugs in the treatment of psoriasis. These drugs can cost $1,500-2,000/month. We think that any discussion about a new drug should include some comment about costs", "answer": 0}, {"article": "Lorren Sandt, chairwoman of the National Viral Hepatitis Roundtable, an advocacy group, called the trial results impressive.\nOf those who got 12 weeks of telaprevir, 75 percent had a sustained viral response, meaning the virus was not detectable in their blood 24 weeks after completing treatment.\nThe virus is transmitted by blood, so most people who have hepatitis C either have injected illegal drugs or received blood transfusions or blood products before the early 1990s.\nThe standard therapy of interferon and ribavirin was given for either 24 weeks or 48 weeks, depending on how the patients were faring after four weeks and 12 weeks.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If you can estimate that a drug is going to\u00a0have sales of\u00a0\"$3 billion a year by 2015,\" then you can estimate how much it is going to cost patients and how much more it is going to cost over existing treatments. This story does neither.", "answer": 0}, {"article": "Public health experts consider medicated-assisted treatment the gold standard of opioid addiction treatment.\nSo, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nThe body also produces natural opioids, but the more narcotics a person takes, the less opioids the body naturally produces.\nIf a person takes an opioid while on naltrexone, it is unlikely they will feel any opioid sensation.\nOn the other hand, naltrexone works by chemically blocking those receptors, which is why someone needs to detox before starting the regimen.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost does not make an appearance. This is a problem for a comparative story, as the prices for these two drugs seem quite different, with Vivitrol looking by far the more expensive.", "answer": 0}, {"article": "In a 2014 CDC report, the U.S. infant mortality rate (6.1 per 1,000 births) put it in 26th place among a selection of developed countries.\nHowever, she said a Centers for Disease Control and Prevention report shows about half of stillbirths occur between 20 and 27 weeks of pregnancy, and the other half at later points.\nBut the question has some doctors reconsidering their assumptions about induction and has sparked criticism by women who contend there is already too much interference with uncomplicated pregnancies.\n\u201cFinally, needless to say, it is expectant mothers that should have the final say as to whether to let nature take its course or undertake this potentially salutary but clearly artificial intervention,\u201d he said.\nFor the women who waited for labor to start on its own, about half ended up being induced for medical complications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of elective induction of labor or how it compares to waiting longer for labor to begin on its own.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nAlthough the brief does not mention costs, calcium supplements are available without a prescription and consumers can easily determine their costs.\n", "answer": 2}, {"article": "Treatment usually involves replacing one of the steroids they are unable to produce - called cortisol - with a medication.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe team found that corticosterone was as effective as cortisol, but had reduced effects on fat cells compared with cortisol.\nThey found the effects were reduced because fat cells have a pump that removes corticosterone - but not cortisol - from the fat cells.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this is basic research at the moment, the study does compare health outcomes between corticosterone\u00a0and an existing treatment.\u00a0 It could well have also offered a preliminary cost assessment.", "answer": 0}, {"article": "He is vice president for health care outcomes and policy at Roswell Park Cancer Institute in Buffalo, N.Y.\n\"The guideline is timely,\" said Dr. Janna Andrews, an attending physician in radiation medicine at Norwell Health Cancer Institute, in Lake Success, N.Y. \"The field of post-mastectomy radiation is changing.\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\n\"The new guidelines say there is clear evidence that the benefit of [post-mastectomy radiation therapy] extends to women with limited lymph node involvement,\" said Dr. Stephen Edge.\nOverall, the guidelines say there's enough evidence to show radiation treatment after a mastectomy decreases the risk of breast cancer recurrence, and that even women with smaller tumors and three or fewer lymph nodes involved can benefit from the therapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed in the story. That\u2019s problematic because, as the American Cancer Society notes, \u201ctreating cancer with radiation can cost a lot.\u201d According to an August 2015 paper in the Journal of Oncology Practice, radiation therapy for breast cancer can cost anywhere from $7,300 to $10,300. That\u2019s a lot of money, and worth noting.", "answer": 0}, {"article": "Some people do need supplements.\nThe mineral found in popular supplement pills \u2014 and in dairy foods, leafy greens and many fortified foods \u2014 is unquestionably good for your bones.\n\u201cThe public has been receiving very confusing and alarming messages about calcium supplements,\u201d says JoAnn Manson, a professor of medicine at Harvard Medical School and chief of preventive medicine at Brigham and Women\u2019s Hospital, Boston.\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\nMost recently, researchers at Johns Hopkins University tracked nearly 3,000 adults and found that those who took calcium supplements at the study outset were 22% more likely to show artery calcification 10 years later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not\u00a0mentioned. While calcium supplements are not prohibitively expensive for most patients (prices vary, but tend to cost less than $10 for several months\u2019 worth of pills), they are not free \u2014 and expense can be an important consideration for many patients. Also, given that most people can get enough calcium through foods and beverages, and yet more than one-third of Americans take calcium in supplement form, it would be informative for the reader to understand how much is spent annually on supplements that may not provide additional benefit.", "answer": 0}, {"article": "\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nWhat we need to do now is to look at a larger study, to confirm that these initial results are valid,\u201d she added.\nAfter 12 months, all the women on hormone replacements had improvements in menopausal symptoms, but those taking vitamin D and calcium did not show any significant improvement.\nBut sales of HRT drugs have fallen sharply since a large study in 2002 found higher rates of ovarian cancer, breast cancer and strokes in women who took the pills, and the search has since been on for alternatives.\nOver a year, 12 women took vitamin D and calcium, 12 took DHEA, 12 took standard HRT and 12 took a synthetic steroid called tibolone which is used to alleviate menopausal symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are missing from the story, and, given that these are well established products, cost information could have been explained.\n\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Because the story discusses the potential harms of oophorectomy, the cost criterion is not necessarily applicable in this case.", "answer": 2}, {"article": "And the study had one particularly unexpected outcome.\nThe advantage of a passive sensor is \"these things are done kind of autonomously so you don't need to do much except check when the resting heart rate starts coming up,\" Clue's head of scientific research, Dr. Vedrana H\u00f6gqvist Tabor, told BuzzFeed News.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\nThe devices also showed that resting heart rate spiked shortly before ovulation began, according to the Berlin company, which presented data from the small, preliminary study at the European Society of Human Reproduction and Embryology's annual meeting this month.\n\u201cYou will get a relative change, even though it might not be as accurate as a chest strap,\u201d said Clue co-founder Mike LaVigne.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes a company official calling this a \u201ccheaper\u201d method for those who want to get pregnant. But no numbers are provided to back this up. Fitbits can cost anywhere from 60 to more than 100 dollars. They also require users to have smartphones or tablets to interact with the fitbit \u2014 and with the (free) app discussed in the bulk of the article. Other technologies are also discussed in the article, with no mention of related costs.", "answer": 0}, {"article": "Each patient completed standardized behavioral rating scales and participated in a semi-structured interview answering five open-ended questions to stimulate conversation, such as \"Do you have hope?\"\n\"When you look around health care facilities, you see tremendous support from technology, but not so much for those who care for mental illness.\n\"These computational approaches provide novel opportunities to apply technological innovations in suicide care and prevention, and it surely is needed,\" says Dr. Pestian.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No\u00a0costs\u00a0are presented.", "answer": 0}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention costs. While it\u2019s too early for an exact figure, we know that this sort of treatment with tailoring the patient\u2019s own cells is very expensive. The competing NY Times story went into detail on costs, reporting:\n\u201cBut such drugs tend to be extremely expensive. A prime example is the Novartis drug Gleevec, which won rapid approval in 2001 for use against certain types of leukemia and gastrointestinal tumors. It can cost more than $5,000 a month, depending on the dosage.\nDr. June said that producing engineered T-cells costs about $20,000 per patient \u2014 far less than the cost of a bone-marrow transplant. Scaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d", "answer": 0}, {"article": "And the experimental combined system itself was not fully automated.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n\u201cThis is an important step in diabetes control because it shows that, with this system, people can sleep safely with minimized risk of hypoglycemia,\u201d said Dr. Eric Renard, a professor of diabetology at Montpellier University Hospital in Montpellier, France.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\n\u201cThe significance is in showing that the existing devices, which are available commercially, can be combined to create the first version of an artificial pancreas,\u201d said Dr. Roman Hovorka, the lead author of the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Like its competitors, the Times did not discuss costs\u2013an\u00a0omission\u00a0which perhaps is more acceptable in this story since it clearly indicated that this is not very close to being a marketable product. Nevertheless, we would have liked to have seen some mention of the financial impact.\u00a0\u00a0 Many patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices.\u00a0It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology. ", "answer": 0}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nThe report documents the experiences of 18 patients in the North Kivu province of the Democratic Republic of Congo who showed symptoms of malaria and were originally treated with the recommended medication: artemisinin-based combination therapy (ACT), which blends artemisinin, a chemical extract from Artemisia annua, with one or more other drugs that attack the malaria parasite in different ways.\nIn addition, while the combination therapy is designed to be less prone to the drug resistance that has rendered previous antimalarial agents ineffective, increasingly the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.\n\"To our knowledge, this is the first report of dried-leaf Artemisia annua controlling ACT-resistant malaria in humans,\" the authors of the Phytomedicine paper note, adding that more comprehensive clinical trials on patients with drug-resistant malaria are warranted.\nWeathers says the superior performance of DLA in comparison to ACT, as well as its ability to kill drug-resistant parasites and avoid the resistance trap, itself, is likely due to the synergistic effects of a complex array of phytochemicals contained in the plant's leaves, several of which are also known to have antimalarial properties and others of which may act both to enhance the absorption of artemisinin into the bloodstream and bolster its effectiveness against malaria.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions this would be an \u201cinexpensive treatment option\u201d and goes into some detail about the economics of the region where the drug was tested and the advantage of a low cost therapy.\n\u201cAnother advantage of DLA over conventional malaria treatments is its low cost and the relative simplicity of its manufacture, Weathers said. While the processes for manufacturing ACT is costlier and requires a higher degree of expertise, producing DLA tablets can be accomplished with simpler equipment and a modest amount of training. Growing Artemisia annua and producing and testing the tablets, Weathers noted, are ideal local business that can provide jobs in impoverished areas and greatly expand access to antimalarial therapy.\u201d\nNormally we like to see specific costs but in this case, an attempt is made to discuss the challenges and opportunities of developing a low cost therapy which seems appropriate here.", "answer": 1}, {"article": "Carlson notes that many cognitive intervention studies last one year or less.\nThe research, published online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, studied participants in the Baltimore Experience Corps, a program that brings retired people into public schools to serve as mentors to young children, working with teachers to help them learn to read in understaffed school libraries.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nThe study was supported by the Johns Hopkins Neurobehavioral Research Unit, the National Institutes of Health's National Institute on Aging (P01 AG027735-03), the Alzheimer's Drug Discovery Foundation and the Johns Hopkins Epidemiology and Biostatistics of Aging Research Fellowship (NIA T32AG000247).\nAt the same time, those with larger increases in the brain's volume over two years also saw the greatest improvements on memory tests, showing a direct correlation between brain volume and the reversal of a type of cognitive decline linked to increased risk for Alzheimer's disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The program under study welcomes study participants as volunteers, so there is no \u201ccost\u201d to them.\u00a0 It is not a drug or device, but we still might encourage the next release to quantify the costs a bit better. Bare minimum Satisfactory for this mention: \u201cExperience Corps is a national program, however it can be costly and isn\u2019t available everywhere.\u201d", "answer": 1}, {"article": "\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\n\"Everybody wants to be creative, but you have to look at the data, and they used TXA,\" Levy said.\nMONDAY, June 14 (HealthDay News) -- A drug commonly used to prevent excess bleeding in surgeries could keep thousands of people from bleeding to death after trauma, a new study suggests.\nFor the study, Roberts and colleagues in the CRASH-2 consortium randomly assigned more than 20,000 trauma patients from 274 hospitals across 40 countries to injections of either TXA or placebo.\n\"It's not our job to tell doctors how to treat their patients, but this is a drug that is safe and effective in a condition where people have a high risk of death,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that TXA is cheap, but we wish it had put\u00a0a dollar amount on it the way competing coverage did. The cost of the medication was\u00a0cited\u00a0in the press release put out by the London School of Hygiene and Tropical Medicine and could easily have been included. \"Cheap\" is relative.\u00a0 And, pertinent to this issue, what\u2019s \"cheap\" in the West may not be so cheap in developing countries. ", "answer": 0}, {"article": "Knowing the genotype helps inform treatment recommendations and the duration of treatment.\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nThe safety and efficacy of Epclusa for 12 weeks was evaluated in three Phase III clinical trials of 1,558 subjects without cirrhosis or with compensated cirrhosis (mild cirrhosis).\nEpclusa carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\nThe FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss cost. The FDA evaluates drugs without consideration of cost, so it\u2019s understandable that they wouldn\u2019t comment on it \u2014 and that\u2019s why we\u2019re rating this Not Applicable.\nWe look forward to the day when any news release about a new drug \u2014 even one from the FDA \u2014 includes some mention of cost in its message. After all, the value of a new drug is a function not just of how well it works, but its cost-effectiveness.", "answer": 2}, {"article": "Moffitt researchers compared the overall survival and the time to diagnosis of a second tumor, if any, of 250,195 breast cancer patients who received either neoadjuvant or adjuvant radiation therapy.\nThis was true for patients who underwent both partial and complete mastectomies.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThe majority of patients who have early stage breast cancer have surgery to remove their tumor or a complete mastectomy.\nSurgery is commonly followed by radiation therapy, which has been shown to increase relapse-free survival.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The costs of neoadjuvant radiotherapy vs. postoperative-adjuvant radiotherapy were not discussed.", "answer": 0}, {"article": "It's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nA stroke occurs when a clot cuts off blood flow to parts of the brain.\nMild strokes -- characterized by such symptoms as clumsiness in the hand, weakness of an extremity, some slurred speech, temporary loss of vision, and/or dizziness -- account for more than half of strokes in the U.S.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the drug costs about $2,000.", "answer": 1}, {"article": "\"There is some limited evidence from my study and others that fish oil may be good for preventing breast cancer, but there is not sufficient evidence to make a public health recommendation right now,\" cautions study researcher Emily White, PhD, an epidemiologist at the Fred Hutchinson Cancer Research Center in Seattle.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\nIn the study, 880 women developed breast cancer during six years of follow-up.\nDuctal breast cancer is the most common type of breast cancer and forms in the milk ducts.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Not discussed, but it should be general knowledge that they\u2019re relatively inexpensive. ", "answer": 2}, {"article": "\u201cIt provides more scientific believability that something in the brain, at a very biological level, seems to be affected by this probiotic.\u201d\n\nNo serious side effects related to the probiotic were reported, suggesting that such a supplement could be a safe way to treat both stomach- and mood-related symptoms.\nResults were similar after 10 weeks, as well.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nThey were followed for 10 weeks; half took a daily dose of the probiotic , and half took a placebo.\nNow, a small study published in the journal suggests that taking a probiotic supplement may provide relief from both conditions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Readers aren\u2019t given information about\u00a0how much the probiotic might cost.", "answer": 0}, {"article": "But are they receiving it?\nIn the case of providing information on differential health risks of nicotine products, \u201cThe evidence to date does not come close to establishing that there would be a loss to public health from making this information widely available from credible sources,\u201d Kozlowski says.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\nTo illustrate their point, Kozlowski and Sweanor use the example that if one type of alcoholic beverage caused 3 in 5 regular users to die prematurely \u2014 as is the case with smoking traditional cigarettes \u2014 while another caused massively fewer deaths, consumers would want to know which product was the safer alternative.\n\u201d\n\nBUFFALO, N.Y. \u2013 Millions of people visit the websites of the Mayo Clinic, American Cancer Society and the Centers for Disease Control and Prevention, among others, seeking authoritative health information.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the costs of either cigarettes (whose cost has skyrocketed in recent years in some areas) or of smokeless tobacco products. One can argue that that is immaterial when comparing lives saved versus lives lost, but that argument may not carry weight with people who are addicted to nicotine, and trying to figure out how to feed their addiction while limiting their risk.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides the variation in cost for different laser eye surgeries. The story also mentions that the surgery may not be covered by insurance. ", "answer": 1}, {"article": "Physical function of their knee also improved, based on an index used to judge the effects of osteoarthritis, Bagla added.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\n\"Perhaps we can demonstrate and prove patients do not need to be on these medications and can alternatively go through a minimally invasive procedure like this to reduce their knee pain,\" Bagla said.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it may be too early to nail down an exact price, the topic of how much this might cost wasn\u2019t broached at all, nor were the costs of currently available treatments.", "answer": 0}, {"article": "\"There are various reasons for that, including the fact that in the U.S. you have a wheat belt that means there is quite a high amount of selenium in the bread staple, which is not the case in the U.K.\"\n\n\"So, we can't extrapolate our findings to the U.S.,\" Rayman said.\nHowever, she cautioned that in general such supplementation has a minor impact and is not advisable as an effective means to combat high cholesterol, particularly for people who already have high blood selenium levels.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\n\"In the U.K., people's baseline selenium levels in the blood are considerably lower than they are in the U.S.,\" she noted.\nDr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that efforts to gauge the potential health impact of selenium have not yet demonstrated any clear benefit attributable to the trace mineral.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of selenium supplements probably isn\u2019t a big issue for most individual consumers, but across our society the costs are\u00a0substantial. Some discussion\u00a0of this would have been appropriate.", "answer": 0}, {"article": "A recent Canadian study looked at the issue, but the analysis had a caveat: Each of the more than 3,400 clinical trial patients received rivaroxaban the first five days after surgery.\nThese days, most patients have a generally low risk of blood clots after knee replacement for a number of reasons.\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\nWhen it comes to preventing blood clots after a knee replacement, good old aspirin may be just as effective as newer, more expensive drugs.\nAfter knee surgery, there's a risk of blood clots in the legs or lungs.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost differences between aspirin and anticoagulant drugs are listed and the potential savings by using aspirin are highlighted.", "answer": 1}, {"article": "\u201cIn contrast, if CPR is not initiated before the arrival of the emergency medical services, only 1 in 30 people survive a cardiac arrest.\u201d\n\nFor the current study, researchers looked at 30-day survival for patients who had cardiac arrests outside of a hospital between 2005 and 2011.\nCardiac arrest may occur with no warning and is often fatal.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\nFor ambulance arrival times up to ten minutes, 6.7 percent in the CPR group and 2.2 percent of the other patients survived.\nWhen ambulances took up to 10 minutes to arrive, bystander CPR was associated with tripled survival odds, the study also found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no direct cost to bystander CPR, so this category is not applicable.", "answer": 2}, {"article": "Information on breast cancer is available at cancer.gov.\nVitamin E supplements do not seem to stave off dementia\n\nIf you\u2019re taking something for heartburn, it may have other, less desirable effects\n\nEating whole-grain foods may be a plus for blood pressure\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\nAspirin has been shown to help keep blood from clotting, which can help prevent heart attacks and ischemic stroke (the type caused by a blocked blood vessel in the brain).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t mentioned. This may be because the story assumes the public knows that low-dose aspirin is inexpensive (a year\u2019s supply would likely be less than $20). It\u2019s good to make that clear, but because of the minimal cost will rate it N/A.", "answer": 2}, {"article": "PROVIDENCE, R.I. [Brown University] -- New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.\nThe finding that less than one month's use of fluorouacil 5% (5-FU) appeared to prevent cancer for up to a year is encouraging, said lead author Dr. Martin A. Weinstock, a professor of dermatology in the Warren Alpert Medical School of Brown University and chief of dermatology at the Providence Veterans Affairs Medical Center.\nIn addition to Weinstock, the new study has many authors from the VAKCC trial including at each of the study's 12 sites: Boston; Bay Pines, Fla.; Chicago, Ill.; Palo Alto, Calif.; Atlanta; Loma Linda Calif.; Minneapolis; Nashville; Denver; Durham, N.C.; Philadelphia; and Miami.\n\"This suggests that using the 5-FU can reduce the resources needed to treat these carcinomas,\" Weinstock said.\nBut in the new study, 5-FU appeared to provide prolonged protection after discontinuation and could be combined with sunscreen, Weinstock said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does mention costs twice, by saying that treating these cancers surgically is more costly, and that the use of the cream \u201ccan reduce the resources needed to treat these carcinomas.\u201d\u00a0 But it doesn\u2019t mention that the fluoroucil cream is fairly expensive. According to GoodRx, one 40g tube of 5% fluorouracil cream ranges from $73 to $136 a different pharmacy retailers. The cost may be considerably reduced by insurance plans, but the release does not address that either.\nAlso of note, according to results in the published study, at least 11\u00a0patients must be treated with the cream in order to possibly prevent one\u00a0additional cancer, leading to a drug cost of over $14,000 to prevent that one cancer. That may exceed the cost of surgery.\u00a0  ", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article carries no information about the cost of bariatric surgery, particularly some of the newer, more minimally invasive procedures. Costs are not trivial, particularly because the overall economic costs of type 2 diabetes aren\u2019t either. The piece cries out for\u00a0some dollar signs.", "answer": 0}, {"article": "But many others are tough calls.\n\"The device is only good for certain lesions, and that's why you have to be a dermatologist to be able to classify and categorize those lesions appropriately,\" said Christy Foreman, director of FDA's Office of Device Evaluation.\n\"A biopsy takes a few minutes in my hands, so if there's an issue with any lesion we will always biopsy, whether we have a MelaFind picture or not,\" said Dr. Leonard Goldberg, a dermatologist at the Texas Medical Center and vice president of the Skin Cancer Foundation, a disease awareness group that accepts donations from makers of sunscreen.\nThe Food and Drug Administration on Wednesday approved a first-of-its-kind device, called MelaFind, that makes detailed, digital images of skin growths and uses a computer to analyze them for signs of cancer, offering a sort of second opinion to doctors.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story takes the rare step of talking about costs from three different angles. The cost to the physician. The cost to the patient. And the cost to insursers. \u201cDoctors will pay a one-time fee of $7,500 to lease and receive training on the device. Patients will pay $150 out of pocket for a MelaFind scan, which analysts say may limit use to more affluent patients who are willing to pay extra for the latest medical care. Mela Sciences does not plan to ask insurers to cover the device until several years from now, after it is more widely used.", "answer": 1}, {"article": "\"The arthritis was so bad that I could barely step down without severe pain.\u201d\n\nBecause she wasn\u2019t eligible for a knee replacement she tried cortisone injections, physical therapy, medications \u2014 nothing relieved her pain.\nThe cost of the treatment is between $2,000 and $4,000.\n\"I thought I was going to limp for the rest of my life,\" she said.\nRecovery time is minimal, with most patients walking immediately after the procedure and resuming normal activities in a day or two.\nWhile it reduces pain, it can't stop the progression of osteoarthritis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are indeed addressed.", "answer": 1}, {"article": "In contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent.\nThe researchers studied 2,915 patients who were tracked by 17 Canadian hospitals in 2004-05.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\nSome patients \"might want to hang out and wait and see what happens,\" Krahn said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes that surgery to replace devices that are the subject of safety advisories can cost thousands of dollars. ", "answer": 1}, {"article": "But at our facility we think it makes caring for a patient much easier.\n\"I'm very encouraged that survival after defibrillator implant is as good as it is for as long as it is,\" co-author Dr. Leslie A. Saxon, chief of the division of cardiovascular medicine at the University of Southern California's Keck School of Medicine in Los Angeles, said in a news release from the American Heart Association.\nThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\n\"It's highly likely the reason these patients did better is that they were receiving earlier diagnoses, and they were also empowered to take charge of their own health care more,\" Saxon said.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of the devices, which is a shame for two reasons. First, these devices are costly, and the procedures to put them in are costly. Costs can run as high as\u00a0$50,000 for the device along with hospital and physician charges. The costs of the remote monitoring program would have been a welcomed addition to the information as well. Given the national discussion on health care cost, some attention to the price of the treatments and monitoring should have been included.\u00a0Secondly, we\u2019re talking about comparing devices, and there should have been some discussion of cost effectiveness. If we are claiming that there is a significant benefit to choosing one device over another or to subscribing to a remote monitoring plan, which the story does say \u201cis typically free with a cardiologist\u2019s recommendation,\u201d we should know how much each approach costs.\n", "answer": 0}, {"article": "To learn more about DOs and the osteopathic approach to medicine, visit http://www.\nWe also know that many people tune out messages about nutrition and exercise until a health crisis gets their attention,\" said Jennifer Caudle, DO, assistant professor of family medicine at Rowan University.\nThe blood test developed by Dr. Nagele has also shown promise in detecting other diseases, including Parkinsons's, multiple sclerosis and breast cancer.\nDetecting Alzheimer's antibodies at the preclinical stage would give patients an opportunity to work with their physician to make lifestyle changes or receive available treatments before they become symptomatic.\nThe osteopathic philosophy of medicine takes a whole person approach to prevention, diagnosis and treatment, giving its practitioners a distinct model for clinical problem solving and patient education.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Our longstanding policy is that if it\u2019s not too early to use such phrases as \u201cnearing development of a blood test\u201d or \u201cclosing in on a blood test\u201d \u2013 as this story does \u2013 then it\u2019s not to early to give at least a ballpark estimate of what this supposedly imminent test would cost. \u00a0There is no discussion of cost in this story,", "answer": 0}, {"article": "Dr. Durado Brooks, director of colorectal cancer at the American Cancer Society, agreed.\n\"You would intuitively think that the G variant would be associated with a poorer prognosis, as it is in late-stage colorectal cancer, but that is not the case,\" Smits said in a statement.\n\"There are 150,000 new cases of colon cancer each year in the United States, treated at an estimated cost of $14 billion,\" noted Dr. David A. Ahlquist, professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, Minn.\n\n\"The dream is to eradicate colon cancer altogether and the most realistic approach to getting there is screening,\" he said.\nIn addition, the test is the only one that is able to identify cancer in all locations throughout the colon, something which other tests either can't or don't do well, Ahlquist said.\nThe new technology, called the Cologuard sDNA test, works by identifying specific altered DNA in cells shed by pre-cancerous or cancerous polyps into the patient's stool.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A hesitant satisfactory score.\u00a0 The story stated, \u201cthe cost of the test has not yet been established. It is expected to cost more than a fecal occult blood test, but far less than a colonoscopy. A fecal occult blood test can cost as little as $23 while a colonoscopy can total $700.\u201d\u00a0 It is expected by whom to cost in that range?\u00a0 What\u2019s the source? (Reuters reported a $300-400 cost estimate from the company.)", "answer": 1}, {"article": "Adamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\n(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc\u2019s treatment for a side effect caused by a commonly prescribed Parkinson\u2019s drug, sending the shares of the drugmaker soaring in after-market trading.\nAdamas\u2019 Gocovri, previously ADS-5102, is the first drug cleared by the FDA to control levodopa-induced dyskinesia (LID).\nThe main ingredient of Gocovri, amantadine, has been available in the market as an antiviral drug for several decades.\nA majority of patients diagnosed with Parkinson\u2019s are treated with levodopa, whose use often leads to dyskinesia - involuntary movements that are non-rhythmic, purposeless and unpredictable.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While raising hopes of patients, it is irresponsible to be mentioning this \u201cnew\u201d drug, as well as its basic, generically-available ingredient, amantadine, without discussing costs to patients. The new drug is likely to be much more expensive than generic amantadine, as this STAT article reports.", "answer": 0}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although diets with more animal protein (e.g. Atkins) are likely to cost more, we don\u2019t think that\u2019s a major consideration with weight loss diets. We\u2019ll call it not applicable.", "answer": 2}, {"article": "About 15 percent of dialysis patients have HCV, the researchers said.\nTUESDAY, Aug. 7, 2018 (HealthDay News) -- Dialysis patients waiting for kidney transplants might safely accept an organ from a donor infected with hepatitis C virus (HCV), a new study finds.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\nSharif acknowledged, however, that using HCV-infected kidneys would represent \"a significant shift in our attitude to risk, procurement of organs and counseling potential recipients appropriately about the risks -- albeit minimal.\"\n\"Because of the opioid crisis, there are many people who die from a drug overdose and have HCV and want to donate their organs.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quoted the lead researcher saying the \u201cpotential cost savings could be significant,\u201d and the alternative \u2014 dialysis \u2014 \u201ccan cost more than $88,000 a year, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\u201d\nBut there was no data on the cost of a transplant or of HCV treatment\u2013which is the intervention being studied.\nAccording to various online sources, kidney transplants in the U.S. average just over $400,000, with the cost of anti-rejection drugs at several hundred dollars a month. Anti-rejection drugs must be taken for life.\nThe HCV treatment used in this study, Zepatier, has a list price of $54,600 for a 12-week treatment course and $72,800 for a 16-week course. Harvoni, which was listed as the best-selling HPV treatment in 2017, cost $63,000 for an eight-week course and $189,000 for a 24-week course.\nThis means that in reality, the cost comparisons are complex, which the story didn\u2019t convey.", "answer": 0}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there was no discussion of costs, the article was clear in stating that vaccines are\u00a0for the most part\u00a0in an early stage of development, so this omission is understandable.", "answer": 2}, {"article": "\"But I would say it would be perhaps more helpful for primary care physicians in an outpatient setting, because that is where it's most challenging to identify heart failure.\nFor more on heart failure, visit the U.S. National Heart, Lung, and Blood Institute.\nThe findings were published March 25 in the Journal of the American College of Cardiology.\nA single breath sample was obtained from each of the patients within 24 hours of admission, as well as from an additional 36 patients with acute decompensated heart failure as an independent point of comparison.\nThe result: The breath test correctly identified all the patients with heart failure, clearly distinguishing them from those cardiac cases where heart failure was not an issue.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This potential test is in the early stages of development. Almost everything about it, from how well it actually works, or how it compares to alternatives, has yet to be studied. The story does quote a researcher saying the test is \u201ctheoretically cheap.\u201d", "answer": 2}, {"article": "[3] Analysis only included cases occurring 10 days after receiving the vaccine to account for the incubation period of the Ebola virus.\nIt was not possible to collect biological samples from people who received the vaccine in order to analyse their immune response.\nAdditional studies are ongoing to provide more data on the safety of the vaccine in children and other vulnerable populations such as people with HIV.\nThe study found that the vaccine was safe and induced an immune response that peaked at 28 days, but decreased during the six months post injection.\nThe trial took place in the coastal region of Basse-Guin\u00e9e, the area of Guinea still experiencing new Ebola cases when the trial started in 2015.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the vaccine is likely to cost.\u00a0Cost is especially important in the developing world where it is most likely to be used and in large quantities.", "answer": 0}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given that this is an illegal substance banned by the U.S. Drug Enforcement Agency, cost as a therapeutic would be difficult to ascertain. We liked that the story took pains to explain that approval of this drug faces many hurdles.", "answer": 2}, {"article": "Autopsies show that most men will develop prostate cancer in their lifetimes but often die of something else.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\nSome doctors fear the cancer is being over-treated, particularly in older men, subjecting them to therapies that leave many impotent and incontinent when their cancer would never bother them if left untreated.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nA large new study is challenging the common practice of recommending that older men forgo treatment for early prostate cancer and instead wait to see whether the malignancy progresses.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not provide any cost information, and there are clearly wide variations in costs among the various prostate cancer treatment options.\u00a0 ", "answer": 0}, {"article": "The Alzheimer's Society has more about cannabis and Alzheimer's disease.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\n\"We would love to see this study done in a larger group of people, to see if it continues to be effective in a larger group, and how worried we need to be about this sedation side effect,\" Fargo said.\n\"This is the first clinical trial to show that a cannabinoid can decrease agitation,\" said lead researcher Krista Lanctot, a senior scientist at Sunnybrook Health Sciences Center in Toronto.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of nabilone is not mentioned.\nAccording to drugs.com:\nThe cost for Cesamet (nabilone) 1 mg capsules is around $2,054 for a supply of 50 capsules, depending on the pharmacy you visit.\nGoodRx.com quotes a similar price point with a 60-count bottle of 1 mg capsules costing $2,300-2,400.\nCost per tablet, therefore, would be roughly $40. Of note, the dosage used in this study wasn\u2019t mentioned.", "answer": 0}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\n\"However, most men complaining of inadequate penile size do have associated sexual problems even if their penile dimensions fall within the normal range -- so-called dysmorphophobic penis,\" said Gontero, an associate professor of urology at the University of Turin.\nIn a review of five evidence-based surgical studies of 121 men and six non-surgical studies of 109 men published between 2000 and 2009, the researchers found that penile extenders -- which stretch the organ over a period of months through traction -- were the most effective among non-invasive methods.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\nStudy co-author Dr. Paolo Gontero said urologists are constantly approached by men concerned about their penis size, despite the fact that the majority are average, with a flaccid length of 1 to 4 inches.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost information was provided, leaving a big hole in the story. The range in costs here is wide, and some of the more invasive procedures would be quite costly. None would be covered by insurance unless necessitated by a medical condition.", "answer": 0}, {"article": "Paul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nFor the study, 105 children ages 2-18 with upper respiratory tract infections that kept them awake at night were given either a dose of buckwheat honey, honey-flavored cough syrup or no treatment half an hour before bedtime.\nThe group that used honey also reported more favorable results than those who used cough syrup, but since the study group was small, those differences weren't statistically significant.\n\"I would be reluctant to routinely recommend to all parents that they give honey, because in some rare cases children can have reactions to honey.\"\nHoney has long been used by some parents as an alternative treatment for cough, although it should not be given to children under 1 year old.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Other than to describe honey as \"cheap\" the story does not discuss costs. However, because honey is a food product, prices are dependent on the store and source.", "answer": 2}, {"article": "\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nHe explained that in men with an initially high level \u2014 say 10 or higher\u2014 velocity is not an issue.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nPSA stands for prostate-specific antigen, a substance produced only by the prostate gland and found in the ejaculate.\n\u201cEven long-distance bikers do not have prostate trauma\u201d that causes their PSA to increase, Dr. Carter said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned.\u00a0 ", "answer": 0}, {"article": "Phd Christian Fabiansen \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 22440844 \n\nMail: chfa@nexs.ku.dk\n\nProfessor Henrik Friis \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 26253968 \n\nMail: hfr@nexs.ku.dk\n\nKristian Levring Madsen \n\nCommunication Manager \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nTelephone: +45 4048 1684 \n\nMail: kma@nexs.ku.dk\nThe study, published Monday 11 September in the open access medical journal PLOS Medicine, showed that corn-soy porridge should be replaced with a lipid-based nutrient supplement (LNS), a fortified peanut butter.\nIt has been a concern that LNS, with its very high fat content, would result mainly in weight gain composed of fat.\nThe study found that children who received LNS experienced greater weight gain, and the large majority of the weight gain was healthy lean tissue.\nBut by using a method based measurement of heavy water in the child's body we have found that LNS mainly increase lean mass, that is muscles and organs, which are important for immune function, survival and development.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No comparison is made in the news release between the cost of the current corn-soy blend (CSB) nutrient supplement and the alternative lipid-based supplement. This is strange considering that the original study devotes some space to addressing the issue of cost-effectiveness. The researchers conclude that although LNS is about twice as expensive as CSB, the possibility that it could require a shorter treatment regimen, is easier to prepare, and has a longer shelf life could make it more cost-effective in the long run. They call for detailed cost-effectiveness studies to inform policy decisions, a point that goes unmentioned in the release.", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe researchers found that combining the DASH diet with weight management and exercise resulted in a 16.1 mm Hg drop in systolic blood pressure compared to 11.2 mm Hg on the DASH diet alone.\nSimilar reductions were seen for diastolic blood pressure.\nThe third study compared an Internet weight-management program with a physician-managed program for extremely obese people that included a liquid diet component, followed by a structured diet, behavioral counseling and diet medications.\nMore than one-third of American adults are obese, and the incidence of obesity has gone up 140 percent over the past decade, Kushner notes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of the medication used in the low-fat diet group.\u00a0Including this information would have helped readers make\u00a0a more\u00a0informed comparison of the two approaches. \u00a0", "answer": 0}, {"article": "ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (\"Volition\") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q\u2122 assays to diagnose men with high-grade prostate cancer.\nThe tests are based on the technology platform of Nucleosomics\u00ae, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.\nThis suggests the assays may provide better risk stratification than that available using PSA tests for men with actual or suspected PCA, leading to better patient management and fewer unnecessary biopsies.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nCommenting on the results, Principal Investigator, Professor Thierry Roumeguere, Head of Urological Services, Erasme Hospital, Brussels, Belgium said \"A non-invasive test to help in the risk stratification of men with suspected or actual prostate cancer will be a major step forward in the management of this disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this blood test is still experimental, the company must have some idea about how much it thinks it will charge if it ever gets into clinical use. Another way the release could have addressed cost, absent an estimated cost for this test, would be to comment on the cost of a PSA, other similar blood tests this company has developed for other conditions, or even the cost of a biopsy that in theory could be avoided.", "answer": 0}, {"article": "The current study compared the use of traditional medical options -- tranexamic acid pills, mefenamic acid (Ponstel), combined estrogen-progestogen and progesterone alone -- to the use of the levonorgestrel intrauterine system.\n\"This study really adds to the evidence that shows how useful this intrauterine system is for heavy menstrual bleeding,\" said Dr. Eve Espey, professor of obstetrics and gynecology at the University of New Mexico School of Medicine in Albuquerque.\nThere was no difference in the rates of surgery or sexual activity between the two groups.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nFor women who do want to get pregnant, Gupta said, taking the blood-clotting drug tranexamic acid during periods is an alternate method of treating heavy periods.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs even though the Mirena\u2019s website has it at about $800 (a significant number of insurers will pay for it).", "answer": 0}, {"article": "\"Our study highlights the fact that laparoscopic anti-reflux surgery is as effective as the open approach, and in 2017, with all its advantages, should be the standard of care,\" said senior study author Marco G. Patti, MD, FACS, a surgeon and Director of the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\nDuring the study period, 58.4 percent of patients underwent laparoscopic procedures and 41.6 percent had open anti-reflux operations performed through a long abdominal incision.\nIts achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients.\n* Heartburn, a burning sensation in the chest, is a common symptom of GERD.\nGERD affects nearly 20 percent of American adults, according to the National Institute of Diabetes and Digestive and Kidney Diseases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story focused on costs, including information about the relative cost comparison between what are called \u201copen\u201d surgeries and those done laparoscopically (with a thin flexible tube.)", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nThe Institute carries out rigorous studies that discover the mechanisms of age-related disease and disability; lead to the prevention, treatment and cure of disease; advance the standard of care for older people; and inform public decision-making.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\nBased in Boston, the non-profit, non-sectarian organization has provided communities and health care for seniors, research into aging, and education for geriatric care providers since 1903.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a bone density scan is not mentioned and this is an important omission. Cardiovascular risk is currently assessed based on the epidemiological data from the Framingham Heart Study. The Framingham Cardiovascular Risk Calculator is based on these data and provides an easily obtained validated 10-year risk assessment. The only tests required are a blood test for total and HDL cholesterol (at a cost of $30-$40).\nThe US Preventive Services Task Force recommends screening for the presence of osteoporosis in women over age 65 years based on a cost-benefit assessment for that disorder. That means the cost of the screening is offset by the clinical benefits obtained. The use of a bone density scan to identify cardiovascular disease, especially in women under the age of 65 specifically for the diagnosis of osteoporosis and cardiovascular disease is a separate issue. While the cost of a bone densit scan is roughly $150-250 and still relatively low compared to other type of scans, it exceeds the cost of a total cholesterol and HDL cholesterol blood test. Unless and until the use of a bone density scan has been shown to provide more precise information, the cost could be viewed as excessive.", "answer": 0}, {"article": "They found people in the bottom 25% scored lower on such mental tests as problem solving, multi-tasking and abstract thinking.\nThe MRIs showed higher white matter hyperintensity volume, tiny lesions in the brain, raising the risk for death, stroke and dementia for the low omega-3 fatty acids group.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nThese contain alpha-linolenic acid (ALA), which the body partially converts to EPA and DHA.\nThey controlled for such risk factors as age, smoking, gender, body mass index, physical activity and APOE, the one known gene linked to dementia risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The recommendations quoted in this story \u2014 get 1000 mg/d of DHA \u2014 are only achievable by taking supplements, so the story should have included a comment about how much these cost.", "answer": 0}, {"article": "The U.S. Preventive Services Task Force on Sunday issued new guidance for the use of cholesterol-busting statin drugs.\nLast month, National Institutes of Health Director Francis Collins wrote in the journal Lancet that \u201cit\u2019s a force for good.\u201d But Rita Redberg, a cardiologist at the University of California at San Francisco and editor of JAMA Internal Medicine, and others have been vocal about their belief that the drugs are overprescribed and that the side effects \u2014 which range from muscle pain and cataracts to possibly an increased risk for diabetes in women \u2014 should be taken more seriously.\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nThe new guidelines, published in the Journal of the American Medical Association, suggests that people ages 40 to 75 who have one or more risk factors \u2014 such as high cholesterol, high blood pressure, diabetes or smoking that put them at a 10 percent or greater risk of having a heart attack or stroke in the next 10 years \u2014 should be on statins.\nStatins are among the best-selling drugs in the United States, with a 2011 study showing at least 32 million Americans were taking them.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the drugs are not included. Recently, total costs for statin therapy in the U.S. were estimated at approximately $17 billion. It would also be useful to know that there is a wide variety in prices over the many statins currently on the market.", "answer": 0}, {"article": "\"Being impotent is no fun.\"\nHowever, he added, \"if we can get the thyroid effect in the liver [where cholesterol is metabolized] but not in other organs, we would be OK.\"\n\nFrequent monitoring showed no ill effects on the hearts and bones of those taking the drug, the report said.\n\"We knew that thyroid hormone could lower lipid [cholesterol] levels but would have side effects on the circulation and bones and cause diarrhea,\" Angelin said.\nIn the trial, various doses of the drug, eprotirome, a laboratory-engineered version of thyroid hormone, were added to statin treatment for 168 people whose high levels of LDL cholesterol had not been lowered by previous use of statins.\nWEDNESDAY, March 10, 2010 (HealthDay News) -- A thyroid-derived cholesterol-lowering drug that could be an alternative to the widely used statin medications has done well in a small, early trial, Swedish and American researchers report.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs \u2013 not even a projection.\u00a0 If you can label something as an \"alternative to statins\" in the headline, then you can certainly at least project for readers what this \"alternative\" might cost.\u00a0 ", "answer": 0}, {"article": "\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\n\u201cIn the particle itself, we\u2019ve built what we call a chemical sensor,\u201d Davis said in a telephone interview.\n\u201cWe\u2019re excited about it because there is a lot of skepticism whenever any new technology comes in,\u201d said Davis, a consultant to privately held Calando Pharmaceuticals Inc, which is developing the therapy.\nBut getting the treatment to the right target in the body has presented a challenge.\nRNA stands for ribonucleic acid \u2014 a chemical messenger that is emerging as a key player in the disease process.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs discussed, but we can understand why given the very early stage of this research. Not applicable in this case.", "answer": 2}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study does not mention the costs of the injections nor does it comment on whether insurance would be likely to cover it for migraines.", "answer": 0}, {"article": "\"Multicentric Cancer Detected at Breast MR Imaging and Not at Mammography: Important or Not?\"\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\nIn 73 of those 285 patients, or 25.6 percent, MRI identified at least one additional cancer in a different quadrant of the breast than the index cancer, or the cancer detected by mammography and/or breast palpation.\n\"Patients with clinically insignificant cancers undergoing potential overtreatment versus patients who may be undertreated is at the heart of the controversy surrounding breast MRI,\" said the study's lead author Chiara Iacconi, M.D., from the Breast Unit at USL1 Massa-Carrara in Carrara, Italy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss the cost of breast MRI or the cost of altering treatment based on the results of the imaging. In addition, we\u2019d note that MRI\u00a0may not be covered depending on insurance, and given the way some of the plans are currently structured, the cost may be prohibitive.", "answer": 0}, {"article": "Neither scenario gives doctors an objective indication of the severity of the injury.\n\"The idea is to get a point-of-care test that could be used on the field, to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play,\" said Papa.\n\"If we could find a simple test that takes the guess work out of diagnosing these kids, that would completely change the way we approach concussions and would certainly give parents greater peace of mind,\" said Papa.\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n\"We were looking at different types of brain lesions detected by the CT scans, ranging from mild to serious injuries, and found that the biomarker we tested for actually corresponded to the injuries.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address cost at all. The release makes clear that the blood test is not ready for clinical use, stating that researchers \u201chope it will be commercially available within the next five years.\u201d However, if the release is going to discuss what such a diagnostic tool would look like (e.g., \u201cmobile devices that could diagnose concussions on the spot\u201d), it should also provide a ballpark figure on what such a diagnostic tool might cost.", "answer": 0}, {"article": "An independent expert, Dr. Clifford Hudis of New York\u2019s Memorial Sloan Kettering Cancer Center, agreed.\nThe test measures the activity of genes that control cell growth, and others that indicate a likely response to hormone therapy treatment.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\nOthers besides Oncotype DX also are on the market, and Hudis said he hopes the new study will encourage more, to compete on price and accuracy.\nBut many women also are urged to have chemo, to help kill any stray cancer cells that may have spread beyond the breast and could seed a new cancer later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states the Oncotype gene test costs $4,175 and adds that many insurers, as well as Medicare, cover it.", "answer": 1}, {"article": "What\u2019s more, say the study\u2019s authors, doctors may also figure out which people are most likely to respond to the two-drug combination of nivolumab (Opdivo) and ipilimumab (Yervoy) and which are not.\nAfter nearly a year, the lung cancer in people taking the immunotherapy was 42% less likely to have progressed than among people getting chemotherapy.\nFor example, newer targeted therapy drugs home in on specific genetic mutations that are responsible for driving a person\u2019s cancer.\nPeople getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\nThe results are even more encouraging for people with early stage lung cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The $150,000-plus annual cost of these drugs isn\u2019t mentioned.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost \u2013 only of sales figures which aren\u2019t much help to the individual consumer. Cymbalta is expensive. ", "answer": 0}, {"article": "This decrease was largely confined to women with hormone receptor-negative tumors and women who were not treated with anti-estrogen therapy such as tamoxifen (which blocks the effects of estrogen).\nIn contrast to some previous research, high levels of isoflavone intake were not associated with greater mortality among women receiving hormonal therapy.\nThis is because in hormone receptor-positive cancer, the most common form of the disease, there are some concerns that high estrogen levels help cancer cells grow and spread, though this remains controversial.\nIn an accompanying editorial, Omer Kucuk, MD, of the Winship Cancer Institute of Emory University, noted that the United States is the number 1 soy producer in the world and is in a great position to initiate changes in health policy encouraging soy intake.\nThe investigators noted that they examined only naturally occurring dietary isoflavones, not isoflavones from supplements.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although a report on this\u00a0study did not necessarily require observations involving the $ sign, the release would have been more helpful had it noted that soy products are relatively inexpensive compared to other sources of protein and might also have mentioned the financial and social costs of breast cancer.", "answer": 2}, {"article": "JACKSONVILLE, Fla. \u2014 Researchers at Mayo Clinic\u2019s campus in Florida have conducted the world\u2019s first prospective, blinded and placebo-controlled clinical study to test the benefit of using bone marrow stem cells, a regenerative medicine therapy, to reduce arthritic pain and disability in knees.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\n\u201cThis is just a theory that can explain our results, so it needs further testing.\u201d\n\nAnother explanation is that merely injecting any substance into a knee offered relief from pain.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\n\u201cThat could be, but both this idea and the notion that a placebo effect could be involved would be surprising, given that some patients are still doing very well years after their study treatment ended,\u201d says Dr. Shapiro.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that patients may pay \u201cthousands\u201d out of pocket. It could have offered some information on the cost of alternative therapies, which would have put the cost burden in context.", "answer": 1}, {"article": "Lee is a professor of medicine and director of the electrophysiology laboratories and clinics at UCSF.\nAlthough the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\nAccording to Dr. Byron Lee of the University of California, San Francisco (UCSF), \"There is a growing body of literature supporting the connection between atrial fibrillation and dementia.\"\nFor the study, Bunch and his colleagues looked at information from more than 76,000 atrial fibrillation patients who had no history of dementia.\n\"Therefore,\" he said, \"we need to be extremely aggressive in treating atrial fibrillation patients with anticoagulants [blood thinners] when indicated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the lead author of the study makes a strong recommendation on behalf of prescribing blood thinners after an atrial fibrillation diagnosis, the text offers no information about what that ongoing treatment would cost. \u00a0While warfarin, the blood thinner identified in the story, remains relatively cheap, other drugs can cost hundreds of dollars per month.", "answer": 0}, {"article": "The World Journal of Surgery article, by lead author breast surgeon Michael J.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nA second study, presented at the American Society for Radiation Oncology (ASTRO) 2016 annual conference, describes the extra utility that BioZorb can provide, by significantly reducing the amount of normal breast and surrounding tissues that are exposed to radiation treatment.\nCross, concluded that the 3-D marker is an \"effective method for delineating the tumor bed with a significant utility for RT (radiation therapy) planning.\"\nThey concluded that the tissue marker could significantly reduce radiation of healthy breast tissue (an average of 65% reduction), as well as avoid irradiating inadvertent seromas that are more common with oncoplastic procedures.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release declares\u00a0the cost of treatment will be cut \u201cby approximately 25%\u201d without indicating a starting cost for treatment without the implant.\nBut the release does go in to some detail on how cost savings were estimated: During the three-year span of the study, the marker facilitated many physicians to shift from traditional external beam radiation to the shorter course hypo-fractionated radiation therapy, which results in a cost savings. The patient outcomes remain similar, however.", "answer": 1}, {"article": "Besides M.D.\nAnd if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nIn the last decade, hopeful of finding a better test, ovarian cancer researchers have invested much time in the investigation of other biomarkers and technologies.\nOvarian cancer, though rare, is the fourth-leading cancer killer among U.S. women.\n\u201cIt's a well-done study about which its authors are appropriately careful in their conclusions,\u201d said Dr. Len Lichtenfeld, deputy medical director at the American Cancer Society.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention how much the blood test and ultrasound cost. The story could have raised the question of whether this might be too expensive given that thousands of women must be tested in order to find one case of ovarian cancer.", "answer": 1}, {"article": "And patients may need to continue treatment.\nThe thought that you could lose your vision is very, very depressing,\" Daniel says.\nFor more than 100 years, the Lighthouse has been the leader worldwide in helping people of all ages who are blind or partially sighted overcome the challenges of vision loss.\n\"Instead of seeing a lot of this squiggling, the lines straighten out,\" he says.\n\"The short-term course, is excellent so far \u2014 beyond our wildest expectations, says Dr. Lawrence Yannuzzi a leading macular generation specialist.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does states that the cost of the drug is about $2000 a month. However, the story should have provided more context by comparing this cost to the cost of other treatments for AMD.", "answer": 1}, {"article": "\"Studies comparing stage of disease with outcome following surgery suggest that death rates frompancreatic cancer would be reduced if the disease were diagnosed at an earlier stage,\" said Dr. Raghu Kalluri, chair of cancer biology at M.D.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\nIf it can be shown that screening improved outcomes, it could one day be used to screen the general population.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study includes no mention of costs for the screening test. While it\u2019s noted that the test has not yet been developed, it would be possible to give a ballpark figure based on similar screening tests.", "answer": 0}, {"article": "Stanford\u2019s Department of Medicine also supported the work.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nOver the 24-week duration of the latest trial, 109 participants received ixekizumab every two weeks; 94 received placebo injections every two weeks; and 111 alternated every two weeks between getting injections of ixekizumab and the placebo.\nWhile 19.5 percent of patients who received only the placebo injections were judged to have met the trial\u2019s specified clinical endpoint \u2014 at least a 20 percent reduction in the number of tender and swollen joints \u2014 the response rate among those getting the real drug every four weeks was 53.3 percent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No cost information was provided, even though the drug is already on the market for another condition. According to GoodRx, one 80 mg auto-injector of the drug costs around $4,700.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs of vitamin D rich foods, vitamin D supplemented foods, or vitamin D containing supplements.\u00a0 Though the story starts with a quip that \"it's free\", this only applies to sunlight.\u00a0 A brief discussion even of the costs of supplements at the doses recommended would have strengthened the story.", "answer": 0}, {"article": "* Anorexia among most common psychiatric disorders in girls\n\nLONDON, March 7 (Reuters) - Scientists have for the first time reported successful use of a brain-stimulating implant to help patients with severe anorexia whose condition had not improved with other treatments.\n\u201c(This) will go some way towards reassuring patients that DBS is not just another treatment designed to fatten them up without making them feel better.\u201d\n\nDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain.\nFor their study, a team at the Krembil Neuroscience Centre and University Health Network in Canada identified an area of the brain known to be important when using DBS in depression.\nImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur, the researchers said.\nThree months after treatment, the weight loss began to reverse in some patients, and after nine months, three patients weighed more than before treatment - the longest period of sustained weight increase since they had become ill. Around half also had better moods and less obsessive-compulsive behaviour.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs, which are significant.\nIn this 2008 Chicago Tribune blog post, the cost of\u00a0DBS was estimated at $150,000 or more per patient in some uses.\u00a0There would also be additional costs for ongoing monitoring and follow-up once the device\u00a0was\u00a0implanted.", "answer": 0}, {"article": "\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\nThe average age of patients was 19 years old.\nThe study examined 121 patients at an average of 51 months post-surgery.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nOf this group, 68 patients had experienced their first dislocation, while 53 had recurrent dislocations after being initially treated non-operatively.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention costs.", "answer": 0}, {"article": "But conventional germicidal lamps aren\u2019t safe for humans to be around.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cYou can sterilize a hospital room, but not when anyone\u2019s inside.\u201d\n\nAbout five years ago, Brenner says, the Columbia team came up with a potential solution.\nFor that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The lead author of the study is quoted as saying \u201cThe lamp we\u2019re using at the moment costs less than $1,000, and you can imagine that if it were put into general circulation, the price would drop dramatically \u2026 we don\u2019t see cost as being a limited factor here.\u201d\nThe first part of the quote gives a frame of reference, though \u201cless than $1,000\u201d is somewhat ambiguous. The second part also is speculative, so this is a barely passing satisfactory.", "answer": 1}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nUp to 78 percent of men receiving the drug combination in the study saw their concentrations drop to no sperm at all, versus only 23 percent of men taking testosterone alone.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nUnfortunately, condoms and vasectomy have remained the only commercially available contraception options for men.\nThat's apart from mild-to-moderate acne or an increase in acne, which was seen in about 21 percent of participants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s probably too early to know what this treatment would cost were it commercially available, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "D'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\nMONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\nThe study results were scheduled for presentation Monday at the annual meeting of the American Chemical Society in Denver.\nVitamin D, known as the \"sunshine vitamin,\" is produced by the body when it's exposed to sun.\n\"In greater than 60 percent of those taking it, vitamin D actually made the cancer better,\" said Hollis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost. While it can be argued that most patients have a rough idea of the price of vitamin D supplements, a quick word on the monthly cost of supplements, or the potential cost-effectiveness of supplementation as part of a larger watchful waiting approach, would have been useful. The article does point out that vitamin D is available in fortified dairy products and directly from El Sol.", "answer": 0}, {"article": "In a prime time news conference, Obama said that doctors may think: \" 'You know what?\n\"It was becoming unacceptable to just take tonsils out because they were there or you had a few infections,\" says Richard Rosenfeld, an ear, nose and throat doctor at SUNY Downstate in Brooklyn, N.Y. \"People were growing up with their tonsils.\"\n\"You could hear him through he closed door, down the hall, snoring, and he would occasionally stop breathing.\"\nLisa Moran of Takoma Park, Md., remembers what it sounded like when her son ,Tyler Scorza, now age 7, slept.\n\"\n\nRosenfeld disputes Obama's claim, saying insurers usually pay a surgeon $200 to $300 for tonsil surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Oddly, the story mentions physician reimbursements for tonsil surgery but makes no mention of patient costs. \u201cRosenfeld disputes Obama\u2019s claim, saying that insurers usually pay a surgeon $200 to $300 for tonsil surgery.\u201d", "answer": 0}, {"article": "Most angioplasties not necessary, study finds\n\nNEW ORLEANS \u2014 More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.\nAbout 1.2 million angioplasties are done in the United States each year.\nAfter five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nIt involved 2,287 patients throughout the U.S. and Canada who had substantial blockages, typically in two arteries, but were medically stable.\nA tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not include a comparison of the costs for the two treatments.\u00a0 This was not a part of the journal article describing the study but was contained within the presentation given at the recent meeting of the American College of Cardiology. (Note: both the journal article and the meeting were mentioned in the story.)", "answer": 0}, {"article": "The negatives?\nGaining and then losing abilities he\u2019d never possessed caused \u201ca mixture of sadness and wonder,\u201d Robison writes, summing up his condition in one word: \u201cjarred.\u201d\n\nRobison has previously written about growing up in Western Massachusetts in an intellectually prominent family (his father taught philosophy, his mother wrote poetry) plagued by alcoholism and mental illness.\nIt was overpowering.\u201d\n\nRobison\u2019s TMS research team was led by Harvard neurologist Dr. Alvaro Pascual-Leone, who supplies an introduction to \u201cSwitched On.\u201d In a separate interview, Pascual-Leone says Robison\u2019s book demonstrates how small changes in brain function, however temporary, can have a life-changing impact.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nI can\u2019t.\u201d\n\nEven a 1 percent chance at success seemed worth the odds, Robison went on.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. The exact number of sessions necessary, the duration of treatment and the repeat treatments through time are not discussed, either. But, an idea of cost is important\u2013this treatment is unlikely to be covered by insurance, and readers given hope by this story will want to know how much it may cost.", "answer": 0}, {"article": "July 7, 2010 -- The FDA says it has approved the use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration.\nThere are two forms of AMD, a wet form and a dry form.\nIt is designed to magnify and project images onto a healthy portion of the afflicted person's retina.\nAbout 8 million people in the U.S. suffer from this condition, and nearly 2 million of them already have significant loss of vision.\nIt damages the center of the retina, or macula, and results in a loss of vision in the center of the visual field.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost as there was in the competing AP story. ", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nThey compared them to 270 more having angiograms to look for evidence of clogged arteries.\nThey graft in a vein to bypass blood flow around the clogged part.\nThey found a way to identify which layers of fat were inflamed and unstable by looking at the size and shape of the cells using computed tomography (CT) scans.\nAbout 750,000 Americans have a heart attack every year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article doesn\u2019t discuss what the study authors new \u201cway\u201d of assessment might add in the way of costs.", "answer": 0}, {"article": "The main stages of NAFLD are:\n\n1.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\nCirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nNon-alcoholic steatohepatitis (NASH) - a more serious form of NAFLD, where the liver has become inflamed; this is estimated to affect up to 5% of the UK population \n\n3.\nSenior author Dr Jelena Mann of Newcastle University's Institute for Cellular Medicine added: \"This is the first time that a DNA methylation 'signature' from the blood has been shown to match the severity of a liver disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The technique is likely not at the stage of commercial availability so costs would be uncertain. Still, cost isn\u2019t mentioned at all, even in an abstract way. Could this be comparable to the cost of existing diagnostic tools? Cheaper? More expensive? There\u2019s still much work to do to demonstrate the value of this test.", "answer": 0}, {"article": "Despite popular lore, agency won't allow labels to say drink is good for consumers' hearts\n\nWASHINGTON - There is no credible scientific evidence that drinking green tea reduces the risk of heart disease, federal regulators said last week in rejecting a petition that sought to allow tea labels to make that claim.\nUnlike black and oolong tea, it is made from unfermented tea leaves.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nGreen tea is brewed from Camellia sinensis, also known as Thea sinensis.\nA message left for a spokesman for Ito En Inc. was not immediately returned last week.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not contain any reference to the cost of green tea.", "answer": 0}, {"article": "Contributing authors Dr. Farid Saad is a full time employee of Bayer Pharma.\n(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.\nWe believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events,\" explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.\nIn the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost estimates for long-term testosterone therapy are missing from this release. This matters because, although health insurance often covers testosterone treatments if a physician deems them warranted, a month\u2019s worth of medication can cost hundreds of dollars.", "answer": 0}, {"article": "The method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\nMany types of dementia are linked to sleep disturbances, including difficulties in falling asleep.\nIt is increasing acknowledged that these sleep disturbances may accelerate memory loss in Alzheimer\u2019s disease.\nIn humans and many animals the lateral sleeping position is the most common one.\nIt is during sleep that the glymphatic pathway is most efficient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not an applicable criteria since there\u2019s no cost associated with sleeping (unless one goes to a sleep clinic).", "answer": 2}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\n\"The question one had to address was how does this play out with people in the real world,\" Jenkins said in a telephone interview.\nIn addition to the soy protein, nuts and whole grains, participants in the diet were encouraged to eat peas, beans and lentils.\nA control group advised to eat a vegetarian, low-saturated diet but not with the cholesterol-lowering foods a saw a slight dip in total cholesterol, from 249 to 246, and in LDL, from 167 to 161.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Same problems here as with the competing LA Times story: The\u00a0post doesn\u2019t address how much it will cost to maintain this diet, which includes some pricey soy-based\u00a0components and\u00a0expensive fortified margarines.", "answer": 0}, {"article": "And AbbeVie is in the midst of phase 3 trials for elagolix to treat uterine fibroids and endometriosis, a disorder in which the tissue that lines the inside of the uterus grows outside of it, causing pelvic pain.\nThe company hopes to have a product available by 2020.\nBut fibroids can grow back after the procedure.\nDietary factors may also play a role.\nIt also decreases the size of fibroids.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not offer any cost information.", "answer": 0}, {"article": "That\u2019s called secondary prevention.\nIf there was a foolproof way to identify individuals at high risk for a future heart attack or stroke, as well as those at high risk for developing complications, we would know who should be taking aspirin for primary prevention and who should not.\nIt is important to note that this draft recommendation applies to people who are not at increased risk for bleeding, have at least a 10-year life expectancy, and are willing to take low-dose aspirin daily.\nIt is important to keep in mind that other therapies, such as statins, have also been proven to decrease the risk of cardiovascular events.\nThe data on aspirin for preventing colorectal cancer are provocative, but are even less robust than for primary prevention of cardiovascular events.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is universally known that aspirin is cheap, sold widely and in a manner where its cost will not be a barrier to consumption, so the cost information is not necessary to reiterate in this report.", "answer": 2}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nThese results are hugely encouraging, but we need to do more studies.\u201d\n\nFor this study, 48 patients who were diagnosed with a kidney tumor on conventional CT or MRI were imaged with sestamibi SPECT/CT at Johns Hopkins prior to surgery.\n\u201cIn the absence of diagnostic certainty, surgeons tend to remove kidney tumors in an abundance of caution, leading to an estimated 5,600 surgically removed benign kidney tumors each year in the United States.\u201d\n\nOther authors on this paper include, Sara Sheikhbahaei, Christopher S. Jones, Kristin K. Porter, Alex S. Baras, Phillip M. Pierorazio, Mark W. Ball, Lilja B. Solnes, Jonathan I. Epstein, and Mehrbod S. Javadi, all of the Johns Hopkins University School of Medicine, and Takahiro Higuchi of Wurzburg University in Germany.\n\u201cSestamibi SPECT/CT lets radiologists and urologists \u2018see\u2019 the most common benign kidney tumor, something CT and MRI have not succeeded in doing alone,\u201d says Mohamad E. Allaf, M.D., MEA Endowed Professor of Urology at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release notes several times that sestamibi SPECT/CT is inexpensive and widely available. It would have been good to include some cost estimates, particularly since reducing unneeded surgeries by the \u201cthousands\u201d presumably would be a huge cost savings.", "answer": 0}, {"article": "After 10 months of following the prescribed protocol, his hippocampal volume increased to the 75th percentile.\nThe study noted that some of the patients who had to quit working as a result of their memory decline, were able to return to work after adopting MEND and participants who were struggling at their jobs reported an improvement in job performance.\nThe MEND protocol, outlined in a 2014 study in the journal Aging, calls for interventions to treat conditions that could be associated with Alzheimer's such as inflammation, stress and diabetes.\nA cure for Alzheimer's disease (AD), a condition marked by progressive, debilitating cognitive decline that affects more than 5.4 million Americans, is the holy grail in disease research.\nBut Bredesen believes that the only way to treat Alzheimer's is to treat all of the underlying problems, which may require intervention with supplements.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss costs. Although the MEND protocol appears to involve many inexpensive interventions, such as reducing processed carbohydrates, practicing yoga, and taking over-the-counter supplements such as melatonin, those expenses aren\u2019t within the reach of millions of Americans. Moreover, the costs of hormones and supplements as well as health coaches to guide patients through the individualized program would be significant.\u00a0The story also does not mention that the researchers recommend widespread genetic testing to determine risk for Alzheimer\u2019s, which comes at a cost, too.", "answer": 0}, {"article": "But the scientific evidence has been slim.\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though melatonin is readily available, no estimates for the cost of treatment were provided.", "answer": 0}, {"article": "\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\nWe want to help improve our patients\u2019 quality of life.\u201d\n\nThe study included 80 patients from 16 ECOG-ACRIN Cancer Research Group sites who had stage three or four HPV-positive squamous cell carcinoma of the oropharynx, and were candidates for surgery.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\nThe study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs. We would have liked some context. What kind of rehabilitation costs are associated with the severe lifelong swallowing side effects that are mitigated by the reduction in dose discussed in the study?", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of therapy is not mentioned in the news release. Media reports have said prices will depend on how often the cap is used during chemotherapy, but it\u2019s likely a course of treatment will cost between $1,500 and $3,000.\nAccording to DigniCap\u2019s website, the company is working toward getting the treatment covered by health insurance. It also states, \u201cDignitana is in the process of setting up a Patient Assistance Program to help subsidize DigniCap\u00ae treatment costs for patients with financial need.\u201d Since there is no discussion of costs in the FDA news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "They were then monitored for 24 hours.\n\u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\n\nResearchers say that drop may seem small, but on a public health level a reduction like that would equate to a 10% reduction in deaths due to heart disease .\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the cost of beetroot juice. We saw some products advertised on Amazon for $8-10 for a 32 oz jar (about 2 days\u2019 worth of juice at the dosage studied).\u00a0Cheaper versions are probably available, or you could juice your own, but the story could have addressed this either way.\nIn keeping with the spirit of this criterion, ALL health care interventions cost something.\u00a0 Only about 30% of the stories we review ever adequately address this issue.\u00a0 Americans spend a greater percentage of their GDP on healthcare than any other country.\u00a0 Costs matter.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article is silent on the price of Rituxan. Since the company is investing a significant sum to research an additional use, the price is worth mentioning.", "answer": 0}, {"article": "Hare was not involved in the study.\n\"This is a groundbreaking study of extreme importance,\" Joshua Hare, MD, director of the University of Miami's Interdisciplinary Stem Cell Institute, tells WebMD via email.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\nNov. 14, 2011 -- The first use of heart stem cells in humans looks like a major breakthrough for people suffering heart failure after heart attacks.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. \n\n\n\nBecause this is a phase 1 study, no costs can be determined at this stage.\u00a0 Needless to say, the costs are likely, however, to be significant. There is widespread concern that when stem cell therapies do become available for some conditions that they will be cost prohibitive. The reason so many stem cell studies have enrolled so few patients is, in part, because research costs are so high, and that translates into higher costs for patients down the road.", "answer": 1}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of not only giving the price of the O-shots, but leaving the reader with the clear understanding that they may be spending money on a therapy for which there is no scientific evidence of benefit. The story could have been strengthened by noting the costs of alternatives to the O-shot.", "answer": 1}, {"article": "TUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n\"The 90 percent detection rate by stool DNA testing is remarkable.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nUnlike common polyps, they tend to be flat and the same color as the colon lining.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 ", "answer": 0}, {"article": "Neither Hologic nor Rovers had input into the research design, analysis or interpretation of results.\nThe home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\n\"We found in this sample, all of the women who had high-grade lesions had HPV-positive home self-collection results,\" Smith said.\n\"This is a proof-in-principle study that we used to determine whether home self-collection is highly effective for detecting high-grade disease,\" Smith said.\n\"This is a demonstration that mailing self-collection kits and returning them to test for high-risk HPV infection has big potential to increase screening access among under-screened women, and to do that successfully,\" said UNC Lineberger's Jennifer S. Smith, the study's senior author, and a professor in the UNC Gillings School of Global Public Health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not place a pricetag on HPV screening \u2014 which would include the test kit, analysis and follow-up clinical visit. However, the release does explicitly say that \u201cthere is more work to be done, such as identifying ways to make the self-collection process more efficient and cost-effective.\u201d That acknowledgment is enough to earn it a satisfactory rating here.", "answer": 1}, {"article": "Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called \u201cbad\u201d cholesterol, but still at risk, seem to be identified, according to Mayo Clinic research being presented at the American College of Cardiology\u2019s 66th Annual Scientific Session.\nOver the eighteen years, researchers recorded occurrences of heart attack, stroke, revascularization and death.\nThe present study is also the first to test its clinical utility in a U.S. population.\nOverall, 5.1 percent of patients had a major cardiovascular event each year.\nResearchers measured four different types of ceramides in the blood at baseline and combined the values into a 12-point scale.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the blood ceramide test costs.", "answer": 0}, {"article": "\"CCSVI equals hope and a lot of MS patients just are completely devoid of hope,\" Stecker says.\nHowever, Zamboni suggests that the disease instead is the result of blocked blood veins \u2014 leading to inflammation, which, in turn, causes the immune system to attack nerves in the brain and spinal cord.\n\"Even if the treatment is not useful for patients with MS, I don't think that we can abandon the idea of vascular involvement in MS,\" Zivadinov says.\nThese discrepancies, and growing public controversy, prompted the National Multiple Sclerosis Society in the U.S. and the Multiple Sclerosis Society of Canada to take Zamboni's claims seriously.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that some patients have flown to Europe and spent their life savings on the procedure, and an expert calls the procedure \u201ccostly to patients.\u201d\u00a0So we can probably assume that\u00a0the procedure is unlikely to be covered by major insurers or Medicare (who would cover those with chronic disability), and that the costs will run into the tens of thousands of dollars or more.\u00a0This is important information for the typical patient who isn\u2019t wealthy enough to\u00a0carry this kind of cost burden.\u00a0The story could have been more explicit about all of this\u00a0and provided more specifics\u00a0about the financial aspects of the procedure. However, we think the main point\u00a0to convey here is that the surgery is expensive and patients will have to pay their own way. The story does this \u2014\u00a0though barely \u2014 so we\u2019ll award a satisfactory.", "answer": 1}, {"article": "As the study's authors point out, \"The mechanism(s) by which circumcision reduced acquisition of an STI [sexually transmitted infection] is thought to be related to the microenvironment of the thin, lightly keratinized mucosal lining of the inner foreskin.\"\nMale-to-male sexual activity has been shown to lead to an increased rate in STIs, including HIV.\nPeople don't even like to say the word out loud.\nThis tissue is subject to small tears that allow potential access of pathogens into the bloodstream.\nIt has long been established that men who are uncircumcised are more prone to contracting sexually transmitted infections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story didn\u2019t discuss costs, we don\u2019t think the cost of circumcisions is really in question.", "answer": 2}, {"article": "Anal Cancer Fund, and a philanthropic donation.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\n\"In this first prospective phase II trial for refractory metastatic SCCA, our exploratory analysis of pre- and on-treatment tissues samples revealed potential correlations between immunologic biomarkers and clinical outcomes to nivolumab,\" said Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology and national study principal investigator.\nStudy team members for the correlative analysis included Armeen Mahvash, M.D., Interventional Radiology; Luis Vence, Ph.D., Jorge Blando, D.V.M., and James Allison, Ph.D., all of Immunology; Robert Wolff, Cancer Medicine; Aki Ohinata, GI Medical Oncology; Chimela Ohaji, Investigational Cancer Therapeutics; and Padmanee Sharma, M.D., Ph.D., Genitourinary Medical Oncology.\nMetastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the sky-high cost of nivolumab, the drug tested in this study. It\u2019s disappointing because it\u2019s at least the second time MD Anderson has failed to mention the cost of this drug in a news release. In a separate review last fall, HealthNewsReview.org calculated the monthly cost of nivolumab to be in the vicinity of $12,600, excluding administration. Nor does this review address whether a patient\u2019s health insurance is likely to cover the cost.", "answer": 0}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nWhile collagenase itself is not patented, the companies do have patents on the use of the enzyme to treat Dupuytren\u2019s and Peyronie\u2019s.\nTwo years ago, the drug giant Pfizer, which sells the erectile dysfunction drug Viagra, licensed the European rights to Xiaflex from Auxilium for an initial payment of $75 million.\nFounded in 1957, it struggled for decades to find uses for the product, almost going out of business before licensing the drug to Auxilium in 2004.\nThey are also shielded from competition for seven years under a federal law aimed at spurring development of drugs for rare, or \u201corphan,\u201d diseases \u2014 even though newer estimates suggest these two diseases are not as rare as thought when the drugs were given orphan status.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The main story estimates a course of treatment will cost\u00a0about $5400,\u00a0and the sidebar helpfully compared this amount to some of the other treatment options including surgery and\u00a0needle aponeurotomy.", "answer": 1}, {"article": "Radical therapy causes lifelong erectile problems and around one in five patients also suffer from incontinence.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\nHe says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the costs of either VTP or of active surveillance, the current standard of care for low-risk prostate cancers. Given that VTP is a new commercialized therapy involving both a drug and a device, it\u2019s likely to be considerably more expensive than monitoring.\nFurthermore, the study indicates that 75 of the 197 patients who started the therapy were retreated within 2 years. \u00a0Because cancer was still being detected during follow up, this implies that these patients will need the same monitoring as those undergoing active surveillance.", "answer": 0}, {"article": "But some cancer organizations reject the panel's advice.\n\"This study will only add to the confusion for women and their physicians,\" said Dr. Daniel B. Kopans, director of breast imaging at Massachusetts General Hospital and a radiology professor at Harvard Medical School.\nOn Tuesday, the American College of Radiology (ACR), the Society of Breast Imaging and the American Society of Breast Disease launched \"Mammography Saves Lives,\" a campaign designed to encourage women to have an annual mammogram starting at age 40.\n\"Mammography is not perfect; no one has claimed that it is,\" said Kopans, a member of the ACR Commission on Breast Imaging.\n\"That physicians are still debating the relative merits of screening mammography despite the wealth of data suggests that the test is surely a close call, a delicate balance between modest benefit and modest harm,\" Welch wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a big one to miss. Mammograms usually are covered by insurance, but because of the conflicting guidelines, there is a concern that some insurance companies won\u2019t want to cover mammograms for women under 50. Also, if a woman doesn\u2019t have insurance and falls into the right demographic, they will need to foot the bill. It would not have been difficult to find out how much they cost and even to find someone to estimate how much is spent every year in the U.S. on mammograms.", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\nTUESDAY, May 31, 2011 (HealthDay News) -- At the moment, a diagnosis of autism is based on subjective evaluations, but a new way of using MRI might be an objective way of spotting the disorder, Columbia University researchers report.\nAlthough this study was done with school-aged children and teens, the same test can be done with children as young as 18 months, Hirsch noted.\nDr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children's Medical Center of New York in Lake Success, said that \"although the investigators did indeed find significant differences on neuroimaging between controls and autistic children, the clinical utility from a diagnostic standpoint is unclear.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story deserves high marks for noting the high costs of an MRI. \u201cThis test costs no more than a standard MRI, which runs around $1,500, Hirsch noted.\u201d", "answer": 1}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Hooray for details on cost, including nuances about \u201cfree\u201d but only with prescription. We also believe the details on availability and position on shelves is very important.\nHere\u2019s what story says:\n\u201cUp until the past few months, the female condom lived on store shelves, usually right next to the male condoms. But it was difficult to get shelf space and secure the product in every outlet, Fisch tells BuzzFeed Health. Plus, the female condoms came in three-packs, making them more expensive than a big box of male condoms.\nRecently, Veru Healthcare moved FC2 behind the counter, where it\u2019s available in packs of 12 with a prescription from your provider. Under the Affordable Care Act, insurance plans must cover at least one form of contraception from each FDA-approved method at no cost. And since FC2 is the only FDA-approved female condom, it will be free with a prescription from your doctor.\u201d", "answer": 1}, {"article": "The study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nIn general, there was a 40 percent increase in prostate cancer in men who had no sons.\nAnd now, a real pill for your unreal illness.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs.", "answer": 0}, {"article": "The test was developed at the University of Bradford, UK.\nCo-first author Dr Mojgan Najafzadeh from the University of Bradford said: \"We feel that we've taken it as far as we can in proving that the test works with high predictability for cancer outcome, and IMSTAR are the right partners to improve it still further.\"\nDr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release\u2019s lead emphasizes efforts to bring this blood test to market, there are no cost estimates in the text. A source affiliated with the company that licensed the test is quoted as valuing the maintenance of \u201caffordable cost,\u201d but we have no idea what that might mean.", "answer": 0}, {"article": "Once that occurs, the team hopes to work with cardiologists to quickly move the research into clinical trials, involving chemotherapy and heart transplant patients.\n\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\n\"This is something that nobody has ever seen before,\" says Marek Michalak, co-principal investigator and a distinguished professor in the Department of Biochemistry at the University of Alberta's Faculty of Medicine & Dentistry.\n\"It offers hope to those who are living with heart failure,\" adds Luis Agellon, co-principal investigator and a professor at McGill University's School of Dietetics and Human Nutrition.\n\"If cardiac fibrosis can be stopped, then that could substantially improve the outcome for people at risk,\" says Agellon.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At this stage of the research, cost is not of major concern. Having said that, tauroursodeoxycholic acid or TUDCA (the bile salt used in the experiments) is readily available from health food stores (for better or worse) and is relatively inexpensive.", "answer": 2}, {"article": "People seemed to have mental health benefits from physical activity regardless of whether they reported working out to the point of exhaustion or barely breaking a sweat.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\nBut when it comes to mental health benefits, \u201cthe majority of the protective effect comes from the first one or two hours of exercise each week,\u201d said study author Samuel Harvey, associate professor of workplace mental health at the Black Dog Institute and the University of New South Wales, in an email.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t a factor in this story given that the researchers are suggesting that even minimal exercise, such as walking and cycling, can lead to the decrease in depression they say that they have found. It costs nothing to walk and, aside from the cost of a bicycle, cycling is also free. Perhaps the biggest cost is a time cost\u2013people who work long hours at sedentary jobs may have a hard time fitting this into their schedules.", "answer": 2}, {"article": "In dark suits and blue shirts, with serious expressions on their round faces, they walked to stand next to their mother in a very beige room outside Washington, D.C.\n\u201cI feel like I walked into the room with a healthy four-year-old boy and I walked out with a child that was dying,\u201d she said.\nBy October 24, they\u2019ll know if they will be able to keep taking that drug.\nAt the time, Rowan was 2, and Betty suspected that he also had the disease; she\u2019d seen how her son struggled to stand up onto a stepstool in the bathroom to brush his teeth.\nThe drug, called Exondys 51 or eteplirsen, allows the genetic machinery that produces the protein to skip over the mutated part to make something that will work better.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost plays an important role in this story, as the drug (should it come to market) would be expensive and there is considerable uncertainty about whether insurance would pay for it.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nThe analysis included over 5,700 colorectal cancer cases and 7,100 controls from the United States, Europe, and Asia.\n\"In the past, substantial differences between assays made it difficult to integrate vitamin D data from different studies,\" explained Regina G. Ziegler, PhD, a National Cancer Institute epidemiologist and co-senior author on the article.\nCompared to participants with circulating vitamin D concentrations considered sufficient for bone health, those with deficient concentrations of vitamin D had a 31% higher risk of colorectal cancer during follow-up, which averaged 5.5 years (range: 1 - 25 years).\nVitamin D, known for its role in maintaining bone health, is hypothesized to lower colorectal cancer risk via several pathways related to cell growth and regulation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release is not reporting on vitamin D supplementation but about circulating levels of vitamin D in the body. Although some readers may not make this distinction, cost is not strictly applicable here and we won\u2019t penalize the release for not mentioning it.", "answer": 2}, {"article": "Ivacaftor works for people with the G551D mutation of cystic fibrosis.\n\u201cEven thought it only affects a small percentage (of patients) the hope is there that we can finally do something about this disease.\u201d\n\nThe study, published in the New England Journal of Medicine Wednesday, looked at 84 people who got the drug.\nDrug recipients could blow out more than 10% more air from their lungs compared with patients who were not taking the drug, and were about half as likely to have a \u201cpulmonary exacerbation\u201d or a worsening of their lung disease that often requires hospitalization.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nAlthough the company that wants to sell this drug has yet to announce a price, blogs that follow pharmaceutical companies quote a Wall Street analyst who predicts the drug will cost about $150,000 a year. That massive price tag for a drug that patients likely would have to continue to take for their entire lives is certainly something that readers should be told about.", "answer": 0}, {"article": "Dr. Christina Luedke of Children\u2019s Hospital Boston said she carefully screens teenagers and their families before prescribing a pump.\nThe pumps are used for those with Type 1 diabetes, which accounts for about 5 to 10 percent of all diabetes cases and used to be called \u201cjuvenile diabetes.\u201d The more common form is Type 2, which is often linked to obesity and more often affects adults.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nThere were two possible suicide attempts by teens who gave themselves too much insulin, according to the analysis.\n\u201cIt is a constant struggle for a patient who is an adolescent to stay in control of any therapy,\u201d said Steve Sabicer, a spokesman for Minneapolis-based Medtronic Inc., which makes the top-selling insulin pump.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The original AP story told readers the cost of devices, approximately $6,000, and monthly supplies, approximately $250.\u00a0 The St. Paul Pioneer Press, in its shortened version of the AP story, left this information out.\u00a0 So our grade is for the Pioneer Press effort, not the original AP story. \u00a0", "answer": 0}, {"article": "But Himpens tells WebMD he's skeptical either would make much difference.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nHe emphasizes he is not against the use of gastric band surgery, but that based on his study results, patients who opt for the procedure should know there's a good chance they will need a follow-up procedure and they may have less weight loss and more complications than those who choose other weight loss surgeries.\nDespite that degree of satisfaction, \"I think people have exaggerated expectations from the band procedure,\" says researcher Jacques Himpens, MD, an attending surgeon at St. Pierre University Hospital in Brussels.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As with the HealthDay story we reviewed, there was no discussion of costs of the banding procedure nor for regular office visits for band adjustment.\u00a0\u00a0Although these costs were not detailed in the study reported on, this information is readily available.\u00a0\u00a0We think that this is unfortunate given the magnitude of the cost of the procedure. We also would have liked to have seen a comment or two about insurance coverage", "answer": 0}, {"article": "For further information about the company go to creativemedicaltechnology.com.\n2013 Jun 9;11:139. https://www.ncbi.nlm.nih.gov/pubmed/23758954\n\nOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n2017 Jun 24. pii: S2405-4569(17)30160-8 https://www.ncbi.nlm.nih.gov/pubmed/28753830\n\n3 Ichim et al.\n\"Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention anything about the cost of the CaverStem procedure. A look on the company\u2019s website FAQ section shows only that it is not covered by insurance, but there is still no mention of actual cost. Given that the piece claims commercialization is imminent, information about the cost of a procedure that is unlikely to be covered by insurance is warranted.", "answer": 0}, {"article": "Botox and Myobloc carry labels warning of possible adverse reactions near the injection site such as drooping eyelids, and of severe difficulty swallowing in patients with neuromuscular disorders.\nThe way it usually works is, the rats and mice die first.\nThose unapproved uses are another concern of the agency.\nMost involved children with serious diseases like cerebral palsy, who got the injections for muscle spasms (an unapproved, though legal, use).\nOne of the deadliest poisons in nature and a possible bioterrorism agent, this neurotoxin reached the market, in very dilute doses, starting in 1989 as Botox.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs of treatment were mentioned but that\u2019s understandable in the context of this story about potential harms. ", "answer": 2}, {"article": "Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Dept.\nThe Lifestyle Interventions and Independence for Elders Study is supported by a National Institutes of Health/National Institute on Aging Cooperative Agreement (U01AG22376) and a supplement from the National Heart, Lung and Blood Institute (3U01AG022376-05A2S), and sponsored in part by the Intramural Research Program, National Institute on Aging, National Institutes of Health.\nIn addition, there were differences in the measured absolute amounts of exercise performed when comparing objective activity monitoring using a wearable \"device\" and self-report of physical activity.\nThere was a continuous, graded effect with the greatest benefits seen in the participants who engaged in at least 48 minutes of physical activity per week.\nIn the study, published in PLOS ONE on Aug. 18, the researchers evaluated how different doses of exercise for adults age 70-89 would impact the benefits.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although there could be modest costs to those who participate in the kinds of exercise used in this study (e.g. a good pair of walking shoes, a set of ankle weights), it\u2019s clear to the reader that walking at a fairly modest clip, and performing some stretches and balance exercises, can be done at home, in malls, in hallways, in public parks and at very little, if any, cost beyond one\u2019s time.\nHowever, the exercise intervention described here included a twice-weekly supervised program. Although many senior centers offer similar programs for free, there may well be costs associated with participation outside the research program.", "answer": 2}, {"article": "The paper \"Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery\" is available online at http://cancerres.\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\n\"In almost all solid-tumor surgeries, there's a question of margins,\" said Dr. Boppart, who also is a medical doctor.\nBecause of this, excess tissue surrounding the tumor is typically removed, but the question lingers of whether any cancer cells remain to re-emerge later as tumors.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the study was not designed to assess relative costs of gold standard histology and OCT. the release would have helped both the news value of the study and the reader\u2019s understanding of technological innovation if it had included some estimate of costs associated with use of the device.\u00a0Operating room time is incredibly expensive, and any procedure that adds significant time will also add significant cost. In addition, prolonging any surgical procedure will extend the amount of time that the patient is under general anesthesia. We suspect (based on experience with the Dune Medical device, which is similar) that the procedure doesn\u2019t take more than about 5-10 minutes, but the release could have made this clear. Another issue could be the cost of the device to the facility. There is no CPT (billing) code for this procedure, so when commercially available, the cost likely cannot be passed along to the patient. Hospitals may not be interested in purchasing this equipment as they may not be able to get reimbursed for the cost of the device.", "answer": 0}, {"article": "Results from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe patients received 10 such injections during a single catheterization procedure.\n\"This treatment targets these small vessels that have been damaged.\n\"Their activities are severely restricted by their chest pain and right now we have little to offer them.\"\nThe stem cells have shown the ability to repair and replace them in animal models.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 A ballpark could have been given.", "answer": 0}, {"article": "People who don\u2019t get this type of minimally invasive surgery may instead get a more invasive procedure that involves surgeons cutting open the chest to repair a damaged valve.\n(Reuters Health) - People who get minimally-invasive surgery to replace damaged heart valves have an easier time completing daily tasks and a better quality of life after the procedure, a research review suggests.\nThe results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\nSurgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nThis procedure, known as a transcatheter aortic valve replacement, is done by threading a catheter to the heart through a small incision in the chest or from the large artery in the groin - it doesn\u2019t require cutting open the chest.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost. TAVR procedures averaged $55,136 in 2013, 8.4% higher than open-heart surgery, according to research covered by MedPage Today. TAVr procedures are more expensive due to the high cost of the device.", "answer": 0}, {"article": "MONDAY, Dec. 7, 2015 (HealthDay News) -- Evidence is mounting that a marijuana-derived oil might benefit some children with epilepsy whose seizures aren't controlled by approved medications, two new studies show.\nAfter three months, seizure frequency declined by an average 45 percent in all participants.\nAlmost half experienced a 50 percent or greater reduction in seizures, and about one of every 10 patients became seizure-free, the study found.\nAll participants in these studies knew they were taking the oil, which could have affected reports of its effectiveness.\nThe results of one major trial are expected in the first quarter of 2016, he added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned.", "answer": 0}, {"article": "TUHS neither provides nor controls the provision of health care.\n\"We show that we can intervene after disease is established and pharmacologically rescue mice that have tau-induced memory deficits,\" explained senior investigator Domenico Pratic\u00f2, MD, Scott Richards North Star Foundation Chair for Alzheimer's Research, Professor in the Departments of Pharmacology and Microbiology, and Director of the Alzheimer's Center at Temple at LKSOM.\nTo recapitulate the clinical situation of dementia in humans, in which patients are already symptomatic by the time they are diagnosed, Dr. Pratic\u00f2 and colleagues used specially engineered tau transgenic mice, which develop tau pathology - characterized by neurofibrillary tangles, disrupted synapses (the junctions between neurons that allow them to communicate with one another), and declines in memory and learning ability - as they age.\n\"At the onset of dementia, leukotrienes attempt to protect nerve cells, but over the long term, they cause damage,\" Dr. Pratic\u00f2 said.\nThey show, for the first time in an animal model, that tau pathology - the second-most important lesion in the brain in patients with Alzheimer's disease - can be reversed by a drug.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At this level of research, speaking to costs would seem to be unnecessary but since the drug used in the study is commercially available, the cost is relevant and should have been mentioned in the release. The drug is expensive \u2014 at $500 to $3,000 a month for asthma patients depending on insurance and co-pays \u2014 even though it\u2019s impossible to know at this stage what \u00a0the costs or dosing would be if it is ever proven to be useful in patients with Alzheimer\u2019s disease. Noting the cost could have been done in the context of the costs to care for someone with Alzheimer\u2019s for years or decades.", "answer": 0}, {"article": "But they can be deadly in the modern era.\nIt\u2019ll be interesting to see how this translates into making it into a pharmacy, and into the hands of patients.\u201d\n\nCorrection: A previous version of the story misstated some aspects of Aimunne\u2019s work on peanut allergies.\nIt was approved by the FDA in 2003 to treat a form of asthma often triggered by allergens, but Stanford researchers are now testing it on patients with food allergies \u2014 and finding that it might help speed along classic allergy desensitization therapy, in which patients are slowly introduced to escalating quantities of the allergen, via allergy shots or those \u201chome brew\u201d concoctions.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the\u00a0story\u00a0cites the hundreds of millions of dollars of investment made by drug companies and research institutions, it doesn\u2019t address the potential costs of some newly developed commercial products, including one in stage 3 clinical trials that (literally) encapsulates bits of peanut protein designed to offer desensitization to peanut allergy. The approach has long depended on what the article calls the \u201chome brews\u201d of food allergy \u201cconcoctions\u201d and injections that have been compounded and prescribed by allergists for decades. Nor does it mention the cost of a biologic made by Genentech that already is on the market for a form of asthma and is likely much more expensive than antihistamines and even the notorious Epi-Pens that would compete for an expanded market.\u00a0The story also mentions Xolair, but does not mention the cost of this drug, which is quite prohibitive.", "answer": 0}, {"article": "WEDNESDAY, Nov. 30, 2011 (HealthDay News) -- Eating baked or broiled fish as little as once a week may boost brain health and lower the risk for mild cognitive impairment and Alzheimer's disease, new brain scan research suggests.\nFor now, the connection must be viewed as an association, rather than a cause-and-effect.\n\"They had larger brain cells in areas of the brain responsible for memory and learning.\nAll the participants underwent 3-D MRIs, so the researchers could map out the size of each individual's gray matter and track it over 10 years.\n\"We're talking about just a half serving a day,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish in the diet wasn\u2019t discussed but we trust most people have a general idea of those costs.\n ", "answer": 2}, {"article": "But there are still hurdles to clear.\nA genetic test would be \u201cthe Holy Grail of personalized medicine,\u201d said Rob Lenz, Amgen\u2019s global development lead for neuroscience, but no one has made one yet.\n\u201cI\u2019m very enthusiastic, as I think everyone in the field is, about having another treatment option for people with migraines,\u201d said Dr. Elizabeth Loder, a professor of neurology at Harvard Medical School and chief of the headache division in the department of neurology at Brigham and Women\u2019s Hospital.\nTo date, none of the companies has reported serious side effects in clinical trials, but they\u2019ve only reported data from 12-week studies on about 1,500 total patients.\nWith the \u201cexquisite sensitivity\u201d of an antibody, however, scientists believe they can block CGRP without triggering dangerous side effects, Alder CEO Randy Schatzman said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost or an expected cost range for these drugs in development is not mentioned in the story, although one drug company source notes that the \u201chypercompetition\u201d among the four companies may well influence price.", "answer": 0}, {"article": "And the chunky monkeys?\nMost researchers agreed that there was something in the wine that offered protection, and a few years later, even the highly cautious federal dietary guidelines say that moderate consumption of red wine can be beneficial.\nThe important thing is that we passed a milestone where we can now make drugs based on this knowledge and we can potentially slow down aging itself,\" Sinclair explains.\n\"When I Googled this resveratrol, I was shocked to find that red wine was the top hit,\" Sinclair remembers.\n\"Our goal is to prevent and forestall many of the diseases that strike us as we reach 50, 60, and 70.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not speculate on the cost of the drug, which could be substantial. If it\u2019s not too early to speculate about all the potential benefits of this drug (how we could all be taking it soon and how it could prevent the diseases of aging) then it\u2019s not too early to speculate about costs.\u00a0 ", "answer": 0}, {"article": "Effects of two weeks of daily mango fruit intake on vascular function, blood pressure and gut fermentation in healthy adult women.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\nThe honey mango (also referred to as Ataulfo) was chosen for the study due to the high concentration of polyphenols in this popular variety.\nYet once mango was consumed, systolic blood pressure was significantly lower two hours after mango intake compared to baseline values.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. That said, if one has access to mangoes, their cost is likely comparable to many other fruits in some parts of the country and higher in others. This raises the question of cost and access to fresh fruits and vegetables \u2014 which is a significant problem in many parts of the U.S. \u2014 but which is beyond the scope of what we can expect to be addressed in a news release. Taking all of this into account, we\u2019ll mark this as \u201cnot applicable.\u201d", "answer": 2}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided information about the costs for the test.", "answer": 1}, {"article": "Also, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\nThe relationship between statins and cancer is unclear, but other research exploring the impact of statins at the molecular level suggests that these cholesterol-lowering drugs may help control the development of tumor, as well as tumor growth.\n\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nThe findings are based on a review of 22 studies published through October 2009 and were presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Even though both brand name and generic versions of statin medication are available, there was no information about costs in this story. Why this is so \u2013 in a story that suggests a possible future expanded market for these already widely-used drugs, is a puzzle.\u00a0\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The story didn\u2019t discuss the costs of multivitamins, but this is common knowledge.", "answer": 2}, {"article": "The results were just published online by the medical journal The Lancet.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nThe researchers recommend that \"tranexamic acid should be available to doctors treating trauma patients in all countries\" and that it be considered for the World Health Organization's roster of essential medicines.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "TXA costs $10 per treatment, according to the story. Although this cost is characterized as low, the story could have noted that the price may be prohibitively expensive\u00a0in many poor countries.\u00a0", "answer": 1}, {"article": "CHICAGO - The majority of patients were pain free after receiving a new image-guided pulsed radiofrequency treatment for low back pain and sciatica, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).\nSix patients required a second pulsed radiofrequency session.\n\"The results have been extraordinary.\nIt is the most common cause of job-related disability.\nEven without touching the disc, the pulsation serves to resolve the herniation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release.", "answer": 0}, {"article": "After six months, they showed less DNA damage, healthier sperm shape and lower levels of metabolic stress factors.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\nWhile it\u2019s not entirely clear why, part of the reason may have to do with the fact that extreme exercise generates body heat, which can be detrimental to sperm health; for marathoners and people training at intense levels, finding ways to dissipate body heat is a major concern.\n\u201cThis fits reasonably well with what we thought about the effects of exercise,\u201d says Dr. Peter Schlegel, vice president of the American Society of Reproductive Medicine and chairman of urology at New York Presbyterian/Weill Cornell Medical Center.\nIn the study, Behzad Maleki at Justus-Liebig University in Germany and his colleagues recruited 280 sedentary, middle-aged men and randomly assigned them to one of three exercise regimens, or to no exercise, and followed them for six months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of the methodology used in this study. Yes, in general exercise is free via walking or jogging, so we\u2019ll rate this N/A. But, it\u2019s worth pointing out that one of the studied exercise methods here\u2013known as high-intensity interval training\u2013was done on a treadmill, and may require paid expertise to learn how to do it safely and correctly.", "answer": 2}, {"article": "\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nAnother 49 women received control acupuncture and 49 received massage.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\nFourteen women who received depression-specific acupuncture reported pain during the needling, as did seven in the control-acupuncture group.\nModern research has most often focused on the effects of acupuncture on painful conditions, like chronic back pain and migraines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of acupuncture, which is relevant, especially since acupuncture is not always covered by insurance", "answer": 0}, {"article": "Moreover, the test's rapid turnaround and relatively low cost, especially compared to next-generation DNA sequencing, provide a potential opportunity for universal monitoring of more patients than is currently done,\" explained lead investigator Hanlee P. Ji, MD, Associate Professor in the Department of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center.\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.\nIn one patient, the assay was able to show the presence of three different mutations.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\nThe three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We like that the cost issue is addressed. But the terms are vague. It says that the test is \u201crelatively low cost.\u201d Relative to what? To traditional \u201cwhole body imaging,\u201d as the release notes above? Then provide some of those costs. It also says, \u201cespecially compared to next-generation DNA sequencing,\u201d which costs how much?", "answer": 0}, {"article": "Pryor believes balloons are a better option for patients who are candidates for weight loss surgery but don't want surgery.\n\"While there is potentially easier insertion that does not require sedation, I still doubt after removal there will be weight loss,\" he said.\nThe study lasted a year, but \"we don't know what happens after that,\" Pryor said.\nWhether the weight loss will last over the long term isn't known, said lead researcher Dr. Aurora Pryor, director of the Bariatric and Metabolic Weight Loss Center at Stony Brook University in New York.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story notes that the U.S. price of the Obalon intragastric balloon has yet to be announced, the story could have reported that the device and related care typically cost $2,500 to $4,000 in Europe, where it has been available for almost three years. Costs are also likely markedly higher than working with a behavioral team.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the technology needed to implement these real-time imaging techniques is costly for hospitals, and lists examples of technologies that range in price from $1.5 million to $7 million. The story could have done even better if it had placed those numbers in context. How much does it normally cost to outfit a surgical suite? And what do these costs mean for patients? It would have been hugely helpful to compare costs for the same surgery with or without the new technology. On a related note: are insurers covering the costs of these real-time imaging procedures?", "answer": 1}, {"article": "The scientists published details of their work online Thursday in the journal Science Translational Medicine.\nThe success represents an advance that is \"absolutely critical in terms of making prosthetics useful,\" says Mike McLoughlin, an engineer at the Johns Hopkins University Applied Physics Laboratory.\nAt the moment, they are still too expensive, too bulky and too finicky to be used outside a laboratory setting.\n\"But we're really not at the point where we could, say, get him to feel the difference between silk and burlap,\" Gaunt says.\n\"We were able to see the parts of his brain that became active when he was watching videos of a hand being touched,\" Gaunt says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states:\u00a0\u201cAt the moment, they [robotic arms\u00a0with touch sensitivity] are still too expensive, too bulky and too finicky to be used outside a laboratory setting.\u201d\nWhile the story\u00a0could have helped provide more\u00a0context by explaining the cost of the experimental surgery on the patient\u2013even without speculating on the cost of the robotic arm\u00a0itself\u2013this is enough to merit a satisfactory rating.", "answer": 1}, {"article": "Do not ignore or delay obtaining professional medical advice because of information accessed through ASN.\n\u201cIn the absence of randomized trials and large individual cohort studies, this study is the best available evidence to drive clinical decision-making by patients and doctors on whole dietary approaches in chronic kidney disease.\u201d\n\nDisclosures: The authors reported no financial disclosures.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nPatients with chronic kidney disease are advised to follow dietary recommendations that restrict individual nutrients such as phosphorus, potassium, protein, and sodium; however, empirical evidence suggests that these restrictions\u2014which can be difficult to abide by\u2014have limited effects on reducing patients\u2019 risk of premature death.\nHighlight\n\u2022 A healthy diet high in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and low in red meat, salt, and refined sugars was linked with a reduced risk of early death in an analysis of 7 studies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release could have explored two aspects of costs: the costs on a per-patient or per-month basis of treating chronic kidney disease and also the costs of eating healthy the way the people in this study did, but we suspect there is little data available on the latter.", "answer": 0}, {"article": "The end point also shifts the paradigm from palliation to cure,\" remarked Dr. Scher.\nHowever, none achieved the primary end point of undetectable PSA with testosterone recovery at 20 months after initiation of therapy with ADT alone, although one patient had a PSA of Of the 15 patients with bone metastases, 14 (93%) reached an undetectable PSA when ADT, surgery, and radiation were used.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nAccording to lead investigator Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, \"The sequential use of the three different modalities helped illustrate the role and importance of each in achieving the undetectable PSA with normal testosterone level end point, which represents a 'no-evidence of disease' status.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed at all. Given the scope of the treatments, we think it\u2019s important for a release like this to at least give some cost estimates. It\u2019s also unclear from the release whether insurance would cover these treatment plans. The study\u00a0noted that one patient could not complete the protocol\u00a0due to lack of insurance coverage.", "answer": 0}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nThe study began in the 1980s, and along the way has recorded valuable data from participants, including diabetes test data.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nNow we can educate the patient sooner and start treatment earlier to prevent complications of diabetes such as heart attack, dialysis and amputations.\"\nThe new study \"helps us move quicker to treat diabetes,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided no information on how much these tests cost. A check online found CVS drug store offered these tests for $59 apiece.", "answer": 0}, {"article": "This translates into a 36 percent lower risk of dying among the screened population.\nThe results are in keeping with those of a much larger study published last month, which showed that these 3-D X-rays, or CT scans, reduced the death rate among 53,000 current and former heavy smokers by 20 percent compared with screening using regular chest X-rays.\nA total of 64 people died in the screened population, the authors report \u2014 but applying the death rate among people with the same underlying characteristics in one of the unscreened populations, they estimated that the number of deaths would have been 100.\nFor instance, to compare death rates, the researchers tracked how many people died among those who were screened, then pulled out all the people with similar underlying characteristics in the other two groups and looked at their death rates, Hanley explained.\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nThe story reports that this sort of scan costs about $300. The story also notes that if screening is effective, the scans would need to be repeated, though there is no consensus on what schedule would make the most sense. The CDC estimates that more than 45 million Americans currently smoke cigarettes and more than that many are former smokers. \nThe story should have more clearly pointed out that the cost of a screening program is not the cost of a single test, but the cumulative cost of repeatedly screening many millions of people as well as the cost follow-up tests and treatments\u2026 both the treatment of potentially dangerous lung cancers, but also the treatment of the many suspicious lesions that turn out not to be cancer. A separate study found a false positive rate of more than 20 percent, suggesting that follow-up tests (and the costs they incur) would be a frequent added expense. The story should have at least referred to the national costs and the additional testing and treatment costs triggered by false positive scans.\n", "answer": 0}, {"article": "Any HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nThe device, created by scientists at Imperial College London and the privately-held U.S. firm DNA Electronics, uses a drop of blood to detect HIV, then creates an electrical signal that can be read by a computer, laptop or handheld device.\nThe researchers say the technology, although still in the early stages, could allow patients to regularly monitor their virus levels in a similar way to diabetes patients checking their blood sugar levels.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The\u00a0cost of\u00a0either test in the study isn\u2019t shared, and it\u2019s a simple question to ask for a ballpark figure on what a mass-produced\u00a0lab-on-a-chip might cost. Absent that number, a comprehensive HIV viral load test with traditional (and bulky) equipment is about $24.90 to $44.07. Such tests are recommended by the World Health Organization (WHO) 6 months after the start of anti-retroviral treatment, at 1 year, then every year after that. \u00a0\u00a0", "answer": 0}, {"article": "This, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nGet the facts.\nAll the evidence shows Gardasil to be safe and to be effective against a virus that causes horrific illnesses.\nAnd please, talk to your board-certified doctor and find out if there are any vaccinations you need.\nDon\u2019t listen to the anti-vaxxers, who just want to scare you.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention was made of the cost of the vaccine.", "answer": 0}, {"article": "Oct. 18, 2010 -- Vitamin B12 may help protect the brain against Alzheimer's disease, according to new evidence that suggests the vitamin and an amino acid called homocysteine may both be involved in the development of Alzheimer\u2019s.\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\nHigh levels of vitamin B12 in the blood are already known to help reduce levels of homocysteine, which has been linked to an increased risk of Alzheimer's disease, memory loss, and stroke.\nIn addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\n\u201cOur findings show the need for further research on the role of vitamin B12 as a marker for identifying people who are at increased risk of Alzheimer\u2019s disease,\u201d says researcher Babak Hooshmand, MD, MSc, with Karolinska Institutet in Stockholm, Sweden, in a news release.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions B12 supplements, but does not discuss their cost. Even if inexpensive, we think cost is important. ", "answer": 0}, {"article": "Such a study is in the works, he added.\nAlthough the trial was primarily designed to look at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual meeting in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and cut LDL, HDL's evil twin, almost in half.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\nTo assess the safety of the trial, investigators randomly chose 1,623 adults with coronary heart disease who were taking cholesterol-lowering statins to receive either anacetrapib or a placebo for 18 months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Because this story clearly points out that the drug is only part way through the clinical trial process and still has a long way to go before it might be on the market, we can excuse it for not giving cost estimates. Nevertheless,  It would have been informative for readers to have made some comment about the potential economic impact of a cholesterol drug, given that over 20 Million Americans are currently taking statin. On the day that the trial results were announced, Merck stock went up even though the market as a whole sagged, demonstrating the financial implications of this research.", "answer": 2}, {"article": "CHICAGO -- Acupuncture gets a thumbs-up for helping relieve pain from chronic headaches, backaches and arthritis in a review of more than two dozen studies -- the latest analysis of an often-studied therapy that has as many fans as critics.\nSeveral weekly sessions are usually involved, typically costing about $60 to $100 per session.\n\"Perhaps a more productive strategy at this point would be to provide whatever benefits we can for our patients, while we continue to explore more carefully all mechanisms of healing,\" he wrote.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe new analysis combined results from studies of patients with common types of chronic pain -- recurring headaches, arthritis or back, neck and shoulder.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that sessions cost $60 to $100 and are covered by some private insurance, but not Medicare.", "answer": 1}, {"article": "Currently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nThe U.S. National Cancer Institute has more on lung cancer.\n\"This drug inhibits the pathway that's activated in smokers.\nIt turned out that gene activity in the PI3K pathway was \"off the chart\" in smokers with lung cancer versus those without the disease.\n\"This definitely has potential.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable because of the early stage of research. ", "answer": 2}, {"article": "For more information, visit http://www.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nToday, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida.\nAlthough a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities.\nFrom 1995 to 2005, according to Science Watch, Hennekens was the third most widely cited medical researcher in the world and five of the top 20 were his former fellows and/or trainees.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Does not mention any costs \u2014 either direct or societal. And because patients over 74 are typically covered by Medicare, the financial costs to society would be substantial. \u00a0In addition to covering the cost of screening mammography, Medicare also covers the use of computer-aided diagnosis (CAD) which multiple studies have found to increase the number of false positives.", "answer": 0}, {"article": "\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nAt the one- and two-year markers, survival rates for that group was approximately 78.5 and 48 percent, respectively.\nBetween 2000 and 2007, the participants were divided into one of two six-month chemotherapy groups: one receiving fluorouracil and folinic acid post-surgery and the other receiving gemcitabine.\nDr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, described the study as \"important,\" but he does not believe it will alter the current approach to post-surgical chemotherapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of these chemotherapy agents are not discussed. The study compared a drug available only as a brand name to a regimen consisting of two drugs available generically.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of sugar pills is not in question. But the story does explore the cost implications of developing more effective placebos. It says, \u201cTo the extent that doctors can use placebos to improve patients\u2019 symptoms, they can use the real drugs less, which may be expensive or toxic.\u201d", "answer": 1}, {"article": "The Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\nThe Brennan family in Glen Rock, New Jersey, believes it works..\n\n\"So we give the kids, and we take it ourselves, elderberry every morning right after breakfast,\" Kevin Brennan told CBS News.\n\"There is not enough research about whether [elderberry] works in children and there is also isn't enough information about the proper dose in children,\" Dr. Anna Minta of Johns Hopkins Children's Center told CBS News.\n\"The duration and the severity of how they get sick is much less and they get healthy quicker,\" he said.\nSome parents and even pediatricians believe elderberry extract or syrup can help kids stay healthy and lessen the symptoms when they do get sick.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The brand of elderberry extract mentioned in this story sells for about a dollar a dose at Walgreens. By our calculations, the daily use recommended by the manufacturer and apparently followed by the family highlighted in this story would cost a family of four about $1500 dollars/year.", "answer": 0}, {"article": "For this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nAll patients were interviewed about diet, health habits and medical history.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nThey found 2,141 people with polyps, leaving 3,166 polyp-free controls.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of fish in the diet is not in question.", "answer": 2}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the cost to the consumer for this product.\u00a0 \nThe story did, however, provide an estimate about projected annual sales.", "answer": 0}, {"article": "Dr. Vijay B. Vad, a sports medicine specialist at the Hospital for Special Surgery in Manhattan, compares the problem to a thermostat in a cool room.\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\nThe study, which was financed by the implant maker Medtronic, followed 100 patients who had undergone spinal surgery and had developed chronic pain in one or both legs.\nThe implants cost about $20,000, and the procedure, hospital care and follow-up can bring the total bill to about $40,000.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes the cost of the device alone ($20,000), the cost inclusive of hospital and other charges ($40,000), and the cost in comparison to other operations (\"cheaper\"). But let\u2019s not forget that the alternatives include non-invasive treatment.\u00a0 ", "answer": 1}, {"article": "For more information, visit the Quaker Oats Center of Excellence at www.QuakerOats.com.\nThe statistically significant results of the randomized, controlled crossover study (n=47) showed that a 250-calorie instant oatmeal serving (with an additional 113 calories of skim milk) enhanced satiety and feelings of fullness, reduced the desire to eat and may even lead to a lower caloric intake at lunch, compared to a 250-calorie serving of cold, oat-based cereal, also served with an additional 113 calories of skim milk.\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\nFor more information, please visit www.QuakerOats.com, www.Facebook.com/Quaker or follow us on Twitter @Quaker.\n\"When we took it a step further and evaluated the intake four hours post-breakfast, we found that after consuming instant oatmeal, the participants chose to eat significantly less at lunch compared to those who ate the oat-based, cold cereal.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the cost per serving of Quaker instant oatmeal versus Honey Nut Cheerios (the brands studied) might be similar, it still would be worth noting as the news release is attempting to make the case that an instant oatmeal breakfast will lead to less caloric intake at lunch. Nevertheless, we\u2019ll rate this Not Applicable since most readers have at least a rough idea of what these products cost.", "answer": 2}, {"article": "On The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nNow, there's new information showing how important folic acid is.\nTo watch the segment,\n\nFor much more on folic acid, from the federal Centers for Disease Control and Prevention, click here.\nCarbon moxoxide is an invisible killer.\nYou can't see or smell it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs in this piece.\u00a0 It would have been very easy to note that it is CHEAP!", "answer": 0}, {"article": "Treatment is authorized and completed under the supervision of a licensed healthcare provider.\nThe peer-reviewed published multi-center Freespira clinical trial, presented by Dr. Tolin, demonstrated that 71% of patients were panic attack free immediately after treatment and 79% of patients were panic attack free 12 months post-treatment.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nThis latest study, conducted as part of the VITAL Program at Allegheny Health Network in Pennsylvania, also demonstrated a 50% reduction in healthcare costs in patients with panic symptoms 12 months after being treated with Freespira.\nSymposium Chair David Tolin, Ph.D., Director of Anxiety Disorders Center, The Institute of Living, and Adjunct Professor of Psychiatry, Yale University School of Medicine, commented, \"Studies of the Freespira treatment have shown that this innovative approach to treating patients suffering from panic symptoms and panic attacks not only significantly reduces or eliminates these symptoms in approximately 80% of patients, but also results in meaningful reduction in health costs.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not give us the cost of the Freespira treatment. This is especially troubling since the release claims that the treatment reduces overall costs \u201cby 50%\u201d after a year of treatment.\nWhen we reviewed a news story about Freespira in 2015, the monthly cost was reported as $500.", "answer": 0}, {"article": "This abstract can be found at sirmeeting.org.\nOne month later, researchers followed the progress of eight patients and found that GAE significantly decreased pain (-58 mm on the Visual Analog Scale), reduced stiffness and increased physical function (-36.3 on the Western Ontario and McMaster University Osteoarthritis Index).\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\n\"This procedure could have a significant impact in the treatment of osteoarthritis pain as a whole,\" said Bagla.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release doesn\u2019t mention anything about the cost of this new procedure although interventional radiography procedures are normally complex and expensive. The release is remiss in not pointing out that GAE is likely to be more costly than other standard treatments for knee OA such as corticosteroid injections, exercise regimens and weight loss.", "answer": 0}, {"article": "A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\nThe drug formulation, which consists of two layers of microbeads with an inner drug-loaded core, delays release of the active ingredient for 8-10 hours and then provides controlled extended release designed to cover the early morning into the evening.\nThe medication was well tolerated, with the main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\n\"Developing new formulations of effective medications for patients with ADHD improves the lives of children with the disorder,\" says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of methylphenidate in this release. While the price of the existing forms of this drug\u00a0are readily obtainable, this research touts a new extended/delayed release form of the medicine and therefore, it is conceivable that the price will be different, and more than likely higher.", "answer": 0}, {"article": "SUNDAY, March 6, 2011 (HealthDay News) -- A simple blood test may one day offer a safe way to detect Down syndrome during pregnancy, researchers say.\n\"Down syndrome is a common birth defect, with one Down syndrome birth in every 600 births in all populations,\" said lead researcher Philippos Patsalis, chief executive medical director of the Cyprus Institute of Neurology and Genetics in Nicosia.\n\"The cost is much lower than the invasive procedures,\" he said.\n\"So they will be able to make a very personal decision without anyone realizing it,\" he said.\nFor more information on Down syndrome, visit the U.S. National Library of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Only mention of cost was the researcher\u2019s quote:\u00a0\u201cThe cost is much lower than the invasive procedures.\u201d\u00a0 Oh?\u00a0 What is that cost?\u00a0 How much lower?\u00a0 We\u2019re not told.", "answer": 0}, {"article": "Research pharmacist, Krista Bohlen, director of personalized pharmaceutical medicine at the Avera Institute for Human Genetics, believes that genetics play a large role in how different individuals react to certain medications, but cautions doctors and patients against relying solely on this method for answers.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nThe test offered by Avera is $179 and is often covered by insurance.\n\"My energy's been really great,\" she says.\n\"I wondered if I would ever find something that works.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the genetic test touted costs $179 and says it is often covered by insurance.", "answer": 1}, {"article": "But investors had been anticipating a bigger effect.\nThe findings, which involved following 9,340 patients for a median 3.8 years, were also published online in the New England Journal of Medicine.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nNovo, the world\u2019s biggest diabetes company, had said in March that Victoza cut heart risks \u201csignificantly\u201d in the study but the scale of the benefit was only disclosed on Monday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of Victoza.\u00a0This would have been easy to include\u00a0given\u00a0the drug is widely prescribed and pricing information is freely available on the internet. The article compares the performance of Victoza against rival diabetes drugs, so it would have been informative to have a comparison of costs as well.", "answer": 0}, {"article": "\"Where's the money going to come from?\n\"I can certainly understand why people are concerned about linking these -- it's clear we're going to have to carve billions out of the health-care system,\" said Thomas Herzog, chairman of gynecologic oncology at Columbia University New York Presbyterian Hospital, speaking on behalf of ACOG.\nThe Obama administration distanced itself from the breast exam guidelines announced Monday by a federal task force, saying the panel does not set government policy or determine what services are covered by the government.\n\"But we don't have any concerns that women are being asked to give up something that is helpful.\nThe American College of Obstetrics and Gynecologists (ACOG) recommended the change after concluding that more frequent testing did not catch significantly more cancers and often resulted in girls and young women experiencing unnecessary stress, anxiety and sometimes harmful treatments because of suspicious growths that would not cause problems.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes two sources who dispute the notion that the guidelines are motivated by a desire to save money. \nUnfortunately, it never says how much money the test costs\u2013or whether applying the new guidelines would cost or save money. ", "answer": 0}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were happy to see some attention to the potential cost of the stent and in comparison to the existing drug eluting stents.\u00a0In addition, the story provided information on the market size at the present time.", "answer": 1}, {"article": "Even so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\n\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nAmong the different bacteria tested were L. acidophilus, S. boulardii, and L. casei, which occur naturally or are added to products like supplements, yogurt, miso, soy milk and some juices.\nOn average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nProbiotics May Help Soothe The Stomach\n\nYogurts and supplements loaded with \"friendly\" bacteria may be able to fight the nefarious ones and soothe fickle bowels, according to a new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Because we always think cost is important \u2013 even if it doesn\u2019t amount to much \u2013 we wish the story had included some cost estimates for probiotics-containing products. Does it add much to the cost of yogurt and other products?", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n\u201cThe patients who came in were treated for the very things that they were sensitive to, and that included indoor allergens, like dustmite and pet dander, as well as outdoor allergens such as tree pollen, grass pollen, ragweed pollen,\u201d Dr. William Reisacher, an associate professor of otolaryngology and director of allergy services at Weill Cornell Medicine/New York-Presbyterian Hospital, told FoxNews.com.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story earns a Satisfactory rating because it says that the toothpaste mentioned in the story costs $400 every three months (or $1,600 per year), and that it isn\u2019t covered by health insurance.\u00a0 But we would have liked it better had the writer offered comparative costs for a year\u2019s worth of the current allergy treatment of choice.", "answer": 1}, {"article": "The boxes are a new idea for many Americans.\nThe idea for baby boxes started in Finland in the 1930s, and is tied to a sharp drop in sudden infant deaths, according to Dr. Kathryn McCans, a pediatrician who chairs New Jersey\u2019s Child Fatality and Near Fatality Review Board.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nBut when they\u2019re linked to a practice that started in Finland decades ago to help babies sleep safely, they\u2019re taking on a new purpose as so-called baby boxes make their way to the U.S.\n\nParents are beginning to take baby boxes home from hospitals along with their newborns.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does say that these boxes are being distributed for free, but by a for-profit company that requires parents to \u201cregister\u201d at a website in order to receive one.\nWe think the collection of information on new parents may benefit the for-profit company. The story would have been stronger if it faced that issue squarely. See more on this under the funding and conflicts of interest criteria section below.", "answer": 1}, {"article": "The answer?\n\"We need more data before we can know what is normal variation in the population at large,\" Gratton said.\nAs such, the technique potentially could be used to distinguish healthy people from people with brain diseases or disorders, and provide insight into variations in cognitive ability and personality traits.\n\"But the individual differences were really easy to pick up, even in a population that is really very similar.\nDuring the scans, each person performed tasks related to vision, memory, reading or motor skills, or rested quietly.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the cost of functional MRIs, or how likely it is that insurance companies might cover that cost.", "answer": 0}, {"article": "People who carry a faulty BRCA1 gene are at high risk of developing aggressive breast cancer.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\nThe research was supported by The National Breast Cancer Foundation, The Qualtrough Cancer Research Fund, The Joan Marshall Breast Cancer Research Fund, the Australian Cancer Research Foundation, Cancer Council Victoria, the Cancer Therapeutics Cooperative Research Centre, an Amgen Preclinical Research Program Grant, the National Health and Medical Research Council, the Victorian Cancer Agency, and the Victorian Government Operational Infrastructure Support Scheme.\nThe research, which also involved researchers at the Australian familial cancer consortium kConFab and US biotechnology company Amgen was published today in Nature Medicine.\n\"This is potentially a very important discovery for women who carry a faulty BRCA1 gene, who have few other options.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. Given that denosumab is already on the market to treat other conditions, under the trade names XGEVA and Prolia, this is a significant oversight. Costs are listed in various public outlets as ranging from $990 for a six-month course to $1,650 per year (neither estimate includes the cost of clinical care to administer the drug).", "answer": 0}, {"article": "Lupron critics said autism parents may not understand the dangers.\nIf you see there is another option out there that can help your child, most parents are going to choose that option.\"\nThe drug mainly is used to treat endometrial cancer in women and prostate cancer in men, and sometimes to chemically castrate sex offenders.\nThe group gives children the cancer drug Lupron to stop their bodies from making testosterone, saying the drug helps expel toxic mercury and quells aggressive or sexually explicit behavior by kids with excessive levels of the male hormone.\n\"These people are preying on the fears of parents.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that Lupron costs about $5,000 a month but is seldom covered by insurance. Good job to address both points. ", "answer": 1}, {"article": "Those studies are expected to launch later this year, including two at Penn.\n\"But we've found this new class of drugs, checkpoint inhibitors, seems to be more effective than what's been available in the past.\"\n\"Some had temporary stoppages, but they were able to continue.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\n\"One great sign in this study is that none of the patients had to stop treatment because of side-effects,\" Alley said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention of costs here. Describing cost information in new cancer therapies is essential as it will have a significant impact on future patient access.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Hormone replacement therapy (HRT) can carry serious health risks, but a new study adds to evidence that menopausal women who use the hormones may have lower odds of developing colon cancer.\nThese latest findings do not alter that advice.\nOver the next decade, 442 women were diagnosed with colon cancer.\nThe implications of that finding, if any, are not yet clear.\nMost of the women were past menopause at the outset, and 61 percent were currently using HRT.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of hormone replacement therapy is not in question.\u00a0 ", "answer": 2}, {"article": "The findings don't confirm that the ancient Chinese discipline relieves hot flashes, and only 14 men participated in the study, which was conducted by researchers at New York Methodist Hospital and Weill Cornell Medical College of Cornell University.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nTheir reported level of hot flashes dropped markedly.\nThe study, published in the April issue of the International Journal of Radiation Oncology, Biology, Physics, also found that acupuncture relieved the heart palpitations and anxiety often associated with hormone therapy for prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have easily provided some cost estimate for four weeks of twice-weekly acupuncture sessions. But it didn\u2019t.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned, but since the story is about an early vaccine trial (one that showed the vaccine to have less than desirable effectiveness), we think cost is not applicable in this case. ", "answer": 2}, {"article": "Although one-third of patients have reported experiencing painful scalp sensations and facial twitching, these tend to fade after several treatments.\nBut the point is that if we can identify the circuit that causes the symptoms, we can target that circuit and make it function better through brain stimulation.\nIts efficacy varies from patient to patient and, like most prescriptions for depression, TMS has its own set of side-effects.\nExperiments treating Parkinson\u2019s and autism, the other two conditions for which TMS is approved, have seen some success among neurologists.\nAccording to Johns Hopkins University School of Medicine\u2019s description of the technique, a coil is fitted to the front of a patient\u2019s head so the electromagnetic pulses can target the prefrontal cortex of the brain, which controls emotion.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is mentioned in the photo caption. And, the reader will find a cautionary comment lower in the story warning that \u201cTMS is not widely covered by health insurance,\u201d although other TMS stories indicate that insurance companies are slowly coming to the table.", "answer": 1}, {"article": "LONDON (Reuters) - Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.\nHis suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.\n\u201cIt is further proof that aspirin is, by a long way, the most amazing drug in the world,\u201d he said.\nAspirin, originally developed by Bayer, is a cheap over-the-counter drug used for pain and to reduce fever.\n\u201cYes, okay, it\u2019s a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nAlthough the story does not discuss costs, the price of aspirin is low and well-known.", "answer": 2}, {"article": "The scientists hypothesized the cancer could use this molecule to render chemotherapy ineffective.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nWe need to wait for these results, expected later this year, to see how effective this approach is compared to chemotherapy alone.\u201d\n\nProfessor Udai Banerji\u200b, author of the study and deputy director of the Drug Development Unit at The ICR and Royal Marsden, acknowledged in an interview with Newsweek the cohort of patients was small, \"however anything more than 20 patients usually gives one a rough idea [of the effectiveness of a treatment].\"\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nConfirmatory studies will be essential and if positive would broaden our armamentarium for fighting this cancer.\u201d\n\nThis article has been updated with comment from Professor Udai Banerji\u200b.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the potential cost of this drug, which is likely to be significant due to the high cost of new cancer therapies. As a comparison, a recently approved new cancer drug also made by Astra Zeneca, Imfinzi, costs $180,000 a year.", "answer": 0}, {"article": "So are lycopene packed tomatoes really the magic fruit?\nBut the foods we eat are complex and filled with many nutrients, making it tough to prove what is really providing benefits.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\nHowever, daily intake of tomatoes may give better protection.\"\nThough the researchers tried to take these lifestyle factors into account when calculating their findings, it may be that these things influenced the outcomes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of tomatoes, or other food sources of lycopene, is not in question.", "answer": 2}, {"article": "TrovaGene is also developing a test for Down syndrome.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nThe tests are not regulated by the Food and Drug Administration because they are not used for medical purposes, a spokeswoman said, but the agency is investigating the explosion of home genetic tests like these and genome-sequencing kits.\nShe was not unhappy, she said, but \u201cit was like the baby boy disappeared.\u201d\n\nWhen the Lewises complained to Acu-Gen\u2019s president, they were told, \u201cWe are very sure that genetically you are having a male,\u201d she said, reading a transcript of the conversation, which they recorded.\nSex-determination tests are part of a new frontier of fetal DNA testing, which can be used to determine paternity and blood type, and is being used to develop early screening tests for genetic diseases or disorders like Down syndrome.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes one price estimate of about $250 for the testing. We would have liked more detail about whether new details on accuracy of the tests might change their status in the marketplace, or whether insurability status might change.", "answer": 1}, {"article": "That post-stroke condition is known as neglect.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\nShe said that because of that, the new findings are \u201cpromising,\u201d but added that brain stimulation is still an experimental technique, and not ready to be used as part of normal stroke rehabilitation.\nFor the study, Italian researchers randomly assigned 20 patients with neglect to get real or fake magnetic stimulation in ten sessions over two weeks, in addition to their conventional rehab program.\nIt\u2019s also not clear if the treatment might help most neglect patients, or if the findings only apply to certain groups, she told Reuters Health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the transcranial magnetic stimulation\u00a0(TMS) machine costs about $50,000, but it could also have noted \u2014 as WebMD did \u2014 that there are\u00a0costs associated with training clinicians to use\u00a0the machine. In addition, neither story tried to estimate what a course of\u00a0treatment might\u00a0cost patients or their insurers \u2014 information which probably could be gleaned by looking at the costs of TMS treatment for depression. Although there was room for improvement here, we think the story does enough to\u00a0merit a satisfactory.", "answer": 1}, {"article": "This was the second time a so-called \"female Viagra\" failed to make it on the market; in 2004, an FDA panel said no to Intrinsa, a testosterone patch meant to hormonally help women with a lack of desire for sex.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\nIn fact, for nearly all alternative practices there are no large-scale studies saying if they work or not.\nOne of Blakeway's patients wrote an article for the magazine, Cookie, about her experience with acupuncture for her flagging sex life.\nTo find a practitioner familiar with Chinese medicine, go to the National Certification Commission for Acupuncture and Oriental Medicine\n\nBlakeway says between acupuncture and Chinese medicine, she's able to help about 65 percent of the women who come to her with sexual problems.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information about costs here \u2014 significant considering that the therapies discussed have very little\u00a0evidence to show that they work and will be paid for out of pocket. ", "answer": 0}, {"article": "SUNDAY, Jan. 17, 2010 (HealthDay News) -- Giving a vaccine through a scratch on the skin (scarification) triggers a stronger immune response than injected vaccines, say U.S. researchers, who also found that scarification requires 100 times less vaccine to prompt an immune response.\n\"The lessons we are learning from these studies of vaccination by scarification could help us develop new and more powerful vaccines for influenza, HIV, malaria and other infectious diseases,\" Kupper explained.\nIn a series of tests, the Brigham and Women's Hospital researchers also found that the memory of T-cells -- the cells that mount an immune response against invading viruses -- may be more important than the antibodies generated by injected vaccines.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"The ability of vaccination through injured epidermis -- or scarification -- to generate such powerful tissue-resident protective T-cells is a completely novel observation that should make us reconsider the way we think about vaccine delivery for all infectious diseases, as well as cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs, but that seems like a minor issue in this context, so we\u2019ll grade this Not Applicable.", "answer": 2}, {"article": "\"Beta- blocker drugs compete with stress hormones and bind to the same target receptors [on a cellular level], but unlike stress hormones, do not activate cancer cells,\" said Dr. Des Powe, a senior healthcare research scientist at Queen's Medical Centre, Nottingham University Hospital NHS Trust, in Nottingham, England.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\nOther experts called the results interesting, but preliminary.\nIt's not known, she said, whether there is a true association or whether it may be due to chance or another factor.\nThey had a 71 percent reduced risk of death from breast cancer during the study compared to those who were either taking other blood pressure drugs or weren't on any blood pressure medications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion regarding the cost of beta blockers. ", "answer": 0}, {"article": "MONDAY, Aug. 6, 2012 (HealthDay News) -- Treatment with growth hormone-releasing hormone improves memory and focus in healthy adults and in those who already show some signs of mental decline, new research finds.\nAll of these hormones are believed to play a role in brain health, and decreasing levels of these hormones are suspected to play a role in the development of Alzheimer's disease.\nPeople with this condition don't yet have Alzheimer's disease, but they do have problems with memory and focus, and they're at higher risk of developing Alzheimer's disease, according to the Alzheimer's Foundation.\nIn all, 137 adults, including 61 with mild cognitive impairment, completed the current study.\nThe study volunteers were between 55 and 87 years old, with an average age of 68, according to the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was never mentioned \u2013 a significant oversight since, as Reuters Health reported, a single shot may cost $700.", "answer": 0}, {"article": "Patients treated with a placebo saw a 1 percent increase in LDL cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nLOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this drug is still experimental, the story should have told readers that some analysts predict that this sort of drug, known as a biologic, will cost at least $10,000 a year, compared to less $200 a year for a generic statin. Many observers predict that the extremely high cost of this new type of cholesterol-lowering treatment is likely to mean it would be used only when statins don\u2019t do the job, which means this line of research may never be relevant to most people.", "answer": 0}, {"article": "\"It was a very aggressive cancer and we needed to start treatment right away,\" said Chris Mullin, Brian's father.\nOne tagged with antibody, the cancer can be more easily recognized and attacked by the body's own white blood cells.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\n\"I've been through it, it was the past, time to move on,\" he said.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even though this is an experimental approach, it is possible to make some estimate of costs and this should have been included in the story.\u00a0 The story reports on two years of research results.\u00a0 You can be assured that somebody is tracking costs after two years. ", "answer": 0}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\nKevin Lee, head of epigenetics discovery research at GSK, who also worked on the study, said he too was excited about the findings, although it will probably be many years before the drug could potentially reach the market.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the extremely early stage of research, we can understand why cost was not discussed.", "answer": 2}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed but it is understandable that they might not be known after an experiment on only 6 people. ", "answer": 2}, {"article": "The Lancet.\n\"If the SCOOP screening strategy was taken up in exactly the same way as in the study in all UK women aged 70-85 years, we estimate that the strategy could prevent up to 8000 hip fractures per year in the UK.\nThe research, involving more than 12,000 older women and carried out in collaboration between the universities of Birmingham, East Anglia, Bristol, Leicester, York and Sheffield, found that screening through GP practices allowed patients to be targeted for treatment.\nThe team used a University of Sheffield developed tool called FRAX, which predicts the probability of a hip fracture or a major osteoporotic fracture (a hip, spine, upper arm or lower arm fracture), to identify older women at high risk.\nA new study, published in The Lancet, has shown that a simple questionnaire, combined with bone mineral density measurements for some, would help identify those at risk of hip fracture.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release was very thorough in most areas. However, we\u2019re only told that the proposed screening program is \u201clow cost.\u201d But the FRAX screening is just a questionnaire, so there is minimal cost to using it.\nThe costs of screening, of course, arise from those women who go on to get bone density scans and get treated for osteoporosis. We think the additional costs of scans and treatment deserved a mention.", "answer": 0}, {"article": "For further information, please visit: http://www.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nInitial clinical trials were carried out on a small number of glaucoma patients and compared with tests on healthy people.\nWe were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine.\nAlthough detection has been improving, most patients have lost a third of vision by the time they are diagnosed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of the test and the potential costs or cost savings of identifying patients earlier than they otherwise would be identified.", "answer": 0}, {"article": "The researchers did two brief sleep experiments.\nIn the real world, when people don\u2019t get enough sleep they tend to overeat, which may limit how much results from this lab experiment might happen in reality, the authors note in a report scheduled for publication in the journal Diabetes Care.\nOn one occasion, the volunteers were permitted just 4.5 hours of rest for four nights, followed by two evenings of extended sleep that amounted to 9.7 hours on average.\n\u201cIt is likely though that if any group of people suffer from sleep loss, getting extra sleep will be beneficial.\u201d\n\nTo assess the impact of sleep on diabetes risk, Broussard and colleagues focused on what\u2019s known as insulin sensitivity, or the body\u2019s ability to use the hormone insulin to regulate blood sugar.\n\u201cThe results from the present study are unlikely to be fully reflective of what may occur in persons who are older, overweight or obese, or have other potent risk factors for diabetes,\u201d said James Gangwisch, a researcher at Columbia University who wasn\u2019t involved in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the \u2018intervention\u2019 (catching up on sleep) is what is at issue here, and that is \u2018free\u2019. So we\u2019ll rule this Not Applicable.", "answer": 2}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nGetting the vaccine makes it less likely that adults will get the painful rash that can occur when the varicella zoster virus, which causes childhood chickenpox, reactivates to cause shingles.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nJan. 11, 2011 -- The herpes zoster vaccine, better known as the shingles vaccine and recommended for adults 60 and older, cuts the risk of getting the painful disease by 55%, new research finds.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThis story includes a comment that \u201cvaccine expense is another barrier for some\u201d and that not all insurance plans cover the cost of this vaccine, but readers are not told that it can cost about $200. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion since cost and insurance are at least addressed.\n", "answer": 1}, {"article": "Over a six-week process, registered dietitians educated and monitored the progress of more than 90 IBS patients.\nMeanwhile, we strongly recommend that IBS patients work with their physician and a registered dietitian to navigate the Low-FODMAP diet to take control of their IBS symptoms.\u201d\n\nEswaran received funding to conduct the research from the University of Michigan Nutritional and Obesity Center and Prometheus Diagnostics.\nMany practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "A low FODMAP diet might raise grocery bills, since it requires specialty products that eliminate wheat, lactose, fructose, and other common ingredients. It\u2019s understandable that the news release doesn\u2019t address a potential modest increase in food expenses. However, the cost of working with a registered dietitian over several months to adopt a low FODMAP diet and tailor it to a patient\u2019s individual food tolerances is significant. That should have been addressed in the news release, along with how that cost might be offset by eliminating less effective pharmaceutical therapies and increasing the productivity of patients who regularly miss work because they are debilitated by IBS symptoms.", "answer": 0}, {"article": "THURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\nSymptoms of breast cancer may include:\n\u2022 A lump in the breast or armpit.\nThis is an important part of breast health,\" she said.\n\"All women should know how their breasts look and feel so they can recognize any changes in them.\n\u2022 Mammogram: An X-ray of the breast used to examine breast changes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article lacked information on costs. Insurance does not always cover screening.", "answer": 0}, {"article": "So he fears that fat injections for breast enlargement could increase unnecessary biopsies.\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nThis kind of is a two-fer: trim fat where you don\u2019t want it and put it where you do.\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says that breast augmentation using fat grafts is usually more expensive than implants, but it does not include any price range for either type of procedure.", "answer": 0}, {"article": "In a separate group of 33 patients with a mutation of the BRAF gene involved in cancer cell growth, the overall response rate was 52 percent for the combination.\nThe combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nThe overall response rate, defined as tumors that shrank by at least 30 percent, was 61 percent for the 72 patients who received the combination versus 11 percent among the 27 who got Yervoy alone.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\n(Reuters) - A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost at all, and it\u2019s a glaring omission. Yervoy costs around $30,000 per injection \u2014 and the combined cost of treatment with the two drugs would likely cost a patient (or that patient\u2019s insurance provider)\u00a0more than a quarter of a million dollars.", "answer": 0}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nIn the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nThe study is published in the online edition of Archives of Neurology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 It\u2019s understandable that costs wouldn\u2019t be discussed at this early stage of research.", "answer": 2}, {"article": "Bochner teamed up with Northwestern oncologist Dr. Leo Gordon and colleagues to test if this BTK inhibitor could shut down an enzyme inside cells that is involved when you have an allergic reaction.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\nCurrently, the study is being expanded to adults with food allergy to see if their skin test and basophil activation test responses show a similar reduction with just a few doses of ibrutinib and how long such benefits might last.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\n\"The hope is that drugs like BTK inhibitors will protect people with food allergies from having anaphylaxis, or at least increase how much of that food they can eat without reacting,\" Bochner said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this line of research is in the earliest stage of human tests, the release should have noted that the drug, as it was used in the study, cost more than $100 a day. Obviously, cost is an issue that would have to be dealt with before declaring that this treatment could be used routinely by allergy sufferers.", "answer": 0}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study suggested a \"clean\" version of torcetrapib could increase so-called good cholesterol without raising blood pressure and causing adverse cardiovascular events.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\n\"It is still possible that CETP inhibitors without off-target effects of torcetrapib could be viable as a therapy for cardiovascular disease,\" said an editorial published in today's edition of the New England Journal of Medicine, which concluded: \"It is possible that CETP inhibition might be better suited to certain subgroups of patients, such as those with impaired clearance of LDL cholesterol or low levels of HDL cholesterol at base line,\" the editorial said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs, or potential costs of the new drug. At least a general statement could have been made about costs of combination drugs. ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - A new study bolsters the case that daily aspirin may help protect against cancer, although the effect seems weaker than previously thought.\nOther researchers are more skeptical.\nBut it didn\u2019t seem to matter whether people had been on aspirin for more or less than five years.\nRay called for trials that specifically check people for new cancers at given intervals to weed out the selection bias marring the previous research.\nThe effect was strongest for gastrointestinal cancers, such as colon cancer and stomach cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin is not in question.", "answer": 2}, {"article": "\"Oh absolutely,\" she said.\nBut this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\n\"It's terrifying to think if she hadn't had the ultrasound.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The broadcast mentioned that a breast ultrasound is less expensive than MRI, but it does not list the cost. Medicare reimbursement for breast ultrasound is $85, \"which does not fully cover the costs of perfoming and interpreting the examination.\" [ref Berg].\u00a0 This highlights the common cost problem of insurance payments not being sufficient to cover costs.\u00a0 The same situation applies for mammography \u2013 hospitals lose money on every mammogram they do.\u00a0 The source article contains information on issues related to increased resources anticipated with additional screening. Discussion could have easily been included.", "answer": 0}, {"article": "The alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nDuring the sessions they received suggestions for mental imagery designed to minimize the intensity of their hot flashes, such as images of a cool place.\nThe women were also given a recording of the hypnotic induction, and they were asked to practice self-hypnosis at home daily.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\nHot flashes and night sweats are the most common symptoms of menopause, affecting some 80% of women.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail the costs of the weekly sessions of therapeutic hypnosis, which are likely to be high.", "answer": 0}, {"article": "The committee reviewed recent studies which had investigated aromatase inhibitors and/or tamoxifen in women with this particular subtype of breast cancer.\n\"We've learned a huge amount about the various side effect profiles of these products,\" said Dr. Harold J. Burstein, co-chair of the ASCO committee which prepared the guidelines and associate professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute in Boston.\nAnd sometimes we have to make decisions about using drugs that are probably a little less effective but at the same time we have to take into account the financial standpoint,\" said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.\nAll three aromatase inhibitors on the market - Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane) - were essentially equal in their benefit.\nAfter a systematic review of medical research on the subject, experts reported that adding an aromatase inhibitor -- a drug that reduces the amount of estrogen produced in the body -- has clearly been shown to reduce the number of tumor recurrences in postmenopausal women compared with the standard drug tamoxifen, which works by blocking the action of estrogen on cancer tumors that are estrogen-receptor positive.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story specifically points out that generic tamoxifen costs $21.90 a month and the aromatase inhibitor, Arimidex\u00ae, costs $379.80 a month. The story was also quick to note that a generic form of Arimidex\u00ae is now available and costs much less. Going one step further, the story included a discussion of\u00a0how the cost of treatment can factor into the decision-making process. ", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of any of the types of hormone therapy, an important piece of information since they are often not covered well by insurance.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nSophisticated imaging of the brain and its function is an expensive diagnostic tool.\u00a0 Applying these sophisticated tests to all children would be a huge expense.\u00a0 While other stories at least mentioned cost (for example the CNN report quoted the author of the study as saying, \u201c\u2026as the usage of fMRI becomes more useful and commonplace, the high cost per scan would go down\u201d) this story fails to do so.", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more on HPV.\nAlthough the U.S. Centers for Disease Control and Prevention recommends that 11- and 12-year-old girls begin receiving the vaccine as part of school vaccination efforts, an advisory panel voted against routine use of the vaccine in boys and men.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\nThe researchers also saw some reduction in the number of precancerous penile lesions, although at this point they said it's impossible to know whether this will result in a lower rate of penile cancers.\n\"Studies like this underscore the 'human' in human papillomavirus,\" said Fred Wyand, director of the HPV Resource Center at the American Social Health Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Yes, the story provides the retail price of the vaccine. But we would have liked mention of the deeper economic questions. Are insurers covering it for young men? Does the overall economics of paying for young men to get it makes sense for society?\u00a0 Cost is part of the reason that only a minority of young women have chosen to get Gardasil, even though it is both available and recommended (by many) for them. Cost is a central issue in how these vaccines will or won\u2019t achieve medical goals of prevention. When writing about vaccination programs, these larger system-wide costs and benefits are an important part of public discussion.\nThe editorial that accompanied the published study in the journal provides additional information on the cost effectiveness of HPV vaccination in boys and girls \u2013 which could have been tapped.\u00a0 ", "answer": 0}, {"article": "The manufacturer of the sleep aid Snooz'n says its 2.5-ounce \"shots\" contain five milligrams of melatonin; Unwind, a \"relaxation blend,\" has three milligrams per 12-ounce can.\nThe number of nonalcoholic beverages making relaxation claims continues to rise; 40 new ones came on the market in 2010, according to Mintel.\nIt's typically released by the pineal gland around 10 p.m.; secretion stops around 4 or 5 a.m., helping to trigger the body to wake up, Scharf says.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\nThe chief ingredient in many of these beverages is melatonin, a hormone that induces sleepiness and helps coordinate the body's biological clock.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "These beverages don\u2019t come cheap, but you wouldn\u2019t know it\u00a0from reading the story, which had no information on costs.\u00a0According to the blog for iChill, one of the drinks mentioned in the story, a 2 oz \u201cshot\u201d\u00a0retails for $2.99 at 7-Eleven.", "answer": 0}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide the cost of either anastrozole or tamoxifen.\u00a0Hormone therapy is a\u00a0regimen of daily medication for 5 years, so whether switching\u00a0medications or continuing with tamoxifen has major cost implications is debatable.\u00a0 Instead of just giving sales figures for Astra-Zeneca, the story should have explained how much these drugs cost consumers. \n\u00a0\n", "answer": 0}, {"article": "Combining ursolic acid with either curcumin or resveratrol prevents cancer cells from gobbling something that they need to grow, glutamine.\nWhen you dine on curry and baked apples, enjoy the fact that you are eating something that could play a role starving -- or even preventing -- cancer.\nPublished online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of adding these foods to your diet would be negligible for most people, although taking supplements over long periods could pose a significant cost.", "answer": 2}, {"article": "Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others: the ability of HETIOZ\u00ae to provide significant benefit in the treatment of the symptoms of jet lag disorder; Vanda's ability to obtain marketing approval for the use of HETLIOZ\u00ae in the treatment of jet lag disorder; and other factors that are described in the \"Risk Factors\" and \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC's website at www.sec.gov.\nThe results of that study were published in The Lancet in 2009.1 The observation that HETLIOZ\u00ae is effective in treating the symptoms caused by an abrupt advance of the circadian cycle of a magnitude of 5 or 8 hours suggests that HETLIOZ\u00ae will be an effective therapeutic tool in the treatment of individuals that experience symptoms of jet lag.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nThe risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ\u00ae is increased by approximately 2-fold compared with younger patients.\nIt is also reported that 8% (approximately 1.6 million) travel in Business or First class.2\n\n\"We are extremely pleased with the outcome of this study which establishes the utility of HETLIOZ\u00ae in the treatment of jet lag disorder as HETLIOZ\u00ae was shown to overcome a significant circadian challenge of an 8 hour phase advance.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Hetlioz currently costs an estimated $280 per capsule or $102,000 a year for the blind and a relatively few non-blind who use it to treat a rare circadian rhythm disturbance. Cost is a significant data point in any story promoting a drug\u2019s benefits, especially if the benefits are relatively modest.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The frequent emergency room visits described in this story represent a big cost burden that this treatment might help alleviate. But the treatment itself is also likely to be expensive and might counteract these benefits. Regardless, the story doesn\u2019t mention costs.", "answer": 0}, {"article": "Yin Cao, an instructor in the Medicine, Clinical and Translational Epidemiology Unit at Massachusetts General Hospital and Harvard Medical School, presented the information Monday at the American Association for Cancer Research meeting in Washington.\nThe study was well conducted and was able to control for a number of important confounders.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nEven the ancient Egyptians used the natural form of it for pain relief centuries ago.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no costs discussed in this story, however, aspirin is ubiquitous and very inexpensive.", "answer": 2}, {"article": "The body mass index, or BMI, associated with the lowest risk of death has increased since the 1970s, a study finds, from 23.7, in the \"normal\" weight category, to 27, which is deemed \"overweight.\"\nI know you journalists always want that,\" Nordestgaard says.\n\"This is total speculation,\" Nordestgaard says.\nMore than 100,000 people were involved.\nSo he and his colleagues sliced and diced the data to see what could account for the shift.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 2}, {"article": "New drug may help MS\n\u201cEven if it doesn\u2019t work, it\u2019s going to be another step down the road.\u201d\n\nIn autoimmune disease, the body\u2019s immune cells mistakenly attack and destroy healthy tissue.\n\u201cIf this works, it is going to be absolutely fantastic,\u201d said Bill Heetderks, who directs outside research at the National Institute of Biomedical Imaging and Bioengineering, part of the National Institutes of Health, which helped pay for the research.\n\u201cYou can try to induce tolerance to peanuts or eggs or shellfish or whatever you are allergic to,\u201d he said.\nCurrently, the main treatment is to suppress the immune system, an approach that can leave patients vulnerable to infections and cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes a researcher saying that one stage of the research\u2026\u201dwas hideously expensive.\u201d \u2026 \u201cIt cost probably about a million dollars to treat 10 patients using live cells,\u201d he said.", "answer": 1}, {"article": "\"And in that case, I see this as just a waste of money.\"\n\"So if there's no targeted treatment to follow up on the results of this kind of scan, then it's just another expensive test for parents who are already barraged with so many tests at diagnosis,\" she said.\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It takes until the very end of the story for there to be a comment on costs. An autism activist mentions,\"So if there\u2019s no targeted treatment to follow up on the results of this kind of scan, then it\u2019s just another expensive test for parents who are already barraged with so many tests at diagnosis,\" she said. \"And in that case, I see this as just a waste of money.\" We don\u2019t know enough about the benefits or the harms so it\u2019s hard to say if it\u2019s a waste of money. The cost information about MRIs would not have been hard to find.", "answer": 0}, {"article": "LONDON (Reuters) - A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient\u2019s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.\nNo significant side-effects remained after two years.\nThe light-sensitive drug used, called WST11, is derived from bacteria found at the bottom of the ocean.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the potential costs of this therapy.", "answer": 0}, {"article": "\u201cModels are models,\u201d Lin said.\nAs a result, when researchers counted deaths in each group, it wasn\u2019t a clean comparison: Rather than comparing screened to unscreened men, they were comparing assigned-to-screening men to not-assigned-to-screening men.\nIn April, however, the task force proposed instead that men aged 55 to 69 discuss PSA\u2019s pros and cons with their doctor and then decide what to do, factoring in that if 1,000 men get regular PSA screening for a decade it will save about one life.\nSome experts in cancer screening and statistics said its novel approach was \u201con shaky ground\u201d and used a \u201ccompletely unverifiable\u201d methodology that they had \u201cnever seen before,\u201d but others praised its \u201cintriguing and innovative approach.\u201d There was one area of agreement, however: \u201cI imagine it\u2019s going to generate some buzz,\u201d said biostatistician Ted Karrison of the University of Chicago.\nAmong other drawbacks, the tests lead to overdiagnosis (meaning a biopsy finds malignant cells but they are so innocuous they would never harm, let alone kill, the man) as well as incontinence and impotence from treatment (including of harmless cancers).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The lack of any cost information is one flaw to this article. Reminding the readers of the costs of PSA screening programs\u2013in terms of the huge volume of medical services that it can catalyze (including the costs of the test itself, the drugs, surgeries, urology consultations, hospital and operating time, as well as the lost income for men who are recovering from treatment)\u2013is a necessary part of the story.", "answer": 0}, {"article": "This determined the most effective treatment frequency.\nOne can expect the effects to be similar to exercise therapy,\" said Dr. Tatsuya Kondo, who lead the research.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\nThe heat shock response (HSR) is activated as a response to stress in the human body, but its function decreased in those with type 2 diabetes.\n\"This device is very easy to use since it simply attaches to the abdomen, and it has a low-impact on the patient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release\u00a0makes no mention of the potential cost of the device. A potential source of comparison is Ab toner and waist trimmer electronic belts of various brands sold at Walmart. They vary from the $21.25 Healthmate Forever AB Muscle Stimulation Multi Belt, to the $149 Ab Transform Pro Abdominal, Arm and Leg Training System.", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wish the story would have at least mentioned whether there were any cost differences among the three diets.\u00a0 Was there a cost to the workplace cafeterias to offer these diets in the specialized manner in which they delivered them?\u00a0 We also wish the story had mentioned whether the study subjects had to pay, or were paid, to participate (a criticism of another diet study).\u00a0 ", "answer": 0}, {"article": "She said self-exams may not reveal tumors early enough to improve survival.\nDuring the women's health movement of the 1970s, the self-exam gained importance as a means for women to take charge and rely less on a paternalistic health system.\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\n\"By the time a breast cancer is large enough to be detected by self-exam, tumor biology is the most important predictor of outcome, not finding a tumor a few months before it would have become apparent,\" she said.\nDr. Elizabeth Steiner, director of the breast health education program at\n\n, said each woman must decide for herself, with full knowledge of the pros and cons, whether to perform self-exams.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It doesn\u2019t cost anything to do a breast self-exam. \nThe story does mention potential harms of increased doctor visits and unnecessary diagnostic procedures triggered by self-exams, with additional cost implied. ", "answer": 1}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nMenopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms.\nThe most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The report lists a variety of methods for reducing menopausal symptoms, but no costs associated with any of the methods are mentioned.\nMany of the recommended methods \u2014 like cognitive behavioral therapy, hypnosis and acupuncture \u2014 may not be covered by insurance or even available to many women depending on their location. ", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t project any ballpark of costs for the drug, yet it was able to project the company\u2019s plans to file for approval within the next two months.\u00a0 You can be sure if they\u2019re ready for that, they have a ballpark idea of how much they will charge for the drug. ", "answer": 0}, {"article": "(Editing by Pravin Char)\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n\u201cThis is one of the first handful of examples of drug repurposing, where a new use has been found for an existing drug,\u201d Vasudevan said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We couldn\u2019t find good cost information for this drug. It hasn\u2019t been on the market, for one, and the company that once had the patent on the drug is now out of business, so there are no good company filings that might shed light.", "answer": 2}, {"article": "\u201cWe believe the benefits increase with age.\nBut there are harms, and particularly in their 40s, women have to make a decision for themselves.\u201d\n\nOne potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless.\nThe guidelines state that from ages 40 to 74, screening will reduce the odds of dying from breast cancer, with women 40 to 49 benefiting the least and those 60 to 69 benefiting the most.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of explaining how the USPSTF recommendations may affect insurance coverage of mammography screening \u2014 which is laudable, given the complexity of the issue. However, the story does not tell readers the bottom line: how much would a mammogram cost if it were not covered by insurance? While we found varying estimates, a 2011 paper stated that the overall cost of a mammogram was $266 \u2014 a considerable sum, and likely out of reach for many women. This was a shortcoming of both the New York Times and Washington Post stories.", "answer": 0}, {"article": "For more information about NIH and its programs, visit http://www.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\nDOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nIn addition to NHBLI, the study received funding from the NIH's National Institute of Diabetes and Digestive and Kidney Disease, the National Institute of Aging, and the National Eye Institute.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The drug being studied,\u00a0fenofibrate, goes by the brand name Tricor. Its costs are well known \u2014 about $100 for 90 pills \u2014 and could easily have been dropped into the release, making it clear how much it would cost for a typical person to replicate the regimen necessary to see any of the benefits seen in the study.", "answer": 0}, {"article": "MONDAY, Dec. 6, 2010 (HealthDay News) -- Long-term use of a daily low-dose aspirin dramatically cuts the risk of dying from a wide array of cancers, a new investigation reveals.\nThe current observations follow prior research conducted by the same study team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the risk of dying from colorectal cancer by a third.\nTwenty years after first beginning a low-dose aspirin program, death risk dropped by 10 percent among prostate cancer patients; 30 percent among lung cancer patients (although only those with adenocarcinomas, the type typically seen in nonsmokers); 40 percent among colorectal cancer patients; and 60 percent among esophageal cancer patients.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin is not in question. Nevertheless, a broad recommendation to begin taking aspirin daily in middle age would likely be followed by at least hundreds of millions of people, thus the cumulative costs would be large. Also, such widespread use would increase the costs of treating bleeding ulcers and other adverse events caused by aspirin, though hoped-for savings in reduced cancer treatment would be an offestting factor to consider. Still, because the cost of aspirin on an individual basis is low and well-known we won\u2019t insist on this point.", "answer": 2}, {"article": "Inexperienced doctors might also take advantage of the robot for surgery if they don\u2019t think they have the skills to do the surgery with only a small cut, Dr. Nezhat said.\nWith the surgeon alone, \u201cthe incision is smaller (and) the manipulations are more controlled,\u201d Dr. Ceana Nezhat, an author on the study and the chair of Obstetrics & Gynecology at Northside Hospital in Atlanta, told Reuters Health.\nBut all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nNEW YORK (Reuters Health) - Robots may not help doctors do a better job on some surgeries, according to a new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter notes that the robots cost $1.5 million apiece, a cost that has to be asorbed at some point by the insurer or the patients. The story also includes some great context from Dr. Tommaso Falcone at Cleveland Clinic saying spending a lot of money on robots might not be money well spent.\nBut we\u2019re not given any per-patient per-treatment cost estimates and we\u2019re not told that the robots may drive up cost with longer operating room time and added costs for facility, anesthesia and surgeon \u2013 huge cost drivers.", "answer": 0}, {"article": "\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\nThe U.S. National Library of Medicine has more on heart disease.\nThen they injected the cells into rats that had heart attacks and tried to manipulate the cells with a toy magnet.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\nWe needed to find a way to guide more of the cells directly to the area of the heart that we want to heal.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable due to very early stage of research. ", "answer": 2}, {"article": "For more information, visit http://www.\nSSIs are the most common hospital-acquired infection and the leading cause of hospital readmission following an operation.1,2,3 Due to the prevalence off SSIs, the WiSOR research team decided to see if postoperative wound monitoring could be effectively achieved by having patients upload photos through the WoundCare app and answer a few brief questions to gather information not easily captured through images.\nPatients gave universally positive feedback about the app's ease of use and the ability to have wounds monitored\n\nCHICAGO (Jan. 19, 2018): A new smartphone app called WoundCare is successfully enabling patients to remotely send images of their surgical wounds for monitoring by nurses.\n\"We set out to come up with a protocol where patients could become active participants in their care and allow us to be in closer communication and monitor their wounds after they leave the hospital,\" said lead study author and general surgery resident Rebecca L. Gunter, MD.\nThe app was developed by researches from the Wisconsin Institute of Surgical Outcomes Research (WiSOR), Department of Surgery, University of Wisconsin, Madison, with the goal of earlier detection of surgical site infections (SSIs) and prevention of hospital readmissions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release addresses the overall cost of post-surgical infections and the potential for cost savings using the monitoring app. The lead author of the study is quoted saying that preventing readmissions due to infection could lead to \u201csignificant savings to the health system,\u201d and the release notes that \u201ccapturing specific numbers related to cost-savings was not part of this study.\u201d\nThe news release helpfully states that providers have to pay for training and in some cases smartphones for patients, and pay staff to monitor the data in a \u201cdedicated transitional care program.\u201d\nThe the app itself is free for patients to download, which isn\u2019t explicitly mentioned. There\u2019s no mention of whether hospitals have to pay to use it.", "answer": 1}, {"article": "The study followed more than 1,600 people over the age of 60 for five years.\n\"No, no, I think if they have high cholesterol, then absolutely, yes then that's a good time to put them on statins,\" Devi said.\n\"What it tells us is that statins might not be effective in slowing the progression of disease, but they might ... prevent disease,\" said Mary Haan of the University of Michigan.\n\"It seems as though the statins because they lower cholesterol reduce production of these plaques,\" said Dr. Gayatri Devi.\nA patient calls you up and says \"I'm losing my memory a little, would you be tempted to put them on a statin, LaPook asked.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The segment does not indicate how much statins cost. They range from pennies to nearly $4 per pill.\u00a0 \nGiven the anchor\u2019s and reporter\u2019s questions about whether people should start taking statins now as a prophylactic despite conflicting research, the price should have been mentioned.\u00a0\n\u00a0", "answer": 0}, {"article": "Other Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\nExcluding patients on placebo, the median survival without disease progression was 29 weeks.\n\u201cMen with late-stage prostate cancer usually die from bone disease.\u201d\n\nAfter 12 weeks of treatment, 31 patients were randomly selected to receive either a placebo or cabozantinib.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of projected costs \u2013 not even a statement that the company has not yet projected costs.\u00a0 We look for cost information in every single story.", "answer": 0}, {"article": "The new drug is no miracle cure and it is not approved for young children, who are one of the most vulnerable groups, so the C.D.C.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nsaid, and should be taken only in the first two days after symptoms like fever, aches and sniffles appear.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story devotes its second paragraph to cost, including how that cost may differ depending on whether patients have insurance. Well done.", "answer": 1}, {"article": "The HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\n\"Acne is among the 10 most prevalent human infectious diseases and recent studies show it has a significant long-term psychological impact on many of the 80+% of teenagers and young adults who suffer from it,\" he added.\nAt 24 hours, the percentage reduction in total acne count with HSRx 2121 was 20 times greater than it was for subjects using the competing product.\nAs with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of cost in the release, not even a mention of where this new product will be on the spectrum of OTC products via-a-vis price. For a product whose manufacturer boasts in the release that it will come out of the gate to become a global competitor, one would expect they\u2019d have a price point to offer.", "answer": 0}, {"article": "This is really about patient care.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\nDespite the fact that all of these patients were capable of leaving the hospital the same day as their procedures, only about 5 percent of these patients actually were discharged without having stayed overnight.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nThe School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost comparison across angioplasty strategies is the raison d\u2019etre of this study and its accompanying news release.\u00a0 The release reflects on costs for both the individual procedure and for the country in great detail.", "answer": 1}, {"article": "\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\nThe risks in the most vulnerable population \u2014 people with other illnesses, like liver disease, or those on blood thinners \u2014 are not known, because these patients are generally excluded from studies.\nThe main advantage of a skin cream is that it bypasses the stomach and much of the bloodstream, theoretically minimizing serious side effects.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nAnd young, healthy patients may not want to bother with creams or gels, which have their maximum effect if applied four times a day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says that the average copayment for a month\u2019s supply of some of the topical NSAID medications is around $30. It would have been nice to include the cost of comparable oral medications.", "answer": 1}, {"article": "And there's another potential problem with existing treatments.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since BMS-790052 is still in early testing, we don\u2019t know what it will cost, so the criterion is not applicable.\u00a0However, given the huge costs of the existing treatment regimen of an interferon and ribavirin, a comment on the potential economic impact of a third drug would have been helpful.\u00a0 Current treatments cost several thousand dollars per month with treatments lasting for 6-12 months.\u00a0 The addition of a third and presumably expensive antiviral is an important aspect of the costs of treatment.\u00a0", "answer": 2}, {"article": "His lab was the first to identify the proteins that can bind marijuana compounds on the surface of immune cells.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\nNewswise \u2014 EAST LANSING, Mich. \u2014 A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is nothing in this release about costs. And there\u2019s really nothing about dosing, either. So a reader and an HIV patient would have no idea what a true marijuana therapy would cost to see any \u2014 assuming there are any \u2014 benefits.\nThe release notes that the study relies on self-reporting of marijuana use by the blood donors and then correlation with THC levels in the blood. We are at least a couple steps away from knowing how much THC is needed for an actual clinical outcome (which is not addressed in the study) and as a consequence would not be able to estimate cost.", "answer": 0}, {"article": "Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\nBotox is currently FDA approved for cosmetic use to lessen frown lines, and for medical use to treat a number of conditions including chronic migraines, bladder incontinence, excessive underarm perspiration, and certain types of neck pain and eye issues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Citing the American Society for Aesthetic Plastic Surgery, the article says that the average cost for a botox treatment\u00a0 was $376 in 2016. We also learn from the article that a typical treatment should confer benefits for about three months. This is important information considering that botox is not currently FDA approved for treatment of depression. Unless a patient is enrolled in a clinical trial, he or she will have to pay the approximately $1300 per year\u00a0out of pocket.", "answer": 1}, {"article": "Chicago \u2014 Local bans on artery-clogging trans fats in restaurant foods led to fewer heart attacks and strokes in several New York counties, a new study suggests.\nThey were once commonly used to make restaurant fried chicken, French fries, doughnuts and other foods and found in grocery items including cookies, crackers and margarine.\nAdmissions for heart attacks and strokes declined in all counties, going from more than 800 to less than 700 per 100,000 people, but the drop was steeper in counties that enacted bans.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThis material may not be published, broadcast, rewritten or redistributed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While there may be costs associated with different food ingredients (i.e., different types of fats), that does not seem relevant here.", "answer": 2}, {"article": "These weekend warriors cram the recommended amount of exercise into one or two days, while the rest of us faithfully head to the gym multiple times a week for a half-hour hamster run on the treadmill.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nThey found the risk of death from all causes was about 30 percent lower for weekend warriors, compared with adults who maintained a sedentary lifestyle.\nOne study, published in 2014 in the journal Heart, suggests that in people with existing heart disease, the risk for cardiac arrest and stroke was the same for people who exercised more than an hour a day compared with those who didn\u2019t exercise at all.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the nature of the study we don\u2019t think that this issue is relevant.", "answer": 2}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of one treatment course is estimated at $750-1,500 and the story says that some may need one one to four treatments.\u00a0 So up to $6,000 for ugly toenails.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear the \u201cbig unknown\u201d remains the price and \u201chow much people are willing to spend to cut a day or so off of a bout of flu.\u201d The story reports that Genentech, the drug\u2019s manufacturer, said it\u2019s too early to comment on the drug\u2019s U.S. price. The story also notes that in Japan, where the drug was invented, it \u201csells for the equivalent of about $43.50.\u201d", "answer": 1}, {"article": "The average age of children in the study was 7.\nBut the most immediate question for Sobel is \"whether an olfactory impairment is at the heart of the social impairment in autism.\"\n\"The difference in sniffing pattern between the typically developing children and children with autism was simply overwhelming,\" says Noam Sobel of the Weizmann Institute of Science in Israel.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address cost at all. And while the release notes that a so-called \u201csniff test\u201d is still far from ready for clinical use, it does expressly discuss the possibility of using such a test as a diagnostic tool. We feel that if it is worth discussing a finding\u2019s clinical application, it\u2019s worth discussing the potential cost. We understand that it may be difficult or impossible to place a dollar value on such a diagnostic tool, but the release likely could have discussed the cost in general terms. For example, does it rely on expensive technologies or specialist skills? Or is it something that could be done by a trained general practitioner with inexpensive items? Or do we simply not know yet? Regardless, a quick sentence or two could have shed some light on the matter.", "answer": 0}, {"article": "The panel evaluated 38 of the most popular or trendy diets this year.\nTUESDAY, Jan. 5, 2016 (HealthDay News) -- For the sixth year in a row, a panel of health experts has named the heart-healthy DASH diet the best overall eating plan, according to U.S. News & World Report's 2016 Best Diets ranking.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\n\"Our rankings put hard numbers on the belief that no one diet is ideal for everybody, but the best food plans overall are sustainable,\" Angela Haupt, senior health editor at U.S. News & World Report, said in a news release from the media company.\n\"Besides the rankings and data, each diet has a detailed profile that includes how it works, evidence that supports or refutes its claims and a nutritional snapshot -- tools that, along with the advice of a physician or nutritionist, can help consumers invest in diets that suit their lifestyles and further their health and wellness goals,\" Haupt said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article doesn\u2019t address costs associated with maintaining a DASH diet or other diets. According to an analysis published study in JAMA Internal Medicine in 2013, adoption of the diet has been low, despite its favorable recommendations by nutritionists. The authors noted, \u201cIts limited uptake might be explained by economic constraints, since food prices influence food choices and constitute a major barrier to dietary change. Nutrient-dense foods, central to DASH, tend to be more costly compared to calorie dense alternatives.\u201c", "answer": 0}, {"article": "The drug lorcaserin works on the serotonin receptor -- the same appetite-controlling hormone targeted by the notorious drug fenfluramine, the \"fen\" component of combination medication fen-phen.\nBut lorcaserin is far more selective than the drug fenfluramine and much safer, its manufacturer says, because it specifically targets the serotonin receptor associated with hunger while having no impact on the heart.\nPeople who continued on the drug for two years were able to maintain their weight loss better than those switched to placebo after one year, researcher Steven R. Smith, MD, of the Florida Hospital and the Sanford-Burnham Institute tells WebMD.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nAll the participants were counseled about diet and exercise.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. If the drug works similarly to fen-phen. Why not at least mention what that drug cost? If you have to take it twice a day for a year to see any results, what might that long term therapy add up to?", "answer": 0}, {"article": "Even participants who had normal-range blood pressure, triglycerides or cholesterol levels before surgery saw improved measures.\nAll three procedures carry the same risks as any surgical procedure, such as infections, blood clots and bleeding, Lenhard said, and a common risk of sleeve gastrectomy is bleeding where the stomach is reconnected.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\n\"One of the surprises was that almost all patients benefited as a result of the surgery,\" says M. James Lenhard, the medical director of Christiana Care Health System's Diabetes & Metabolic Diseases Center in Wilmington, Del., who was not involved in the study.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost of these procedures or whether they are covered by insurance. The average cost of gastric bypass surgery is $23,000, the average cost of lap band is $14,500, and the average cost of sleeve gastrectomy surgery $14,900, according to the web site ObesityCoverage.", "answer": 0}, {"article": "To learn more about the Society and the field of endocrinology, visit our site at http://www.\n\"Our study is the largest and longest controlled study of growth hormone treatment for osteoporosis in postmenopausal women to date,\" said one of the study's authors, Emily Krantz, MD, of S\u00f6dra \u00c4lvsborgs Hospital in Bor\u00e5s, Sweden.\nWashington, DC--For years after it was administered, growth hormone continued to reduce the risk of fractures and helped maintain bone density in postmenopausal women who had osteoporosis, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\nMore than 10 million American adults have osteoporosis, and 80 percent of the people being treated for the condition nationwide are women, according to the Society's Endocrine Facts and Figures Report.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost at all, possibly because the study was conducted in Sweden, which has a taxpayer-funded public health system. However, in the U.S., growth hormone treatments can cost hundreds of dollars per month \u2014 and it\u2019s not clear if that would be covered by insurance for treating osteoporosis. This high cost is certainly worth mentioning.", "answer": 0}, {"article": "All the women were between the ages of 18 and 45 and their contraceptives were within six months of expiring before they enrolled in the study.\nMORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nTwo highly effective contraceptives\u2014the intrauterine device (IUD) and the implant\u2014actually last much longer than they are currently recommended, according to new research.\nThough the data is preliminary, the researchers say they believe that the hormonal IUD and the implant can both be used for an additional year longer than the FDA recommends.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions potential savings, but we would have liked some figures to give us context. We aren\u2019t given the cost of an office visit and procedure to insert either of the devices being studied, and nobody tries to calculate what a year\u2019s extra contraception is \u201cworth\u201d to a typical woman.", "answer": 1}, {"article": "Powerful chemotherapy and radiation treatments for cancer can impair a woman's fertility.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n\"This procedure is gaining ground worldwide as an optional fertility treatment for fertile female cancer patients who after cancer treatment most likely will be infertile,\" said lead researcher Dr. Annette Jensen, from the Laboratory of Reproductive Biology at Rigshospitalet in Copenhagen.\n\"The pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\" he said, referring to another option for women hoping for a future pregnancy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Surgery to remove a healthy ovary,\u00a0storage of that tissue for as long as a decade,\u00a0and surgical reimplantation all involve\u00a0substantial cost. The story doesn\u2019t help the reader begin to put this in context. If the patient requires IVF, in-vitro fertilization, when she hopes to conceive again, the costs will go much higher. Almost half of the pregnancies in the study required IVF, according to the story. The story let the readers down here. (Here\u2019s more about the high costs of infertility treatment from an advocacy group.)", "answer": 0}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The company behind the product undoubtedly has done market research about\u00a0how much of this product it might sell and at what price. At a minimum, that information should have been included here.", "answer": 0}, {"article": "Researchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\n\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n\"We have found that even a very brief intervention of a video showing patients how to use saline nasal irrigation can improve symptoms, help people feel they do not need to see the doctor to manage the problem, and reduce the amount of over-the-counter medication they need to use,\" said Dr. Paul Little, Primary Care and Population Sciences Unit, University of Southampton, Southampton, United Kingdom.\nSince the impact was less than in previous studies that had used more intensive coaching about nasal irrigation, the authors suggest that further research is needed to understand how much coaching of patients is required.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost. Normal saline can easily be made at home or purchased from a local pharmacy. The cost is low in both cases and it should have been mentioned in the story especially in contrast to the cost of antibiotics.", "answer": 0}, {"article": "The survival benefits were restricted to men under 65.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\n\"Our findings show that some tumors that are considered to be low-risk at diagnosis do pose a threat to life, especially if they are not surgically removed,\" the study authors write.\nThis is important, because experts believe many prostate tumors found by PSA are likely to be slow-growing \u2014 perhaps so slow they will never cause a problem before the man dies of something else.\nNow, a Swedish study suggests that radical prostatectomy \u2014 complete removal of the prostate gland \u2014 is better than \"watchful waiting\" for the treatment of younger men with low-risk prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Costs would include treating the double digit rates of incontinence and erectile dysfunction in these younger men who do have surgery. The surgery may help them live longer, but many, especially since younger at time of surgery, live decades with these potential harms and folllowup costs of the surgical choice.\u00a0 This should get at least a line in such stories.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does compare average costs of one course of IVF treatments with one course of IVM treatments. Given the lack of proven success with IVM, multiple rounds of treatments may be necessary to conceive.\u00a0 This is not specifically stated and the focus of the story is promoting IVM as a more cost-effective method of fertility treatments. This emphasis is misplaced.\u00a0 \nThere NO evidence that anyone has data that directly compares IVF and IVM, let alone understands cost per cycle, conception, or healthy pregnancy. \n\u00a0\nKathie, confused here and not sure if we should ding given that they did list the cost of each treatment?\u00a0", "answer": 0}, {"article": "With statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nThe cost of this drug will also play a role in determining which patients might use it, Fong and Young say.\nBut they also note that \"patients who cannot tolerate statins could benefit greatly.\"\nIf these initial results pan out in larger trials, the drug could prove to be more effective than statins, the widely prescribed drugs which have been very successful in lowering levels of LDL - or bad cholesterol.\nSoon, we can expect more human trials in which investigators will dissect the properties of different PCSK9 antibodies and assess the effect of these agents.\u201d\n\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, Young and Fong caution that it will remain unclear how important this class of drugs will be.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story noted that two editorial writers \u201ccaution that it will remain unclear how important this\u00a0class of drugs will be. The cost of this drug will also play a role in determining which patients might use it.\u201d\nBut better cost context could have easily been provided.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\nAbout the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services.\nThe researchers analyzed records from the NICHD Fetal Growth Study, a large observational study that recruited more than 2,000 low-risk pregnant women from 12 U.S. clinical sites between 2009 and 2013.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\nHowever, HbA1c levels increased in the final third of pregnancy, which is consistent with the decrease in sensitivity to insulin that often occurs during this time period.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The absence of cost information is unfortunate in this release. \u00a0In general, the public has little experience of or understanding of the overall costs of routine, widespread screening. Sources put the cost of A1C screening at anywhere from $12 to $65. There are nearly 4 million live births in the U.S. each year, and many more pregnancies. Even if we use a $35 midpoint price, that\u2019s $140 million just to screen for gestational diabetes. Worth it? Maybe. Particularly given that the glucose tolerance test given later in pregnancy has an average cost of $60 to $85, according to some sources. And the savings to be realized in potentially preventing gestational diabetes could be substantial. In any case, cost considerations are important in the overall scheme of health care delivery and limited health care dollars.", "answer": 0}, {"article": "June 22, 2010 -- Drinking lots of coffee probably isn't entirely good for you, but it does lower your risk of mouth and throat cancer.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThe protection was seen for oral and pharyngeal cancer, but not for cancer of the larynx.\nGaleone and colleagues note that coffee contains more than a thousand chemicals.\nGaleone and colleagues report their findings in the July issue of Cancer Epidemiology, Biomarkers, & Prevention.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable \u2013 the cost of coffee is not in question. ", "answer": 2}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release could have used some explicit indication of the potential cost of adding estriol to treatment with injectable glatiramer acetate. The text suggests that the hormone is widely available and thus likely to be simpler and less costly to take.\nIn the United States estriol is available only as a vaginal cream, not in tablet form. It is mostly used in \u201cbioidentical\u201d hormone replacement products obtained from compounding pharmacies.", "answer": 0}, {"article": "Also unknown: Will insurers pay for the expensive test without evidence it leads to better care or saves lives?\nThe results suggest the test could triple the number of men thought to be at such low risk for aggressive disease that monitoring is a clearly safe option.\n\"We're not giving patients enough information to make their decision,\" said Dr. Peter Carroll, chairman of urology at the University of California, San Francisco.\nIndependent experts say such a test is desperately needed but that it's unclear how much information this one adds or whether it will be enough to persuade men with low-risk tumors to forgo treatment, and treat it only if it gets worse.\n\"I would suspect that having cancer and having to live with it would be very difficult for them,\" but it doesn't bother him, Smith said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the new test \u2013 and of one that recently came on the market \u2013 were listed (> $3,000 each). And the story explained it\u2019s not known if insurers will pay for the tests.", "answer": 1}, {"article": "Women may also experience severe anxiety or feel disconnected from the baby.\n\"We tested acupuncture as a standalone treatment, and the results are very positive,\" said study author Rachel Manber, a professor at the Stanford University School of Medicine Sleep Medicine Center in Redwood City, Calif.\nThe researchers found a 63 percent response rate in women who received the depression-specific acupuncture, while the response rate was 44.3 percent in the control acupuncture and massage groups.\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nThe women were randomly assigned to one of three groups: depression-specific acupuncture (52 women), control acupuncture (49 women) or massage (49 women).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs or insurance coverage for acupuncture in the context of partum depression. Costs could be a significant barrier to getting the treatment for many women. The story points out that it is important that women are fully treated into remission, yet it makes no estimate of the cost of the full 12 sessions as described in the study.", "answer": 0}, {"article": "One study published in Psychological Science trained 16 college-aged adults and 16 older adults (around age 71) with Gabor patch exercises for 1.5 hours per day for seven days.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nAfter first taking in \u201craw data\u201d of an image through the eye, different sets of neurons in the brain process it as separate features like edges and colors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The column provides\u00a0clear\u00a0information about the cost of the app tried by the writer. It would have been strengthened by information about the cost of bifocals and, in particular, over-the-counter drugstore \u201creaders.\u201d", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of vitamin B12 supplements were not discussed and whether they are often covered by insurance was not explored.", "answer": 0}, {"article": "She noted a second study in Nature that used transplant tissue grown in the laboratory from stem cells to treat damaged corneas, saying it also holds promise.\nHe also pointed out that the study involved infants, and that adults -- the most common cataract patients -- have a different regenerative capacity of lens epithelial stem cells.\n\"The main excitement for me is the ability to regenerate an organ or a tissue within an organ,\" said Canto-Soler, a retina specialist.\nIn addition, we are testing if this approach can be used in treating other leading causes of blindness, such as macular degeneration and glaucoma,\" said Zhang.\nTraditional surgery can cause opacity in the line of a child's vision and, because the eye is still growing, it is difficult to provide good vision with eye glasses, explained Julie T. Daniels, from University College London Institute of Ophthalmology, in an accompanying commentary in Nature.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss\u00a0costs for this new approach. One web source points to an average cost of $3,400 per eye for conventional\u00a0cataract surgery, although the costs can be considerably less under some insurance plans. The story does not make clear if this\u00a0procedure would be similarly priced.", "answer": 0}, {"article": "And if patients are given a choice of catheterization sites, what factors should they consider?\nOnly 1 percent of the 1.2 million cardiac catheterizations performed annually in the United States are done through the wrist; the newer approach is often preferred for patients who are extremely obese or have poor leg circulation.\n\"There's a lot of buzz about this right now,\" he said of radial procedures, which account for about 150 of the 8,000 cardiac catheterizations done at his hospital annually.\nQuestions about the best method of performing cardiac catheterizations, one of the most common procedures in medicine and among the most profitable for hospitals -- Medicare reimburses GWU about $10,600 for an angioplasty involving one stent -- reflect some of the issues in the roiling health-care debate.\nThe femoral artery, approximately the width of a pinkie, presents a direct route to the heart; to a physician, it's a straight stretch of freeway that can be navigated easily.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that using the wrist may better enable patients to avoid an \"expensive overnight hospital stay\" and that Medicare reimbursement was the same even though this route for catheterization may involve more physician time. But the story didn\u2019t include any specific cost information about this new approach.\u00a0 Shouldn\u2019t the physicians interviewed know whether their charge to patients depends on the vessel used? Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.  ", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reported that Abraxane \u201cwill cost $6,000 to $8,000 a month\u201d for pancreatic cancer patients. And then placed the cost and potential benefit into context: \u201cHow much of an extension of life is meaningful to patients is a matter of some debate, especially with cancer drugs costing thousands of dollars a month.\u201d", "answer": 1}, {"article": "Gaining too much weight is tied to an increased risk of complications for both mother and child, according to the researchers, who completed the review for The Cochrane Collaboration, an international organization that evaluates medical research.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\n\u201cThis was very reassuring that there wasn\u2019t an increased risk of preterm birth with moderate exercise,\u201d said Thornburg, a high-risk pregnancy expert at the University of Rochester Medical Center in New York.\n\u201cMost people gain more weight than they probably should during pregnancy,\u201d Thornburg, who was not involved with the review, told Reuters Health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address costs. But the interventions are so broadly defined that it would be difficult or impossible to address cost in a meaningful way. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "reconstructions\u201d currently being conducted on injured knees \u201ccould be avoided without adversely affecting outcomes.\u201d\n\nThis possibility should reverberate across playing fields nationwide, where, at the moment, preseason high school, collegiate and adult-league sports practices are under way, with a concomitant surge in A.C.L.\nFor them, it seems, \u201cthe desire to undergo surgery was based on expectations rather than symptoms,\u201d the authors told me.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\n\u201cOn the basis of our study results, we\u2019d tell patients\u201d that \u201cthere is no apparent downside of starting a good rehab program and waiting with the surgery decision to see if it is needed or not,\u201d the authors wrote to me.\nThey agreed, rather bravely, to be randomly assigned to one of two groups and accept radically different treatments for their torn A.C.L.\u2019s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The author briefly mentions that the operation \"can be expensive.\" A little more detail about the costs and economic forces would\u2019ve been great. We consistently grade such vague references as unsatisfactory. ", "answer": 0}, {"article": "A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\nTesting of the TCD technique at the sideline at the time of injury will be an important next step to determine its ultimate utility,\" said Randolph S. Marshall, MD, MS, with Columbia Presbyterian Medical Center in New York and a member of the American Academy of Neurology's Science Committee.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the study\u2019s principle investigator notes that the device may be \u201cless expensive\u201d than MRI, costs are not broached in the text. To have one of these devices at all sport events, say, starting at high school and beyond, would be quite expensive. Plus, staff would need to be trained to use the device and interpret the results. Dopplers are not used and interpreted by the lay public. The practicality of this was not mentioned.", "answer": 0}, {"article": "And you could see that they were sort of asking, 'Why can't they do something for me?'\"\nIt was the worst kind of luck that gave Kanzius the idea to use radio waves to kill cancer cells: six years ago, he was diagnosed with terminal leukemia and since then has undergone 36 rounds of toxic chemotherapy.\nIt's not something that a layman like me should be in, it should be left to doctors and research people,\" he told Stahl.\nHere's how it works: one box sends radio waves over to the other, creating enough energy to activate gas in a fluorescent light.\nHis name is John Kanzius, and as correspondent Lesley Stahl first reported last April, he's a former businessman and radio technician who built a radio wave machine that has cancer researchers so enthusiastic about its potential they're pouring money and effort into testing it out.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs at this point would be purely speculative, as it\u2019s not clear what kind of nanoparticles would be used, what the machines would cost to build, the many factors which will likely complicate the process even before it reaches human testing. \nIt\u2019s not necessary in this case for the story to mention costs. ", "answer": 2}, {"article": "By doing so, it can save the lives of some men who would otherwise have died of the disease.\"\nThe argument over whether PSA screening saves men's lives or merely leads to the overdiagnosis of very slow-growing cancers (with attendant worry and overtreatment) has bedeviled the medical world for years.\nHowever, he believes that with the results of the new 14-year study, \"it feels ethically difficult not at least to inform all men over the age of 50 about PSA and its possibilities.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\nIn men younger than 60 at study entry, the effect was even more pronounced -- only one-quarter of expected deaths occurred,\" Hugosson said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0While mentioning that PSA testing is rather routine practice in the US, there was no indication of its cost. Now, while the cost of PSA testing itself is relatively minimal, this was a study not just about screening but treatment.\u00a0 As Dr. Otis Brawley of the American Cancer Society wrote on the ACS blog: \nSo we think the story should have included at least a nod in the direction of WHAT\u00a0IT\u00a0COST to achieve the result trumpeted in the headline \u2013 especially given the proliferation of expensive robotic surgical systems and newer radiation therapy techniques. \u00a0\nThis is a classic example of how cost gets left out of the discussion. ", "answer": 0}, {"article": "Dr. Bremner said he typically suggests a trial of therapy for up to a year to see if sexual function or other symptoms improve.\nThe most common reason men seek testosterone therapy is waning sexual desire or performance, although the ability of the hormone to relieve sexual symptoms is unpredictable.\nThe risk of prostate cancer is of greater concern, given that suppressing the body\u2019s natural production of testosterone can cause this cancer to regress.\nCiting the results of many small studies, Dr. Bremner said, \u201cThere is good evidence that testosterone administration can improve muscle mass and strength and increase bone density\u201d in men with subnormal levels.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the controversies about the benefit of testosterone replacement treatment in andropausal men, the costs of care are an important consideration. Testosterone replacement therapies can range from $10 to $300 a month\u00a0not including testing and physician visits.", "answer": 0}, {"article": "\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\n\"Regardless of how the response was quantified, how the sleep deprivation was delivered, or the type of depression the subject was experiencing, we found a nearly equivalent response rate.\"\nThe findings of this meta-analysis hope to provide relief for the estimated 16.1 million adults who experienced a major depressive episode in 2014.\nSuch drugs typically take weeks or longer to experience results, yet 16.7 percent of 242 million U.S. adults filled one or more prescriptions for psychiatric drugs in 2013.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs. One may assume there is no cost to sleep deprivation but the release notes that the deprivation in the studies was mostly monitored in inpatient facilities. That has a cost. However, if the intervention is not done in an inpatient facility there would not be a directly attributable cost so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nBut women who consumed the most blueberries and strawberries had a 32% reduced risk of heart attack compared with the women who ate berries once a month or less.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nIt is a powerful message that we can prevent cardiovascular disease by what we eat.\u201d Something worth remembering the next time you\u2019re in the produce aisle.\n\u201cThis supports growing lab data showing that these compounds can help keep arteries healthy and flexible.\u201d\n\nSo what is it about berries that help the heart?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost of berries not discussed, but we can assume most readers know the ballpark costs.", "answer": 2}, {"article": "TUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nSimilarly, weight loss reduced stress and depression.\nDuring this part of the trial, the participants lost an average of almost 14 pounds.\nThis study encourages weight loss in a more holistic context,\" he said.\nThose in the second phase of the trial continued their diet and exercise program.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Did not mention cost of treatment", "answer": 0}, {"article": "Daily aspirin doubles a person's gastrointestinal bleeding risk to about 2 in every 1,000 people a year.\n\"This is definitely the first time that research has shown that long-term aspirin use can reduce the risk of deaths due to cancer,\" Dr. Asad Umar of the National Cancer Institute's division of cancer prevention tells Shots.\n\"So I think in the fullness of time, preventing cancer will be seen to be the main reason for taking aspirin in healthy individuals,\" Rothwell says.\nStill, none of the big guns in cancer and prevention -- the National Cancer Institute, the American Cancer Society, or the U.S. Preventive Services Task Force -- are ready to advise healthy people to start taking aspirin to prevent cancer.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss the cost of daily aspirin intake. Because the cost to individuals is low and well-known, we won\u2019t insist on this point. Nevertheless, were a recommendation made for everyone to begin taking aspirin daily starting at age 45 the national price tag would be substantial. Readers would also benefit from an acknowledgement that such a recommendation would lead to higher spending on treatment of bleeding ulcers and other adverse events that would offset some of the potential cancer-related savings.", "answer": 2}, {"article": "- The herpes zoster vaccine could prevent tens of thousands of cases of shingles each year if it was offered to everyone who is eligible, with vaccinated adults half as likely to develop shingles, a study said.\n\u201cAdult medicine is really geared toward diagnosis and treatment of existing diseases.\nThe adult medical community is not as attuned to preventing disease... as pediatricians are,\u201d he told Reuters Health.\n\u201cWe didn\u2019t know how well the vaccine actually performed in the community setting,\u201d Tseng told Reuters Health.\nUsing electronic health records, researchers tracked patients for up to three years after vaccination.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story reports that the vaccine can cost $200.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no estimate provided for the cost of the drug.", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of medication to treat bipolar disorder; however, the story and evidence from the study cited\u00a0are advocating fewer anti-depressant medications.\u00a0\u00a0 So cost seems less of an issue in this case.\u00a0 However, the story missed an opportunity to talk about the cost of bipolar disease (90 million work loss days annually in the U.S) and associated health care/treament costs.", "answer": 2}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states early on that the cost of Spire is $150. The story also mentions the costs of the breathing classes offered by Dr. Belisa Vranich. Readers who are interested in taking the classes or purchasing Spire know what to expect in terms of cost.", "answer": 1}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\nWhile there are drugs given to patients after surgery to prevent cancer cells from adhering to each other or other tissues, these drugs do not rid the body of cancer cells or collect them to allow an assessment of the patient\u2019s status.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\nCurrently, there are many treatments for primary tumors but they do little to prevent metastasis and stray cancer cells from relocating to another part of the body.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned. While it can be extremely difficult to place a precise cost on early stage medical technologies, the issue can be addressed in broader terms. Is the technology difficult to make? Can it be produced on a large scale? Are those questions that still need to be explored? This release neglects to do so, which is particularly problematic in a news release that is focused on the announcement of a patent. Patents are designed to secure intellectual property, allowing people and institutions to profit from their discoveries. As such, this release is effectively about business. Failing to address potential costs, even in the most general terms, is a significant oversight.", "answer": 0}, {"article": "In 2013, it was 12.6.\nThe rate is five per 100,000 in the organization's general population, which is well below the national average and has remained steady despite an increasing rate of suicide statewide.\nWhile the homicide rate in the U.S. has dropped 50 percent since the early 1990s, the suicide rate is higher than it was a decade ago.\n\"There is no question that the message I got from Day 1 is that they knew they could help me, and they would help me,\" Lynn says.\nBut there are training costs involved, and the Henry Ford system has had to keep its staffing up to be able to provide care for people who need it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At issue in the story is the health system\u2019s so-called \u201cperfect depression care,\u201d which incorporates depression screening into primary care. Patients deemed to have, or be at risk of, depression are then given appropriate treatment. It\u2019s difficult to pin a specific cost to this. The matter is further complicated by the fact that treating depression can also save money by driving down costs related to associated health problems. However, the story notes that Centerstone \u2014 a separate health system that has adopted the Henry Ford Health System\u2019s model for a smaller cohort of patients \u2014 did do a cost/benefit analysis and found that it resulted in savings of more than $400,000 per year. While we\u2019ll award a Satisfactory, we think there was a muddling here of Henry Ford\u2019s global screening strategy with the intense care provision in the Centerstone model. It is not appropriate to apply the cost analysis of the latter to the former. In addition, it can be argued that\u00a0screening every patient at every visit it wasteful. The story reads/sounds somewhat like a paean to doing as much as you can and adopting a kitchen-sink approach rather than a carefully honed and efficient one.", "answer": 1}, {"article": "WATCH: The naked mole rat might help us cure cancer\nThe research, led by Richard Wilson of Harvard University, revealed that in more than 500 US counties, mammography screening programs were linked with more diagnoses of smaller breast cancers \u2014 but not with fewer deaths or with fewer larger breast cancers (which theoretically would be prevented by finding the disease early through screening).\nThe US Preventive Services Task Force, which analyzes the best available evidence to create guidelines for doctors, now recommends biennial mammography screening for the general population in women ages 50 to 74.\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in this story or of insurance coverage for mammography. While many readers may understand that screening mammography is generally covered by insurance, it would have been helpful to state explicitly that mammograms in the U.S. are covered by the Affordable Care Act. More broadly, given that this study questions the effectiveness of mass breast screening, it\u2019s worth at least asking what such screening is costing the health care system.", "answer": 0}, {"article": "Tamoxifen, a generic drug, is already approved for reducing the risk of breast cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of either drug, nor of the overall cost-effectiveness of this approach to preventing breast cancer, including savings on cancers prevented compared with no treatment. This would also have included an estimate of the costs of monitoring and treatment for the possible side effects, particularly uterine problems\u2013which led to hysterectomy in more than 350 women during the trial.", "answer": 0}, {"article": "Over two years, both groups showed steady improvement.\nBut by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\nDr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not touch on costs for the more comprehensive treatment \u2014 including educating families and providing more counseling for patients.\u00a0True costs and potential savings would be very hard to quantify, and would accrue over time as people hopefully stay in school and jobs, and have fewer admissions to the hospital etc. Even if the story couldn\u2019t address these issues precisely, some mention of them would have been helpful. We do applaud the story for exploring the political and reimbursement context. This was especially good:\nIts [study] findings have already trickled out to government agencies: On Friday, the Centers for Medicare & Medicaid Services published in its influential guidelines a strong endorsement of the combined-therapy approach.Mental health reform bills now being circulated in Congress \u201cmention the study by name,\u201d said Dr. Robert K. Heinssen, the director of services and intervention research at the centers, who oversaw the research.", "answer": 0}, {"article": "European regulatory bodies recommend pharmaceutical-grade chondroitin sulfate as well as pharmaceutical-grade glucosamine sulfate as first-line treatments for osteoarthritis, Reginster said by email, because of the side effects associated with celecoxib and other non-steroidal inflammatory drugs (NSAIDs) including stomach ulcers, bleeding, liver and kidney problems.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\nReginster told Reuters Health the findings are in line with earlier studies showing pharmaceutical-grade chondroitin sulfate could significantly decrease the progression of knee osteoarthritis over a period of three years.\nSome have found the supplements to be as effective as ibuprofen (also an NSAID), and some have found that chondroitin sulfate is no more effective than placebo, he told Reuters Health.\nIt should be used in conjunction with these measures,\u201d said Wolfe, who wasn\u2019t involved in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article makes no\u00a0mention of how much pharmaceutical-grade chondroitin costs.", "answer": 0}, {"article": "Cholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\nThey then interfered with production of the molecule and found it slowed the cancer cells\u2019 growth by between 30% and 50%.\nThe scientists grew cancer cells in the lab in the absence of oestrogen and found they produced an alternative fuel, in the form of the cholesterol molecule.\nThe scientists say the findings are boosted by two studies which found the over-activation of certain genes linked to cholesterol production were linked with a poorer response to the anti-cancer drugs.\nIt can mimic oestrogen and encourage tumours to grow.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the cost of statins, which is readily available data.", "answer": 0}, {"article": "In a study presented Tuesday at the American Chemical Society's spring national meeting in San Diego, 16 overweight young adults took, by turns, a low dose of green coffee bean extract, a high dose of the supplement, and a placebo.\nIt would be difficult to take without a lot of water, Vinson reported.\nIn fact, it is already available as a naturopathic medicine and antioxidant.\nThe trial was conducted in India and paid for by Applied Food Sciences Inc. of Austin, Tex., a manufacturer of green coffee bean extract.\nBut the more extract they consumed, the more weight and fat they lost.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that green coffee extract is available at roughly $20 per month.", "answer": 1}, {"article": "Both studies are published in the Journal of Psychopharmacology on Dec. 1.\n\"Before beginning the study, it wasn't clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,\" says Griffiths.\n\"The most interesting and remarkable finding is that a single dose of psilocybin, which lasts four to six hours, produced enduring decreases in depression and anxiety symptoms, and this may represent a fascinating new model for treating some psychiatric conditions,\" says Roland Griffiths, Ph.D., professor of behavioral biology in the Departments of Psychiatry and Behavioral Sciences and of Neuroscience at the Johns Hopkins University School of Medicine.\nTo measure the changes in attitudes, moods and behavior over time, the researchers administered a questionnaire that assessed negative or positive changes in attitudes about life, mood and behavior.\nThe researchers assessed each participant's mood, attitude about life, behaviors and spirituality with questionnaires and structured interviews before the first session, seven hours after taking the psilocybin, five weeks after each session and six months after the second session.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed at all.\nThe costs associated with cancer treatments has been the topic of discussion for some time. So, cost of palliative treatments are important. \u00a0While there may not be any good estimates of a commercially available product at the moment, the regulatory issues associated with psilocybin are considerable and are likely to have a large impact on cost. The release could have addressed this in a general way, even if specific cost figures are not available.\u00a0", "answer": 0}, {"article": "They used functional magnetic resonance imaging (fMRI) to study this phenomenon.\nThis was another small study -- 20 dyslexic volunteers and 21 participants without the condition -- testing how people identify shapes, navigate a virtual environment, and do other tasks involving spatial reasoning.\nHere's another insight about dyslexia: men with the condition may have enhanced visual-spatial abilities, according to a study in the journal Learning and Individual Differences.\nThe most important intervention is a direct, explicit teaching of phonics, or how symbols correspond with sounds, Branstetter said.\nThe potential to alarm a child isn't worth it, and he doesn't trust that this method would offer definitive information.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nNone of the stories we reviewed gave readers sufficient information on the cost of the research scans used in the study. This story includes a comment from a researcher saying that increased use of this type of brain scan would bring the \u201chigh cost\u201d down, but it doesn\u2019t provide an estimate of the current cost or any comparison to alternative methods of assessing reading ability or other features of dyslexia.", "answer": 0}, {"article": "Zyban, a repackaging of the antidepressant Wellbutrin, was approved by the F.D.A.\nAlthough smoking rates in the United States have declined in recent decades, tens of millions of adults continue to smoke, and the habit causes more than 440,000 deaths a year, according to the Centers for Disease Control and Prevention.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide even an estimate of the cost of the vaccine. There is the suggestion that if the vaccine were approved it could be a financial boon for Nabi Biopharmaceuticals. Consumers want to know what it may cost them. ", "answer": 0}, {"article": "But these methods alone don't give reliable results.\nThe scientists at Hopkins have already launched their next study, which could involve tens of thousands of apparently healthy volunteers who are enrolled in the Geisinger Health Plan in Pennsylvania.\nAnd for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\n\"The thing we worry about quite often is ... if we have a test result that is negative we don't want to give false reassurance to the patient,\" he says.\nFor instance, if the success rate is around 40 percent at detecting cancer, that means it misses cancers more often than it finds it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes it clear that cost of the test is currently speculative (\u201ccould cost about $500\u201d) and goes even further to caution that: \u201cJohns Hopkins holds the patent and has not licensed it as yet to a company that would ultimately set the price.\u201d", "answer": 1}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nThe volunteers took pills once a day for six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nFasting blood samples were taken at the start of the trial and then at intervals of one, three, and six weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of the cost of the supplements used in the study. Doesn\u2019t cost matter? ", "answer": 0}, {"article": "Colic is usually defined as excessive and inconsolable crying for at least three hours a day for more than three days a week over more than three weeks.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote.\n\"It's reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children's Medical Center of New York.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs. Some of the products described could end up being quite costly, and chiropractic treatment would definitely be an expensive option. At a minimum, we would have liked to have seen some description of the range of costs, from the minimal cost of a few cents a day using a sugar-water mixture to the large cost of chiropractic treatment.", "answer": 0}, {"article": "Shi's lab has developed a promising live-attenuated Zika vaccine candidate called ZIKV-LAV that had been shown to be safe, non-virulent, and effective in protecting against infection in mice and non-human primates.\nWhen the team injected this ZIKV-LAV into the brains of mice, they saw no health effects on the mice, no weight loss, and no behavioral abnormalities such as loss of appetite, depression, lethargy, or self-injury.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\nThe ZIKV-LAV has a small deletion from the viral genome that prevents it from replicating itself efficiently.\nFor example, Man explains, the researchers could add an immune modulator as a 'cargo' in the viral genome.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release reports results of a clinical trial in mice. It\u2019s too early to estimate costs for human treatment.", "answer": 2}, {"article": "The pill is his blood pressure medication.\n\"The good news is that we can control blood pressure now,\" says Maria Carrillo, the group's chief science officer.\nBut high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\nAnd when the heart pushes too hard, as it does when blood pressure is elevated, it can cause damage that can lead to a stroke.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No specific brand name interventions mentioned, though it\u2019s implied that medication is frequently used.\nWhile we wouldn\u2019t expect the story to list the prices of the many drugs for high blood pressure, we do think the story could have discussed this aspect of seeking treatment. Is it a factor in why so many people don\u2019t treat their high blood pressure?", "answer": 2}, {"article": "Less Fat.\u201d\n\nMeanwhile, Erchonia Medical, based in McKinney, Tex., has aggressively marketed its Zerona laser as \u201cthe first non-invasive body contouring procedure to effectively remove excess fat\u201d even though it has yet to receive F.D.A.\nIf you\u2019re sedentary and not eating healthy food, he said, then once fat is leaked after Zerona treatments, \u201cyour body will just store it again.\u201d\n\nHow the body rids itself of fat, and how quickly, after any noninvasive body slimming procedure is unclear, said Dr. Lawrence S. Bass, a plastic surgeon in Manhattan who started using a Zeltiq device last July.\nThat said, a doctor with a Zeltiq device isn\u2019t hard for patients to find.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\nIt has cleared the Zerona laser for pain reduction 24 hours after breast augmentation or as a way to decrease the pain associated with recovering from liposuction.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states the price for the Zerona device: $1,700 to $3,800 for six sessions. The price of Zeltiq is also reported but is not as clear:\u00a0We learn only that one doctor charges \"$700 per spot\"\u2013but not how many treatments are provided or needed, what constitues as \"spot,\" and so on.\u00a0 ", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The drug has only been tested in a phase I trial and a discussion of cost is not applicable at this time.", "answer": 2}, {"article": "For more information, visit http://www.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nClip-on Repellent Device With Metofluthrin Tested on Aedes aegypti (Diptera: Culicidae) for Mortality at Different Time Intervals and Distances,\" is available at http://dx.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\n\"In vector control, we see more often than not that tools available for consumers don't work for the intended purpose,\" said Bibbs.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t provide any information about the device\u2019s cost. A quick online search found the OFF! Clip-On starter pack going for $9.49 at Target. After the initial purchase, consumers must continue to buy refills and batteries. The monetary impact is huge if you consider the the volume of potential sales.", "answer": 0}, {"article": "The pain relief could last for weeks.\n\u201cBut it\u2019s not.\u201d The pain associated with tendinopathies tends to fall somewhere around a 7 or so on a 10-point scale of pain.\nIn one study that the researchers reviewed, \u201can average of four injections resulted in a 57 percent worse outcome when compared to one injection,\u201d Dr. Vicenzino said.\nBut in the decades since, numerous studies have shown, persuasively, that these overuse injuries do not involve inflammation.\nThe evidence for cortisone as a treatment for other aching tendons, like sore shoulders and Achilles-tendon pain, was slight and conflicting, the review found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe New York Times article did not discuss the costs of steroid injections or other treatments. It would have been useful if the article could have pointed out that the long-term costs of steroid injections haven\u2019t been documented.\n", "answer": 0}, {"article": "They later found the women possessed T cells that were naturally immune quiescent.\n\"We know that some drugs taken orally never make it to the vaginal tract, so this implant could provide a more reliable way to encourage T cells not to respond to infection and therefore more reliably and cheaply prevent transmission,\" said Emmanuel Ho, a professor in the School of Pharmacy at Waterloo.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\n\"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The lead author is quoted as stating the implant could prevent HIV infection \u201cmore reliably and cheaply,\u201d but the cost is not provided in the release.\nThe cost may well be unknown since the treatment is experimental and in development. However, the published research states that the active ingredient \u2014 hydroxychloroquine, or HCQ \u2014 \u201cis an inexpensive drug.\u201d Perhaps that price could have been included.\nAnd cost is relevant since the vast majority of HIV infections occur in the developing world where cost could have a major influence on compliance with prevention measures.", "answer": 0}, {"article": "(Reuters Health) - Taking one or two baby aspirins a day for at least five years was tied to a lower risk of colorectal cancer in a study from Denmark.\n\u201cSelf-medication with aspirin or non-aspirin NSAIDs is strongly discouraged, due to the possibility of serious adverse events,\u201d Dr. Friis said.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\nAspirin and NSAIDs carry their own risks, however.\nMore than 90 percent of cases are diagnosed in people older than 50, according to the National Cancer Institute.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention was made of costs, but anyone who has been to a drugstore knows that aspirin is cheap.", "answer": 2}, {"article": "\"A lot of the time, people have quite painful and challenging experiences revisiting the trauma, and [MDMA] can help them do it without being overwhelmed or numbed out,\" he says.\nThis was the first clinical trial to explore the therapeutic potential of MDMA since the drug was outlawed in 1985, and the researchers required the permission of the National Institutes of Health, the Food and Drug Administration , and the Drug Enforcement Administration.\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe use of MDMA in psychotherapy has been studied for decades, but research in the U.S. all but ground to a halt after the drug became illegal.\nThe drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At a minimum, the story could quote the DEA, FBI or other law enforcement source on a price range for a typical dose of MDMA. The reporter also could have asked the authors how they obtained MDMA\u00a0and how much it cost them.", "answer": 0}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\n\"Some people with stage 1 and 2 diseases may even get cured.\nFollowing the surgery, about 76 percent of patients had \"clinically significant\" improvement in quality of life, as measured by various validated scales.\n\"I don't think it means everyone with CRS should consider surgery.\nThis is a wonderful renewed hope of feeling better.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price of cola products is well known. ", "answer": 2}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says foreigners are \u201cpaying up to $2,500 a week to drink the elixir,\u201d though it does not say whether this is typical. The story could have elaborated by describing the costs of travel and living expenses while taking the substance, too. There are hidden costs to think about, too, such as treating the negative adverse effects of the drug", "answer": 1}, {"article": "SUNDAY, Dec. 5, 2010 (HealthDay News) -- Using gene therapy, German researchers report that they managed to \"correct\" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.\nPreviously there had been some concern that drugs needed to get the stem cells out of the bone marrow and into the bloodstream where they could be accessed might pose a risk of leukemia.\nThe study was based on questionnaires returned from more than 12,500 donors, which also showed the donors tended to be in good health and were willing to donate again.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene.\nEven if a good match is found, transplant recipients can go on to have more problems with infections, such as graft-versus-host disease, in which the body basically rejects the foreign elements.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We think it\u2019s too early to guess at what any therapy based on this technique would cost, so we won\u2019t flag the story for not mentioning costs.", "answer": 2}, {"article": "\"Apixaban is now the first oral anticoagulant [blood thinner] to show a statistically significant improvement in survival over warfarin in atrial fibrillation patients,\" Fonarow said.\nAccording to the researchers, apixaban reduced this risk by 50 percent, preventing four patients from having this type of stroke and two patients from having an ischemic stroke (cause by a vessel blockage) or stroke of uncertain origin.\n\"The three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population.\nHowever, \"in that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners,\" Ansell noted.\nThe major effect on stroke was preventing hemorrhagic stroke, which is caused by bleeding in the brain and is the most serious type of stroke.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that apixabane would cost more than warafarin, and included a quote from a company spokesperson to indicate that the exact price is uncertain as the medication has not yet been approved. \u00a0The story also presented a reasoned examination of total costs for the use of warafin that accounted not just for per pill costs but also the expenses associated with the routine blood draws to examine warafarin levels.", "answer": 1}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\n(Performance Health Brands, maker of Thera-Band, provided the FlexBars for the study but did not fund it.)\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nIn addition to tennis players, Bishop sees the injury in gardeners with their shovels and trowels; painters with brushes; and golfers with clubs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the FlexBar costs between $16 and $33. It could have compared this cost with that of some other treatment options, which can be quite expensive.", "answer": 1}, {"article": "The children were assessed 11 times between birth and the age of 6 years.\n\"This study highlights the fact that in utero exposure can have a profound effect on the fetus that lasts through childhood,\" said Dr. Jennifer Wu, an obstetrician-gynecologist from Lenox Hill Hospital in New York City.\n\"The body composition at age 6 years in children given fish oil supplementation was characterized by a proportional increase in lean, bone and fat mass, suggesting a general growth-stimulating effect,\" the researchers, who were led by Hans Bisgaard, from the University of Copenhagen, wrote in the report.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story doesn\u2019t mention the costs of the fish oil supplements it appears to support. However, the cost of such supplements is reasonable and the period in which they\u2019re recommended is short \u2014 the last trimester of pregnancy \u2014 making cost a lesser concern than in some cases.", "answer": 2}, {"article": "The scientists then ran each volunteer through a large array of physical and cognitive tests.\nBut science has not been able to establish definitively whether such changes result primarily from the passage of time \u2014 in which case they are inevitable for anyone with birthdays \u2014 or result at least in part from lifestyle, meaning that they are mutable.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nBut even the oldest cyclists in this study averaged barely 5 seconds for the walk, which is \u201cwell within the norm reported for healthy young adults,\u201d the study authors write.\nOlder people tend to be quite sedentary nowadays, and being sedentary affects health, making it difficult to separate the effects of not moving from those of getting older.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s difficult for many people to be active as cyclists, especially in low-income areas that lack bicycle paths. It\u2019s also difficult for many to afford to spend the time needed to exercise. The story notes that older people today tend to be \u201cquite sedentary.\u201d Perhaps cost is a contributing factor.", "answer": 0}, {"article": "Ulcerative colitis is a chronic inflammatory bowel disease.\nWEDNESDAY, May 3, 2017 (HealthDay News) -- A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis.\nThe first two trials looked at more than 1,100 patients with moderate to severe ulcerative colitis who had failed with conventional treatment or treatment with newer \"tumor necrosis factor antagonist\" drugs, such as Remicade (infliximab).\n\"I am not going out on a limb and say this should be the first choice, because we don't have enough data to say that's the way it should be positioned.\"\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost. This is a significant oversight, given that a glance at online pricing guides indicate the drug costs around $4,000 per month (treatment for the bulk of the clinical trial patients was for two months, though some patients took lower \u201cmaintenance\u201d doses for a year).", "answer": 0}, {"article": "The study, \"Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men,\" will be published online at http://press.\n\"More research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception,\" Festin said.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\nThe hormones were effective in reducing the sperm count to 1 million/ml or less within 24 weeks in 274 of the participants.\nThe research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD (using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of these hormone injections isn\u2019t mentioned, and there\u2019s no assessment of how the cost might compare with other forms of birth control. It should be noted that people interested in using this injection for birth control would also need to factor in clinic visit costs and potential treatment of side effects.", "answer": 0}, {"article": "\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nOf 4,065 boys and men aged 16 to 26 from 18 countries, vaccination with an HPV vaccine that targets four types of HPV infection -- HPV-6, HPV-11, HPV-16, and HPV-18 -- protects against infection with these types of HPV and potentially the development of related external genital warts or lesions.\nHPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nThe vaccine is recommended for optional use in boys and men.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wish the story had provided the cost of roughly $375 for the Gardasil vaccine involved in the study. But the story did a much better job on deadline than the competing HealthDay story of posing the deeper question of the overall dispute and society-level debate over universal vaccination.\nIt quotes one researcher saying only: \u201cThe main disadvantage is cost, because thus far the vaccine appears to be safe. It\u2019s less cost-effective because most of the serious diseases such as cervical cancer occur in women, not men.\u201d\nSo why not provide the cost figures?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article\u2019s main focus is about robotic surgery for prostate cancer, although other applications are mentioned. Comparitive costs are given for a robotic radical prostatectomy, laparoscopic prostatectomy, and open prostatectomy. ", "answer": 1}, {"article": "Sixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\nThe study included the participants' history of falls and their fear of falling, blood tests at the beginning and at end of the trial to measure 25-hydroxyvitamin D (biomarker for vitamin D in blood), and a monthly diary recording falls during the trial period.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of the cost of Vitamin D supplements, which would likely be important to the elderly population, many of whom live on fixed incomes.\u00a0Nor does it mention a key fact about the Older Americans Act that was cited in the study itself: \u201cAlthough OAA nutrition programs can provide education and counseling to encourage the use of vitamin-mineral supplements, the provision of vitamin-mineral supplements is currently not a fundable OAA service.\u201d Relatively speaking, the cost of such supplements is minimal, but readers may not be aware of that.", "answer": 0}, {"article": "She worries about the small chance of benefit in light of the larger chance of finding and treating a cancer that did not need to be treated.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\nThey also found, though, that the death rate fell by 8 percent in women over 70 who had the new treatment teams but had not been invited to have mammograms.\nIs it worth it to risk becoming a patient without it being necessary?\u201d\n\nMany women may still want mammograms, she says, and that is fine.\nHis approach, he says, is \u201cminimax\u201d \u2014 he wants to minimize the maximum risk \u2014 which, in this case, is dying of a cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story does not mention the costs of screening or follow-up tests or treatment \u2013 to the individual or, collectively, to society.\u00a0 Those costs are significant.\u00a0 ", "answer": 0}, {"article": "The study was to be presented Sunday at the Alzheimer's Association International Conference in Washington, D.C.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\nIn the study, Sapkota's team tested the saliva of 22 people with Alzheimer's disease, 25 people with what's known as mild cognitive impairment (a decline in memory and thinking that's sometimes a precursor to dementia), as well as 35 people whose mental skills were normal for their age.\nSUNDAY, July 19, 2015 (HealthDay News) -- It's still very early, but scientists say a test based on a patient's saliva might someday help detect Alzheimer's disease.\nIf a saliva test lives up to its promise, one advantage is \"the ease of obtaining a sample,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention in this short story about the potential costs of such a test, if it proved to be viable. Of course, it\u2019s too early to say anything definitive about cost, and offering a specific number might mislead readers by implying that the test is anywhere near ready to be used. But we think the story could have offered some sense of the technology behind the test and whether it\u2019s advanced/expensive or cheap/widely available. Other tests using saliva are in use today and could offer a general comparison point to suggest the costs of a new test.", "answer": 0}, {"article": "The primary efficacy endpoint \u2013 change from baseline to day 28 in MADRS total score \u2013 was assessed among patients who received \u22651 dose of (nasal spray and oral) study medication by mixed-effects model using repeated measures using a one-sided significance level of 0.025.\nThe results from these studies will inform regulatory filings for esketamine nasal spray in treatment-resistant depression, for which Janssen has received Breakthrough Therapy Designations from the U.S. FDA.\nTo put this into context, an analysis of placebo-controlled data from three prior studies conducted by Duru and Fantino determined that a minimum change in MADRS of 1.9 was clinically meaningful.2 In addition, the average difference is between 2-3 points for currently approved antidepressants vs. placebo.3\n\nSafety results were consistent with previous studies of esketamine in younger adult populations.\nEsketamine received Breakthrough Therapy Designations from the U.S. FDA in November 2013 for treatment-resistant depression and in August 2016 for the indication of major depressive disorder with imminent risk for suicide.4\n\nAbout Major Depressive Disorder\n\nMajor depressive disorder affects nearly 300 million people of all ages globally and is the leading cause of disability worldwide.5 Individuals with depression, including major depressive disorder, experience continuous suffering from a serious, biologically based disease which has a significant negative impact on all aspects of life, including quality of life and function.5 Although currently available antidepressants are effective for many patients, about one third of patients do not respond to treatment and are thought to have treatment-resistant depression.6\n\nAbout the Janssen Pharmaceutical Companies of Johnson & Johnson\n\nAt the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease.\n\"With about 30 percent of patients with major depression failing to respond to currently available antidepressants1, treatment-resistant depression represents a major public health need,\" said Husseini K. Manji, MD, Global Head, Neuroscience Therapeutic Area, Janssen Research & Development, LLC.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed and they should be. While esketamine spray is a newer version of ketamine, which has been in use as a general anesthetic for 50 years, that drug has been off-patent for many years. A new version of the drug, presented in a nasal spray formula, is eligible for patent protection once it is approved by the FDA.", "answer": 0}, {"article": "The men, 35 to 79 years old, had systolic blood pressure of 140 or more.\nIn participants assigned to the pharmacist-led program, the average reductions in systolic and diastolic blood pressure were 21.6 and 14.9 greater, respectively, than in those assigned to the control group at six months, the researchers found.\nThe study, published Monday in the New England Journal of Medicine , tested whether pharmacist-led programs in barbershops could significantly lower high blood pressure in black men in the United States.\nAlso, pharmacists aimed to lower blood pressure in the program participants to less than 130/80, whereas the primary care providers of those in the control group probably targeted a blood pressure of less than 140/90.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs in this story although the costs of some antihypertensive drugs can be moderately high. Neither did the story disclose that study participants received vouchers for monthly haircuts as well as a small monetary payment to offset the costs of drugs and transportation as enticements to continue with the program, information that was contained in the journal paper but excluded in the story.\u00a0 Regardless, we don\u2019t believe that information is that important to readers in this case so we\u2019ll rate this category as non-applicable.", "answer": 2}, {"article": "Twenty of the 44 children in the vapor rub group suffered mild side effects including skin irritation and burning sensation of the eyes and nose.\nIn the study, funded by an unrestricted research grant from Procter & Gamble, makers of Vicks, researchers took 138 children between the ages of 2 and 11, with symptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\n\"I have found that when used properly it can be a good option for parents who want to relieve some cold symptoms in their children.\n\"This was based in part on some of the studies that we have conducted at Penn State.\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nOne could say that the cost of VapoRub is not an important factor, but given how easy it would be to note the price of VapoRub, especially for the amount used in the study, we think the story should have included it.", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story does include some discussion of costs, the specifics implied that smartphone app systems are inherently less expensive than alternatives. However, as the story points out, the actual costs and effectiveness of the apps discussed are still being studied. The hoped-for cost savings might not materialize. It\u2019s possible that the apps might be cheaper, but also less effective, perhaps leading to more expensive remedial interventions or poorer health outcomes. The story did not address several important cost questions. Even if insurers or public programs paid for the apps, who would pay for the smartphones, data plans and other costs? For people with low incomes, these costs could create barriers to treatment.", "answer": 0}, {"article": "LeFevre worked on the 2009 aspirin recommendations from the U.S. Preventive Services Task Force (USPSTF), a federally supported expert panel.\n\u201cIn my mind, if you have diabetes or multiple risk factors for heart disease \u2014 such as smoking or obesity \u2014 it is reasonable to take aspirin.\u201d\n\nIn addition, working to eliminate those risk factors by other means will not only slash the risk of heart disease, but also a host of other health problems.\n\u201cThe number of events that you prevent depends on your baseline risk,\u201d LeFevre concluded.\nIn the current study, published in the American Journal of Cardiology, the researchers also report small decreases in stroke and death risks with aspirin, although those changes might have been due to chance.\nBut the blood-thinning drug doesn\u2019t appear to cut the chances of dying from the disease, at least not enough that researchers can say for certain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll accept the brief mention \u2013 at the very end of the story about aspiring being \u201ccheap\u201d and \u201ccost effective for men over 45.\u201d\u00a0 We all know it\u2019s cheap.\u00a0 But it doesn\u2019t hurt to include a few words about cost and cost-effectiveness.", "answer": 1}, {"article": "in July to prevent clots in hip and knee replacement surgeries, goes to an F.D.A.\nevent of the year.\u201d\n\n\u201cIf everything checks out,\u201d Jami Rubin of Goldman Sachs said in an interview, \u201cthat will confirm in our minds that Eliquis has potential to take a majority share of the $10 billion anticoagulation market.\u201d\n\nMore than 2.6 million people have atrial fibrillation in the United States, according to the Centers for Disease Control and Prevention.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nIt combines both greater efficacy in terms of prevention of stroke with a substantial reduction to bleeding risk, and that package is one that will be particularly compelling.\u201d\n\nWall Street has high expectations, too.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that it was expected that the drug reported on would cost $8/day as compared with <$1/day for warfarin.\nOne aspect of costs that were not considered in this story is the difference in monitoring, which would be less with patients using Eliquis. The competing HealthDay story did a better job on this latter point.", "answer": 1}, {"article": "(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nA patient undergoes an electroencephalogram while doing a cognitive task, and the EEG records how the brain responds.\n\"By actually (measuring) the brain network activity directly, you can look at really what is the functional health of the brain,\" he said.\nIn the study, those who had used anti-inflammatory medications were the ones with longer-term symptoms.\nThere are also tools that look at the electrical networks that brains form, he said, disclosing that he is consulting for a company working on one such technology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides no discussion of how much this test might cost if and when it comes to market.", "answer": 0}, {"article": "\"The challenge in prostate cancer is how to look at all of these patterns within a cell, but hone in on the gene activity that suggests cancer, and not only this, what type of cancer - dangerous or manageable?\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nProfessor Norman Maitland, from the University of York's Department of Biology, said: \"Unnecessary prostate treatment has both physical consequences for patients and their families, but is also a substantial financial burden on the NHS, where each operation will cost around \u00a310,000.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\nA team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release does not mention costs. This is likely because, as we said above, the test is still experimental, and not something available to the general public.\nIn comparison, available genomic tests run around $4,000.", "answer": 0}, {"article": "For more information about NIH and its programs, visit www.nih.gov.\n\u201cThis rigorous trial confirms that Eylea, Avastin, and Lucentis are all effective treatments for diabetic macular edema,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D. \u201cEye care providers and patients can have confidence in all three drugs.\u201d\n\nEylea, Avastin, and Lucentis are all widely used to treat DME, a consequence of diabetes that can cause blurring of central vision due to the leakage of fluid from abnormal blood vessels in the retina.\nThe clinical trial was conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), which is funded by the National Eye Institute, part of the National Institutes of Health.\nHowever, patients with 20/50 or worse vision loss may benefit from Eylea, which over the course of the two-year study outperformed Lucentis and Avastin.\u201d\n\nThe number of injections participants needed was about the same for all three treatment groups.\nBased on Medicare allowable charges, the per-injection costs of each drug at the doses used in this study were about $1850 for Eylea, about $60 for Avastin, and about $1200 for Lucentis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release states that based on Medicare allowable charges, each injection of Eylea costs $1,850, Lucentis is $1,200 per injection and Avastin is $60 per injection. Patients received nine monthly injections, on average. This is good detail, although total costs of all treatments (medication plus laser) would have been even more helpful.", "answer": 1}, {"article": "There was still a benefit four weeks later.\nThere are still many questions, including whether the drug would benefit people with insomnia due to a health condition, which doctors call secondary insomnia.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\nThe study, published online Nov. 28 and in the Dec. 4 print issue of the journal Neurology, included 254 healthy adults with primary insomnia, which means it wasn't caused by an underlying physical or mental health problem.\nBut, he said, suvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 If the drug has been submitted to the FDA for marketing approval, as the story states, you know that the company has price estimates. It\u2019s the job of journalism to give more cost context.", "answer": 0}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions neither of two costs that merited discussion: the cost of following a Mediterranean diet and the cost of the study itself. The former is important to anyone who may want to follow the diet if it proves to delay cognitive decline; the latter because it might explain why few such studies exist.\nIt\u2019s also important to note here that the olive oil and nuts were provided to participants in this study free of charge. And the participants consumed a lot of high-quality olive oil \u2014 a liter per week per family. So the costs of replicating this diet would not be trivial, especially for older adults who may be on fixed incomes (i.e. the kind of people enrolled in the study). And that cost might in turn affect how well people outside of the study can adhere to this diet.", "answer": 0}, {"article": "Risk reduction [was] probably in the range of 80 to 95 percent,\" said researcher Timothy Rebbeck, an epidemiologist at the University of Pennsylvania.\nA new study in the Journal of the American Medical Association shows the clearest evidence yet that women carrying the BRCA1 and BRCA2 genes should consider preventive surgery because they are at a very high risk for breast and ovarian cancers.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n\"My mother left me when I was 26, and it was extremely painful and traumatic for my entire life,\" she says.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story hints at the financial implications when it notes that the woman featured did not want her last name used because she is worried about her health coverage, but it does not report the cost of testing (which ranges from several hundred to several thousand dollars and may not be covered by insurance) nor the cost of intensive surveillance or surgery.", "answer": 0}, {"article": "CHICAGO (Reuters) - Lightly shocking a person\u2019s brain just before they learned a new task appeared to strengthen memory in a handful of patients with epilepsy, a tantalizing result that could have implications for Alzheimer\u2019s disease, U.S. researchers said on Wednesday.\nIn a study published in the Annals of Neurology in 2010 researchers tested deep brain stimulation in six patients over the course of a year and found the treatment to be relatively safe.\nThe Obama administration said on Wednesday it plans to spend an additional $156 million over the next two years to help find an effective treatment for Alzheimer\u2019s.\nThe current study was done at the University of California at Los Angeles in seven epileptic patients awaiting surgery who had electrodes implanted deep in their brains to help pinpoint the source of their seizures.\n\u201cThe question would be whether this can help memory in patients with memory impairments,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This line of research is so preliminary that we don\u2019t think it\u2019s necessary that stories report specific cost estimates. This story did include a comment about similar treatments being very expensive.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were discussed. But the story didn\u2019t discuss insurance coverage.\u00a0 One online reader did, though, writing:\n\u201cInteresting how while plastic surgery isn\u2019t covered by health insurance, the follow-up care and complications often are. The side effects of this procedure sound horrific, and we all get to pay for it.\u201d", "answer": 1}, {"article": "Women more likely to have serious mental health problems than men, study says\n\nNIH's mental health chief on why he's leaving for Google: Technology may hold key to better diagnosis\n\nMost Americans will get a wrong diagnosis at least once in their lives\nThe research, published Wednesday in JAMA Psychiatry, is significant because major depression is one of the most common mental health disorders in the United States and one of the leading causes of disability worldwide.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nThis study \"shows a new, proven-safe treatment of depression that is probably both more effective and less expensive than drug treatment or anything else,\" said Dan Kripke, a psychiatrist and professor emeritus at the University of California, San Diego, who has studied the topic but was not involved in the latest trial.\nMost people typically receive medication and psychotherapy \u2014 but medications don't work in all cases and there's a shortage of providers in many areas.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story squeaks by on this with mention that light therapy is \u201ccheap\u201d and easy to use. We would have preferred some numbers giving prices for the light sources that patients typically use at home and some estimate for a therapeutic course of psychotherapy (which is often provided in combination with light therapy).", "answer": 1}, {"article": "What are the limitations of IVM?\nAlthough IVM may eventually become more common, IVF still remains the standard of care and the most effective way for women to get pregnant.\nThey also note that the technology hasn\u2019t been widely used and that there are no studies looking at the outcomes of birth defects or developmental delays.\nAlthough ICSI is safe and effective, the bigger concern is if a patient going through IVM doesn\u2019t use ICSI, Shastri said.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the article states that IVM is less expensive than standard IVF because women undergo fewer hormone injections, it does not cite any cost figures for either procedure, or other assisted reproductive technologies. And it should.", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\n\n\nThe story does not include any estimate of the cost of the drug, but the treatment is still experimental, so it is not surprising that there is no firm estimate of the drug\u2019s price. The story does note the high costs of other recently approved drugs to treat advanced prostate cancer\u2026 and that cost may be an issue for this product as well.", "answer": 1}, {"article": "That accounts for a small percentage of people.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t mentioned. The BRCA testing appears to be part of the $199 \u201chealth + ancestry service\u201d package provided by 23andMe \u2014 though the package description on the company website did not include BRCA at the time of this writing. While this is a significant out-of-pocket expense for most people, it is somewhat less expensive than some other genetic testing options. However, those other testing options are significantly more extensive. In other words, as one genetic counselor notes in a related article in The Atlantic, \u201c[23andMe] is not an inexpensive way to get your testing done more cheaply.\u201d", "answer": 0}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "But for precisely those reasons, the story gets a strike for passing on the unchallenged speculations that the hypothetical tool could be cheap.\u00a0 Unsound journalistic practice. ", "answer": 0}, {"article": "Those medications can produce adverse side effects like gastrointestinal distress and fractures of the femur.\n\u201cBy opposing one group of muscles against another, it stimulates osteocytes, the bone-making cells.\u201d\n\nMost experts argue that it\u2019s difficult, perhaps impossible, for adults to gain significant bone mass.\nThe findings, as reported last month in Topics of Geriatric Rehabilitation, showed improved bone density in the spine and femur of the 227 participants who were moderately or fully compliant with the assigned yoga exercises.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nIf you don\u2019t fall, you greatly reduce your risk of a serious fracture.\u201d\n\nFor more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the article did not specifically state how much it costs to do a 12 minute yoga session everyday, one can assume it is relatively inexpensive and cost is not really an issue here. \u00a0Where it becomes an issue is when yoga practitioners attend expensive classes, feel compelled to buy expensive yoga accessories, travel to India to spend time with yoga gurus, and generally spend lots of personal time practicing it, all which could lead to considerable costs.", "answer": 2}, {"article": "Here's the scientific proof.\nHowever, the reanalysis regarding psychotic disorders contradicted the earlier conclusions -- that there indeed appeared to be a higher risk of psychotic disorders among marijuana users in the study versus non-users that approached statistical significance when using a more liberal test.\nOne major limitation of the study is that it ends when the men are in their 30s \"which may be too early for decrements in health to emerge,\" the authors acknowledge.\nWith the widespread availability of marijuana in recent years thanks to its legalization in a growing number of states, there has been increasing concern about the long-term health consequences on teens who might be able to get easier access to it illegally.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this Not Applicable. \u00a0The story didn\u2019t discuss costs, and we acknowledge it would be difficult to pin down marijuana costs from different sources \u2013 from the time period in question in the analysis \u2013 or today.", "answer": 2}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nIn a study published in the American Journal of Cardiology, scientists from the National Heart and Lung Institute at Imperial College London calculated that the reduction in heart disease risk offered by a statin could offset the increase in risk from eating a cheeseburger and a milkshake.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In this context, the cost discussion works, even though it is only a passing reference. The authors are trying to argue that statins would not cost much for fast food restaurants. \"It would cost less than 5 pence ($0.07) per customer \u2014 not much different to a sachet of ketchup,\" says one of the authors. It would have been nice to have some clarity on whether that is a wholesale cost, retail cost or a British government cost. For this sort of plan to work in the U.S., assuming it even makes sense, the cost likely would be much higher.", "answer": 1}, {"article": "Researchers report these findings in the journal Archives of General Psychiatry.\nThe research builds on a 2006 Lancet Neurology study that followed patients for a median of 5.2 years, beginning with a group of 137 volunteers with mild cognitive impairment.The new study is important because of the long follow-up period, according to Adam Brickman, assistant professor of neuropsychology at Columbia University School of Medicine, who was not involved in the research.\nThe results from the study suggest that beta-amyloid is a much earlier predictor of Alzheimer's disease than tau, which supports the hypothesis that beta-amyloid accumulation in the brain occurs first in the course of the disease.\nTau has been tied to neurofibrillary tangles in the brain; researchers find that an increase in tau in cerebrospinal fluid is associated with Alzheimer's also.\nThe association between biomarkers in the fluid and Alzheimer's was also described in studies in December 2009 and August 2010, building on the idea that a spinal tap could be useful in predicting Alzheimer's.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 Yes, we know that it\u2019s too early to use this in clinical settings, but the story makes the case that this builds on research following patients for as long as 12 years.\u00a0 Any predictive test would hold appeal for many people \u2013 so cost ramifications are important to discuss even at this early stage. Both tests are available at the present time so that with a little bit of digging, the costs could have been provided.", "answer": 0}, {"article": "The American Heart Association recommends that adults eat less than 1.5 g of sodium per day.\nThe supplement is based on the seaweed extract alginate, a thickening agent and a common ingredient in foods like soups and jellies.\nBut when all 96 original participants were included in the analysis, the researchers found no significant difference in weight loss between the two treatment groups.\nThere are many different types of alginate, said Richard Mattes, who has studied the effect of alginate fiber on appetite at Purdue University in West Lafayette, Indiana \u2014 so the trick is to find the right alginate in the right dose.\nAt times during the trials, systolic blood pressure increased in the alginate group by one to two points.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained that alginate as an aid to weight loss is already available in pill form, selling for around $45 for a seven-day supply.", "answer": 1}, {"article": "The medical approach to treating tonsil infections has evolved over recent decades.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\n\"The decision about whether those children should have tonsillectomy for that temporary benefit is really tied to what those children need or what they're suffering with,\" Chinnadurai said.\n\"Though a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\" Chinnadurai said.\n\"But for the tonsils and adenoids, there are great quality-of-life benefits that are evident for the surgery, but no child has ever died because they haven't gone through the surgery.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nowhere in this HealthDay story is the subject of costs mentioned. While tonsillectomy is considered a common treatment, it is still surgery, and therefore somewhat expensive.\u00a0 One source online, insurer Blue Cross Blue Shield, quotes the average cost of the procedure as $5,442, although some or all of that may be covered by insurance. Even considering the cost of multiple doctors\u2019 visits and prescribed medication for throat infections over a year or two, the surgical cost still is higher, and that point should have been made in this story.", "answer": 0}, {"article": "A hijab, a turban, a beard: What aren\u2019t you seeing?\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\nA former gang member recently recalled when he decided to join the gang.\nHere\u2019s how he got out.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the costs associated with the type of physical therapy discussed or whether such therapy is covered by insurance or Medicare.", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Thought there was no discussion of cost, most people have a general idea how much cocoa costs.", "answer": 2}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of treatment \u2013 $60 for 60 pills. The story should have compared this cost to the alternative \u2013 sunscreen.", "answer": 1}, {"article": "WEDNESDAY, Feb. 6, 2013 (HealthDay News) -- Enduring dietary wisdom -- that polyunsaturated vegetable fats are better for your heart than saturated animal fats -- may be turned on its head by a fresh analysis of a nearly 50-year-old study.\nThey may also be involved in inflammation, oxidation or clotting.\nThe reasoning has been that a diet rich in omega-6 polyunsaturated fats lowers cholesterol, and is therefore good for heart health.\n\"Because there's very robust evidence showing the cardiovascular benefit of linoleic acid.\nFor more on AHA guidelines regarding linoleic acid, visit the American Heart Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of vegetable oil and other sources of linoleic acid is not really in question.", "answer": 2}, {"article": "WEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nAfter looking for other possibilities, those who took statins regularly had a 41 percent lower risk of developing rheumatoid arthritis compared with people who were not taking statins regularly.\nThe only way to prove the connection is with a clinical trial, Myerburg said.\n\"Patients who were covered for more than 80 percent of the time, had a 40 percent lower risk of developing rheumatoid arthritis,\" Chodick said.\nThis work received no outside or corporate finding, the researchers noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThere is no mention of costs in this story, either the direct costs of the drugs or the associated costs of testing and monitoring.", "answer": 0}, {"article": "Line Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nSo the researchers use infrared light, delivered by an extremely fast-pulse laser.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nCataracts can be treated by lens-replacement surgery, but the procedure is invasive and costly, requiring special equipment and skilled eye surgeons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. Costs not discussed, which is understandable at this early stage of research.\u00a0 ", "answer": 2}, {"article": "Dr. Oken said the new study might have shown no benefit in 18-month-olds because effects in infants might be \u201chard to measure\u201d or \u201cit may be that the benefit of DHA is not as important as when you\u2019re 4.\u201d\n\nDr. Makrides\u2019s team plans assessments at 4 and 7.\nincreases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nAnd the new study showed small reductions in postpartum depression in women with histories or high risk of depression.\n\u201cThere\u2019s no harm that we know of at all, in contrast to many antidepressants,\u201d he said.\nShe said babies in her study might have received more DHA than those in this study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost and we always think there should be. ", "answer": 0}, {"article": "Even as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\n\u201cIt was receding.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the price has not yet been set, which we\u2019ll call good enough for a Satisfactory rating. It could have noted whether insurers are likely to pay for the treatment.", "answer": 1}, {"article": "\u201cHe also had elements of what I know a lot of folks would call \u2018chemo brain.\u2019 He would get very frustrated and very angry, all normal because his little body was just being invaded by this intense medication and rounds of chemotherapy treatment.\u201d Throughout that year, Riddle and her son traveled back and forth from Colorado to Utah, so he could continue chemo, but this time with the aid of cannabis, to make treatment more bearable.\nShe was willing to do whatever it took to keep him on cannabis.\nBut his mother was now refusing to follow his doctors\u2019 orders.\nShe decided to start Landon on cannabis.\nThe proteins on the cell membrane (receptors) recognize the chemical compound, CBD.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of the cannabis treatment.", "answer": 0}, {"article": "Commenting on the Nature Medicine study, he tells Newsweek the paper is \u201cvery interesting on a number of levels.\u201d\n\n\u201cFirst of all there\u2019s clearly growing interest in the potential therapeutic role of cannabinoids and in this particular case THC on various human conditions,\u201d he says.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\nThis is a challenge faced by anyone wanting to develop a therapy for a human disorder such as dementia.\nThe team argues that while they do not yet know if these findings would be same in humans, it could lead to new treatments to prevent cognitive decline in older people: \u201cCannabis preparations and THC are used for medicinal purposes,\u201d they write.\nThe first involved a water maze, where mice have to learn and then remember how to navigate their way to the end.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story describes mouse experiments, it draws parallels to human marijuana use and some mention of the cost of its use\u2013recreationally or medicinally\u2013would have been useful.", "answer": 0}, {"article": "The World Health Organisation has predicted that by 2020 depression will be the second biggest cause of health problems in the world.\nIt would accelerate our therapeutic interventions and make them more tailored to the needs of the patient.\u201d\n\nBut further clinical research is needed to see if the findings can be applied in a clinical setting, Hallstrom added.\nThese initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not included. If it\u2019s not too soon to speculate that \u201cthis\u00a0breakthrough could lead to depressed patients receiving personalized treatments that are more likely to relieve their symptoms,\u201d then it\u2019s not too soon to think about what that test might cost.\u00a0", "answer": 0}, {"article": "Dr. Beth Karlan, director of gynecologic oncology at Cedars Sinai Medical Center in , said the results of the new trial would \u201cmake us all rethink the approach to treating patients with recurrent ovarian cancer.\u201d\n\nDr. Karlan, who was not involved in the study but presented a commentary on it, said CA125 testing should be done less frequently.\nThis new study does not refer to initial diagnosis of ovarian cancer, only to a relapse.\nBut for relapsed ovarian cancer, surgery is usually not an option.\nOther were resistant to chemotherapy and would not respond to treatment no matter when it was given.\n\u201cMany women often say they live from one CA125 to the next,\u201d she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not describe the cost of CA-125.", "answer": 0}, {"article": ", and receive monthly highlights by signing up at http://www.\n\"Inflammation plays a critical role in acute and chronic tendon injuries and healing,\" said Chang H. Lee, Ph.D., a researcher involved in the work and an assistant professor at the Regenerative Engineering Laboratory (Columbia University Irving Medical Center, New York).\nIt is the world's most cited biology journal according to the Institute for Scientific Information and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century.\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This is basic research, so no one is in a position to talk about specific costs. But when a release broaches therapy as a likely goal, as is the case, then it indeed needs to speak to cost. Such treatments run into the thousands of dollars, with iffy participation by insurance companies.", "answer": 0}, {"article": "itself the first clear and reproducible example of cancer immunotherapy, developed at Fred Hutch ?\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nAn independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this research in still in early stages, the release could have noted that immunotherapy can be very expensive. Some courses of treatment cost $100,000, while others need to be given continually at a cost that can exceed $10,000/month.", "answer": 0}, {"article": "Larger studies in many more patients are needed before the drug will be available, though, she says.\nOct. 8, 2012 (Boston) -- An experimental Alzheimer \u2019s treatment slowed memory loss by about one-third in people with mild Alzheimer's , offering hope that the drug can alter the course of the progressive disease.\nWhen the findings of the two studies were looked at individually, patients given solanezumab for 18 months didn\u2019t do better on either a test used to measure patients' symptoms or a measure of how well patients are functioning than patients given a placebo.\nThe benefit is small and studies have been inconsistent, says researcher Rachelle Doody, MD, head of Alzheimer\u2019s disease research at Baylor College of Medicine.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though it is too early to have a firm price, the story notes that similar drugs can cost hundreds of dollars per month. This price reference is more specific than the one in the AP story.", "answer": 1}, {"article": "The trial was funded by Pfizer.\nThe combination - of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant - slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast cancer.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nThe research showed that using 'liquid biopsies' that measure cancer DNA circulating in the blood to detect PIK3CA, and tests for blood hormone levels, the palbociclib combination worked in all types of hormone-receptor positive, HER2 negative breast cancer.\nIn the trial, researchers from 144 research centres in 17 countries followed 521 women allocated to receive either palbociclib and fulvestrant, or a dummy pill and fulvestrant.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention cost. The wholesale cost for fulvestrant 500 MG is $1,845/month and palbociclib is approximately $9,850. A 2015 report on palbociclib\u2019s cost by a pharmacy benefits manager stated it could potentially be one of the top 10 most costly cancer drugs.", "answer": 0}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any cost information for Exelon (rivastigmine). ", "answer": 0}, {"article": "\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\nThe findings came from an analysis of data on 136,474 people who did not have Parkinson's at the start of the study.\nParkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nIn a six-year span, 293 were diagnosed with the disease.\nThose who took the largest doses of ibuprofen were less likely to have developed Parkinson's than were those who took smaller amounts of the drug, the study found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not discussed but most people know that ibuprofen products are inexpensive. ", "answer": 2}, {"article": "But there are dangers to this approach.\n\u201cIt was not known that inflammation was a common feature of different types of epilepsy.\u201d\n\nNormal brain function is regulated by the glial cells, which protect neurons and induce an inflammatory response if the brain is injured.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\n\u201cLike any new field, there\u2019s a lot of enthusiasm and almost a bit of religion involved,\u201d said Dr. Tallie Z. Baram, an epilepsy expert at the University of California, Irvine.\n\u201cOver time, both of them may feed off each other.\u201d\n\nAbout 50 million people worldwide, including more than 2.7 million people in the United States, are struggling with epilepsy in some form.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of taking anti-inflammatory drugs \u2013 steroids or otherwise \u2013 could be significant over a lifetime. Some of those drugs already are on the market and, as the anecdotes in this story indicate, already being used by some doctors to treat epileptic patients. A few calls and a check on Drugstore.com could have provided readers a range of prices.", "answer": 0}, {"article": "Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time.\nThe risks and uncertainties include, but are not limited to, the following:\n\u2022 the proposed combination with Baxalta may not be completed due to a failure to satisfy certain closing conditions, including any shareholder or regulatory approvals or the receipt of applicable tax opinions;\n\u2022 disruption from the proposed transaction with Baxalta may make it more difficult to conduct business as usual or maintain relationships with patients, physicians, employees or suppliers;\n\u2022 the combined company may not achieve some or all of the anticipated benefits of Baxalta's spin-off from Baxter International, Inc. (\"Baxter\") and the proposed transaction may have an adverse impact on Baxalta's existing arrangements with Baxter, including those related to transition, manufacturing and supply services and tax matters;\n\u2022 the failure to achieve the strategic objectives with respect to the proposed combination with Baxalta may adversely affect the combined company's financial condition and results of operations;\n\u2022 products and product candidates may not achieve commercial success;\n\u2022 product sales from ADDERALL XR and INTUNIV are subject to generic competition;\n\u2022 the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payers in a timely manner for the combined company's products may affect future revenues, financial condition and results of operations, particularly if there is pressure on pricing of products to treat rare diseases;\n\u2022 supply chain or manufacturing disruptions may result in declines in revenue for affected products and commercial traction from competitors; regulatory actions associated with product approvals or changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;\n\u2022 the successful development of products in various stages of research and development is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;\n\u2022 the actions of certain customers could affect the combined company's ability to sell or market products profitably, and fluctuations in buying or distribution patterns by such customers can adversely affect the combined company's revenues, financial condition or results of operations;\n\u2022 investigations or enforcement action by regulatory authorities or law enforcement agencies relating to the combined company's activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;\n\u2022 adverse outcomes in legal matters and other disputes, including the combined company's ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the combined company's revenues, financial condition or results of operations;\n\u2022 Shire is undergoing a corporate reorganization and was the subject of an unsuccessful acquisition proposal and the consequent uncertainty could adversely affect the combined company's ability to attract and/or retain the highly skilled personnel needed to meet its strategic objectives;\n\u2022 failure to achieve the strategic objectives with respect to Shire's acquisition of NPS Pharmaceuticals Inc. or Dyax Corp. (\"Dyax\") may adversely affect the combined company's financial condition and results of operations;\n\u2022 the combined company will be dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on the combined company's revenues, financial condition or results of operations;\n\u2022 the combined company may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners;\n\u2022 difficulties in integrating Dyax or Baxalta into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and other risks and uncertainties detailed from time to time in Shire's, Dyax's or Baxalta's filings with the Securities and Exchange Commission (\"SEC\"), including those risks outlined in \"ITEM 1A: Risk Factors\" in Shire's and Baxalta's Annual Reports on Form 10-K for the year ended .\nDr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\n\"We are pleased with the positive results of the SHP465-305 study,\" said Philip J. Vickers, Ph.D., Head of Research & Development, Shire.\nThe completion of SHP465-305 addresses an FDA requirement to evaluate the safety and efficacy of SHP465 in children and adolescents prior to filing a Class 2 resubmission of the medicine for FDA approval.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the eventual price point of this drug. This is important if commonly used drugs like Adderall are becoming available as a generic and subsequently much less expensive. According to GoodRx.com, the cost for a 30-day supply of Adderall ranges from $75 to $150. Costs for Vyvanse, a newer stimulant for ADHD, costs around $250 for 30 pills. Concerta, which came on the market around the same time as Vyvanse, costs about $250 for 30 pills. Generic Ritalin (one of the oldest ADHD stimulant drugs) averages around $45 for a month\u2019s supply.\nCompanies sometimes develop new, yet no more effective or safe, formulations because they can sell them at higher costs as a new patented drug.", "answer": 0}, {"article": "The current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOf these, 20,279 were admitted on weekends and 58,378 during the week.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n(See Reuters Health report, March 8, 2007).\n(See Reuters Health report, March 17, 2007).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As with the HealthDay report, this article did not mention costs.", "answer": 0}, {"article": "Fried, a dermatologist and clinical psychologist, points out that psoriasis itself can be associated with mental health problems.\nThe Food and Drug Administration (FDA) has approved the injectable drug Siliq (broadalumab) for the treatment of moderate-to-severe plaque psoriasis in adults.\nIn the three clinical trials considered for drug approval, more than 50% of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nBecause of an association with suicidal thoughts and behaviors, Siliq will be sold with a \u201cblack box\u201d warning and should be considered only for patients whose psoriasis has not responded\u2014or has stopped responding\u2014to phototherapy or to other systemic medicines taken orally or via injection.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give this story credit for mentioning cost, when it states\u00a0\u201cpricing information is not available at this time.\u201d However, the story would have been stronger if it had explained the known costs of similar injectable drugs, as we mention in our review of the FDA news release on this drug, and\u00a0as discussed here. It\u2019s likely this new drug would be in a similar price range.", "answer": 1}, {"article": "Newman was not involved in the study.\nWith $45 billion pledge to charity, Mark Zuckerberg and wife imagine \u2018a world without suffering from disease\u2019\n\nThe myth of sugar-free drinks, candy: Study shows they can wreak havoc on teeth, too\n\nModern men tend to overeat like cavemen as a way of showing off to women\n\nFor more health news, you can sign up for our weekly newsletter here.\nHere's how he survived]\n\nPrevious research has reached the same conclusion, but a significant problem with this study and others like it is that they rely on retrospective data, looking back over any number of years, said Michael S. Sabel, the chief of surgical oncology at the University of Michigan, who was not involved in the newly published study.\n\"It's premature to suggest, and it\u2019s a difficult conversation to have with patients, that removing the breast will help them live longer in the face of Stage 4 disease,\" Sabel said.\nWhen the researchers examined a small subset of the group \u2014 those who survived 10 years \u2014 they found that 9.6 percent had chosen to have surgery while 2.9 percent had not.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of breast surgery in the US varies widely depending on the type, hospital and region, and so we acknowledge that it would have been difficult to provide solid numbers here. Nevertheless, we feel\u00a0that cost remains relevant for this piece. This study basically argues that surgery plus other aggressive non-surgical treatment vs. non-surgical treatment alone may lead to longer survival. Since this isn\u2019t proven, one could reasonably ask about the costs of these two approaches. This may be analogous to the prior use of autologous bone marrow transplantation (BMT) in women with metastatic breast cancer. The high cost of this treatment led to fights with insurers over coverage and finally to a randomized trial that showed no benefit. We don\u2019t do autologous BMT anymore. Could a similar scenario play out here? The question seems worth asking and addressing.", "answer": 0}, {"article": "The changes do not apply to women with certain health problems that could make them more prone to aggressive cervical cancer, including H.I.V.\nRepresentative Rosa DeLauro, Democrat of Connecticut, said that the new guidelines would have no effect on federal policy and that \u201cRepublicans are using these new recommendations as a distraction.\u201d\n\n\u201cMaking such arguments, especially at this critical point in the debate, merely clouds the very simple issue that our health reform bill would increase access to care for millions of women across the country,\u201d she said.\nStill, the new recommendations for Pap tests are likely to feed a political debate in Washington over health care overhaul proposals.\nMs. Guetta has three daughters, ages 17, 14 and 8, and at the moment, she would not encourage them to wait until they turn 21.\nDemocratic proposals to involve the government more deeply in the nation\u2019s health care system, he said, would lead the new mammography, Pap smear and other guidelines to be adopted without regard to patient differences, hurting many people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The report does not mention costs. Price should be taken into account whenever population screening is an issue. \nGiven how much emphasis the story puts on the political ramifications for health care reform, the omission is particularly unfortunate.\u00a0 ", "answer": 0}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed but this drug is still in development. ", "answer": 2}, {"article": "In those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nSmokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story addresses the broad scope of costs: \u201cAmerican smokers spend more than $1.5 billion on nicotine gum, patches and related products each year, according to the study. Much of that comes from public health programs, which are facing further rounds of budget cuts.\u201d\nWe would have liked to see actual costs for some of these products and a comparison to cigarettes. People might be more likely to continue buying nicotine products if they are cheaper than the cigarettes themselves.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable because the cost of strawberries is not in question.", "answer": 2}, {"article": "\u201c[PRP] works, and the results have been amazing,\u2019\u2019 says John Ferrell, the sports medicine physician who treated me.\nWe will be able to treat ailments noninvasively, and at an earlier stage.\u2019\u2019\n\nThe procedure involves collecting several ounces of blood from a patient\u2019s arm, spinning the blood in a centrifuge to concentrate the platelets and injecting the concentrated platelets into the injury site to stimulate healing.\nThe average treatment is two injections, which costs about $1,000 at his practice, whereas rotator-cuff surgery runs about $13,000, he says, although insurance often covers most of the costs of surgery.\n\u201cThe potential for benefit from PRP is real.\u2019\u2019\n\nI had my first appointment with Ferrell last October to find out whether PRP might help me.\nBefore undergoing PRP treatment, I read quite a bit about it, learning that it holds promise for healing soft-tissue injuries such as tearing of the rotator cuff (the group of tendons and muscles that provide stability to the shoulder), tennis elbow, plantar fasciitis, Achilles tendinitis, patella tendinitis and hamstring tears; it may even provide relief for mild to moderate osteoarthritis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story attempted to discuss cost by citing the difference in price\u00a0between shoulder surgery ($13,000) and the PRP treatment ($1,000, in this case for two injections). This is sufficient enough for a Satisfactory rating, but barely.\nWhile this does give readers some idea of the possible cost difference in treatments, there is no assurance that the charges in the author\u2019s case are typical for those for the general\u00a0public. It is simply one single data point which is fairly useless to the public. And, since there is no evidence of benefit or how many shots one might require, cost could be all over the place.", "answer": 1}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nAt the annual Alzheimer\u2019s Association International Conference, researchers say they have found a series of substances in saliva that can distinguish between people who experience normal aging, those with mild cognitive dementia (MCI, which in some cases can lead to Alzheimer\u2019s and in other cases not), and Alzheimer\u2019s disease.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention in this short story about the potential costs of such a test, if it proved to be viable. Of course, it\u2019s too early to say anything definitive about cost, and offering a specific number might mislead readers by implying that the test is anywhere near ready to be used. But we think the story could have offered some sense of the technology behind the test and whether it\u2019s advanced/expensive or cheap/widely available. Other tests using saliva are in use today and could offer a general comparison point to suggest the costs of a new test.", "answer": 0}, {"article": "In March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThis question weighs heavily on doctors and patients, but now, with the Oncotype DX AR-V7 test, we can provide them the confidence to know whether continuing with hormonal therapy or switching to chemotherapy will result in better survival outcomes,\" said Ryan Dittamore, chief of medical innovation at Epic Sciences and a co-author on the study.\nThe results were that patients positive for AR-V7 who were treated with taxane-based chemotherapy had superior overall survival (OS) relative to those treated with ARSI therapy (median OS, 14.3 vs. 7.3 months).\nThe blood test called, Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 is commercially available in the U.S. through Epic Science's partnership with Genomic Health, Inc. (NASDAQ: GHDX).\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The $3,980 price tag for this test wasn\u2019t mentioned. The release notes that the Centers for Medicare and Medicaid Services (CMS) are currently evaluating whether the test will be covered in the future. In other words, it is not currently covered by Medicare.\u00a0 We aren\u2019t told whether other insurers cover the test.\nThere was also no information about the costs of the treatments involved. Hormone therapies for prostate cancer are especially pricey, running more than $10,000 a month, according to published reports.", "answer": 0}, {"article": "Doctors currently diagnose colds and flus through a patchwork of testing, observation and process of elimination.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nIt tests for a dozen viruses, including several types of influenza, two types of respiratory syncytial virus, or RSV, three types of parainfluenza, adenovirus and even rhinovirus, which causes the common cold.\nAccording to data submitted to the FDA, the test detects each virus 78% to 100% of the time, depending on the type, and has few false positives.\nCurrently available tests can yield results in a half hour, though accuracy varies and they typically screen for only one or two viruses.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does a good job of providing\u00a0the cost of the\u00a0XTag respiratory panel, $300-400,\u00a0and cost-related information.\u00a0 The test\u00a0is relatively expensive but is also covered by insurance.", "answer": 1}, {"article": "Your skin vs. the sun: A sunscreen pill?\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nThe basics: Almost everybody would love to have a \"healthy\" bronze glow, but almost everybody now also understands that the sun isn't our friend and that our skin needs to be protected from its stealthy attacks.\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The costs of Fernblock are not discussed. For all we know, it might be free. As the story says, \"There\u2019s no reason\" not to try it.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story is concise but thorough. In three sentences it reports that few insurers cover the procedure because it is new, that the cost ranges from $12-18,000 and also that some patients with severe asthma may spend a similar amount on standard care (including hospitalizations.) ", "answer": 1}, {"article": "Or she could allow doctors to implant two long, thin electrodes deep into her brain, along with an electrical generator about the size of an iPod in her chest.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nThe results come at time when a growing number of people are reaching their late 50s and early 60s, when they are most likely to be diagnosed with the disease, which affects between 500,000 and 1.5 million Americans.\n\"This (the JAMA study) is the largest, most complete and thorough analysis of deep brain stimulation to date,\" Hiner said.\nIn a sense it's a field of science that works backward: Stimulation is applied to the brain, some people get better, and doctors try to figure out why.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that the procedure costs about $120,000. \nBut we wish it had given the price of the many drugs and treatments used in conventional therapy for Parkinson\u2019s disease. As a consequence, the reader is led to believe the cost comparision is $120,000 vs. $0. In fact it\u2019s $120,000 vs. some other number, perhaps a higher one. Some comparison would have been useful.\u00a0 ", "answer": 1}, {"article": "By contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nJudson Emerick, an art history professor at Pomona College in Claremont, Calif., had varicose veins so troublesome that he kept getting skin ulcers that failed to heal.\nEighty-seven percent of people with varicose veins do not seek treatment, according to a 2008 survey of roughly 1,000 adults conducted nationwide by Vein Clinics of America and Opinion Research Corporation.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\nVein specialists must first figure out which patients would benefit from sclerotherapy alone, and which need inner varicose veins treated before injections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2014 a big hole when we\u2019re talking about\u00a0treatments that are\u00a0highly profitable for specialists and are often\u00a0sought out for cosmetic reasons and not because of any health risk. \u00a0", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A close call here. The story does discuss costs, but perhaps not adequately. It cites a range of costs early on \u2014 \u201c$3,000-5,000\u201d \u2014 but it\u2019s not clear whether that\u2019s for PET scans or transcranial magnetic stimulation or whether that range covers both.", "answer": 1}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included prices for several of the products described.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion\u00a0about the actual or anticipated added costs of the new nuclear imaging tests compared to current diagnostic tests. Nor is there a sense of the overall costs of treatment.", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the test is still under study, the costs of a diagnostic test is an important consideration even in reporting on a drug under study. \u00a0PET scans are extraordinarily expensive, so much so that the business implications are noted but the costs are not. \u00a0Noting the expected size of the market for this test without discussing projected or estimated cost of use even in vague terms seems inconsistent.\u00a0 ", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs associated with either procedure.", "answer": 0}, {"article": "At dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nHe lifted weights, using dumbbells and bars, moving quickly from exercise to exercise.\nOr the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself.\nSo he left for the gym before dawn on a recent chilly morning.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no telling what any tests or treatments\u00a0commercialized from this research might cost.", "answer": 2}]